<SEC-DOCUMENT>0001217234-23-000096.txt : 20230510
<SEC-HEADER>0001217234-23-000096.hdr.sgml : 20230510
<ACCEPTANCE-DATETIME>20230510162016
ACCESSION NUMBER:		0001217234-23-000096
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		91
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230510
DATE AS OF CHANGE:		20230510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CareDx, Inc.
		CENTRAL INDEX KEY:			0001217234
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				943316839
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36536
		FILM NUMBER:		23906710

	BUSINESS ADDRESS:	
		STREET 1:		8000 MARINA BLVD
		STREET 2:		4TH FLOOR
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		415-287-2300

	MAIL ADDRESS:	
		STREET 1:		8000 MARINA BLVD
		STREET 2:		4TH FLOOR
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XDx, Inc.
		DATE OF NAME CHANGE:	20071010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXPRESSION DIAGNOSTICS INC
		DATE OF NAME CHANGE:	20030203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cdna-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:c6b1ad27-1676-415f-b1d2-9124c5a59c19,g:635f8054-df92-419b-85ba-772c4e54710d,d:dd35c15ee381485cb38f052732749537--><html xmlns:srt="http://fasb.org/srt/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:cdna="http://www.caredxinc.com/20230331" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cdna-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180L2ZyYWc6NThiYTg5MmI3M2JlNGNjODhmMGFhYTEwNzFlOThkMjcvdGFibGU6ZTkxZGY2NTM2ZTU5NDE2MDg5NjNlYjE4YjE3NTMxYjQvdGFibGVyYW5nZTplOTFkZjY1MzZlNTk0MTYwODk2M2ViMThiMTc1MzFiNF8zLTEtMS0xLTk1MTMy_d0b38cb1-a9a7-404c-b102-f34dba742387">false</ix:nonNumeric><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180L2ZyYWc6NThiYTg5MmI3M2JlNGNjODhmMGFhYTEwNzFlOThkMjcvdGFibGU6ZTkxZGY2NTM2ZTU5NDE2MDg5NjNlYjE4YjE3NTMxYjQvdGFibGVyYW5nZTplOTFkZjY1MzZlNTk0MTYwODk2M2ViMThiMTc1MzFiNF81LTEtMS0xLTk1MTMy_e24c694b-4218-4558-ad7d-89bf09148fde">2023</ix:nonNumeric><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180L2ZyYWc6NThiYTg5MmI3M2JlNGNjODhmMGFhYTEwNzFlOThkMjcvdGFibGU6ZTkxZGY2NTM2ZTU5NDE2MDg5NjNlYjE4YjE3NTMxYjQvdGFibGVyYW5nZTplOTFkZjY1MzZlNTk0MTYwODk2M2ViMThiMTc1MzFiNF82LTEtMS0xLTk1MTMy_657a940d-05ea-40ed-af42-232c6c0fd4f7">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180L2ZyYWc6NThiYTg5MmI3M2JlNGNjODhmMGFhYTEwNzFlOThkMjcvdGFibGU6ZTkxZGY2NTM2ZTU5NDE2MDg5NjNlYjE4YjE3NTMxYjQvdGFibGVyYW5nZTplOTFkZjY1MzZlNTk0MTYwODk2M2ViMThiMTc1MzFiNF85LTEtMS0xLTk1MTMy_4ab7107b-4d66-481d-95a3-6a93a6d1e3f3">0001217234</ix:nonNumeric><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180L2ZyYWc6NThiYTg5MmI3M2JlNGNjODhmMGFhYTEwNzFlOThkMjcvdGFibGU6ZTkxZGY2NTM2ZTU5NDE2MDg5NjNlYjE4YjE3NTMxYjQvdGFibGVyYW5nZTplOTFkZjY1MzZlNTk0MTYwODk2M2ViMThiMTc1MzFiNF8xMC0xLTEtMS05NTEzMg_6eb642eb-f59d-4192-abfe-0f7667a0e566">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfMTY0OTI2NzQ2ODUyOQ_d306f6fa-aeb4-45bb-9b54-7cf758f0a757">http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities</ix:nonNumeric><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:DefinedBenefitPlanTypeExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182NC9mcmFnOjE5MTc0ZWRlNzIyMTQzNzk5MGY3ZjY0YTAzNjU2YzA2L3RleHRyZWdpb246MTkxNzRlZGU3MjIxNDM3OTkwZjdmNjRhMDM2NTZjMDZfNDYx_ec00229a-4fdc-4dab-8f7d-959d1d68ae6f">http://fasb.org/us-gaap/2022#PostemploymentRetirementBenefitsMember</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cdna-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0cc34f656aa40379ccfb7e710773180_I20230508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i0947b2db32e4416394c995e30d617446_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i6522c13470244b44971d6dd1d0a8251b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68b6550537c1477c960fc12e49544478_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaaeba5a92a4430cb59489d292860cd5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie44565fb103943ffa2a40292b86d6156_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b1a5c19190949f3825408e0497964b7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:PatientAndDigitalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5765e29984cc4e398fbf04608384a068_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:PatientAndDigitalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic611516b5add4872b60d9c652badf864_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a6d44a3abca4ba3b4f503e0dcb0f387_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36c952509b554d799ce4307c24d429f4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18517199530c487d95a3770298ef6712_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cd78f083d3d4b31a05c871b74ccd486_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d0a7130850648eab89a8d43a4c1ce07_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia157657bf6274daf9ecad3067cda452b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f6f203285f84a9cbfbb59ef13288eed_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eedb204e8ae4bd78694426f6de765ea_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i095e80c2be4542a187a6b71e2c8912a8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia36947927580425597efbfc7d9f7b2f4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc0f9c53c619457c8f7d4a6e8c2e7bd8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadfb87bf8c0c4c87b3a3c4f7ac571e08_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e2a29906d48436bb130104a234b2747_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccd28932ec064ace80e89c8bc1d8e174_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b018026854c4fe38de8981410c77132_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36d5eba90bd24be5bcb0bc0710b286df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6f9bdaf73bf44fd8daa2e9dab7b62d7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fcff3c7939a4cfb982b7424fcde9b5c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62ae858d67e14b07a24b5f0253cb996d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b40220e05cd4b1b8d17422a7fcc2436_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2db4a258dcb471894674a74f87706e3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb8496c939a64c02bd82917d2197df9e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56d4e08f2ddf42d38ac10990bd19ec5b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a81a2a7282d4109b94562c6de746780_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30a9b5385be843b8be329d54dfcdc192_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b98eb7a2f97454dad8515edac4bcb72_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cdna:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:AlloSureKidneyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d63bba5fe4f40ce95ab4d66330c93ad_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cdna:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:AlloMapHeartMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bb05103813e4dd493ad38b4d1893919_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:AlloSureHeartMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cdna:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaefdfbd1b7ec4bf389377b07e872b922_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cdna:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:AlloSureKidneyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>cdna:Claim</xbrli:measure></xbrli:unit><xbrli:context id="i784e3baffdcb4192964759f0c56d78ad_D20210501-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cdna:MiromatrixIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf4af37bc739426e912a71dac9ba281d_I20180131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patient"><xbrli:measure>cdna:patient</xbrli:measure></xbrli:unit><xbrli:context id="iab7d98285c4b4d9ea5dd55cf1942b127_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdna:XynManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="unique_solution"><xbrli:measure>cdna:unique_solution</xbrli:measure></xbrli:unit><xbrli:context id="i696a715cb3c04fb38124dcb7c37602f8_I20220414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdna:AtTheMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaeec918b90c4ba5bb1acfd6106ce79b_D20220414-20220414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdna:AtTheMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-14</xbrli:startDate><xbrli:endDate>2022-04-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i13b9c2985d5d4d1e9ce7abfd085614c5_I20221203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcd6a13ba0f945cbb58e45d6f9688338_D20221208-20221208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-08</xbrli:startDate><xbrli:endDate>2022-12-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a52955612044b80bdc44719634b8f15_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cdna:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00bf0bbaedf542d7bd5c59ac9504d720_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cdna:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i380c3aacb19e456dab0fbafc4081feb5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cdna:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if08f4ea8cdfd44269e800431266d73fc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cdna:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a65e524e31741e4b69720fd09cbf601_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i739a68ac0826477da4feb1f814aab614_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff28c97b627c426b88f8092a57b829b0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdna:EmployeeAndNonEmployeeStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia352f8b90bf24904ace711c2756fde74_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdna:EmployeeAndNonEmployeeStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98353659a42b486aba5e86487dd2ed3a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dbca87d33d445efa90f6f1256c6c729_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i916c5dbd66ef41e99dfbf453408341f9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd28b8c71bc54b94ac5b492390a28cbd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6feff843c95d4820a893f80a14e8974a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83fa354129c74d06b48b4acdeb58085e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i954505cbda704b1997a446ed7dc5bd79_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d197e2a742549a0b82fa9569fafad92_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78df972b73c44af19aec5841bf4e9ad2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c8f35fd17864198ae29d7c623d57285_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4eb3ec4739c24023b02eae3760c24976_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6385983faf6b4ce4907f11e0e0784a5a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i982c944f16354821a3a11af57a4d12f5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d76a02eaa334c0ca21f02a12b008068_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6e9038b180d4f5f9f7579ef703bdcc8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe1d6bd783044aa7ae7f1fa51bf4c2df_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78142f02b6eb4ccfb1656d6f5f294a1d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i802bf2c987da4c38af0138cb12b63a7a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie661294c5d0d4cd39e08f501d3969965_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9400f589c5241c0a57ababdfed3f710_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a757ccddcac4f5d8f4be791fe555e95_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9b3c2ab35bb493688fa7d78b10d9620_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1ba9d00e75545f2a72fabc1672b6a66_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f8db3692ea64671bcb30a21ef69e03c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4021690bcfc849d6bf7e8343dba5b82b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i548930b493bb4158a0dbc5d41dc95b2c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7530e38c229d4e808c0bcbedf20ea6e4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4527e5b34bee42669774ad27f3195476_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5c804bdf4f040aca96273d8934d4389_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cdna:CommonStockWarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76877b7701634ea681c1e7599813ad95_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cdna:ContingentConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d7cf5ad6102439bacdb4213332c001a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia96d97ee1a464c7ca2c6ded0200614bc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84b41750f227461d843bbebd7625f870_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i205add77cb4a43d28264c36e6bb99b5e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i326a94ee25204ee282ab17ca652c83d6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3863806f5974329a5f25691cef5e10f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69def961a87843fcb2b9a4f9b65fc946_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5655b5a1a84d4b98979a99a6db9e0ff2_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdna:HLADataSystemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdna:HLADataSystemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e8dea3df85a402dbf74f31228595f6c_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdna:HLADataSystemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib370105b87eb4834ba579147ac153394_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdna:HLADataSystemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58e73d1a09944b02869b176e945eb1ef_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdna:HLADataSystemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd80e498ad9d43fcaa85af5f97ce31df_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdna:HLADataSystemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i354e7a3f27e044eab26ae4b1d2cde545_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdna:HLADataSystemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fe8183fbe32453d99cc54713eadebe2_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdna:HLADataSystemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib01dc638da5843b694334d2ca357325f_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdna:HLADataSystemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2fc3487bfd640a096722284a0d737e0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cdna:AcquiredAndDevelopedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2aa30743f4a44b15900e7f593b2ae88b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cdna:AcquiredAndDevelopedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82959e331a5e485bbf7ae6493073076f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9bc39941c984943b121612207ca37ea_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81dc9074721e44aba01ef41b26358b4c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cdna:CommercializationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacaeaa220cfc409e84deae3b9074cbe5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cdna:CommercializationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if342038ec26148cfaed98ce1574cd8a0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0036ec09081944e38ff9a50586cb6917_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6ec54cc1d354dcc992a0bee7218aeb2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cdna:AcquiredInProcessTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a7b81e566d3418c8a4da63e000dd0da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cdna:AcquiredAndDevelopedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefc3516196544bbba967fcfe05accd44_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cdna:AcquiredAndDevelopedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia62355ec8eeb43cb853e7e57dc207494_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib827b41ea375450e89bc78d2c9d5f1e8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib63ef863071a4109a09043df7d31f2f0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cdna:CommercializationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d9134ab3e244582ae611652d1ce3c6e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cdna:CommercializationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5e54691c1394d72bf91f3d75605544b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6c57f7627c542678d43812cf1f234ae_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if016caa1aa6b4d3e9e03eaa31d2e3b97_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cdna:AcquiredInProcessTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie657b500f633441d881331275caa19f4_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia89f50d5989f473cbde4f16140a46923_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cdna:AcquiredAndDevelopedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c08b28aa3d0463a87a6374e3e679813_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cdna:CommercializationRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ecfb95f5ca641be8f0f195a6fa22f65_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15c9947ac20a442e90a185154951f24c_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i857e050dfe06462ebf29ac3ad1bbd400_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f9048fade524f0d937582e2d0737bbd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">cdna:CostOfTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8d2b80178a040808832e847918f0f37_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">cdna:CostOfTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5130eca1ccf4f738a701a55a747d5d9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">cdna:CostOfProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb4b7444c8a54bf5b1e67a533d029b35_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">cdna:CostOfProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i538eccbc464c49cd93e1c60f3af790b5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">cdna:CostOfPatientAndDigitalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id192b96ed2d2443395a41393430289fe_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">cdna:CostOfPatientAndDigitalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb5085de4360418c9f60a706e826ebd0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2bb0753ed6b4970916acf1662850bff_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a267b7775a54bb9a849620727f55b45_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">cdna:CostOfTestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i283ae31574f24307803aaab45920bc0e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">cdna:CostOfProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i369258cc427d43d7bd2ea30b3bff4f3c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">cdna:CostOfPatientAndDigitalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86b184c24c09473f91a3c5a799e0ecaf_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57bbabe758fa4226abdab65dc6f55edf_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5afb8931ba0448dfa451bb6fd9433b11_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ea7fda0a4594bc7876d19e0b646c9d4_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f5640bdc5dc463690fc0aee32a95b31_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i195cf846109945d0a76d6e7ce2543162_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53037b4e60e34295bb200d6c520f42c0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cdna:LeasesCommencedInJuly2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70089bac7d1149d68e8faf8be4a0818a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cdna:LeasesCommencedInJuly2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0938e8abbbf424194441e38319e63da_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cdna:LeasesCommencedInAugust2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38fbe91f8cb446a1a44ae2e5489e72d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cdna:LeasesCommencedInAugust2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49912c99c82e4c2a9d7a1da7ab8fdcfa_D20140601-20140630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-06-01</xbrli:startDate><xbrli:endDate>2014-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="milestone_payment"><xbrli:measure>cdna:milestone_payment</xbrli:measure></xbrli:unit><xbrli:context id="ib4b52828eb9044d3949685e3c2d4b00d_D20220307-20220314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cdna:CAREDXINCVsNateraIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-07</xbrli:startDate><xbrli:endDate>2022-03-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b275c7553774ac3ac576327338fbb57_D20220307-20220314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cdna:CAREDXINCVsNateraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cdna:CompensatoryDamagesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-07</xbrli:startDate><xbrli:endDate>2022-03-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33ad911706e74747a0d127ced9ed8f7c_D20220307-20220314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cdna:CAREDXINCVsNateraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cdna:PunitiveDamagesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-07</xbrli:startDate><xbrli:endDate>2022-03-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd7b677ac2f44bbba944e499e4c5e1c2_D20220513-20220513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cdna:CAREDXINCVsNateraIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-13</xbrli:startDate><xbrli:endDate>2022-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="complaint"><xbrli:measure>cdna:complaint</xbrli:measure></xbrli:unit><xbrli:context id="i0ee630c440d5470482172c2d5805345d_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i445ae0f9731748a8a1bcab34010dc63a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id490782a3afe4f6a9743acac4922431f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff2ee009736640978c0e8cdec25086bf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12f532855bf14a43998b04ac7db3ddfd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i565db6f072c74a3dbfeac9d900d2d797_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2b2e52a6bb948f2b6b0826f266d5493_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26d6663b7c774332a4c9fa15e23e3b34_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdna:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7773cc52f31449008e2a2da976fb5dbc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdna:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40b3e213d2c44ed3bf2769319aee962b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdna:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e23905672f3405495bcc17dd04c3467_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia24f76f7b5ed46cf96e628a538a6e320_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i404725fbc6564a3193b67907dbbe80e6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4783302274d944709ef6bd9aac018c00_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b063cbad6df47aeadbd66f77725b34e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a8e83ffc79746499f241de17f14762c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfc21a0301ce4966b0e2d787749a63dd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4085e2e2596a4c689ebf01b80b2c5c82_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f7a16d338ed4ab3939bc3f47e6c75cf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ab6496f097a4ebc957f05bf6f2a67a7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39f90c981a414baca25472855eb286a8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cdna:RestOfTheWorldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic03e1001adae4271911ad4bdce2d0981_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cdna:RestOfTheWorldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id58767c1d8084713916edd6596399012_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15533108dd8044e8a8072baeebce60f2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c59122b69b444ae819cdc8aae3be5b9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c618998e62f418a831eb3095a8a2c36_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec20c3548df44cde8bb311b72dae19bd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cdna:RestOfTheWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i441bbf95c9a74c9f8bcc5339145c212a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cdna:RestOfTheWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a6d052a98b04c87b9036941a8a6a5c8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:PatientAndDigitalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i128a8bcd322647b8a897eae3a619355d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:PatientAndDigitalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccd964cbefaa49e2a61aabfee7302e19_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:PatientAndDigitalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeaf539bfe39471ba59a24aa7f4ce0e0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:PatientAndDigitalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcc6d18dcb4b4287b16ec15dafbee2d7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:PatientAndDigitalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cdna:RestOfTheWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib52598d086dd497d8f54897e6cabc808_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:PatientAndDigitalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cdna:RestOfTheWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1620b425a8304d7d9b96f7bafd09516e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b98c1259e7b4de198ec8628fc9720f5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8553922693ab40cfadd6ab80368405fe_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i233add0bbd014f5982408f02ff0d7cef_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic034aa3435224d08892ec111ab99fe01_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cdna:RestOfTheWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7961f0ef0c9b4553b4637f426c4f87c8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cdna:RestOfTheWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61c592955b9b4fce84fc074131d238b5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i877626f277b84c4c83cb6ce132b835a6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0849fd3f28ca472abc8fd430de00bd14_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fd093ee1cfc4c4d8bbb09c7524ee14b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa00d894ab6f41268315eb34dc054cd4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cdna:RestOfTheWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac91ecb914ad42ab9e94c27584c8b7a8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001217234</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cdna:RestOfTheWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="idd35c15ee381485cb38f052732749537_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">__________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNTAx_a13b1806-f00e-47a0-ab86-825c05641251">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">__________________________________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGFibGU6ZjU1NjBjNGI5MzllNDJlZWE0Nzg5MmMzMDdhZmY0MzEvdGFibGVyYW5nZTpmNTU2MGM0YjkzOWU0MmVlYTQ3ODkyYzMwN2FmZjQzMV8wLTAtMS0xLTk1MTMy_490b2e52-9d6c-49ba-8315-4a980801ca28">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yMzQ_58e7403a-6302-41df-8969-a4a9e15dbdc5">March&#160;31, 2023</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGFibGU6ZWQ4MDczYzY2OWFkNGU5ZDljOGZjOGE5NjIxMTU4MjgvdGFibGVyYW5nZTplZDgwNzNjNjY5YWQ0ZTlkOWM4ZmM4YTk2MjExNTgyOF8wLTAtMS0xLTk1MTMy_7c2c9441-e137-4c7a-bae0-fae703a6eb6a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNTAy_bc3418ab-c0c6-4ffe-bbe1-d73d31d1b061">001-36536</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">__________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNTA1_59cab145-7281-4c42-8d28-f784b107cae8">CAREDX, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">__________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.113%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGFibGU6MDU3ZDJmNWUwZTgyNGUzNGExMGNkODNhN2E1ZTk5NjgvdGFibGVyYW5nZTowNTdkMmY1ZTBlODI0ZTM0YTEwY2Q4M2E3YTVlOTk2OF8wLTAtMS0xLTk1MTMy_897828c6-44e9-4dc6-b87c-7a84a86bdf02">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGFibGU6MDU3ZDJmNWUwZTgyNGUzNGExMGNkODNhN2E1ZTk5NjgvdGFibGVyYW5nZTowNTdkMmY1ZTBlODI0ZTM0YTEwY2Q4M2E3YTVlOTk2OF8wLTItMS0xLTk1MTMy_37ecbc7b-5548-4fbe-a0e0-ce9cf45df568">94-3316839</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNTA2_ab723096-d43b-4ec5-a291-0ec51b6fccd0">8000 Marina Boulevard, 4th Floor</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNTAz_50d15be8-2714-412d-af61-ac5f70e7e097">Brisbane</ix:nonNumeric>, <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNTEw_baecf137-3fd7-423a-874c-151be9a8cd0b">California</ix:nonNumeric> <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNTEx_512a8176-af07-4b27-8588-0297b6afb1dc">94005</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNTEy_3d958ca2-42dc-4047-8223-c5b81a6e86c2">415</ix:nonNumeric>) <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNTA0_b6c27122-523b-4436-a9ad-5544a4a079f3">287-2300</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">__________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.294%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGFibGU6OTg3ZWM4NGIyZDcyNDY2YWFhZTJmOTE4MmRiYzdlOGEvdGFibGVyYW5nZTo5ODdlYzg0YjJkNzI0NjZhYWFlMmY5MTgyZGJjN2U4YV8xLTAtMS0xLTk1MTMy_85eeabb5-2236-4833-b4ed-217c2357e6e5">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGFibGU6OTg3ZWM4NGIyZDcyNDY2YWFhZTJmOTE4MmRiYzdlOGEvdGFibGVyYW5nZTo5ODdlYzg0YjJkNzI0NjZhYWFlMmY5MTgyZGJjN2U4YV8xLTEtMS0xLTk1MTMy_24bb5a34-4ce4-4070-a817-f0889814f941">CDNA</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGFibGU6OTg3ZWM4NGIyZDcyNDY2YWFhZTJmOTE4MmRiYzdlOGEvdGFibGVyYW5nZTo5ODdlYzg0YjJkNzI0NjZhYWFlMmY5MTgyZGJjN2U4YV8xLTItMS0xLTk1MTMy_aabf1cda-4d9c-42e4-9c87-2a776b67edfd">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;<ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNDk5_34f983c7-67be-44c0-8ae5-8b29890f1191">Yes</ix:nonNumeric> &#9746;&#160;&#160;No &#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNTA4_82bf3bef-7dbf-44c7-b4e7-6b3b2f1d8891">Yes</ix:nonNumeric> &#9746;&#160;&#160;No &#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2&#160;of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.735%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGFibGU6ZTBmNGRkOWQyZTQ2NDQxN2E3ZjkwMzg1OTJiMDk0YzYvdGFibGVyYW5nZTplMGY0ZGQ5ZDJlNDY0NDE3YTdmOTAzODU5MmIwOTRjNl8wLTAtMS0xLTk1MTMy_69cfaa80-f084-41b2-8fda-4661b1979830">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGFibGU6ZTBmNGRkOWQyZTQ2NDQxN2E3ZjkwMzg1OTJiMDk0YzYvdGFibGVyYW5nZTplMGY0ZGQ5ZDJlNDY0NDE3YTdmOTAzODU5MmIwOTRjNl8yLTQtMS0xLTk1MTMy_7d0df442-2246-453e-98ba-686b675f81a1">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGFibGU6ZTBmNGRkOWQyZTQ2NDQxN2E3ZjkwMzg1OTJiMDk0YzYvdGFibGVyYW5nZTplMGY0ZGQ5ZDJlNDY0NDE3YTdmOTAzODU5MmIwOTRjNl80LTQtMS0xLTk1MTMy_77ee0d1f-1ad3-418c-b5dd-c6785fb99f76">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;Yes &#9744;&#160;&#160;No <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNTA5_f49b6edb-3788-4a58-b3fd-f2b42bf393bd">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="shares" contextRef="ia0cc34f656aa40379ccfb7e710773180_I20230508" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNDI0_2bc422e3-f555-439c-94be-b459ecbf1ece">53,793,067</ix:nonFraction> shares of the registrant&#8217;s Common Stock issued and outstanding as of May&#160;8, 2023.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="idd35c15ee381485cb38f052732749537_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CareDx, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:89.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.257%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page No.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd35c15ee381485cb38f052732749537_10">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_13">Item 1. Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd35c15ee381485cb38f052732749537_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_16">Condensed Consolidated Balance Sheets as of </a>March&#160;31, 2023<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_16"> and </a>December&#160;31, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd35c15ee381485cb38f052732749537_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_19">Condensed Consolidated Statements of Operations for the </a>Three<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_19"> </a>Months <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_19">Ended </a>March&#160;31, 2023<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_19"> and </a>2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd35c15ee381485cb38f052732749537_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_22">Condensed Consolidated Statements of Comprehensive Loss for the</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_22"> </a>Three Months Ended</span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">March&#160;31, 2023<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_22"> and </a>2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd35c15ee381485cb38f052732749537_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_25">Condensed Consolidated Statements of Stockholders&#8217; Equity for the </a>Three Months Ended</span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">March&#160;31, 2023<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_25"> and </a>2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd35c15ee381485cb38f052732749537_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_28">Condensed Consolidated Statements of Cash Flows for the </a>Three Months Ended<br/>March 31, 2023<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_28"> and </a>2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd35c15ee381485cb38f052732749537_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_31">Notes to Unaudited Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd35c15ee381485cb38f052732749537_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_82">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd35c15ee381485cb38f052732749537_82">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_112">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd35c15ee381485cb38f052732749537_112">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_115">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd35c15ee381485cb38f052732749537_115">49</a></span></div></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_118">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd35c15ee381485cb38f052732749537_118">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_121">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd35c15ee381485cb38f052732749537_121">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_124">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd35c15ee381485cb38f052732749537_124">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_127">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd35c15ee381485cb38f052732749537_127">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_130">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd35c15ee381485cb38f052732749537_130">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_133">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd35c15ee381485cb38f052732749537_133">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_136">Item 5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd35c15ee381485cb38f052732749537_136">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_139">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd35c15ee381485cb38f052732749537_139">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_142">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#idd35c15ee381485cb38f052732749537_142">68</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="idd35c15ee381485cb38f052732749537_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="idd35c15ee381485cb38f052732749537_13"></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="idd35c15ee381485cb38f052732749537_16"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CareDx, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.014%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMy0xLTEtMS05NTEzMg_840e10cf-893c-47ee-838a-7d89ffbcf525">74,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMy0zLTEtMS05NTEzMg_da0f02e7-662d-4e4e-bd1f-75bf1b8daa7c">89,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfNC0xLTEtMS05NTEzMg_264a5fbc-9249-4d0e-8797-ef8231cdc08d">211,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfNC0zLTEtMS05NTEzMg_9ee8d728-d799-46d7-a6e6-cca62aef2f8f">203,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfNS0xLTEtMS05NTEzMg_30eaca67-d530-4b9b-83ae-db4600d4df3b">59,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfNS0zLTEtMS05NTEzMg_19a32e91-e9e2-4cb5-83bd-98c77d7a70f3">66,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfNi0xLTEtMS05NTEzMg_dd7dfaa6-5668-4c19-b1aa-e30aa97168f3">18,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfNi0zLTEtMS05NTEzMg_3eb6ea2e-ef5b-4c9f-a22f-d1c471d0f8ac">19,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfNy0xLTEtMS05NTEzMg_8e5ad845-a13f-462a-a557-bbf088027d26">8,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfNy0zLTEtMS05NTEzMg_4de65782-fe35-4766-9e22-543253f3d793">9,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfOC0xLTEtMS05NTEzMg_7ee9e63b-23c1-410d-96f2-af312d1b3951">371,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfOC0zLTEtMS05NTEzMg_d52d0cd2-334f-4f83-be70-69f6a4a8cc64">387,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfOS0xLTEtMS05NTEzMg_0098751f-7f85-4410-8007-4a386ad621b8">35,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfOS0zLTEtMS05NTEzMg_86bf74b6-8c35-4f3f-865f-acf178ab8048">35,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTAtMS0xLTEtOTUxMzI_05dea15d-e913-4236-befe-780d27536c49">33,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTAtMy0xLTEtOTUxMzI_5b48360c-9f61-454d-9d14-0995a2cdc4af">34,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTEtMS0xLTEtOTUxMzI_45a38ba8-b679-49f8-921a-ece66885a7be">45,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTEtMy0xLTEtOTUxMzI_fff2848c-f71e-4631-ae6a-299541b13e25">43,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTItMS0xLTEtOTUxMzI_cb75648d-ad15-4312-8b57-6f36b5930e76">39,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTItMy0xLTEtOTUxMzI_77c1e9ba-8eb4-483d-a25b-a43cceeb8800">37,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTMtMS0xLTEtOTUxMzI_adf0097c-5e1a-4c93-aaa7-448262749ce4">520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTMtMy0xLTEtOTUxMzI_3b6f66e9-251e-4708-b634-2e10b40558c3">522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTQtMS0xLTEtOTUxMzI_0b4cf103-5f66-495d-bafb-bb5ecea4ef2e">2,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTQtMy0xLTEtOTUxMzI_693c26eb-9637-4a9d-9d7b-b8c1bd534461">3,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTUtMS0xLTEtOTUxMzI_de1376a7-876b-4e40-ada1-a670a9e1cf7e">528,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTUtMy0xLTEtOTUxMzI_09e3dbb0-3c7f-48fc-86c0-97ba36ceb4bc">542,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTgtMS0xLTEtOTUxMzI_64233050-5ff2-4349-9ca7-412ee69a71cd">12,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTgtMy0xLTEtOTUxMzI_826d293f-2975-47f2-839e-0a40db34048a">9,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTktMS0xLTEtOTUxMzI_0322e3af-615d-4857-89e1-af9227986f7d">12,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTktMy0xLTEtOTUxMzI_2a81853b-0a87-4d46-b665-65b2aa33edf9">16,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjAtMS0xLTEtOTUxMzI_79e3a2b0-91ae-4527-99f5-0ff06a981900">46,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjAtMy0xLTEtOTUxMzI_7fef1ff0-388a-446c-82db-3c8d3a321067">49,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjItMS0xLTEtOTUxMzI_3bc95966-4b2e-494c-9179-036d3750f7de">71,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjItMy0xLTEtOTUxMzI_f56dc911-8d21-4825-b038-b1735277ae27">75,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjQtMS0xLTEtOTUxMzI_c2102a0d-933f-4196-9482-98112de994d3">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjQtMy0xLTEtOTUxMzI_0b70c6cc-435b-4b38-94ae-47cd9f096789">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred payments for intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="cdna:DeferredPaymentsForIntangibleAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjUtMS0xLTEtOTUxMzI_38a8dace-863d-4e91-8128-045b9ec3a864">4,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="cdna:DeferredPaymentsForIntangibleAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjUtMy0xLTEtOTUxMzI_5c95f1b2-599e-404d-9da4-14da2860625d">2,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, less current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjYtMS0xLTEtOTUxMzI_151157e0-0901-4d82-b986-e25cedb66530">32,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjYtMy0xLTEtOTUxMzI_dfc8b515-943a-4f4e-b462-12963e29311f">33,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjctMS0xLTEtOTUxMzI_3b27a433-c1d4-4fdb-8932-d8d297d7cb6f">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjctMy0xLTEtOTUxMzI_12c35c1e-a55a-4a3b-9a45-389512941f47">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjgtMS0xLTEtOTUxMzI_7f775939-dabf-497f-93a9-987e158797ba">108,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjgtMy0xLTEtOTUxMzI_00ebeb8b-bea9-4f4a-b886-9c0bce45a7ed">112,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 9)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjktMS0xLTEtOTUxMzI_ae435f2e-1b37-4fd2-b69e-c8431f0c19cc"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjktMy0xLTEtOTUxMzI_386bea72-0abb-4292-b7dc-3a68659fce13"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock: $<ix:nonFraction unitRef="usdPerShare" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzEtMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjpmNTg4MmQ1Y2VhYWM0MzY4YTgwNjEwN2RhYmI5ZWZlY18yMg_c8c9a7f8-340e-4641-a2ca-bc0f8d817cad"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzEtMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjpmNTg4MmQ1Y2VhYWM0MzY4YTgwNjEwN2RhYmI5ZWZlY18yMg_d34136f6-050b-4adf-97f3-e270018817f3">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzEtMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjpmNTg4MmQ1Y2VhYWM0MzY4YTgwNjEwN2RhYmI5ZWZlY18zNg_50f0a352-2b8c-45db-a02c-a6b0478d5d56"><ix:nonFraction unitRef="shares" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzEtMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjpmNTg4MmQ1Y2VhYWM0MzY4YTgwNjEwN2RhYmI5ZWZlY18zNg_98900e18-f3b0-4d7a-9ee6-6c9aba65c06c">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2023 and December&#160;31, 2022; <ix:nonFraction unitRef="shares" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzEtMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjpmNTg4MmQ1Y2VhYWM0MzY4YTgwNjEwN2RhYmI5ZWZlY183MQ_2703c27c-33d6-4a17-bba9-9a2f9db7ebde"><ix:nonFraction unitRef="shares" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzEtMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjpmNTg4MmQ1Y2VhYWM0MzY4YTgwNjEwN2RhYmI5ZWZlY183MQ_5244fe44-8eb9-4254-acca-db2e9b9c5481"><ix:nonFraction unitRef="shares" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzEtMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjpmNTg4MmQ1Y2VhYWM0MzY4YTgwNjEwN2RhYmI5ZWZlY183MQ_9058c1c5-1959-4974-a831-a99b1bb1facf"><ix:nonFraction unitRef="shares" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzEtMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjpmNTg4MmQ1Y2VhYWM0MzY4YTgwNjEwN2RhYmI5ZWZlY183MQ_ffc5b428-b8a1-4192-8dbe-67885624bdc4">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzEtMS0xLTEtOTUxMzI_95b8b180-455e-4d5b-b67e-78cb28f3eed7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzEtMy0xLTEtOTUxMzI_b6b0cd48-1c07-45f8-864e-63aef39807f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock: $<ix:nonFraction unitRef="usdPerShare" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzItMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjphYzRiYTI4NTZhYjk0MDM1OTM2ZjExNmU4ODQ2MzdiMl8xOQ_24df2855-d117-4c01-8f0d-a347018ac1d2"><ix:nonFraction unitRef="usdPerShare" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzItMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjphYzRiYTI4NTZhYjk0MDM1OTM2ZjExNmU4ODQ2MzdiMl8xOQ_d51a9bd3-5be2-47c1-8a3d-81b68d6ec066">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzItMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjphYzRiYTI4NTZhYjk0MDM1OTM2ZjExNmU4ODQ2MzdiMl8zMw_00291993-fba0-4c47-9f4f-cab3ba22e154"><ix:nonFraction unitRef="shares" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzItMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjphYzRiYTI4NTZhYjk0MDM1OTM2ZjExNmU4ODQ2MzdiMl8zMw_784e37cd-339b-498d-bb80-98315f662d03">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2023 and December&#160;31, 2022; <ix:nonFraction unitRef="shares" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzItMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjphYzRiYTI4NTZhYjk0MDM1OTM2ZjExNmU4ODQ2MzdiMl82OA_4bf42e20-b729-423c-9eee-7ab87040eebf">53,712,654</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzItMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjphYzRiYTI4NTZhYjk0MDM1OTM2ZjExNmU4ODQ2MzdiMl84Mg_c8c54ddc-9514-4c4b-912c-796447295bc3">53,583,301</ix:nonFraction> shares issued at March&#160;31, 2023 and December&#160;31, 2022, respectively; <ix:nonFraction unitRef="shares" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzItMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjphYzRiYTI4NTZhYjk0MDM1OTM2ZjExNmU4ODQ2MzdiMl81NDk3NTU4MTQwOTU_a0feb40f-cd74-4ae5-8e74-0ca91d212bb2">53,653,182</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzItMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjphYzRiYTI4NTZhYjk0MDM1OTM2ZjExNmU4ODQ2MzdiMl81NDk3NTU4MTQxMDM_92e9b0ad-62fe-4ae9-bac3-6b21d1693b8b">53,533,250</ix:nonFraction> shares outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzItMS0xLTEtOTUxMzI_a3eb8c45-ebc3-447d-b465-032ccf52963d">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzItMy0xLTEtOTUxMzI_cbaa5f28-a9c8-4fcb-9b92-97ad52ce5ec9">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzMtMS0xLTEtOTUxMzI_092f3d7e-b5ca-4d78-b215-7fca6551727f">912,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzMtMy0xLTEtOTUxMzI_b81d14ad-5ab9-41f6-aff4-ba01ccff2cce">898,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzQtMS0xLTEtOTUxMzI_5725fc85-e06c-4abe-89c2-02c37397204b">7,439</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzQtMy0xLTEtOTUxMzI_2b63a18c-94e9-4e65-8cf2-1fc7b835fd03">7,503</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzUtMS0xLTEtOTUxMzI_e98df74c-7fac-4b99-a1a1-49def63e827d">484,883</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzUtMy0xLTEtOTUxMzI_0ff6e738-193a-43f6-b44e-cb3c783761f8">460,444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzYtMS0xLTEtOTUxMzI_ab37c2ae-2d88-4db5-bd98-edf041f38eff">420,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzYtMy0xLTEtOTUxMzI_b3380ab0-6707-43dd-b4c1-51dd4629bc1f">430,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzctMS0xLTEtOTUxMzI_e6ae08c2-3b51-40ce-9114-4c117a430578">528,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzctMy0xLTEtOTUxMzI_cb295d22-fe6e-41c1-9c2b-9e4ff203693a">542,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="idd35c15ee381485cb38f052732749537_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CareDx, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:72.832%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.552%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.554%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Testing services revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6522c13470244b44971d6dd1d0a8251b_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMy01LTEtMS05NTEzMg_6f1165f4-37c6-4f2a-a999-3ab9d325002e">61,784</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68b6550537c1477c960fc12e49544478_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMy03LTEtMS05NTEzMg_4d48ae9b-9684-4670-9443-3f7fcc1a1956">66,444</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaaeba5a92a4430cb59489d292860cd5_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfNC01LTEtMS05NTEzMg_e0f27458-19bd-401f-b254-0d170863a7d8">6,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44565fb103943ffa2a40292b86d6156_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfNC03LTEtMS05NTEzMg_1b8d142e-945f-4fe5-8182-5e322d7c2822">6,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient and digital solutions revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b1a5c19190949f3825408e0497964b7_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfNS01LTEtMS05NTEzMg_b02b96e0-1e87-48e2-be72-dc8dd053f599">8,617</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5765e29984cc4e398fbf04608384a068_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfNS03LTEtMS05NTEzMg_c8baaaf6-2a41-4033-b606-4590688b7f31">6,184</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfNi01LTEtMS05NTEzMg_4652c80a-4aad-46e9-9856-5e0cbd639241">77,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfNi03LTEtMS05NTEzMg_1f0fe443-a4a0-41a1-9b3e-5f7f279ea24a">79,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of testing services</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6522c13470244b44971d6dd1d0a8251b_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfOC01LTEtMS05NTEzMg_38e37670-cfb8-4a9c-bd7b-55a8dc5b0432">15,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68b6550537c1477c960fc12e49544478_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfOC03LTEtMS05NTEzMg_f3ae3f46-0b62-41b2-809d-b86e4edabfe1">17,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaaeba5a92a4430cb59489d292860cd5_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfOS01LTEtMS05NTEzMg_cccc6396-9310-4301-b184-2343b15c695a">4,066</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44565fb103943ffa2a40292b86d6156_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfOS03LTEtMS05NTEzMg_968d2b51-b2f3-412b-ae0b-3ac1b0f16e22">4,399</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of patient and digital solutions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b1a5c19190949f3825408e0497964b7_D20230101-20230331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTAtNS0xLTEtOTUxMzI_79d21c79-bc7c-4238-8bc1-49fc67e951a0">6,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5765e29984cc4e398fbf04608384a068_D20220101-20220331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTAtNy0xLTEtOTUxMzI_9c1743c0-73d1-4855-bd9e-04b54087e693">4,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTEtNS0xLTEtOTUxMzI_fdca3197-c4a3-40a5-910c-86bf217ac86c">24,357</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTEtNy0xLTEtOTUxMzI_a2199987-f0fb-47c9-95f3-29631577f2da">21,880</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTItNS0xLTEtOTUxMzI_61427c34-7ad7-4a33-ad83-bcb181affa1d">23,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTItNy0xLTEtOTUxMzI_01dd931f-28a3-47fc-9903-bfccc26bd089">23,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTMtNS0xLTEtOTUxMzI_a3ca07a1-7713-4b18-9785-9074d99a657b">28,032</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTMtNy0xLTEtOTUxMzI_120ba1c5-a889-47b3-be56-7dbc6b53161f">26,559</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTQtNS0xLTEtOTUxMzI_61f4238d-8e7f-4139-b30e-0e9cdc167729">101,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTQtNy0xLTEtOTUxMzI_0e9f9bdf-7473-41b0-809a-b1c8c3cc1f00">98,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTUtNS0xLTEtOTUxMzI_1b5d43d2-7beb-4a02-90ee-ea4121034521">24,324</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTUtNy0xLTEtOTUxMzI_2a1f3990-97e1-47f8-b7b7-ed02d2d3aa2e">19,053</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTctNS0xLTEtOTUxMzI_a4567702-0af0-40c4-874c-de90b6aad54d">2,666</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTctNy0xLTEtOTUxMzI_7b48f8eb-dc5b-45ca-a534-cf6bd79235f4">189</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in estimated fair value of common stock warrant liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTgtNS0xLTEtOTUxMzI_dce63d5d-6100-434a-b550-a6643d15941f">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTgtNy0xLTEtOTUxMzI_a6dba46b-a239-4c92-8c6e-02a5e962f36d">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTktNS0xLTEtOTUxMzI_4cf169c3-bfde-4fe2-8430-fa23a3122acc">1,974</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTktNy0xLTEtOTUxMzI_b0429845-7965-4dc8-bdeb-5401d5838c0a">823</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjAtNS0xLTEtOTUxMzI_202f4b85-fa48-4f25-8d03-403dfad27ccd">699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjAtNy0xLTEtOTUxMzI_253c4d86-1264-4414-b735-ebfce4df2a56">607</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjEtNS0xLTEtOTUxMzI_80fef415-a6de-416e-85a0-a1c8aa2d7217">23,625</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjEtNy0xLTEtOTUxMzI_55557c6d-b8c4-434e-bd66-a641b6780974">19,660</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjItNS0xLTEtOTUxMzI_768114ed-c76c-49dd-960e-f781072e4d58">124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjItNy0xLTEtOTUxMzI_1e5315c3-2d1c-4d95-8877-9737930c6bc7">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjMtNS0xLTEtOTUxMzI_b05a76e0-9bf8-4620-9a6f-af3d3bbeb9b5">23,749</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjMtNy0xLTEtOTUxMzI_72c5f981-b2de-4883-977a-415ef14a37ea">19,648</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share (Note 3):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjUtNS0xLTEtOTUxMzI_97a77087-675e-450c-a742-43a779c76aaf">0.44</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjUtNy0xLTEtOTUxMzI_7432d592-db73-4e60-b8d6-644ab7a178db">0.37</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjYtNS0xLTEtOTUxMzI_6aca73d2-944b-4b2a-9ce7-7deb0cbf63da">0.44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjYtNy0xLTEtOTUxMzI_c2ed815d-2846-4745-9253-cff8c229ab65">0.37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute net loss per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjgtNS0xLTEtOTUxMzI_aded7773-2f3c-4d28-afcf-9d97422b6749">53,643,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjgtNy0xLTEtOTUxMzI_8665af09-5fc9-4bcd-b0c6-de26dbc2e2d7">53,015,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjktNS0xLTEtOTUxMzI_58a83c1b-3c27-4d33-8c6d-5db261b53343">53,643,216</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjktNy0xLTEtOTUxMzI_bdc2c6c9-67f2-4e0c-86de-3f98c9ab44e2">53,015,459</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="idd35c15ee381485cb38f052732749537_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CareDx, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:72.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.534%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yMi9mcmFnOmM1ZTg2MWJiODczZjRlZjI4YjE4Y2UwZTgxY2VhYTAwL3RhYmxlOjU3ODAwY2U0MjBhNzQ0OGRiYTNlOTFiNDRlMGEwMzY0L3RhYmxlcmFuZ2U6NTc4MDBjZTQyMGE3NDQ4ZGJhM2U5MWI0NGUwYTAzNjRfMi0xLTEtMS05NTEzMg_0c6fd940-3339-4cd0-a680-c19ea9bdbe60">23,749</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yMi9mcmFnOmM1ZTg2MWJiODczZjRlZjI4YjE4Y2UwZTgxY2VhYTAwL3RhYmxlOjU3ODAwY2U0MjBhNzQ0OGRiYTNlOTFiNDRlMGEwMzY0L3RhYmxlcmFuZ2U6NTc4MDBjZTQyMGE3NDQ4ZGJhM2U5MWI0NGUwYTAzNjRfMi0zLTEtMS05NTEzMg_513461ef-3ade-4f71-a7f2-034e78f7e631">19,648</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net of tax</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yMi9mcmFnOmM1ZTg2MWJiODczZjRlZjI4YjE4Y2UwZTgxY2VhYTAwL3RhYmxlOjU3ODAwY2U0MjBhNzQ0OGRiYTNlOTFiNDRlMGEwMzY0L3RhYmxlcmFuZ2U6NTc4MDBjZTQyMGE3NDQ4ZGJhM2U5MWI0NGUwYTAzNjRfNC0xLTEtMS05NTEzMg_3af1b193-f221-495f-b206-49913e76d23d">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yMi9mcmFnOmM1ZTg2MWJiODczZjRlZjI4YjE4Y2UwZTgxY2VhYTAwL3RhYmxlOjU3ODAwY2U0MjBhNzQ0OGRiYTNlOTFiNDRlMGEwMzY0L3RhYmxlcmFuZ2U6NTc4MDBjZTQyMGE3NDQ4ZGJhM2U5MWI0NGUwYTAzNjRfNC0zLTEtMS05NTEzMg_45e45b85-918d-4587-b86e-24068c382325">420</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net comprehensive loss</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yMi9mcmFnOmM1ZTg2MWJiODczZjRlZjI4YjE4Y2UwZTgxY2VhYTAwL3RhYmxlOjU3ODAwY2U0MjBhNzQ0OGRiYTNlOTFiNDRlMGEwMzY0L3RhYmxlcmFuZ2U6NTc4MDBjZTQyMGE3NDQ4ZGJhM2U5MWI0NGUwYTAzNjRfNS0xLTEtMS05NTEzMg_a5e5b71e-f186-40f5-914d-6049b1220c61">23,685</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yMi9mcmFnOmM1ZTg2MWJiODczZjRlZjI4YjE4Y2UwZTgxY2VhYTAwL3RhYmxlOjU3ODAwY2U0MjBhNzQ0OGRiYTNlOTFiNDRlMGEwMzY0L3RhYmxlcmFuZ2U6NTc4MDBjZTQyMGE3NDQ4ZGJhM2U5MWI0NGUwYTAzNjRfNS0zLTEtMS05NTEzMg_e02632ee-05f8-4ccd-98b9-a4917d93134a">20,068</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="idd35c15ee381485cb38f052732749537_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CareDx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:37.248%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.378%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic611516b5add4872b60d9c652badf864_I20221231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMi0xLTEtMS05NTEzMg_514f49f5-b1bf-49ae-9db8-89a35cf599fc">53,533,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic611516b5add4872b60d9c652badf864_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMi0zLTEtMS05NTEzMg_40d434dc-1c6d-404d-ac83-2eab8290e2c9">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a6d44a3abca4ba3b4f503e0dcb0f387_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMi01LTEtMS05NTEzMg_df530501-7a14-465f-94d2-16feb1704cf6">898,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36c952509b554d799ce4307c24d429f4_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMi03LTEtMS05NTEzMg_1d4518a4-8bea-4423-9454-99aa1f1b3f20">7,503</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18517199530c487d95a3770298ef6712_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMi05LTEtMS05NTEzMg_bca27565-cfba-4312-ab2f-5a70ef0ca953">460,444</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMi0xMS0xLTEtOTUxMzI_cabc6cc2-b55f-4dce-835c-fdbf65447d81">430,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9cd78f083d3d4b31a05c871b74ccd486_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNC0xLTEtMS05NTEzMg_cc5afbd3-b936-4f1f-9c54-018525fa6bb0">47,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d0a7130850648eab89a8d43a4c1ce07_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNC01LTEtMS05NTEzMg_ebc66d5d-3eaf-4fb8-9ff3-277cce16c4c0">456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNC0xMS0xLTEtOTUxMzI_9fe5a070-4bc3-4f26-aa1e-13f38b872ff1">456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase and retirement of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9cd78f083d3d4b31a05c871b74ccd486_D20230101-20230331" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNS0xLTEtMS05NjE1NQ_020d44a1-eee9-4b45-a685-de2a679cff23">59,472</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia157657bf6274daf9ecad3067cda452b_D20230101-20230331" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNS05LTEtMS05NjE4NQ_28538cd7-fcfb-462d-a00c-bf4665fc8180">690</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNS0xMS0xLTEtOTYxOTI_55e8cef5-6234-410a-baa1-c35f02c58731">690</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RSU settlements, net of shares withheld</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9cd78f083d3d4b31a05c871b74ccd486_D20230101-20230331" decimals="INF" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNS0xLTEtMS05NTEzMg_50f6496f-867a-4480-b2bb-1a9cb39460b4">123,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d0a7130850648eab89a8d43a4c1ce07_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNS01LTEtMS05NTEzMg_c312679e-d3b5-44aa-a695-014407544200">785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNS0xMS0xLTEtOTUxMzI_dc6517e7-5520-40c8-a843-ba3009d6ae41">785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9cd78f083d3d4b31a05c871b74ccd486_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNi0xLTEtMS05NTEzMg_c842c48d-404b-4eae-a81a-96c61b1478f5">7,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d0a7130850648eab89a8d43a4c1ce07_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNi01LTEtMS05NTEzMg_7a0fb411-3c5d-435a-86e0-440f07f8fda5">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNi0xMS0xLTEtOTUxMzI_62eb1b48-b055-4feb-95e2-b97e9758673c">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9cd78f083d3d4b31a05c871b74ccd486_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNy0xLTEtMS05NTEzMg_82c920bf-3725-4426-ba14-49719f237039">820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d0a7130850648eab89a8d43a4c1ce07_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNy01LTEtMS05NTEzMg_8dec72f1-7d17-4a09-ae75-8993764c001c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNy0xMS0xLTEtOTUxMzI_dcef23ee-a482-4c37-979d-4e8501a2a171">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d0a7130850648eab89a8d43a4c1ce07_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfOS01LTEtMS05NTEzMg_02af9f5e-37bd-4c47-9795-0b0e9370b02e">13,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfOS0xMS0xLTEtOTUxMzI_dc94e290-1c7a-4113-a404-44e7ba540c94">13,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6f203285f84a9cbfbb59ef13288eed_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMTAtNy0xLTEtOTUxMzI_d2287891-4b11-4631-9e1c-8f4cac1dca25">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMTAtMTEtMS0xLTk1MTMy_50686494-e78e-4775-b4b8-3e50bebbaf9e">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia157657bf6274daf9ecad3067cda452b_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMTEtOS0xLTEtOTUxMzI_154a7416-7b68-41c7-bf2d-9ea213aa1439">23,749</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMTEtMTEtMS0xLTk1MTMy_87be45b1-e78d-4209-83e7-a2c35a1fca8f">23,749</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9eedb204e8ae4bd78694426f6de765ea_I20230331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMTItMS0xLTEtOTUxMzI_13ab3f79-1dd5-40c9-b0b5-ce6358edeb2a">53,653,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eedb204e8ae4bd78694426f6de765ea_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMTItMy0xLTEtOTUxMzI_77272986-6223-45d2-9615-9fd4bbc784da">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i095e80c2be4542a187a6b71e2c8912a8_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMTItNS0xLTEtOTUxMzI_a1a7a0e3-c214-41df-a296-05c19a3e8d95">912,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia36947927580425597efbfc7d9f7b2f4_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMTItNy0xLTEtOTUxMzI_5e5e73b7-8c88-4e77-a62e-79ce91cecc7e">7,439</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc0f9c53c619457c8f7d4a6e8c2e7bd8_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMTItOS0xLTEtOTUxMzI_994d7872-299b-4908-bb23-5b10e6d4d4a8">484,883</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMTItMTEtMS0xLTk1MTMy_939705a2-fcad-4a89-ae97-dfafa50ee1fd">420,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CareDx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:37.248%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.378%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iadfb87bf8c0c4c87b3a3c4f7ac571e08_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMi0xLTEtMS05NTEzMg_efa4c922-0095-440a-93ef-b0a96406e162">52,923,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadfb87bf8c0c4c87b3a3c4f7ac571e08_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMi0zLTEtMS05NTEzMg_19db80aa-0eef-4522-b742-5dc995567fe5">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2a29906d48436bb130104a234b2747_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMi01LTEtMS05NTEzMg_92d36530-75d2-4f63-b341-8c999be03c0e">853,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccd28932ec064ace80e89c8bc1d8e174_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMi03LTEtMS05NTEzMg_a7c7bc47-f760-4a52-b52c-8a2353833c54">4,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b018026854c4fe38de8981410c77132_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMi05LTEtMS05NTEzMg_f79b35f5-8a33-4c67-8762-908b3b6e63ac">383,189</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36d5eba90bd24be5bcb0bc0710b286df_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMi0xMS0xLTEtOTUxMzI_ca8307d0-5cd9-480f-8b73-eaf3b0bcb79e">465,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6f9bdaf73bf44fd8daa2e9dab7b62d7_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNC0xLTEtMS05NTEzMg_2a244ec7-835c-4359-9736-a9bb83c98ee9">25,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcff3c7939a4cfb982b7424fcde9b5c_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNC01LTEtMS05NTEzMg_123e3c3a-0ffb-46fd-b2b6-bc2d4561449c">999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNC0xMS0xLTEtOTUxMzI_732591c4-569a-409b-a81e-6dc4885821d5">999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RSU settlements, net of shares withheld</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6f9bdaf73bf44fd8daa2e9dab7b62d7_D20220101-20220331" decimals="INF" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNS0xLTEtMS05NTEzMg_118b1221-9984-4718-aa09-b5b0cbb2a32c">64,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fcff3c7939a4cfb982b7424fcde9b5c_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNS01LTEtMS05NTEzMg_088e0e71-8389-4c80-a630-d8e9c238e0b9">1,482</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNS0xMS0xLTEtOTUxMzI_b28ca925-e83a-42f4-aa39-92cdca88efe7">1,482</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6f9bdaf73bf44fd8daa2e9dab7b62d7_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNi0xLTEtMS05NTEzMg_3b1c09e4-47f4-4237-9a0f-af1331a9930d">1,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcff3c7939a4cfb982b7424fcde9b5c_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNi01LTEtMS05NTEzMg_ec7fca80-7566-486c-8b62-b67d1b13e1e1">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNi0xMS0xLTEtOTUxMzI_330c92d5-73a4-4928-baec-00af1bae1b8a">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash upon exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6f9bdaf73bf44fd8daa2e9dab7b62d7_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNy0xLTEtMS05NTEzMg_95ff98ad-bb5a-4c26-ac6c-694e0cd08e58">69,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcff3c7939a4cfb982b7424fcde9b5c_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNy01LTEtMS05NTEzMg_3a8c9ef0-ef3e-4671-b27e-e25b10edc3cf">1,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNy0xMS0xLTEtOTUxMzI_9141ca07-92e4-4aee-b0ee-8af06a10fff2">1,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcff3c7939a4cfb982b7424fcde9b5c_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfOS01LTEtMS05NTEzMg_1e35d310-260d-4c3d-9bca-fad5bff241cd">10,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfOS0xMS0xLTEtOTUxMzI_17a4b4ed-46be-45b5-89e8-079c57b59a7d">10,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62ae858d67e14b07a24b5f0253cb996d_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMTAtNy0xLTEtOTUxMzI_1c02588e-8c6c-4b8a-9761-59e978621dac">420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMTAtMTEtMS0xLTk1MTMy_d1710de9-2b0b-42a1-b1b6-5661c2da6908">420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b40220e05cd4b1b8d17422a7fcc2436_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMTEtOS0xLTEtOTUxMzI_d259200d-59c9-47f2-8831-87bcc6e65cb1">19,648</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMTEtMTEtMS0xLTk1MTMy_ebedf2b9-d581-455f-bc10-d53be6a2299e">19,648</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2db4a258dcb471894674a74f87706e3_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMTItMS0xLTEtOTUxMzI_e34a021b-a27c-41b4-8c4d-d8e114bbc6ed">53,085,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2db4a258dcb471894674a74f87706e3_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMTItMy0xLTEtOTUxMzI_a104c100-5607-40ea-a7bf-14966947c86b">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8496c939a64c02bd82917d2197df9e_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMTItNS0xLTEtOTUxMzI_90f00249-6921-4b6a-ba6b-b54aedb13f2e">865,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56d4e08f2ddf42d38ac10990bd19ec5b_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMTItNy0xLTEtOTUxMzI_062c1dc2-f727-4048-86f0-5f7b9d449360">5,090</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a81a2a7282d4109b94562c6de746780_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMTItOS0xLTEtOTUxMzI_d3479d2a-ced1-43b8-97aa-c6a26b7729d7">402,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a9b5385be843b8be329d54dfcdc192_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMTItMTEtMS0xLTk1MTMy_e82f5add-738a-4be6-b8c8-a4a568544e10">457,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="idd35c15ee381485cb38f052732749537_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CareDx, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMy0xLTEtMS05NTEzMg_a4c25c80-5fc3-47a0-8c88-bb792acdb38a">23,749</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMy0zLTEtMS05NTEzMg_97f3b5a7-8692-49fb-9cd1-779f3eece735">19,648</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNS0xLTEtMS05NTEzMg_10959ca2-bf21-40c7-b513-2d254d9cee39">13,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNS0zLTEtMS05NTEzMg_2725f613-c521-4084-814c-a0fd9f6d792b">10,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of common stock warrant liability to estimated fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNi0xLTEtMS05NTEzMg_c3bf38f8-2269-4071-9a5b-d286a79057a1">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNi0zLTEtMS05NTEzMg_7efd0da6-f8b6-4d8d-80f3-34919e97f56c">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNy0xLTEtMS05NTEzMg_2094869e-106f-4b09-a51e-882f1b53a377">3,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNy0zLTEtMS05NTEzMg_049dc163-7057-4c60-85a2-77ad1b8c5490">2,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments and write-downs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfOC0xLTEtMS05NTEzMg_5344292e-6ad5-490c-b0be-1dbb79fe77c7">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfOC0zLTEtMS05NTEzMg_0e6122e3-4e6c-4195-b1cf-73ac32aeddb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfOS0xLTEtMS05NTEzMg_8ba30e1e-7ec0-42f3-9f96-2a32c3f799be">1,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfOS0zLTEtMS05NTEzMg_4df26526-5e55-48f4-a012-85117cfa0eb3">915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on long-term marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTAtMS0xLTEtOTUxMzI_88774637-ccbe-446c-8608-958a5c76f9ea">905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTAtMy0xLTEtOTUxMzI_21c52517-ea44-4aa8-81b1-c8bd545aa2e8">507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of contingent consideration to estimated fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTEtMS0xLTEtOTUxMzI_d795cbf3-4b3b-4a85-9b53-aa9f94ccc5f2">364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTEtMy0xLTEtOTUxMzI_d05eb28b-b04d-4654-b363-c58be06e81a7">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premium on short-term marketable securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTMtMS0xLTEtOTUxMzI_e6ba1109-e43d-470f-a72e-1922de58e19c">773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTMtMy0xLTEtOTUxMzI_e11fd507-3652-40a1-a297-9819d7d4ec52">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTUtMS0xLTEtOTUxMzI_971fc35a-74fa-4b6e-9a4d-7c26afb3f6d2">7,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTUtMy0xLTEtOTUxMzI_98856498-9ec4-4358-9f8a-ee4ff5c2a78e">5,591</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTYtMS0xLTEtOTUxMzI_6de1927d-370d-493f-b1b2-1f9525bb736c">1,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTYtMy0xLTEtOTUxMzI_1a93b7f7-fcb4-43ef-8d27-eb1f62ad8329">1,060</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTctMS0xLTEtOTUxMzI_8ff84566-ae99-4ab1-9a6a-7e2e028db861">1,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTctMy0xLTEtOTUxMzI_33becde1-f064-4769-ade2-2bb2799bc6ae">567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" sign="-" name="cdna:IncreaseDecreaseInOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTgtMS0xLTEtOTUxMzI_29ee4e16-9daa-4086-93e6-7aa81759da23">1,333</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="cdna:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTgtMy0xLTEtOTUxMzI_98f63df2-b950-4aea-af45-0317e9a67e7e">969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTktMS0xLTEtOTUxMzI_3c13c9b5-35a4-46e6-8737-a6f7509d359f">2,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTktMy0xLTEtOTUxMzI_6a64ceb5-ebbe-4196-8daa-45067f01feaa">1,549</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedSalaries" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjAtMS0xLTEtOTUxMzI_3b7aa384-7e01-470f-9782-6f87ce4fa127">4,888</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedSalaries" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjAtMy0xLTEtOTUxMzI_7406570f-18e1-40b5-a53d-518b786f3114">14,634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjEtMS0xLTEtOTUxMzI_8f5abd07-3e99-4c20-98ad-1daaa48e4228">2,352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjEtMy0xLTEtOTUxMzI_b2005ee4-f2f6-4281-a3b1-d625996b8d2a">7,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjMtMS0xLTEtOTUxMzI_7a679343-e439-4083-ba29-d7ba0090ea74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjMtMy0xLTEtOTUxMzI_0f75445b-5df1-4b57-b763-78c7316df075">217</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjQtMS0xLTEtOTUxMzI_725d612f-9664-490b-bbe5-7f9d1e846eed">671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjQtMy0xLTEtOTUxMzI_cc7983e0-331a-4c4e-bbca-13a4b38d4d0b">21,468</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of business, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjYtMS0xLTEtOTUxMzI_5c736fac-e71c-46a5-ae4d-75143fb4846c">4,562</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjYtMy0xLTEtOTUxMzI_d7096355-6fce-49c4-a72a-f137ff37a11d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjctMS0xLTEtOTUxMzI_e62a9bf1-2b47-404c-95ca-bc19e979c468">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjctMy0xLTEtOTUxMzI_b0f50fb8-f5c7-4f90-abaa-061b1271f4bd">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of short-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjgtMS0xLTEtOTUxMzI_84d90f2e-8dbf-43fa-bce7-d797c1381e80">86,310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjgtMy0xLTEtOTUxMzI_85a97872-4611-4779-968c-e9275dc60375">148,522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of short-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjktMS0xLTEtOTUxMzI_753a766d-68b6-4fff-b571-74eae4625fda">78,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjktMy0xLTEtOTUxMzI_b60c5a33-5a0a-4783-99a3-b6c68c93f682">1,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of corporate equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjktMS0xLTEtMTAzOTQ5_78f3767b-e516-4a15-8ca8-0ef4119f7506">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjktMy0xLTEtMTAzOTQ5_50cba429-d636-47a6-a7e8-92030b59c5ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions of capital expenditures, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="cdna:PaymentsToAcquireCapitalExpendituresNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMzEtMS0xLTEtOTUxMzI_6be13171-d93b-4c47-bfde-a5b8b7e7cf47">2,771</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="cdna:PaymentsToAcquireCapitalExpendituresNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMzEtMy0xLTEtOTUxMzI_b370b3d6-ffc4-46d8-b73e-4bba8f0112c8">8,463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMzItMS0xLTEtOTUxMzI_0dc0cc84-a608-4db3-98b8-6c4980740884">14,771</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMzItMy0xLTEtOTUxMzI_8629a483-e5bf-464a-9fbb-c85da06a2487">156,032</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMzctMS0xLTEtOTUxMzI_eb847d90-acb5-4d6a-8dd2-e4c3f3309803">456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromStockPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMzctMy0xLTEtOTUxMzI_aeff1c34-6c5d-409c-8c3c-5a8382ea3907">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="cdna:TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMzgtMS0xLTEtOTUxMzI_027c9f6d-569d-4a19-8476-908f0750c9f0">656</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="cdna:TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMzgtMy0xLTEtOTUxMzI_2973281a-5982-4ba3-abf9-6fa8c6179c65">1,482</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDAtMS0xLTEtOTUxMzI_6bdb6c97-cd85-4711-9a54-e7346011c6fa">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDAtMy0xLTEtOTUxMzI_e0d8f8a1-c9bf-44b7-83db-3a68effbcdfb">1,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDItMS0xLTEtOTUxMzI_67ce4b51-9a31-40a6-aa46-5410c8db7671">250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDItMy0xLTEtOTUxMzI_3fc6682e-bae6-45bd-b840-efa88b7da9a4">250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase and retirement of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDMtMS0xLTEtOTc4MDg_b6ace350-9e3c-41c2-9a54-0ec999e9d4a1">690</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDMtMy0xLTEtOTc4MDg_41c27ac3-ecbb-4c69-ab23-8221aae4ebe1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDQtMS0xLTEtOTUxMzI_5a341559-5151-4056-8a96-2b14dac901f9">1,138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDQtMy0xLTEtOTUxMzI_e3f2788d-5d08-4e61-825b-dd3156ab61e5">865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDUtMS0xLTEtOTUxMzI_3e0687e1-a516-402e-bde5-6736b5c27b94">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDUtMy0xLTEtOTUxMzI_948961fe-8223-47f5-b036-d1fa8b6f4ab6">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDYtMS0xLTEtOTUxMzI_f558220f-46f2-4730-aa8c-395507f26d5e">15,263</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDYtMy0xLTEtOTUxMzI_6121c81e-2b57-4483-9786-01976a6b58ab">176,590</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDctMS0xLTEtOTUxMzI_781aab29-0741-4883-af3a-398bb181eb99">90,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36d5eba90bd24be5bcb0bc0710b286df_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDctMy0xLTEtOTUxMzI_85539eb5-17ca-49e5-99b1-91a82ca42226">348,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDgtMS0xLTEtOTUxMzI_d70392e7-a3dc-43a6-b6ae-67986d22f763">75,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a9b5385be843b8be329d54dfcdc192_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDgtMy0xLTEtOTUxMzI_1b802e02-cf21-440f-84f4-0d150b4610a2">172,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="idd35c15ee381485cb38f052732749537_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CareDx, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Condensed Consolidated Financial Statements</span></div><div id="idd35c15ee381485cb38f052732749537_34"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfMTQ0NjM_01b5c6d9-9c63-4d58-b6f7-c00cdcc1f114" continuedAt="id28dd3a27e854297b759abcba5d4faf7" escape="true">ORGANIZATION AND DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="id28dd3a27e854297b759abcba5d4faf7" continuedAt="i74dff8423bf44d3f82e9d5cdd436e303"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CareDx, Inc. (&#8220;CareDx&#8221; or the &#8220;Company&#8221;), together with its subsidiaries, is a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients and caregivers. The Company&#8217;s headquarters are in Brisbane, California. The primary operations are in Brisbane, California; Omaha, Nebraska; Fremantle, Australia; and Stockholm, Sweden.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s commercially available testing services consist of AlloSure&#174; Kidney, a donor-derived cell-free DNA (&#8220;dd-cfDNA&#8221;) solution for kidney transplant patients, AlloMap&#174; Heart, a gene expression solution for heart transplant patients, AlloSure&#174; Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure&#174; Lung, a dd-cfDNA solution for lung transplant patients. The Company has initiated several clinical studies to generate data on its existing and planned future testing services. In April 2020, the Company announced its first biopharma research partnership for AlloCell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants. The Company also offers high-quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. The Company also provides digital solutions to transplant centers following the acquisitions of Ottr Complete Transplant Management (&#8220;Ottr&#8221;) and XynManagement, Inc. (&#8220;XynManagement&#8221;), as well as the acquisitions of TransChart LLC (&#8220;TransChart&#8221;), MedActionPlan.com, LLC (&#8220;MedActionPlan&#8221;) The Transplant Pharmacy, LLC (&#8220;TTP&#8221;) in 2021 and HLA Data Systems, LLC ("HLA Data Systems") in January 2023.</span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Testing Services </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloSure Kidney has been a covered service for Medicare beneficiaries since October 2017 through a Local Coverage Determination (&#8220;LCD&#8221;) first issued by Palmetto MolDX (&#8220;MolDX&#8221;), which was formed to identify and establish coverage and reimbursement for molecular diagnostics tests, and adopted by Noridian Healthcare Solutions, the Company&#8217;s Medicare Administrative Contractor (&#8220;Noridian&#8221;). The Medicare reimbursement rate for AlloSure Kidney is currently $<ix:nonFraction unitRef="usd" contextRef="i6b98eb7a2f97454dad8515edac4bcb72_D20230101-20230331" decimals="INF" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNTQ5NzU1ODc1NDE2_337f48c1-bbdc-46ff-a311-9401ebffe370">2,841</ix:nonFraction>. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloMap Heart has been a covered service for Medicare beneficiaries since January 2006. The Medicare reimbursement rate for AlloMap Heart is currently $<ix:nonFraction unitRef="usd" contextRef="i0d63bba5fe4f40ce95ab4d66330c93ad_D20230101-20230331" decimals="INF" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNTQ5NzU1ODc1NDI1_c8998739-9e03-47f7-8a1f-4f00864c0629">3,240</ix:nonFraction>. In October 2020, the Company received a final MolDX Medicare coverage decision for AlloSure Heart. Noridian issued a parallel coverage policy granting coverage for AlloSure Heart when used in conjunction with AlloMap Heart, which became effective in December 2020. The Medicare reimbursement rate for AlloSure Heart is currently $<ix:nonFraction unitRef="usd" contextRef="i7bb05103813e4dd493ad38b4d1893919_D20230101-20230331" decimals="INF" name="us-gaap:RecoveryOfDirectCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNTQ5NzU1ODc1NDM0_9fcaa934-6d79-4f73-b5f7-de89ee60aed5">2,753</ix:nonFraction>.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MolDX issued a new billing article, with an effective date of March&#160;31, 2023, related to the LCD entitled Molecular Testing for Solid Organ Allograft Rejection (the &#8220;Billing Article&#8221;). Prior to the Billing Article&#8217;s effective date, MolDX informed the affected parties, including CareDx, that enforcement of the revised billing practices outlined in the Billing Article will not be implemented until June&#160;30, 2023.  MolDX informed CareDx that its automatic adjudication process would remain in place until June 30, 2023, though claims submitted prior to that date must comply with the applicable LCDs. On May&#160;4, 2023, MolDX issued a revised new billing article with an effective date of March&#160;31, 2023 (the &#8220;Revised Billing Article&#8221; and together with the Billing Article, the &#8220;Billing Articles&#8221;).  The Revised Billing Article impacts Medicare coverage for AlloSure Kidney, AlloSure Heart and AlloMap Heart and requires certain companies, including CareDx, to implement new processes to address the requirements related to Medicare claim submissions. MolDX has stated that it views the Billing Article as clarifying existing coverage, especially as it relates to when tests are covered in the for-cause and surveillance contexts.  MolDX has acknowledged, however, that the Billing Article is a change as it relates to billing more than one test during a single patient encounter. Noridian has not yet adopted the new Billing Articles.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company believes the Billing Articles are inconsistent with the LCDs, Noridian&#8217;s and MolDX&#8217;s responses to public comments explaining the intended scope of various LCDs, and medical necessity, the Company determined to pause its Medicare reimbursement submissions for AlloSure Kidney commencing on March&#160;7, 2023 to allow the Company further time to evaluate the implications of the Billing Article and update its billing processes for AlloSure Kidney tests by educating clinicians and working with centers to update CareDx&#8217;s test order forms to capture the new information required under the Billing Article. Accordingly, the Company did not submit claims for approximately <ix:nonFraction unitRef="claim" contextRef="iaefdfbd1b7ec4bf389377b07e872b922_I20230331" decimals="-2" name="cdna:UnsubmittedReimbursementClaimsForMedicare" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNTQ5NzU1ODc1NjYx_ad0ba58b-3442-4103-a803-ea0ccbcc23ce">3,200</ix:nonFraction> AlloSure Kidney tests for Medicare reimbursement for the period from March&#160;7, 2023 through March&#160;31, 2023 and did not recognize revenue on these claims in the first quarter of 2023 aggregating to approximately $<ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-5" name="cdna:UnsubmittedClaimsRevenueNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNTQ5NzU1ODc1NjU1_3d74d8e8-5e1b-45c7-8b08-bd48cd2bb137">8.9</ix:nonFraction> million (the &#8220;Impacted March Tests&#8221;).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2023, the Company plans to submit claims for Medicare reimbursement for the Impacted March Tests, following the delivery by the Company of a letter to Noridian explaining, among other things, (i) the Company&#8217;s belief that the Billing Articles impose new restrictions on Medicare coverage for the CareDx tests from those contained in the existing LCDs, (ii) that the Company plans to submit claims for reimbursement for the Impacted March Tests for which the Company has not obtained additional information from the ordering physicians to be able to specifically determine whether these tests meet the new coverage restrictions contained in the Billing Articles, and (iii) that AlloSure Kidney orders with a date of service on or after March&#160;31, 2023 for other indications outside the parameters of the Revised Billing Article, or where the reason for testing </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><ix:continuation id="i74dff8423bf44d3f82e9d5cdd436e303" continuedAt="ia00b55d30c3748e6ba96ede70caf1f5a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is not specified by the ordering physician, will either be held pending the receipt of additional information regarding medical necessity or submitted with a test description that is intended to identify those tests as falling outside the parameters of the Revised Billing Article.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CareDx continued the Medicare reimbursement submissions for AlloMap Heart or AlloSure Heart following the issuance of the Billing Articles. In addition, CareDx is considering informing Noridian that until Noridian adopts the Revised Billing Article, CareDx will continue to submit AlloSure Heart tests for reimbursement only when used in conjunction with AlloMap Heart. The Company is also considering informing Noridian that (i) until June 30, 2023, it plans to submit claims for reimbursement for AlloMap Heart and AlloSure Heart tests for which the Company has not obtained additional information from the ordering physicians to be able to specifically determine whether these tests meet the new coverage restrictions contained in the Billing Articles, and (ii) AlloSure Heart and AlloMap Heart orders placed on or after June&#160;30, 2023 for other indications outside the surveillance and for-cause parameters of the Billing Article, or where the reason for testing is not specified by the ordering physician, will either be held pending the receipt of additional information regarding medical necessity or submitted with a test description that is intended to identify those tests as falling outside the parameters of the Billing Articles. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloSure Kidney has received positive coverage decisions from several commercial payers, and is reimbursed by other private payers on a case-by-case basis.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloMap Heart has also received positive coverage decisions for reimbursement from many of the largest U.S. private payers.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021 and March 2023, the Company purchased a minority investment of common stock in the biotechnology company Miromatrix Medical, Inc. (&#8220;Miromatrix&#8221;), for an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i784e3baffdcb4192964759f0c56d78ad_D20210501-20230331" decimals="-5" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfMjk1OA_507e8ffa-dc65-49e5-8722-eb41bfa8598f">5.1</ix:nonFraction> million, and the investment is marked to market. Miromatrix works to eliminate the need for an organ transplant waiting list through the development of implantable engineered biological organs.</span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Studies</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company initiated the Kidney Allograft Outcomes AlloSure Kidney Registry study (&#8220;K-OAR&#8221;), to develop additional data on the clinical utility of AlloSure Kidney for surveillance of kidney transplant recipients. K-OAR is a multicenter, non-blinded, prospective observational cohort study which has enrolled more than <ix:nonFraction unitRef="patient" contextRef="ibf4af37bc739426e912a71dac9ba281d_I20180131" decimals="-2" name="cdna:NumberOfRenalTransplantPatients" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfMzUwMA_daaa864f-0a54-4820-bce4-e01e4899fd16">1,700</ix:nonFraction> renal transplant patients who will receive AlloSure Kidney long-term surveillance.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company initiated the Surveillance HeartCare&#8482; Outcomes Registry (&#8220;SHORE&#8221;). SHORE is a prospective, multi-center, observational registry of patients receiving HeartCare for surveillance. HeartCare combines the gene expression profiling technology of AlloMap Heart with the dd-cfDNA analysis of AlloSure&#174; Heart in one surveillance solution.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, AlloSure&#174; Lung became available for lung transplant patients through a compassionate use program while the test is undergoing further studies. In June 2020, the Company submitted an AlloSure Lung application to the Palmetto MolDx Technical Assessment program seeking coverage and reimbursement for Medicare beneficiaries.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company announced the commencement of the Outcomes of KidneyCare on Renal Allografts (&#8220;OKRA&#8221;) study, which is an extension of K-OAR. OKRA is a prospective, multi-center, observational, registry of patients receiving KidneyCare for surveillance. KidneyCare combines the dd-cfDNA analysis of AlloSure Kidney with the gene expression profiling technology of AlloMap Kidney and the predictive artificial intelligence technology of iBox for a multimodality surveillance solution. The Company has not yet made any applications to private payers for reimbursement coverage of AlloMap Kidney or KidneyCare.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Products</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s suite of AlloSeq products are commercial next generation sequencing (&#8220;NGS&#8221;)-based kitted solutions. These products include: AlloSeq&#8482; Tx, a high-resolution Human Leukocyte Antigen (&#8220;HLA&#8221;) typing solution, AlloSeq&#8482; cfDNA, a surveillance solution designed to measure dd-cfDNA in blood to detect active rejection in transplant recipients, and AlloSeq&#8482; HCT, a solution for chimerism testing for stem cell transplant recipients.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's other HLA typing products include: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Olerup </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SSP</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on the sequence specific primer (&#8220;SSP&#8221;) technology; and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QTYPE</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which uses real-time polymerase chain reaction </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;PCR&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> methodology, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to perform HLA typing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company acquired certain assets of BFS Molecular S.R.L. (&#8220;BFS Molecular&#8221;), a software company focused on NGS-based patient testing solutions. BFS Molecular brings extensive software and algorithm development capabilities for NGS transplant surveillance products.</span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Patient and Digital Solutions</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the acquisitions of both Ottr and XynManagement, the Company is a leading provider of transplant patient management software (&#8220;Ottr software&#8221;), as well as of transplant quality tracking and waitlist management solutions. Ottr software provides comprehensive solutions for transplant patient management and enables integration with electronic medical </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><ix:continuation id="ia00b55d30c3748e6ba96ede70caf1f5a"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">record (&#8220;EMR&#8221;) systems providing patient surveillance management tools and outcomes data to transplant centers. XynManagement provides <ix:nonFraction unitRef="unique_solution" contextRef="iab7d98285c4b4d9ea5dd55cf1942b127_D20230101-20230331" decimals="INF" name="cdna:NumberOfUniqueSolutions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNjQ0NQ_83ceae4d-08e1-4cf3-97b2-2f108b36d608">two</ix:nonFraction> unique solutions, XynQAPI software (&#8220;XynQAPI&#8221;) and XynCare. XynQAPI simplifies transplant quality tracking and Scientific Registry of Transplant Recipients reporting. XynCare includes a team of transplant assistants who maintain regular contact with patients on the waitlist to help prepare for their transplant and maintain eligibility.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company launched AlloCare, a mobile app that provides a patient-centric resource for transplant recipients to manage medication adherence, coordinate with Patient Care Managers for AlloSure scheduling and measure health metrics.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company acquired TransChart. TransChart provides EMR software to hospitals throughout the U.S. to care for patients who have or may need an organ transplant. As part of the Company's acquisition of TransChart in January 2021, the Company acquired TxAccess, a cloud-based service that allows nephrologists and dialysis centers to electronically submit referrals to transplant programs, closely follow and assist patients through the transplant waitlist process, and ultimately, through transplantation.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company acquired the Transplant Hero patient application. The application helps patients manage their medications through alarms and interactive logging of medication eve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nts</span><span style="color:#548dd4;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in June 2021, the Company entered into a strategic agreement with OrganX, which was amended in April 2022, to develop clinical decision support tools across the transplant patient journey. Together, the Company and OrganX will develop advanced analytics that integrate AlloSure, the first transplant specific dd-cfDNA assay, with large transplant databases to provide clinical data solutions. This partnership delivers the next level of innovation beyond multi-modality by incorporating a variety of clinical inputs to create a universal composite scoring system. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreed to potential future milestone payments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company acquired MedActionPlan, a New Jersey-based provider of medication safety, medication adherence and patient education. MedActionPlan is a leader in patient medication management for transplant patients and beyond.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company acquired TTP, a transplant focused pharmacy located in Mississippi. TTP provides individualized transplant pharmacy services for patients at multiple transplant centers located throughout the U.S.</span></div><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="cdna:LiquidityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfMTQ0Njc_30ed1e80-f1f5-4ead-a475-2b8c510c186e" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred significant losses and negative cash flows from operations since its inception and had an accumulated deficit of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfMTI2NTY_6657f1dd-2b4e-4be4-954a-bcbd85c054a6">484.9</ix:nonFraction> million at March&#160;31, 2023. As of March&#160;31, 2023, the Company had cash, cash equivalents and marketable securities of $<ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfMTI3NDQ_757e4eae-f729-49e4-ba8c-8979de74b365">285.9</ix:nonFraction> million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no debt outstanding.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At-the-Market Equity Offering</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 14, 2022, the Company entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with Jefferies, LLC as sales agent (&#8220;Jefferies&#8221;), pursuant to which the Company may offer and sell, from time to time, through Jefferies, up to $<ix:nonFraction unitRef="usd" contextRef="i696a715cb3c04fb38124dcb7c37602f8_I20220414" decimals="-5" name="cdna:SaleOfStockAuthorizedConsiderationAmountMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNjU5NzA2OTc4OTcxMA_97c50e36-c904-4d80-99fc-dd6531af8f03">200.0</ix:nonFraction>&#160;million in shares of our common stock, by any method permitted by law deemed to be an &#8220;at-the-market&#8221; offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. Jefferies is entitled to compensation for its services equal to <ix:nonFraction unitRef="number" contextRef="iaaeec918b90c4ba5bb1acfd6106ce79b_D20220414-20220414" decimals="INF" name="cdna:SaleOfStockCommissionFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNjU5NzA2OTc4OTcyOQ_1b024e99-cb50-4953-99df-76ece5d17577">3</ix:nonFraction>% of the gross proceeds of any shares of common stock sold through Jefferies under the Sales Agreement. Any shares of common stock offered and sold pursuant to the Sales Agreement will be issued and sold pursuant to our Registration Statement on Form S-3ASR (File No. 333-239049), filed with the SEC on June 9, 2020 (the &#8220;Registration Statement&#8221;), including a base prospectus dated June 9, 2020, and a prospectus supplement dated April 14, 2022. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Registration Statement will expire on June 9, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Repurchase Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;3, 2022, the Company's Board of Directors approved a stock repurchase program (the "Repurchase Program"), whereby the Company may purchase up to $<ix:nonFraction unitRef="usd" contextRef="i13b9c2985d5d4d1e9ce7abfd085614c5_I20221203" decimals="-6" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNjU5NzA2OTc4OTg4Nw_7c5124e2-77e1-405e-89ea-f65ae163be00">50</ix:nonFraction>&#160;million in shares of our common stock over a period of up to <ix:nonNumeric contextRef="ifcd6a13ba0f945cbb58e45d6f9688338_D20221208-20221208" name="us-gaap:StockRepurchaseProgramPeriodInForce1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfMjc0ODc3OTA5NTU1NQ_90160a65-1db5-4387-8bf1-1bf0445a7327">two years</ix:nonNumeric>, commencing on December&#160;8, 2022. The Repurchase Program may be carried out at the discretion of a committee of the Board of Directors through open market purchases, one or more Rule 10b5-1 trading plans, block trades and in privately negotiated transactions. During the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company purchased an aggregate of <ix:nonFraction unitRef="shares" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNjU5NzA2OTc5MDI0NQ_c95f7f29-a0e4-490c-a0f0-357c273befc8">59,472</ix:nonFraction> shares of its common stock under the Repurchase Program for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNjU5NzA2OTc5MDM0MA_1443c92a-3a93-4818-b6b1-7a917d0a0d7c">0.7</ix:nonFraction> million. As of March&#160;31, 2023, $<ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-5" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNjU5NzA2OTc5MDM1Ng_a1465332-2c6e-4f81-9480-09bddefd2dd7">48.7</ix:nonFraction> million remained available for future share repurchase under the Repurchase Program.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="idd35c15ee381485cb38f052732749537_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMTE3NzY_6c0e34db-cf84-48ab-937a-4896bdb1347d" continuedAt="i106bb089c24a4373986f73a6372176df" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i106bb089c24a4373986f73a6372176df" continuedAt="if070bbf3f0bf4f25bb9b7da45db2da8a"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies and estimates used in preparation of the unaudited condensed consolidated financial statements are described in the Company&#8217;s audited consolidated financial statements as of and for the year ended December&#160;31, 2022, and the notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the Securities and Exchange Commission (the "SEC") on February&#160;27, 2023. Material changes to the significant accounting policies previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022 are reflected below.</span></div><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMTE3Nzc_6779409b-ee5c-47b6-81fa-3241cf49531b" escape="true"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;), and follow the requirements of the SEC for interim reporting. As permitted under those rules, certain notes and other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company&#8217;s financial information. The condensed consolidated balance sheet as of December&#160;31, 2022 has been derived from audited consolidated financial statements as of that date but does not include all of the financial information required by U.S. GAAP for complete financial statements. Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMTE3ODI_f5976829-25eb-4c26-8c4c-b15cf4acf2cc" escape="true"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to transaction price estimates used for testing services revenue; standalone fair value of patient and digital solutions revenue performance obligations; accrued expenses for clinical studies;&#160;inventory valuation;&#160;the fair value of issued common stock warrants and embedded derivatives; the fair value of assets and liabilities acquired in a business combination or an assets acquisition (including identifiable intangible assets acquired);&#160;the fair value of contingent consideration recorded in connection with a business combination or an asset acquisition; the grant date fair value assumptions used to estimate stock-based compensation expense; income taxes; impairment of long-lived assets and indefinite-lived assets (including goodwill); and legal contingencies. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMTE3ODg_874c17a0-dae8-4225-bb1a-b0234c0825c1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Concentrations of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, approximately <ix:nonFraction unitRef="number" contextRef="i3a52955612044b80bdc44719634b8f15_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMzEzNw_bbebe8da-0893-4bc1-8d8b-238a7baf00cf">42</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i00bf0bbaedf542d7bd5c59ac9504d720_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMzE0NA_25295896-d0d2-4b90-8063-603e9c7926ce">54</ix:nonFraction>%, respectively, of total revenue was derived from Medicare. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, approximately <ix:nonFraction unitRef="number" contextRef="i380c3aacb19e456dab0fbafc4081feb5_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMzIzOA_96dc7022-8cb4-467d-8da7-0418de448e72">26</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="if08f4ea8cdfd44269e800431266d73fc_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMzI0NQ_f789d90a-77c4-46c0-aa02-c0731fe47189">27</ix:nonFraction>%, respectively, of accounts receivable was due from Medicare. No other payer or customer represented more than 10% of accounts receivable at either March&#160;31, 2023 or December&#160;31, 2022.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMTE3ODM_8abab440-ddc3-4791-9c24-d0e17af482fe" continuedAt="ib79e35ff9e604d52a0b0a5e3b5e95c95" escape="true"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketable Securities</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments in securities with a maturity of greater than three months at the time of purchase to be marketable securities. As of March&#160;31, 2023, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s short-term marketable securities consisted of corporate debt securities with maturities of greater than three months but less than twelve months at the time of purchase, which were classified as current assets on the condensed consolidated balance sheet</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its short-term marketable securities as held-to-maturity at the time of purchase and reevaluates such designation at each balance sheet date. The Company has the positive intent and ability to hold these marketable securities to maturity. Short-term marketable securities are carried at amortized cost and are adjusted for amortization of premiums and accretion of discounts to maturity, which is included i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n interest income (expense), net on the condensed consolidated statements of operations. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on short-term marketable securities are included in interest income (expense), net. The cost of securities sold will be determined using specific identification.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers investments in securities with remaining maturities of over one year as long-term investments. As of March&#160;31, 2023, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company's long-term marketable securities consisted of corporate equity securities and corporate debt securities. These long-term marketable securities are classified as other assets on the condensed consolidated balance sheet</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><ix:continuation id="if070bbf3f0bf4f25bb9b7da45db2da8a" continuedAt="ib577015ca48b495b87ee4338a0683457"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib79e35ff9e604d52a0b0a5e3b5e95c95" continuedAt="i8a9834a6ad7d4562871be4b8d5f52133">The Company classifies its long-term marketable debt securities as available-for-sale and reevaluates such designation at each balance sheet date. Unrealized gains and losses from the reevaluation of the long-term marketable debt securities, if any, are included in other comprehensive gain (loss) in the condensed consolidated statement of comprehensive income (loss). Realized gains and losses and declines in value judged to be other-than-temporary, if any, on long-term marketable securities are included in interest income, net.</ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8a9834a6ad7d4562871be4b8d5f52133">The Company records its long-term marketable equity securities at fair market value. Unrealized gains and losses from the remeasurement of the long-term marketable equity securities to fair value are included in other income (expense), net, in the condensed consolidated statements of operations.</ix:continuation> </span></div><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMTE3ODk_3315efa1-3c53-4af6-8b22-9ded09662578" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted Accounting Standard Codification (&#8220;ASC&#8221;) Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and determines if an arrangement is or contains a lease at contract inception. A right-of-use (&#8220;ROU&#8221;) asset, representing the underlying asset during the lease term, and a lease liability, representing the payment obligation arising from the lease, are recognized on the condensed consolidated balance sheet at lease commencement based on the present value of the payment obligation. For operating leases, expense is recognized on a straight-line basis over the lease term. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the ROU asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company's facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with an initial term of 12 months or less.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company&#8217;s leases had remaining terms of <ix:nonNumeric contextRef="i8a65e524e31741e4b69720fd09cbf601_D20230101-20230331" name="cdna:RemainingOperatingAndFinanceLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMTE3ODU_e55b3ea4-d16d-4ac5-84f2-31a1fd46674b">0.67</ix:nonNumeric> years to <ix:nonNumeric contextRef="i739a68ac0826477da4feb1f814aab614_D20230101-20230331" name="cdna:RemainingOperatingAndFinanceLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMTE3ODY_5d94d058-68f6-4bb9-9b8b-605c976239bb">9.85</ix:nonNumeric> years, some of which include options to extend the lease term.</span></div><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMjE5OTAyMzI3OTcyNQ_a28287e5-baf0-449b-a43a-5e091595dfb4" continuedAt="i5911c6fdc315445398038dbacd6e0275" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from testing services, product sales and patient and digital solutions revenue in the amount that reflects the consideration that it expects to be entitled in exchange for goods or services as it transfers control to its customers. Revenue is recorded considering a five-step revenue recognition model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations and recognizing revenue when, or as, an entity satisfies a performance obligation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Testing Services Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloSure Kidney, AlloMap Heart, AlloSure Heart and AlloSure Lung patient tests are ordered by healthcare providers. The Company receives a test requisition form with payer information along with a collected patient blood sample. The Company considers the patient to be its customer and the test requisition form to be the contract. Testing services are performed in the Company&#8217;s laboratory. Testing services represent one performance obligation in a contract and are performed when results of the test are provided to the healthcare provider, at a point in time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare providers that order the tests and on whose behalf the Company provides testing services are generally not responsible for the payment of these services. The first and second revenue recognition criteria are satisfied when the Company receives a test requisition form with payer information from the healthcare provider. Generally, the Company bills third-party payers upon delivery of an AlloSure Kidney, AlloMap Heart, AlloSure Heart or AlloSure Lung test result to the healthcare provider. Amounts received may vary amongst payers based on coverage practices and policies of the payer. The Company has used the portfolio approach under Accounting Standards Codification ("ASC") Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to identify financial classes of payers. Revenue recognized for Medicare and other contracted payers is based on the agreed current reimbursement rate per test, adjusted for historical collection trends where applicable. The Company estimates revenue for non-contracted payers and self-payers using transaction prices determined for each financial class of payers using history of reimbursements. This includes analysis of an average reimbursement per test and a percentage of tests reimbursed. This estimate requires significant judgment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors revenue estimates at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Changes in transaction price estimates are updated quarterly based on actual cash collected or changes made to contracted rates.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><ix:continuation id="ib577015ca48b495b87ee4338a0683457" continuedAt="if179b00c05a6450484211fa57584d60d"><ix:continuation id="i5911c6fdc315445398038dbacd6e0275"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 2, 2023, MolDX issued a new Billing Article, with an effective date of March&#160;31, 2023. The Billing Article impacts Medicare coverage for AlloSure Kidney, AlloSure Heart and AlloMap and requires the Company to implement new processes to address requirements related to Medicare claim submissions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 606-10-25-1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> requires the Company to assess whether it is probable that it will collect substantially all of the consideration to which it will be entitled. Based upon the Company&#8217;s review of the Billing Article, it was determined to pause Medicare reimbursement submissions for AlloSure Kidney commencing on March&#160;7, 2023 that created uncertainty around the collection of the claims. Accordingly, the Company did not recognize revenue for approximately <ix:nonFraction unitRef="unique_solution" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="INF" name="cdna:UnsubmittedReimbursementClaimsForMedicare" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMzg0ODI5MDcyNjAyOQ_f0f9c07b-80fa-489b-8e29-56503f8f3eb8">3,200</ix:nonFraction> AlloSure Kidney tests aggregating to $<ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-5" name="cdna:UnsubmittedClaimsRevenueNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfNTQ5NzU1ODQyMjc3_3d74d8e8-5e1b-45c7-8b08-bd48cd2bb137">8.9</ix:nonFraction> million for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is recognized from the sale of products to end-users, distributors and strategic partners when all revenue recognition criteria are satisfied. The Company generally has a contract or a purchase order from a customer with the specified required terms of order, including the number of products ordered. Transaction prices are determinable and products are delivered and risk of loss passed to the customer upon either shipping or delivery, as per the terms of the agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient and Digital Solutions Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient and digital solutions revenue is mainly derived from a combination of software as a service ("SaaS") and perpetual software license agreements entered into with various transplant centers, which are the Company's customers for this class of revenue. The main performance obligations in connection with the Company's SaaS and perpetual software license agreement are the following: (i) implementation services and delivery of the perpetual software license are considered a single performance obligation, and (ii) post contract support. The Company allocates the transaction price to each performance obligation based on relative stand-alone selling prices of each distinct performance obligation. Digital revenue in connection with perpetual software license agreements is recognized over time based on the Company&#8217;s satisfaction of each distinct performance obligation in each agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Perpetual software license agreements typically require advance payments from customers upon the achievement of certain milestones. The Company records deferred revenue in relation to these agreements when cash payments are received, or invoices are issued in advance of the Company&#8217;s performance, and generally recognizes revenue over the contractual term, as performance obligations are fulfilled.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company derives patient and digital solutions revenue from software subscriptions and medication sales. The Company generally bills software subscription fees in advance. Revenue from software subscriptions is deferred and recognized ratably over the subscription term. The medication sales revenue is recognized based on the negotiated contract price with the governmental, commercial and non-commercial payers with any applicable patient co-pay. The Company recognizes revenue from medication sales when prescriptions are delivered.</span></div></ix:continuation><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMTE3ODQ_3b8be661-26b1-439f-854a-0961b68ebb01" continuedAt="if0a710b0a14645f28459702bcb9a4084" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which contains amendments that require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model. The disclosures include (1) the types of assistance, (2) an entity&#8217;s accounting for the assistance, and (3) the effect of the assistance on an entity&#8217;s financial statements. The amendments set forth in this ASU are effective for all entities for annual periods beginning after December 15, 2021. Early application of the amendments in this ASU is permitted. The amendments in this ASU should be applied either (1) prospectively to all transactions within the scope of the amendments that are reflected in financial statements at the date of initial application and new transactions that are entered into after the date of initial application or (2) retrospectively to those transactions. The Company adopted the standard prospectively on January 1, 2022. The adoption of this new standard had no impact on the Company's consolidated financial statements and disclosures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that an entity recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with ASC 606 as if it had originated the contracts. The amendments set forth in this ASU are effective for fiscal years beginning after December 15, 2022. Early adoption of the amendments is permitted. The amendments in this ASU should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company adopted the standard prospectively on January 1, 2022. The adoption of this new standard had no material impact on the Company's consolidated financial statements and disclosures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if179b00c05a6450484211fa57584d60d"><ix:continuation id="if0a710b0a14645f28459702bcb9a4084">Written Call Options (a consensus of the FASB Emerging Issues Task Force), which contains amendments that clarify and reduce diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after modification or exchange. The amendments set forth in this ASU are effective for all entities for annual periods beginning after December 15, 2021. Early application of the amendments in this ASU is permitted for all entities. The amendments in this ASU should be applied prospectively. The Company adopted the standard prospectively on January 1, 2022. The adoption of this new standard had no impact on the Company's consolidated financial statements and disclosures.</ix:continuation></ix:continuation></span></div><div id="idd35c15ee381485cb38f052732749537_40"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RleHRyZWdpb246YjZkNDdlMGViMjhiNDcxMzg2NzYzYTIwMWUzOTRmYjhfNTk0_5613cab7-7ab7-4fb8-9447-4fcc4c5a8453" continuedAt="i787f5d20e37b45029d4b9005fa1420e6" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i787f5d20e37b45029d4b9005fa1420e6"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share have been computed by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of common share equivalents as their effect would have been antidilutive.</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RleHRyZWdpb246YjZkNDdlMGViMjhiNDcxMzg2NzYzYTIwMWUzOTRmYjhfNTkx_1d7f30da-a2d7-4dd0-bece-db00da0b7757" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the computation of the Company&#8217;s basic and diluted net loss per share (in thousands, except shares and per share data):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:73.825%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.214%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss used to compute basic and diluted net loss per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfMy01LTEtMS05NTEzMg_2b0a312a-c249-49a5-b8bb-4990a34fc25f"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfMy01LTEtMS05NTEzMg_aa960fac-62ca-4263-8285-aded1a0ac094">23,749</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfMy03LTEtMS05NTEzMg_5aca0ac1-feac-4bd8-8d3d-91d1342455a4"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfMy03LTEtMS05NTEzMg_9ee5bbc9-a7ca-4524-becc-59adf7d944d7">19,648</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute basic and diluted net loss per share</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfNS01LTEtMS05NTEzMg_27555fdf-b150-45bd-8d79-0e160aa5eef5"><ix:nonFraction unitRef="shares" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfNS01LTEtMS05NTEzMg_68a8a31c-d2a1-4e50-89fa-89a4ee7e6f91">53,643,216</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfNS03LTEtMS05NTEzMg_c0a28f3c-ff35-4803-9c6d-5afa001f38d2"><ix:nonFraction unitRef="shares" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfNS03LTEtMS05NTEzMg_dd92497a-008b-494d-8ef3-7bd2f0f90bff">53,015,459</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfNy01LTEtMS05NTEzMg_4a9506fc-f7b9-4ab8-a340-1f726553cc05"><ix:nonFraction unitRef="usdPerShare" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfNy01LTEtMS05NTEzMg_9fa1ba20-87a2-48cf-8147-bbe08700a6d6">0.44</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfNy03LTEtMS05NTEzMg_add1db06-fa70-4e5a-923a-853cc05f779f"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfNy03LTEtMS05NTEzMg_dea698bb-4af8-4cef-beba-cd026f5c6aa2">0.37</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:10pt"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RleHRyZWdpb246YjZkNDdlMGViMjhiNDcxMzg2NzYzYTIwMWUzOTRmYjhfNTky_cac96c93-07f6-4869-b644-3277d7bf6012" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from diluted net loss per share as of March&#160;31, 2023 and 2022 because their effect would be antidilutive:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock subject to outstanding options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff28c97b627c426b88f8092a57b829b0_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOjQwODRjZTMzMzRhNDQ5OGY5YmRkYzU4ZjQ0YjYzMGVkL3RhYmxlcmFuZ2U6NDA4NGNlMzMzNGE0NDk4ZjliZGRjNThmNDRiNjMwZWRfMi0xLTEtMS05NTEzMg_37b9dd1b-cf96-40c6-b940-6325ff108536">3,248,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia352f8b90bf24904ace711c2756fde74_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOjQwODRjZTMzMzRhNDQ5OGY5YmRkYzU4ZjQ0YjYzMGVkL3RhYmxlcmFuZ2U6NDA4NGNlMzMzNGE0NDk4ZjliZGRjNThmNDRiNjMwZWRfMi0zLTEtMS05NTEzMg_6f2ac600-fe4c-4b2e-b18c-b6898d55aa1f">2,091,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock subject to outstanding common stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i98353659a42b486aba5e86487dd2ed3a_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOjQwODRjZTMzMzRhNDQ5OGY5YmRkYzU4ZjQ0YjYzMGVkL3RhYmxlcmFuZ2U6NDA4NGNlMzMzNGE0NDk4ZjliZGRjNThmNDRiNjMwZWRfMy0xLTEtMS05NTEzMg_ee1f82d3-b53b-4d8b-8658-6c630537c4c5">3,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6dbca87d33d445efa90f6f1256c6c729_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOjQwODRjZTMzMzRhNDQ5OGY5YmRkYzU4ZjQ0YjYzMGVkL3RhYmxlcmFuZ2U6NDA4NGNlMzMzNGE0NDk4ZjliZGRjNThmNDRiNjMwZWRfMy0zLTEtMS05NTEzMg_d3178eb8-2798-40be-a475-848bc6df3d1f">3,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i916c5dbd66ef41e99dfbf453408341f9_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOjQwODRjZTMzMzRhNDQ5OGY5YmRkYzU4ZjQ0YjYzMGVkL3RhYmxlcmFuZ2U6NDA4NGNlMzMzNGE0NDk4ZjliZGRjNThmNDRiNjMwZWRfNS0xLTEtMS05NTEzMg_8a256d21-df3d-495f-af4d-e595655dedba">4,096,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd28b8c71bc54b94ac5b492390a28cbd_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOjQwODRjZTMzMzRhNDQ5OGY5YmRkYzU4ZjQ0YjYzMGVkL3RhYmxlcmFuZ2U6NDA4NGNlMzMzNGE0NDk4ZjliZGRjNThmNDRiNjMwZWRfNS0zLTEtMS05NTEzMg_c2219d49-6047-43ce-bf6d-f03317bfa315">2,047,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOjQwODRjZTMzMzRhNDQ5OGY5YmRkYzU4ZjQ0YjYzMGVkL3RhYmxlcmFuZ2U6NDA4NGNlMzMzNGE0NDk4ZjliZGRjNThmNDRiNjMwZWRfNi0xLTEtMS05NTEzMg_cedef7af-e12c-40ce-ac40-9f6888052c83">7,347,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOjQwODRjZTMzMzRhNDQ5OGY5YmRkYzU4ZjQ0YjYzMGVkL3RhYmxlcmFuZ2U6NDA4NGNlMzMzNGE0NDk4ZjliZGRjNThmNDRiNjMwZWRfNi0zLTEtMS05NTEzMg_05ca5320-18b7-4af2-a1e3-edb0806ce65a">4,142,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="idd35c15ee381485cb38f052732749537_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RleHRyZWdpb246YjNjMzVhMmQxYzU4NGQ1MWE1ZjE4YWUyODA1MGEyMjRfNjE2Nw_a0daf0e5-7e5c-4fff-bcfd-beb7fcf2b284" continuedAt="i2e1a6a09e0774f4cbd11caf0133c46c5" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i2e1a6a09e0774f4cbd11caf0133c46c5" continuedAt="i36ca53613aa24246aff0751bfdea2c09"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records its financial assets and liabilities at fair value.&#160;The carrying amounts of certain financial instruments of the Company, including cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities.&#160;&#160;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date.&#160;The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1: Inputs that include quoted prices in active markets for identical assets and liabilities.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:10pt"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RleHRyZWdpb246YjNjMzVhMmQxYzU4NGQ1MWE1ZjE4YWUyODA1MGEyMjRfNjE2Mw_15e7c17e-e550-4fc7-8f81-4f6e7b23a881" continuedAt="iec14061b88ee42e4a59f016dd7e43a04" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the Company&#8217;s financial assets and liabilities, measured at fair value on a recurring basis, as of March&#160;31, 2023 and December&#160;31, 2022 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measured Using</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6feff843c95d4820a893f80a14e8974a_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfNS0xLTEtMS05NTEzMg_b0cae7a9-cfed-4d35-83bc-412ea26c53bd">55,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83fa354129c74d06b48b4acdeb58085e_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfNS0zLTEtMS05NTEzMg_49a59c7d-ae55-4b1e-ac15-14924469944a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i954505cbda704b1997a446ed7dc5bd79_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfNS01LTEtMS05NTEzMg_5de66cca-4f29-4628-819a-c652a9a63f8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d197e2a742549a0b82fa9569fafad92_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfNS03LTEtMS05NTEzMg_d00bf6e4-e301-430b-8c18-896612c1ffd4">55,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78df972b73c44af19aec5841bf4e9ad2_I20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfNy0xLTEtMS05NTEzMg_2a62cf31-3626-4be3-87e1-7f93cf25b5a6">1,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c8f35fd17864198ae29d7c623d57285_I20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfNy0zLTEtMS05NTEzMg_f40abad3-539a-415c-944d-54a25ca5f626">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eb3ec4739c24023b02eae3760c24976_I20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfNy01LTEtMS05NTEzMg_529d23c5-6aa9-4f38-b92d-cb529b9d9c37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6385983faf6b4ce4907f11e0e0784a5a_I20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfNy03LTEtMS05NTEzMg_53674581-68a5-454e-9413-6db0db8b91dc">1,272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i982c944f16354821a3a11af57a4d12f5_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfOS0xLTEtMS05NTEzMg_b7e6df9d-c766-466c-901a-e45eb74469b4">56,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d76a02eaa334c0ca21f02a12b008068_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfOS0zLTEtMS05NTEzMg_be64c7cd-5636-4578-b71b-a5ad05e9a84e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e9038b180d4f5f9f7579ef703bdcc8_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfOS01LTEtMS05NTEzMg_6496835e-9ef7-48df-aa25-319f9204cfd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe1d6bd783044aa7ae7f1fa51bf4c2df_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfOS03LTEtMS05NTEzMg_ea9de254-cf4c-41b0-afbf-e7010ee48b45">56,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i982c944f16354821a3a11af57a4d12f5_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTItMS0xLTEtOTUxMzI_87f48de9-49c5-4d04-a520-c1c86e4aa4c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d76a02eaa334c0ca21f02a12b008068_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTItMy0xLTEtOTUxMzI_5918ad2f-00d2-46a9-a3b8-fcb9c8885e94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e9038b180d4f5f9f7579ef703bdcc8_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTItNS0xLTEtOTUxMzI_6fad805f-6c86-433b-81e7-96b0ad288d55">825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe1d6bd783044aa7ae7f1fa51bf4c2df_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTItNy0xLTEtOTUxMzI_a706750c-5827-47c8-a831-6df0def16558">825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i982c944f16354821a3a11af57a4d12f5_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTQtMS0xLTEtOTUxMzI_11970131-a219-42a8-8298-7c4b778896f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d76a02eaa334c0ca21f02a12b008068_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTQtMy0xLTEtOTUxMzI_7ea8b507-b87b-4637-8927-6fa7322aefc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e9038b180d4f5f9f7579ef703bdcc8_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTQtNS0xLTEtOTUxMzI_4b571e34-6907-4265-a570-cdb5a88a10a2">4,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe1d6bd783044aa7ae7f1fa51bf4c2df_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTQtNy0xLTEtOTUxMzI_15328c1c-35b5-436e-8d70-1bbd8780bca8">4,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i982c944f16354821a3a11af57a4d12f5_I20230331" decimals="-3" name="cdna:CommonStockWarrantLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTUtMS0xLTEtOTUxMzI_b0c92c28-8a35-4ba7-8f18-74234b226474">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d76a02eaa334c0ca21f02a12b008068_I20230331" decimals="-3" name="cdna:CommonStockWarrantLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTUtMy0xLTEtOTUxMzI_431785b2-9b05-4186-8936-89fba73d20c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e9038b180d4f5f9f7579ef703bdcc8_I20230331" decimals="-3" name="cdna:CommonStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTUtNS0xLTEtOTUxMzI_eab0c277-3901-42e9-97cd-8316480db1d3">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe1d6bd783044aa7ae7f1fa51bf4c2df_I20230331" decimals="-3" name="cdna:CommonStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTUtNy0xLTEtOTUxMzI_2a048cff-bc84-46ff-a3cf-885b3473416b">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i982c944f16354821a3a11af57a4d12f5_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTYtMS0xLTEtOTUxMzI_97733878-a5b1-4284-b5d2-64556b19c281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d76a02eaa334c0ca21f02a12b008068_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTYtMy0xLTEtOTUxMzI_6c7c7fd1-a3f4-4009-bdef-0cf8860be790">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e9038b180d4f5f9f7579ef703bdcc8_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTYtNS0xLTEtOTUxMzI_999fd05b-d09a-4a70-9d12-8ea82145f209">4,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe1d6bd783044aa7ae7f1fa51bf4c2df_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTYtNy0xLTEtOTUxMzI_d9816eb7-122d-499d-99f5-f912f7195fba">4,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><ix:continuation id="i36ca53613aa24246aff0751bfdea2c09" continuedAt="i1a3d1106f105455e8f31a3d3eccd3c08"><div><ix:continuation id="iec14061b88ee42e4a59f016dd7e43a04"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measured Using</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78142f02b6eb4ccfb1656d6f5f294a1d_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfNS0xLTEtMS05NTEzMg_de335ce2-62fa-43a3-9e5a-d44fef6e3990">66,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i802bf2c987da4c38af0138cb12b63a7a_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfNS0zLTEtMS05NTEzMg_227b0b85-535d-462e-bc1e-362a277cfc6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie661294c5d0d4cd39e08f501d3969965_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfNS01LTEtMS05NTEzMg_6999a07d-64cf-4522-a980-bb61a379193b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9400f589c5241c0a57ababdfed3f710_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfNS03LTEtMS05NTEzMg_ada319dd-cc23-4d3a-a506-06950c651eee">66,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a757ccddcac4f5d8f4be791fe555e95_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfNy0xLTEtMS05NTEzMg_97d5bc92-e277-475e-85ee-ee0cd02c99aa">2,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9b3c2ab35bb493688fa7d78b10d9620_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfNy0zLTEtMS05NTEzMg_6fab2d42-589e-493c-9c36-a3ff807f4671">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1ba9d00e75545f2a72fabc1672b6a66_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfNy01LTEtMS05NTEzMg_8f1d4e60-6dd6-4b30-964c-6a1b86414c93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f8db3692ea64671bcb30a21ef69e03c_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfNy03LTEtMS05NTEzMg_dfc47c99-aad3-4b33-8af5-782c879fc253">2,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4021690bcfc849d6bf7e8343dba5b82b_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfOS0xLTEtMS05NTEzMg_724e36b7-15eb-49f7-875f-bba08e81f089">68,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i548930b493bb4158a0dbc5d41dc95b2c_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfOS0zLTEtMS05NTEzMg_52aa893c-7227-4787-bef9-7a43f7478cb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7530e38c229d4e808c0bcbedf20ea6e4_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfOS01LTEtMS05NTEzMg_75c19057-c06e-472b-9c5f-0e8679a377bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4527e5b34bee42669774ad27f3195476_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfOS03LTEtMS05NTEzMg_5313166e-2a7a-476b-86a3-2d5b589bb64e">68,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4021690bcfc849d6bf7e8343dba5b82b_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTItMS0xLTEtOTUxMzI_4040051d-1143-4da9-9e30-9ab35267b73e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i548930b493bb4158a0dbc5d41dc95b2c_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTItMy0xLTEtOTUxMzI_b3beff05-39df-4c5f-bcdd-7d30b557fee0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7530e38c229d4e808c0bcbedf20ea6e4_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTItNS0xLTEtOTUxMzI_93c8e812-cc84-4d09-88ee-6759084a3343">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4527e5b34bee42669774ad27f3195476_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTItNy0xLTEtOTUxMzI_4facfe0a-b71b-4510-a9d8-b3585b01184b">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4021690bcfc849d6bf7e8343dba5b82b_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTQtMS0xLTEtOTUxMzI_e9c10c6b-ba19-4e09-88ac-f066c71911c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i548930b493bb4158a0dbc5d41dc95b2c_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTQtMy0xLTEtOTUxMzI_08e138bc-6995-479d-82e3-9c408652f94b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7530e38c229d4e808c0bcbedf20ea6e4_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTQtNS0xLTEtOTUxMzI_1d86f210-2e89-402a-94dd-c165bbcf8d8e">2,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4527e5b34bee42669774ad27f3195476_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTQtNy0xLTEtOTUxMzI_ad3d0e93-5da0-4a1b-9ed1-78fdec5acc44">2,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4021690bcfc849d6bf7e8343dba5b82b_I20221231" decimals="-3" name="cdna:CommonStockWarrantLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTUtMS0xLTEtOTUxMzI_f35fc619-6e62-4c55-9746-f8523b3d9718">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i548930b493bb4158a0dbc5d41dc95b2c_I20221231" decimals="-3" name="cdna:CommonStockWarrantLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTUtMy0xLTEtOTUxMzI_663b324f-8e3a-4844-ac09-d33906137136">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7530e38c229d4e808c0bcbedf20ea6e4_I20221231" decimals="-3" name="cdna:CommonStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTUtNS0xLTEtOTUxMzI_f3c4c964-85bf-48f0-9372-b103f11c9aad">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4527e5b34bee42669774ad27f3195476_I20221231" decimals="-3" name="cdna:CommonStockWarrantLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTUtNy0xLTEtOTUxMzI_6c5019ed-ec04-40a7-93d1-a45f46aff0f3">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4021690bcfc849d6bf7e8343dba5b82b_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTYtMS0xLTEtOTUxMzI_23e37576-6796-4c4f-a372-51601624acd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i548930b493bb4158a0dbc5d41dc95b2c_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTYtMy0xLTEtOTUxMzI_a5814005-1a7d-4ff6-8852-969b356a0b6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7530e38c229d4e808c0bcbedf20ea6e4_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTYtNS0xLTEtOTUxMzI_448b6546-4093-43f4-906d-903f51b32088">3,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4527e5b34bee42669774ad27f3195476_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTYtNy0xLTEtOTUxMzI_3ac389e8-beb9-4ab7-bbb2-05c01e1b3884">3,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:10pt"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RleHRyZWdpb246YjNjMzVhMmQxYzU4NGQ1MWE1ZjE4YWUyODA1MGEyMjRfNjE2NA_c9557401-dbe0-483d-8e28-0de5ad301bf4" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the issuances, exercises, changes in fair value and reclassifications of the Company&#8217;s Level 3 financial instruments that are measured at fair value on a recurring basis (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:87.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrant Liability and Contingent Consideration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmE1MWY1ZTUzMDQ5MzQ5Mjg4M2ZhZTU1OTdkZWYwYTc4L3RhYmxlcmFuZ2U6YTUxZjVlNTMwNDkzNDkyODgzZmFlNTU5N2RlZjBhNzhfMi0xLTEtMS05NTEzMg_6ad87ca9-11f7-4396-8b34-782e5baa2328">3,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in estimated fair value of common stock warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c804bdf4f040aca96273d8934d4389_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmE1MWY1ZTUzMDQ5MzQ5Mjg4M2ZhZTU1OTdkZWYwYTc4L3RhYmxlcmFuZ2U6YTUxZjVlNTMwNDkzNDkyODgzZmFlNTU5N2RlZjBhNzhfNC0xLTEtMS05NTEzMg_c7052dbd-1aa2-4ed3-a832-1816eae340af">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in estimated fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76877b7701634ea681c1e7599813ad95_D20230101-20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmE1MWY1ZTUzMDQ5MzQ5Mjg4M2ZhZTU1OTdkZWYwYTc4L3RhYmxlcmFuZ2U6YTUxZjVlNTMwNDkzNDkyODgzZmFlNTU5N2RlZjBhNzhfNi0xLTEtMS05NTEzMg_6bca7471-5dd5-46a1-81f5-b02bf1dd9ac5">421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Addition of estimated fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76877b7701634ea681c1e7599813ad95_D20230101-20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmE1MWY1ZTUzMDQ5MzQ5Mjg4M2ZhZTU1OTdkZWYwYTc4L3RhYmxlcmFuZ2U6YTUxZjVlNTMwNDkzNDkyODgzZmFlNTU5N2RlZjBhNzhfNy0xLTEtMS0xMDMwMTg_323eea26-c130-4a15-994c-dccb14b481cf">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments related to contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76877b7701634ea681c1e7599813ad95_D20230101-20230331" decimals="-3" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmE1MWY1ZTUzMDQ5MzQ5Mjg4M2ZhZTU1OTdkZWYwYTc4L3RhYmxlcmFuZ2U6YTUxZjVlNTMwNDkzNDkyODgzZmFlNTU5N2RlZjBhNzhfNy0xLTEtMS05NTEzMg_9d9d8094-9cf5-4479-88e2-fabcb9e1ea46">250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmE1MWY1ZTUzMDQ5MzQ5Mjg4M2ZhZTU1OTdkZWYwYTc4L3RhYmxlcmFuZ2U6YTUxZjVlNTMwNDkzNDkyODgzZmFlNTU5N2RlZjBhNzhfOC0xLTEtMS05NTEzMg_8b3d0ece-6880-4dc7-95e6-72dde76b11fc">4,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2023, the Company wrote off $<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RleHRyZWdpb246YjNjMzVhMmQxYzU4NGQ1MWE1ZjE4YWUyODA1MGEyMjRfMjE5OTAyMzI2MzMzMg_fb98c909-a523-4926-ada1-1305fae50f57">1.0</ix:nonFraction>&#160;million of its investment in convertible preferred shares from a private company which was carried at cost.  This private company's operations are in the process of being liquidated.  The fair value of this investment was based on Level 3 inputs. &#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining fair value, the Company uses various valuation approaches within the fair value measurement framework.&#160;&#160;The valuation methodologies used for the Company&#8217;s instruments measured at fair value and their classification in the valuation hierarchy are summarized below:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Investments in money market funds are classified within Level 1. Money market funds are valued at the closing price reported by the fund sponsor from an actively traded exchange.&#160;At March&#160;31, 2023 and December&#160;31, 2022, money market funds were included as cash and cash equivalents in the condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Short-term marketable securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Investments in short-term marketable securities are classified within Level 2. The securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Long-term marketable equity and debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Investments in long-term marketable equity securities are classified within Level 1. The securities are recorded at fair value based on readily available quoted market prices in active markets. Investments in long-term marketable debt securities are classified within Level 2. The securities are recorded at fair value based on observable inputs for quoted prices for identical or similar assets in markets that are not active. Long-term marketable securities are located within other assets on the condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration is classified within Level 3. Contingent consideration relates to asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquisitions and business combinations. The Company recorded the estimate of the fair value of the contingent consideration based on its evaluation of the probability of the achievement of the contractual </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1a3d1106f105455e8f31a3d3eccd3c08" continuedAt="i1af9878d5f5f488193be47c1decf97e9">conditions that would result in the payment of the contingent consideration. Contingent consideration was estimated using the fair value of the milestones to be paid if the contingency is met multiplied by management&#8217;s estimate of the probability of success at a discounted rate of <ix:nonFraction unitRef="number" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="2" name="cdna:BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RleHRyZWdpb246YjNjMzVhMmQxYzU4NGQ1MWE1ZjE4YWUyODA1MGEyMjRfMjE5OTAyMzI2MzMyOA_ed933709-4602-4509-8f13-95904cc5d34d">7</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i8d7cf5ad6102439bacdb4213332c001a_D20220101-20221231" decimals="2" name="cdna:BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RleHRyZWdpb246YjNjMzVhMmQxYzU4NGQ1MWE1ZjE4YWUyODA1MGEyMjRfNDE3Mg_138ee33c-4893-4007-bd89-1746797a6e65">12</ix:nonFraction>% at March&#160;31, 2023 and December&#160;31, 2022, respectively. The significant input in the Level 3 measurement that is not supported by market activity is the Company&#8217;s probability assessment of the achievement of the milestones. The value of the liability is subsequently remeasured to fair value at each reporting date, and the change in estimated fair value is recorded as a component of operating expenses until the milestones are paid, expire or are no longer achievable. Increases or decreases in the estimation of the probability percentage result in a directionally similar impact to the fair value measurement of the contingent consideration liability. The carrying amount of the contingent consideration liability represents its fair value. </ix:continuation></span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><ix:continuation id="i1af9878d5f5f488193be47c1decf97e9" continuedAt="ida556019566b4d5aa0bf681a5f5b266e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Common stock warrant liability</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ida556019566b4d5aa0bf681a5f5b266e"> &#8211; Common stock warrant liability is classified within Level 3. The Company utilizes intrinsic value to estimate the fair value of the warrants.&#160;The intrinsic value is computed as the difference between the fair value of the Company&#8217;s common stock on the valuation date and the exercise price of the warrants. Increases (decreases) in the Company's stock price discussed above result in a directionally similar impact to the fair value of the common stock warrant liability.</ix:continuation> </span></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="idd35c15ee381485cb38f052732749537_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RleHRyZWdpb246NjZhOGNjNmU4YmM0NDM0YTk5YmQyNWE5NDRlNWNmM2JfMTYyOQ_19a462e1-9804-4e46-ae7d-f2ed0f578f71" continuedAt="ic412bea6493546419af8214f151306c9" escape="true">CASH AND MARKETABLE SECURITIES</ix:nonNumeric></span></div><ix:continuation id="ic412bea6493546419af8214f151306c9" continuedAt="i76d5e0e78f5441dfb4766713009986d7"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RleHRyZWdpb246NjZhOGNjNmU4YmM0NDM0YTk5YmQyNWE5NDRlNWNmM2JfMTYzMA_0541b856-ad6d-44b4-846b-83b45ba5e593" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the amount reported within the condensed consolidated statements of cash flows is shown in the table below (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjU5ZDAwMmRlMjdkNjQyMjhiYWE4N2I0MWQ3ZGM1ZmVmL3RhYmxlcmFuZ2U6NTlkMDAyZGUyN2Q2NDIyOGJhYTg3YjQxZDdkYzVmZWZfMS0xLTEtMS05NTEzMg_ff8d817c-b8d7-4120-ba3a-bccc956d016e">74,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a9b5385be843b8be329d54dfcdc192_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjU5ZDAwMmRlMjdkNjQyMjhiYWE4N2I0MWQ3ZGM1ZmVmL3RhYmxlcmFuZ2U6NTlkMDAyZGUyN2Q2NDIyOGJhYTg3YjQxZDdkYzVmZWZfMS01LTEtMS05NTEzMg_2331ea47-c82a-4459-ac7d-d74f60a850dc">171,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjU5ZDAwMmRlMjdkNjQyMjhiYWE4N2I0MWQ3ZGM1ZmVmL3RhYmxlcmFuZ2U6NTlkMDAyZGUyN2Q2NDIyOGJhYTg3YjQxZDdkYzVmZWZfMi0xLTEtMS05NTEzMg_75649166-9782-4a43-b9b1-627528848397">520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a9b5385be843b8be329d54dfcdc192_I20220331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjU5ZDAwMmRlMjdkNjQyMjhiYWE4N2I0MWQ3ZGM1ZmVmL3RhYmxlcmFuZ2U6NTlkMDAyZGUyN2Q2NDIyOGJhYTg3YjQxZDdkYzVmZWZfMi01LTEtMS05NTEzMg_87e21a43-f14f-4cf1-8e14-2baf427fe624">214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjU5ZDAwMmRlMjdkNjQyMjhiYWE4N2I0MWQ3ZGM1ZmVmL3RhYmxlcmFuZ2U6NTlkMDAyZGUyN2Q2NDIyOGJhYTg3YjQxZDdkYzVmZWZfMy0xLTEtMS05NTEzMg_e1024d5b-217c-4024-a7ac-a8fab41980b9">75,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a9b5385be843b8be329d54dfcdc192_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjU5ZDAwMmRlMjdkNjQyMjhiYWE4N2I0MWQ3ZGM1ZmVmL3RhYmxlcmFuZ2U6NTlkMDAyZGUyN2Q2NDIyOGJhYTg3YjQxZDdkYzVmZWZfMy01LTEtMS05NTEzMg_f0b9c75b-52e3-4e6a-9e67-f8f061200e41">172,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketable Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All short-term marketable securities were considered held-to-maturity at March&#160;31, 2023. At March&#160;31, 2023, some of the Company&#8217;s short-term marketable securities were in an unrealized loss position. The Company determined that it had the positive intent and ability to hold until maturity all short-term marketable securities that have been in a continuous loss position, thus there was no recognition of any other-than-temporary impairment as of March&#160;31, 2023. All short-term marketable securities with unrealized losses as of the balance sheet date have been in a loss position for less than twelve months. Contractual maturities of the short-term marketable securities were within one year or less at March&#160;31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The long-term marketable equity securities were recorded at fair market value with changes in the fair value recognized in earnings at March&#160;31, 2023 and December&#160;31, 2022. The long-term marketable debt securities were considered available-for-sale at March&#160;31, 2023 and December&#160;31, 2022. The contractual maturities of the long-term marketable debt securities are less than three years.</span></div><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RleHRyZWdpb246NjZhOGNjNmU4YmM0NDM0YTk5YmQyNWE5NDRlNWNmM2JfMTYzMQ_c99b4993-6f64-4ad4-94a6-37c11b72a46c" continuedAt="i6bc965fab5334b6080882ae0ee3eb807" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding losses, and fair value of the Company&#8217;s marketable securities by major security type at each balance sheet date are summarized in the tables below (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia96d97ee1a464c7ca2c6ded0200614bc_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfMy0xLTEtMS05NjYyNQ_d06a707d-f307-49b8-ac00-68032778e0df">92,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia96d97ee1a464c7ca2c6ded0200614bc_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfMy0zLTEtMS05NjYyNQ_7228d154-d86e-4aae-9ff3-94771e386175">1,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia96d97ee1a464c7ca2c6ded0200614bc_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfMy01LTEtMS05NjYyNQ_860cab64-ea72-4f7c-b20e-2e95d48b3fe2">94,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84b41750f227461d843bbebd7625f870_I20230331" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfMy0xLTEtMS05NTEzMg_2e012d5c-a4af-49c6-b68c-c9de8acbe230">118,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84b41750f227461d843bbebd7625f870_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfMy0zLTEtMS05NTEzMg_a9db434a-7146-462f-b0d4-40209500d9a2">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84b41750f227461d843bbebd7625f870_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfMy01LTEtMS05NTEzMg_e1804196-3fc1-40a9-9d1e-08e7ddcab055">118,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="cdna:MarketableSecuritiesAmortizedCostShortTerm" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfNC0xLTEtMS05NTEzMg_7657e692-c7de-4937-9966-291794a217b9">211,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="cdna:MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfNC0zLTEtMS05NTEzMg_e0297370-e023-45a7-83d2-cdcfc364fea5">1,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="cdna:MarketableSecuritiesFairValueShortTerm" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfNC01LTEtMS05NTEzMg_e09cffcd-0ade-4767-a634-dd92fde09aed">212,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i205add77cb4a43d28264c36e6bb99b5e_I20230331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfNi0xLTEtMS05NTEzMg_96b3880e-3e90-4ac2-9c85-3dc05d9f0813">5,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i205add77cb4a43d28264c36e6bb99b5e_I20230331" decimals="-3" sign="-" name="cdna:EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfNi0zLTEtMS05NTEzMg_eebe3091-69eb-4b58-92a7-eb0722f7e48c">3,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i205add77cb4a43d28264c36e6bb99b5e_I20230331" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfNi01LTEtMS05NTEzMg_01ad7d20-bb86-46d6-bf74-586564b83ce2">1,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84b41750f227461d843bbebd7625f870_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfNy0xLTEtMS05NTEzMg_04731bab-15fa-45fa-8525-205adf4e1c00">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84b41750f227461d843bbebd7625f870_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfNy0zLTEtMS05NTEzMg_b965744e-ce64-4240-b39f-622f936c8212">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84b41750f227461d843bbebd7625f870_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfNy01LTEtMS05NTEzMg_e37949c0-5eee-4cb4-974a-a7514a9af3ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="cdna:MarketableSecuritiesAmortizedCostLongTerm" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfOC0xLTEtMS05NTEzMg_975e1748-0256-4633-8574-16d2ef224858">5,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" sign="-" name="cdna:MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfOC0zLTEtMS05NTEzMg_6689d1e1-d65a-4e2c-9b92-cf9579f7eb97">3,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="cdna:MarketableSecuritiesFairValueLongTerm" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfOC01LTEtMS05NTEzMg_ddb36e4b-a204-415a-ad70-e02114223428">1,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="cdna:MarketableSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfOS0xLTEtMS05NTEzMg_a7e2ef15-35cd-4064-a026-35058a498a0a">216,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" sign="-" name="cdna:MarketableSecuritiesAccumulatedUnrecognizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfOS0zLTEtMS05NTEzMg_5cabf40f-b1a8-4920-a872-5ff9962e839b">2,493</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfOS01LTEtMS05NTEzMg_6dede251-939b-4115-8794-f21e2bfad9dd">213,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i326a94ee25204ee282ab17ca652c83d6_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfMy0xLTEtMS05NjY1Mg_8771214d-9e67-43e8-b605-aa0e78768b99">79,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i326a94ee25204ee282ab17ca652c83d6_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfMy0zLTEtMS05NjY1Mg_89562a2d-3d78-4efc-bb4c-610ed42d9f6b">452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i326a94ee25204ee282ab17ca652c83d6_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfMy01LTEtMS05NjY1Mg_25655564-2bd5-4227-b779-135634f27453">79,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3863806f5974329a5f25691cef5e10f_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNC0xLTEtMS05NjY1Mg_10664323-b875-4dae-904e-5ae54220f2e2">123,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3863806f5974329a5f25691cef5e10f_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNC0zLTEtMS05NjY1Mg_3fa5e895-f092-489c-a006-a344107be725">220</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3863806f5974329a5f25691cef5e10f_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNC01LTEtMS05NjY1Mg_01a6fe4d-c6ae-4204-857e-17c53e3efa00">123,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="cdna:MarketableSecuritiesAmortizedCostShortTerm" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNS0xLTEtMS05NjY1Mg_4a91a320-a497-48eb-8e52-20c590410b3f">203,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="cdna:MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNS0zLTEtMS05NjY1Mg_22f6b7b1-413a-4784-8a67-10a7e448a6b7">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="cdna:MarketableSecuritiesFairValueShortTerm" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNS01LTEtMS05NjY1Mg_fa981085-bdc6-4edf-89fd-af14e8252ff8">203,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69def961a87843fcb2b9a4f9b65fc946_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfMy0xLTEtMS05NTEzMg_cc333e89-03f5-4bc0-8157-4253b656260c">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69def961a87843fcb2b9a4f9b65fc946_I20221231" decimals="-3" sign="-" name="cdna:EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfMy0zLTEtMS05NTEzMg_3c7a4beb-4b1f-4a68-b2d0-ba1773866f65">2,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69def961a87843fcb2b9a4f9b65fc946_I20221231" decimals="-3" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfMy01LTEtMS05NTEzMg_c04b0b0c-0984-4e74-b32d-023a741cb5ad">2,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="cdna:MarketableSecuritiesAmortizedCostLongTerm" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNC0xLTEtMS05NTEzMg_174d158a-f1b5-41e1-880f-048ab6c6ae07">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" sign="-" name="cdna:MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNC0zLTEtMS05NTEzMg_1551589a-aae0-4e97-a32d-06e00d09a720">2,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="cdna:MarketableSecuritiesFairValueLongTerm" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNC01LTEtMS05NTEzMg_8896e358-3a2a-4772-9c2e-0e594434c7c8">2,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="cdna:MarketableSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNS0xLTEtMS05NTEzMg_f82a267c-cae7-434d-b4d7-7f9cd7c28e16">208,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" sign="-" name="cdna:MarketableSecuritiesAccumulatedUnrecognizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNS0zLTEtMS05NTEzMg_6f4e788c-cca8-40e5-b479-d4ab364e8b53">2,692</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:MarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNS01LTEtMS05NTEzMg_92cbe509-1750-4b08-956d-00cd518e1adc">205,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><ix:continuation id="i76d5e0e78f5441dfb4766713009986d7"><ix:continuation id="i6bc965fab5334b6080882ae0ee3eb807"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of the marketable securities at each balance sheet date are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjRjYTlkZjg0MzZhZTQ2ODI5ZmI5NTE3NTEzNzAyZjU5L3RhYmxlcmFuZ2U6NGNhOWRmODQzNmFlNDY4MjlmYjk1MTc1MTM3MDJmNTlfMS0xLTEtMS05NTEzMg_bdacb43f-1047-4b70-af74-4fbd48fb3afd">211,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjRjYTlkZjg0MzZhZTQ2ODI5ZmI5NTE3NTEzNzAyZjU5L3RhYmxlcmFuZ2U6NGNhOWRmODQzNmFlNDY4MjlmYjk1MTc1MTM3MDJmNTlfMS0yLTEtMS05NTEzMg_9bec87ba-338a-4448-87a5-0ed57c75df69">203,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjRjYTlkZjg0MzZhZTQ2ODI5ZmI5NTE3NTEzNzAyZjU5L3RhYmxlcmFuZ2U6NGNhOWRmODQzNmFlNDY4MjlmYjk1MTc1MTM3MDJmNTlfMi0xLTEtMS05NTEzMg_ff84118c-2e3b-4a55-af0d-df473b8c689a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjRjYTlkZjg0MzZhZTQ2ODI5ZmI5NTE3NTEzNzAyZjU5L3RhYmxlcmFuZ2U6NGNhOWRmODQzNmFlNDY4MjlmYjk1MTc1MTM3MDJmNTlfMi0yLTEtMS05NTEzMg_f8c738cf-713e-4d37-a223-2c4ab8153a5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjRjYTlkZjg0MzZhZTQ2ODI5ZmI5NTE3NTEzNzAyZjU5L3RhYmxlcmFuZ2U6NGNhOWRmODQzNmFlNDY4MjlmYjk1MTc1MTM3MDJmNTlfMy0xLTEtMS05NTEzMg_1da62c2c-cdbd-40d6-ae75-021dd7266939">211,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjRjYTlkZjg0MzZhZTQ2ODI5ZmI5NTE3NTEzNzAyZjU5L3RhYmxlcmFuZ2U6NGNhOWRmODQzNmFlNDY4MjlmYjk1MTc1MTM3MDJmNTlfMy0yLTEtMS05NTEzMg_2f2f0cb2-47da-4d68-bf54-255160641e57">203,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation></ix:continuation><div id="idd35c15ee381485cb38f052732749537_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RleHRyZWdpb246MmQxOWJkMDBiMTdmNGE3NGIyZjQ3MTU2NjM2Yjc3MjBfNjMxNQ_cd8f8683-5049-4d1e-81be-444c25b81def" continuedAt="i2ef287e200b84bb6961d7ae79a442eef" escape="true">BUSINESS COMBINATIONS</ix:nonNumeric></span></div><ix:continuation id="i2ef287e200b84bb6961d7ae79a442eef" continuedAt="i3019ff9dc2c447b6bb2b7f59bcb8130e"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">HLA Data Systems</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company acquired HLA Data Systems, a Texas-based company that provides software and interoperability solutions for the histocompatibility and immunogenetics community. The Company acquired HLA Data Systems with a combination of cash consideration paid upfront and contingent consideration with a fair value of $<ix:nonFraction unitRef="usd" contextRef="i5655b5a1a84d4b98979a99a6db9e0ff2_D20230101-20230131" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RleHRyZWdpb246MmQxOWJkMDBiMTdmNGE3NGIyZjQ3MTU2NjM2Yjc3MjBfNTQ5NzU1ODM3NzQ5_7334affe-c7d7-4289-b766-56687080b499">1.3</ix:nonFraction>&#160;million. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for the transaction as a business combination using the acquisition method of accounting. Acquisition-related costs of $<ix:nonFraction unitRef="usd" contextRef="i5655b5a1a84d4b98979a99a6db9e0ff2_D20230101-20230131" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RleHRyZWdpb246MmQxOWJkMDBiMTdmNGE3NGIyZjQ3MTU2NjM2Yjc3MjBfNTQ5NzU1ODM3NzY3_26d32481-142d-4fe6-aa79-278469d63f3d">0.4</ix:nonFraction>&#160;million associated with the acquisition were expensed as incurred, and classified as part of general and administrative expenses in the condensed consolidated statement of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill of $<ix:nonFraction unitRef="usd" contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RleHRyZWdpb246MmQxOWJkMDBiMTdmNGE3NGIyZjQ3MTU2NjM2Yjc3MjBfNTQ5NzU1ODM3Nzg1_3120655f-d92f-4e7b-bf3c-825008085ae6">2.1</ix:nonFraction>&#160;million arising from the acquisition primarily consists of synergies from integrating HLA Data Systems' technology with the current testing and digital solutions offered by the Company. The acquisition of HLA Data Systems will provide a robust and comprehensive Laboratory Information Management System and support the laboratory workflows. <ix:nonFraction unitRef="usd" contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131" decimals="-5" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RleHRyZWdpb246MmQxOWJkMDBiMTdmNGE3NGIyZjQ3MTU2NjM2Yjc3MjBfMTA5OTUxMTY1MTk2NA_48a3889c-d2e4-4fa6-b737-17bdf21663bc">None</ix:nonFraction> of the goodwill is expected to be deductible for income tax purposes. All of the goodwill has been assigned to the Company&#8217;s existing operating segment.</span></div><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RleHRyZWdpb246MmQxOWJkMDBiMTdmNGE3NGIyZjQ3MTU2NjM2Yjc3MjBfMTY0OTI2NzQ2NTc4NQ_61ba866e-cd55-49ff-a6a8-6b49ac095113" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair values of the intangible assets acquired as of the acquisition date ($ in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:69.264%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Estimated Fair Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Estimated Useful Lives (Years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Customer relationships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e8dea3df85a402dbf74f31228595f6c_I20230131" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjBhYmY1NDA5YTIyNjQwNmY4ZGU1NDEwMjE2ODk3YTA3L3RhYmxlcmFuZ2U6MGFiZjU0MDlhMjI2NDA2ZjhkZTU0MTAyMTY4OTdhMDdfMS0xLTEtMS0xMDAxOTA_6933e97b-a2c7-4116-bf25-36cd5151c6bd">3,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib370105b87eb4834ba579147ac153394_D20230101-20230131" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjBhYmY1NDA5YTIyNjQwNmY4ZGU1NDEwMjE2ODk3YTA3L3RhYmxlcmFuZ2U6MGFiZjU0MDlhMjI2NDA2ZjhkZTU0MTAyMTY4OTdhMDdfMS0zLTEtMS0xMDMxNjA_3afceab2-cc1b-45ee-bff9-a3e5468dd605">13</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Developed technology</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58e73d1a09944b02869b176e945eb1ef_I20230131" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjBhYmY1NDA5YTIyNjQwNmY4ZGU1NDEwMjE2ODk3YTA3L3RhYmxlcmFuZ2U6MGFiZjU0MDlhMjI2NDA2ZjhkZTU0MTAyMTY4OTdhMDdfMi0xLTEtMS0xMDAxOTA_c068ccae-103a-49d1-a3c0-fc4c76118c7f">770</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibd80e498ad9d43fcaa85af5f97ce31df_D20230101-20230131" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjBhYmY1NDA5YTIyNjQwNmY4ZGU1NDEwMjE2ODk3YTA3L3RhYmxlcmFuZ2U6MGFiZjU0MDlhMjI2NDA2ZjhkZTU0MTAyMTY4OTdhMDdfMi0zLTEtMS0xMDMxNjA_3aaff3f9-dabc-42f2-9d96-3b57e5da524a">11</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i354e7a3f27e044eab26ae4b1d2cde545_I20230131" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjBhYmY1NDA5YTIyNjQwNmY4ZGU1NDEwMjE2ODk3YTA3L3RhYmxlcmFuZ2U6MGFiZjU0MDlhMjI2NDA2ZjhkZTU0MTAyMTY4OTdhMDdfMy0xLTEtMS0xMDAxOTA_fcfc6c3d-51ab-47f9-b239-879d70c68d28">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2fe8183fbe32453d99cc54713eadebe2_D20230101-20230131" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjBhYmY1NDA5YTIyNjQwNmY4ZGU1NDEwMjE2ODk3YTA3L3RhYmxlcmFuZ2U6MGFiZjU0MDlhMjI2NDA2ZjhkZTU0MTAyMTY4OTdhMDdfMy0zLTEtMS0xMDMxNjA_d36f82a7-5209-4852-8d5c-84e7a88a810d">17</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjBhYmY1NDA5YTIyNjQwNmY4ZGU1NDEwMjE2ODk3YTA3L3RhYmxlcmFuZ2U6MGFiZjU0MDlhMjI2NDA2ZjhkZTU0MTAyMTY4OTdhMDdfNC0xLTEtMS0xMDAxOTA_a00f4b9e-069a-46f8-904c-4a6af15f2c95">4,100</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships acquired by the Company represent the fair value of future projected revenue that is expected to be derived from sales of HLA Data Systems&#8217; products to existing customers. The customer relationships&#8217; fair value has been estimated utilizing a multi-period excess earnings method under the income approach, which reflects the present value of the projected cash flows that are expected to be generated by the customer relationships, less charges representing the contribution of other assets to those cash flows that use projected cash flows with and without the intangible asset in place. The economic useful life was determined based on the distribution of the present value of the cash flows attributable to the intangible asset.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquired developed technology represents the fair value of HLA Data Systems' proprietary software. The trademark acquired consists primarily of the HLA Data Systems brand and markings. The fair value of both the developed technology and the trademark were determined using the relief-from-royalty method under the income approach. This method considers the value of the asset to be the value of the royalty payments from which the Company is relieved due to its ownership of the asset. The royalty rates of <ix:nonFraction unitRef="number" contextRef="i58e73d1a09944b02869b176e945eb1ef_I20230131" decimals="2" name="cdna:IntangibleAssetMeasurementInputRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RleHRyZWdpb246MmQxOWJkMDBiMTdmNGE3NGIyZjQ3MTU2NjM2Yjc3MjBfNTQ5NzU1ODM3Nzk2_58d9b2f4-90c9-4160-a0b9-2312ffe8f0ad">10</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i354e7a3f27e044eab26ae4b1d2cde545_I20230131" decimals="2" name="cdna:IntangibleAssetMeasurementInputRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RleHRyZWdpb246MmQxOWJkMDBiMTdmNGE3NGIyZjQ3MTU2NjM2Yjc3MjBfNTQ5NzU1ODM3ODAy_98df6334-8864-4ccd-b4a6-91616ec88c3b">2</ix:nonFraction>% were used to estimate the fair value of the developed technology and the trademark, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A discount rate of <ix:nonFraction unitRef="number" contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131" decimals="2" name="cdna:IntangibleAssetMeasurementInputDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RleHRyZWdpb246MmQxOWJkMDBiMTdmNGE3NGIyZjQ3MTU2NjM2Yjc3MjBfMTA5OTUxMTY1MTk1NA_9df37599-3d5f-4d83-b1d0-ff061f31b964">24</ix:nonFraction>% was utilized in estimating the fair value of these three intangible assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pro forma impact of the HLA Data Systems acquisition is not material, and the results of operations of the acquisition have been included in the Company's condensed consolidated statements of operations from the respective acquisition date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration Paid</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RleHRyZWdpb246MmQxOWJkMDBiMTdmNGE3NGIyZjQ3MTU2NjM2Yjc3MjBfMTY0OTI2NzQ2NTc4Ng_39dd1fe7-afe1-426e-961b-83ccc5677d7e" continuedAt="ie25eab3db93441cfa2ba7a7a8bfc5e08" escape="true">The following table summarizes the consideration paid for HLA Data Systems and the amounts of the assets acquired and liabilities assumed recognized at their estimated fair value at the acquisition date (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><ix:continuation id="i3019ff9dc2c447b6bb2b7f59bcb8130e"><div style="margin-top:6pt"><ix:continuation id="ie25eab3db93441cfa2ba7a7a8bfc5e08"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.076%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Consideration</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib01dc638da5843b694334d2ca357325f_D20210101-20210131" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjJjMWM0ZDViODQ1OTRkOWQ5Mjc4MmU0YWMxNzc3YjNkL3RhYmxlcmFuZ2U6MmMxYzRkNWI4NDU5NGQ5ZDkyNzgyZTRhYzE3NzdiM2RfMi0xLTEtMS0xMDMyMzk_459f21bc-48e8-4015-b0fe-f30ef2221df7">4,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total consideration</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib01dc638da5843b694334d2ca357325f_D20210101-20210131" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjJjMWM0ZDViODQ1OTRkOWQ5Mjc4MmU0YWMxNzc3YjNkL3RhYmxlcmFuZ2U6MmMxYzRkNWI4NDU5NGQ5ZDkyNzgyZTRhYzE3NzdiM2RfMy0xLTEtMS0xMDMyMzk_62573fa5-3962-4107-b630-e51142742125">4,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recognized amounts of identifiable assets acquired and liabilities assumed</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjJjMWM0ZDViODQ1OTRkOWQ5Mjc4MmU0YWMxNzc3YjNkL3RhYmxlcmFuZ2U6MmMxYzRkNWI4NDU5NGQ5ZDkyNzgyZTRhYzE3NzdiM2RfNi0xLTEtMS0xMDMyMzk_6024b899-9a21-41b1-ae3e-64e47b82a137">1,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Identifiable intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjJjMWM0ZDViODQ1OTRkOWQ5Mjc4MmU0YWMxNzc3YjNkL3RhYmxlcmFuZ2U6MmMxYzRkNWI4NDU5NGQ5ZDkyNzgyZTRhYzE3NzdiM2RfNy0xLTEtMS0xMDMyMzk_9ca5d8ba-d0e5-495d-a21b-73331c96a185">4,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjJjMWM0ZDViODQ1OTRkOWQ5Mjc4MmU0YWMxNzc3YjNkL3RhYmxlcmFuZ2U6MmMxYzRkNWI4NDU5NGQ5ZDkyNzgyZTRhYzE3NzdiM2RfOC0xLTEtMS0xMDMyMzk_590b2375-a08c-4467-9a37-3196ba4b324b">786</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjJjMWM0ZDViODQ1OTRkOWQ5Mjc4MmU0YWMxNzc3YjNkL3RhYmxlcmFuZ2U6MmMxYzRkNWI4NDU5NGQ5ZDkyNzgyZTRhYzE3NzdiM2RfOS0xLTEtMS0xMDMyMzk_eb698f92-d628-4fb3-997e-ad1eddbaf7f7">699</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Contingent considerations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131" decimals="-3" name="cdna:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjJjMWM0ZDViODQ1OTRkOWQ5Mjc4MmU0YWMxNzc3YjNkL3RhYmxlcmFuZ2U6MmMxYzRkNWI4NDU5NGQ5ZDkyNzgyZTRhYzE3NzdiM2RfMTAtMS0xLTEtMTAzMjM5_7943953e-5664-4d12-8f52-c674cb619b0e">1,300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjJjMWM0ZDViODQ1OTRkOWQ5Mjc4MmU0YWMxNzc3YjNkL3RhYmxlcmFuZ2U6MmMxYzRkNWI4NDU5NGQ5ZDkyNzgyZTRhYzE3NzdiM2RfMTEtMS0xLTEtMTAzMjM5_236ec469-60df-480f-a009-6ce0c0aff9c2">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total identifiable net assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjJjMWM0ZDViODQ1OTRkOWQ5Mjc4MmU0YWMxNzc3YjNkL3RhYmxlcmFuZ2U6MmMxYzRkNWI4NDU5NGQ5ZDkyNzgyZTRhYzE3NzdiM2RfMTItMS0xLTEtMTAzMjM5_bfd503cc-25bf-42a8-ad37-a694c5ac9c17">2,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjJjMWM0ZDViODQ1OTRkOWQ5Mjc4MmU0YWMxNzc3YjNkL3RhYmxlcmFuZ2U6MmMxYzRkNWI4NDU5NGQ5ZDkyNzgyZTRhYzE3NzdiM2RfMTMtMS0xLTEtMTAzMjM5_4c45d22a-df1d-4371-aa7a-bb665b084702">2,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjJjMWM0ZDViODQ1OTRkOWQ5Mjc4MmU0YWMxNzc3YjNkL3RhYmxlcmFuZ2U6MmMxYzRkNWI4NDU5NGQ5ZDkyNzgyZTRhYzE3NzdiM2RfMTQtMS0xLTEtMTAzMjM5_8d372774-85c3-4729-ab34-1412dd822074">4,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the purchase price to assets acquired and liabilities assumed was based on the fair value of such assets and liabilities as of the acquisition date.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="idd35c15ee381485cb38f052732749537_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfMjM3OQ_88f72cf4-fa4a-495f-91a7-186be7e66a27" continuedAt="ide7488493b9b4b04812a71433fc27646" escape="true">GOODWILL AND INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="ide7488493b9b4b04812a71433fc27646" continuedAt="ic998898e3f9146ca96add9515b29fc02"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Goodwill</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is recorded when the purchase price of an acquisition exceeds the fair value of the net tangible and identified intangible assets acquired.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested annually for impairment at the reporting unit level during the fourth quarter or earlier upon the occurrence of certain events or substantive changes in circumstances. There were no indicators of impairment in the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended March&#160;31, 2023. The balance of the Company's goodwill was $<ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfNjU5NzA2OTc2OTA1NA_0882c184-d0a2-484c-a541-61787c760a5f">39.6</ix:nonFraction>&#160;million as of March&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfNjU5NzA2OTc2OTA0MQ_94eecdd3-5dd3-41a7-92a0-75a6ebf90d20">37.5</ix:nonFraction>&#160;million as of December&#160;31, 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intangible Assets</span></div><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="cdna:ScheduleOfIntangibleAssetsTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfMjM4MA_0081022e-0616-4bce-9ac3-2263a7003df1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of the Company&#8217;s intangible assets as of March&#160;31, 2023 ($ in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:34.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Useful&#160;Life<br/>(In&#160;Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with finite lives:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired and developed technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2fc3487bfd640a096722284a0d737e0_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfMy0xLTEtMS05NTEzMg_ff0bd697-8a8e-46af-bd2f-633e6a367d1a">36,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2fc3487bfd640a096722284a0d737e0_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfMy0zLTEtMS05NTEzMg_4fc3bf8c-4fdd-41d6-ba31-41df91d7acb6">15,931</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2fc3487bfd640a096722284a0d737e0_I20230331" decimals="-3" name="cdna:FiniteLivedIntangibleForeignCurrencyTranslation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfMy01LTEtMS05NTEzMg_b12377f7-6fa1-4338-accd-dd972b372701">2,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2fc3487bfd640a096722284a0d737e0_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfMy03LTEtMS05NTEzMg_b91c10a9-1f7a-4fa2-b73a-77de6d93d211">18,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2aa30743f4a44b15900e7f593b2ae88b_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfMy05LTEtMS05NTEzMg_24269283-3610-407b-8612-740a5711ef4d">7.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82959e331a5e485bbf7ae6493073076f_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNC0xLTEtMS05NTEzMg_f5e17cac-714e-4270-afb6-1531fb6e5b95">24,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82959e331a5e485bbf7ae6493073076f_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNC0zLTEtMS05NTEzMg_bb85c5bc-7ac2-4eb2-9d35-01c85e63159b">7,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82959e331a5e485bbf7ae6493073076f_I20230331" decimals="-3" name="cdna:FiniteLivedIntangibleForeignCurrencyTranslation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNC01LTEtMS05NTEzMg_e10017b9-d901-4077-9c2e-27dd059f92ee">2,067</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82959e331a5e485bbf7ae6493073076f_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNC03LTEtMS05NTEzMg_405851b6-67be-4262-8119-d8fed8b0006b">14,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib9bc39941c984943b121612207ca37ea_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNC05LTEtMS05NTEzMg_0157b84a-b9e7-4fc7-9396-5b3928ede4fb">9.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercialization rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81dc9074721e44aba01ef41b26358b4c_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNS0xLTEtMS05NTEzMg_c8258b82-6472-40db-9ed7-ad47042659e3">11,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81dc9074721e44aba01ef41b26358b4c_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNS0zLTEtMS05NTEzMg_b69b6078-982b-4fe8-971e-58dcc0c44e27">3,549</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81dc9074721e44aba01ef41b26358b4c_I20230331" decimals="-3" name="cdna:FiniteLivedIntangibleForeignCurrencyTranslation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNS01LTEtMS05NTEzMg_1f77486e-b532-45a7-85b3-040f23c214f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81dc9074721e44aba01ef41b26358b4c_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNS03LTEtMS05NTEzMg_7851a29f-e69f-460d-8b53-02e3b6fd29ec">8,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iacaeaa220cfc409e84deae3b9074cbe5_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNS05LTEtMS05NTEzMg_8473ad17-0a7b-4825-8c1d-018ab6660816">6.3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and tradenames</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if342038ec26148cfaed98ce1574cd8a0_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNi0xLTEtMS05NTEzMg_274bf4df-0748-4b6f-a2ee-fa0924494247">4,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if342038ec26148cfaed98ce1574cd8a0_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNi0zLTEtMS05NTEzMg_78324181-7a0b-4763-bd3c-c47357edcac9">1,434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if342038ec26148cfaed98ce1574cd8a0_I20230331" decimals="-3" name="cdna:FiniteLivedIntangibleForeignCurrencyTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNi01LTEtMS05NTEzMg_280a4b2b-5cdf-4de1-a0ca-f199c20bc7cb">308</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if342038ec26148cfaed98ce1574cd8a0_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNi03LTEtMS05NTEzMg_dd8e465e-02f1-428e-b3d4-5cf407f7599c">3,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0036ec09081944e38ff9a50586cb6917_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNi05LTEtMS05NTEzMg_7e00b21b-174f-4e7f-af1e-96b4e48e55f4">9.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets with finite lives</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfOC0xLTEtMS05NTEzMg_0a9f3411-f7a5-4bc8-a87a-213a88884042">77,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfOC0zLTEtMS05NTEzMg_ac4a99e8-3098-4782-99a1-428b4e6e7535">28,766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="cdna:FiniteLivedIntangibleForeignCurrencyTranslation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfOC01LTEtMS05NTEzMg_aee19827-3c48-4b06-a39f-306f2ee2ec45">4,711</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfOC03LTEtMS05NTEzMg_93c2fa3b-79f0-4a30-a35d-a559a083b7ee">44,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6ec54cc1d354dcc992a0bee7218aeb2_I20230331" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfOS0xLTEtMS05NTEzMg_19c6251f-cd16-49be-983a-7ddc31508766">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6ec54cc1d354dcc992a0bee7218aeb2_I20230331" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfOS03LTEtMS05NTEzMg_50ba3d03-1f66-4a77-b890-16b68f4cfa59">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfMTAtMS0xLTEtOTUxMzI_e0ca68ae-44ec-4190-a1fa-cb025cac8cec">79,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfMTAtMy0xLTEtOTUxMzI_20bc3140-9811-4641-92a8-c6b83778ac3b">28,766</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="cdna:FiniteLivedIntangibleForeignCurrencyTranslation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfMTAtNS0xLTEtOTUxMzI_ef388e49-f7ad-4dba-b786-9d59a2163650">4,711</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfMTAtNy0xLTEtOTUxMzI_be399f1a-fdef-4582-a1e9-51a8ec7b5fd7">45,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of the Company&#8217;s intangible assets as of December&#160;31, 2022 ($ in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:34.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Useful&#160;Life<br/>(In&#160;Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with finite lives:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired and developed technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a7b81e566d3418c8a4da63e000dd0da_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfMy0xLTEtMS05NTEzMg_24ac2494-9ede-401f-949d-609685810246">35,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a7b81e566d3418c8a4da63e000dd0da_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfMy0zLTEtMS05NTEzMg_e6a4bfc3-8c18-40d8-b85d-b86740202150">15,138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a7b81e566d3418c8a4da63e000dd0da_I20221231" decimals="-3" name="cdna:FiniteLivedIntangibleForeignCurrencyTranslation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfMy01LTEtMS05NTEzMg_9b4bc3fc-b8c1-47ab-b332-17c86e389e20">2,369</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a7b81e566d3418c8a4da63e000dd0da_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfMy03LTEtMS05NTEzMg_cc3f61b0-49fc-4b37-ba6e-2055c227e5f6">18,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iefc3516196544bbba967fcfe05accd44_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfMy05LTEtMS05NTEzMg_1f0d95d7-9839-473b-8e54-bb972804c245">7.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia62355ec8eeb43cb853e7e57dc207494_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNC0xLTEtMS05NTEzMg_aaac9426-acc7-4fdb-98dc-98b24a55482c">21,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia62355ec8eeb43cb853e7e57dc207494_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNC0zLTEtMS05NTEzMg_ffd9bd19-cb67-4306-b2ea-46bc0f76a1dd">7,459</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia62355ec8eeb43cb853e7e57dc207494_I20221231" decimals="-3" name="cdna:FiniteLivedIntangibleForeignCurrencyTranslation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNC01LTEtMS05NTEzMg_dc4b863c-8d34-44a8-88cb-88964aa763f0">2,104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia62355ec8eeb43cb853e7e57dc207494_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNC03LTEtMS05NTEzMg_afa60bc1-2329-4ba2-bf5f-6f20094075b5">12,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib827b41ea375450e89bc78d2c9d5f1e8_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNC05LTEtMS05NTEzMg_dc2491b3-6d0a-4fe2-8d41-c7844fdee854">9.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercialization rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63ef863071a4109a09043df7d31f2f0_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNS0xLTEtMS05NTEzMg_1acf81ef-af7d-4729-a0e7-c477061a4509">11,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63ef863071a4109a09043df7d31f2f0_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNS0zLTEtMS05NTEzMg_7ee48615-e6f5-4dcc-ac4f-ccc2d9d2475a">3,233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63ef863071a4109a09043df7d31f2f0_I20221231" decimals="-3" name="cdna:FiniteLivedIntangibleForeignCurrencyTranslation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNS01LTEtMS05NTEzMg_6b46dc1a-1ddf-4e7a-a478-57b3811b8709">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib63ef863071a4109a09043df7d31f2f0_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNS03LTEtMS05NTEzMg_ebe96bde-b1b9-40cf-83fb-0d6a5f104314">8,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0d9134ab3e244582ae611652d1ce3c6e_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNS05LTEtMS05NTEzMg_6b68dd05-6389-4235-9333-4e45f088aeac">6.6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and tradenames</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e54691c1394d72bf91f3d75605544b_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNi0xLTEtMS05NTEzMg_f29440e8-2fc3-475d-bd10-95006f9382a6">4,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5e54691c1394d72bf91f3d75605544b_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNi0zLTEtMS05NTEzMg_9a254360-f46f-4d91-8cc7-f89acf4d0caa">1,345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5e54691c1394d72bf91f3d75605544b_I20221231" decimals="-3" name="cdna:FiniteLivedIntangibleForeignCurrencyTranslation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNi01LTEtMS05NTEzMg_0b305fdc-461a-4e4d-8e45-6bcaad81a9bf">315</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e54691c1394d72bf91f3d75605544b_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNi03LTEtMS05NTEzMg_5daa1381-7863-4a42-bec8-6d1f25b0c203">2,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib6c57f7627c542678d43812cf1f234ae_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNi05LTEtMS05NTEzMg_36a1d5c4-e5a8-4719-8ae0-fcb54b458390">8.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets with finite lives</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfOC0xLTEtMS05NTEzMg_4a18d912-b7f0-479d-aeeb-f16bb846937b">73,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfOC0zLTEtMS05NTEzMg_c08b2246-0793-46ce-8554-83bdc7e35915">27,175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="cdna:FiniteLivedIntangibleForeignCurrencyTranslation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfOC01LTEtMS05NTEzMg_9019c222-8c16-473c-89f9-7326352cfcb4">4,788</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfOC03LTEtMS05NTEzMg_e2cc213a-fa9e-4c90-b304-393740beda8c">41,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if016caa1aa6b4d3e9e03eaa31d2e3b97_I20221231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfOS0xLTEtMS05NTEzMg_44e2444f-8323-4726-93fe-b378403fbcdb">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if016caa1aa6b4d3e9e03eaa31d2e3b97_I20221231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfOS03LTEtMS05NTEzMg_726454ad-7486-45ee-bbb1-70ffe6a5fdb7">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfMTAtMS0xLTEtOTUxMzI_0076958e-f514-4c67-aff6-b3099a292593">75,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfMTAtMy0xLTEtOTUxMzI_e1dba62b-0cd9-43c5-8e78-39b4461cfae7">27,175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="cdna:FiniteLivedIntangibleForeignCurrencyTranslation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfMTAtNS0xLTEtOTUxMzI_002eadc2-f8e6-4d35-94f3-5613b549b75f">4,788</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfMTAtNy0xLTEtOTUxMzI_fe0c597d-ad9f-4f9e-b08b-a9313e66a645">43,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Acquisition of Intangible Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company acquired commercialization rights in an exclusive partnership for comprehensive data analytics in relation to NGS-based metagenomics testing for infectious diseases. In 2022, the Company incurred additional costs related to this partnership of $<ix:nonFraction unitRef="usd" contextRef="i0d9134ab3e244582ae611652d1ce3c6e_D20220101-20221231" decimals="-5" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfNTQ5NzU1ODE4MDc0_69ec42a4-acf6-4fb2-864e-14a7f3446c2f">1.0</ix:nonFraction> million. These are included within commercialization rights as of March&#160;31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company acquired the Transplant Hero patient application. The patient application is included in Acquired and developed technology as of March&#160;31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2021, acquisition of intangible assets increased $<ix:nonFraction unitRef="usd" contextRef="ie657b500f633441d881331275caa19f4_D20211001-20211231" decimals="-5" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfMTI0OA_feba47d1-60a8-4c91-b9b0-8e9f89d95c49">13.4</ix:nonFraction>&#160;million primarily from business combinations. These acquisitions included $<ix:nonFraction unitRef="usd" contextRef="ia89f50d5989f473cbde4f16140a46923_D20211001-20211231" decimals="-5" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfMTMxNw_cf0e00b8-f31a-48a2-ac19-c243cbf2db22">4.7</ix:nonFraction>&#160;million of Acquired and developed technology, $<ix:nonFraction unitRef="usd" contextRef="i2c08b28aa3d0463a87a6374e3e679813_D20211001-20211231" decimals="-5" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfMTM1OA_51162c42-0293-45c3-a542-841efc0bbc96">2.5</ix:nonFraction>&#160;million of Commercialization rights, $<ix:nonFraction unitRef="usd" contextRef="i9ecfb95f5ca641be8f0f195a6fa22f65_D20211001-20211231" decimals="-5" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfMTM5MA_83f86670-de2d-4d78-8637-1f6f7b7a302c">3.7</ix:nonFraction>&#160;million of Customer relationships, $<ix:nonFraction unitRef="usd" contextRef="i15c9947ac20a442e90a185154951f24c_D20211001-20211231" decimals="-5" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfMTQyMA_2cf88438-74b3-489a-aa96-42db2b80b5d2">2.2</ix:nonFraction>&#160;million of Trademarks and tradenames and $<ix:nonFraction unitRef="usd" contextRef="i857e050dfe06462ebf29ac3ad1bbd400_D20211001-20211231" decimals="-5" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfMTQ1Ng_ab91f64f-2d47-435f-9e58-088540fb6565">0.3</ix:nonFraction>&#160;million of Other intangible assets.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><ix:continuation id="ic998898e3f9146ca96add9515b29fc02"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amortization of Intangible Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are carried at cost less accumulated amortization. Amortization expenses are recorded to cost of testing services, cost of product, cost of patient and digital solutions, and sales and marketing expenses in the condensed consolidated statements of operations.</span></div><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfMjE5OTAyMzI2MDU0Ng_e5a902ec-d59e-4029-b6a3-66bf07f53511" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's amortization expense of intangible assets (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of testing services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f9048fade524f0d937582e2d0737bbd_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjU3ZjlmZTMyMzE2YTQyYThhMDdkYTlkOTVhMDM5MzM4L3RhYmxlcmFuZ2U6NTdmOWZlMzIzMTZhNDJhOGEwN2RhOWQ5NWEwMzkzMzhfMi0xLTEtMS05Njg5Nw_f29ad979-a47f-485b-8c5d-5f2df0b8eb03">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8d2b80178a040808832e847918f0f37_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjU3ZjlmZTMyMzE2YTQyYThhMDdkYTlkOTVhMDM5MzM4L3RhYmxlcmFuZ2U6NTdmOWZlMzIzMTZhNDJhOGEwN2RhOWQ5NWEwMzkzMzhfMi0zLTEtMS05Njg4Mw_f5270601-3694-49b1-a694-ace6f6412906">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5130eca1ccf4f738a701a55a747d5d9_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjU3ZjlmZTMyMzE2YTQyYThhMDdkYTlkOTVhMDM5MzM4L3RhYmxlcmFuZ2U6NTdmOWZlMzIzMTZhNDJhOGEwN2RhOWQ5NWEwMzkzMzhfMy0xLTEtMS05Njg5Nw_8cd1f993-d9c0-47b2-977a-362944b37ace">418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb4b7444c8a54bf5b1e67a533d029b35_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjU3ZjlmZTMyMzE2YTQyYThhMDdkYTlkOTVhMDM5MzM4L3RhYmxlcmFuZ2U6NTdmOWZlMzIzMTZhNDJhOGEwN2RhOWQ5NWEwMzkzMzhfMy0zLTEtMS05Njg4Mw_bd3b358a-8ae1-456e-9009-67acaa93a0bb">453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of patient and digital solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i538eccbc464c49cd93e1c60f3af790b5_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjU3ZjlmZTMyMzE2YTQyYThhMDdkYTlkOTVhMDM5MzM4L3RhYmxlcmFuZ2U6NTdmOWZlMzIzMTZhNDJhOGEwN2RhOWQ5NWEwMzkzMzhfNC0xLTEtMS05Njg5Nw_2daa03b1-6411-4739-b848-a13911c4267f">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id192b96ed2d2443395a41393430289fe_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjU3ZjlmZTMyMzE2YTQyYThhMDdkYTlkOTVhMDM5MzM4L3RhYmxlcmFuZ2U6NTdmOWZlMzIzMTZhNDJhOGEwN2RhOWQ5NWEwMzkzMzhfNC0zLTEtMS05Njg4Mw_8bf20b20-4a82-4e84-a0cf-be3c8a3554d5">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales &amp; marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb5085de4360418c9f60a706e826ebd0_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjU3ZjlmZTMyMzE2YTQyYThhMDdkYTlkOTVhMDM5MzM4L3RhYmxlcmFuZ2U6NTdmOWZlMzIzMTZhNDJhOGEwN2RhOWQ5NWEwMzkzMzhfNS0xLTEtMS05Njg5Nw_60649b02-86bd-4d35-9409-a987836c1f6f">595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2bb0753ed6b4970916acf1662850bff_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjU3ZjlmZTMyMzE2YTQyYThhMDdkYTlkOTVhMDM5MzM4L3RhYmxlcmFuZ2U6NTdmOWZlMzIzMTZhNDJhOGEwN2RhOWQ5NWEwMzkzMzhfNS0zLTEtMS05Njg4Mw_2c1ca40b-2a61-487f-91a1-799efc0cd7d5">605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjU3ZjlmZTMyMzE2YTQyYThhMDdkYTlkOTVhMDM5MzM4L3RhYmxlcmFuZ2U6NTdmOWZlMzIzMTZhNDJhOGEwN2RhOWQ5NWEwMzkzMzhfNi0xLTEtMS05Nzg1NA_b901196e-dd54-4c02-9296-fcc56c03b4c3">1,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjU3ZjlmZTMyMzE2YTQyYThhMDdkYTlkOTVhMDM5MzM4L3RhYmxlcmFuZ2U6NTdmOWZlMzIzMTZhNDJhOGEwN2RhOWQ5NWEwMzkzMzhfNi0zLTEtMS05Nzg1NA_62e79204-d544-4ec5-a9b3-9c6d748c6b2c">1,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;margin-top:10pt"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfMjM3Nw_34f5d07c-2f19-48b3-9c95-55cad9b230e1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s estimated future amortization expense of intangible assets with finite lives as of March&#160;31, 2023 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost of Testing Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost of Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost of Patient and Digital Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales and Marketing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a267b7775a54bb9a849620727f55b45_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMS0yLTEtMS05NTEzMg_6f5a8584-ebf9-4ef2-834b-463e36a1970c">987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i283ae31574f24307803aaab45920bc0e_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMS00LTEtMS05NTEzMg_7bb6af11-33e1-49ee-a3dc-77203382fb82">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369258cc427d43d7bd2ea30b3bff4f3c_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMS02LTEtMS05NTEzMg_c9f6bebf-ef1e-43d7-a416-7ac447632962">761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b184c24c09473f91a3c5a799e0ecaf_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMS04LTEtMS05NTEzMg_4c857eca-434c-41b4-bf25-16a4619d12d5">1,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMS0xMC0xLTEtOTUxMzI_02b9db19-5dc4-4fd2-8fe7-d700b39d7dac">4,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a267b7775a54bb9a849620727f55b45_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMi0yLTEtMS05NTEzMg_c8a73bd7-4021-4e7b-8beb-390e0e464369">1,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i283ae31574f24307803aaab45920bc0e_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMi00LTEtMS05NTEzMg_f80c32bc-98be-4002-b7b0-70fb6fd23b6a">1,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369258cc427d43d7bd2ea30b3bff4f3c_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMi02LTEtMS05NTEzMg_a5ce8a68-ba85-48a1-ba38-2e025e48c64c">779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b184c24c09473f91a3c5a799e0ecaf_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMi04LTEtMS05NTEzMg_154eac38-dfa7-4cf5-95a9-e91c74d84b91">2,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMi0xMC0xLTEtOTUxMzI_5dd9cf0f-f23c-4e12-9f76-d196c95623fd">6,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a267b7775a54bb9a849620727f55b45_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMy0yLTEtMS05NTEzMg_ffd6c17d-1339-4599-b8b2-c6e81d00b0fc">1,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i283ae31574f24307803aaab45920bc0e_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMy00LTEtMS05NTEzMg_079bd5ee-e37c-4262-a82e-2ff6a1d81103">1,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369258cc427d43d7bd2ea30b3bff4f3c_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMy02LTEtMS05NTEzMg_f96d2b31-6f52-4a35-8d3b-77e51ac2a9ee">610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b184c24c09473f91a3c5a799e0ecaf_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMy04LTEtMS05NTEzMg_b1d5727d-0b4d-4ce4-b518-db91dfda39b4">2,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMy0xMC0xLTEtOTUxMzI_33a07b85-fd31-4f14-85cb-4357611f3c92">6,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a267b7775a54bb9a849620727f55b45_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNC0yLTEtMS05NTEzMg_f3a47a0f-17ba-49a0-a5bc-af0779663713">1,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i283ae31574f24307803aaab45920bc0e_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNC00LTEtMS05NTEzMg_0b1e2c05-bdeb-476e-aa2f-afec07cba9a2">745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369258cc427d43d7bd2ea30b3bff4f3c_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNC02LTEtMS05NTEzMg_8ede7a34-03ba-4d4f-a5fe-e6cb497f4ee1">610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b184c24c09473f91a3c5a799e0ecaf_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNC04LTEtMS05NTEzMg_65bde8c5-98a6-46aa-b19f-4b99f20eccf2">2,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNC0xMC0xLTEtOTUxMzI_73620810-10d0-47d5-b035-6882474ab933">5,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a267b7775a54bb9a849620727f55b45_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNS0yLTEtMS05NTEzMg_9967c503-ecb5-4b4b-9012-291f3b2cb77c">1,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i283ae31574f24307803aaab45920bc0e_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNS00LTEtMS05NTEzMg_b2da53b7-1b83-4f2c-9867-3bd65c17286a">745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369258cc427d43d7bd2ea30b3bff4f3c_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNS02LTEtMS05NTEzMg_8dfa8724-36d4-4658-af20-3ea378ea221c">610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b184c24c09473f91a3c5a799e0ecaf_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNS04LTEtMS05NTEzMg_d0fde412-0a09-44eb-b64c-4ad0652990d5">2,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNS0xMC0xLTEtOTUxMzI_beb8ed0b-eee0-4d73-8053-a993851fe5f9">5,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a267b7775a54bb9a849620727f55b45_I20230331" decimals="-3" name="cdna:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNi0yLTEtMS05NTEzMg_b543c0c5-e058-4927-b7f9-9c4664127f8b">2,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i283ae31574f24307803aaab45920bc0e_I20230331" decimals="-3" name="cdna:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNi00LTEtMS05NTEzMg_f6dec02a-1bbf-40a2-8dae-0a672a432b28">3,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369258cc427d43d7bd2ea30b3bff4f3c_I20230331" decimals="-3" name="cdna:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNi02LTEtMS05NTEzMg_a6479fcb-32c2-4459-8a4a-aebe05871775">1,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b184c24c09473f91a3c5a799e0ecaf_I20230331" decimals="-3" name="cdna:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNi04LTEtMS05NTEzMg_128478aa-1e2d-4d68-ac9c-08f7833266d0">9,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="cdna:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNi0xMC0xLTEtOTUxMzI_2a6b1843-6924-45e1-b3a7-4072f145697c">16,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a267b7775a54bb9a849620727f55b45_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNy0yLTEtMS05NTEzMg_f968f325-50d8-4b0b-b5f2-7e0751e289f9">9,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i283ae31574f24307803aaab45920bc0e_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNy00LTEtMS05NTEzMg_f55d9859-bede-4f33-99a4-24db1d69a306">9,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i369258cc427d43d7bd2ea30b3bff4f3c_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNy02LTEtMS05NTEzMg_45b9b86d-2dab-4917-bcf3-fb9e595b4921">4,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b184c24c09473f91a3c5a799e0ecaf_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNy04LTEtMS05NTEzMg_fcc70f50-4eb4-41fe-b5c5-8ae6f0e7ba77">20,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNy0xMC0xLTEtOTUxMzI_a2f313ed-daf1-422a-b20c-39a59d0a1ef5">44,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="idd35c15ee381485cb38f052732749537_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RleHRyZWdpb246YmI2ZTViY2FjOTBhNGFmZmJiMjk1YTE4ZjYwYjNlOWZfMTExOQ_1f04c1ee-7d90-4722-9531-45a37f202f04" continuedAt="i616944a24c1f4e21be538cfa2cee5741" escape="true">BALANCE SHEET COMPONENTS</ix:nonNumeric></span></div><ix:continuation id="i616944a24c1f4e21be538cfa2cee5741"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inventory</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RleHRyZWdpb246YmI2ZTViY2FjOTBhNGFmZmJiMjk1YTE4ZjYwYjNlOWZfMTExNA_ba315bb2-682f-4268-b412-fd67ba3021ca" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjBkMWFkODhkOWUyYzQ3OWFhMzBkYjZhZTNhNjkwOTI2L3RhYmxlcmFuZ2U6MGQxYWQ4OGQ5ZTJjNDc5YWEzMGRiNmFlM2E2OTA5MjZfMS0xLTEtMS05NTEzMg_b84c5866-7046-4119-b523-206d3a71f215">3,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjBkMWFkODhkOWUyYzQ3OWFhMzBkYjZhZTNhNjkwOTI2L3RhYmxlcmFuZ2U6MGQxYWQ4OGQ5ZTJjNDc5YWEzMGRiNmFlM2E2OTA5MjZfMS0zLTEtMS05NTEzMg_0e7720e7-d4d9-47b6-99be-fc361ee96d02">2,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjBkMWFkODhkOWUyYzQ3OWFhMzBkYjZhZTNhNjkwOTI2L3RhYmxlcmFuZ2U6MGQxYWQ4OGQ5ZTJjNDc5YWEzMGRiNmFlM2E2OTA5MjZfMi0xLTEtMS05NTEzMg_2a8e2852-c614-427b-b5cf-bea644df591d">4,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjBkMWFkODhkOWUyYzQ3OWFhMzBkYjZhZTNhNjkwOTI2L3RhYmxlcmFuZ2U6MGQxYWQ4OGQ5ZTJjNDc5YWEzMGRiNmFlM2E2OTA5MjZfMi0zLTEtMS05NTEzMg_99887d4a-a578-4dc1-9338-2e819b16c4aa">4,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjBkMWFkODhkOWUyYzQ3OWFhMzBkYjZhZTNhNjkwOTI2L3RhYmxlcmFuZ2U6MGQxYWQ4OGQ5ZTJjNDc5YWEzMGRiNmFlM2E2OTA5MjZfMy0xLTEtMS05NTEzMg_1497f671-ff3c-4716-ad11-70ac71d29940">10,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjBkMWFkODhkOWUyYzQ3OWFhMzBkYjZhZTNhNjkwOTI2L3RhYmxlcmFuZ2U6MGQxYWQ4OGQ5ZTJjNDc5YWEzMGRiNmFlM2E2OTA5MjZfMy0zLTEtMS05NTEzMg_87f4d46a-61d5-4f22-b121-c4bb6581f808">11,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjBkMWFkODhkOWUyYzQ3OWFhMzBkYjZhZTNhNjkwOTI2L3RhYmxlcmFuZ2U6MGQxYWQ4OGQ5ZTJjNDc5YWEzMGRiNmFlM2E2OTA5MjZfNC0xLTEtMS05NTEzMg_f4b0b033-dbae-4c67-ac79-1b7e1238f228">18,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjBkMWFkODhkOWUyYzQ3OWFhMzBkYjZhZTNhNjkwOTI2L3RhYmxlcmFuZ2U6MGQxYWQ4OGQ5ZTJjNDc5YWEzMGRiNmFlM2E2OTA5MjZfNC0zLTEtMS05NTEzMg_9119ef12-2a12-4832-bd68-5a93658ea7cd">19,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accrued and Other Liabilities</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RleHRyZWdpb246YmI2ZTViY2FjOTBhNGFmZmJiMjk1YTE4ZjYwYjNlOWZfMTExNQ_668c44ea-88b1-48c4-99bb-2bf72443902e" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other liabilities consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical studies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="cdna:AccruedClinicalAndCostOfOtherStudiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfMS0xLTEtMS05NTEzMg_172a987e-1864-431f-af14-4a182136c6c9">13,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="cdna:AccruedClinicalAndCostOfOtherStudiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfMS0zLTEtMS05NTEzMg_fac1b1d2-cb81-4bf1-9c29-c5cf1e1c91f9">14,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfMi0xLTEtMS05NTEzMg_e317d2b0-a920-4720-963c-66aab5f72bfd">8,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfMi0zLTEtMS05NTEzMg_ce6b3ad1-c81d-4b1a-820c-9590b7595122">6,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNC0xLTEtMS05NTEzMg_55777f27-8a75-4722-b502-fcf485b87f63">5,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNC0zLTEtMS05NTEzMg_9778e58e-8d95-43c8-a33b-ab36b0490c15">5,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNS0xLTEtMS0xMDA2OTk_51a0b192-d592-421e-a085-7523840d0d34">5,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNS0zLTEtMS0xMDA2OTk_432d266d-9680-4546-942b-ca59a3c5a037">5,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred payments for intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="cdna:DeferredPaymentsForIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNS0xLTEtMS0xMDA3MTI_c859d0b8-4424-4ec0-8b8f-e7524b72b51a">2,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="cdna:DeferredPaymentsForIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNS0zLTEtMS0xMDA3MTI_7b4751a1-07e4-46e0-a870-6ba859388eba">2,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalty</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNS0xLTEtMS05NTEzMg_136f1de0-c54d-4042-9cbe-95fb09567dd3">2,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNS0zLTEtMS05NTEzMg_4bb53d0e-cfe0-49ec-a134-86a4b33618ca">4,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory processing fees and materials </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="cdna:AccruedSampleProcessingFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNi0xLTEtMS05NzAyNw_b2a64f76-2577-42a7-9056-52269da3b3e4">1,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="cdna:AccruedSampleProcessingFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNi0zLTEtMS05NzAyNw_2284033a-226b-46ce-a12d-66951cd0f55f">2,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other collaboration fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="cdna:AccruedLicenseAndOtherCollaborationFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNi0xLTEtMS05NTEzMg_a64b6c57-f8aa-488b-b2af-b1519a0c5054">1,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="cdna:AccruedLicenseAndOtherCollaborationFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNi0zLTEtMS05NTEzMg_98f7382a-773b-4534-892f-66fe95e7a355">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNy0xLTEtMS05NTEzMg_de748e7b-a511-4eba-85c7-f78be1da7259">825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNy0zLTEtMS05NTEzMg_b664ad65-6fec-4667-9760-100517741204">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued shipping expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="cdna:AccruedShippingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfOC0xLTEtMS05NTEzMg_0829fabb-1d35-47c9-abc4-fa31936b8cf2">459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="cdna:AccruedShippingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfOC0zLTEtMS05NTEzMg_c1a618bc-5bac-4a9e-ba55-315ae2bff656">489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="cdna:AccruedCapitalExpenditures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfOS0xLTEtMS05NTEzMg_4e4643d0-b6ce-4257-955c-26de86d98e53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="cdna:AccruedCapitalExpenditures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfOS0zLTEtMS05NTEzMg_302525a5-692b-4bb3-827f-5dcd52a5c4ab">1,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfMTAtMS0xLTEtOTUxMzI_516c0715-dc94-469a-8dc5-db81e5e63ac7">4,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfMTAtMy0xLTEtOTUxMzI_b9c5987e-9ccc-41e5-824f-9c1a61cb45f8">4,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued and other liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfMTEtMS0xLTEtOTUxMzI_4a2a53f5-36b9-42e4-bbfe-d7cff20c6800">46,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfMTEtMy0xLTEtOTUxMzI_ee305dad-d39c-42d4-89b1-cd2eeb33bdd4">49,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="idd35c15ee381485cb38f052732749537_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjg2OQ_e024785b-855d-4339-b51d-a4d2a23e66d4" continuedAt="i7c4b0b5215f146ac939d68183e759acb" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i7c4b0b5215f146ac939d68183e759acb" continuedAt="i976c2599eabd4e5795c54f67abf8e027"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its operating and office facilities for various terms under long-term, non-cancelable operating lease agreements in Brisbane, California; Columbus, Ohio; West Chester, Pennsylvania; Flowood, Mississippi; Gaithersburg, Maryland; Fremantle, Australia; and Stockholm, Sweden.&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's facility leases expire at various dates through 2033. In the normal course of business, it is expected that these leases will be renewed or replaced by leases on other properties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the carrying value of the ROU asset was $<ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjE1_cb07a629-6651-4e47-8a24-782320cf249d">33.4</ix:nonFraction> million. The related current and non-current liabilities as of March&#160;31, 2023 were $<ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjgx_266b75f7-7f84-47d9-96a4-0440f763e1be">5.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjg4_e021cd0b-7b00-42c3-9743-f7707bf23a49">32.0</ix:nonFraction> million, respectively. The current and non-current lease liabilities are included in accrued and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfMTY0OTI2NzQ2ODUyOQ_d306f6fa-aeb4-45bb-9b54-7cf758f0a757">other current liabilities</span> and operating lease liability, less current portion, respectively, in the condensed consolidated balance sheets.</span></div><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjg2NQ_b1be6d7e-8687-4b1f-ab5b-e3883150177c" continuedAt="ie0fe7950b1df4fc3ae616499c2ee9337" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the lease cost for the three months ended March 31, 2023 and 2022 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjRiODU0NGRmY2UzNDRmMDU5MzFjMTk0MTg5YjYzMThiL3RhYmxlcmFuZ2U6NGI4NTQ0ZGZjZTM0NGYwNTkzMWMxOTQxODliNjMxOGJfMi0xLTEtMS05NTEzMg_62bf665e-dc14-4f58-8f9d-96f1106f71f6">1,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjRiODU0NGRmY2UzNDRmMDU5MzFjMTk0MTg5YjYzMThiL3RhYmxlcmFuZ2U6NGI4NTQ0ZGZjZTM0NGYwNTkzMWMxOTQxODliNjMxOGJfMi0zLTEtMS05NTEzMg_de40f032-71e6-4296-bb85-6e8002036fe8">1,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjRiODU0NGRmY2UzNDRmMDU5MzFjMTk0MTg5YjYzMThiL3RhYmxlcmFuZ2U6NGI4NTQ0ZGZjZTM0NGYwNTkzMWMxOTQxODliNjMxOGJfNC0xLTEtMS05NTEzMg_6d3497b6-b982-4cf3-a281-a3153f9a91dc">1,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjRiODU0NGRmY2UzNDRmMDU5MzFjMTk0MTg5YjYzMThiL3RhYmxlcmFuZ2U6NGI4NTQ0ZGZjZTM0NGYwNTkzMWMxOTQxODliNjMxOGJfNC0zLTEtMS05NTEzMg_796434a0-975b-457b-8cad-32dee490f425">1,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.789%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjE3MjkwODNhNDNkNDQyZTQ5NzdmMTZlNGRjMzc4NDA1L3RhYmxlcmFuZ2U6MTcyOTA4M2E0M2Q0NDJlNDk3N2YxNmU0ZGMzNzg0MDVfMi0xLTEtMS05NTEzMg_e2b622d6-325a-4dc0-ba8f-8ccc0e923ff1">6.05</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate (%)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjE3MjkwODNhNDNkNDQyZTQ5NzdmMTZlNGRjMzc4NDA1L3RhYmxlcmFuZ2U6MTcyOTA4M2E0M2Q0NDJlNDk3N2YxNmU0ZGMzNzg0MDVfNC0xLTEtMS05NTEzMg_63fb6c4b-7c9d-4026-afef-159ee8f28035">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February and June 2022, the Company entered into various lease agreements to lease office buildings in California, Nebraska, and Australia with lease terms ranging from <ix:nonNumeric contextRef="i57bbabe758fa4226abdab65dc6f55edf_I20220228" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc3NDYwMg_1ba951a8-d507-4cae-8b3f-c5553c6299a6"><ix:nonNumeric contextRef="i5afb8931ba0448dfa451bb6fd9433b11_I20220630" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc3NDYwMg_b9fdb76e-828c-497c-a40d-3c5e32c6bc8e">2</ix:nonNumeric></ix:nonNumeric> to <ix:nonNumeric contextRef="i2ea7fda0a4594bc7876d19e0b646c9d4_I20220228" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc3NDYwNA_a24c68a2-0c29-4986-837f-69c7c356f8fd"><ix:nonNumeric contextRef="i5f5640bdc5dc463690fc0aee32a95b31_I20220630" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc3NDYwNA_c1c4c82e-fbe5-46fb-b49d-464ec443b785">10.5</ix:nonNumeric></ix:nonNumeric> years. Certain leases have options to renew the respective lease terms ranging from <ix:nonNumeric contextRef="i57bbabe758fa4226abdab65dc6f55edf_I20220228" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc3NDYwNg_1185ab0f-954d-4f15-b28b-3d17b483c6e3"><ix:nonNumeric contextRef="i5afb8931ba0448dfa451bb6fd9433b11_I20220630" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc3NDYwNg_9ea3d11d-bf82-48c1-bfbf-52cc1c010588">5</ix:nonNumeric></ix:nonNumeric> to <ix:nonNumeric contextRef="i2ea7fda0a4594bc7876d19e0b646c9d4_I20220228" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc3NDYwOA_2ec9f44f-6f8d-48fc-b424-5862acfe3c70"><ix:nonNumeric contextRef="i5f5640bdc5dc463690fc0aee32a95b31_I20220630" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc3NDYwOA_fe194e58-6706-46ea-90ce-020fc0ff1ba4">10</ix:nonNumeric></ix:nonNumeric> years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company modified the termination date of the lease agreement for its headquarters in South San Francisco, California from December 31, 2022 to July 15, 2022. As a result, the Company remeasured its lease liability using the current incremental borrowing rate and made an adjustment by reducing the ROU asset and lease liability by $<ix:nonFraction unitRef="usd" contextRef="i195cf846109945d0a76d6e7ce2543162_D20220601-20220630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc3NDYyMw_a0656d0e-808c-444d-8985-fcfe3d8398db"><ix:nonFraction unitRef="usd" contextRef="i195cf846109945d0a76d6e7ce2543162_D20220601-20220630" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc3NDYyMw_a0990cf9-a6a0-4382-b4dc-34915e15ab97">0.5</ix:nonFraction></ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities for the lease agreements made in February and June 2022 are recognized at the present value of the fixed lease payments using the current incremental borrowing rate at the lease commencement date.  ROU assets are recognized based on the initial present value of the fixed lease payments.</span></div><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="cdna:ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfMTY0OTI2NzQ3MzQ2NQ_43d41dd4-434e-46d3-9db2-a7aa4f45eb0a" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the ROU assets and lease liabilities for certain lease agreements which commenced in July 2022 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53037b4e60e34295bb200d6c520f42c0_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmU5ZGU3NzJjYTYxNDQ2ZWU5ZWU5MzM5M2Y0MDIwZjAyL3RhYmxlcmFuZ2U6ZTlkZTc3MmNhNjE0NDZlZTllZTkzMzkzZjQwMjBmMDJfMS0xLTEtMS0xMDEyODU_a345f663-7273-4bda-9cb7-5788710f6255">13,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70089bac7d1149d68e8faf8be4a0818a_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmU5ZGU3NzJjYTYxNDQ2ZWU5ZWU5MzM5M2Y0MDIwZjAyL3RhYmxlcmFuZ2U6ZTlkZTc3MmNhNjE0NDZlZTllZTkzMzkzZjQwMjBmMDJfMS0zLTEtMS0xMDEyOTU_dfd8f97b-b689-48e1-a789-977c1cb491d3">14,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53037b4e60e34295bb200d6c520f42c0_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmU5ZGU3NzJjYTYxNDQ2ZWU5ZWU5MzM5M2Y0MDIwZjAyL3RhYmxlcmFuZ2U6ZTlkZTc3MmNhNjE0NDZlZTllZTkzMzkzZjQwMjBmMDJfMi0xLTEtMS0xMDEyODU_87981409-d1dc-4e1f-8c4f-9e795c00adbb">14,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70089bac7d1149d68e8faf8be4a0818a_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmU5ZGU3NzJjYTYxNDQ2ZWU5ZWU5MzM5M2Y0MDIwZjAyL3RhYmxlcmFuZ2U6ZTlkZTc3MmNhNjE0NDZlZTllZTkzMzkzZjQwMjBmMDJfMi0zLTEtMS0xMDEyOTU_ecd32821-358e-4290-b824-5491125eb440">15,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the ROU assets and lease liabilities for certain lease agreements which commenced in August 2022 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0938e8abbbf424194441e38319e63da_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjcwODQwNmJkYmEyOTQxNTFiYTAzYjQwOWE0OWIzZWJhL3RhYmxlcmFuZ2U6NzA4NDA2YmRiYTI5NDE1MWJhMDNiNDA5YTQ5YjNlYmFfMS0xLTEtMS0xMDEzMDc_69ed6848-8dd0-478d-871b-bb709d0b9810">5,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38fbe91f8cb446a1a44ae2e5489e72d5_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjcwODQwNmJkYmEyOTQxNTFiYTAzYjQwOWE0OWIzZWJhL3RhYmxlcmFuZ2U6NzA4NDA2YmRiYTI5NDE1MWJhMDNiNDA5YTQ5YjNlYmFfMS0zLTEtMS0xMDEzMTY_e096bb57-63cf-440a-83c8-b58900a1a7e0">5,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0938e8abbbf424194441e38319e63da_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjcwODQwNmJkYmEyOTQxNTFiYTAzYjQwOWE0OWIzZWJhL3RhYmxlcmFuZ2U6NzA4NDA2YmRiYTI5NDE1MWJhMDNiNDA5YTQ5YjNlYmFfMi0xLTEtMS0xMDEzMDc_2ca2be11-5e24-468d-bb65-75815cea5ba0">5,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38fbe91f8cb446a1a44ae2e5489e72d5_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjcwODQwNmJkYmEyOTQxNTFiYTAzYjQwOWE0OWIzZWJhL3RhYmxlcmFuZ2U6NzA4NDA2YmRiYTI5NDE1MWJhMDNiNDA5YTQ5YjNlYmFfMi0zLTEtMS0xMDEzMTY_ca77946f-19b2-46f1-9c38-a8c069940be0">6,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><ix:continuation id="i976c2599eabd4e5795c54f67abf8e027" continuedAt="ia5a46c47f59b4f49aef0dbbfc6ab6710"><div><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="cdna:ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjg3Mw_0dc44458-14ea-47b8-b05a-eaae1f32eb0a" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities as of March&#160;31, 2023 are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmM0NzNiNDJiMzYxYzQ2MWI5OTg3NjQ3Y2JlMTRmNTlkL3RhYmxlcmFuZ2U6YzQ3M2I0MmIzNjFjNDYxYjk5ODc2NDdjYmUxNGY1OWRfMS00LTEtMS05NTEzMg_e07d1cfa-a52b-456f-9b26-102f3bfeb4c5">5,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmM0NzNiNDJiMzYxYzQ2MWI5OTg3NjQ3Y2JlMTRmNTlkL3RhYmxlcmFuZ2U6YzQ3M2I0MmIzNjFjNDYxYjk5ODc2NDdjYmUxNGY1OWRfMi00LTEtMS05NTEzMg_bb67e412-efa5-490c-b1f5-29c1ead0e567">7,931</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmM0NzNiNDJiMzYxYzQ2MWI5OTg3NjQ3Y2JlMTRmNTlkL3RhYmxlcmFuZ2U6YzQ3M2I0MmIzNjFjNDYxYjk5ODc2NDdjYmUxNGY1OWRfMy00LTEtMS05NTEzMg_f7a65669-adf7-4d16-b25d-1691ec58a618">7,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmM0NzNiNDJiMzYxYzQ2MWI5OTg3NjQ3Y2JlMTRmNTlkL3RhYmxlcmFuZ2U6YzQ3M2I0MmIzNjFjNDYxYjk5ODc2NDdjYmUxNGY1OWRfNC00LTEtMS05NTEzMg_c8ea82bd-8c85-446c-9239-1ad81804ac27">7,019</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmM0NzNiNDJiMzYxYzQ2MWI5OTg3NjQ3Y2JlMTRmNTlkL3RhYmxlcmFuZ2U6YzQ3M2I0MmIzNjFjNDYxYjk5ODc2NDdjYmUxNGY1OWRfNS00LTEtMS05NTEzMg_936815ac-2783-4dc0-a733-84c40b669fd4">7,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="cdna:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmM0NzNiNDJiMzYxYzQ2MWI5OTg3NjQ3Y2JlMTRmNTlkL3RhYmxlcmFuZ2U6YzQ3M2I0MmIzNjFjNDYxYjk5ODc2NDdjYmUxNGY1OWRfNi00LTEtMS05NTEzMg_8d7ea38f-ed4e-4444-9b4b-3286c48b6563">10,604</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmM0NzNiNDJiMzYxYzQ2MWI5OTg3NjQ3Y2JlMTRmNTlkL3RhYmxlcmFuZ2U6YzQ3M2I0MmIzNjFjNDYxYjk5ODc2NDdjYmUxNGY1OWRfNy00LTEtMS05NTEzMg_ecfb6285-5b1c-4fdd-9a71-33a551df6779">46,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmM0NzNiNDJiMzYxYzQ2MWI5OTg3NjQ3Y2JlMTRmNTlkL3RhYmxlcmFuZ2U6YzQ3M2I0MmIzNjFjNDYxYjk5ODc2NDdjYmUxNGY1OWRfOC00LTEtMS05NTEzMg_7074e4db-aa96-42ed-a4c4-0571df5e93d9">8,511</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmM0NzNiNDJiMzYxYzQ2MWI5OTg3NjQ3Y2JlMTRmNTlkL3RhYmxlcmFuZ2U6YzQ3M2I0MmIzNjFjNDYxYjk5ODc2NDdjYmUxNGY1OWRfOS00LTEtMS05NTEzMg_07b15310-98a6-4759-bc53-a786826b8b5b">37,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less operating lease liability, current portion</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmM0NzNiNDJiMzYxYzQ2MWI5OTg3NjQ3Y2JlMTRmNTlkL3RhYmxlcmFuZ2U6YzQ3M2I0MmIzNjFjNDYxYjk5ODc2NDdjYmUxNGY1OWRfMTAtNC0xLTEtOTUxMzI_b06b2d5e-be4f-4192-be84-2297c805a67a">5,738</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, long-term portion</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmM0NzNiNDJiMzYxYzQ2MWI5OTg3NjQ3Y2JlMTRmNTlkL3RhYmxlcmFuZ2U6YzQ3M2I0MmIzNjFjNDYxYjk5ODc2NDdjYmUxNGY1OWRfMTEtNC0xLTEtOTUxMzI_51b98095-649c-4855-94ad-8a6a3fc00bdd">32,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><ix:continuation id="ie0fe7950b1df4fc3ae616499c2ee9337"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the supplemental cash flow information related to leases for the three months ended March 31, 2023 and 2022 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used for operating leases</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjVjNTZiYjY2YmFlMDRmMTI4MGMyZWE1Njg1NTQ4MDY3L3RhYmxlcmFuZ2U6NWM1NmJiNjZiYWUwNGYxMjgwYzJlYTU2ODU1NDgwNjdfMy0xLTEtMS05NzMyNA_e59f4958-b00f-4911-b3cf-4e9a99f284c2">1,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjVjNTZiYjY2YmFlMDRmMTI4MGMyZWE1Njg1NTQ4MDY3L3RhYmxlcmFuZ2U6NWM1NmJiNjZiYWUwNGYxMjgwYzJlYTU2ODU1NDgwNjdfMy0zLTEtMS05NzMzMg_5ca3287c-e449-4f99-a333-19efacacff7a">972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Royalty Commitments</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">The Board of Trustees of the Leland Stanford Junior University (&#8220;Stanford&#8221;)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, the Company entered into a license agreement with Stanford (the &#8220;Stanford License&#8221;), which granted the Company an exclusive license to a patent relating to the diagnosis of rejection in organ transplant recipients using dd-cfDNA. Under the terms of the Stanford License, the Company is required to pay an annual license maintenance fee, <ix:nonFraction unitRef="milestone_payment" contextRef="i49912c99c82e4c2a9d7a1da7ab8fdcfa_D20140601-20140630" decimals="INF" name="cdna:NumberOfMilestonePayments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfMTYzMQ_61fb1fa0-5d7b-4b3e-b9fd-eba9496b4536">six</ix:nonFraction> milestone payments and royalties in the low single digits of net sales of products incorporating the licensed technology.  In March 2023. the Stanford License agreement was amended, which reduces the maximum royalty rate to a lower rate at which the Company may be liable to Stanford effective from April 2022. As a result, the Company reversed the excess liability in March 2023.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Illumina</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2018, the Company entered into a license agreement with Illumina, Inc. (the &#8220;Illumina Agreement&#8221;). The Illumina Agreement requires the Company to pay royalties in the mid-single to low-double digits on sales of products covered by the Illumina Agreement.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cibiltech Commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to that certain license and commercialization agreement that the Company entered into with Cibiltech SAS (&#8220;Cibiltech&#8221;) effective April 30, 2019, the Company will share an agreed-upon percentage of revenue with Cibiltech, if and when revenues are generated from iBox.&#160;&#160;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Illumina Agreement, the Company has agreed to minimum purchase commitments of finished products and raw materials from Illumina, Inc. through 2023.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation and Indemnification Obligations</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In response to the Company's false advertising suit filed against Natera Inc. (&#8220;Natera&#8221;), on April 10, 2019, Natera filed a counterclaim against the Company on February 18, 2020, in the U.S. District Court for the District of Delaware (the &#8220;Court&#8221;) alleging the Company made false and misleading claims about the performance capabilities of AlloSure. The suit seeks injunctive relief and unspecified monetary relief. On September 30, 2020, Natera requested leave of Court to amend its counterclaims to include additional allegations regarding purportedly false claims the Company made with respect to AlloSure, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><ix:continuation id="ia5a46c47f59b4f49aef0dbbfc6ab6710" continuedAt="i8c9a118e64dd4c078769ebba9fcfdfb6"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and the Court granted Natera&#8217;s request. The trial commenced on March 7, 2022 and concluded on March 14, 2022, with the jury awarding the Company $<ix:nonFraction unitRef="usd" contextRef="ib4b52828eb9044d3949685e3c2d4b00d_D20220307-20220314" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc5MDc1MA_5d706e23-6f39-4bf7-8eb8-639ec2acba4f">44.9</ix:nonFraction>&#160;million in damages, comprised of $<ix:nonFraction unitRef="usd" contextRef="i1b275c7553774ac3ac576327338fbb57_D20220307-20220314" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc5MDc2NQ_4228fdea-ddbb-4fde-a30b-3ac8be9712c3">21.2</ix:nonFraction>&#160;million in compensatory damages and $<ix:nonFraction unitRef="usd" contextRef="i33ad911706e74747a0d127ced9ed8f7c_D20220307-20220314" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc5MDc5NA_b4e80368-8e03-42d4-83a5-3e5abc9a7898">23.7</ix:nonFraction>&#160;million in punitive damages. Post-trial motion practice remains pending. The Company will not record the award until cash is received or the matter is otherwise resolved. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2022, the United States Court of Appeals for the Federal Circuit affirmed the Court&#8217;s judgment dismissing the Company&#8217;s patent infringement suit against Natera. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Natera filed suit against the Company on January 13, 2020, in the Court alleging, among other things, that AlloSure infringes Natera&#8217;s U.S. Patent 10,526,658. This case was consolidated with the Company&#8217;s patent infringement suit on February 4, 2020. On March 25, 2020, Natera filed an amendment to the suit alleging, among other things, that AlloSure also infringes Natera&#8217;s U.S. Patent 10,597,724. The suit seeks a judgment that the Company has infringed Natera&#8217;s patents, an order preliminarily and permanently enjoining the Company from any further infringement of such patents and unspecified damages. On May 13, 2022, Natera filed <ix:nonFraction unitRef="complaint" contextRef="icd7b677ac2f44bbba944e499e4c5e1c2_D20220513-20220513" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc5MDgxMg_40b2da70-e751-403a-a5aa-ff3c9535ac03">two</ix:nonFraction> new complaints alleging that AlloSure infringes Natera&#8217;s U.S. Patents 10,655,180 and 11,111,544. These <ix:nonFraction unitRef="complaint" contextRef="icd7b677ac2f44bbba944e499e4c5e1c2_D20220513-20220513" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNTQ5NzU1ODQwNzQ4_40b2da70-e751-403a-a5aa-ff3c9535ac03">two</ix:nonFraction> cases were consolidated with the patent infringement case on June 15, 2022. On May 17, 2022, Natera agreed to dismiss the case alleging infringement of Natera&#8217;s U.S. Patent 10,526,658. On July 6, 2022, the Company moved to dismiss the rest of Natera&#8217;s claims. On September 6, 2022, the Company withdrew its motion to dismiss. Discovery is ongoing. The Company intends to defend both of these matters vigorously, and believes that the Company has good and substantial defenses to the claims alleged in the suits, but there is no guarantee that the Company will prevail. The Company has not recorded any liabilities for these suits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States Department of Justice and United States Securities and Exchange Commission Investigations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in 2021, the Company received a civil investigative demand (&#8220;CID&#8221;) from the United States Department of Justice (&#8220;DOJ&#8221;) requesting that the Company produce certain documents in connection with a False Claims Act investigation being conducted by the DOJ regarding certain business practices related to the Company's kidney testing and phlebotomy services, and a subpoena from the United States Securities and Exchange Commission (&#8220;SEC&#8221;) in relation to an investigation by the SEC in respect of matters similar to those identified in the CID, as well as certain of the Company&#8217;s accounting and public reporting practices. The Company also received an information request from a state regulatory agency.  This state regulatory agency advised the Company that it has completed its review of the Company&#8217;s business practices and determined that no further information or action is required. In late 2022, the Company received a request for information from a separate state regulatory agency concerning specimen collection by a vendor in the state. The Company may receive additional requests for information from the DOJ, SEC, or other regulatory and governmental agencies regarding similar or related subject matters. The Company does not believe that the CID, the SEC subpoena or the state regulatory agency information request raise any issues regarding the safety or efficacy of any of the Company's products or services and are cooperating fully with the investigations and the requests for information. Although the Company remains committed to compliance with all applicable laws and regulations, it cannot predict the outcome of the DOJ or SEC investigations, the state regulatory agency information request, or any other requests or investigations that may arise in the future regarding these or other subject matters.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become involved in litigation and other legal actions. The Company estimates the range of liability related to any pending litigation where the amount and range of loss can be estimated. The Company records its best estimate of a loss when the loss is considered probable. Where a liability is probable and there is a range of estimated loss with no best estimate in the range, the Company records a charge equal to at least the minimum estimated liability for a loss contingency when both of the following conditions are met: (i) information available prior to issuance of the condensed consolidated financial statements indicates that it is probable that a liability had been incurred at the date of the condensed consolidated financial statements, and (ii) the range of loss can be reasonably estimated.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Olymbios Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2022, a complaint was filed by Michael Olymbios against the Company in the Superior Court of the State of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California for the County of San Mateo (the &#8220;San Mateo County Court&#8221;). The complaint alleges that the Company failed to pay certain fees and costs required to continue an arbitration proceeding against Dr. Olymbios, and that the Company has defamed Dr. Olymbios. Dr. Olymbios also seeks to void restrictive covenants previously agreed to by him in favor of the Company and to recover damages purportedly incurred by Dr. Olymbios. The Company filed a motion to compel arbitration and dismiss the case. On April 25, 2022, the San Mateo County Court granted the Company&#8217;s </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex parte</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> application to stay the case and advance the hearing date to June 10, 2022 for the motion to compel arbitration and dismiss. At the June 10, 2022 hearing, the San Mateo County Court found that the decision should be made by the arbitrator, and stayed the case. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2022, Olymbios filed a motion to withdraw from arbitration before JAMS, which was denied on August 18, 2022. The matter is currently proceeding in arbitration. The Company intends to vigorously pursue its arbitration proceeding against Olymbios and to vigorously defend itself against Olymbios&#8217; claims. The Company believes it has good and substantial support for it claims and good and </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><ix:continuation id="i8c9a118e64dd4c078769ebba9fcfdfb6"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantial defenses to the claims alleged in the suit by Olymbios, but there is no guarantee that the Company will prevail if the case continues. The </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company has not recorded any liabilities for this suit.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Class Action</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 23, 2022, Plumbers &amp; Pipefitters Local Union #295 Pension Fund filed a federal securities class action in the U.S. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">District Court for the Northern District of California against the Company, Reginald Seeto, its President, Chief Executive Officer and member of the Company&#8217;s Board of Directors, Ankur Dhingra, its former Chief Financial Officer, Marcel Konrad, its former interim Chief Financial Officer and former Senior Vice President of Finance &amp; Accounting, and Peter Maag, its former President, former Chief Executive Officer, former Chairman of the Board and current member of the Company&#8217;s Board of Directors. The action alleges that the Company and the individual defendants made materially false and/or misleading statements and/or omissions and that such statements violated Section 10(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Rule 10b-5 promulgated thereunder. The action also alleges that the individual defendants are liable pursuant to Section 20(a) of the Exchange Act as controlling persons of the Company. The suit seeks to recover damages caused by the alleged violations of federal securities laws, along with the plaintiffs&#8217; costs incurred in the lawsuit, including their reasonable attorneys&#8217; and experts&#8217; witness fees and other costs. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 25, 2022, the court appointed an investor group led by the Oklahoma Police Pension and Retirement System as lead plaintiffs and appointed Saxena White P.A. and Robbins Geller Rudman &amp; Dowd LLP as lead counsels. Plaintiffs filed an amended complaint on November 28, 2022. On January 27, 2023, defendants moved to dismiss all claims and to strike certain allegations in the amended complaint. A hearing on these motions is scheduled for May 16, 2023. The Company intends to defend itself vigorously, and believes that the Company has good and substantial defenses to the claims alleged in the suit, but there is no guarantee that the Company will prevail. The Company has not recorded any liabilities for this suit. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Derivative Actions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 21, 2022, Jeffrey Edelman brought a stockholder derivative action complaint in the U.S. District Court for the Northern District of California against the Company as nominal defendant and Drs. Seeto and Maag and Mr. Dhingra, and other current and former members of the Company&#8217;s Board of Directors (the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Edelman Derivative Action</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The plaintiff alleges that the individual defendants breached their fiduciary duties as directors and/or officers of the Company and engaged in insider trading, waste of corporate assets, unjust enrichment and violations of Sections 14(a) and 20(a) of the Exchange Act. The action alleges that the individual defendants are liable pursuant to Section 20(a) of the Exchange Act as controlling persons of the Company. The suit seeks a declaration that the individual defendants breached their fiduciary duties to the Company, violated Sections 14(a) and 20(a) of the Exchange Act and were unjustly enriched, and also seeks to recover damages sustained by the Company as a result of the alleged violations, along with the plaintiff&#8217;s costs incurred in the lawsuit, including reasonable attorneys&#8217; and experts&#8217; fees, costs and expenses. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On December 8, 2022, the court stayed the Edelman Derivative Action until twenty (20) days after the earlier of the following events: (a) the securities class action is dismissed in its entirety with prejudice; (b) the motion to dismiss in the securities class action is denied; (c) a joint request by plaintiff and defendants to lift the stay; (d) notification that a related derivative action that has been filed is not stayed or is no longer stayed; or (e) notification that there has been a settlement reached in the securities class action or any related derivative action.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2023, Jaysen Stevenson brought a stockholder derivative action complaint in the U.S. District Court for the Northern District of California against the Company as nominal defendant and Drs. Seeto and Maag and Mr. Dhingra and other current and former members of the Company&#8217;s Board of Directors (the &#8220;Stevenson Derivative Action&#8221;). The claims and allegations in the Stevenson Derivative Action are substantially similar to those in the Edelman Derivative Action. The plaintiff alleges that the individual defendants breached their fiduciary duties as directors and/or officers of the Company and engaged in insider trading, waste of corporate assets, unjust enrichment and violations of Sections 14(a) and 20(a) of the Exchange Act. The suit seeks declaratory relief and to recover alleged damages sustained by the Company as a result of the alleged violations, along with the plaintiff&#8217;s costs incurred in the lawsuit, including reasonable attorneys&#8217; and experts&#8217; fees, costs and expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to defend itself vigorously, and believes that the Company has good and substantial defenses to the claims alleged in the suits, but there are no guarantees that the Company will prevail.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company filed a lawsuit against its Directors and Officers liability insurance carriers in San Mateo County Superior Court.  The Company seeks a declaration that costs and fees incurred by the Company in responding to governmental investigatory requests are covered under its policies.  The Company also asserts breach of contract against its primary insurer Great American Insurance Company for denying the claim.  The policies provide up to $<ix:nonFraction unitRef="usd" contextRef="i0ee630c440d5470482172c2d5805345d_D20221201-20221231" decimals="-6" name="us-gaap:MalpracticeInsuranceMaximumCoveragePerIncident" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfMjE5OTAyMzI4NzM1OA_40f50380-6a45-4eb7-9d36-2e9ec34eaec2">15</ix:nonFraction>&#160;million in coverage limits.  The Company intends to vigorously pursue its claims.  The Company believes it has good and substantial support for its claims, but there is no guarantee that the Company will prevail in these claims.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="idd35c15ee381485cb38f052732749537_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182NC9mcmFnOjE5MTc0ZWRlNzIyMTQzNzk5MGY3ZjY0YTAzNjU2YzA2L3RleHRyZWdpb246MTkxNzRlZGU3MjIxNDM3OTkwZjdmNjRhMDM2NTZjMDZfNDYw_471ecb7e-95fb-4d16-b4bc-7ad9859937ee" continuedAt="i1050c8f23ae6408a99982c3974ede0cf" escape="true">401(K) PLAN</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1050c8f23ae6408a99982c3974ede0cf">The Company sponsors a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182NC9mcmFnOjE5MTc0ZWRlNzIyMTQzNzk5MGY3ZjY0YTAzNjU2YzA2L3RleHRyZWdpb246MTkxNzRlZGU3MjIxNDM3OTkwZjdmNjRhMDM2NTZjMDZfNDYx_ec00229a-4fdc-4dab-8f7d-959d1d68ae6f">401(k)</span> defined contribution plan (the "401(k) Plan") covering all U.S. employees under the Internal Revenue Code of 1986, as amended. Employee contributions to the 401(k) Plan are voluntary and are determined on an individual basis subject to the maximum allowable under federal tax regulations. The Company incurred expenses related to contributions to the 401(k) Plan of $<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182NC9mcmFnOjE5MTc0ZWRlNzIyMTQzNzk5MGY3ZjY0YTAzNjU2YzA2L3RleHRyZWdpb246MTkxNzRlZGU3MjIxNDM3OTkwZjdmNjRhMDM2NTZjMDZfNDE3_8954c617-e4b9-430b-b04f-da527b3e954e"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182NC9mcmFnOjE5MTc0ZWRlNzIyMTQzNzk5MGY3ZjY0YTAzNjU2YzA2L3RleHRyZWdpb246MTkxNzRlZGU3MjIxNDM3OTkwZjdmNjRhMDM2NTZjMDZfNDE3_ba1864e6-e277-4cf8-8bef-cb299c9aff5c">0.7</ix:nonFraction></ix:nonFraction> million for each of the three months ended March 31, 2023 and 2022.</ix:continuation></span></div><div id="idd35c15ee381485cb38f052732749537_67"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="cdna:WarrantsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182Ny9mcmFnOjZkZTE2MjIyODg3NzQ4ZDI4YzMzOWFmY2IyYjZkMDY5L3RleHRyZWdpb246NmRlMTYyMjI4ODc3NDhkMjhjMzM5YWZjYjJiNmQwNjlfMTA1Ng_b00ab134-5f53-4846-bb35-2274ae4e380d" continuedAt="i3828d0fa66eb46bab3d56d1897c018be" escape="true">WARRANTS</ix:nonNumeric></span></div><ix:continuation id="i3828d0fa66eb46bab3d56d1897c018be"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues common stock warrants in connection with debt or equity financings to lenders, placement agents and investors. Issued warrants are considered standalone financial instruments and the terms of each warrant are analyzed for equity or liability classification in accordance with U.S. GAAP. Warrants that are classified as liabilities usually have various features that would require net-cash settlement by the Company. Warrants that are not liabilities, derivatives and/or meet the exception criteria are classified as equity. Warrants liabilities are remeasured at fair value at each period end with changes in fair value recorded in the condensed consolidated statements of operations until expired or exercised. Warrants that are classified as equity are valued at their relative fair value on the date of issuance, recorded in additional paid in capital and not remeasured.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended March 31, 2023 and 2022, <ix:nonFraction unitRef="shares" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="INF" name="cdna:NumberOfWarrantsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182Ny9mcmFnOjZkZTE2MjIyODg3NzQ4ZDI4YzMzOWFmY2IyYjZkMDY5L3RleHRyZWdpb246NmRlMTYyMjI4ODc3NDhkMjhjMzM5YWZjYjJiNmQwNjlfOTMw_47e5dca7-3391-4f9e-8ee4-dc358f39c689"><ix:nonFraction unitRef="shares" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="INF" name="cdna:NumberOfWarrantsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182Ny9mcmFnOjZkZTE2MjIyODg3NzQ4ZDI4YzMzOWFmY2IyYjZkMDY5L3RleHRyZWdpb246NmRlMTYyMjI4ODc3NDhkMjhjMzM5YWZjYjJiNmQwNjlfOTMw_55a01862-4f04-4e0e-a76e-793dbccb7a1d">no</ix:nonFraction></ix:nonFraction> warrants to purchase shares of common stock were exercised.</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182Ny9mcmFnOjZkZTE2MjIyODg3NzQ4ZDI4YzMzOWFmY2IyYjZkMDY5L3RleHRyZWdpb246NmRlMTYyMjI4ODc3NDhkMjhjMzM5YWZjYjJiNmQwNjlfMTA1Nw_c23edeb7-aa2d-45ce-9fe1-8a4566569b81" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, outstanding warrants to purchase common stock were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classified as</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Original Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Underlying Warrants</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original issue date:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i445ae0f9731748a8a1bcab34010dc63a_D20230101-20230331" name="cdna:WarrantFairValueAssumptionsExpectedTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182Ny9mcmFnOjZkZTE2MjIyODg3NzQ4ZDI4YzMzOWFmY2IyYjZkMDY5L3RhYmxlOjYzMjFlYWUzMDIxMTQwNzM5YWJkZDU5ZDhhZjczMDFjL3RhYmxlcmFuZ2U6NjMyMWVhZTMwMjExNDA3MzlhYmRkNTlkOGFmNzMwMWNfMi0zLTEtMS05NTEzMg_c2f35753-353d-4b92-b2c5-19610e258b83">7</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9eedb204e8ae4bd78694426f6de765ea_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182Ny9mcmFnOjZkZTE2MjIyODg3NzQ4ZDI4YzMzOWFmY2IyYjZkMDY5L3RhYmxlOjYzMjFlYWUzMDIxMTQwNzM5YWJkZDU5ZDhhZjczMDFjL3RhYmxlcmFuZ2U6NjMyMWVhZTMwMjExNDA3MzlhYmRkNTlkOGFmNzMwMWNfMi01LTEtMS05NTEzMg_61385b36-c515-49b5-9ac2-52bd62febe1d">1.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9eedb204e8ae4bd78694426f6de765ea_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182Ny9mcmFnOjZkZTE2MjIyODg3NzQ4ZDI4YzMzOWFmY2IyYjZkMDY5L3RhYmxlOjYzMjFlYWUzMDIxMTQwNzM5YWJkZDU5ZDhhZjczMDFjL3RhYmxlcmFuZ2U6NjMyMWVhZTMwMjExNDA3MzlhYmRkNTlkOGFmNzMwMWNfMi03LTEtMS05NTEzMg_c92f71bf-358f-4131-92a3-345720823b27">3,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9eedb204e8ae4bd78694426f6de765ea_I20230331" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182Ny9mcmFnOjZkZTE2MjIyODg3NzQ4ZDI4YzMzOWFmY2IyYjZkMDY5L3RhYmxlOjYzMjFlYWUzMDIxMTQwNzM5YWJkZDU5ZDhhZjczMDFjL3RhYmxlcmFuZ2U6NjMyMWVhZTMwMjExNDA3MzlhYmRkNTlkOGFmNzMwMWNfMy03LTEtMS05NTEzMg_bf593e3b-d8cf-45f2-950c-3109a4492173">3,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div id="idd35c15ee381485cb38f052732749537_70"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMzY2Mw_099de24c-9aa3-43b7-b672-ad400fd30ead" continuedAt="i6c863ada6e4743e7a31913d0d8ea7be3" escape="true">STOCK INCENTIVE PLANS</ix:nonNumeric></span></div><ix:continuation id="i6c863ada6e4743e7a31913d0d8ea7be3" continuedAt="i956d2e2a24d84c46a891b23c42bc0fa9"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock Options and Restricted Stock Units (&#8220;RSU&#8221;)</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="cdna:ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMzY2NA_81c5420d-de93-4c3f-b628-dee76735611b" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option and RSU activity under the Company&#8217;s 2014 Equity Incentive Plan, 2016 Inducement Equity Incentive Plan, and 2019 Inducement Equity Incentive Plan, and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>Available<br/>for Grant</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>RSU Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance&#8212;December 31, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMS0xLTEtMS05NTEzMg_ede2510e-ae94-4888-9d7f-087ecf2d0711">1,490,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMS0zLTEtMS05NTEzMg_d64a1cc5-2001-41a3-8fb7-a3871d9b0a57">2,921,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMS01LTEtMS05NTEzMg_451c9341-6d0b-40ea-b9c3-7b59950de595">28.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id490782a3afe4f6a9743acac4922431f_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMS03LTEtMS05NTEzMg_6fc9b981-b171-4755-b6e4-d2107927a765">3,094,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id490782a3afe4f6a9743acac4922431f_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMS05LTEtMS05NTEzMg_35de0a37-dea3-4646-b2cf-baa6aca9a96e">37.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional shares authorized</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMi0xLTEtMS05NTEzMg_4ef83bed-62ab-4368-b85f-578dc4ab4242">2,141,330</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock awards for services</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="INF" name="cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMy0xLTEtMS05NTEzMg_a94435ef-a1ce-4342-86f7-a30ea0bba7af">7,649</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfNC0xLTEtMS05NTEzMg_182883d3-15ef-441a-b350-779c012b98f6">1,262,588</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff2ee009736640978c0e8cdec25086bf_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfNC03LTEtMS05NTEzMg_3f170a10-61b1-4e57-80c5-37a9bd8032fb">1,262,588</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff2ee009736640978c0e8cdec25086bf_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfNC05LTEtMS05NTEzMg_5ec88cca-3237-48ce-a45d-eee6a1ee30a6">15.27</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs vested</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iff2ee009736640978c0e8cdec25086bf_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfNS03LTEtMS05NTEzMg_d0e8a594-f08f-4b7e-89e3-bdd4e0185adc">170,077</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff2ee009736640978c0e8cdec25086bf_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfNS05LTEtMS05NTEzMg_323ed74e-4fed-413c-8ce1-3f3a69ab84a1">52.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfNi0xLTEtMS05NTEzMg_3a04f8bd-9021-42b9-822d-3166ad47159a">418,564</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfNi0zLTEtMS05NTEzMg_11e3cb9f-d269-43d8-b764-b5688ba51bc9">418,564</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfNi01LTEtMS05NTEzMg_e070b661-716d-4567-8813-a3a06473295a">15.50</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfNy0zLTEtMS05NTEzMg_4d5af6ff-07a8-4b56-9b11-597a1dc0bcf6">820</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfNy01LTEtMS05NTEzMg_1c3633b7-6cba-4f01-ab14-5f089deb3f43">2.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock under employee incentive plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="INF" name="cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfOC0xLTEtMS05NTEzMg_6481465a-6155-4048-8a26-60ee97414093">50,254</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs forfeited</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfOS0xLTEtMS05NTEzMg_396b17e2-d387-460e-958c-ed7c40a97fe7">91,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iff2ee009736640978c0e8cdec25086bf_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfOS03LTEtMS05NTEzMg_e316ae2e-a4c2-4266-94f6-0cb8fd1a4939">91,291</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff2ee009736640978c0e8cdec25086bf_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfOS05LTEtMS05NTEzMg_7dd37b43-085a-425f-befd-5a9ed187750f">36.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMTAtMS0xLTEtOTUxMzI_77e10518-5d50-4a11-9963-1724485f2982">12,949</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMTAtMy0xLTEtOTUxMzI_5c115322-13e7-4694-b2c2-4077d9ccb135">12,949</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMTAtNS0xLTEtOTUxMzI_1f0a6908-65f4-4d17-8869-65c2e56aa7bf">31.32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options expired</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMTEtMS0xLTEtOTUxMzI_0e634e11-e9cf-4047-96af-bf526091e577">78,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMTEtMy0xLTEtOTUxMzI_703a19bd-c21a-4362-a79b-c59dfbbf1ace">78,024</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMTEtNS0xLTEtOTUxMzI_d5d2bb2e-f62b-4c77-8161-57c1c9c04c07">33.81</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance&#8212;March 31, 2023</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMTItMS0xLTEtOTUxMzI_3142c518-96b3-4cd2-8d71-e137b1152fea">2,175,509</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMTItMy0xLTEtOTUxMzI_fca9a6d6-3459-4c2f-9d44-bc586b23e753">3,248,696</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMTItNS0xLTEtOTUxMzI_1073b822-c8d5-4681-8bab-131316839a3a">26.52</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12f532855bf14a43998b04ac7db3ddfd_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMTItNy0xLTEtOTUxMzI_dfc6de79-c453-4b50-b9ea-dece2de01a10">4,095,616</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i12f532855bf14a43998b04ac7db3ddfd_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMTItOS0xLTEtOTUxMzI_074880fd-fc8a-406b-8940-f648f69a757e">29.87</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMzQy_3e216750-fb8e-4df8-9c71-12a07326bc56">0.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMzQ5_71a9c2bd-f11f-4a58-9540-08f1dac336a0">1.0</ix:nonFraction> million for the three months ended March&#160;31, 2023 and 2022, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the total intrinsic value of outstanding RSUs was approximately $<ix:nonFraction unitRef="usd" contextRef="i12f532855bf14a43998b04ac7db3ddfd_I20230331" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfNDc2_c05bcb01-948d-4257-a58d-da0f1a4f6b1d">38.8</ix:nonFraction> million and there were $<ix:nonFraction unitRef="usd" contextRef="i12f532855bf14a43998b04ac7db3ddfd_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfNDk0_96d86626-f988-4cef-8aa3-517dba883c00">74.2</ix:nonFraction> million of unrecognized compensation costs related to RSUs, which are expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="iff2ee009736640978c0e8cdec25086bf_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfNjE5_3ee5a857-3fbb-43a1-bb04-ecd359f65df5">2.65</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><ix:continuation id="i956d2e2a24d84c46a891b23c42bc0fa9" continuedAt="i30cedfcdd73743879634c935d72e8073"><div style="margin-top:6pt"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMzY1OQ_9f6f10a1-3ffe-4226-92de-60b8493adb45" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding that have vested and are expected to vest at March&#160;31, 2023 are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Issued <br/>(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic&#160;Value<br/>(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="INF" name="cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjYxNzc4ZjE0MjNmMzQ0NGVhMTI3NzgyYTdjODAwOGQyL3RhYmxlcmFuZ2U6NjE3NzhmMTQyM2YzNDQ0ZWExMjc3ODJhN2M4MDA4ZDJfMS0xLTEtMS05NTEzMg_47239f59-e2a4-4f5d-91b6-00d1b74f8989">1,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="2" name="cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjYxNzc4ZjE0MjNmMzQ0NGVhMTI3NzgyYTdjODAwOGQyL3RhYmxlcmFuZ2U6NjE3NzhmMTQyM2YzNDQ0ZWExMjc3ODJhN2M4MDA4ZDJfMS0zLTEtMS05NTEzMg_11bce669-0cef-4cc5-ad42-ea6cabd52b0a">25.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjYxNzc4ZjE0MjNmMzQ0NGVhMTI3NzgyYTdjODAwOGQyL3RhYmxlcmFuZ2U6NjE3NzhmMTQyM2YzNDQ0ZWExMjc3ODJhN2M4MDA4ZDJfMS01LTEtMS05NTEzMg_43abb107-f93b-4f6c-b653-8cce1986e2f4">5.72</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjYxNzc4ZjE0MjNmMzQ0NGVhMTI3NzgyYTdjODAwOGQyL3RhYmxlcmFuZ2U6NjE3NzhmMTQyM2YzNDQ0ZWExMjc3ODJhN2M4MDA4ZDJfMS03LTEtMS05NTEzMg_1cd4abd7-80c1-4b1c-85a9-3855537e12a0">1,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="INF" name="cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjYxNzc4ZjE0MjNmMzQ0NGVhMTI3NzgyYTdjODAwOGQyL3RhYmxlcmFuZ2U6NjE3NzhmMTQyM2YzNDQ0ZWExMjc3ODJhN2M4MDA4ZDJfMi0xLTEtMS05NTEzMg_31734775-afe4-4fcd-8897-dfd58b3c04de">1,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="2" name="cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjYxNzc4ZjE0MjNmMzQ0NGVhMTI3NzgyYTdjODAwOGQyL3RhYmxlcmFuZ2U6NjE3NzhmMTQyM2YzNDQ0ZWExMjc3ODJhN2M4MDA4ZDJfMi0zLTEtMS05NTEzMg_b5117f9d-5757-4052-825f-7cf8cbd997a4">27.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjYxNzc4ZjE0MjNmMzQ0NGVhMTI3NzgyYTdjODAwOGQyL3RhYmxlcmFuZ2U6NjE3NzhmMTQyM2YzNDQ0ZWExMjc3ODJhN2M4MDA4ZDJfMi01LTEtMS05NTEzMg_38bde528-250a-4191-b7db-737d3675614c">8.97</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjYxNzc4ZjE0MjNmMzQ0NGVhMTI3NzgyYTdjODAwOGQyL3RhYmxlcmFuZ2U6NjE3NzhmMTQyM2YzNDQ0ZWExMjc3ODJhN2M4MDA4ZDJfMi03LTEtMS05NTEzMg_a079bb69-df64-4d83-89e3-8b9982bc18bf">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjYxNzc4ZjE0MjNmMzQ0NGVhMTI3NzgyYTdjODAwOGQyL3RhYmxlcmFuZ2U6NjE3NzhmMTQyM2YzNDQ0ZWExMjc3ODJhN2M4MDA4ZDJfMy0xLTEtMS05NTEzMg_e709b096-8a33-4732-b56a-0972fc5c25e1">2,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjYxNzc4ZjE0MjNmMzQ0NGVhMTI3NzgyYTdjODAwOGQyL3RhYmxlcmFuZ2U6NjE3NzhmMTQyM2YzNDQ0ZWExMjc3ODJhN2M4MDA4ZDJfMy03LTEtMS05NTEzMg_649a15f1-d78e-4bf5-ad82-34791816760d">1,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&#8217;s common stock at March&#160;31, 2023 for stock options that were in-the-money.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of options that vested during the three months ended March&#160;31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="i565db6f072c74a3dbfeac9d900d2d797_D20230101-20230331" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMTAwNg_5d930c27-ec40-4f58-9275-f9edb91159bb">4.2</ix:nonFraction> million. As of March&#160;31, 2023, there were approximately $<ix:nonFraction unitRef="usd" contextRef="ib2b2e52a6bb948f2b6b0826f266d5493_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMTA0NQ_207314e2-8076-4006-a322-025b78a017c6">26.3</ix:nonFraction> million of unrecognized compensation costs related to stock options, which are expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i565db6f072c74a3dbfeac9d900d2d797_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMTE3OQ_d73cf192-215b-415d-ab4c-5fbaec171aff">3.02</ix:nonNumeric> years.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2014 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), under which employees can purchase shares of its common stock based on a percentage of their compensation, but not greater than <ix:nonFraction unitRef="number" contextRef="i26d6663b7c774332a4c9fa15e23e3b34_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMTQwNw_7a2a2a94-bf92-4376-b7de-9dc8e2df1529">15</ix:nonFraction>% of their respective earnings; provided, however, an eligible employee&#8217;s right to purchase shares of the Company&#8217;s common stock may not accrue at a rate which exceeds $<ix:nonFraction unitRef="usd" contextRef="i7773cc52f31449008e2a2da976fb5dbc_D20230101-20230331" decimals="INF" name="cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMTU3Ng_9cfc1e7e-6421-402f-a14c-6bf375ae9747">25,000</ix:nonFraction> of the fair market value of such shares for each calendar year in which such rights are outstanding. The ESPP has consecutive offering periods of approximately <ix:nonNumeric contextRef="i7773cc52f31449008e2a2da976fb5dbc_D20230101-20230331" name="cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMTczOQ_2e32644c-d556-42c5-b7cd-f24ada5713d0">six months</ix:nonNumeric> in length. The purchase price per share must be equal to the lower of <ix:nonFraction unitRef="number" contextRef="i7773cc52f31449008e2a2da976fb5dbc_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMTgxMg_41b0aa6e-e7e2-417e-8219-3b1e943caf54">85</ix:nonFraction>% of the fair value of the common stock on the first day of the offering period or on the exercise date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the offering period in 2022 that ended on December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="i40b3e213d2c44ed3bf2769319aee962b_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMTk2OQ_d7a70ffd-b68a-43d4-8083-6b194b5a3432">47,025</ix:nonFraction> shares were purchased pursuant to the ESPP for aggregate proceeds of $<ix:nonFraction unitRef="usd" contextRef="i40b3e213d2c44ed3bf2769319aee962b_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMjA0MQ_d87f0758-c3dd-430d-a294-025efc8ca651">0.5</ix:nonFraction> million from the issuance of such shares, which occurred on January 2, 2023.&#160;&#160;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Valuation Assumptions</span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMzY2MA_86826351-dfbb-47d2-90a7-266313c7a2bf" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of employee stock options and ESPP shares were estimated using the Black-Scholes option pricing model based on the following weighted average assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.476%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee stock options</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i565db6f072c74a3dbfeac9d900d2d797_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfMy0yLTEtMS05NTEzMg_06ab5e77-60c6-4d24-9fba-b199a1897c73">6.0</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9e23905672f3405495bcc17dd04c3467_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfMy00LTEtMS05NTEzMg_48cbe4f9-6c7b-42be-be05-7d8b730ad207">6.0</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i565db6f072c74a3dbfeac9d900d2d797_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfNC0yLTEtMS05NTEzMg_6fe3bcac-a9fe-4f96-b21a-df045c5684e1">78.63</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9e23905672f3405495bcc17dd04c3467_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfNC00LTEtMS05NTEzMg_91cca92b-faae-4de1-b27a-e194b13d7926">76.93</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i565db6f072c74a3dbfeac9d900d2d797_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfNS0yLTEtMS05NTEzMg_f0f310b3-eee7-44d0-bdc3-cea9a8c5a2bf">3.46</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9e23905672f3405495bcc17dd04c3467_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfNS00LTEtMS05NTEzMg_76d4b220-6860-4967-bd33-b42a774edb61">1.65</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i565db6f072c74a3dbfeac9d900d2d797_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfNi0yLTEtMS05NTEzMg_233f7f1c-5cdb-4196-ba16-c41ccc0ed524">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9e23905672f3405495bcc17dd04c3467_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfNi00LTEtMS05NTEzMg_d88d8281-caa4-40d3-8e34-93665a9ad7eb">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia24f76f7b5ed46cf96e628a538a6e320_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfOC0yLTEtMS05NTEzMg_b35f6040-5bc5-479f-be3b-ae41c547fd27">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i404725fbc6564a3193b67907dbbe80e6_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfOC00LTEtMS05NTEzMg_3fcf1b34-08a3-480e-9c7c-d7359f4b13de">0.5</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia24f76f7b5ed46cf96e628a538a6e320_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfOS0yLTEtMS05NTEzMg_456f7be8-ec23-4673-a68b-b08f0ae75a3a">77.88</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i404725fbc6564a3193b67907dbbe80e6_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfOS00LTEtMS05NTEzMg_7cd8dfcc-11be-4971-bff2-a0ac376dc5f9">67.79</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia24f76f7b5ed46cf96e628a538a6e320_D20230101-20230331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfMTAtMi0xLTEtOTUxMzI_e486794c-0984-4688-ada8-157721fcfee3">4.94</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i404725fbc6564a3193b67907dbbe80e6_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfMTAtNC0xLTEtOTUxMzI_7a0b190c-ae7c-418d-b2fd-ccdf2d7b7120">1.06</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia24f76f7b5ed46cf96e628a538a6e320_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfMTEtMi0xLTEtOTUxMzI_eceec28d-51b2-4dab-be91-91a67f994eb8">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i404725fbc6564a3193b67907dbbe80e6_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfMTEtNC0xLTEtOTUxMzI_0aa36272-d137-424c-a32a-7c98b1c649a0">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free Interest Rate:&#160;The Company based the risk-free interest rate over the expected term of the award based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of grant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">:&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used an average historical stock price volatility of its own stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected Term: The expected term represents the period for which the Company&#8217;s stock-based compensation awards are expected to be outstanding and is based on analyzing the vesting and contractual terms of the awards and the holders&#8217; historical exercise patterns and termination behavior.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected Dividends</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has not paid and does not anticipate paying any dividends in the near future.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><ix:continuation id="i30cedfcdd73743879634c935d72e8073"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMzY2MQ_9ce52d5a-2721-4be8-9b33-99537e4e5111" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expense relating to employee and non-employee stock-based awards for the three months ended March&#160;31, 2023 and 2022, included in the condensed consolidated statements of operations as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.183%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of testing services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f9048fade524f0d937582e2d0737bbd_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfMi0xLTEtMS05NTEzMg_2ba2bf5e-4d6e-486c-8d90-2ba24c5571c6">479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8d2b80178a040808832e847918f0f37_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfMi0zLTEtMS05NTEzMg_6e485e60-7705-4af5-ae53-3808afc44e06">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5130eca1ccf4f738a701a55a747d5d9_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfMy0xLTEtMS05NTEzMg_0a308a45-16b3-412c-935b-1b1e2d7d29ad">360</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb4b7444c8a54bf5b1e67a533d029b35_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfMy0zLTEtMS05NTEzMg_9ee59da3-9ffd-4e19-8c63-37edf3785ff2">128</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of patient and digital solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i538eccbc464c49cd93e1c60f3af790b5_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfNC0xLTEtMS05NTEzMg_333e87f4-1b6f-475c-98c9-b72b64d8d4e8">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id192b96ed2d2443395a41393430289fe_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfNC0zLTEtMS05NTEzMg_79b0e61f-f936-4540-97ae-eb1390b7b7d7">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4783302274d944709ef6bd9aac018c00_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfNS0xLTEtMS05NTEzMg_b638dc85-fc4e-493e-9955-053a15646741">1,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b063cbad6df47aeadbd66f77725b34e_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfNS0zLTEtMS05NTEzMg_e5134bcf-9a6a-46a7-9fdf-32cb195e2d10">2,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb5085de4360418c9f60a706e826ebd0_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfNi0xLTEtMS05NTEzMg_3e9f40b8-08b4-47d4-9a99-b4959fa91697">3,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2bb0753ed6b4970916acf1662850bff_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfNi0zLTEtMS05NTEzMg_0b6debb4-677f-4fdc-baae-5ca8ab7f0a39">3,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a8e83ffc79746499f241de17f14762c_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfNy0xLTEtMS05NTEzMg_d8fbde7f-34e6-4bcf-b99a-2ea1db3cc954">6,814</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfc21a0301ce4966b0e2d787749a63dd_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfNy0zLTEtMS05NTEzMg_4056f655-3746-4dca-997b-3c3eef9f1a6c">4,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfOC0xLTEtMS05NTEzMg_f4f24a1c-c73a-4a7b-ab43-6d42698d3d9c">13,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfOC0zLTEtMS05NTEzMg_77e31057-f8f9-490a-a1c2-7e101dbccb7c">10,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMzI5OA_505779a7-282a-4915-bb51-7e36ee29b063">No</ix:nonFraction> tax benefit was recognized related to stock-based compensation expense since the Company has never reported taxable income and has established a full valuation allowance to offset all of the potential tax benefits associated with its deferred tax assets.&#160;&#160;In addition, <ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMzU3MA_20819e0b-f690-4474-bc83-a90a8e7da902">no</ix:nonFraction> amounts of stock-based compensation expense were capitalized for the periods presented.</span></div></ix:continuation><div id="idd35c15ee381485cb38f052732749537_73"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183My9mcmFnOmI2N2JjZmU3YWMxNDQ1ZjA5Y2U4ZTVmNGI5MjBkOTNhL3RleHRyZWdpb246YjY3YmNmZTdhYzE0NDVmMDljZThlNWY0YjkyMGQ5M2FfMTM3Ng_db69c249-8b3a-4f35-a064-512f25f2e329" continuedAt="ic78dfb86e576466ea483490ff2950356" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="ic78dfb86e576466ea483490ff2950356"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective tax rate may vary from the U.S. federal statutory tax rate due to the change in the mix of earnings in tax jurisdictions with different statutory rates, benefits related to tax credits, and the tax impact of non-deductible expenses and other permanent differences between income before income taxes and taxable income.&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023 and 2022, the Company recorded an income tax expense of $<ix:nonFraction unitRef="usd" contextRef="i4085e2e2596a4c689ebf01b80b2c5c82_D20230101-20230331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183My9mcmFnOmI2N2JjZmU3YWMxNDQ1ZjA5Y2U4ZTVmNGI5MjBkOTNhL3RleHRyZWdpb246YjY3YmNmZTdhYzE0NDVmMDljZThlNWY0YjkyMGQ5M2FfNDQ3_67155dc2-6032-46f6-8a6a-0e1f86c26e4d">0.1</ix:nonFraction> million and an income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183My9mcmFnOmI2N2JjZmU3YWMxNDQ1ZjA5Y2U4ZTVmNGI5MjBkOTNhL3RleHRyZWdpb246YjY3YmNmZTdhYzE0NDVmMDljZThlNWY0YjkyMGQ5M2FfNTQ5NzU1ODE3MDc3_b533b08f-b745-41ce-8f44-f0b8ece7acce">12,000</ix:nonFraction>, respectively. The income tax expense of $<ix:nonFraction unitRef="usd" contextRef="i4085e2e2596a4c689ebf01b80b2c5c82_D20230101-20230331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183My9mcmFnOmI2N2JjZmU3YWMxNDQ1ZjA5Y2U4ZTVmNGI5MjBkOTNhL3RleHRyZWdpb246YjY3YmNmZTdhYzE0NDVmMDljZThlNWY0YjkyMGQ5M2FfNDk4_67155dc2-6032-46f6-8a6a-0e1f86c26e4d">0.1</ix:nonFraction> million is primarily attributable to the U.S. current tax expense.&#160;The Company assesses the realizability of its net deferred tax assets by evaluating all available evidence, both positive and negative, including (i) cumulative results of operations in recent years, (ii) sources of recent losses, (iii) estimates of future taxable income, and (iv) the length of net operating loss carryforward periods. The Company believes that based on the history of its U.S. losses and other factors, the weight of available evidence indicates that it is more likely than not that it will not be able to realize its U.S. consolidated net deferred tax assets. The Company has also placed a valuation allowance on the net deferred tax assets of its Sweden operations. Accordingly, the U.S. and Sweden net deferred tax assets have been offset by a full valuation allowance.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="idd35c15ee381485cb38f052732749537_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RleHRyZWdpb246NjZiYzFjMzlhODk2NGIwM2I3MDRmMTI0ZTcxNzY2NjdfMTAwOQ_94b35c91-3e6e-4ac2-a77d-068c5801e628" continuedAt="i6805b1de160947ec9bf7f65c6b4580aa" escape="true">SEGMENT REPORTING</ix:nonNumeric></span></div><ix:continuation id="i6805b1de160947ec9bf7f65c6b4580aa"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the Company's Chief Operating Decision Maker (&#8220;CODM&#8221;), or decision making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its Chief Executive Officer as the CODM. In determining its reportable segments, the Company considered the markets and types of customers served and the products or services provided in those markets. The Company operates in a single reportable segment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic regions are based upon the customers&#8217; ship-to address for product revenue and the region of testing for testing services revenue. <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RleHRyZWdpb246NjZiYzFjMzlhODk2NGIwM2I3MDRmMTI0ZTcxNzY2NjdfMTAxMA_103b9871-7f41-49e7-b2b7-edf220f5380d" continuedAt="i23a1d2f0005e496cb2de0ccd12f45f1a" escape="true">The following table summarizes reportable revenues by geographic regions (in thousands):</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="i23a1d2f0005e496cb2de0ccd12f45f1a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Testing services revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f7a16d338ed4ab3939bc3f47e6c75cf_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMy0xLTEtMS05NTEzMg_2723a96c-df9d-40dc-ab2e-b2d0abc0405f">61,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ab6496f097a4ebc957f05bf6f2a67a7_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMy0zLTEtMS05NTEzMg_b9d76191-1dc2-4536-a78e-e5552643f35a">66,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39f90c981a414baca25472855eb286a8_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfNC0xLTEtMS05NTEzMg_fda4f352-ad34-4b95-b2f4-5ad8d81bf7b8">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic03e1001adae4271911ad4bdce2d0981_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfNC0zLTEtMS05NTEzMg_87a6a7fd-4160-4b98-8dd3-ea51555c3eda">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6522c13470244b44971d6dd1d0a8251b_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfNS0xLTEtMS05NTEzMg_9e6a1f49-0bf1-44e7-b981-302b94308d2a">61,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68b6550537c1477c960fc12e49544478_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfNS0zLTEtMS05NTEzMg_ad6b3157-f5f4-417f-9579-67a49174beb8">66,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id58767c1d8084713916edd6596399012_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfNy0xLTEtMS05NTEzMg_506a1cd2-f8b1-4450-af49-c3fa91b1b76c">3,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15533108dd8044e8a8072baeebce60f2_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfNy0zLTEtMS05NTEzMg_253808fb-e4aa-49da-9128-74a40ca953df">3,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c59122b69b444ae819cdc8aae3be5b9_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfOC0xLTEtMS05NTEzMg_5c754474-390f-41a9-afde-1cf00fd6c07a">2,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c618998e62f418a831eb3095a8a2c36_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfOC0zLTEtMS05NTEzMg_7ddbbc66-6577-4cee-95ba-10c44cccaf71">2,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec20c3548df44cde8bb311b72dae19bd_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfOS0xLTEtMS05NTEzMg_ae198235-f8e6-4adb-8476-cc0b0265dbfb">673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i441bbf95c9a74c9f8bcc5339145c212a_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfOS0zLTEtMS05NTEzMg_51c9fdcf-37f8-4d26-941c-ec6d79122bcd">933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaaeba5a92a4430cb59489d292860cd5_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTAtMS0xLTEtOTUxMzI_aaead0d6-0ad5-410b-bc98-a4210123093e">6,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie44565fb103943ffa2a40292b86d6156_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTAtMy0xLTEtOTUxMzI_bb728009-9119-461b-a400-3793570fe943">6,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient and digital solutions revenue</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a6d052a98b04c87b9036941a8a6a5c8_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTItMS0xLTEtOTUxMzI_94e63bb3-767f-430d-8cdf-441445cea410">8,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i128a8bcd322647b8a897eae3a619355d_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTItMy0xLTEtOTUxMzI_00d63bb7-982b-4009-b8e9-80d98f7fbdbc">6,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd964cbefaa49e2a61aabfee7302e19_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTMtMS0xLTEtOTUxMzI_a73986e0-e93b-4fd6-9674-fd7d5dacc26a">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeaf539bfe39471ba59a24aa7f4ce0e0_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTMtMy0xLTEtOTUxMzI_9bbfffa8-8a1b-4acc-a4f7-2bc91c8e6c68">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcc6d18dcb4b4287b16ec15dafbee2d7_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTQtMS0xLTEtOTUxMzI_9946df33-4414-41c5-9288-65418625f04c">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib52598d086dd497d8f54897e6cabc808_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTQtMy0xLTEtOTUxMzI_32209506-f97c-4fe3-ae8b-a4442cf87d47">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b1a5c19190949f3825408e0497964b7_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTUtMS0xLTEtOTUxMzI_60b8d295-8c9f-4035-ab7b-38cf50c1575c">8,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5765e29984cc4e398fbf04608384a068_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTUtMy0xLTEtOTUxMzI_3874ef81-b689-4e37-b012-c8415b599693">6,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1620b425a8304d7d9b96f7bafd09516e_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTctMS0xLTEtOTUxMzI_4b959824-7e1e-44da-8578-359fdbb6e121">73,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b98c1259e7b4de198ec8628fc9720f5_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTctMy0xLTEtOTUxMzI_1d72c0f5-6172-4330-98e4-5c8d695086eb">75,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Europe</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8553922693ab40cfadd6ab80368405fe_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTgtMS0xLTEtOTUxMzI_3101fa2f-4a2a-48e1-a13e-62973bda2b46">2,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233add0bbd014f5982408f02ff0d7cef_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTgtMy0xLTEtOTUxMzI_ef913c2a-b2de-44c5-94ac-9781c8eafa83">2,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Rest of World</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic034aa3435224d08892ec111ab99fe01_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTktMS0xLTEtOTUxMzI_74348e15-ba4d-4c1c-998a-39a5af451499">837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7961f0ef0c9b4553b4637f426c4f87c8_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTktMy0xLTEtOTUxMzI_97c61752-e39e-4f41-a000-5f1b19607fbd">1,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMjEtMS0xLTEtOTUxMzI_f7c6769a-1057-4dbf-9fc1-a7451f846454">77,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMjEtMy0xLTEtOTUxMzI_f7042644-c121-419a-a8e9-304b453c1103">79,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:10pt"><ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RleHRyZWdpb246NjZiYzFjMzlhODk2NGIwM2I3MDRmMTI0ZTcxNzY2NjdfMTAxMQ_e3bc8fee-0b15-406d-8ca5-1a20daced2bd" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-lived assets, consisting of property and equipment, net, by geographic regions (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61c592955b9b4fce84fc074131d238b5_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOmM1ODY1MmVlNDg2NDQ1NTg4NmEzZjA5ZWRmYzRjYjg1L3RhYmxlcmFuZ2U6YzU4NjUyZWU0ODY0NDU1ODg2YTNmMDllZGZjNGNiODVfMi0xLTEtMS05NTEzMg_afcc8496-96b5-4df6-b4f6-dd5e8ff87501">34,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i877626f277b84c4c83cb6ce132b835a6_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOmM1ODY1MmVlNDg2NDQ1NTg4NmEzZjA5ZWRmYzRjYjg1L3RhYmxlcmFuZ2U6YzU4NjUyZWU0ODY0NDU1ODg2YTNmMDllZGZjNGNiODVfMi0zLTEtMS05NTEzMg_fd74b5d9-d599-488c-979c-ea45993e6532">35,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0849fd3f28ca472abc8fd430de00bd14_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOmM1ODY1MmVlNDg2NDQ1NTg4NmEzZjA5ZWRmYzRjYjg1L3RhYmxlcmFuZ2U6YzU4NjUyZWU0ODY0NDU1ODg2YTNmMDllZGZjNGNiODVfMy0xLTEtMS05NTEzMg_a0f59602-f35b-4412-855d-107686470fdd">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fd093ee1cfc4c4d8bbb09c7524ee14b_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOmM1ODY1MmVlNDg2NDQ1NTg4NmEzZjA5ZWRmYzRjYjg1L3RhYmxlcmFuZ2U6YzU4NjUyZWU0ODY0NDU1ODg2YTNmMDllZGZjNGNiODVfMy0zLTEtMS05NTEzMg_6dc7f3fe-2910-4d42-8c2d-db426792e7c1">405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa00d894ab6f41268315eb34dc054cd4_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOmM1ODY1MmVlNDg2NDQ1NTg4NmEzZjA5ZWRmYzRjYjg1L3RhYmxlcmFuZ2U6YzU4NjUyZWU0ODY0NDU1ODg2YTNmMDllZGZjNGNiODVfNC0xLTEtMS05NTEzMg_4f9b780f-8b0b-404e-985f-617210500ed0">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac91ecb914ad42ab9e94c27584c8b7a8_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOmM1ODY1MmVlNDg2NDQ1NTg4NmEzZjA5ZWRmYzRjYjg1L3RhYmxlcmFuZ2U6YzU4NjUyZWU0ODY0NDU1ODg2YTNmMDllZGZjNGNiODVfNC0zLTEtMS05NTEzMg_ed90c778-62ed-4508-972f-83d68d4926b6">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOmM1ODY1MmVlNDg2NDQ1NTg4NmEzZjA5ZWRmYzRjYjg1L3RhYmxlcmFuZ2U6YzU4NjUyZWU0ODY0NDU1ODg2YTNmMDllZGZjNGNiODVfNS0xLTEtMS05NTEzMg_e0cf1e37-0a4f-4cb2-9485-a37a349f3186">35,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0947b2db32e4416394c995e30d617446_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOmM1ODY1MmVlNDg2NDQ1NTg4NmEzZjA5ZWRmYzRjYjg1L3RhYmxlcmFuZ2U6YzU4NjUyZWU0ODY0NDU1ODg2YTNmMDllZGZjNGNiODVfNS0zLTEtMS05NTEzMg_b03099e9-63e4-4c82-83a0-812d855deb04">35,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="idd35c15ee381485cb38f052732749537_79"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.  <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183OS9mcmFnOjhmNTA3Nzc4YTg2MjRhZTk5YzNiNTUyNWRlY2I2NTk2L3RleHRyZWdpb246OGY1MDc3NzhhODYyNGFlOTljM2I1NTI1ZGVjYjY1OTZfMTY0OTI2NzQ0NzQ1Mw_64144445-d0a5-45ff-9a68-5be726913b79" continuedAt="ifc8066ebb1974040a4b9e72c21826704" escape="true">RESTRUCTURING</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifc8066ebb1974040a4b9e72c21826704">In January 2023, the Company announced a restructuring plan that is intended to optimize costs and simplify its organizational and corporate structure. The restructuring plan includes the discontinuation of the Company's operations in Fremantle, Australia, terminating its employees in that location and vacating its facilities there. As a result of this plan, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" decimals="-4" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183OS9mcmFnOjhmNTA3Nzc4YTg2MjRhZTk5YzNiNTUyNWRlY2I2NTk2L3RleHRyZWdpb246OGY1MDc3NzhhODYyNGFlOTljM2I1NTI1ZGVjYjY1OTZfNTQ5NzU1ODE5Mzg3_a775da4f-25d2-4e4d-98ce-2a6f04b45274">0.06</ix:nonFraction>&#160;million in restructuring charges for the three months ended March&#160;31, 2023. The Company expects to complete the closure of its Australia location in June 2024.</ix:continuation></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="idd35c15ee381485cb38f052732749537_1077"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xMDc3L2ZyYWc6ZGU0MGNkZTBhYmYyNDZkNTg0NjNmYThiNmI1NmY3ZjkvdGV4dHJlZ2lvbjpkZTQwY2RlMGFiZjI0NmQ1ODQ2M2ZhOGI2YjU2ZjdmOV8xNjQ5MjY3NDQxOTE3_d454891d-7526-41af-a7a0-904bbaaf0495" continuedAt="if23f5029e5594049ad5ad1e40593bc17" escape="true">SUBSEQUENT EVENT</ix:nonNumeric></span></div><ix:continuation id="if23f5029e5594049ad5ad1e40593bc17"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Restructuring Plan</span></div><div style="margin-top:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Company announced a reduction of its U.S. workforce to simplify and streamline its organization and strengthen the overall effectiveness of its operations.  The restructuring charges are primarily related to employee severance pay and related costs.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="idd35c15ee381485cb38f052732749537_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and related notes included elsewhere in Item&#160;1 of Part I of this Quarterly Report on&#160;Form&#160;10-Q&#160;and with the audited consolidated financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022, filed with the Securities and Exchange Commission, or the SEC, on February&#160;27, 2023.</span></div><div id="idd35c15ee381485cb38f052732749537_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Quarterly Report on Form 10-Q other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;potentially,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;plan,&#8221; &#8220;target,&#8221; &#8220;contemplate,&#8221; &#8220;predict,&#8221; &#8220;expect&#8221; and the negative and plural forms of these words and similar expressions are intended to identify forward-looking statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements may include, but are not limited to, statements concerning the following:</span></div><div style="margin-top:3pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to generate revenue and increase the commercial success of our current and future testing services, products and patient and digital solutions;</span></div><div style="margin-top:3pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to obtain, maintain, continue and expand reimbursement coverage from payers for our current and other future testing services, if any, including with respect to AlloSure Kidney;</span></div><div style="margin-top:3pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our plans and ability to continue updating our testing services, products and patient and digital solutions to maintain our leading position in transplantations;</span></div><div style="margin-top:3pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the outcome or success of our clinical trial collaborations and registry studies, including Kidney Allograft Outcomes AlloSure Registry, or K-OAR, the Outcomes of KidneyCare</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on Renal Allografts registry study, or OKRA, and the Surveillance HeartCare Outcomes Registry, or SHORE;</span></div><div style="margin-top:3pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the favorable review of our testing services and product offerings, and our future solutions, if any, in peer-reviewed publications;</span></div><div style="margin-top:3pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to obtain additional financing on terms favorable to us, or at all;</span></div><div style="margin-top:3pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our anticipated cash needs and our anticipated uses of our funds, including our estimates regarding operating expenses and capital requirements;</span></div><div style="margin-top:3pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">anticipated trends and challenges in our business and the markets in which we operate;</span></div><div style="margin-top:3pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our dependence on certain of our suppliers, service providers and other distribution partners;</span></div><div style="margin-top:3pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disruptions to our business, including disruptions at our laboratories and manufacturing facilities;</span></div><div style="margin-top:3pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to retain key members of our management team;</span></div><div style="margin-top:3pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to make successful acquisitions or investments and to manage the integration of such acquisitions or investments;</span></div><div style="margin-top:3pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to expand internationally;</span></div><div style="margin-top:3pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our compliance with federal, state and foreign regulatory requirements;</span></div><div style="margin-top:3pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to protect and enforce our intellectual property rights, our strategies regarding filing additional patent applications to strengthen our intellectual property rights, and our ability to defend against intellectual property claims that may be brought against us;</span></div><div style="margin-top:3pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to successfully assert, defend against or settle any litigation brought by or against us or other legal matters or disputes;</span></div><div style="margin-top:3pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our plans with respect to certain future Medicare reimbursement submissions;</span></div><div style="margin-top:3pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to remediate the material weaknesses in our internal control over financial reporting of December 31, 2022; and</span></div><div style="margin-top:3pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to comply with the requirements of being a public company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the section entitled &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the fiscal </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December&#160;31, 2022, filed with the SEC on February&#160;27, 2023.&#160;Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially and adversely from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Quarterly Report on Form 10-Q and the documents that we reference in this Quarterly Report on Form 10-Q and have filed with the SEC as exhibits to this Quarterly Report on Form 10-Q with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.&#160;We qualify all forward-looking statements by these cautionary statements.</span></div><div id="idd35c15ee381485cb38f052732749537_88"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview and Recent Highlights</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CareDx, Inc., or collectively, the Company, we, us and our, is a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients and caregivers. We offer testing services, products, and patient and digital healthcare solutions along the pre- and post-transplant patient journey, and we are a leading provider of genomics-based information for transplant patients.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Highlights for the Three Months Ended March&#160;31, 2023 and Recent Highlights</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delivered record number of patient test results for AlloMap&#174; and AlloSure&#174; of approximately 49,900 tests, growing year-over-year by 17%, and exceeding year-over-year market growth of 10%.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reported revenue of $77.3 million, a decrease of 3% year-over year. This excludes approximately $8.9 million in revenue associated with approximately 3,200 AlloSure Kidney Medicare tests that the Company did not submit for reimbursement in Q1 2023 (the &#8220;Impacted March Tests&#8221;), and plans to  submit in Q2 2023. This was to allow the Company further time to understand and evaluate the implications of the new Billing Article </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the Local Coverage Determination covering AlloSure Kidney entitled Molecular Testing for Solid Organ Allograft Rejection (the &#8220;Billing Article&#8221;) issued in early March 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Including the revenue associated with the Impacted March Tests, total revenue would have been $86.2 million and testing services revenue would have been $70.7 million, increases of 9% and 6% year-over-year, respectively, which would have been the highest ever quarterly revenues for the Company and its Testing Services business. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Achieved record revenues of $8.6 million for Patient and Digital Solutions business, an increase of 39% year-over-year.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reported GAAP net loss of $23.7 million, non-GAAP net loss of $5.8 million and adjusted EBITDA loss of $6.4 million. Including revenue associated with the Impacted March Tests, the Company would have achieved a positive adjusted EBITDA of $2.5 million. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Maintained strong balance sheet with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$285.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> million in cash and cash equivalents and marketable securities, with no debt. Generated </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.7 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in net cash from operating activities compared to $21.5 million of cash used in operating activities in the first quarter of 2022. This represents the second consecutive quarter where the Company generated positive cash from its operating activities. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Achieved cash collections at 110% of revenue for testing services, representing an approximate 10% year-over-year increase, and demonstrating continued strong operational progress on this key initiative.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Strong transplant ecosystem support in response to the Billing Article from leading professional and patient societies, including the American Society of Transplantation, American Society of Transplant Surgeons, and the International Society for Heart and Lung Transplantation.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Leading patient groups, including the Transplant Life Foundation, Transplant Recipients International Organization (TRIO), Transplant Families, and the Heart Brothers Foundation announced in a press release the results of a survey </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from over 1,000 patients, as well as caregivers and family members that 95% of patients surveyed are concerned that a new Medicare Billing Article limits coverage of non-invasive post-transplant tests.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Testing Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kidney</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloSure Kidney, our transplant surveillance solution, was commercially launched in October 2017 and is our donor-derived cell-free DNA, or dd-cfDNA offering built on a next generation sequencing, or NGS, platform. In transplantation, more than </span><span style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> papers from over </span><span style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> studies globally have shown the value of dd-cfDNA in the management of solid organ transplantation. AlloSure Kidney is able to discriminate dd-cfDNA from recipient-cell-free DNA, targeting polymorphisms between donor and recipient. This single nucleotide polymorphism, or SNP, approach across all the somatic chromosomes is specifically designed for transplantation, allowing a scalable, high-quality test to differentiate dd-cfDNA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloSure Kidney has been a covered service for Medicare beneficiaries since October 2017 through a Local Coverage Determination, or LCD, first issued by Palmetto MolDX, or MolDX, which was formed to identify and establish coverage and reimbursement for molecular diagnostics tests, and adopted by Noridian Healthcare Solutions, our Medicare Administrative Contractor, or Noridian. The Medicare reimbursement rate for AlloSure Kidney is currently $2,841. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;2, 2023, MolDX issued a new billing article, with an effective date of March&#160;31, 2023, related to the LCD entitled Molecular Testing for Solid Organ Allograft Rejection, or the Billing Article. Prior to the Billing Article&#8217;s effective date, MolDX informed the affected parties, including CareDx, that enforcement of the revised billing practices outlined in the Billing Article will not be implemented until June&#160;30, 2023.  MolDX informed us that its automatic adjudication process would remain in place until June 30, 2023, though claims submitted prior to that date must comply with the applicable LCDs. On May&#160;4, 2023, MolDX issued a revised new billing article with an effective date of March&#160;31, 2023, or the Revised Billing Article, and together with the Billing Article, the Billing Articles.  The Revised Billing Article impacts Medicare coverage for AlloSure Kidney, AlloSure Heart and AlloMap Heart and requires certain companies, including CareDx, to implement new processes to address the requirements related to Medicare claim submissions. MolDX has stated that it views the Billing Article as clarifying existing coverage, especially as it relates to when tests are covered in the for-cause and surveillance contexts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MolDX has acknowledged, however, that the Billing Article is a change as it relates to billing more than one test during a single patient encounter. Noridian has not yet adopted the new Billing Articles.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe the Billing Articles are inconsistent with the LCDs, Noridian&#8217;s and MolDX&#8217;s responses to public comments explaining the intended scope of various LCDs, and medical necessity, we determined to pause our Medicare reimbursement submissions for AlloSure Kidney commencing on March&#160;7, 2023 to allow us further time to evaluate the implications of the Billing Article and update our billing processes for AlloSure Kidney tests by educating clinicians and working with centers to update CareDx&#8217;s test order forms to capture the new information required under the Billing Article. Accordingly, we did not submit claims for approximately 3200 AlloSure Kidney tests for Medicare reimbursement for the period from March&#160;7, 2023 through March&#160;31, 2023 and did not recognize revenue on these claims in the first quarter of 2023 aggregating to approximately $8.9 million, or the Impacted March Tests.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2023, we plan to submit claims for Medicare reimbursement for the Impacted March Tests, following the delivery by us of a letter to Noridian explaining, among other things, (i) our belief that the Billing Articles impose new restrictions on Medicare coverage for the CareDx tests from those contained in the existing LCDs, (ii) that we plan to submit claims for reimbursement for the Impacted March Tests for which we have not obtained additional information from the ordering physicians to be able to specifically determine whether these tests meet the new coverage restrictions contained in the Billing Articles, and (iii) that AlloSure Kidney orders with a date of service on or after March&#160;31, 2023 for other indications outside the parameters of the Revised Billing Article, or where the reason for testing is not specified by the ordering physician, will either be held pending the receipt of additional information regarding medical necessity or submitted with a test description that is intended to identify those tests as falling outside the parameters of the Revised Billing Article. Although we plan to submit claims for Medicare reimbursement for the Impacted March Tests, there is a risk that the claims are denied or that any reimbursement of such claims is subject to forfeiture.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloSure Kidney has received positive coverage decisions from several commercial payers, and is reimbursed by other private payers on a case-by-case basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple studies have demonstrated that significant allograft injury can occur in the absence of changes in serum creatinine. Thus, clinicians have limited ability to detect injury early and intervene to prevent long-term damage using this marker. While histologic analysis of the allograft biopsy specimen remains the standard method used to assess injury and differentiate rejection from other injury in kidney transplants, as an invasive test with complications, repetitive biopsies are not well tolerated. AlloSure Kidney provides a non-invasive test, assessing allograft injury that enables more frequent, quantitative and safer assessment of allograft rejection and injury status. Beyond allograft rejection, the assessment of molecular inflammation has </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shown further utility in the assessment of proteinuria, the formation of De Novo donor specific antibodies, or DSAs, and as a surrogate predictive measure of estimated glomerular filtration rate, or eGFR, decline. Monitoring of graft injury through AlloSure Kidney allows clinicians to optimize allograft biopsies, identify allograft injury and guide immunosuppression management more accurately.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the analytical validation paper in the Journal of Molecular Diagnostics in 2016 before the commercial launch of AlloSure Kidney, there has been an increasing body of evidence supporting the use of AlloSure Kidney dd-cfDNA in the assessment and surveillance of kidney transplants. Bloom et al evaluated </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> kidney recipients and demonstrated that dd-cfDNA levels could discriminate accurately and non-invasively distinguish rejection from other types of graft injury. In contrast, serum creatinine has area under the curve of 50%, showing no significant difference between patients with and without rejection. Multiple publications and abstracts have shown AlloSure Kidney&#8217;s value in the management of BK viremia, as well as numerous pathologies that cause molecular inflammation and injury such as DSAs and eGFR decline. Most recently its utility in the assessment of T-cell mediated rejection (TCMR) 1A and borderline rejection was published in the American Journal of Transplant, or AJT, and the outcomes of 1,000 patients were published in Kidney International.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prospective multicenter trial, the K-OAR study, has enrolled over </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patients, with plans to survey patients with AlloSure Kidney for 3 years and provide further clinical utility of AlloSure Kidney in the surveillance of kidney transplant recipients.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">KidneyCare</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KidneyCare combines the dd-cfDNA analysis of AlloSure Kidney with the gene expression profiling technology of AlloMap Kidney and the predictive artificial intelligence technology of iBox in one surveillance solution. We have not yet made any applications to private payers for reimbursement coverage of AlloMap Kidney or iBox.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we announced the enrollment of the first patient in the OKRA study, which is an extension of the K-OAR study. OKRA is a prospective, multi-center, observational registry of patients receiving KidneyCare for surveillance. Combined with K-OAR, more than 3,000 patients have been enrolled into the study.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Heart</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloMap Heart is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate-to-severe acute cellular rejection. Since 2008, we have sought to expand the adoption and utilization of our AlloMap Heart solution through ongoing studies to substantiate the clinical utility and actionability of AlloMap Heart, secure positive reimbursement decisions from large private and public payers, develop and enhance our relationships with key members of the transplant community, including opinion leaders at major transplant centers, and explore opportunities and technologies for the development of additional solutions for post-transplant surveillance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the use of AlloMap Heart, in conjunction with other clinical indicators, can help healthcare providers and their patients better manage long-term care following a heart transplant, can improve patient care by helping healthcare providers avoid the use of unnecessary, invasive surveillance biopsies and may help to determine the appropriate dosage levels of immunosuppressants. In 2008, AlloMap Heart received 510(k) clearance from the U.S. Food and Drug Administration for marketing and sale as a test to aid in the identification of heart transplant recipients, who have a low probability of moderate/severe acute cellular rejection at the time of testing, in conjunction with standard clinical assessment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloMap Heart has been a covered service for Medicare beneficiaries since January 1, 2006. The Medicare reimbursement rate for AlloMap Heart is currently $3,240. The Revised Billing Article impacts Medicare coverage for AlloMap Heart and requires certain companies, including CareDx, to implement new processes to address the requirements related to Medicare claim submissions. MolDX has stated that it views the Billing Article as clarifying existing coverage, though acknowledged that the Billing Article is a change as to its previous billing article, which provided coverage only where AlloSure Heart was used in conjunction with AlloMap Heart. As previously discussed, Noridian has not adopted the Billing Articles. We continued the Medicare reimbursement submissions for AlloMap Heart following the issuance of the new Billing Articles. In addition, we are considering informing Noridian that until Noridian adopts the Revised Billing Article, we will continue to submit AlloMap Heart tests for reimbursement only when used in conjunction with AlloSure Heart. We are also considering informing Noridian that (i) until June 30, 2023, we plan to submit claims for reimbursement for AlloMap Heart tests for which we have not obtained additional information from the ordering physicians to be able to specifically determine whether these tests meet the new coverage restrictions contained in the Billing Articles, and (ii) AlloMap Heart orders placed on or after June 30, 2023 for other indications outside the surveillance and for-cause parameters of the Billing Article, or where the reason for testing is not specified by the ordering physician, will either be held pending the receipt of additional information regarding medical necessity or submitted with a test description that is intended to identify those tests as falling outside the parameters of the Billing Articles. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloMap Heart has received positive coverage decisions for reimbursement from many of the largest U.S. private payers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we received a final Palmetto MolDx Medicare coverage decision for AlloSure Heart. In November 2020, Noridian issued a parallel coverage policy granting coverage when used in conjunction with AlloMap Heart, which became effective in December 2020. The Medicare reimbursement rate for AlloSure Heart is currently $2,753. The Revised Billing Article impacts Medicare coverage for AlloSure Heart and requires certain companies, including CareDx, to implement new processes to address requirements related to Medicare claim submissions. We continued the Medicare reimbursement submissions for AlloSure Heart following the issuance of the Billing Articles. In addition, we are considering informing Noridian that until Noridian adopts the Revised Billing Article, we will continue to submit AlloSure Heart tests for reimbursement only when used in conjunction with AlloMap Heart. We are also considering informing Noridian that (i) until June 30, 2023, we plan to submit claims for reimbursement for AlloSure Heart tests for which we have not obtained additional information from the ordering physicians to be able to specifically determine whether these tests meet the new coverage restrictions contained in the Billing Articles, and (ii) AlloSure Heart orders placed on or after June 30, 2023 for other indications outside the surveillance and for-cause parameters of the Billing Article, or where the reason for testing is not specified by the ordering physician, will either be held pending the receipt of additional information regarding medical necessity or submitted with a test description that is intended to identify those tests as falling outside the parameters of the Billing Articles. Additionally, although we have submitted to Medicare AlloMap Heart and AlloSure Heart tests for March 2023 without confirming whether they meet the Revised Billing Article&#8217;s parameters, there is a risk that any reimbursement of such claims are subject to forfeiture. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also successfully completed several landmark clinical trials in the transplant field demonstrating the clinical utility of AlloMap Heart for surveillance of heart transplant recipients. We initially established the analytical and clinical validity of AlloMap Heart based on our Cardiac Allograft Rejection Gene Expression Observational (Deng, M. et al., Am J Transplantation 2006) study, which was published in the AJT. A subsequent clinical utility trial, Invasive Monitoring Attenuation through Gene Expression (Pham MX et al., N. Eng. J. Med., 2010), published in The New England Journal of Medicine, demonstrated that clinical outcomes in recipients managed with AlloMap Heart surveillance were equivalent (non-inferior) to outcomes in recipients managed with biopsies. The results of our clinical trials have also been presented at major medical society congresses. AlloMap Heart is now recommended as part of the International Society for Heart and Lung Transplantation, or ISHLT, guidelines.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HeartCare</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HeartCare includes the gene expression profiling technology of AlloMap Heart with the dd-cfDNA analysis of AlloSure Heart in one surveillance solution. An approach to surveillance using HeartCare provides information from two complementary measures: (i) AlloMap Heart &#8211; a measure of immune activation, and (ii) AlloSure Heart &#8211; a measure of graft injury.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical validation data from the Donor-Derived Cell-Free DNA-Outcomes AlloMap Registry (NCT02178943), or D-OAR, was published in the AJT in 2019. D-OAR was an observational, prospective, multicenter study to characterize the AlloSure Heart dd-cfDNA in a routine, clinical surveillance setting with heart transplant recipients. The D-OAR study was designed to validate that plasma levels of AlloSure Heart dd-cfDNA can discriminate acute rejection from no rejection, as determined by endomyocardial biopsy criteria.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HeartCare provides robust information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection and antibody mediated rejection. In September 2018, we initiated the SHORE study. SHORE is a prospective, multi-center, observational, registry of patients receiving HeartCare for surveillance. Patients enrolled in SHORE will be followed for 5 years with collection of clinical data and assessment of 5-year outcomes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most recent ISHLT guidelines published in 2022 reinforced their use of AlloMap Heart, and referenced the combined use of AlloSure Heart and AlloMap Heart for surveillance purposes.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lung</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, AlloSure Lung became available for lung transplant patients through a compassionate use program while the test is undergoing further studies. One of these studies, launched in April 2020, is the ALARM study, or AlloSure Lung Allograft Remote Monitoring, with Johns Hopkins University, where the impact of AlloSure Lung combined with RemoTraC is being measured. AlloSure Lung applies proprietary NGS technology to measure dd-cfDNA from the donor lung in the recipient bloodstream to monitor graft injury. In June 2020, we submitted an application to the Palmetto MolDx Technology Assessment program seeking coverage and reimbursement for AlloSure Lung and since then we have been in active discussions with Palmetto. In October 2021, we launched AlloSure Lung as part of the CHEST 2021 Annual Meeting. We have gained early adoption with some commercial payers.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cellular Therapy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we initiated a research partnership for AlloCell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy. AlloCell is being commercialized through research </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreements with biopharma companies developing cell therapies. In 2021, we executed multiple additional agreements with biopharma therapeutics companies to use AlloCell in research and clinical studies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we launched the Assessing Chimerism and Relapse of Bone marrow/ HCT transplant using AlloHeme Testing, or ACROBAT study. The ACROBAT study is a prospective, multicenter, observational cohort study to evaluate the use of AlloHeme, a microchimerism NGS tool to predict post-transplant relapse in patients with allogeneic hematopoietic cell transplants, or HCT. This study is currently enrolling patients.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Products</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We develop, manufacture, market and sell products that increase the chance of successful transplants by facilitating a better match between a solid organ or stem cell donor and a recipient, and help to provide post-transplant surveillance of these recipients.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our historical product portfolio includes QTYPE and Olerup SSP. QTYPE enables Human Leukocyte Antigen, or HLA, typing at a low to intermediate resolution for samples that require a fast turn-around-time and uses real-time polymerase chain reaction, or PCR, methodology. Olerup SSP is used to type HLA alleles based on the sequence specific primer, or SSP, technology.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2018, we entered into a license and collaboration agreement with Illumina, Inc., or Illumina, which provides us with worldwide distribution, development and commercialization rights to Illumina&#8217;s NGS products and technologies for use in transplantation diagnostic testing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, we became the exclusive worldwide distributor of Illumina&#8217;s TruSight HLA product line. TruSight HLA was discontinued in December 2021 and we have progressively converted existing customers to AlloSeq.  In addition, we were granted the exclusive right to develop and commercialize other NGS product lines in the field of bone marrow and solid organ transplantation on diagnostic testing. These NGS products include: AlloSeq Tx, a high-resolution HLA typing solution, AlloSeq cfDNA, our surveillance solution designed to measure dd-cfDNA in blood to detect active rejection in transplant recipients, and AlloSeq HCT, a NGS solution for chimerism testing for stem cell transplant recipients.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we commercially launched AlloSeq cfDNA, our surveillance solution designed to measure dd-cfDNA in blood to detect active rejection in transplant recipients, and we received CE mark authorization on January 10, 2020. Our ability to increase the clinical uptake for AlloSeq cfDNA will be a result of multiple factors, including local clinical education, customer lab technical proficiency and levels of country-specific reimbursement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in September 2019, we commercially launched AlloSeq Tx, the first of its kind NGS high-resolution HLA typing solution utilizing hybrid capture technology. This technology enables the most comprehensive sequencing, covering more of the HLA genes than other solutions on the market and adding coverage of non-HLA genes that may impact transplant patient matching and management. AlloSeq Tx has simple NGS workflow, with a single tube for processing and steps to reduce errors. AlloSeq Tx 17 received CE mark authorization on May 15, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we commercially launched AlloSeq HCT, a NGS solution for chimerism testing for stem cell transplant recipients. This technology has the potential to provide better sensitivity and data analysis compared to current solutions on the market. AlloSeq HCT received CE mark authorization in May 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we acquired certain assets of BFS Molecular S.R.L., or BFS Molecular, a software company focused on NGS-based patient testing solutions. BFS Molecular brings extensive software and algorithm development capabilities for NGS transplant surveillance products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we commercially launched Tx9, a high throughput version of Tx17 for HLA typing in high volume laboratories. Tx9 received CE mark authorization in August 2022.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Patient and Digital Solutions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we began providing digital solutions to transplant centers following the acquisitions of Ottr, Inc., or Ottr and XynManagement, Inc., or XynManagement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 7, 2019, we acquired 100% of the outstanding common stock of Ottr. Ottr was formed in 1993 and is a leading provider of transplant patient management software, or the Ottr software, which provides comprehensive solutions for transplant patient management. The Ottr software enables integration with electronic medical records, or EMR, systems, including Cerner and Epic, providing patient surveillance management tools and outcomes data to transplant centers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 26, 2019, we acquired 100% of the outstanding common stock of XynManagement. XynManagement provides two unique solutions, XynQAPI software, or XynQAPI and XynCare. XynQAPI simplifies transplant quality tracking and Scientific </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registry of Transplant Recipients reporting. XynCare includes a team of transplant assistants who maintain regular contact with patients on the waitlist to help prepare for their transplant and maintain eligibility.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020 we launched AlloCare, a mobile app that provides a patient-centric resource for transplant recipients to manage medication adherence, coordinate with Patient Care Managers for AlloSure scheduling and measure health metrics.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we acquired TransChart, LLC, or TransChart. TransChart provides EMR software to hospitals throughout the United States to care for patients who have or may need an organ transplant. As part of our acquisition of TransChart in January 2021, we acquired Tx Access, a cloud-based service that allows nephrologists and dialysis centers to electronically submit referrals to transplant programs, closely follow and assist patients through the transplant waitlist process, and ultimately, through transplantation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we acquired the Transplant Hero patient application. The application helps patients manage their medications through alarms and interactive logging of medication events.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we entered into a strategic agreement, which was amended in April 2022, with OrganX to develop clinical decision support tools across the transplant patient journey. Together, we and OrganX will develop advanced analytics that integrate AlloSure, the first transplant specific dd-cfDNA assay, with large transplant databases to provide clinical data solutions. This partnership delivers the next level of innovation beyond multi-modality by incorporating a variety of clinical inputs to create a universal composite scoring system.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we acquired MedActionPlan.com, LLC, or MedActionPlan, a New Jersey-based provider of medication safety, medication adherence and patient education. MedActionPlan is a leader in patient medication management for transplant patients and beyond.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we acquired the Transplant Pharmacy, or TTP, a transplant focused pharmacy located in Mississippi. TTP provides individualized transplant pharmacy services for patients at multiple transplant centers located throughout the U.S.  In January 2023, we acquired HLA Data Systems, a Texas-based company that provides software and interoperability solutions for the histocompatibility and immunogenetics community.  HLA Data Systems is a leader in the laboratory information management industry for human leukocyte antigen laboratories.</span></div><div id="idd35c15ee381485cb38f052732749537_91"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive our revenue from testing services, products sales, patient and digital solutions revenues. Revenue is recorded considering a five-step revenue recognition model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations and recognizing revenue when, or as, an entity satisfies a performance obligation.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Testing Services Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our testing services revenue is derived from AlloSure Kidney, AlloMap Heart, AlloSure Heart and AlloSure Lung tests, which represented 80% and 84% of our total revenue for the three months ended March&#160;31, 2023 and 2022, respectively. Our testing services revenue depends on a number of factors, including (i)&#160;the number of tests performed; (ii)&#160;establishment of coverage policies by third-party insurers and government payers; (iii)&#160;our ability to collect from payers with whom we do not have positive coverage determination, which often requires that we pursue a case-by-case appeals process; (iv)&#160;our ability to recognize revenues on tests billed prior to the establishment of reimbursement policies, contracts or payment histories; and (v)&#160;how quickly we can successfully commercialize new product offerings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloSure Kidney has been a covered service for Medicare beneficiaries since October 2017 through a LCD first issued by MolDX, which was formed to identify and establish coverage and reimbursement for molecular diagnostics tests, and adopted by Noridian. The Medicare reimbursement rate for AlloSure Kidney is currently $2,841. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloMap Heart has been a covered service for Medicare beneficiaries since January 2006. The Medicare reimbursement rate for AlloMap Heart is currently $3,240. In October 2020, we received a final MolDX Medicare coverage decision for AlloSure Heart. Noridian issued a parallel coverage policy granting coverage for AlloSure Heart when used in conjunction with AlloMap Heart, which became effective in December 2020. The Medicare reimbursement rate for AlloSure Heart is currently $2,753.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;2, 2023, MolDX issued the Billing Article , with an effective date of March&#160;31, 2023. Prior to the Billing Article&#8217;s effective date, MolDX informed the affected parties, including CareDx, that enforcement of the revised billing practices outlined in the Billing Article will not be implemented until June&#160;30, 2023. MolDX informed us that its automatic adjudication process would remain in place until June 30, 2023, though claims submitted prior to that date must comply with the applicable LCDs. On May&#160;4, 2023, MolDX issued a the Revised Billing Article.  The Revised Billing Article impacts Medicare coverage for AlloSure Kidney, AlloSure Heart and AlloMap Heart and requires certain companies, including CareDx, to implement new </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">processes to address the requirements related to Medicare claim submissions. MolDX has stated that it views the Billing Article as clarifying existing coverage, though acknowledged that the Billing Article is a change as to our previous billing article, which provided coverage only where AlloSure Heart was used in conjunction with AlloMap Heart. Noridian has not adopted the new Billing Articles.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe the Billing Articles are inconsistent with the LCDs, Noridian&#8217;s and MolDX&#8217;s responses to public comments explaining the intended scope of various LCDs, and medical necessity, we determined to pause our Medicare reimbursement submissions for AlloSure Kidney commencing on March&#160;7, 2023 to allow us further time to evaluate the implications of the Billing Article and update our billing processes for AlloSure Kidney tests by educating clinicians and working with centers to update CareDx&#8217;s test order forms to capture the new information required under the Billing Article. Accordingly, we did not submit claims for approximately 3200 AlloSure Kidney tests for Medicare reimbursement for the period from March&#160;7, 2023 through March&#160;31, 2023 and did not recognize revenue on these claims in the first quarter of 2023 aggregating to approximately $8.9 million, or the Impacted March Tests.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2023, we plan to submit claims for Medicare reimbursement for the Impacted March Tests, following the delivery by us of a letter to Noridian explaining, among other things, (i) our belief that the Billing Articles impose new restrictions on Medicare coverage for the CareDx tests from those contained in the existing LCDs, (ii) that we plan to submit claims for reimbursement for the Impacted March Tests for which we have not obtained additional information from the ordering physicians to be able to specifically determine whether these tests meet the new coverage restrictions contained in the Billing Articles, and (iii) that AlloSure Kidney orders with a date of service on or after March 31, 2023 for other indications outside the parameters of the Revised Billing Article, or where the reason for testing is not specified by the ordering physician, will either be held pending the receipt of additional information regarding medical necessity or submitted with a test description that is intended to identify those tests as falling outside the parameters of the Revised Billing Article. Although we plan to submit claims for Medicare reimbursement for the Impacted March Tests, there is a risk that the claims are denied or that any reimbursement of such claims is subject to forfeiture.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continued the Medicare reimbursement submissions for AlloMap Heart or AlloSure Heart following the issuance of the Billing Articles. In addition, we are considering informing Noridian that until Noridian adopts the Revised Billing Article, we will continue to submit AlloSure Heart tests for reimbursement only when used in conjunction with AlloMap Heart. We are also considering informing Noridian that (i) until June 30, 2023, we plan to submit claims for reimbursement for AlloMap Heart and AlloSure Heart tests for which we have not obtained additional information from the ordering physicians to be able to specifically determine whether these tests meet the new coverage restrictions contained in the Billing Articles, and (ii) AlloSure Heart and AlloMap Heart orders placed on or after June 30, 2023 for other indications outside the surveillance and for-cause parameters of the Billing Article, or where the reason for testing is not specified by the ordering physician, will either be held pending the receipt of additional information regarding medical necessity or submitted with a test description that is intended to identify those tests as falling outside the parameters of the Billing Articles. Additionally, although we have submitted to Medicare AlloMap Heart and AlloSure Heart tests for March 2023 without confirming whether they meet the Revised Billing Article&#8217;s parameters, there is a risk that any reimbursement of such claims are subject to forfeiture. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloSure Kidney has received positive coverage decisions from several commercial payers, and is reimbursed by other private payers on a case-by-case basis.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloMap Heart has also received positive coverage decisions for reimbursement from many of the largest U.S. private payers. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product revenue is derived primarily from sales of AlloSeq Tx, Olerup SSP and QTYPE products.&#160;Product revenue represented 9% of our total revenue for each of the three months ended March&#160;31, 2023 and 2022.&#160;We recognize product revenue from the sale of products to end-users, distributors and strategic partners when all revenue recognition criteria are satisfied. We generally have a contract or a purchase order from a customer with the specified required terms of order, including the number of products ordered. Transaction prices are determinable and products are delivered and risk of loss passed to the customer upon either shipping or delivery, as per the terms of the agreement. There are no further performance obligations related to a contract and revenue is recognized at the point of delivery consistent with the terms of the contract or purchase order.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient and Digital Solutions Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patient and digital solutions revenue is mainly derived from sales of our Ottr software, XynQAPI, MedActionPlan, TTP, TransChart and Tx Access licenses, services and SaaS agreements across the digital portfolio, as well as our pharmacy sales at TTP. Patient and digital solutions revenue represented 11% and 7% of total revenue for the three months ended March&#160;31, 2023 and 2022, respectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="idd35c15ee381485cb38f052732749537_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with United States Generally Accepted Accounting Principles. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in Note 2 of the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. Some of these accounting policies require us to make difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. We believe that the following critical accounting policies reflect the more significant estimates and assumptions used in the preparation of our financial statements. We believe the following critical accounting policies are affected by significant judgments and estimates used in the preparation of our unaudited condensed consolidated financial statements:</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revenue recognition;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Business combinations;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acquired intangible assets;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Impairment of goodwill, intangible assets and other long-lived assets;</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Stock-based compensation; and</span></div><div style="margin-top:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Common stock warrant liability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material changes in the matters for which we make critical accounting estimates in the preparation of our unaudited condensed consolidated financial statements during the three months ended March&#160;31, 2023 as compared to those disclosed in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC on February&#160;27, 2023.</span></div><div id="idd35c15ee381485cb38f052732749537_97"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 2, Summary of Significant Accounting Policies - Recent Accounting Pronouncements, to the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for a description of recently issued accounting pronouncements, including the expected dates of adoption and estimated effects on our results of operations, financial position and cash flows.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="idd35c15ee381485cb38f052732749537_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March 31, 2023 and 2022</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Testing services revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,660)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient and digital solutions revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,416&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,154)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of testing services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,296&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,332)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of patient and digital solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,469&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,324)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,053)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,271)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in estimated fair value of common stock warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(823)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,151)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(607)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,625)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,660)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,965)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax (expense) benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,749)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,648)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,101)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Testing Services Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Testing services revenue decreased by $4.7&#160;million, or (7)%, for the three months ended March 31, 2023 compared to the same period in 2022. The decrease is primarily due to our determination, in light of the Billing Article, to pause our Medicare reimbursement submissions for AlloSure Kidney commencing on March 7, 2023 to allow us further time to evaluate the implications of the Billing Article and update our billing processes for AlloSure Kidney by educating clinicians and working with centers to update the test order forms to capture the new information required under the Billing Article. The decrease in revenue was primarily driven by non-submission of approximately 3200 AlloSure Kidney tests in the quarter representing approximately $8.9 million in revenues.  Overall, volume of tests increase of 17% year-over-year and an improvement in cash collections help partially offset this impact.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Patient and Digital Solutions Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient and digital solutions revenue increased by $2.4&#160;million, or 39%, for the three months ended March 31, 2023 compared to the same period in 2022, primarily due to an increase in pharmacy revenue of $1.3 million and an increase in software revenue of $1.2 million.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Testing Services</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of testing services decreased by $2.3&#160;million, or (13)%, for the three months ended March 31, 2023, compared to the same period in 2022. The decrease is primarily due to a reduction in royalty expense because of an amendment to the Stanford License agreement, which reduced the maximum royalty rate on AlloSure tests done from April 2022 and resulted in a reversal of the excess liability in March 2023, partially offset by an increase in sample and consumable costs due to high volume growth.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Product</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product decreased by $0.3&#160;million, or (8)%, for the three months ended March 31, 2023, compared to the same period in 2022. The decrease is primarily due to adjustments in production variance.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cost of Patient and Digital Solutions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of patient and digital solutions increased by $1.7 million, or 36%, for the three months ended March 31, 2023, compared to the same period in 2022. The increase is primarily due to cost of goods from sales in the pharmacy business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and Development </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $2.5&#160;million, or 11%, for the three months ended March 31, 2023, compared to the same period in 2022. The increase is primarily due to an increase in personnel-related costs, including stock-based compensation of $0.6 million, an increase in clinical trial-related expense of $1.2 million and an increase in other expenses of $0.6 million.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General and Administrative</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $1.5&#160;million, or 6%, for the three months ended March 31, 2023, compared to the same period in 2022. The increase is primarily due to an increase in personnel-related costs, including stock-based compensation expense of $1.3 million, and an increase in rent and utility expense of $0.7 million, partially offset by a decrease in legal expenses of $0.7 million.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other expense, net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net decreased by $1.2&#160;million for the three months ended March 31, 2023, compared to the same period in 2022, primarily due to $1.0 million in investment write-off.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest income, net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net increased by $2.5&#160;million for the three months ended March 31, 2023, compared to the same period in 2022. The increase is primarily due to interest income earned on U.S. agency securities and corporate debt securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income tax (expense) benefit</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax (expense) benefit decreased by $0.1&#160;million for the three months ended March 31, 2023, compared to the same period in 2022. The decrease is primarily attributable to the U.S. current tax expense. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows for the Three Months Ended March 31, 2023 and 2022</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the primary sources and uses of cash for the periods presented:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,468)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,771)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156,032)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents and restricted cash</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,263)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176,590)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities consists of net loss, adjusted for certain noncash items in the condensed consolidated statements of operations and changes in operating assets and liabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities for the three months ended March&#160;31, 2023 was $0.7&#160;million. Net operating assets increased $4.4&#160;million. Our noncash items included $13.8&#160;million in stock-based compensation expense, $3.4&#160;million of depreciation and amortization expense, $1.3&#160;million of amortization of right-of-use assets, $0.9&#160;million of unrealized loss on long-term marketable equity securities, $1.0&#160;million of asset impairment and write-downs and $0.8&#160;million of amortization of premium on short-term marketable securities, net.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities for the three months ended March&#160;31, 2022 was $21.5&#160;million. Our net loss of $19.6&#160;million was our primary use of cash in operating activities that included a number of noncash items. Our noncash items included </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10.6&#160;million in stock-based compensation expense, $2.6&#160;million of depreciation and amortization expense and $0.9&#160;million of amortization of right-of-use assets. Net operating assets decreased $16.7&#160;million.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investing Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023, net cash used in investing activities of $14.8&#160;million was primarily related to the purchases of marketable securities of $86.3&#160;million and $2.8&#160;million related to additions of capital expenditures, net. These payments were offset by maturities of marketable securities of $79.0&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2022, net cash used in investing activities of $156.0&#160;million was primarily related to the purchases of marketable securities of $148.5&#160;million and $8.5&#160;million related to additions of capital expenditures, net.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financing Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities for the three months ended March&#160;31, 2023 of $1.1&#160;million was primarily due to taxes paid related to net share settlements of restricted stock units of $0.7&#160;million, repurchase and retirement of common stock of $0.7&#160;million and payments of contingent consideration $0.3&#160;million. These payments were partially offset by proceeds from issuances of common stock under our employee stock purchase plan of $0.5&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended March&#160;31, 2022 of $0.9&#160;million was primarily related to proceeds from exercises of stock options of $1.6&#160;million and proceeds from issuances of common stock under our employee stock purchase plan of $1.0&#160;million. These proceeds were partially offset by taxes paid related to net share settlements of restricted stock units of $1.5&#160;million and payments of contingent consideration $0.3&#160;million.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant losses and negative cash flows from operations since our inception and had an accumulated deficit of $484.9&#160;million at March&#160;31, 2023.&#160;As of March&#160;31, 2023, we had cash, cash&#160;equivalents and marketable securities of $285.9&#160;million and no debt outstanding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With our continuing growth, we may require additional financing in the future to fund working capital and our development of future products. Additional financing might include issuance of equity securities, including through underwritten public offerings or &#8220;at-the-market&#8221; offerings, debt offerings or financings or a combination of these financings. There can be no assurance that we will be successful in acquiring additional funding at levels sufficient to fund our operations or on terms favorable to us. We believe our existing cash balance and expected cash from existing operations, including cash from current license agreements and future license and collaboration agreements, or a combination of these, will be sufficient to meet our anticipated cash requirements for the next 12 months.$30.0&#160;billion</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At-the-Market Equity Offering</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April&#160;14, 2022, we entered into a sales agreement, or the Sales Agreement, with Jefferies, LLC as sales agent, or Jefferies, pursuant to which we may offer and sell, from time to time, through Jefferies, up to $200.0&#160;million in shares of our common stock, by any method permitted by law deemed to be an &#8220;at-the-market&#8221; offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. Jefferies is entitled to compensation for its services equal to 3% of the gross proceeds of any shares of common stock sold through Jefferies under the Sales Agreement. Any shares of common stock offered and sold pursuant to the Sales Agreement will be issued and sold pursuant to our Registration Statement on Form S-3ASR (File No. 333-239049), filed with the SEC on June 9, 2020, or the Registration Statement, including a base prospectus dated June 9, 2020, and a prospectus supplement dated April 14, 2022. The Registration Statement will expire on June 9, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Repurchase Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2022, our Board of Directors approved our Stock Repurchase Program, or the Repurchase Program, whereby we may purchase up to $50&#160;million in shares of our common stock over a period of up to two years, commencing on December 8, 2022. The Repurchase Program may be carried out at the discretion of a committee of our Board of Directors through open market purchases, one or more Rule 10b5-1 trading plans, block trades and in privately negotiated transactions. During the three months ended March&#160;31, 2023, we purchased an aggregate of 59,472 shares of our common stock under the Repurchase Program for an aggregate purchase price of $0.7 million. As of March&#160;31, 2023, $48.7 million remained available for future share repurchases under the Repurchase Program.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="idd35c15ee381485cb38f052732749537_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Factors Affecting Our Performance</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">The Number of AlloMap Heart, AlloSure Lung, AlloSure Kidney and AlloSure Heart Tests We Receive and Report</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The growth of our testing services business is tied to the number of AlloSure Kidney, AlloSure Lung, AlloMap Heart and AlloSure Heart patient samples we receive and patient results we report. We incur costs in connection with collecting and shipping all samples and a portion of the costs when we cannot ultimately issue a report. As a result, the number of patient samples received largely correlates directly to the number of patient results reported.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloSure Kidney has been a covered service for Medicare beneficiaries since October 2017 through a LCD first issued by MolDX&#8221;, which was formed to identify and establish coverage and reimbursement for molecular diagnostics tests, and adopted by Noridian. The Medicare reimbursement rate for AlloSure Kidney is currently $2,841. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloMap Heart has been a covered service for Medicare beneficiaries since January 2006. The Medicare reimbursement rate for AlloMap Heart is currently $3,240. In October 2020, we received a final MolDX Medicare coverage decision for AlloSure Heart. Noridian issued a parallel coverage policy granting coverage for AlloSure Heart when used in conjunction with AlloMap Heart, which became effective in December 2020. The Medicare reimbursement rate for AlloSure Heart is currently $2,753. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;2, 2023, MolDX issued the Billing Article. Prior to the Billing Article&#8217;s effective date, MolDX informed the affected parties, including CareDx, that enforcement of the revised billing practices outlined in the Billing Article will not be implemented until June&#160;30, 2023.  MolDX informed us that its automatic adjudication process would remain in place until June 30, 2023, though claims submitted prior to that date must comply with the applicable LCDs. On May&#160;4, 2023, MolDX issued the Revised Billing Article.  The Revised Billing Article impacts Medicare coverage for AlloSure Kidney, AlloSure Heart and AlloMap Heart and requires certain companies, including CareDx, to implement new processes to address the requirements related to Medicare claim submissions. MolDX has stated that it views the Billing Article as clarifying existing coverage, especially as it relates to when tests are covered in the for-cause and surveillance contexts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MolDX has acknowledged, however, that the Billing Article is a change as it relates to billing more than one test during a single patient encounter. Noridian has not yet adopted the new Billing Articles.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe the Billing Articles are inconsistent with the LCDs, Noridian&#8217;s and MolDX&#8217;s responses to public comments explaining the intended scope of various LCDs, and medical necessity, we determined to pause our Medicare reimbursement submissions for AlloSure Kidney commencing on March&#160;7, 2023 to allow us further time to evaluate the implications of the Billing Article and update our billing processes for AlloSure Kidney tests by educating clinicians and working with centers to update CareDx&#8217;s test order forms to capture the new information required under the Billing Article. Accordingly, we did not submit claims for approximately 3200 AlloSure Kidney tests for Medicare reimbursement for the period from March&#160;7, 2023 through March&#160;31, 2023 and did not recognize revenue on these claims in the first quarter of 2023 aggregating to approximately $8.9 million, or the Impacted March Tests.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2023, we plan to submit claims for Medicare reimbursement for the Impacted March Tests, following the delivery by us of a letter to Noridian explaining, among other things, (i) our belief that the Billing Articles impose new restrictions on Medicare coverage for the CareDx tests from those contained in the existing LCDs, (ii) that we plan to submit claims for reimbursement for the Impacted March Tests for which we have not obtained additional information from the ordering physicians to be able to specifically determine whether these tests meet the new coverage restrictions contained in the Billing Articles, and (iii) that AlloSure Kidney orders with a date of service on or after March 31, 2023 for other indications outside the parameters of the Revised Billing Article, or where the reason for testing is not specified by the ordering physician, will either be held pending the receipt of additional information regarding medical necessity or submitted with a test description that is intended to identify those tests as falling outside the parameters of the Revised Billing Article. Although we plan to submit claims for Medicare reimbursement for the Impacted March Tests, there is a risk that the claims are denied or that any reimbursement of such claims is subject to forfeiture.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continued the Medicare reimbursement submissions for AlloMap Heart or AlloSure Heart following the issuance of the Billing Articles. In addition, we are considering informing Noridian that until Noridian adopts the Revised Billing Article, we will continue to submit AlloSure Heart tests for reimbursement only when used in conjunction with AlloMap Heart. We are also considering informing Noridian that (i) until June 30, 2023, we plan to submit claims for reimbursement for AlloMap Heart and AlloSure Heart tests for which we have not obtained additional information from the ordering physicians to be able to specifically determine whether these tests meet the new coverage restrictions contained in the Billing Articles, and (ii) AlloSure Heart and AlloMap Heart orders placed on or after June 30, 2023 for other indications outside the surveillance and for-cause parameters of the Billing Article, or where the reason for testing is not specified by the ordering physician, will either be held pending the receipt of additional information regarding medical necessity or submitted with a test description that is intended to identify those tests as falling outside the parameters of the Billing Articles. Additionally, although we have submitted to Medicare AlloMap Heart and AlloSure Heart tests for March 2023 without confirming whether they meet the Revised Billing Article&#8217;s parameters, there is a risk that any reimbursement of such claims are subject to forfeiture. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloSure Kidney has received positive coverage decisions from several commercial payers, and is reimbursed by other private payers on a case-by-case basis. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloMap Heart has also received positive coverage decisions for reimbursement from many of the largest U.S. private payers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Reimbursement for AlloMap Heart</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloMap Heart test volume and the corresponding reimbursement revenue has generally increased over time since the launch of AlloMap Heart, as the ISHLT included AlloMap in guidelines, payers adopted coverage policies and no longer consider AlloMap Heart to be experimental and investigational. The rate at which our tests are covered and reimbursed has varied, and is expected to continue to vary by payer. Revenue growth depends on our ability to maintain Medicare and third party payer reimbursement, and to expand utilization by healthcare providers. See the discussion above under "The Number of AlloMap Heart, AlloSure Lung, AlloSure Kidney and AlloSure Heart Tests We Receive and Report".</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Protecting Access to Medicare Act of 2014, or PAMA, included a substantial new payment system for clinical laboratory tests under the Clinical Laboratory Fee Schedule, or CLFS. Under PAMA, laboratories that receive the majority of their Medicare revenues from payments made under the CLFS would report initially and then on a subsequent three-year basis thereafter (or annually for advanced diagnostic laboratory tests, or ADLTs), private payer payment rates and volumes for their tests. The final PAMA ruling was issued June 17, 2016 indicating that data for reporting for the new PAMA process would begin in 2017 and the new market based rates took effect on January 1, 2018. Effective January 1, 2018, Medicare reimburses us $3,240 for AlloMap Heart testing of Medicare beneficiaries, an increase from the 2017 reimbursement rate of $2,841. The CARES Act froze then-current (2020) CMS CLFS rates through 2021. Further, the CARES Act delayed the reporting cycle under PAMA to January 1 and March 31, 2022. The next data collection period will become January 1 through June 30, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloMap Heart has also received positive coverage decisions for reimbursement from many of the largest U.S. private payers.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Reimbursement for AlloSure Kidney</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 26, 2017, we received notice that the MolDX Program developed by Palmetto GBA had set AlloSure Kidney reimbursement at $2,841. Effective October 9, 2017, AlloSure Kidney was made available for commercial testing with Medicare coverage and reimbursement. See the discussion above under "The Number of AlloMap Heart, AlloSure Lung, AlloSure Kidney and AlloSure Heart Tests We Receive and Report".  We believe the use of AlloSure Kidney, in conjunction with other clinical indicators, can help healthcare providers and their patients better manage long-term care following a kidney transplant. In particular, we believe AlloSure Kidney can improve patient care by helping healthcare providers to reduce the use of invasive biopsies and determine the appropriate dosage levels of immunosuppressants.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Reimbursement for AlloSure Heart</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we received a final Palmetto MolDx Medicare coverage decision for AlloSure Heart. In </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2020, Noridian Healthcare Solutions, our Medicare Administrative Contractor, issued a parallel coverage policy granting coverage when used in conjunction with AlloMap Heart, which became effective in December 2020. The Medicare reimbursement rate for AlloSure Heart is currently $2,753.  See the discussion above under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"The Number of AlloMap Heart, AlloSure Lung, AlloSure Kidney and AlloSure Heart Tests We Receive and Report". </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Continued Growth of Product Sales</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We develop, manufacture, market and sell products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> stem cells and solid organs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our historical product portfolio includes QTYPE and Olerup SSP.</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QTYPE enables speed and precision in HLA typing at a low to intermediate resolution for samples that require a fast turn-around-time and uses real-time PCR methodology. QTYPE received CE mark certification on April 10, 2018. Olerup SSP is used to type HLA alleles based on the SSP technology.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2018, we entered into a license and collaboration agreement with Illumina, which provides us with worldwide distribution, development and commercialization rights to Illumina's NGS product line for use in transplantation diagnostic testing. As a result, on June 1, 2018, we became the exclusive worldwide distributor of Illumina&#8217;s TruSight HLA product line. TruSight HLA was discontinued in December 2021 and we have progressively converted existing customers to AlloSeq. In addition, we were granted the exclusive right to develop and commercialize other NGS product lines in the field of bone marrow and solid organ transplantation on diagnostic testing. These NGS products include: AlloSeq Tx, a high-resolution HLA typing solution, AlloSeq cfDNA, our surveillance solution designed to measure dd-cfDNA in blood to detect active rejection in transplant recipients, and AlloSeq HCT, a NGS solution for chimerism testing for stem cell transplant recipients.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we commercially launched AlloSeq cfDNA, our surveillance solution designed to measure dd-cfDNA in blood to detect active rejection in transplant recipients, which received CE mark authorization on January 20, 2020. Our ability </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to increase the clinical uptake for AlloSeq cfDNA will be a result of multiple factors, including local clinical education, customer lab technical proficiency and levels of country-specific reimbursement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in September 2019, we commercially launched AlloSeq Tx, the first of its kind NGS high-resolution HLA typing solution utilizing hybrid capture technology. This technology enables the most comprehensive sequencing, covering more of the HLA genes than current solutions and adding coverage of non-HLA genes that may impact transplant patient matching and management. AlloSeq Tx has a simple NGS workflow that reduces complexity and can reduce errors. AlloSeq Tx 17 received CE mark authorization on May 15, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we commercially launched AlloSeq HCT, a NGS solution for chimerism testing for stem cell transplant recipients. This technology has the potential to provide better sensitivity and data analysis compared to current solutions on the market. AlloSeq HCT received CE mark authorization in May 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Continued Growth of Patient and Digital Sales</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The growth of our patient and digital revenues is tied to the continued successful implementation of our Ottr, MedActionPlan and XynQAPI software businesses, as well as continued support and maintenance of existing MedActionPlan, Ottr and XynManagement customers. The Ottr software, TransChart, Tx Access and XynQAPI are currently implemented in multiple locations in the U.S. The Ottr software implementation and XynQAPI implementation and support teams are based in Omaha, Nebraska. In addition, patient solutions offered by TTP in Flowood, Mississippi include hospital-affiliated pharmacies located on-site at the transplant center and specialty pharmacies that provide transplant-specific care and dispensing services.  With the addition of HLA Data Systems, we are now able to support HLA laboratories in managing their day-to-day workflow.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Development of Additional Services and Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our development pipeline includes other transplant diagnostic solutions to help clinicians and transplant centers make personalized treatment decisions throughout a transplant patient&#8217;s lifetime. We expect to invest in research and development in order to develop additional products. Our success in developing new products and services will be important in our efforts to grow our business by expanding the potential market for our services and products and diversifying our sources of revenue.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Timing of Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our spending on research and development may vary substantially from quarter to quarter. We conduct clinical studies to validate our new products, as well as on-going clinical and outcome studies to further the published evidence to support our commercialized tests. Spending on research and development for both experiments and studies may vary significantly by quarter depending on the timing of these various expenses.</span></div><div id="idd35c15ee381485cb38f052732749537_106"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion regarding our significant contractual obligations as of March&#160;31, 2023 and the effect those obligations are expected to have on our liquidity and cash flows in future periods, please refer to Note 9 of the condensed consolidated financial statements, and the section entitled &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8212;Liquidity and Capital Resources&#8221;, respectively, included elsewhere in this Quarterly Report on Form 10-Q.</span></div><div id="idd35c15ee381485cb38f052732749537_109"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Operations </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated balance sheets contain certain recorded assets in foreign countries, namely Stockholm, Sweden and Fremantle, Australia.&#160;Although these countries are considered economically stable and we have experienced no notable burden from foreign exchange transactions, export duties or government regulations, unanticipated events in foreign countries could&#160;have a material adverse effect on our operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="idd35c15ee381485cb38f052732749537_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Rate Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business.&#160;&#160;We had cash, cash equivalents and marketable securities of $285.9&#160;million at March&#160;31, 2023, which consisted of bank deposits, money market funds and corporate debt securities, and we had cash and cash equivalents of $293.1&#160;million at December&#160;31, 2022, which consisted of bank deposits and money market funds.&#160;However, we have not been exposed to, nor do we anticipate being exposed to, material risks due to changes in interest rates. A hypothetical 100 basis point increase or decrease in interest rates during any of the periods presented would have an approximate impact of $2.9&#160;million on our condensed consolidated financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Currency Exchange Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have operations in Sweden and Australia and sell to other countries throughout the world.&#160;As a result, we are subject to significant foreign currency risks, including transacting in foreign currencies, investment in a foreign entity, as well as assets and debts denominated in foreign currencies.&#160;Our testing services revenue is primarily denominated in U.S. dollars.&#160;Our product revenue is denominated primarily in U.S. dollars and the Euro.&#160;Our patient and digital solutions revenue is primarily denominated in U.S. dollars. Consequently, our revenue denominated in foreign currency is subject to foreign currency exchange risk.&#160;A portion of our operating expenses are incurred outside of the U.S. and are denominated in Swedish Krona, the Euro, and the Australian Dollar, which are also subject to fluctuations due to changes in foreign currency exchange rates.&#160;An unfavorable 10% change in foreign currency exchange rates for our assets and liabilities denominated in foreign currencies at March&#160;31, 2023, would have negatively impacted our financial results for the three months ended March&#160;31, 2023 by $0.4&#160;million and our product revenue by $0.3&#160;million.&#160;Currently, we do not have any near-term plans to enter into a formal hedging program to mitigate the effects of foreign currency volatility.&#160;We will continue to reassess our approach to managing our risk relating to fluctuations in foreign currency exchange rates.</span></div><div id="idd35c15ee381485cb38f052732749537_115"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures, as such terms are defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act, as of March&#160;31, 2023.&#160;In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of  March&#160;31, 2023, in light of the material weaknesses identified in our internal control over financial reporting described below,  our disclosure controls and procedures were not effective at the reasonable assurance level and are not effective to provide reasonable assurance that information required to be disclosed in the reports we file and submit under the Exchange Act, is (i) recorded, processed, summarized and reported as and when required and (ii) accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely discussion regarding required disclosure. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Previously Reported Material Weaknesses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed in Item 9A, &#8220;Controls and Procedures&#8221; within our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on February 27, 2023, the following material weaknesses were identified as of December 31, 2022:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Information Technology Controls.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We did not design and maintain effective general information technology controls (&#8220;GITCs&#8221;), for information systems and applications that are relevant to the preparation of the consolidated financial statements. Specifically, we did not design and maintain: (i) sufficient user access controls to ensure appropriate segregation of duties, logical access controls to prevent unauthorized user access and adequately restrict user and privileged access to financial applications, programs and data to appropriate Company personnel; (ii) program change management controls to ensure that information technology (&#8220;IT&#8221;), program and data changes affecting financial IT applications and underlying accounting records are identified, tested, authorized and implemented appropriately with appropriate segregation of duties; and (iii) Computer and Network operations controls to ensure that batch and interface jobs are monitored and privileges are appropriately granted, authorized and monitored. As a result, business process controls (automated and manual) that are dependent on the ineffective GITCs, or that rely on data produced from systems impacted by the ineffective GITCs, are also deemed ineffective, which affects substantially all financial statement account balances and disclosures. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Order Approval Workflow.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We did not design and maintain effective process-level control activities related to procurement to ensure appropriate approval of purchase orders, which could affect the amount and classification of costs capitalized or expensed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COSO Framework.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We did not fully maintain components of the COSO framework, including elements of the control environment, information and communication, and control activities and monitoring activities components, relating to: (i) sufficiency of competent personnel to perform internal control activities and support the achievement of our internal control objectives; (ii) enforcing accountability of personnel for the performance of their internal control responsibilities across the organization in the pursuit of objectives; (iii) designing and maintaining general control activities over technology to support the achievement of our internal control objectives; (iv) performing control activities in accordance with established policies in a timely manner; and (v) performing sufficient reviews of information to assess its relevance, accuracy, and completeness in supporting the internal control components. As such, our management concluded that we did not have an adequate process in place to complete our assessment of the design and operating effectiveness of internal control over financial reporting in a timely manner.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After giving full consideration to these material weaknesses, and the additional analyses and other procedures we performed to ensure that our condensed consolidated financial statements included in this Quarterly Report on Form 10-Q were prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP, our management has concluded that our condensed consolidated financial statements present fairly, in all material respects, our financial position, results of operations and cash flows for the periods disclosed in conformity with U.S. GAAP.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Plan to Remediate the Material Weaknesses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has been engaged in developing and implementing remediation plans to address the material weaknesses described above. These remediation efforts are ongoing and are expected to include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Enhancing the design and control procedures of the GITCs to ensure that the control activities related to GITCs are functioning appropriately;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Improving the control environment in relation to personnel training and accountability of Sarbanes-Oxley Act of 2002 ("SOX") control activities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Hiring additional personnel in the IT and Finance and Accounting departments with an appropriate level of knowledge and experience to effectively execute our processes and procedures; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Expanding controls and/or applying appropriate procedures to address the design and operation of internal controls related to the procure-to-pay process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023 to date, we have hired three additional full time and contractors resources in our IT and Finance and Accounting departments to support our remediation efforts. We expect, and are planning, to continue adding incremental staffing in these departments throughout the year. We are in the process of developing and delivering SOX compliance training to control owners and are also actively working on and updating the design of our controls and controls procedures to ensure we address the root causes of the material weaknesses. We have also enhanced our communication by frequently holding meetings with key management personnel and members of the Audit Committee to discuss the SOX program.  In regards to the procure-to-pay process, we are implementing a new automated control for the purchase order approval workflow and a new accounts payable system. In addition, we are investing in and implementing other systems that will assist us in monitoring the timely execution of controls, and we expect to continue to implement these throughout the remaining part of the year.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to continuing to implement a strong system of controls and believe that our ongoing remediation efforts particularly in the improvement of our control environment will result in significant improvements to our system of controls and that we believe will remediate the material weaknesses. However, material weaknesses are not considered remediated until the new controls have been operational for a period of time, are tested, and management concludes that these controls are operating effectively. This remediation process will require resources and time to implement. We will continue to monitor the effectiveness of these remediation measures, and we will make any changes to the design of our remediation plans and take such other actions that we deem appropriate given the circumstances.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the changes associated with the material weaknesses and remediation actions noted above, there have been no changes in our internal control over financial reporting during the quarter ended March&#160;31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="idd35c15ee381485cb38f052732749537_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="idd35c15ee381485cb38f052732749537_121"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1. LEGAL PROCEEDINGS</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information set forth in Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under the caption &#8220;Litigation and Indemnification Obligations&#8221;, to the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q is incorporated herein by reference.</span></div><div id="idd35c15ee381485cb38f052732749537_124"></div><div style="margin-top:12pt;padding-left:144pt;text-indent:-144pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A. RISK FACTORS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the Securities and Exchange Commission or the SEC, on February&#160;27, 2023, or the Form 10-K, Part I &#8211;Item 1A, Risk Factors, describes important risk factors that could cause our business, financial condition, results of operations and growth prospects to differ materially from those indicated or suggested by forward-looking statements made in this Quarterly Report on Form 10-Q or presented elsewhere by management from time to time.&#160;&#160;There have been no material changes in the risk factors that appear in Part I - Item 1A of our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC on February&#160;27, 2023, other than those listed below.&#160;Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially and adversely affect our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of losses, and we expect to incur net losses for the next several years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred substantial net losses since our inception, and we may continue to incur additional losses for the next several years. For the quarter ended March&#160;31, 2023, our net loss was $23.7&#160;million. As of March&#160;31, 2023, we had an accumulated deficit of $484.9&#160;million. We expect to continue to incur significant operating expenses and anticipate that our expenses will increase due to costs relating to, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">researching, developing, validating and commercializing potential new testing services, products and patient and digital solutions, including additional expenses in connection with our continuing development and commercialization of KidneyCare, HeartCare, AlloSeq, AiTraC and other future solutions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing, presenting and publishing additional clinical and economic utility data intended to increase payer coverage and clinician adoption of our current and future solutions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of our operating capabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintenance, expansion and protection of our intellectual property portfolio and trade secrets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the process of fully integrating acquired companies and operations and the associated potential disruptions to our business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of the size and geographic reach of our sales force and our marketing capabilities to commercialize our existing and future solutions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employment of additional clinical, quality control, scientific, customer service, laboratory, billing and reimbursement and management personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with existing and changing laws, regulations and standards, including those relating to corporate governance and public disclosure and regulations implemented by the Securities and Exchange Commission, or the SEC, and The Nasdaq Stock Market LLC;&#160;&#160;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employment of operational, financial, accounting and information systems personnel, consistent with expanding our operations and our status as a public company; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to achieve expected operating results may cause a future impairment of goodwill or other assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we achieve significant revenues, we may not become profitable, and even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain consistently profitable could adversely affect the market price of our common stock and could significantly impair our ability to raise capital, expand our business or continue to pursue our growth strategy or even continue to operate. For a detailed discussion of our financial condition and results of operations, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We receive a substantial portion of our revenues from Medicare, and the loss of, or a significant reduction in, reimbursement from Medicare would severely and adversely affect our financial performance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarter ended March&#160;31, 2023, revenue from Medicare for AlloMap Heart, AlloSure Kidney and AlloSure Heart represented 53% of testing services revenue. However, we may not be able to maintain or increase our tests reimbursed by Medicare for a variety of reasons, including changes in reimbursement practices, general policy shifts, or reductions in reimbursement amounts. We cannot predict whether Medicare reimbursements will continue at the same payment amount or with the same breadth of coverage in the future, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Protecting Access to Medicare Act of 2014, or PAMA, included a substantial new payment system for clinical laboratory tests under the Clinical Laboratory Fee Schedule, or CLFS. Under PAMA, laboratories that receive the majority of their Medicare revenues from payments made under the CLFS report initially and then on a subsequent three-year basis thereafter (or annually for advanced diagnostic laboratory tests, or ADLTs), private payer payment rates and volumes for their tests. The final PAMA ruling was issued on June 17, 2016 and the new market based rates took effect on January 1, 2018. The Centers for Medicare &amp; Medicaid Services, or CMS, uses the rates and volumes reported by laboratories to develop Medicare payment rates for the tests equal to the volume-weighted median of the private payer payment rates for the tests. Under PAMA, the reimbursement rate for AlloMap Heart is currently $3,240 for Medicare beneficiaries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 26, 2017, we announced that the Molecular Diagnostic Services, or MolDX, Program developed by Palmetto GBA, or Palmetto, has set AlloSure Kidney reimbursement at $2,841. AlloSure Kidney began to be reimbursed for kidney transplants covered by Medicare across the United States on October 9, 2017, the effective date of the Palmetto local coverage determination, or LCD.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloSure Kidney has been a covered service for Medicare beneficiaries since October 2017 through an LCD first issued by Palmetto MolDX, or MolDX, which was formed to identify and establish coverage and reimbursement for molecular diagnostics tests, and adopted by Noridian Healthcare Solutions, the Company&#8217;s Medicare Administrative Contractor, or Noridian. The Medicare reimbursement rate for AlloSure Kidney is currently $2,841. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloMap Heart has been a covered service for Medicare beneficiaries since January 2006. The Medicare reimbursement rate for AlloMap Heart is currently $3,240. In October 2020, we received a final MolDX Medicare coverage decision for AlloSure Heart. Noridian issued a parallel coverage policy granting coverage for AlloSure Heart when used in conjunction with AlloMap Heart, which became effective in December 2020. The Medicare reimbursement rate for AlloSure Heart is currently $2,753.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;2, 2023, MolDX issued a new billing article, with an effective date of March&#160;31, 2023, related to the LCD entitled Molecular Testing for Solid Organ Allograft Rejection, or the Billing Article. Prior to the Billing Article&#8217;s effective date, MolDX informed the affected parties, including CareDx, that enforcement of the revised billing practices outlined in the Billing Article will not be implemented until June&#160;30, 2023.  MolDX informed us that its automatic adjudication process would remain in place until June 30, 2023, though claims submitted prior to that date must comply with the applicable LCDs. On May&#160;4, 2023, MolDX issued a revised new billing article with an effective date of March&#160;31, 2023, or the Revised Billing Article, and together with the Billing Article, the Billing Articles.  The Revised Billing Article impacts Medicare coverage for AlloSure Kidney, AlloSure Heart and AlloMap Heart and requires certain companies, including CareDx, to implement new processes to address the requirements related to Medicare claim submissions. MolDX has stated that it views the Billing Article as clarifying existing coverage, especially as it relates to when tests are covered in the for-cause and surveillance contexts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MolDX has acknowledged, however, that the Billing Article is a change as it relates to billing more than one test during a single patient encounter. Noridian has not yet adopted the new Billing Articles.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe the Billing Articles are inconsistent with the LCDs, Noridian&#8217;s and MolDX&#8217;s responses to public comments explaining the intended scope of various LCDs, and medical necessity, we determined to pause its Medicare reimbursement submissions for AlloSure Kidney commencing on March&#160;7, 2023 to allow us further time to evaluate the implications of the Billing Article and update its billing processes for AlloSure Kidney tests by educating clinicians and working with centers to update our test order forms to capture the new information required under the Billing Article. Accordingly, we did not submit claims for approximately 3200 AlloSure Kidney tests for Medicare reimbursement for the period from March&#160;7, 2023 through March&#160;31, 2023 and did not recognize revenue on these claims in the first quarter of 2023 aggregating to approximately $8.9 million, or the Impacted March Tests.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2023, we plan to submit claims for Medicare reimbursement for the Impacted March Tests, following the delivery by our of a letter to Noridian explaining, among other things, (i) we believe that the Billing Articles impose new restrictions on Medicare coverage for our tests from those contained in the existing LCDs, (ii) that we plan to submit claims for reimbursement for the Impacted March Tests for which we have not obtained additional information from the ordering physicians to be able to specifically determine whether these tests meet the new coverage restrictions contained in the Billing Articles, and (iii) that AlloSure Kidney orders with a date of service on or after March&#160;31, 2023 for other indications outside the parameters of the Revised Billing Article, or where the reason for testing is not specified by the ordering physician, will either be held pending the receipt of additional information regarding medical necessity or submitted with a test description that is </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intended to identify those tests as falling outside the parameters of the Revised Billing Article. Although we plan to submit claims for Medicare reimbursement for the Impacted March Tests, there is a risk that the claims are denied or that any reimbursement of such claims is subject to forfeiture. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continued the Medicare reimbursement submissions for AlloMap Heart or AlloSure Heart following the issuance of the Billing Articles. In addition, we are considering informing Noridian that until Noridian adopts the Revised Billing Article, we will continue to submit AlloSure Heart tests for reimbursement only when used in conjunction with AlloMap Heart. We are also considering informing Noridian that (i) until June&#160;30, 2023, we plan to submit claims for reimbursement for AlloMap Heart and AlloSure Heart tests for which we have not obtained additional information from the ordering physicians to be able to specifically determine whether these tests meet the new coverage restrictions contained in the Billing Articles, and (ii) AlloSure Heart and AlloMap Heart orders placed on or after June&#160;30, 2023 for other indications outside the surveillance and for-cause parameters of the Billing Article, or where the reason for testing is not specified by the ordering physician, will either be held pending the receipt of additional information regarding medical necessity or submitted with a test description that is intended to identify those tests as falling outside the parameters of the Billing Articles. There is a risk that claims submitted for reimbursement through June&#160;30, 2023 for AlloMap Heart and AlloSure Heart tests for which we have not obtained additional information from the ordering physicians to be able to specifically determine whether these tests meet the new coverage restrictions contained in the Billing Articles subject to forfeiture.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an AlloMap Heart, AlloSure Kidney or AlloSure Heart reimbursement rate that is significantly lower than the current rate is set by CMS or MolDx in the future, it could cause us to discontinue AlloMap Heart, AlloSure Kidney or AlloSure Heart testing for Medicare patients because providing tests at a substantially lowered reimbursement rate may not be economically viable. In addition, our revenues for AlloSure Kidney in 2023 are expected to be materially lower than in prior periods as a result of lower overall testing volumes in 2023 due to the impact of the Billing Articles. Given the significant portion of payments represented by Medicare, our remaining test revenue may be insufficient to sustain our operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If future reimbursement price levels are less than the current price, our revenues and our ability to achieve profitability could be impaired, and the market price of our common stock could decline. We may also not be able to maintain or increase the portion of our tests reimbursed by Medicare for a variety of other reasons, including changes in reimbursement practices and general policy shifts, including the Billing Articles.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a five-year rotational basis, Medicare requests bids for its regional Medicare Administrative Contractors, or MAC, services. The MAC for California is currently Noridian Healthcare Solutions. Our current Medicare coverage through Noridian provides for reimbursement for tests performed for qualifying Medicare patients throughout the U.S. so long as the tests are performed in our California laboratory. We cannot predict whether Noridian or any future MAC will continue to provide reimbursement for AlloMap Heart, AlloSure Kidney or AlloSure Heart at the same payment amount or with the same breadth of coverage in the future, if at all. Additional changes in the MAC processing Medicare claims for AlloSure Kidney, AlloMap Heart or AlloSure Heart could impact the coverage or payment amount for our tests and our ability to obtain Medicare coverage for any products we may launch in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any decision by CMS or its local contractors to reduce or deny coverage for our tests, including as a result of the Billing Articles or otherwise, would have a significant adverse effect on our revenue and results of operations and ability to operate and raise capital. Any such decision could also cause affected clinicians treating Medicare covered patients to reduce or discontinue the use of our tests.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our financial results currently are largely dependent on sales of AlloSure Kidney, AlloMap Heart and AlloSure Lung tests and products, and we will need to generate sufficient revenues from these and other solutions and tests we develop to grow our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that sales of testing services and products will account for a substantial portion of our revenue for at least the next two years. If we are unable to increase sales of our testing services or products or successfully develop and commercialize other solutions, tests or enhancements, or if we do not recommence our Medicare reimbursement submissions for AlloSure Kidney in the near term or at the same levels in place prior to the Billing Articles, our revenues and ability to achieve profitability would be impaired, and the market price of our common stock could decline.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health insurers and other third-party payers may decide to revoke coverage of our existing test, decide not to cover our future solutions or may provide inadequate reimbursement, which could jeopardize our commercial prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful commercialization of AlloSure Kidney, AlloSure Lung, AlloMap Heart and AlloSure Heart depends, in large part, on the availability of coverage and adequate reimbursement from government and private payers. Favorable third-party payer coverage and reimbursement are essential to meeting our immediate objectives and long-term commercial goals.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For new diagnostic testing services, each private and government payer decides whether to cover the test, the amount it will reimburse for a covered test and the specific conditions for reimbursement. Clinicians and recipients may be likely not to order </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a diagnostic test unless third-party payers pay a substantial portion of the test price. Therefore, coverage determinations and reimbursement levels and conditions are critical to the commercial success of a diagnostic testing service, and if we are not able to secure positive coverage determinations and reimbursement levels, our business will be materially adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage and reimbursement by a commercial payer may depend on a number of factors, including a payer&#8217;s determination that our current and future testing services are:</span></div><div><span><br/></span></div><div style="padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">not experimental or investigational;</span></div><div style="padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">medically necessary or redundant;</span></div><div style="padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">lead to improved patient outcomes;</span></div><div style="padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">appropriate for the specific recipient;</span></div><div style="padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">cost-saving or cost-effective; and</span></div><div style="padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">supported by peer-reviewed publications.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payers have in the past disallowed, and may in the future disallow, in whole or in part, requests for reimbursement based on determinations that the member is not eligible for coverage, certain amounts are not reimbursable under plan coverage or were for services provided that were not medically necessary or were redundant or not coupled with other specified tests or services or additional supporting documentation is necessary. Retroactive adjustments may change amounts realized from third-party payers. We are also subject to claims reviews and/or audits by such payers, including governmental audits of our Medicare claims, and have in the past been required to repay these payers in certain circumstances where a preliminary finding was made that we were incorrectly reimbursed. We may also in the future be required to repay these payers if a finding is made that we were incorrectly reimbursed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, several payers and other entities conduct technology assessments of new medical tests and devices and provide and/or sell the results of their assessments to other parties. These assessments may be used by third-party payers and healthcare providers as grounds to deny coverage for or refuse to use a test or procedure. We have received a negative technology assessment from at least one of these entities and could receive more.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If third-party payers decide not to cover our diagnostic testing services or if they offer inadequate payment amounts, our ability to generate revenue from AlloSure Kidney, AlloMap Heart, AlloSure Heart and future solutions could be limited. Payment for diagnostic tests furnished to Medicare beneficiaries is typically made based on a fee schedule set by CMS. In recent years, payments under these fee schedules have decreased and may decrease further.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any third-party payer may stop or lower payment at any time, which could substantially reduce our revenue. See the risk factor above titled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;We receive a substantial portion of our revenues from Medicare, and the loss of, or a significant reduction in, reimbursement from Medicare would severely and adversely affect our financial performance&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since each payer makes its own decision as to whether to establish a policy to reimburse for a test, seeking payer coverage and other approvals is a time-consuming and costly process. We cannot be certain that adequate coverage and reimbursement for AlloSure Kidney, AlloSure Lung, AlloMap Heart, AlloSure Heart, or future solutions will be provided in the future by any third-party payer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement for AlloSure Kidney, AlloMap Heart and AlloSure Heart comes primarily from Medicare and private third party payers such as insurance companies and managed care organizations. The reimbursement process can take six months or more to complete depending on the payer.  AlloSure Kidney has been a covered service for Medicare beneficiaries since October 2017 through a LCD first issued by MolDX, which was formed to identify and establish coverage and reimbursement for molecular diagnostics tests, and adopted by Noridian. The Medicare reimbursement rate for AlloSure Kidney is currently $2,841. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloMap Heart has been a covered service for Medicare beneficiaries since January 2006. The Medicare reimbursement rate for AlloMap Heart is currently $3,240. In October 2020, we received a final MolDX Medicare coverage decision for AlloSure Heart. Noridian issued a parallel coverage policy granting coverage for AlloSure Heart when used in conjunction with AlloMap Heart, which became effective in December 2020. The Medicare reimbursement rate for AlloSure Heart is currently $2,753.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the discussion regarding the Billing Articles under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the risk factor above titled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;We receive a substantial portion of our revenues from Medicare, and the loss of, or a significant reduction in, reimbursement from Medicare would severely and adversely affect our financial performance&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage policies approving AlloMap Heart have been adopted by many of the largest private payers. Many of the payers with positive coverage policies have also entered into contracts with us to formalize pricing and payment terms. We continue to work with third-party payers to expand and seek such coverage and to appeal denial decisions based on existing and ongoing studies, peer reviewed publications, support from physician and patient groups and the growing number of AlloMap Heart tests that have been reimbursed by public and private payers. There are no assurances that the current policies will not be modified in the future. If our test is considered on a policy-wide level by major third-party payers, whether at our request or on their own initiative, and our test is determined to be ineligible for coverage and reimbursement by such payers, if we do not submit for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare reimbursement for AlloSure Kidney for certain prior or future periods or if the Billing Articles limit Medicare reimbursement for AlloSure Heart or AlloMap Heart commencing on June&#160;30, 2023, our collection efforts and potential for revenue growth could be adversely impacted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medicare Part B coverage for AlloSure Kidney and AlloMap Heart is included in a formal local coverage decision for molecular diagnostics. However, any change in this coverage decision or other future adverse coverage decisions by the CMS, including with respect to coding or as a result of the Billing Articles, could substantially reduce our revenue.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare reimbursements currently comprise a significant portion of our revenue. Our current Medicare Part B reimbursement was not set pursuant to a national coverage determination by CMS. Although we believe that coverage is available under Medicare Part B even without such a determination, we currently lack the national coverage certainty afforded by a formal coverage determination by CMS. This means that Medicare contractors, including our California Medicare contractor, currently may continue to develop their own coverage and reimbursement policies with respect to our technology.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until 2016, AlloMap Heart was billed using an unlisted Current Procedural Terminology, or CPT, code, but in 2016 a new CPT Category 1 Multianalyte Assays with Algorithmic Analyses, or MAAA, code was added that specifically describes the test. Further, pursuant to MolDX billing requirements, the AlloMap Heart test also has been assigned a McKesson Diagnostics Z code&#8482;, which is included on all Medicare claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If in the future CMS makes a determination not to pay for this code, or for any MAAA codes, this could be harmful to our business, and could have negative spillover implications that prevent or limit coverage by other third-party payers that might mirror aspects of Medicare payment criteria.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the launch of AlloSure Kidney in October 2016, and at the instruction of the MolDX Program of Palmetto, the test has been billed utilizing an unlisted CPT code. If in the future CMS makes a determination to no longer provide coverage for services billed with an unlisted CPT code, our ability to bill and obtain reimbursement from public and private payers could be negatively impacted. In addition, the Billing Article indicates that we will need to obtain additional &#8220;Z&#8221; codes for AlloSure Kidney in order to submit for future Medicare reimbursement. In addition, there can be no assurance that any of our tests or other offerings currently being promoted or on the market or being leveraged by clinicians or patients without FDA clearance or approval will continue to be allowed without such clearance or approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are and could become subject to legal proceedings that could be time consuming, result in costly litigation and settlements/judgments, require significant amounts of management attention and result in the diversion of significant operational resources, which could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past been, and from time to time in the future may become, involved in lawsuits, claims and proceedings incident to the ordinary course of, or otherwise in connection with, our business. For example, in response to our false advertising suit filed against Natera Inc., or Natera, on April 10, 2019, Natera filed a counterclaim against us on February 18, 2020 in the U.S. District Court for the District of Delaware, or the Court, alleging we made false and misleading claims about the performance capabilities of AlloSure. The suit seeks injunctive relief and unspecified monetary relief. On September 30, 2020, Natera requested leave of the Court to amend its counterclaims to include additional allegations regarding purportedly false claims we made with respect to AlloSure, and the Court granted Natera&#8217;s request. The trial commenced on March 7, 2022 and concluded on March 14, 2022, with the jury awarding us $44.9 million in damages, comprised of $21.2 million in compensatory damages and $23.7 million in punitive damages. As of the date of this report, the post-trial motion practice remains pending. We will not record the award until cash is received or the matter is otherwise resolved. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2022, the United States Court of Appeals for the Federal Circuit affirmed the Court's judgment dismissing our patent infringement suit against Natera.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in response to our patent infringement suit filed against Natera on March 26, 2019, Natera filed suit against us on January 13, 2020 in the Court alleging, among other things, that AlloSure infringes Natera&#8217;s U.S. Patent 10,526,658. This case was consolidated with our patent infringement suit on February 4, 2020. On March 25, 2020, Natera filed an amendment to the suit alleging, among other things, that AlloSure also infringes Natera&#8217;s U.S. Patent 10,597,724. The suit seeks a judgment that we have infringed Natera&#8217;s patents, an order preliminarily and permanently enjoining us from any further infringement of such patents and unspecified damages. On May 13, 2022, Natera filed two new complaints alleging that AlloSure infringes Natera&#8217;s U.S. Patents 10,655,180 and 11,111,544. These two cases were consolidated with the patent infringement case on June 15, 2022. On May 17, 2022, Natera agreed to dismiss the case alleging infringement of Natera&#8217;s U.S. Patent 10,526,658. On July 6, 2022, we moved to dismiss the rest of Natera&#8217;s claims. On September 6, 2022, we withdrew the motion to dismiss. Discovery is ongoing. We intend to defend both of these matters vigorously, and believe that we have good and substantial defenses to the claims alleged in the suits, but there is no guarantee that we will prevail.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, on May 23, 2022, Plumbers &amp; Pipefitters Local Union #295 Pension Fund filed a federal securities class action in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the U.S. District Court for the Northern District of California against us, Reginald Seeto, our President, Chief Executive Officer </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and member of our Board of Directors, Ankur Dhingra, our former Chief Financial Officer; Marcel Konrad, our former interim Chief Financial Officer and former Senior Vice President of Finance &amp; Accounting; and Peter Maag, our former President, former Chief Executive Officer, former Chairman of the Board and current member of our Board of Directors. The action alleges that we and the individual defendants made materially false and/or misleading statements and/or omissions and that such statements violated Section 10(b) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and Rule 10b-5 promulgated thereunder. The action also alleges that the individual defendants are liable pursuant to Section 20(a) of the Exchange Act as controlling persons of our Company. The suit seeks to recover damages caused by the alleged violations of federal securities laws, along with the plaintiffs&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> costs incurred in the lawsuit, including their reasonable attorneys&#8217; and experts&#8217; witness fees and other costs. We intend to defend ourselves vigorously, and believe that we have good and substantial defenses to the claims alleged in the suit, but there is no guarantee that we will prevail.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 25, 2022, the court appointed an investor group led by the Oklahoma Police Pension and Retirement System as lead plaintiffs and appointed Saxena White P.A. and Robbins Geller Rudman &amp; Dowd LLP as lead counsels. Plaintiffs filed an amended complaint on November 28, 2022. On January 27, 2023, defendants moved to dismiss all claims and to strike certain allegations in the amended complaint. A hearing on these motions is scheduled for May 16, 2023. We intend to defend ourselves vigorously, and believes that we have good and substantial defenses to the claims alleged in the suit, but there is no guarantee that we will prevail. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on September 21, 2022, Jeffrey Edelman brought a stockholder derivative action complaint in the U.S. District </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Court for the Northern District of California, or the Edelman Derivative Action, against us as nominal defendant and Reginald Seeto, our President, Chief Executive Officer and member of our Board of Directors, Ankur Dhingra, our former Chief Financial Officer, Peter Maag, our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">former President, former Chief Executive Officer, former Chairman of the Board and current member of our Board of Directors, and the other members of our Board of Directors. The plaintiff alleges that the individual defendants breached their fiduciary duties as directors and/or officers of our Company and engaged in insider trading, waste of corporate assets, unjust enrichment and violations of Sections 14(a) and 20(a) of the Exchange Act. The action alleges that the individual defendants are liable pursuant to Section 20(a) of the Exchange Act as controlling persons of our Company. The suit seeks a declaration that the individual defendants breached their fiduciary duties to us, violated Sections 14(a) and 20(a) of the Exchange Act and were unjustly enriched, and also seeks to recover damages sustained by us as a result of the alleged violations, along with the plaintiff&#8217;s costs incurred in the lawsuit, including reasonable attorneys&#8217; and experts&#8217; fees, costs and expenses. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, on February 7, 2023, Jaysen Stevenson brought a stockholder derivative action complaint in the U.S. District Court for the Northern District of California, or </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Stevenson Derivative Action,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> against us as nominal defendant and Reginald Seeto, Ankur Dhingra, Peter Maag and other current and former members of our Board of Directors. The claims and allegations in the Stevenson Derivative Action are substantially similar to those in the Edelman Derivative Action. The plaintiff alleges that the individual defendants breached their fiduciary duties as our directors and/or officers and engaged in insider trading, waste of corporate assets, unjust enrichment and violations of Sections 14(a) and 20(a) of the Exchange Act. The suit seeks declaratory relief and to recover alleged damages sustained by us as a result of the alleged violations, along with the plaintiff&#8217;s costs incurred in the lawsuit, including reasonable attorneys&#8217; and experts&#8217; fees, costs and expenses. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to defend ourselves vigorously, and we believe that we have good and substantial defenses to the claims alleged in the Edelman Derivative Action and the Stevenson Derivative Action, but there is no guarantee that we will prevail.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation is inherently unpredictable. It is possible that an adverse result in one or more of these possible future events could have a material adverse effect on us including increased expenses to defend, settle or resolve such litigation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our financial results have been, and we expect that our operating results will continue to be, subject to quarterly fluctuations. Our net income (loss) and other operating results will be affected by numerous factors, including:</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to successfully market and sell our testing services and products;</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to successfully commercialize new diagnostic solutions;</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the amount of our research and development expenditures;</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing of cash collections from third-party payers;</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the extent to which our current and future solutions, if any, are eligible for coverage and reimbursement from third-party payers;</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the process of integrating new acquisitions, and the associated potential disruption to our business;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in coverage and reimbursement or in reimbursement-related laws directly affecting our business, including as a result of the Billing Articles;</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">our decision to recommence Medicare reimbursement submissions for AlloSure Kidney;</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">our decision to issue future financial guidance and the terms of such guidance;</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which we may become involved or that otherwise may affect our intellectual property position;</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">announcements by our competitors of new or competitive products;</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">regulatory or legal developments affecting our test or competing products;</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">total operating expenses; and</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in expectation as to our future financial performance, including financial estimates, publications or research reports by securities analysts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transplant centers may not adopt AlloSure Kidney, AlloSure Lung, AlloMap Heart, AlloSure Heart, or our other solutions due to historical practices or due to more favorable reimbursement policies associated with other means of monitoring transplants.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the historically limited monitoring options and the well-established coverage and reimbursement for biopsies, clinicians are accustomed to monitoring for acute rejection in kidney and heart transplant recipients by utilizing biopsies. Many clinicians use AlloSure Kidney, AlloSure Lung, AlloMap Heart and AlloSure Heart in parallel with biopsies rather than as an alternative to biopsies. While we do not market AlloSure Kidney, AlloSure Lung, AlloMap Heart or AlloSure Heart as biopsy alternatives, per se, if treatment center administrators view our test as an alternative to a biopsy but believe they would derive more revenue from the performance of biopsies, such administrators may be motivated to reduce or avoid the use of our test. While biopsies are less common for monitoring kidney transplant patients, there are transplant centers that manage patients with protocol biopsies, which could impact AlloSure Kidney revenue. We cannot provide assurance that our efforts will increase the use of our test by new or existing customers. Our failure to increase the frequency of use of our test by new and existing customers would adversely affect our growth and revenues.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our past revenue growth rates may not be indicative of future growth, and we may not grow at all, and revenue may decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 2021 to 2022, our revenue grew from $296.4 million to $321.8 million, which represents annual growth of 9%. In the future, our revenue may not grow at all and it may decline. We believe that our future revenue will depend on, among other factors:</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the continued usage and acceptance of our current and future solutions;</span></div><div style="margin-top:4pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">demand for our testing services, products and patient and digital solutions;</span></div><div style="margin-top:4pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the introduction and acceptance of new or enhanced products or services by us or by competitors;</span></div><div style="margin-top:4pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to maintain reimbursement for AlloSure Kidney, AlloSure Lung, AlloMap Heart and AlloSure Heart and secure reimbursement for our future solutions;</span></div><div style="margin-top:4pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">our decision to recommence Medicare reimbursement submissions for AlloSure Kidney;</span></div><div style="margin-top:4pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">our decision to issue future financial guidance and the terms of such guidance;</span></div><div style="margin-top:4pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to anticipate and effectively adapt to developing markets and to rapidly changing technologies;</span></div><div style="margin-top:4pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to attract, retain and motivate qualified personnel;</span></div><div style="margin-top:4pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the initiation, renewal or expiration of significant contracts with our commercial partners;</span></div><div style="margin-top:4pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">pricing changes by us, our suppliers or our competitors; and</span></div><div style="margin-top:4pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">general economic conditions and other factors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be successful in our efforts to manage any of the foregoing, and any failure to be successful in these efforts could materially and adversely affect revenue growth. You should not consider our past revenue growth to be indicative of future growth.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to raise additional capital on acceptable terms in the future, it may limit our ability to develop and commercialize new diagnostic solutions and technologies, and we may have to curtail or cease operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had cash, cash equivalents and marketable securities of $285.9 million and an accumulated deficit of $484.9 million. We expect capital outlays and operating expenditures to increase over the next several years as we expand our infrastructure, commercial operations and research and development activities. Specifically, we may need to raise additional capital to, among other things:</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">develop other solutions for clinical surveillance in transplantation;</span></div><div style="margin-top:5pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">increase our selling and marketing efforts to drive market adoption and address competitive developments;</span></div><div style="margin-top:5pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expand our clinical laboratory operations;</span></div><div style="margin-top:5pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">fund our clinical validation study activities;</span></div><div style="margin-top:5pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expand our research and development activities;</span></div><div style="margin-top:5pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">sustain or achieve broader commercialization of AlloSure Kidney, AlloSure Lung, KidneyCare, AlloMap Heart, AlloSure Heart, HeartCare, our products and patient and digital solutions or enhancements to those tests, products and patient and digital solutions;</span></div><div style="margin-top:5pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">acquire or license products or technologies including through acquisitions; and</span></div><div style="margin-top:5pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">finance our capital expenditures and general and administrative expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our present and future funding requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the level of research and development investment required to develop our new solutions;</span></div><div style="margin-top:5pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">costs of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights;</span></div><div style="margin-top:5pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our need or decision to acquire or license complementary technologies or acquire complementary businesses;</span></div><div style="margin-top:5pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in test development plans needed to address any difficulties in commercialization;</span></div><div style="margin-top:5pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">competing technological and market developments;</span></div><div style="margin-top:5pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">whether our diagnostic solutions become subject to additional FDA or other regulation; and</span></div><div style="margin-top:5pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in regulatory policies or laws that affect our operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional capital, if needed, may not be available on satisfactory terms, or at all, and might include the issuance of equity securities, debt, cash from collaboration agreements, or a combination of these. Furthermore, if we raise additional funds by issuing equity securities, dilution to our existing stockholders could result. Any equity securities issued also may provide for rights, preferences or privileges senior to those of holders of our common stock and would result in dilution to our stockholders. Moreover, we have the ability to sell up to $200.0&#160;million of additional shares of our common stock to the public through an &#8220;at the market&#8221; offering pursuant to a Sales Agreement we entered into with Jefferies, LLC on April 14, 2022. Any shares of common stock issued in the at-the-market offering will result in dilution to our existing stockholders. If we raise additional funds by issuing debt securities, these debt securities would have rights, preferences and privileges senior to those of holders of our common stock, and the terms of the debt securities issued could impose significant restrictions on our operations. If we raise additional funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our technologies or our solutions under development, or grant licenses on terms that are not favorable to us, which could lower the economic value of those programs to us. If adequate funds are not available, we may have to scale back our operations or limit our research and development activities, which may cause us to grow at a slower pace, or not at all, and our business could be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results may be adversely affected by unfavorable economic and market conditions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the countries in which we operate, including the U.S. and several of the members of the European Union, or EU, have experienced and continue to experience uncertain economic conditions resulting from global as well as local factors. On June 23, 2016, the United Kingdom, or the UK, held a referendum pursuant to which voters elected to leave the EU, commonly </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">referred to as Brexit. The UK formally left the EU on January 31, 2020 and began a transition period that ended on December 31, 2020. Although the ultimate effects of Brexit have yet to be seen, and the UK is in the process of negotiating trade deals with other countries, Brexit has created additional uncertainties that may ultimately result in new regulatory costs and challenges for companies and increased restrictions on imports and exports throughout Europe, which could adversely affect our ability to conduct and expand our operations in Europe and which may have an adverse effect on our business, financial condition and results of operations. Additionally, Brexit may increase the possibility that other countries may decide to leave the EU in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business or financial results may be adversely impacted by these uncertain economic conditions, including: adverse changes in interest rates, foreign currency exchange rates, tax laws or tax rates; increased inflation globally and in the U.S. in particular; the government closure of Silicon Valley Bank and potential liquidity concerns at other financial institutions; a potential economic recession; contraction in the availability of credit in the marketplace due to legislation or other economic conditions, which may potentially impair our ability to access the capital markets on terms acceptable to us or at all; and the effects of government initiatives to manage economic conditions. A severe or prolonged economic downturn, such as the global financial crisis, could result in a variety of risks to our business, including a decrease in the demand for our tests and in our ability to raise additional capital when needed on acceptable terms, if at all. In addition, we cannot predict how future economic conditions will affect our critical customers, suppliers and distributors and any negative impact on our critical customers, suppliers or distributors may also have an adverse impact on our results of operations or financial condition. We cannot anticipate all of the ways in which the foregoing, and the current economic climate and financial market conditions generally, could adversely impact our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current or future restructuring plans, including our recent decision to discontinue our operations in Fremantle, Australia, may not optimize costs and simplify our organizational and corporate structure and may materially impair our business operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we announced a restructuring plan intended to optimize costs and simplify our organizational and corporate structure. Our restructuring plan includes the discontinuation of our operations in Fremantle, Australia, terminating our employees in that location and vacating our facilities there. The winding down of our operations in Australia has, and any additional restructuring efforts may, divert management's attention, increase expenses on a short term basis and lead to potential issues with employees, customers, or suppliers. If we do not complete these activities in a timely manner; or do not realize anticipated cost savings, synergies and efficiencies; or business disruption occurs during or following such activities; or we incur unanticipated charges, our business, financial condition, operating results, and cash flows may be materially impaired.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Billing and Reimbursement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Billing complexities associated with obtaining payment or reimbursement for our current and future solutions may negatively affect our revenue, cash flows and profitability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Billing for clinical laboratory testing services is complex. In cases where we do not have a contract in place requiring the payment of a fixed fee per test, we perform tests in advance of payment and without certainty as to the outcome of the billing process. In cases where we do receive a fixed fee per test, we may still have disputes over pricing and billing. We receive payment from individual recipients and from a variety of payers, such as commercial insurance carriers and governmental programs, primarily Medicare. Each payer typically has different billing requirements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among the factors complicating our billing of third-party payers are:</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes among payers regarding which party is responsible for payment;</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disparity in coverage among various payers;</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">different process, information and billing requirements among payers; and</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">incorrect or missing billing information, which is required to be provided by the prescribing clinician.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the discussion of the Billing Articles under the risk factor above titled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Health insurers and other third-party payers may decide to revoke coverage of our existing test, decide not to cover our future solutions or may provide inadequate reimbursement, which could jeopardize our commercial prospects"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, from time to time, payers change processes that may affect timely payment. For example, some commercial payers have instituted prior authorization requirements before our testing is performed. These changes may result in uneven cash flow or impact the timing of revenue recognized with these payers. With respect to payments received from governmental </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">programs, factors such as a prolonged government shutdown could cause significant regulatory delays or could result in attempts to reduce payments made to us by federal government healthcare programs. In addition, payers may refuse to ultimately make payment if their processes and requirements have not been met on a timely basis. In addition, we are subject to and expect to continue to be subject to one or more audits under the CMS Recovery Audit Contractor, or RAC, program, the CMS Targeted Probe and Educate, or TPE, program, the Unified Program Integrity Contractors, or UPIC, program and other federal and state audits. Following two rounds of TPE audit in which AlloSure Kidney and AlloSure Heart claims were reviewed and denied, Noridian informed us it was making a referral to CMS given disagreement as to the interpretation of the applicable LCDs.  We appealed claims which had a basis for appeal and those claims were denied.  We continue to pursue appeals of these claims consistent with our statutory rights. We have met with CMS to discuss the difference in interpretation and intend to continue this dialogue regarding our position that the Noridian interpretation is inconsistent with the LCD, MolDX&#8217;s and Noridian&#8217;s prior associated responses to public comments, and medical necessity.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect further intensification of the regulatory environment surrounding the healthcare industry, as third-party firms engaged by CMS and others conduct extensive pre and post-payment audits of claims data as well as medical and other records in order to identify improper payments to healthcare providers under the Medicare and Medicaid programs. We could be forced to expend considerable resources responding to these audits or other inquiries. These billing complexities, and the resulting uncertainty in obtaining payment for AlloSure Kidney, AlloMap Heart, AlloSure Heart and future solutions, as well as the results of Noridian's referral to CMS and any audits or inquiries evaluating the medical necessity of our services creates a risk that our claims are denied or that any historical reimbursement of such claims is subject to forfeiture and could negatively affect our revenue, cash flows and profitability.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our competitive position depends on maintaining intellectual property protection.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete and to achieve and maintain profitability depends on our ability to protect our proprietary discoveries and technologies. We currently rely on a combination of patents, copyrights, trademarks, trade secrets, confidentiality agreements and license agreements to protect our intellectual property rights.</span></div><div style="margin-top:6pt"><span id="ic2bd2d46d2f3476d899e5302c66c711d_604091"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patent position for AlloMap Heart is based on issued patents and patent applications disclosing identification of genes differentially expressed between activated and quiescent leukocytes and demonstration of correlation between gene expression patterns and specific clinical states and outcomes. As of March&#160;31, 2023, we had 20 issued U.S. patents related to transplant rejection and autoimmunity. Among those, we have one issued U.S. patent covering methods of diagnosing transplant rejection using all 11&#160;informative genes measured in AlloMap Heart, which will expire in March 2024. We have four additional patents covering additional genes or gene variants for diagnosing transplant rejection or autoimmune disease, which will expire between August 2024 and September 2029.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our June 2014 acquisition of ImmuMetrix, Inc., we obtained an exclusive license from Stanford to one U.S. patent issued in April 2014 relating to the diagnosis of rejection in organ transplant recipients using dd-cfDNA. Additional patents from Stanford included in the exclusive license were issued, including one in 2017, two in 2019, four in 2021, two in 2022 and one in 2023, that further cover the use of dd-cfDNA to diagnose and predict transplant status or outcome. These patents will expire between 2030 and 2032.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patents and the patents we exclusively license from others may be successfully challenged by third parties as being invalid or unenforceable. For example, in September 2021, the Court in the patent infringement case against Natera ruled that three of the patents we asserted against Natera are invalid. The Court&#8217;s finding does not have any impact on our ability to continue providing AlloSure. This ruling may limit our ability to prevent Natera and other competitors and third parties from developing and marketing products similar to ours and we may not be able to prevent Natera and others from developing or selling products that are covered by our products or technologies, without payment to us. On March 29, 2023, we entered into an agreement with Stanford whereby we agreed, among other things, to seek a review from the United States Supreme Court, or the Review. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the pendency of the Review, certain of our licensing payment and reporting obligations to Stanford with respect to licensed products sold in the U.S., and our right to terminate the Exclusive Agreement upon 30 days&#8217; advance notice to Stanford, are suspended. However, there can be no assurance that the Review will be granted or that any decision by the Supreme Court will be granted in our favor. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may independently develop similar or competing technology that avoids the patents we own or exclusively license. We cannot be certain that the steps we have taken will prevent the misappropriation and use of our intellectual property, particularly in foreign countries where the laws may not protect our proprietary rights as fully as in the United States.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the patent rights of life sciences companies effectively protect their products and technologies is often highly uncertain and involves complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the proper scope of allowable claims of patents held by such companies has emerged to date in the United States. Various courts, including the United States Supreme Court, have rendered decisions that impact the scope of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patentability of certain inventions or discoveries relating to diagnostic solutions or genomic diagnostics. In the Ariosa Diagnostics, Inc. v. Sequenom, Inc. (Fed. Cir. 2015) case, a federal court recently determined that a cfDNA product for fetal testing was not eligible for patent protection. These decisions generally stand for the proposition that inventions that recite laws of nature are not themselves patentable unless they have sufficient additional features that provide practical assurance that the processes are genuine inventive applications of those laws rather than patent drafting efforts designed to monopolize a law of nature itself. What constitutes a &#8220;sufficient&#8221; additional feature for this purpose is uncertain. This evolving case law in the United States may adversely impact our ability to obtain new patents and may facilitate third-party challenges to our existing owned and exclusively licensed patents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or in interpretations of patent laws in the United States or other countries may diminish the value of our intellectual property rights. In particular, in September 2011, the United States Congress passed the Leahy-Smith America Invents Act, or the AIA, which became effective in March 2013. The AIA reforms United States patent law in part by changing the standard for patent approval for certain patents from a &#8220;first to invent&#8221; standard to a &#8220;first to file&#8221; standard and developing a post-grant review system. This has not yet had a material impact on the operation of our business and the protection and enforcement of our intellectual property, but it may in the future. The AIA and its implementation could still increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. Patent applications in the United States and many foreign jurisdictions are not published until at least eighteen months after filing, and it is possible for a patent application filed in the United States to be maintained in secrecy until a patent is issued on the application. In addition, publications in the scientific literature often lag behind actual discoveries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We therefore cannot be certain that others have not filed patent applications that cover inventions that are the subject of pending applications that we own or exclusively license or that we or our licensors, as applicable, were the first to invent the technology (pre-AIA) or first to file (post-AIA). Our competitors may have filed, and may in the future file, patent applications covering technology that is similar to or the same as our technology. Any such patent application may have priority over patent applications that we own or exclusively license and, if a patent issues on such patent application, we could be required to obtain a license to such patent in order to carry on our business. If another party has filed a United States patent application covering an invention that is similar to, or the same as, an invention that we own or license, we or our licensors may have to participate in an interference or other proceeding in the PTO or a court to determine priority of invention in the United States for pre-AIA applications and patents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For post-AIA applications and patents, we or our licensors may have to participate in a derivation proceeding to resolve disputes relating to inventorship. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful, resulting in our inability to obtain or retain any United States patent rights with respect to such invention.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results may fluctuate, which could cause our stock price to decrease.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our operating results may lead to fluctuations, including declines, in the share price for our common stock. From January 3, 2023 to March&#160;31, 2023, our closing stock price ranged </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $8.83 to $17.61</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our operating results and our share price may fluctuate from period to period due to a variety of factors, including:</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">demand by clinicians and recipients for our current and future solutions, if any;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">coverage and reimbursement decisions by third-party payers and announcements of those decisions;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">clinical trial results and publication of results in peer-reviewed journals or the presentation at medical conferences;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the inclusion or exclusion of our current and future solutions in large clinical trials conducted by others;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">new or less expensive tests and services or new technology introduced or offered by our competitors or us;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the level of our development activity conducted for new solutions, and our success in commercializing these developments;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to efficiently integrate the business of new acquisitions;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the level of our spending on test commercialization efforts, licensing and acquisition initiatives, clinical trials, and internal research and development;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in the regulatory environment, including any announcement from the FDA regarding its decisions in regulating our activities;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in recommendations of securities analysts or lack of analyst coverage;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">failure to meet analyst expectations regarding our operating results;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">additions or departures of key personnel;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">public health emergencies such as the COVID-19 pandemic; </span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">share repurchases completed by us; and</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">general market conditions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variations in the timing of our future revenues and expenses could also cause significant fluctuations in our operating results from period to period and may result in unanticipated earning shortfalls or losses. In addition, national stock exchanges, and in particular the market for life science companies, have experienced significant price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Moreover, we may be subject to additional securities class action litigation as a result of volatility in the price of our common stock, which could result in substantial costs and diversion of management&#8217;s attention and resources and could harm our stock price, business, prospects, results of operations and financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock has been and will likely continue to be volatile, and you could lose all or part of your investment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is currently traded on the Nasdaq Global Market, but we can provide no assurances that there will be active trading on that market or on any other market in the future. If there is no active market or if the volume of trading is limited, holders of our common stock may have difficulty selling their shares. The market price of our common stock has been and may continue to be subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the SEC on February&#160;27, 2023, factors that could cause fluctuations in the market price of our common stock include the following:</span></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">price and volume fluctuations in the overall stock market from time to time;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">volatility in the market prices and trading volumes of life sciences stocks;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in operating performance and stock market valuations of other life sciences companies generally, or those in our industry in particular;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">sales of shares of our common stock by us or our stockholders;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">entering into financing or other arrangements with rights or terms senior to the interests of common stockholders;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">failure of securities analysts to maintain coverage of us, changes in financial estimates by securities analysts who follow our company, or our failure to meet these estimates or the expectations of investors;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the financial projections we may provide to the public, any changes in those projections or failure to meet those projections;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">announcements by us or our competitors of new products or services;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the public&#8217;s reaction to our press releases, other public announcements and filings with the SEC;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">rumors and market speculation involving us or other companies in our industry;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">actual or anticipated changes in our operating results or fluctuations in our operating results;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">actual or anticipated developments in our business, our competitors&#8217; businesses or the competitive landscape generally;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">litigation involving us, our industry or both, or investigations by regulators into our operations or those of our competitors;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developments or disputes concerning our intellectual property or other proprietary rights;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">announced or completed acquisitions of businesses or technologies by us or our competitors;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">new laws or regulations or new interpretations of existing laws or regulations applicable to our business;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in accounting standards, policies, guidelines, interpretations or principles;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any significant change in our management;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">public health emergencies, including the COVID-19 pandemic;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">our prior decision to withdraw our revenue guidance for fiscal 2023;</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31.8pt">our decision to issue future financial guidance and the terms of such guidance; and</span></div><div style="margin-top:2pt;padding-left:108pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">general economic conditions and slow or negative growth of our markets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our principal stockholders, executive officers and directors choose to act together, they may be able to control our management and operations, which may prevent us from taking actions that may be favorable to you.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers, directors and holders of 5% or more of our outstanding common stock (based on the most recent public filings), and entities affiliated with them, beneficially own in the aggregate approximately 62.1% of our common stock as of May&#160;8, 2023. These stockholders, acting together, will have the ability to exert substantial influence over all matters requiring approval by our stockholders, including the election and removal of directors and any proposed merger, consolidation or sale of all or substantially all of our assets. In addition, they could dictate the management of our business and affairs. This concentration of ownership could have the effect of delaying, deferring or preventing a change in control of us or impeding a merger or consolidation, takeover or other business combination that could be favorable to you.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may elect to repurchase shares of our common stock, which might limit our ability to pursue other growth opportunities.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2022, our board of directors authorized a stock repurchase program, whereby we may purchase up to $50 million in shares of our common stock over a period of up to two years, commencing on December 8, 2022, or the Repurchase Program. The Repurchase Program may be carried out at the discretion of a committee of our Board of Directors through open market purchases, one or more Rule 10b5-1 trading plans, block trades and in privately negotiated transactions. Any repurchase of shares of our common stock under the Repurchase Program will depend on several factors, including, but not limited to, results of operations, capital requirements, financial conditions, available capital from operations or other sources, including debt, and the market price of our common stock. In addition, on August 16, 2022, the U.S. enacted the Inflation Reduction Act of 2022, which, among other things, imposes an excise tax of 1% tax on the fair market value of net stock repurchases made after December 31, 2022. Therefore, there is no assurance with respect to the amount, price or timing of any such repurchases. We may elect to retain all future earnings for the operation and expansion of our business, rather than repurchasing shares of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we purchased an aggregate of 59,472 shares of our common stock under the Repurchase Program for an aggregate purchase price of $0.7 million. As of March&#160;31, 2023, $48.7 million remained available for future share repurchase under the Repurchase Program.</span></div><div style="margin-top:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event we make any additional stock repurchases in the future, our ability to finance any material expansion of our business, including through acquisitions, investments or increased capital spending, or to fund our operations, may be limited. In addition, any repurchases we may make in the future may not prove to be at optimal prices. Our Board of Directors may modify or amend the Repurchase Program, or adopt a new stock repurchase program, at any time at its discretion without stockholder approval.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have identified material weaknesses in our internal control over financial reporting as of December 31, 2022. If we are unable to remediate these material weaknesses and maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results in a timely manner.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective internal control over financial reporting is necessary for us to provide reasonable assurance regarding the preparation and fair presentation of published consolidated financial statements in accordance with accounting principles generally accepted in the United States. In connection with the preparation of our consolidated financial statements as of December 31, 2022 and for the year then ended, we identified material weaknesses in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management concluded that we had the following material weaknesses as of December 31, 2022:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">General Information Technology Controls</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We did not design and maintain effective general information technology controls (&#8220;GITCs&#8221;), for information systems and applications that are relevant to the preparation of the consolidated financial statements. Specifically, we did not design and maintain: (i) sufficient user access controls to ensure appropriate segregation of duties, logical access controls to prevent unauthorized user access and adequately restrict user and privileged access to financial applications, programs and data to appropriate Company personnel; (ii) program change management controls to ensure that information technology (&#8220;IT&#8221;), program and data changes affecting financial IT applications and underlying accounting records are identified, tested, authorized and implemented appropriately with appropriate segregation of duties; and (iii) Computer and Network operations controls to ensure that batch and interface jobs are monitored and privileges are appropriately granted, authorized and monitored. As a result, business process controls (automated and manual) that are dependent on the ineffective GITCs, or that rely on data produced from systems impacted by the ineffective GITCs, are also deemed ineffective, which affects substantially all financial statement account balances and disclosures.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Purchase Order Approval Workflow</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We did not design and maintain effective process-level control activities related to procurement to ensure appropriate approval of purchase orders, which could affect the amount and classification of costs capitalized or expensed. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Committee of Sponsoring Organizations of the Treadway Commission (COSO) Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We did not fully maintain components of the COSO framework, including elements of the control environment, information and communication, and control activities and monitoring activities components, relating to: (i) sufficiency of competent personnel to perform internal control activities and support the achievement of our internal control objectives; (ii) enforcing accountability of personnel for the performance of their internal control responsibilities across the organization in the pursuit of objectives; (iii) designing and maintaining general control activities over technology to support the achievement of our internal control objectives; (iv) performing control activities in accordance with established policies in a timely manner; and (v) performing sufficient reviews of information to assess its relevance, accuracy, and completeness in supporting the internal control components. As such, our management concluded that we did not have an adequate process in place to complete its assessment of the design and operating effectiveness of internal control over financial reporting in a timely manner.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These material weaknesses have not been remediated as of the date of this Quarterly Report on Form 10-Q. Our management has been engaged in developing and implementing remediation plans to address the material weaknesses described above. However, the material weaknesses will not be fully remediated until management can demonstrate the full effectiveness of controls over a sufficient period of time, and we can give no assurance on the success of such measures or the outcome of our assessment of these measures at this time. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the steps we take to remediate the material weaknesses are ineffective, these material weaknesses could result in material misstatements to our annual or interim consolidated financial statements that might not be prevented or detected on a timely basis, or in delayed filings of our required periodic reports. This might lead to investors losing confidence in the accuracy and completeness of our financial reports, the market price of the common stock could be adversely affected, and we could become subject to litigation or investigations by The Nasdaq Stock Market LLC, the SEC or other regulatory authorities, which could require additional financial and management resources.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, if we identify any new material weaknesses in the future, any such newly identified material weakness could limit our ability to prevent or detect a misstatement of our accounts or disclosures that could result in a material misstatement of our annual or interim financial statements. In such case, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial reporting and our stock price may decline as a result. We cannot assure you that the measures we have taken to date, or any measures we may take in the future, will be sufficient to remediate our existing material weaknesses or avoid potential future material weaknesses.</span></div><div id="idd35c15ee381485cb38f052732749537_127"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We satisfy certain U.S. federal and state tax withholding obligations due upon the vesting of restricted stock unit awards by automatically withholding from the shares being issued in connection with such award a number of shares of our common stock with an aggregate fair market value on the date of vesting equal to the minimum tax withholding obligations. The following table sets forth information with respect to shares of our common stock repurchased by us or withheld to satisfy certain tax withholding obligations during the three months ended March&#160;31, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average Price Paid per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Program</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023 - January 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1, 2023 - February 28, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023 - March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,472&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Comprised of: (a) 12,289 shares of our common stock withheld from employees for the payment of taxes, for which the average price paid per share with respect to withheld shares was $13.06 which represents the average fair market value of common stock on the date of withholding, and (b) 17,702 shares of our common stock repurchased pursuant to our stock repurchase program at an average price per repurchased share of $12.81.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Comprised of: (a) 31,202 shares of our common stock withheld from employees for the payment of taxes, for which the average price paid per share with respect to withheld shares was $16.85 which represents the average fair market value of common stock on the date of withholding, and (b) 9,220 shares of our common stock repurchased pursuant to our stock repurchase program at an average price per repurchased share of $15.11.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Comprised of: (a) 6,763 shares of our common stock withheld from employees for the payment of taxes, for which the average price paid per share with respect to withheld shares was $10.74 which represents the average fair market value of common stock on the date of withholding, and (b) 32,550 shares of our common stock repurchased pursuant to our stock repurchase program at an average price per repurchased share of $9.91.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) On December 3, 2022, our Board of Directors approved our stock repurchase program, authorizing us to purchase up to $50&#160;million in shares of our common stock over a period of up to two years, commencing on December 8, 2022. The Repurchase Program may be carried out at the discretion of a committee of our Board of Directors through open market purchases, one or more Rule 10b5-1 trading plans, block trades and in privately negotiated transactions. </span></div><div id="idd35c15ee381485cb38f052732749537_130"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="idd35c15ee381485cb38f052732749537_133"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="idd35c15ee381485cb38f052732749537_136"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="idd35c15ee381485cb38f052732749537_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;6.&#160;&#160;&#160;&#160;EXHIBITS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.437%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1217234/000119312514325391/d757814dex31.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1217234/000119312521193438/d93632dex31.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of CareDx, Inc., filed June 17, 2021.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3(3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1217234/000119312521193438/d93632dex32.htm">Amended and Restated Bylaws.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1(4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001217234/000119312515113712/d852478dex41.htm">Form of Registrant&#8217;s common stock certificate.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2(5)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1217234/000121723421000190/caredx-exhibit42.htm">2014 Equity Incentive Plan, as amended.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3(6)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001217234/000119312517308447/d461639dex99d3.htm">Form of Option Agreement under the 2014 Equity Incentive Plan for New Options.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4(7)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001217234/000119312514272190/d758902dex45.htm">2014 Employee Stock Purchase Plan and forms of agreements thereunder.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5(8)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1217234/000121723421000190/exhibit45.htm">2016 Inducement Equity Incentive Plan.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6(9)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001217234/000119312516541424/d172722dex103.htm">Form of Warrant.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7(10)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1217234/000121723421000190/exhibit47.htm">CareDx, Inc. 2019 Inducement Equity Incentive Plan.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cdna-20230331x10qxexx101.htm">CareDx, Inc. Outside Director Compensation Policy, effective April 1, 2023.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cdna-20230331x10xqxexx102.htm">Agreement Regarding Payment of Royalties and Amendment to the Amended and Restated Exclusive License, by and between The Board of Trustees of the Leland Stanford Junior University and the Registrant, entered into on March 29, 2023.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cdna-20230331x10qxexx311.htm">Certification of Periodic Report by Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cdna-20230331x10qxexx312.htm">Certification of Periodic Report by Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="cdna-20230331x10qxexx321.htm">Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Form 10-Q filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on August 28, 2014.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Form 8-K filed with the SEC on June 21, 2021.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Form 8-K filed with the SEC on June 21, 2021.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Form 10-K filed with the SEC on March 31, 2015.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Form 10-Q filed with the SEC on July 29, 2021.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 99(d)(3) to the Registrant's Form SC TO-I filed with the SEC on October 12, 2017.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 4.5 to the Registrant&#8217;s Form S-8 filed with the SEC on July 18, 2014.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 4.5 to the Registrant&#8217;s Form 10-Q filed with the SEC on July 29, 2021.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Form 8-K filed with the SEC on April 14, 2016.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incorporated by reference to Exhibit 4.7 to the Registrant&#8217;s Form 10-Q filed with the SEC on July 29, 2021.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates management contract or compensatory plan or arrangement.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.437%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furnished herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain identified information has been omitted pursuant to Item 601(b)(10) of Regulation S-K because such information is both (i) not material and (ii) information that the Registrant treats as private or confidential. The Registrant hereby undertakes to furnish supplemental copies of the unredacted exhibit upon request by the SEC.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="idd35c15ee381485cb38f052732749537_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#idd35c15ee381485cb38f052732749537_7">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.609%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.080%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAREDX, INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 10, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ REGINALD SEETO, MBBS</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reginald Seeto, MBBS</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ ABHISHEK JAIN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abhishek Jain</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting and Financial Officer)</span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>cdna-20230331x10qxexx101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ifdc941b5b8e64cb69fe44fe884c8d8d5_38"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">CareDx, Inc.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">OUTSIDE DIRECTOR COMPENSATION POLICY</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Most Recently Amended Effective as of April 1, 2023</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CareDx, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#160;believes that the granting of equity and cash compensation to its members of the Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">,&#8221; and members of the Board, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#160;represents an effective tool to attract, retain and reward Directors who are not employees of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Outside Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). This Outside Director Compensation Policy (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#160;is intended to formalize the Company&#8217;s policy regarding cash compensation and grants of equity to its Outside Directors.  Unless otherwise defined herein, capitalized terms used in this Policy will have the meaning given such term in the Company&#8217;s 2014 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). Each Outside Director will be solely responsible for any tax obligations incurred by such Outside Director as a result of the equity and cash payments such Outside Director receives under this Policy.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.75pt;text-decoration:underline">Retainers</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BOARD MEMBERSHIP</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chairman of Board&#58;&#160;&#160;&#160;&#160;$80,000&#160;&#160;&#160;&#160;Annual Retainer</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Outside Directors (including Chairman)&#58;&#160;&#160;&#160;&#160;$45,000&#160;&#160;&#160;&#160;Annual Retainer</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AUDIT &#38; FINANCE COMMITTEE</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Annual compensation for Audit &#38; Finance Committee members is as follows&#58;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chairman of Committee&#58;&#160;&#160;&#160;&#160;$20,000&#160;&#160;&#160;&#160;Annual Retainer</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Committee Members (other than Chairman)&#160;&#160;&#160;&#160;$10,000&#160;&#160;&#160;&#160;Annual Retainer</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">COMPENSATION &#38; HUMAN CAPITAL COMMITTEE</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Annual compensation for the Compensation &#38; Human Capital Committee is as follows&#58;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chairman of Committee&#58;&#160;&#160;&#160;&#160;$15,000&#160;&#160;&#160;&#160;Annual Retainer</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Committee Members (other than Chairman)&#160;&#160;&#160;&#160;$7,500&#160;&#160;&#160;&#160;Annual Retainer</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">GOVERNANCE &#38; NOMINATING COMMITTEE</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Compensation for the Governance &#38; Nominating Committee is as follows&#58;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chairman of Committee&#58;&#160;&#160;&#160;&#160;$10,000&#160;&#160;&#160;&#160;Annual Retainer</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Committee Members (other than Chairman)&#58;&#160;&#160;&#160;&#160;$5,000&#160;&#160;&#160;&#160;Annual Retainer</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SCIENCE &#38; TECHNOLOGY COMMITTEE</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Compensation for the Science &#38; Technology Committee is as follows&#58;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chairman of Committee&#58;&#160;&#160;&#160;&#160;$10,000&#160;&#160;&#160;&#160;Annual Retainer</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Committee Members (other than Chairman)&#58;&#160;&#160;&#160;&#160;$5,000&#160;&#160;&#160;&#160;Annual Retainer</font></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no per meeting attendance fees for attending Board, Audit &#38; Finance Committee, Compensation &#38; Human Capital Committee, Governance &#38; Nominating Committee and&#47;or Science &#38; Technology Committee meetings.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Retainers (other than chairman retainers) will be paid quarterly in arrears on a prorated basis.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The retainers will be paid in shares of Company common stock (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and&#47;or in cash. Each Director can elect the ratio of Shares to cash for the payment of these retainers by notifying the Company in writing (with email notification being sufficient). Such elections will be effective commencing in the first quarter after the quarter in which they are made. For purposes of determining the payment of the retainer, Shares will be valued at the average closing price in the quarter for which the retainer is paid.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.75pt;text-decoration:underline">Equity Compensation</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Outside Directors will be entitled to receive all types of Awards (except Incentive Stock Options)&#160;under the Plan (or the applicable equity plan in place at the time of grant), including discretionary Awards not covered under this Policy. All grants of Awards to Outside Directors pursuant to Section 2&#160;of this Policy will be automatic and nondiscretionary, except as otherwise provided herein, and will be made in accordance with the following provisions&#58;</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">No Discretion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. No person will have any discretion to select which Outside Directors will be granted any Awards&#160;under this Policy or to determine the number of Shares to be covered by such Awards.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Appointment Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to Section 11 of the Plan, upon an Outside Director&#8217;s appointment to the Board, such Outside Director automatically will be granted (i) a Nonstatutory Stock Option to purchase Shares having a grant date fair value of $100,000, rounded down to the nearest whole share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NSO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Appointment Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and (ii) Restricted Stock Units having a grant date fair value of $100,000, rounded down to the nearest whole share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RSU Appointment Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to Section 5 below and Section 14 of the Plan, each NSO Appointment Award will vest in thirty-six (36) equal, monthly installments beginning with the first monthly anniversary after the grant date, and each RSU Appointment Award will vest in three (3), equal, annual installments beginning with the first annual anniversary after the grant date. Each NSO Appointment Award and RSU Appointment Award will vest fully upon a Change in Control (as defined in the Plan), in each case, provided that the Outside Director continues to serve as a Service Provider through the applicable vesting date or Change in Control, as applicable.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Subject to Section 11 of the Plan, on the first business day after each Annual Meeting&#160;of the Company&#8217;s stockholders (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Annual Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) beginning with the 2019 Annual Meeting, each Outside Director automatically will be granted (i) a Nonstatutory Stock Option to purchase Shares having a grant date fair value of $150,000, rounded down to the nearest whole share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Annual NSO Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and (ii) Restricted Stock Units having a grant date fair value of $150,000, rounded down to the nearest whole share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Annual RSU Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to Section 5 below and Section 14 of the Plan, each Annual NSO Award will vest in twelve (12) equal, monthly installments beginning with the first monthly anniversary after the grant date, and each Annual RSU Award will vest in one (1) installment on the one year anniversary of the grant date. Each Annual NSO Award and Annual RSU Award will vest fully upon a Change in Control (as defined in the Plan), in each case, provided that the Outside Director continues to serve as a Service Provider through the applicable vesting date or Change in Control, as applicable.</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Terms Applicable to all Options Granted Under this Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The per Share exercise price for all other Options granted under this Outside Director Compensation Policy will be one hundred percent (100%) of the Fair Market Value on the grant date.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.75pt;text-decoration:underline">Travel Expenses</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each Outside Director&#8217;s reasonable, customary and documented travel expenses to Board meetings will be reimbursed by the Company.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.75pt;text-decoration:underline">Additional Provisions</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All provisions of the Plan not inconsistent with this Policy will apply to Awards granted to Outside Directors.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.75pt;text-decoration:underline">Adjustments</font></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event that any dividend or other distribution (whether in the form of cash, Shares, other securities or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, repurchase, or exchange of Shares or other securities of the Company or other change in the corporate structure of the Company affecting the Shares occurs, the Administrator, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under this Policy, will adjust the number of Shares issuable pursuant to Awards granted under this Policy.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9.75pt;text-decoration:underline">Revisions</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Board in its discretion may change and otherwise revise the terms of Awards granted under this Policy, including, without limitation, the number of Shares subject thereto, for Awards of the same or different type granted on or after the date the Board determines to make any such change or revision. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>cdna-20230331x10xqxexx102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic10e87ea27d84a08a696504ae0be544d_38"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">***Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) information that the Registrant treats as private or confidential. Such omitted information is indicated by brackets (&#8220;&#91;...***...&#93;&#8221;) in this exhibit. ***</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AGREEMENT REGARDING PAYMENT OF ROYALTIES AND AMENDMENT TO THE AMENDED AND RESTATED EXCLUSIVE LICENSE</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Effective the 3rd day of February 2023, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (&#8220;Stanford&#8221;), an institution of higher education having powers under the laws of the State of California, and CareDx, Inc. (&#8220;CareDx&#8221;), a Delaware corporation with an address at 8000 Marine Blvd., Brisbane, California 94005, agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">BACKGROUND</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt">Stanford and ImmuMetrix, Inc. are parties to a January 27, 2014 Amended and Restated Exclusive Agreement (the &#8220;License Agreement&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">CareDx acquired ImmuMetrix, Inc. on June 14, 2014 and assumed ImmuMetrix Inc.&#8217;s rights and obligations under the License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt">In 2019, CareDx initiated litigation against Natera, Inc. and Eurofins Viracor, Inc. in the U.S. District Court for the District of Delaware (Docket Nos. 19-cv-567 and 19-cv-1804) alleging infringement of United States Patent Number 8,703,652, United States Patent Number 9,845,497, and United States Patent Number 10,329,607 (the &#8220;Patents&#8221;) and Stanford was added as necessary party for standing purposes in accordance with the terms of the License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">On September 28, 2021, the District Court granted Natera&#8217;s and Eurofins&#8217; motion for summary judgment, declaring that the Patents were invalid.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt">On July 18, 2022, in Decision 2022-1027, the United States Court of Appeals for the Federal Circuit affirmed the District Court&#8217;s decision and the parties&#8217; petition for reconsideration or an en banc review was denied.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.01pt">On September 8, 2022, CareDx and Stanford entered into a letter agreement entitled &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AGREEMENT REGARDING PAYMENT OF ROYALTIES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">as amended</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (&#8220;Letter Agreement&#8221;) governing the payment and reporting obligations of CareDx during the Litigation, now expired.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">CareDx and Stanford wish to seek </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Supreme Court</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> review of the Federal Circuit&#8217;s July 18, 2022 decision (&#8220;Appeal&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Pursuit of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Supreme Court</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> Appeal And Amendment to the License Agreement</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt">CareDx has instructed the parties&#8217; counsel to seek Supreme Court review of the Federal Circuit&#8217;s decision. CareDx shall be responsible for the legal fees and costs of both parties associated with the initial </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">certiorari</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> petition.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">If the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">cert</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> petition is granted, the parties shall &#91;...***...&#93; all legal fees and costs of both parties incurred in pursuit of the appeal post </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">cert</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> petition &#91;...***...&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt">Subject to compliance with Sections B.1 and B.2 above, until completion of the Supreme Court Review, any licensing payment and reporting obligations by CareDx for Licensed Products sold in the US under the License Agreement shall be suspended and shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">become payable only as expressly set forth in Section B. 5 or 6 below.  The Supreme Court&#8217;s review shall be deemed completed upon a written denial of the petition for </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">cert</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">iorari review or, if the petition is granted, the issuance of a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Supreme Court</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> decision or dismissal of the case as improvidently granted.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">During the pendency of the Supreme Court&#8217;s review, CareDx&#8217;s right to terminate pursuant to Section 15.1 of the License Agreement is suspended.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt">If the Federal Circuit&#8217;s decision is fully reversed or vacated with respect to any of the patents in suit by the Supreme Court, CareDx shall pay a &#91;...***...&#93;% earned royalty on Net Sales of&#58; (a) any Licensed Product that was sold prior to the decision for which no royalty has been paid (&#8220;Past Royalties&#8221;)&#59; and (b) any Licensed Product sold following the Supreme Court&#8217;s decision until the termination of the License Agreement (&#8220;Future Royalties&#8221;).  Payment of earned royalties for Past Royalties will be due &#91;...***...&#93;, and payment for Future Royalties will be made in a manner that is consistent with prior practice under Paragraph 8.1 of the License Agreement.  For purposes of this Agreement and the License Agreement only, CareDx agrees to treat AlloSure products as royalty bearing Licensed Products.  Stanford will not rely on such treatment herein as an admission that they are Licensed Products&#59; however, this does not limit Stanford&#8217;s ability to rely on any other past, present, or future statements, acts, or omissions for such purpose.  This Section applies to CareDx sales globally and to Net Sales of each Licensed Product sold by a sublicensee.  This Section B.5 shall constitute the parties&#8217; entire agreement with respect to earned royalty rate for Future Royalties and the &#91;...***...&#93;% royalty rate may not be further reduced or adjusted unless this Section B.5 is amended in writing by the parties.  For the avoidance of doubt, the newly amended royalty rate shall not result in any adjustment or refund for royalties that were paid prior to the date of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.01pt">If the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">cert</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> petition for review is denied or dismissed, or if the petition is granted but the Supreme Court&#8217;s decision does not fully reverse or vacate with respect to any of the patents in suit&#91;...***...&#93;.  Within &#91;...***...&#93; following &#91;...***...&#93;, CareDx will pay Stanford on Past Royalties in an amount equal to &#91;...***...&#93;% of the earned royalty that would otherwise be owed to Stanford under the License Agreement at &#91;...***...&#93;.  For example, if $&#91;...***...&#93; of earned royalty is owed under the License Agreement at &#91;...***...&#93;, CareDx would only need to pay Stanford $&#91;...***...&#93; upon &#91;...***...&#93;.  &#91;...***...&#93;.  This payment shall constitute the parties&#8217; entire agreement with respect to &#91;...***...&#93; and, upon payment, CareDx shall be released from any further obligation to pay Past Royalties arising out of the Licensing Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">This Agreement may only be terminated upon mutual written agreement of the parties.  The parties hereby acknowledge and agree that the License Agreement is amended as expressly set forth herein.  All terms not defined in this Agreement shall have the meaning set forth in the License Agreement, except as amended or clarified herein.  This Agreement contains the entire understanding of the parties with respect to the matters set forth herein.  In the event of any conflict or inconsistency between the terms of this Agreement, the License Agreement, the Letter Agreement, or any prior letter agreement(s) or amendment thereof between the parties concerning the License Agreement and litigation described herein, the terms set forth in this Agreement shall control.  This Agreement hereby incorporates by reference Sections 16-19 of the License Agreement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">In the event that Stanford enters into negotiations for the rights to the Licensed Patents with third parties, Stanford will notify CareDx.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br><br>In witness hereof, this Agreement is signed by the duly authorized representatives of the parties.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">The Board of Trustees of the Leland Stanford Junior University</font></td><td colspan="3" style="padding:2px 1pt 2px 4.12pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CareDx, Inc.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Sunita Rajdev</font></div><div style="margin-bottom:12pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Sunita Rajdev</font></div><div style="margin-bottom:12pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Director &#8211; Life Sciences, OTL</font></div><div style="margin-bottom:12pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">29-Mar-2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Signature&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Reginald Seeto, MBBS</font></div><div style="margin-bottom:12pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Print Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reginald Seeto, MBBS</font></div><div style="margin-bottom:12pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">President &#38; CEO</font></div><div style="margin-bottom:12pt;padding-left:3.1pt;padding-right:3.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">29-Mar-2023</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>cdna-20230331x10qxexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id94b1531aec045ccbe3a1fdb69879bc3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Reginald Seeto, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form 10-Q of CareDx, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:10pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.474%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 10, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Reginald Seeto, MBBS</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reginald Seeto, MBBS</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>cdna-20230331x10qxexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ifa717720a46d49458719ead1436978e4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Abhishek Jain, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this Quarterly Report on Form 10-Q of CareDx, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:10pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.474%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 10, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Abhishek Jain</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abhishek Jain</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting and Financial Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>cdna-20230331x10qxexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i711991cf01b44faabe86de7a522eabee_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of CareDx, Inc. (the &#8220;Company&#8221;) for the period ended March&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to their knowledge that&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company</font></div><div style="margin-bottom:10pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:3.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.177%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Reginald Seeto, MBBS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Abhishek Jain</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reginald Seeto, MBBS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Abhishek Jain</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Accounting and Financial Officer)</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 10, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May 10, 2023</font></td></tr></table></div><div style="margin-top:10pt;text-indent:36pt"><font><br></font></div><div style="margin-top:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the&#160;Securities&#160;and Exchange Commission or its staff upon request.</font></div><div style="margin-top:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Report, is not deemed filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;),&#160;or&#160;otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>cdna-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:c6b1ad27-1676-415f-b1d2-9124c5a59c19,g:635f8054-df92-419b-85ba-772c4e54710d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cdna="http://www.caredxinc.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.caredxinc.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdna-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdna-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdna-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdna-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.caredxinc.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.caredxinc.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusiness" roleURI="http://www.caredxinc.com/role/OrganizationandDescriptionofBusiness">
        <link:definition>0000008 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.caredxinc.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.caredxinc.com/role/NetLossPerShare">
        <link:definition>0000010 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.caredxinc.com/role/FairValueMeasurements">
        <link:definition>0000011 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandMarketableSecurities" roleURI="http://www.caredxinc.com/role/CashandMarketableSecurities">
        <link:definition>0000012 - Disclosure - Cash and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinations" roleURI="http://www.caredxinc.com/role/BusinessCombinations">
        <link:definition>0000013 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.caredxinc.com/role/GoodwillandIntangibleAssets">
        <link:definition>0000014 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://www.caredxinc.com/role/BalanceSheetComponents">
        <link:definition>0000015 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.caredxinc.com/role/CommitmentsandContingencies">
        <link:definition>0000016 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401KPlan" roleURI="http://www.caredxinc.com/role/A401KPlan">
        <link:definition>0000017 - Disclosure - 401(K) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Warrants" roleURI="http://www.caredxinc.com/role/Warrants">
        <link:definition>0000018 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlans" roleURI="http://www.caredxinc.com/role/StockIncentivePlans">
        <link:definition>0000019 - Disclosure - Stock Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.caredxinc.com/role/IncomeTaxes">
        <link:definition>0000020 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.caredxinc.com/role/SegmentReporting">
        <link:definition>0000021 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.caredxinc.com/role/Restructuring">
        <link:definition>0000022 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.caredxinc.com/role/SubsequentEvents">
        <link:definition>0000023 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000024 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.caredxinc.com/role/NetLossPerShareTables">
        <link:definition>0000025 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.caredxinc.com/role/FairValueMeasurementsTables">
        <link:definition>0000026 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandMarketableSecuritiesTables" roleURI="http://www.caredxinc.com/role/CashandMarketableSecuritiesTables">
        <link:definition>0000027 - Disclosure - Cash and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsTables" roleURI="http://www.caredxinc.com/role/BusinessCombinationsTables">
        <link:definition>0000028 - Disclosure - Business Combinations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>0000029 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://www.caredxinc.com/role/BalanceSheetComponentsTables">
        <link:definition>0000030 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.caredxinc.com/role/CommitmentsandContingenciesTables">
        <link:definition>0000031 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsTables" roleURI="http://www.caredxinc.com/role/WarrantsTables">
        <link:definition>0000032 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansTables" roleURI="http://www.caredxinc.com/role/StockIncentivePlansTables">
        <link:definition>0000033 - Disclosure - Stock Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.caredxinc.com/role/SegmentReportingTables">
        <link:definition>0000034 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusinessAdditionalInformationDetails" roleURI="http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails">
        <link:definition>0000035 - Disclosure - Organization and Description of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" roleURI="http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails">
        <link:definition>0000036 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesLeasesDetails" roleURI="http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails">
        <link:definition>0000037 - Disclosure - Summary of Significant Accounting Policies - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRevenueDetails" roleURI="http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesRevenueDetails">
        <link:definition>0000038 - Disclosure - Summary of Significant Accounting Policies - Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareSummaryofComputationofBasicandDilutedNetLossPerShareDetails" roleURI="http://www.caredxinc.com/role/NetLossPerShareSummaryofComputationofBasicandDilutedNetLossPerShareDetails">
        <link:definition>0000039 - Disclosure - Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromDilutedNetLossPerShareDetails" roleURI="http://www.caredxinc.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromDilutedNetLossPerShareDetails">
        <link:definition>0000040 - Disclosure - Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails" roleURI="http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails">
        <link:definition>0000041 - Disclosure - Fair Value Measurements - Summary of Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofIssuancesExercisesChangesinFairValueandReclassificationsofLevel3FinancialInstrumentsDetails" roleURI="http://www.caredxinc.com/role/FairValueMeasurementsSummaryofIssuancesExercisesChangesinFairValueandReclassificationsofLevel3FinancialInstrumentsDetails">
        <link:definition>0000042 - Disclosure - Fair Value Measurements - Summary of Issuances, Exercises, Changes in Fair Value and Reclassifications of Level 3 Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativesDetails" roleURI="http://www.caredxinc.com/role/FairValueMeasurementsNarrativesDetails">
        <link:definition>0000043 - Disclosure - Fair Value Measurements - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandMarketableSecuritiesReconciliationofCashandCashEquivalentsDetails" roleURI="http://www.caredxinc.com/role/CashandMarketableSecuritiesReconciliationofCashandCashEquivalentsDetails">
        <link:definition>0000044 - Disclosure - Cash and Marketable Securities - Reconciliation of Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails" roleURI="http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails">
        <link:definition>0000045 - Disclosure - Cash and Marketable Securities - Components of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails_1" roleURI="http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails_1">
        <link:definition>0000045 - Disclosure - Cash and Marketable Securities - Components of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandMarketableSecuritiesScheduleofMaturityDetails" roleURI="http://www.caredxinc.com/role/CashandMarketableSecuritiesScheduleofMaturityDetails">
        <link:definition>0000046 - Disclosure - Cash and Marketable Securities - Schedule of Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsAdditionalInformationDetails" roleURI="http://www.caredxinc.com/role/BusinessCombinationsAdditionalInformationDetails">
        <link:definition>0000047 - Disclosure - Business Combinations - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsSummaryofIdentifiedIntangibleAssetsAcquiredatAcquisitionDateDetails" roleURI="http://www.caredxinc.com/role/BusinessCombinationsSummaryofIdentifiedIntangibleAssetsAcquiredatAcquisitionDateDetails">
        <link:definition>0000048 - Disclosure - Business Combinations - Summary of Identified Intangible Assets Acquired at Acquisition Date (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails" roleURI="http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails">
        <link:definition>0000049 - Disclosure - Business Combinations - Summary of Consideration Paid and Provisional Amounts of Assets Acquired and Liabilities Assumed Recognized at Their Estimated Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsAdditionalInformationDetails" roleURI="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails">
        <link:definition>0000050 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails" roleURI="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails">
        <link:definition>0000051 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails_1" roleURI="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails_1">
        <link:definition>0000051 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsSummaryofFiniteLivedIntangibleAssetsAmortizationExpenseDetails" roleURI="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofFiniteLivedIntangibleAssetsAmortizationExpenseDetails">
        <link:definition>0000052 - Disclosure - Goodwill and Intangible Assets - Summary of Finite-Lived Intangible Assets Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails" roleURI="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails">
        <link:definition>0000053 - Disclosure - Goodwill and Intangible Assets - Summary of Estimated Future Amortization Expense of Intangible Assets with Finite Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsSummaryofInventoryDetails" roleURI="http://www.caredxinc.com/role/BalanceSheetComponentsSummaryofInventoryDetails">
        <link:definition>0000054 - Disclosure - Balance Sheet Components - Summary of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails" roleURI="http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails">
        <link:definition>0000055 - Disclosure - Balance Sheet Components - Components of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>0000056 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofLeaseCostDetails" roleURI="http://www.caredxinc.com/role/CommitmentsandContingenciesSummaryofLeaseCostDetails">
        <link:definition>0000057 - Disclosure - Commitments and Contingencies - Summary of Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofOtherInformationRelatedtoLeaseDetails" roleURI="http://www.caredxinc.com/role/CommitmentsandContingenciesSummaryofOtherInformationRelatedtoLeaseDetails">
        <link:definition>0000058 - Disclosure - Commitments and Contingencies - Summary of Other Information Related to Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummarizesROUAssetsandLeaseLiabilitiesforLeaseAgreementsDetails" roleURI="http://www.caredxinc.com/role/CommitmentsandContingenciesSummarizesROUAssetsandLeaseLiabilitiesforLeaseAgreementsDetails">
        <link:definition>0000059 - Disclosure - Commitments and Contingencies - Summarizes ROU Assets and Lease Liabilities for Lease Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails" roleURI="http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails">
        <link:definition>0000060 - Disclosure - Commitments and Contingencies - Future Minimum Lease Commitments under Operating and Finance Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails_1" roleURI="http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails_1">
        <link:definition>0000060 - Disclosure - Commitments and Contingencies - Future Minimum Lease Commitments under Operating and Finance Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummarizestheNoncashInformationDetails" roleURI="http://www.caredxinc.com/role/CommitmentsandContingenciesSummarizestheNoncashInformationDetails">
        <link:definition>0000061 - Disclosure - Commitments and Contingencies - Summarizes the Noncash Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401KPlanAdditionalInformationDetail" roleURI="http://www.caredxinc.com/role/A401KPlanAdditionalInformationDetail">
        <link:definition>0000062 - Disclosure - 401(K) Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsAdditionalInformationDetail" roleURI="http://www.caredxinc.com/role/WarrantsAdditionalInformationDetail">
        <link:definition>0000063 - Disclosure - Warrants - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsOutstandingWarrantsToPurchaseCommonStockWarrantsDetail" roleURI="http://www.caredxinc.com/role/WarrantsOutstandingWarrantsToPurchaseCommonStockWarrantsDetail">
        <link:definition>0000064 - Disclosure - Warrants - Outstanding Warrants To Purchase Common Stock Warrants (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail" roleURI="http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail">
        <link:definition>0000065 - Disclosure - Stock Incentive Plans - Summary of Option, Unvested RSU Activity under 2014 Equity Incentive Plan and 2016 Inducement Equity Incentive Plan and Related Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansAdditionalInformationDetail" roleURI="http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail">
        <link:definition>0000066 - Disclosure - Stock Incentive Plans - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail" roleURI="http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail">
        <link:definition>0000067 - Disclosure - Stock Incentive Plans - Summary of Options Outstanding Vested and Expected to Vest (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansSummaryofWeightedAverageAssumptionsUsedtoEstimatedFairValuesofShareBasedAwardsDetail" roleURI="http://www.caredxinc.com/role/StockIncentivePlansSummaryofWeightedAverageAssumptionsUsedtoEstimatedFairValuesofShareBasedAwardsDetail">
        <link:definition>0000068 - Disclosure - Stock Incentive Plans - Summary of Weighted-Average Assumptions Used to Estimated Fair Values of Share-Based Awards (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockIncentivePlansSummaryofExpenseRelatingtoEmployeeandNonemployeeStockBasedPaymentAwardsfromStockOptionsandRSUsDetail" roleURI="http://www.caredxinc.com/role/StockIncentivePlansSummaryofExpenseRelatingtoEmployeeandNonemployeeStockBasedPaymentAwardsfromStockOptionsandRSUsDetail">
        <link:definition>0000069 - Disclosure - Stock Incentive Plans - Summary of Expense Relating to Employee and Nonemployee Stock-Based Payment Awards from Stock Options and RSUs (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetail" roleURI="http://www.caredxinc.com/role/IncomeTaxesAdditionalInformationDetail">
        <link:definition>0000070 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail" roleURI="http://www.caredxinc.com/role/SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail">
        <link:definition>0000071 - Disclosure - Segment Reporting - Summary of Reportable Revenues by Geographic Regions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSummaryofLongLivedAssetsConsistingofPropertyandEquipmentNetbyGeographicRegionsDetail" roleURI="http://www.caredxinc.com/role/SegmentReportingSummaryofLongLivedAssetsConsistingofPropertyandEquipmentNetbyGeographicRegionsDetail">
        <link:definition>0000072 - Disclosure - Segment Reporting - Summary of Long-Lived Assets Consisting of Property and Equipment, Net by Geographic Regions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringDetails" roleURI="http://www.caredxinc.com/role/RestructuringDetails">
        <link:definition>0000073 - Disclosure - Restructuring (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cdna_DeferredPaymentsForIntangibleAssetsNoncurrent" abstract="false" name="DeferredPaymentsForIntangibleAssetsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm" abstract="false" name="MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_MarketableSecuritiesFairValueLongTerm" abstract="false" name="MarketableSecuritiesFairValueLongTerm" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_AcquiredInProcessTechnologyMember" abstract="true" name="AcquiredInProcessTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_CostOfPatientAndDigitalSolutionsMember" abstract="true" name="CostOfPatientAndDigitalSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cdna_AlloSureKidneyMember" abstract="true" name="AlloSureKidneyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_NumberOfUniqueSolutions" abstract="false" name="NumberOfUniqueSolutions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cdna_AlloMapHeartMember" abstract="true" name="AlloMapHeartMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_CommercializationRightsMember" abstract="true" name="CommercializationRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_CompensatoryDamagesMember" abstract="true" name="CompensatoryDamagesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_PunitiveDamagesMember" abstract="true" name="PunitiveDamagesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_PaymentsToAcquireCapitalExpendituresNet" abstract="false" name="PaymentsToAcquireCapitalExpendituresNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_SaleOfStockCommissionFeePercentage" abstract="false" name="SaleOfStockCommissionFeePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cdna_HLADataSystemsMember" abstract="true" name="HLADataSystemsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_UnsubmittedReimbursementClaimsForMedicare" abstract="false" name="UnsubmittedReimbursementClaimsForMedicare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cdna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_LiquidityPolicyTextBlock" abstract="false" name="LiquidityPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cdna_WarrantFairValueAssumptionsExpectedTerm" abstract="false" name="WarrantFairValueAssumptionsExpectedTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cdna_ShortTermMarketableSecuritiesAbstract" abstract="true" name="ShortTermMarketableSecuritiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cdna_GoodwillAndIntangibleAssetsTable" abstract="true" name="GoodwillAndIntangibleAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cdna_PatientAndDigitalSolutionsMember" abstract="true" name="PatientAndDigitalSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock" abstract="false" name="ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cdna_CommonStockWarrantLiabilityMember" abstract="true" name="CommonStockWarrantLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_LongTermMarketableSecuritiesAbstract" abstract="true" name="LongTermMarketableSecuritiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cdna_IntangibleAssetMeasurementInputRoyaltyRate" abstract="false" name="IntangibleAssetMeasurementInputRoyaltyRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="cdna_LeaseOtherInformationAbstract" abstract="true" name="LeaseOtherInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cdna_ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock" abstract="false" name="ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cdna_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandAndFourteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_AccruedCapitalExpenditures" abstract="false" name="AccruedCapitalExpenditures" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_ContingentConsiderationMember" abstract="true" name="ContingentConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="cdna_AccruedShippingExpenses" abstract="false" name="AccruedShippingExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_GoodwillAndIntangibleAssetsLineItems" abstract="true" name="GoodwillAndIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cdna_FiniteLivedIntangibleForeignCurrencyTranslation" abstract="false" name="FiniteLivedIntangibleForeignCurrencyTranslation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_RemainingOperatingAndFinanceLeaseTerm" abstract="false" name="RemainingOperatingAndFinanceLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cdna_SaleOfStockAuthorizedConsiderationAmountMaximum" abstract="false" name="SaleOfStockAuthorizedConsiderationAmountMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cdna_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm" abstract="false" name="MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_RestOfTheWorldMember" abstract="true" name="RestOfTheWorldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss" abstract="false" name="MarketableSecuritiesAccumulatedUnrecognizedGainLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_AccruedSampleProcessingFees" abstract="false" name="AccruedSampleProcessingFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax" abstract="false" name="EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_WarrantsDisclosureTextBlock" abstract="false" name="WarrantsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cdna_IntangibleAssetMeasurementInputDiscountRate" abstract="false" name="IntangibleAssetMeasurementInputDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="cdna_MiromatrixIncMember" abstract="true" name="MiromatrixIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock" abstract="false" name="ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cdna_MarketableSecuritiesAmortizedCostLongTerm" abstract="false" name="MarketableSecuritiesAmortizedCostLongTerm" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_UnsubmittedClaimsRevenueNotYetRecognized" abstract="false" name="UnsubmittedClaimsRevenueNotYetRecognized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_AccruedClinicalAndCostOfOtherStudiesCurrent" abstract="false" name="AccruedClinicalAndCostOfOtherStudiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits" abstract="false" name="TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_EmployeeAndNonEmployeeStockOptionsMember" abstract="true" name="EmployeeAndNonEmployeeStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_LeasesCommencedInAugust2022Member" abstract="true" name="LeasesCommencedInAugust2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cdna_DeferredPaymentsForIntangibleAssets" abstract="false" name="DeferredPaymentsForIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="cdna_CAREDXINCVsNateraIncMember" abstract="true" name="CAREDXINCVsNateraIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_MarketableSecuritiesAmortizedCost" abstract="false" name="MarketableSecuritiesAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_ScheduleOfIntangibleAssetsTableTableTextBlock" abstract="false" name="ScheduleOfIntangibleAssetsTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cdna_AlloSureHeartMember" abstract="true" name="AlloSureHeartMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" abstract="true" name="EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cdna_AtTheMarketEquityOfferingMember" abstract="true" name="AtTheMarketEquityOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_AccruedLicenseAndOtherCollaborationFees" abstract="false" name="AccruedLicenseAndOtherCollaborationFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_MarketableSecuritiesFairValueShortTerm" abstract="false" name="MarketableSecuritiesFairValueShortTerm" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems" abstract="true" name="ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cdna_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cdna_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cdna_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_NumberOfMilestonePayments" abstract="false" name="NumberOfMilestonePayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cdna_CostOfTestingMember" abstract="true" name="CostOfTestingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_EarningPerShareBasicAndDilutedAbstract" abstract="true" name="EarningPerShareBasicAndDilutedAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cdna_NumberOfWarrantsExercised" abstract="false" name="NumberOfWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cdna_NumberOfRenalTransplantPatients" abstract="false" name="NumberOfRenalTransplantPatients" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_CostOfProductMember" abstract="true" name="CostOfProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_AcquiredAndDevelopedTechnologyMember" abstract="true" name="AcquiredAndDevelopedTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_XynManagementIncMember" abstract="true" name="XynManagementIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_LeasesCommencedInJuly2022Member" abstract="true" name="LeasesCommencedInJuly2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable" abstract="true" name="ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cdna_MarketableSecuritiesAmortizedCostShortTerm" abstract="false" name="MarketableSecuritiesAmortizedCostShortTerm" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdna_CommonStockWarrantLiability" abstract="false" name="CommonStockWarrantLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>cdna-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:c6b1ad27-1676-415f-b1d2-9124c5a59c19,g:635f8054-df92-419b-85ba-772c4e54710d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cdna-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_293add14-01b1-4754-a5d5-81401997f710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_577f72b8-3e7d-447b-93a1-82ae81a9db6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_293add14-01b1-4754-a5d5-81401997f710" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_577f72b8-3e7d-447b-93a1-82ae81a9db6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_cf231ba9-ae1c-4ff2-b17c-4437786787d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_293add14-01b1-4754-a5d5-81401997f710" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_cf231ba9-ae1c-4ff2-b17c-4437786787d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eb2c4efc-c34c-4a43-817b-ae12bc3f6f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_293add14-01b1-4754-a5d5-81401997f710" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eb2c4efc-c34c-4a43-817b-ae12bc3f6f11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f9d56cb2-c8de-4909-ad04-2333a5ad6e25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_293add14-01b1-4754-a5d5-81401997f710" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f9d56cb2-c8de-4909-ad04-2333a5ad6e25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6b4dfd84-7350-428a-9bc8-c8f251c41d09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_293add14-01b1-4754-a5d5-81401997f710" xlink:to="loc_us-gaap_InventoryNet_6b4dfd84-7350-428a-9bc8-c8f251c41d09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e7d47feb-79a8-4428-a83a-af747ec2bbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_809a821b-e512-4877-b02a-1427e00934a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e7d47feb-79a8-4428-a83a-af747ec2bbd5" xlink:to="loc_us-gaap_LiabilitiesCurrent_809a821b-e512-4877-b02a-1427e00934a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_32ee6ea0-a23d-4a38-a8d8-1819aae64d05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e7d47feb-79a8-4428-a83a-af747ec2bbd5" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_32ee6ea0-a23d-4a38-a8d8-1819aae64d05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_DeferredPaymentsForIntangibleAssetsNoncurrent_81cfe9c8-b4e2-4e8e-9b2f-8546a163adcc" xlink:href="cdna-20230331.xsd#cdna_DeferredPaymentsForIntangibleAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e7d47feb-79a8-4428-a83a-af747ec2bbd5" xlink:to="loc_cdna_DeferredPaymentsForIntangibleAssetsNoncurrent_81cfe9c8-b4e2-4e8e-9b2f-8546a163adcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c464b1f0-0c0f-4576-bf89-43af57d6521b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e7d47feb-79a8-4428-a83a-af747ec2bbd5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c464b1f0-0c0f-4576-bf89-43af57d6521b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f428ddba-19de-42bf-899e-afed72c2bf26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e7d47feb-79a8-4428-a83a-af747ec2bbd5" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f428ddba-19de-42bf-899e-afed72c2bf26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d4ef59fb-f41b-4fe9-a908-bc813c234b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8f7bb2ad-1c22-4287-a026-b58777481cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d4ef59fb-f41b-4fe9-a908-bc813c234b9b" xlink:to="loc_us-gaap_PreferredStockValue_8f7bb2ad-1c22-4287-a026-b58777481cff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e49405cc-96e3-4f3d-80a6-56059cf7c82a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d4ef59fb-f41b-4fe9-a908-bc813c234b9b" xlink:to="loc_us-gaap_CommonStockValue_e49405cc-96e3-4f3d-80a6-56059cf7c82a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5093bbab-ae85-4fad-a945-69add35dd173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d4ef59fb-f41b-4fe9-a908-bc813c234b9b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_5093bbab-ae85-4fad-a945-69add35dd173" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b17449a2-2f6e-45c1-98f1-734442fd9f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d4ef59fb-f41b-4fe9-a908-bc813c234b9b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b17449a2-2f6e-45c1-98f1-734442fd9f28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_80ebad42-d897-4482-b050-bc72e0a178a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d4ef59fb-f41b-4fe9-a908-bc813c234b9b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_80ebad42-d897-4482-b050-bc72e0a178a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a6ad0e43-ff81-4029-beca-2e0435d4a17e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_357bea9f-e082-42cc-a5e3-57cca5a3884b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a6ad0e43-ff81-4029-beca-2e0435d4a17e" xlink:to="loc_us-gaap_AccountsPayableCurrent_357bea9f-e082-42cc-a5e3-57cca5a3884b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_efe930a5-1e1d-49a2-94d8-a5f30cf36335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a6ad0e43-ff81-4029-beca-2e0435d4a17e" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_efe930a5-1e1d-49a2-94d8-a5f30cf36335" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_f50a8ab0-b124-4363-bc40-3e4fdd3a98c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a6ad0e43-ff81-4029-beca-2e0435d4a17e" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_f50a8ab0-b124-4363-bc40-3e4fdd3a98c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_73e23956-5419-49e7-a617-f98b42e801b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_dfb4696c-b531-4722-a5ad-3b89e40d292d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_73e23956-5419-49e7-a617-f98b42e801b8" xlink:to="loc_us-gaap_Liabilities_dfb4696c-b531-4722-a5ad-3b89e40d292d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_7903c543-983b-4708-8703-7befb720654a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_73e23956-5419-49e7-a617-f98b42e801b8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_7903c543-983b-4708-8703-7befb720654a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4b2b1645-a532-4cb4-af7c-fe726e9ebbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_73e23956-5419-49e7-a617-f98b42e801b8" xlink:to="loc_us-gaap_StockholdersEquity_4b2b1645-a532-4cb4-af7c-fe726e9ebbb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_10863964-a97f-4516-a92a-7b325f17ba28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0d86724e-2d49-4a04-a171-23675c070dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_10863964-a97f-4516-a92a-7b325f17ba28" xlink:to="loc_us-gaap_AssetsCurrent_0d86724e-2d49-4a04-a171-23675c070dd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5c5f5368-397e-4c77-bfc1-ef5a74ba8d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_10863964-a97f-4516-a92a-7b325f17ba28" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5c5f5368-397e-4c77-bfc1-ef5a74ba8d07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_760ae948-943b-4afe-9ad5-ed7ce8f03ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_10863964-a97f-4516-a92a-7b325f17ba28" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_760ae948-943b-4afe-9ad5-ed7ce8f03ecb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d9c35c0f-27fd-4fb4-a227-b0ce2b3b67f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_10863964-a97f-4516-a92a-7b325f17ba28" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d9c35c0f-27fd-4fb4-a227-b0ce2b3b67f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_699b2e26-d81f-4c21-94d1-5d18d281c419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_10863964-a97f-4516-a92a-7b325f17ba28" xlink:to="loc_us-gaap_Goodwill_699b2e26-d81f-4c21-94d1-5d18d281c419" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_c44b3847-d6c3-4033-afab-91cf6718164b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_10863964-a97f-4516-a92a-7b325f17ba28" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_c44b3847-d6c3-4033-afab-91cf6718164b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_30342f65-14e8-4d6b-9017-6f09b2e11211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_10863964-a97f-4516-a92a-7b325f17ba28" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_30342f65-14e8-4d6b-9017-6f09b2e11211" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cdna-20230331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c4cbb477-17d6-479d-aef3-e5a3c63af948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f5ed3daf-ab2a-44ff-a845-8bdcb13743e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c4cbb477-17d6-479d-aef3-e5a3c63af948" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f5ed3daf-ab2a-44ff-a845-8bdcb13743e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a901d67c-56e4-461c-852c-f57f9729bb46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c4cbb477-17d6-479d-aef3-e5a3c63af948" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a901d67c-56e4-461c-852c-f57f9729bb46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_9020fa28-9272-4bd8-b813-a6e1bdcbc86b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c4cbb477-17d6-479d-aef3-e5a3c63af948" xlink:to="loc_us-gaap_SellingAndMarketingExpense_9020fa28-9272-4bd8-b813-a6e1bdcbc86b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_47121411-83a9-4dff-81ac-0020957f4505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c4cbb477-17d6-479d-aef3-e5a3c63af948" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_47121411-83a9-4dff-81ac-0020957f4505" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e82a67b7-25f2-441d-9d61-c36d4fd85b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1048a74c-3e00-4f31-a375-bd1bdbfa7b27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_e82a67b7-25f2-441d-9d61-c36d4fd85b8d" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_1048a74c-3e00-4f31-a375-bd1bdbfa7b27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7adddccb-9ab1-48cf-a8de-402ce3f5d504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_e82a67b7-25f2-441d-9d61-c36d4fd85b8d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7adddccb-9ab1-48cf-a8de-402ce3f5d504" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_c5d6dc07-fc73-41f6-8886-d9a1680d932b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_e82a67b7-25f2-441d-9d61-c36d4fd85b8d" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_c5d6dc07-fc73-41f6-8886-d9a1680d932b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5790d1d4-1fca-41c6-9a55-d6fdbd1c3888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ee22641f-b1a9-41cc-87cd-cd7dade5d304" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5790d1d4-1fca-41c6-9a55-d6fdbd1c3888" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ee22641f-b1a9-41cc-87cd-cd7dade5d304" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_eb28e6ab-79a4-4257-a8de-97b1a636cf9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5790d1d4-1fca-41c6-9a55-d6fdbd1c3888" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_eb28e6ab-79a4-4257-a8de-97b1a636cf9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4f07d5ed-f5ac-4332-9d17-68956907f2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f0c58262-61cb-42bd-a6e6-08f9f76396c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4f07d5ed-f5ac-4332-9d17-68956907f2b8" xlink:to="loc_us-gaap_OperatingIncomeLoss_f0c58262-61cb-42bd-a6e6-08f9f76396c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_41690efa-a7c0-4d2f-bd67-518d79a7e48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4f07d5ed-f5ac-4332-9d17-68956907f2b8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_41690efa-a7c0-4d2f-bd67-518d79a7e48c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_46f0dc8a-b15b-454a-b624-32fcde722a65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94a9501c-708d-4f1d-bdde-d68400cb4214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_46f0dc8a-b15b-454a-b624-32fcde722a65" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_94a9501c-708d-4f1d-bdde-d68400cb4214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d45e9b10-fa25-43d5-82b9-78a625835620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_46f0dc8a-b15b-454a-b624-32fcde722a65" xlink:to="loc_us-gaap_OperatingExpenses_d45e9b10-fa25-43d5-82b9-78a625835620" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="cdna-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.caredxinc.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5fd8dcbd-9b9e-42b0-81bc-9295242caf18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_02aad91b-ca92-4d74-9f31-37889a2a7293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5fd8dcbd-9b9e-42b0-81bc-9295242caf18" xlink:to="loc_us-gaap_ProfitLoss_02aad91b-ca92-4d74-9f31-37889a2a7293" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6c46e385-2f75-4073-9406-bf6ba5602671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5fd8dcbd-9b9e-42b0-81bc-9295242caf18" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6c46e385-2f75-4073-9406-bf6ba5602671" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cdna-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1eb9ceb7-79f3-4bf9-9c64-a94c3bc280ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_f76f244e-149e-4c8d-905b-74564b983e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1eb9ceb7-79f3-4bf9-9c64-a94c3bc280ac" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_f76f244e-149e-4c8d-905b-74564b983e7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_PaymentsToAcquireCapitalExpendituresNet_beb8ce68-adef-425e-b6e3-53385e7f4f18" xlink:href="cdna-20230331.xsd#cdna_PaymentsToAcquireCapitalExpendituresNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1eb9ceb7-79f3-4bf9-9c64-a94c3bc280ac" xlink:to="loc_cdna_PaymentsToAcquireCapitalExpendituresNet_beb8ce68-adef-425e-b6e3-53385e7f4f18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_0f55eef9-01c0-4eb8-ac9c-98faab54542b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1eb9ceb7-79f3-4bf9-9c64-a94c3bc280ac" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_0f55eef9-01c0-4eb8-ac9c-98faab54542b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_35db4660-ee62-4256-8713-bee0dd6688dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1eb9ceb7-79f3-4bf9-9c64-a94c3bc280ac" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_35db4660-ee62-4256-8713-bee0dd6688dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2a9d2b5c-8a7c-40da-b2be-c034cb8c298d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1eb9ceb7-79f3-4bf9-9c64-a94c3bc280ac" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2a9d2b5c-8a7c-40da-b2be-c034cb8c298d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_8ba3720c-ebe4-4987-bc95-2dbfe48dfffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1eb9ceb7-79f3-4bf9-9c64-a94c3bc280ac" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_8ba3720c-ebe4-4987-bc95-2dbfe48dfffd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_42c123e6-8dc2-4eab-afc6-ee0ef05e776f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9722f4b3-77a3-43df-8057-af544fca4477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_42c123e6-8dc2-4eab-afc6-ee0ef05e776f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9722f4b3-77a3-43df-8057-af544fca4477" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_317983e3-7772-4dd1-aac9-4e466779d5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_42c123e6-8dc2-4eab-afc6-ee0ef05e776f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_317983e3-7772-4dd1-aac9-4e466779d5e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3be28275-b245-4737-a3bb-12f7716fe3ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_42c123e6-8dc2-4eab-afc6-ee0ef05e776f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3be28275-b245-4737-a3bb-12f7716fe3ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0357f65c-a915-4815-bdb8-76a935eaf6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_42c123e6-8dc2-4eab-afc6-ee0ef05e776f" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0357f65c-a915-4815-bdb8-76a935eaf6ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7f4c277-1e99-4ca1-91d9-01c949467354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_77eb5f3b-491d-42f0-8b10-fd4a53e94ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7f4c277-1e99-4ca1-91d9-01c949467354" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_77eb5f3b-491d-42f0-8b10-fd4a53e94ecf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_de2f52a4-81b2-47fb-bb5e-6db8bde578ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7f4c277-1e99-4ca1-91d9-01c949467354" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_de2f52a4-81b2-47fb-bb5e-6db8bde578ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_IncreaseDecreaseInOperatingLeaseLiabilities_2c2eb96a-a9c3-4763-b97b-6d9088fe6c0d" xlink:href="cdna-20230331.xsd#cdna_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7f4c277-1e99-4ca1-91d9-01c949467354" xlink:to="loc_cdna_IncreaseDecreaseInOperatingLeaseLiabilities_2c2eb96a-a9c3-4763-b97b-6d9088fe6c0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_cec6aace-78f5-461a-88c1-b7018d4a2115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7f4c277-1e99-4ca1-91d9-01c949467354" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_cec6aace-78f5-461a-88c1-b7018d4a2115" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_7c62b488-b6bc-4a0b-af0f-df5a02745d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7f4c277-1e99-4ca1-91d9-01c949467354" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_7c62b488-b6bc-4a0b-af0f-df5a02745d5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_dcb8e113-b1bd-412a-abaf-2fd5f7dde645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7f4c277-1e99-4ca1-91d9-01c949467354" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_dcb8e113-b1bd-412a-abaf-2fd5f7dde645" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_14bf8177-4a2c-45a3-9856-d1169fe51d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7f4c277-1e99-4ca1-91d9-01c949467354" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_14bf8177-4a2c-45a3-9856-d1169fe51d46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_e07a996f-90ff-427f-b593-91f9c4be43a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7f4c277-1e99-4ca1-91d9-01c949467354" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_e07a996f-90ff-427f-b593-91f9c4be43a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_09bc0c33-5a4a-4d6e-896a-84d753b355d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7f4c277-1e99-4ca1-91d9-01c949467354" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_09bc0c33-5a4a-4d6e-896a-84d753b355d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_fa677ff1-3aeb-48a6-be95-5487437522dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7f4c277-1e99-4ca1-91d9-01c949467354" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_fa677ff1-3aeb-48a6-be95-5487437522dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_03cf8fda-59fb-499d-b7de-987121503d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7f4c277-1e99-4ca1-91d9-01c949467354" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_03cf8fda-59fb-499d-b7de-987121503d3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_682db252-d29c-4292-b26a-bd07b7f190d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7f4c277-1e99-4ca1-91d9-01c949467354" xlink:to="loc_us-gaap_ShareBasedCompensation_682db252-d29c-4292-b26a-bd07b7f190d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a2adbee9-80d0-4817-a388-c9e723ebc3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7f4c277-1e99-4ca1-91d9-01c949467354" xlink:to="loc_us-gaap_ProfitLoss_a2adbee9-80d0-4817-a388-c9e723ebc3b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_e9d64473-fc78-429b-80b4-b9de813bcfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7f4c277-1e99-4ca1-91d9-01c949467354" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_e9d64473-fc78-429b-80b4-b9de813bcfc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_1d8866b6-dfa0-46e6-b316-5d1936f82f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7f4c277-1e99-4ca1-91d9-01c949467354" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_1d8866b6-dfa0-46e6-b316-5d1936f82f06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_56fce13e-6729-45fe-8774-c6ee1416c715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7f4c277-1e99-4ca1-91d9-01c949467354" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_56fce13e-6729-45fe-8774-c6ee1416c715" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_79ed2f5c-6cc5-45a7-9396-011cd6a2bbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e7f4c277-1e99-4ca1-91d9-01c949467354" xlink:to="loc_us-gaap_AssetImpairmentCharges_79ed2f5c-6cc5-45a7-9396-011cd6a2bbe8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ea52b934-b252-4797-ab2d-c41f1e369b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_d0f97e53-719e-4ad2-89c3-52ae99066377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ea52b934-b252-4797-ab2d-c41f1e369b9c" xlink:to="loc_us-gaap_ProceedsFromStockPlans_d0f97e53-719e-4ad2-89c3-52ae99066377" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits_427447fc-4ef2-4da0-85f1-502ee5059981" xlink:href="cdna-20230331.xsd#cdna_TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ea52b934-b252-4797-ab2d-c41f1e369b9c" xlink:to="loc_cdna_TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits_427447fc-4ef2-4da0-85f1-502ee5059981" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b636e6de-9a3c-4a92-9faf-f220e871090c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ea52b934-b252-4797-ab2d-c41f1e369b9c" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b636e6de-9a3c-4a92-9faf-f220e871090c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ba202937-84de-4afb-8706-aa5ac7fb45c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ea52b934-b252-4797-ab2d-c41f1e369b9c" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ba202937-84de-4afb-8706-aa5ac7fb45c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_382b9a8d-b275-45c4-ae80-46776c76f2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ea52b934-b252-4797-ab2d-c41f1e369b9c" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_382b9a8d-b275-45c4-ae80-46776c76f2ab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f8e15a70-5cff-4ea3-af9a-303323afddbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_fce76261-e2e8-4566-a0ef-02b89b62e38e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f8e15a70-5cff-4ea3-af9a-303323afddbe" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_fce76261-e2e8-4566-a0ef-02b89b62e38e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a983eb6a-250f-4fc9-a82e-7be8d5dbbf6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f8e15a70-5cff-4ea3-af9a-303323afddbe" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a983eb6a-250f-4fc9-a82e-7be8d5dbbf6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_52f075a0-0dc0-4440-9614-1a23d4b5a6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_0dbc4dfb-2697-429b-99e3-46a99a886f58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_52f075a0-0dc0-4440-9614-1a23d4b5a6a3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_0dbc4dfb-2697-429b-99e3-46a99a886f58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5d790f88-2e3a-4ebc-bbf7-ceca8062fe9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_52f075a0-0dc0-4440-9614-1a23d4b5a6a3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_5d790f88-2e3a-4ebc-bbf7-ceca8062fe9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CommonStockWarrantLiability_a53657a9-d543-4a41-b4c0-12b851363256" xlink:href="cdna-20230331.xsd#cdna_CommonStockWarrantLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_52f075a0-0dc0-4440-9614-1a23d4b5a6a3" xlink:to="loc_cdna_CommonStockWarrantLiability_a53657a9-d543-4a41-b4c0-12b851363256" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CashandMarketableSecuritiesReconciliationofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#CashandMarketableSecuritiesReconciliationofCashandCashEquivalentsDetails"/>
  <link:calculationLink xlink:role="http://www.caredxinc.com/role/CashandMarketableSecuritiesReconciliationofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6dc1ef14-2a49-40e4-b7e7-991f16a0eb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8587ccb8-e3f1-45a7-80b3-2b57f07588aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6dc1ef14-2a49-40e4-b7e7-991f16a0eb1d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8587ccb8-e3f1-45a7-80b3-2b57f07588aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_ec5ffa6f-64df-46ec-9d87-976b638141f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6dc1ef14-2a49-40e4-b7e7-991f16a0eb1d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_ec5ffa6f-64df-46ec-9d87-976b638141f9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e7bbf5af-b786-4708-a1d3-f1aadf6b1a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_41bfb9d2-1fdd-4218-b716-b757a64a1172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e7bbf5af-b786-4708-a1d3-f1aadf6b1a8a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_41bfb9d2-1fdd-4218-b716-b757a64a1172" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ac406ff8-21a3-4eb4-852d-2ca603604858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e7bbf5af-b786-4708-a1d3-f1aadf6b1a8a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ac406ff8-21a3-4eb4-852d-2ca603604858" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAmortizedCost_89c0d7ad-10f9-44f9-8a6a-6488558b6a15" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_7f07aa3c-1aea-437d-9693-3f00dcb28fb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cdna_MarketableSecuritiesAmortizedCost_89c0d7ad-10f9-44f9-8a6a-6488558b6a15" xlink:to="loc_us-gaap_MarketableSecurities_7f07aa3c-1aea-437d-9693-3f00dcb28fb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss_44f0f34e-b353-493d-834a-4e8a22bb5b69" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cdna_MarketableSecuritiesAmortizedCost_89c0d7ad-10f9-44f9-8a6a-6488558b6a15" xlink:to="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss_44f0f34e-b353-493d-834a-4e8a22bb5b69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_99b44c59-1397-4c25-8685-56d8495fbfa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_e2fdab3c-2e21-4450-a7e6-51f7527062d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_99b44c59-1397-4c25-8685-56d8495fbfa4" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_e2fdab3c-2e21-4450-a7e6-51f7527062d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax_184306f4-0cbb-47d2-aff5-ad490d5162ba" xlink:href="cdna-20230331.xsd#cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_99b44c59-1397-4c25-8685-56d8495fbfa4" xlink:to="loc_cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax_184306f4-0cbb-47d2-aff5-ad490d5162ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAmortizedCostShortTerm_2828c33f-6961-4d8a-91f9-34443fecc7a1" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAmortizedCostShortTerm"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesFairValueShortTerm_e195f676-62bb-49ee-b500-5d9b26bfe7d2" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesFairValueShortTerm"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cdna_MarketableSecuritiesAmortizedCostShortTerm_2828c33f-6961-4d8a-91f9-34443fecc7a1" xlink:to="loc_cdna_MarketableSecuritiesFairValueShortTerm_e195f676-62bb-49ee-b500-5d9b26bfe7d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm_236c07fe-f4d8-438e-a499-962462192eaa" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cdna_MarketableSecuritiesAmortizedCostShortTerm_2828c33f-6961-4d8a-91f9-34443fecc7a1" xlink:to="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm_236c07fe-f4d8-438e-a499-962462192eaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAmortizedCostLongTerm_18dacf83-a966-441a-9e3a-547f84c0c1d4" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAmortizedCostLongTerm"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm_bc3d81d2-e420-4dc0-9908-15b27902ebb4" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cdna_MarketableSecuritiesAmortizedCostLongTerm_18dacf83-a966-441a-9e3a-547f84c0c1d4" xlink:to="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm_bc3d81d2-e420-4dc0-9908-15b27902ebb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesFairValueLongTerm_20ec13fe-c564-4f58-816d-ba29852a79ac" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesFairValueLongTerm"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cdna_MarketableSecuritiesAmortizedCostLongTerm_18dacf83-a966-441a-9e3a-547f84c0c1d4" xlink:to="loc_cdna_MarketableSecuritiesFairValueLongTerm_20ec13fe-c564-4f58-816d-ba29852a79ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_41e23929-a4de-4f2a-bd33-6992fc0d21ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_8d799297-5274-422b-a6d0-43ba659bc2a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_41e23929-a4de-4f2a-bd33-6992fc0d21ba" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_8d799297-5274-422b-a6d0-43ba659bc2a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_4873cd4d-6499-4960-b787-f015fc0234df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_41e23929-a4de-4f2a-bd33-6992fc0d21ba" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_4873cd4d-6499-4960-b787-f015fc0234df" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails_1" xlink:type="simple" xlink:href="cdna-20230331.xsd#CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_e6bac35a-4ae4-4821-9aec-b15827abe2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_7cd97ef7-03d4-4175-a347-c8bbc853fa7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_e6bac35a-4ae4-4821-9aec-b15827abe2f9" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_7cd97ef7-03d4-4175-a347-c8bbc853fa7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_bf177e07-92c5-4ce7-bcab-ae6a3e40138f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_e6bac35a-4ae4-4821-9aec-b15827abe2f9" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_bf177e07-92c5-4ce7-bcab-ae6a3e40138f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CashandMarketableSecuritiesScheduleofMaturityDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#CashandMarketableSecuritiesScheduleofMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.caredxinc.com/role/CashandMarketableSecuritiesScheduleofMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_4bde3d8e-75d0-400b-8ca8-cc72844020a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_054426f4-f878-4189-bcca-bb0f16455a46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_4bde3d8e-75d0-400b-8ca8-cc72844020a7" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_054426f4-f878-4189-bcca-bb0f16455a46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_41b25314-a376-4117-9099-9b350d965042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_4bde3d8e-75d0-400b-8ca8-cc72844020a7" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_41b25314-a376-4117-9099-9b350d965042" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_21906f4d-09d5-48a3-b835-1f2db2115efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_d3708c20-5506-4200-91aa-061f04f728f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_21906f4d-09d5-48a3-b835-1f2db2115efb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_d3708c20-5506-4200-91aa-061f04f728f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_1cac6bd3-c8f3-4b42-a6ae-c526cdac8e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_21906f4d-09d5-48a3-b835-1f2db2115efb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_1cac6bd3-c8f3-4b42-a6ae-c526cdac8e3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion_9402d0c3-c333-4a45-8ab3-109675560169" xlink:href="cdna-20230331.xsd#cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_21906f4d-09d5-48a3-b835-1f2db2115efb" xlink:to="loc_cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion_9402d0c3-c333-4a45-8ab3-109675560169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_a9901814-8246-4095-b647-b0152f6eb04d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_21906f4d-09d5-48a3-b835-1f2db2115efb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_a9901814-8246-4095-b647-b0152f6eb04d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_bc4b03a8-f71e-4b65-9bfe-03fe3ce4c07c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_21906f4d-09d5-48a3-b835-1f2db2115efb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_bc4b03a8-f71e-4b65-9bfe-03fe3ce4c07c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_a9bdf897-76b9-477a-88ef-9ab544db106b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_21906f4d-09d5-48a3-b835-1f2db2115efb" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_a9bdf897-76b9-477a-88ef-9ab544db106b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_685b9ea9-437e-47a6-b087-d05486e50c15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_b963017a-c61c-4e14-b311-9aaaec94c0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_685b9ea9-437e-47a6-b087-d05486e50c15" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_b963017a-c61c-4e14-b311-9aaaec94c0c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_60ec8fe7-ded5-410b-9578-639521c15a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_685b9ea9-437e-47a6-b087-d05486e50c15" xlink:to="loc_us-gaap_Goodwill_60ec8fe7-ded5-410b-9578-639521c15a15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_cd20380a-af2f-4d62-b2bc-fafc7aab9df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_b9430661-46e0-479b-9815-40a74f7c4528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_cd20380a-af2f-4d62-b2bc-fafc7aab9df9" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_b9430661-46e0-479b-9815-40a74f7c4528" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ee176060-6d01-4804-884f-b7bdbf6c9f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_abc9cc8a-861d-4d54-bdf9-82afe8609274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ee176060-6d01-4804-884f-b7bdbf6c9f9e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_abc9cc8a-861d-4d54-bdf9-82afe8609274" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cfac22e8-4131-4795-ad29-659da1d616cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ee176060-6d01-4804-884f-b7bdbf6c9f9e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cfac22e8-4131-4795-ad29-659da1d616cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a9cd1e6d-4ec6-4865-b55a-0f83dafd18fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a7d20306-7014-42b5-9d96-e807f656045e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a9cd1e6d-4ec6-4865-b55a-0f83dafd18fa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a7d20306-7014-42b5-9d96-e807f656045e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0ce801f5-b1c7-473f-a235-955d38ed3c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a9cd1e6d-4ec6-4865-b55a-0f83dafd18fa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0ce801f5-b1c7-473f-a235-955d38ed3c82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_FiniteLivedIntangibleForeignCurrencyTranslation_9d4dd4fb-28a0-437f-b873-ca1b0e7be1a4" xlink:href="cdna-20230331.xsd#cdna_FiniteLivedIntangibleForeignCurrencyTranslation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a9cd1e6d-4ec6-4865-b55a-0f83dafd18fa" xlink:to="loc_cdna_FiniteLivedIntangibleForeignCurrencyTranslation_9d4dd4fb-28a0-437f-b873-ca1b0e7be1a4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="cdna-20230331.xsd#GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_14369ef7-8016-4022-b85b-03ae3a32860c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a8fdfe4f-7dea-4e2e-ace1-ac1f8292ca2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_14369ef7-8016-4022-b85b-03ae3a32860c" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a8fdfe4f-7dea-4e2e-ace1-ac1f8292ca2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d07d81ab-a012-47e2-9bac-f69b5f314770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_14369ef7-8016-4022-b85b-03ae3a32860c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d07d81ab-a012-47e2-9bac-f69b5f314770" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_FiniteLivedIntangibleForeignCurrencyTranslation_c78f141b-1d23-444b-bbc6-af13eb721ca3" xlink:href="cdna-20230331.xsd#cdna_FiniteLivedIntangibleForeignCurrencyTranslation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_14369ef7-8016-4022-b85b-03ae3a32860c" xlink:to="loc_cdna_FiniteLivedIntangibleForeignCurrencyTranslation_c78f141b-1d23-444b-bbc6-af13eb721ca3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails"/>
  <link:calculationLink xlink:role="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_04a82546-97c2-417e-b6b1-fb4b732b44bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bb31093d-96b6-415b-9f34-a1050421495b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_04a82546-97c2-417e-b6b1-fb4b732b44bd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bb31093d-96b6-415b-9f34-a1050421495b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_639f23a8-a44b-4068-8502-be7c41e89a3e" xlink:href="cdna-20230331.xsd#cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_04a82546-97c2-417e-b6b1-fb4b732b44bd" xlink:to="loc_cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_639f23a8-a44b-4068-8502-be7c41e89a3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_db83df9e-5684-44a9-81eb-32d53a0366b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_04a82546-97c2-417e-b6b1-fb4b732b44bd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_db83df9e-5684-44a9-81eb-32d53a0366b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e2e93820-7284-4796-9741-6f8799921c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_04a82546-97c2-417e-b6b1-fb4b732b44bd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e2e93820-7284-4796-9741-6f8799921c38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e8702af2-98d7-4c38-962e-77a747fa3147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_04a82546-97c2-417e-b6b1-fb4b732b44bd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e8702af2-98d7-4c38-962e-77a747fa3147" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_74f0aac3-360e-4701-9612-46148d99a7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_04a82546-97c2-417e-b6b1-fb4b732b44bd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_74f0aac3-360e-4701-9612-46148d99a7ce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/BalanceSheetComponentsSummaryofInventoryDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#BalanceSheetComponentsSummaryofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.caredxinc.com/role/BalanceSheetComponentsSummaryofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_3056fd3f-0623-4c20-8d72-bd4d3d6bc5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_4a7f7ebd-f197-4b9e-be34-7bcedb45f49e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_3056fd3f-0623-4c20-8d72-bd4d3d6bc5d5" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_4a7f7ebd-f197-4b9e-be34-7bcedb45f49e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_52f236a7-a795-4870-8120-8360e7bebe0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_3056fd3f-0623-4c20-8d72-bd4d3d6bc5d5" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_52f236a7-a795-4870-8120-8360e7bebe0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_6f30e232-078a-40a0-93ef-03e3fd8e6d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_3056fd3f-0623-4c20-8d72-bd4d3d6bc5d5" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_6f30e232-078a-40a0-93ef-03e3fd8e6d7e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_187ff5dc-1095-4254-9e98-5b1ae92b5f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_DeferredPaymentsForIntangibleAssets_b816c526-fe3a-42b8-acb4-12e8c9fdc86b" xlink:href="cdna-20230331.xsd#cdna_DeferredPaymentsForIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_187ff5dc-1095-4254-9e98-5b1ae92b5f7d" xlink:to="loc_cdna_DeferredPaymentsForIntangibleAssets_b816c526-fe3a-42b8-acb4-12e8c9fdc86b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_cc9719c3-0fbe-47d9-bf0a-7835f8f0d815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_187ff5dc-1095-4254-9e98-5b1ae92b5f7d" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_cc9719c3-0fbe-47d9-bf0a-7835f8f0d815" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_60d841dd-7632-48ca-a309-ed6747e20e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_187ff5dc-1095-4254-9e98-5b1ae92b5f7d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_60d841dd-7632-48ca-a309-ed6747e20e62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3543800b-f49b-4505-b776-679b472bec72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_187ff5dc-1095-4254-9e98-5b1ae92b5f7d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3543800b-f49b-4505-b776-679b472bec72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AccruedCapitalExpenditures_5be4b2d9-1886-4061-a860-f1c4edee0338" xlink:href="cdna-20230331.xsd#cdna_AccruedCapitalExpenditures"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_187ff5dc-1095-4254-9e98-5b1ae92b5f7d" xlink:to="loc_cdna_AccruedCapitalExpenditures_5be4b2d9-1886-4061-a860-f1c4edee0338" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AccruedClinicalAndCostOfOtherStudiesCurrent_1bcbda8c-703c-41a2-9a3c-dfa7b29855ed" xlink:href="cdna-20230331.xsd#cdna_AccruedClinicalAndCostOfOtherStudiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_187ff5dc-1095-4254-9e98-5b1ae92b5f7d" xlink:to="loc_cdna_AccruedClinicalAndCostOfOtherStudiesCurrent_1bcbda8c-703c-41a2-9a3c-dfa7b29855ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_04c1236f-9f8a-4723-bc86-95d0629ae674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_187ff5dc-1095-4254-9e98-5b1ae92b5f7d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_04c1236f-9f8a-4723-bc86-95d0629ae674" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7761aa07-c440-4a65-ab15-85a8d4ac6667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_187ff5dc-1095-4254-9e98-5b1ae92b5f7d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7761aa07-c440-4a65-ab15-85a8d4ac6667" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AccruedShippingExpenses_968b085a-8db0-43ae-8705-b7d9de3f31cb" xlink:href="cdna-20230331.xsd#cdna_AccruedShippingExpenses"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_187ff5dc-1095-4254-9e98-5b1ae92b5f7d" xlink:to="loc_cdna_AccruedShippingExpenses_968b085a-8db0-43ae-8705-b7d9de3f31cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AccruedSampleProcessingFees_34661862-a04b-4bfc-9a48-2ae376969adb" xlink:href="cdna-20230331.xsd#cdna_AccruedSampleProcessingFees"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_187ff5dc-1095-4254-9e98-5b1ae92b5f7d" xlink:to="loc_cdna_AccruedSampleProcessingFees_34661862-a04b-4bfc-9a48-2ae376969adb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AccruedLicenseAndOtherCollaborationFees_a915dd76-7589-4218-91bb-017c59f1105e" xlink:href="cdna-20230331.xsd#cdna_AccruedLicenseAndOtherCollaborationFees"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_187ff5dc-1095-4254-9e98-5b1ae92b5f7d" xlink:to="loc_cdna_AccruedLicenseAndOtherCollaborationFees_a915dd76-7589-4218-91bb-017c59f1105e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_ddb96070-a855-48cf-8ce1-fc2b930acdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_187ff5dc-1095-4254-9e98-5b1ae92b5f7d" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_ddb96070-a855-48cf-8ce1-fc2b930acdf8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37438d6a-ed4c-46da-8ea0-6b041b456331" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fa3bae15-e2cc-4a33-aeb9-0ba16493f5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37438d6a-ed4c-46da-8ea0-6b041b456331" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fa3bae15-e2cc-4a33-aeb9-0ba16493f5c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_da4cdf65-2f82-4d5a-ac61-0ad4b95afc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37438d6a-ed4c-46da-8ea0-6b041b456331" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_da4cdf65-2f82-4d5a-ac61-0ad4b95afc4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3db7f87a-d42b-48ef-b2cc-d9a7213161fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37438d6a-ed4c-46da-8ea0-6b041b456331" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3db7f87a-d42b-48ef-b2cc-d9a7213161fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_8a76cac7-af8c-4a12-ae95-36993b135d75" xlink:href="cdna-20230331.xsd#cdna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37438d6a-ed4c-46da-8ea0-6b041b456331" xlink:to="loc_cdna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_8a76cac7-af8c-4a12-ae95-36993b135d75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_df633bc0-42e9-44c9-8baf-59f96b4a1941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37438d6a-ed4c-46da-8ea0-6b041b456331" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_df633bc0-42e9-44c9-8baf-59f96b4a1941" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_797921ec-f24a-4216-a1be-fc8836e14d79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37438d6a-ed4c-46da-8ea0-6b041b456331" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_797921ec-f24a-4216-a1be-fc8836e14d79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bf88ea4a-a6c6-4f80-9dd3-bd2ee7f45b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_507ca702-2e92-4823-989e-3ca3b213e487" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_bf88ea4a-a6c6-4f80-9dd3-bd2ee7f45b97" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_507ca702-2e92-4823-989e-3ca3b213e487" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_18b7cfbf-69d5-4cb9-a302-b75feacb0fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_bf88ea4a-a6c6-4f80-9dd3-bd2ee7f45b97" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_18b7cfbf-69d5-4cb9-a302-b75feacb0fb0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails_1" xlink:type="simple" xlink:href="cdna-20230331.xsd#CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ffe425f0-9c8a-45a6-b643-26460ef6b563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b87fad90-53ac-4905-8b33-a68aca24f8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ffe425f0-9c8a-45a6-b643-26460ef6b563" xlink:to="loc_us-gaap_OperatingLeaseLiability_b87fad90-53ac-4905-8b33-a68aca24f8ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_babf62d9-eb27-4093-b34f-b2a0308a52ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ffe425f0-9c8a-45a6-b643-26460ef6b563" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_babf62d9-eb27-4093-b34f-b2a0308a52ef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail" xlink:type="simple" xlink:href="cdna-20230331.xsd#StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail"/>
  <link:calculationLink xlink:role="http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_3d8bc8ad-b2a5-471c-b1c3-bd9bf75c2292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber_91cbf9f2-c839-49eb-9185-da30f15c92e3" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_3d8bc8ad-b2a5-471c-b1c3-bd9bf75c2292" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber_91cbf9f2-c839-49eb-9185-da30f15c92e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber_e32ade73-8194-4f6a-8ac8-1fc25dab2b08" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_3d8bc8ad-b2a5-471c-b1c3-bd9bf75c2292" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber_e32ade73-8194-4f6a-8ac8-1fc25dab2b08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_bc7edc6f-d474-4698-9d63-c706da3dc260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_148a4db6-63d3-469b-b8fb-c1dda15cfb3a" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_bc7edc6f-d474-4698-9d63-c706da3dc260" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_148a4db6-63d3-469b-b8fb-c1dda15cfb3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue_e72916f7-76d6-4c94-8970-1bae6fc53c92" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_bc7edc6f-d474-4698-9d63-c706da3dc260" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue_e72916f7-76d6-4c94-8970-1bae6fc53c92" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>cdna-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:c6b1ad27-1676-415f-b1d2-9124c5a59c19,g:635f8054-df92-419b-85ba-772c4e54710d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cdna-20230331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="i648b1c52b2b5415a89d756e9287388de_CondensedConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dcab316f-89f4-45aa-980a-92be7bcaa9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_7f1f685d-c62a-4c3e-be08-61e62d24bf6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dcab316f-89f4-45aa-980a-92be7bcaa9be" xlink:to="loc_us-gaap_RevenuesAbstract_7f1f685d-c62a-4c3e-be08-61e62d24bf6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_17efefdb-fc27-4fc9-b2f4-92b0ba5b96b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_7f1f685d-c62a-4c3e-be08-61e62d24bf6b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_17efefdb-fc27-4fc9-b2f4-92b0ba5b96b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ac6cab73-1931-46c0-9e28-eb71254b9dad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dcab316f-89f4-45aa-980a-92be7bcaa9be" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ac6cab73-1931-46c0-9e28-eb71254b9dad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_fdb0f82f-6162-438b-903a-8de51b189c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac6cab73-1931-46c0-9e28-eb71254b9dad" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_fdb0f82f-6162-438b-903a-8de51b189c19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_47615552-af40-4517-ae54-c9ac7257fda5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac6cab73-1931-46c0-9e28-eb71254b9dad" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_47615552-af40-4517-ae54-c9ac7257fda5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_9fc009ed-f3a1-4f56-9353-6dfb87251b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac6cab73-1931-46c0-9e28-eb71254b9dad" xlink:to="loc_us-gaap_SellingAndMarketingExpense_9fc009ed-f3a1-4f56-9353-6dfb87251b8f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0965c95c-26b7-4ed1-aad3-7f9d41e1bdbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac6cab73-1931-46c0-9e28-eb71254b9dad" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0965c95c-26b7-4ed1-aad3-7f9d41e1bdbc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_781c9d3b-a7cb-4306-9441-079cd3cbd53e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac6cab73-1931-46c0-9e28-eb71254b9dad" xlink:to="loc_us-gaap_OperatingExpenses_781c9d3b-a7cb-4306-9441-079cd3cbd53e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c5980a54-ff40-4707-8c4d-4080c2ce83a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dcab316f-89f4-45aa-980a-92be7bcaa9be" xlink:to="loc_us-gaap_OperatingIncomeLoss_c5980a54-ff40-4707-8c4d-4080c2ce83a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_7202c796-7d78-421b-8507-4bed25b7c7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dcab316f-89f4-45aa-980a-92be7bcaa9be" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_7202c796-7d78-421b-8507-4bed25b7c7f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_ab82a076-b06b-425c-a345-7a022f14b93a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_7202c796-7d78-421b-8507-4bed25b7c7f4" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_ab82a076-b06b-425c-a345-7a022f14b93a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_769d0045-eebb-44f9-ae7c-775f8b31a508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_7202c796-7d78-421b-8507-4bed25b7c7f4" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_769d0045-eebb-44f9-ae7c-775f8b31a508" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_80240041-6725-48a8-a48b-f73ad3efb5ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_7202c796-7d78-421b-8507-4bed25b7c7f4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_80240041-6725-48a8-a48b-f73ad3efb5ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_79858f32-31f0-48fa-89f5-5787fe313882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_7202c796-7d78-421b-8507-4bed25b7c7f4" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_79858f32-31f0-48fa-89f5-5787fe313882" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d1ee8e28-4979-42b1-a164-4bea0c57854f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dcab316f-89f4-45aa-980a-92be7bcaa9be" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d1ee8e28-4979-42b1-a164-4bea0c57854f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7183bd9c-22b3-4e78-ac03-a5361ba0eb5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dcab316f-89f4-45aa-980a-92be7bcaa9be" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7183bd9c-22b3-4e78-ac03-a5361ba0eb5c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_91136c42-4de3-4a8e-9f5d-fc905692860a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dcab316f-89f4-45aa-980a-92be7bcaa9be" xlink:to="loc_us-gaap_NetIncomeLoss_91136c42-4de3-4a8e-9f5d-fc905692860a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8cc5d85a-f235-47f6-a109-594d58855a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dcab316f-89f4-45aa-980a-92be7bcaa9be" xlink:to="loc_us-gaap_EarningsPerShareAbstract_8cc5d85a-f235-47f6-a109-594d58855a1c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_47b00ff2-4045-4c0b-93f3-f61f987bdadd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8cc5d85a-f235-47f6-a109-594d58855a1c" xlink:to="loc_us-gaap_EarningsPerShareBasic_47b00ff2-4045-4c0b-93f3-f61f987bdadd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_57a762e2-2c64-4a91-a66c-37a193437d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8cc5d85a-f235-47f6-a109-594d58855a1c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_57a762e2-2c64-4a91-a66c-37a193437d70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_60e14c35-4cb1-42db-9232-10e531712364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dcab316f-89f4-45aa-980a-92be7bcaa9be" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_60e14c35-4cb1-42db-9232-10e531712364" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a759e187-9b18-4f40-b312-29b99e4934e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_60e14c35-4cb1-42db-9232-10e531712364" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a759e187-9b18-4f40-b312-29b99e4934e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4b22a1fd-f110-49a0-a2af-4ff732546a00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_60e14c35-4cb1-42db-9232-10e531712364" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4b22a1fd-f110-49a0-a2af-4ff732546a00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b18fd3da-99ae-4f6d-a906-b02d96cb804b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_dcab316f-89f4-45aa-980a-92be7bcaa9be" xlink:to="loc_us-gaap_StatementTable_b18fd3da-99ae-4f6d-a906-b02d96cb804b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_15289894-5483-4b10-9aab-a9b5a512e8e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b18fd3da-99ae-4f6d-a906-b02d96cb804b" xlink:to="loc_srt_ProductOrServiceAxis_15289894-5483-4b10-9aab-a9b5a512e8e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_15289894-5483-4b10-9aab-a9b5a512e8e5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_15289894-5483-4b10-9aab-a9b5a512e8e5" xlink:to="loc_srt_ProductsAndServicesDomain_15289894-5483-4b10-9aab-a9b5a512e8e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f19ff2c0-2952-4c0d-970d-9a8e8fa96cae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_15289894-5483-4b10-9aab-a9b5a512e8e5" xlink:to="loc_srt_ProductsAndServicesDomain_f19ff2c0-2952-4c0d-970d-9a8e8fa96cae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_d38c358b-4722-4a8a-b5d8-d4a100c4177c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f19ff2c0-2952-4c0d-970d-9a8e8fa96cae" xlink:to="loc_us-gaap_ServiceMember_d38c358b-4722-4a8a-b5d8-d4a100c4177c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_bc69f50d-17c5-4904-89e1-fe4e9d524935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f19ff2c0-2952-4c0d-970d-9a8e8fa96cae" xlink:to="loc_us-gaap_ProductMember_bc69f50d-17c5-4904-89e1-fe4e9d524935" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_PatientAndDigitalSolutionsMember_e4c28d08-fbba-42e8-81a0-a964b6fbdd0f" xlink:href="cdna-20230331.xsd#cdna_PatientAndDigitalSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f19ff2c0-2952-4c0d-970d-9a8e8fa96cae" xlink:to="loc_cdna_PatientAndDigitalSolutionsMember_e4c28d08-fbba-42e8-81a0-a964b6fbdd0f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="cdna-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i6dc55d2553174211aede310936102bc8_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1f3dd0a3-aa26-434f-98e7-85859aeb96e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1f3dd0a3-aa26-434f-98e7-85859aeb96e5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_454e6dfb-4750-4ee5-ab52-a9321f8db088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_SharesOutstanding_454e6dfb-4750-4ee5-ab52-a9321f8db088" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_90be7f5a-4207-422b-9ea2-9631600ca143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_90be7f5a-4207-422b-9ea2-9631600ca143" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_78e2e7e7-086a-41a2-83df-2fd5f6690e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_78e2e7e7-086a-41a2-83df-2fd5f6690e45" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_218a6638-646a-49b5-9e59-019358d04240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_218a6638-646a-49b5-9e59-019358d04240" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_af8f84f6-8754-4069-8a8e-80683b58b8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_af8f84f6-8754-4069-8a8e-80683b58b8d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_85e287da-5273-4e68-ab9b-c487fbaf71fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_85e287da-5273-4e68-ab9b-c487fbaf71fe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_d361c619-d9f2-416c-abd9-f38fae310fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_d361c619-d9f2-416c-abd9-f38fae310fb1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_10898719-18ee-4d55-a6a5-e65d4e2e12e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_10898719-18ee-4d55-a6a5-e65d4e2e12e0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_a3483b18-104e-4da3-9279-9f9cb0d04a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_a3483b18-104e-4da3-9279-9f9cb0d04a2f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_f13d16fb-49da-4863-a52e-0620b6d94e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_f13d16fb-49da-4863-a52e-0620b6d94e5e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11733cdf-7f83-447d-ada6-03dcd03d3d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11733cdf-7f83-447d-ada6-03dcd03d3d3b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_55bb8abe-b4f1-449b-b8c8-7f27f5812693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_55bb8abe-b4f1-449b-b8c8-7f27f5812693" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d0499393-3b20-4bab-a76b-ba93c57d444c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d0499393-3b20-4bab-a76b-ba93c57d444c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c7807b75-598a-448b-ab1f-06a9c803fbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c7807b75-598a-448b-ab1f-06a9c803fbd1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ddbc2022-4456-44cc-b300-744f072606d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_NetIncomeLoss_ddbc2022-4456-44cc-b300-744f072606d5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a4d1a172-2bc9-4718-86aa-cde44109af15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6a634bbd-e65f-41be-bf3e-29c7149b4205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3622ba34-39fe-4f71-b29b-51dba4f13227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1f3dd0a3-aa26-434f-98e7-85859aeb96e5" xlink:to="loc_us-gaap_StatementTable_3622ba34-39fe-4f71-b29b-51dba4f13227" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_054caeeb-3cb4-473a-b993-78d5f09a1030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3622ba34-39fe-4f71-b29b-51dba4f13227" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_054caeeb-3cb4-473a-b993-78d5f09a1030" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_054caeeb-3cb4-473a-b993-78d5f09a1030_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_054caeeb-3cb4-473a-b993-78d5f09a1030" xlink:to="loc_us-gaap_EquityComponentDomain_054caeeb-3cb4-473a-b993-78d5f09a1030_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7e702860-310b-463f-a8b6-1b8c446b4995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_054caeeb-3cb4-473a-b993-78d5f09a1030" xlink:to="loc_us-gaap_EquityComponentDomain_7e702860-310b-463f-a8b6-1b8c446b4995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_91aedcfc-584f-44b7-a0f1-3f38177d875f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7e702860-310b-463f-a8b6-1b8c446b4995" xlink:to="loc_us-gaap_CommonStockMember_91aedcfc-584f-44b7-a0f1-3f38177d875f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8d0f8996-9628-49a3-9813-a63a292dc956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7e702860-310b-463f-a8b6-1b8c446b4995" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8d0f8996-9628-49a3-9813-a63a292dc956" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cb1d0592-f61c-41c9-914f-e7eed9cfc0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7e702860-310b-463f-a8b6-1b8c446b4995" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cb1d0592-f61c-41c9-914f-e7eed9cfc0d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_752357a0-2c4a-4cae-a642-9ff9647b5d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7e702860-310b-463f-a8b6-1b8c446b4995" xlink:to="loc_us-gaap_RetainedEarningsMember_752357a0-2c4a-4cae-a642-9ff9647b5d64" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#OrganizationandDescriptionofBusinessAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails" xlink:type="extended" id="i4d27461fe26d4ba29b6e44f368bf8ca2_OrganizationandDescriptionofBusinessAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_571d8f3d-f225-41dc-b9b0-7ff2a289a3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_571d8f3d-f225-41dc-b9b0-7ff2a289a3ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_UnsubmittedReimbursementClaimsForMedicare_0d806d42-fd03-40bd-ad61-dd2a49c58a39" xlink:href="cdna-20230331.xsd#cdna_UnsubmittedReimbursementClaimsForMedicare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_cdna_UnsubmittedReimbursementClaimsForMedicare_0d806d42-fd03-40bd-ad61-dd2a49c58a39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_UnsubmittedClaimsRevenueNotYetRecognized_9ccd0bb7-d10f-4b58-9d50-596247077909" xlink:href="cdna-20230331.xsd#cdna_UnsubmittedClaimsRevenueNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_cdna_UnsubmittedClaimsRevenueNotYetRecognized_9ccd0bb7-d10f-4b58-9d50-596247077909" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_83be88bb-c4ad-459e-8f9a-befcb6240913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_83be88bb-c4ad-459e-8f9a-befcb6240913" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_NumberOfRenalTransplantPatients_60d6cae7-7e97-41a1-bb1e-8ab744ef25f2" xlink:href="cdna-20230331.xsd#cdna_NumberOfRenalTransplantPatients"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_cdna_NumberOfRenalTransplantPatients_60d6cae7-7e97-41a1-bb1e-8ab744ef25f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_NumberOfUniqueSolutions_7a2b3fe5-2419-4069-bc29-53a900998c06" xlink:href="cdna-20230331.xsd#cdna_NumberOfUniqueSolutions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_cdna_NumberOfUniqueSolutions_7a2b3fe5-2419-4069-bc29-53a900998c06" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aef5ce3c-f72d-4d12-8d3a-1f25fb69a354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aef5ce3c-f72d-4d12-8d3a-1f25fb69a354" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_0335629c-0450-4639-b166-883ff9067561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_0335629c-0450-4639-b166-883ff9067561" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_SaleOfStockAuthorizedConsiderationAmountMaximum_a2126461-6aa6-466e-90b7-287a0b01da7c" xlink:href="cdna-20230331.xsd#cdna_SaleOfStockAuthorizedConsiderationAmountMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_cdna_SaleOfStockAuthorizedConsiderationAmountMaximum_a2126461-6aa6-466e-90b7-287a0b01da7c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_SaleOfStockCommissionFeePercentage_22a6ddae-9acb-4fa7-9ffd-67777f9c5824" xlink:href="cdna-20230331.xsd#cdna_SaleOfStockCommissionFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_cdna_SaleOfStockCommissionFeePercentage_22a6ddae-9acb-4fa7-9ffd-67777f9c5824" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d9ded15a-c006-4386-ae99-2e57409d99d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d9ded15a-c006-4386-ae99-2e57409d99d5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_8c0547b3-1137-4d84-a008-dc2776fb6270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_8c0547b3-1137-4d84-a008-dc2776fb6270" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_ff053e52-0e75-49f1-8582-e54f39af3f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_ff053e52-0e75-49f1-8582-e54f39af3f1a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_d54f552f-6410-4671-9d99-b1bd890692ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_d54f552f-6410-4671-9d99-b1bd890692ab" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_9b21a844-60b9-4671-818f-c448a48a3fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_9b21a844-60b9-4671-818f-c448a48a3fc0" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_d3c47791-e74e-41ec-91a6-62a58d8cd0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityTable_d3c47791-e74e-41ec-91a6-62a58d8cd0b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a4377ab4-822c-43ea-9b68-0b91b5d1e1c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_d3c47791-e74e-41ec-91a6-62a58d8cd0b7" xlink:to="loc_srt_MajorCustomersAxis_a4377ab4-822c-43ea-9b68-0b91b5d1e1c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a4377ab4-822c-43ea-9b68-0b91b5d1e1c7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_a4377ab4-822c-43ea-9b68-0b91b5d1e1c7" xlink:to="loc_srt_NameOfMajorCustomerDomain_a4377ab4-822c-43ea-9b68-0b91b5d1e1c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f38ce9ba-6278-45fb-a76b-78d0ca0c9748" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_a4377ab4-822c-43ea-9b68-0b91b5d1e1c7" xlink:to="loc_srt_NameOfMajorCustomerDomain_f38ce9ba-6278-45fb-a76b-78d0ca0c9748" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MedicareMember_0ff6b058-d846-4106-bc6f-9cfa7952389c" xlink:href="cdna-20230331.xsd#cdna_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f38ce9ba-6278-45fb-a76b-78d0ca0c9748" xlink:to="loc_cdna_MedicareMember_0ff6b058-d846-4106-bc6f-9cfa7952389c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3e6ca906-2827-4632-b08f-a11d9c7871b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_d3c47791-e74e-41ec-91a6-62a58d8cd0b7" xlink:to="loc_srt_ProductOrServiceAxis_3e6ca906-2827-4632-b08f-a11d9c7871b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3e6ca906-2827-4632-b08f-a11d9c7871b9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3e6ca906-2827-4632-b08f-a11d9c7871b9" xlink:to="loc_srt_ProductsAndServicesDomain_3e6ca906-2827-4632-b08f-a11d9c7871b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_040dbd97-7a64-4422-9467-ab61ef2651dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3e6ca906-2827-4632-b08f-a11d9c7871b9" xlink:to="loc_srt_ProductsAndServicesDomain_040dbd97-7a64-4422-9467-ab61ef2651dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AlloSureKidneyMember_a94018c7-c492-4a91-8405-c2d8639a46a1" xlink:href="cdna-20230331.xsd#cdna_AlloSureKidneyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_040dbd97-7a64-4422-9467-ab61ef2651dd" xlink:to="loc_cdna_AlloSureKidneyMember_a94018c7-c492-4a91-8405-c2d8639a46a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AlloMapHeartMember_ad73bb69-8cd6-4f8a-afeb-9545a24880de" xlink:href="cdna-20230331.xsd#cdna_AlloMapHeartMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_040dbd97-7a64-4422-9467-ab61ef2651dd" xlink:to="loc_cdna_AlloMapHeartMember_ad73bb69-8cd6-4f8a-afeb-9545a24880de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AlloSureHeartMember_9bd029b4-4dfa-44be-9078-d2af772eabf2" xlink:href="cdna-20230331.xsd#cdna_AlloSureHeartMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_040dbd97-7a64-4422-9467-ab61ef2651dd" xlink:to="loc_cdna_AlloSureHeartMember_9bd029b4-4dfa-44be-9078-d2af772eabf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7b40e4b3-30cb-49e1-b448-5685143b9eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_d3c47791-e74e-41ec-91a6-62a58d8cd0b7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7b40e4b3-30cb-49e1-b448-5685143b9eb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7b40e4b3-30cb-49e1-b448-5685143b9eb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7b40e4b3-30cb-49e1-b448-5685143b9eb4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7b40e4b3-30cb-49e1-b448-5685143b9eb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_74d8cae8-e01f-4dc8-ab64-289530e00129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7b40e4b3-30cb-49e1-b448-5685143b9eb4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_74d8cae8-e01f-4dc8-ab64-289530e00129" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_XynManagementIncMember_4af252b1-1a0c-4493-8ee9-32ff8328d51c" xlink:href="cdna-20230331.xsd#cdna_XynManagementIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_74d8cae8-e01f-4dc8-ab64-289530e00129" xlink:to="loc_cdna_XynManagementIncMember_4af252b1-1a0c-4493-8ee9-32ff8328d51c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c5e7a445-7c7b-4841-b5e4-8ec7ebdd4320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_d3c47791-e74e-41ec-91a6-62a58d8cd0b7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c5e7a445-7c7b-4841-b5e4-8ec7ebdd4320" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c5e7a445-7c7b-4841-b5e4-8ec7ebdd4320_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c5e7a445-7c7b-4841-b5e4-8ec7ebdd4320" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c5e7a445-7c7b-4841-b5e4-8ec7ebdd4320_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d8d26f9-8bba-4c77-9194-be48da561e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c5e7a445-7c7b-4841-b5e4-8ec7ebdd4320" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d8d26f9-8bba-4c77-9194-be48da561e21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AtTheMarketEquityOfferingMember_0f7be3e9-eb6c-47c6-8c69-10eb0199d7f9" xlink:href="cdna-20230331.xsd#cdna_AtTheMarketEquityOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d8d26f9-8bba-4c77-9194-be48da561e21" xlink:to="loc_cdna_AtTheMarketEquityOfferingMember_0f7be3e9-eb6c-47c6-8c69-10eb0199d7f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_64bcf084-70b0-4bc7-9ebe-8a5d1c362729" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_d3c47791-e74e-41ec-91a6-62a58d8cd0b7" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_64bcf084-70b0-4bc7-9ebe-8a5d1c362729" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_64bcf084-70b0-4bc7-9ebe-8a5d1c362729_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_64bcf084-70b0-4bc7-9ebe-8a5d1c362729" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_64bcf084-70b0-4bc7-9ebe-8a5d1c362729_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6cfffd0d-0ef3-46c9-a990-427b7654f2e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_64bcf084-70b0-4bc7-9ebe-8a5d1c362729" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6cfffd0d-0ef3-46c9-a990-427b7654f2e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MiromatrixIncMember_8a55883f-6444-48ca-aba8-d15bf41e9250" xlink:href="cdna-20230331.xsd#cdna_MiromatrixIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6cfffd0d-0ef3-46c9-a990-427b7654f2e8" xlink:to="loc_cdna_MiromatrixIncMember_8a55883f-6444-48ca-aba8-d15bf41e9250" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" xlink:type="extended" id="i087edf1129be450b9f66395e0046e87b_SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_d9dd65fa-6c84-4710-9a8a-6b9ce84c9b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_85a63de4-fede-4a94-8a12-df9a449636b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_d9dd65fa-6c84-4710-9a8a-6b9ce84c9b89" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_85a63de4-fede-4a94-8a12-df9a449636b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_3cde6d56-948c-456f-aa19-722034f25691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_d9dd65fa-6c84-4710-9a8a-6b9ce84c9b89" xlink:to="loc_us-gaap_ConcentrationRiskTable_3cde6d56-948c-456f-aa19-722034f25691" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_de450d9c-277d-4bfb-bcfa-036dde8330ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_3cde6d56-948c-456f-aa19-722034f25691" xlink:to="loc_srt_MajorCustomersAxis_de450d9c-277d-4bfb-bcfa-036dde8330ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_de450d9c-277d-4bfb-bcfa-036dde8330ca_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_de450d9c-277d-4bfb-bcfa-036dde8330ca" xlink:to="loc_srt_NameOfMajorCustomerDomain_de450d9c-277d-4bfb-bcfa-036dde8330ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b5c13d3c-8c70-453e-8fcb-94354e5a63cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_de450d9c-277d-4bfb-bcfa-036dde8330ca" xlink:to="loc_srt_NameOfMajorCustomerDomain_b5c13d3c-8c70-453e-8fcb-94354e5a63cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MedicareMember_e6d5080c-5866-4c2f-8a49-0af9dfff2415" xlink:href="cdna-20230331.xsd#cdna_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b5c13d3c-8c70-453e-8fcb-94354e5a63cc" xlink:to="loc_cdna_MedicareMember_e6d5080c-5866-4c2f-8a49-0af9dfff2415" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1d2cf9ee-f562-411a-b025-991b0dd5911f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_3cde6d56-948c-456f-aa19-722034f25691" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1d2cf9ee-f562-411a-b025-991b0dd5911f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1d2cf9ee-f562-411a-b025-991b0dd5911f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1d2cf9ee-f562-411a-b025-991b0dd5911f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1d2cf9ee-f562-411a-b025-991b0dd5911f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_29d72715-2d9a-48c0-9ea4-0c1c2619a7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1d2cf9ee-f562-411a-b025-991b0dd5911f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_29d72715-2d9a-48c0-9ea4-0c1c2619a7bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_a1412ffc-34fa-4215-ac0d-2fcd7fcc6185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_29d72715-2d9a-48c0-9ea4-0c1c2619a7bd" xlink:to="loc_us-gaap_SalesRevenueNetMember_a1412ffc-34fa-4215-ac0d-2fcd7fcc6185" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_7f3035e9-ef4a-4d35-bf37-1fe97a55415d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_29d72715-2d9a-48c0-9ea4-0c1c2619a7bd" xlink:to="loc_us-gaap_AccountsReceivableMember_7f3035e9-ef4a-4d35-bf37-1fe97a55415d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c3b6678a-39fd-4927-a2d9-e8c7bcadcf1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_3cde6d56-948c-456f-aa19-722034f25691" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c3b6678a-39fd-4927-a2d9-e8c7bcadcf1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c3b6678a-39fd-4927-a2d9-e8c7bcadcf1c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c3b6678a-39fd-4927-a2d9-e8c7bcadcf1c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c3b6678a-39fd-4927-a2d9-e8c7bcadcf1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e301355d-edb3-4f1b-8eee-dddaeda268f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c3b6678a-39fd-4927-a2d9-e8c7bcadcf1c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e301355d-edb3-4f1b-8eee-dddaeda268f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a61c1f1c-c124-4414-a5a6-f588f86d1871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e301355d-edb3-4f1b-8eee-dddaeda268f5" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a61c1f1c-c124-4414-a5a6-f588f86d1871" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_9e8ff09e-438a-4328-b5ca-236bc2afc15c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e301355d-edb3-4f1b-8eee-dddaeda268f5" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_9e8ff09e-438a-4328-b5ca-236bc2afc15c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#SummaryofSignificantAccountingPoliciesLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="extended" id="i164432bbb6114a41aaeefbb0a609e327_SummaryofSignificantAccountingPoliciesLeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_cdna_SummaryOfSignificantAccountingPoliciesLineItems_85f6f96e-ea67-49a0-9551-fd94e03a9256" xlink:href="cdna-20230331.xsd#cdna_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_RemainingOperatingAndFinanceLeaseTerm_efc01c0c-6244-438e-9186-75252887daec" xlink:href="cdna-20230331.xsd#cdna_RemainingOperatingAndFinanceLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_SummaryOfSignificantAccountingPoliciesLineItems_85f6f96e-ea67-49a0-9551-fd94e03a9256" xlink:to="loc_cdna_RemainingOperatingAndFinanceLeaseTerm_efc01c0c-6244-438e-9186-75252887daec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_SummaryOfSignificantAccountingPoliciesTable_28e0ac96-3f5c-4809-861c-10337c825fcf" xlink:href="cdna-20230331.xsd#cdna_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cdna_SummaryOfSignificantAccountingPoliciesLineItems_85f6f96e-ea67-49a0-9551-fd94e03a9256" xlink:to="loc_cdna_SummaryOfSignificantAccountingPoliciesTable_28e0ac96-3f5c-4809-861c-10337c825fcf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8c310c8c-ad9b-4c64-a989-ccdc6a80773a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cdna_SummaryOfSignificantAccountingPoliciesTable_28e0ac96-3f5c-4809-861c-10337c825fcf" xlink:to="loc_srt_RangeAxis_8c310c8c-ad9b-4c64-a989-ccdc6a80773a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8c310c8c-ad9b-4c64-a989-ccdc6a80773a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8c310c8c-ad9b-4c64-a989-ccdc6a80773a" xlink:to="loc_srt_RangeMember_8c310c8c-ad9b-4c64-a989-ccdc6a80773a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f278457f-e256-410d-9076-124826f38814" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8c310c8c-ad9b-4c64-a989-ccdc6a80773a" xlink:to="loc_srt_RangeMember_f278457f-e256-410d-9076-124826f38814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_70de0d38-7a5e-4805-9e91-fc36ee9181e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f278457f-e256-410d-9076-124826f38814" xlink:to="loc_srt_MinimumMember_70de0d38-7a5e-4805-9e91-fc36ee9181e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1955ae03-7486-4950-931c-a7ffef1dff0d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f278457f-e256-410d-9076-124826f38814" xlink:to="loc_srt_MaximumMember_1955ae03-7486-4950-931c-a7ffef1dff0d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromDilutedNetLossPerShareDetails" xlink:type="extended" id="i001938ca4b1f425dbdec67a1a36b8990_NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_10b1c728-4fe8-4045-8cc7-594700e5c4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f4e466e8-3dba-4e25-b807-533f6d4f02a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_10b1c728-4fe8-4045-8cc7-594700e5c4a4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f4e466e8-3dba-4e25-b807-533f6d4f02a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f6f803e1-e26c-4085-9e4c-9ec340873d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_10b1c728-4fe8-4045-8cc7-594700e5c4a4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f6f803e1-e26c-4085-9e4c-9ec340873d2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ed9d7b9f-9c34-4e30-99f5-2d1c0bcc423c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f6f803e1-e26c-4085-9e4c-9ec340873d2d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ed9d7b9f-9c34-4e30-99f5-2d1c0bcc423c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ed9d7b9f-9c34-4e30-99f5-2d1c0bcc423c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ed9d7b9f-9c34-4e30-99f5-2d1c0bcc423c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ed9d7b9f-9c34-4e30-99f5-2d1c0bcc423c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e01c062a-93e9-49ff-805d-b4e1024d3f47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ed9d7b9f-9c34-4e30-99f5-2d1c0bcc423c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e01c062a-93e9-49ff-805d-b4e1024d3f47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_EmployeeAndNonEmployeeStockOptionsMember_1631e450-ca69-4dcc-8893-83013983319c" xlink:href="cdna-20230331.xsd#cdna_EmployeeAndNonEmployeeStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e01c062a-93e9-49ff-805d-b4e1024d3f47" xlink:to="loc_cdna_EmployeeAndNonEmployeeStockOptionsMember_1631e450-ca69-4dcc-8893-83013983319c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_fe75e45e-3f21-44e6-b72b-85d54890c9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e01c062a-93e9-49ff-805d-b4e1024d3f47" xlink:to="loc_us-gaap_WarrantMember_fe75e45e-3f21-44e6-b72b-85d54890c9c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fd895a6b-9750-4b13-98b4-ca97e0d5476f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e01c062a-93e9-49ff-805d-b4e1024d3f47" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fd895a6b-9750-4b13-98b4-ca97e0d5476f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended" id="i4156873d723b4c629fff97a38ef41a89_FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_164d727d-04a1-452a-9141-c27979ac01f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_53e7c6df-d9d0-4271-a8a7-3128229a056e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_164d727d-04a1-452a-9141-c27979ac01f9" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_53e7c6df-d9d0-4271-a8a7-3128229a056e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5c912982-3bf2-4e4c-bef4-f3ee03dd390a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_53e7c6df-d9d0-4271-a8a7-3128229a056e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5c912982-3bf2-4e4c-bef4-f3ee03dd390a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_81a3dd10-d51d-4293-83e0-2a3653b03265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_53e7c6df-d9d0-4271-a8a7-3128229a056e" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_81a3dd10-d51d-4293-83e0-2a3653b03265" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f4957524-134e-4880-87b2-4ff39fb916fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_53e7c6df-d9d0-4271-a8a7-3128229a056e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_f4957524-134e-4880-87b2-4ff39fb916fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_76e2b776-61c6-41eb-9b4a-5afdf4d7e42e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_164d727d-04a1-452a-9141-c27979ac01f9" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_76e2b776-61c6-41eb-9b4a-5afdf4d7e42e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_313a5f80-fe33-476f-b02f-043e6ab78c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_76e2b776-61c6-41eb-9b4a-5afdf4d7e42e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_313a5f80-fe33-476f-b02f-043e6ab78c19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_202e16a2-6afd-4e68-a07b-74441d79a3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_313a5f80-fe33-476f-b02f-043e6ab78c19" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_202e16a2-6afd-4e68-a07b-74441d79a3ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_5c2313b3-c26c-4e82-9885-c2b88aa08406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_76e2b776-61c6-41eb-9b4a-5afdf4d7e42e" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_5c2313b3-c26c-4e82-9885-c2b88aa08406" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8cc45c4d-1272-4895-845d-dfc4d66eca0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5c2313b3-c26c-4e82-9885-c2b88aa08406" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8cc45c4d-1272-4895-845d-dfc4d66eca0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CommonStockWarrantLiability_432afe5b-f8d8-4de0-89e4-f9b8524cd885" xlink:href="cdna-20230331.xsd#cdna_CommonStockWarrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5c2313b3-c26c-4e82-9885-c2b88aa08406" xlink:to="loc_cdna_CommonStockWarrantLiability_432afe5b-f8d8-4de0-89e4-f9b8524cd885" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_0b61b1f4-efe1-4acc-b6a4-bffacb9239ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_76e2b776-61c6-41eb-9b4a-5afdf4d7e42e" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_0b61b1f4-efe1-4acc-b6a4-bffacb9239ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83790f60-aa87-40f9-982a-87830a113077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_164d727d-04a1-452a-9141-c27979ac01f9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83790f60-aa87-40f9-982a-87830a113077" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c08f8d48-4419-4537-b690-539960ac78c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83790f60-aa87-40f9-982a-87830a113077" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c08f8d48-4419-4537-b690-539960ac78c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c08f8d48-4419-4537-b690-539960ac78c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c08f8d48-4419-4537-b690-539960ac78c3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c08f8d48-4419-4537-b690-539960ac78c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a627bd18-cc88-4edb-b392-2884a9c99089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c08f8d48-4419-4537-b690-539960ac78c3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a627bd18-cc88-4edb-b392-2884a9c99089" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d5258e08-4f1e-4300-acef-5e9ee8a23f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a627bd18-cc88-4edb-b392-2884a9c99089" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d5258e08-4f1e-4300-acef-5e9ee8a23f24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8ec38e1c-2492-458f-99a7-97eb23cb176a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a627bd18-cc88-4edb-b392-2884a9c99089" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8ec38e1c-2492-458f-99a7-97eb23cb176a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_751b6b57-fa08-4291-9aee-226d3a2fdf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a627bd18-cc88-4edb-b392-2884a9c99089" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_751b6b57-fa08-4291-9aee-226d3a2fdf8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8b339871-8f27-480b-a605-82fa1b240e39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83790f60-aa87-40f9-982a-87830a113077" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8b339871-8f27-480b-a605-82fa1b240e39" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8b339871-8f27-480b-a605-82fa1b240e39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8b339871-8f27-480b-a605-82fa1b240e39" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8b339871-8f27-480b-a605-82fa1b240e39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_649f27af-859a-4e59-9b2a-116b40056177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8b339871-8f27-480b-a605-82fa1b240e39" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_649f27af-859a-4e59-9b2a-116b40056177" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2428f421-57f1-43bc-ba2e-525be111affc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_649f27af-859a-4e59-9b2a-116b40056177" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2428f421-57f1-43bc-ba2e-525be111affc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_67ba7eab-a3f3-4060-b063-a1c5933b01d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83790f60-aa87-40f9-982a-87830a113077" xlink:to="loc_us-gaap_FinancialInstrumentAxis_67ba7eab-a3f3-4060-b063-a1c5933b01d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_67ba7eab-a3f3-4060-b063-a1c5933b01d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_67ba7eab-a3f3-4060-b063-a1c5933b01d6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_67ba7eab-a3f3-4060-b063-a1c5933b01d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2404f045-3155-4d6a-8c87-bf78697a160b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_67ba7eab-a3f3-4060-b063-a1c5933b01d6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2404f045-3155-4d6a-8c87-bf78697a160b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0e4b2562-422d-4df5-bae5-a3ccfc55382e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2404f045-3155-4d6a-8c87-bf78697a160b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0e4b2562-422d-4df5-bae5-a3ccfc55382e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_efe6a295-b459-494e-b643-21ddfa3b4216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2404f045-3155-4d6a-8c87-bf78697a160b" xlink:to="loc_us-gaap_EquitySecuritiesMember_efe6a295-b459-494e-b643-21ddfa3b4216" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/FairValueMeasurementsSummaryofIssuancesExercisesChangesinFairValueandReclassificationsofLevel3FinancialInstrumentsDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#FairValueMeasurementsSummaryofIssuancesExercisesChangesinFairValueandReclassificationsofLevel3FinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/FairValueMeasurementsSummaryofIssuancesExercisesChangesinFairValueandReclassificationsofLevel3FinancialInstrumentsDetails" xlink:type="extended" id="ia35df6325add4cc2a55f150c8e02bef7_FairValueMeasurementsSummaryofIssuancesExercisesChangesinFairValueandReclassificationsofLevel3FinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_21bbc028-abbc-4c0b-933e-9b915ca92839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_efad9ce7-16dc-4dee-9599-175f98e78f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_21bbc028-abbc-4c0b-933e-9b915ca92839" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_efad9ce7-16dc-4dee-9599-175f98e78f6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1bad8840-3847-4db5-9aea-2519b8047e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_efad9ce7-16dc-4dee-9599-175f98e78f6a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1bad8840-3847-4db5-9aea-2519b8047e06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2c1ae2fc-26fa-49af-ad9f-21963aeedb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_efad9ce7-16dc-4dee-9599-175f98e78f6a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2c1ae2fc-26fa-49af-ad9f-21963aeedb2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_53762db4-71fd-4cec-8bdc-15af93e1f579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_efad9ce7-16dc-4dee-9599-175f98e78f6a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_53762db4-71fd-4cec-8bdc-15af93e1f579" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_7c929314-830e-45b8-809b-01eccba58588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_efad9ce7-16dc-4dee-9599-175f98e78f6a" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_7c929314-830e-45b8-809b-01eccba58588" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_05f53f81-92cd-451a-b9ac-33a545ed8e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2b9ca803-d7d7-4da9-acaa-5d68a79aa287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_21bbc028-abbc-4c0b-933e-9b915ca92839" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2b9ca803-d7d7-4da9-acaa-5d68a79aa287" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_acc93cc1-1ab2-44ff-b3d9-3228365fe22a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2b9ca803-d7d7-4da9-acaa-5d68a79aa287" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_acc93cc1-1ab2-44ff-b3d9-3228365fe22a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_acc93cc1-1ab2-44ff-b3d9-3228365fe22a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_acc93cc1-1ab2-44ff-b3d9-3228365fe22a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_acc93cc1-1ab2-44ff-b3d9-3228365fe22a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1f7dcccd-3d80-4776-ba26-7b143d31771b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_acc93cc1-1ab2-44ff-b3d9-3228365fe22a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1f7dcccd-3d80-4776-ba26-7b143d31771b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CommonStockWarrantLiabilityMember_41aa3315-a64f-4f8b-8f45-40efab03c09c" xlink:href="cdna-20230331.xsd#cdna_CommonStockWarrantLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1f7dcccd-3d80-4776-ba26-7b143d31771b" xlink:to="loc_cdna_CommonStockWarrantLiabilityMember_41aa3315-a64f-4f8b-8f45-40efab03c09c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ContingentConsiderationMember_65950ca1-3388-44df-a78e-0629b36a7eec" xlink:href="cdna-20230331.xsd#cdna_ContingentConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1f7dcccd-3d80-4776-ba26-7b143d31771b" xlink:to="loc_cdna_ContingentConsiderationMember_65950ca1-3388-44df-a78e-0629b36a7eec" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails" xlink:type="extended" id="ifb7ac538aa3746be960f89f116a85b3a_CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_d4fdc8af-e162-4902-bf4f-afa8736a790e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShortTermMarketableSecuritiesAbstract_9d8a1bc1-e03d-486a-820e-346b6b3782ef" xlink:href="cdna-20230331.xsd#cdna_ShortTermMarketableSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_d4fdc8af-e162-4902-bf4f-afa8736a790e" xlink:to="loc_cdna_ShortTermMarketableSecuritiesAbstract_9d8a1bc1-e03d-486a-820e-346b6b3782ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_db45c96c-9be5-415e-87b0-e25ff59021e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ShortTermMarketableSecuritiesAbstract_9d8a1bc1-e03d-486a-820e-346b6b3782ef" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_db45c96c-9be5-415e-87b0-e25ff59021e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_36d8d40b-0a8c-4fc0-9fc3-c19c698258f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ShortTermMarketableSecuritiesAbstract_9d8a1bc1-e03d-486a-820e-346b6b3782ef" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_36d8d40b-0a8c-4fc0-9fc3-c19c698258f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_15b891d2-e0b0-4eea-b373-c511e2649ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ShortTermMarketableSecuritiesAbstract_9d8a1bc1-e03d-486a-820e-346b6b3782ef" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_15b891d2-e0b0-4eea-b373-c511e2649ddc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_88b73126-1ae9-4e72-9166-aeab588ce3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ShortTermMarketableSecuritiesAbstract_9d8a1bc1-e03d-486a-820e-346b6b3782ef" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_88b73126-1ae9-4e72-9166-aeab588ce3f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAmortizedCostShortTerm_ac62e8ac-acb8-4e0a-b7a0-94503a74ef10" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAmortizedCostShortTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ShortTermMarketableSecuritiesAbstract_9d8a1bc1-e03d-486a-820e-346b6b3782ef" xlink:to="loc_cdna_MarketableSecuritiesAmortizedCostShortTerm_ac62e8ac-acb8-4e0a-b7a0-94503a74ef10" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm_55259925-514b-4e71-8874-bd4ac474cdd2" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ShortTermMarketableSecuritiesAbstract_9d8a1bc1-e03d-486a-820e-346b6b3782ef" xlink:to="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm_55259925-514b-4e71-8874-bd4ac474cdd2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesFairValueShortTerm_4aaaf710-12a6-49bd-b714-a6a35f6dee0d" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesFairValueShortTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ShortTermMarketableSecuritiesAbstract_9d8a1bc1-e03d-486a-820e-346b6b3782ef" xlink:to="loc_cdna_MarketableSecuritiesFairValueShortTerm_4aaaf710-12a6-49bd-b714-a6a35f6dee0d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_LongTermMarketableSecuritiesAbstract_f936477b-3a31-43ff-81c5-94f0b7166e52" xlink:href="cdna-20230331.xsd#cdna_LongTermMarketableSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_d4fdc8af-e162-4902-bf4f-afa8736a790e" xlink:to="loc_cdna_LongTermMarketableSecuritiesAbstract_f936477b-3a31-43ff-81c5-94f0b7166e52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_8e3d0a31-dcb1-4b0c-b255-07c5811995ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_LongTermMarketableSecuritiesAbstract_f936477b-3a31-43ff-81c5-94f0b7166e52" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_8e3d0a31-dcb1-4b0c-b255-07c5811995ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax_78725f7b-ef6f-4d39-8f9e-59de9d1c03e1" xlink:href="cdna-20230331.xsd#cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_LongTermMarketableSecuritiesAbstract_f936477b-3a31-43ff-81c5-94f0b7166e52" xlink:to="loc_cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax_78725f7b-ef6f-4d39-8f9e-59de9d1c03e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_c9200169-7808-495a-930d-4bb9bca92f82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_LongTermMarketableSecuritiesAbstract_f936477b-3a31-43ff-81c5-94f0b7166e52" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_c9200169-7808-495a-930d-4bb9bca92f82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_37382f15-c49d-4534-99e1-89f64f144861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_LongTermMarketableSecuritiesAbstract_f936477b-3a31-43ff-81c5-94f0b7166e52" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_37382f15-c49d-4534-99e1-89f64f144861" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2a0e8608-d12d-4eaf-bc90-bff006b5cdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_LongTermMarketableSecuritiesAbstract_f936477b-3a31-43ff-81c5-94f0b7166e52" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2a0e8608-d12d-4eaf-bc90-bff006b5cdf9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc448077-25ab-48c7-8fd9-8fce3da314df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_LongTermMarketableSecuritiesAbstract_f936477b-3a31-43ff-81c5-94f0b7166e52" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc448077-25ab-48c7-8fd9-8fce3da314df" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAmortizedCostLongTerm_6279242b-628e-42e2-9661-569f3eac8add" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAmortizedCostLongTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_LongTermMarketableSecuritiesAbstract_f936477b-3a31-43ff-81c5-94f0b7166e52" xlink:to="loc_cdna_MarketableSecuritiesAmortizedCostLongTerm_6279242b-628e-42e2-9661-569f3eac8add" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm_1c018403-82e3-4663-8b6e-41a4ecca53ab" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_LongTermMarketableSecuritiesAbstract_f936477b-3a31-43ff-81c5-94f0b7166e52" xlink:to="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm_1c018403-82e3-4663-8b6e-41a4ecca53ab" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesFairValueLongTerm_5e25122c-eb2c-49f0-8f83-4c3ecc8a54bf" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesFairValueLongTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_LongTermMarketableSecuritiesAbstract_f936477b-3a31-43ff-81c5-94f0b7166e52" xlink:to="loc_cdna_MarketableSecuritiesFairValueLongTerm_5e25122c-eb2c-49f0-8f83-4c3ecc8a54bf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAmortizedCost_7090075f-7215-455d-9a88-ac75b3db542e" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_d4fdc8af-e162-4902-bf4f-afa8736a790e" xlink:to="loc_cdna_MarketableSecuritiesAmortizedCost_7090075f-7215-455d-9a88-ac75b3db542e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss_9ff7bb31-a6ce-4e75-8a20-e6a4383c6ede" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_d4fdc8af-e162-4902-bf4f-afa8736a790e" xlink:to="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss_9ff7bb31-a6ce-4e75-8a20-e6a4383c6ede" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_43051402-6035-4b0f-9fdb-9d50d594ac2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_d4fdc8af-e162-4902-bf4f-afa8736a790e" xlink:to="loc_us-gaap_MarketableSecurities_43051402-6035-4b0f-9fdb-9d50d594ac2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_4f67239f-b38e-4077-a9e4-011247d28d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_d4fdc8af-e162-4902-bf4f-afa8736a790e" xlink:to="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_4f67239f-b38e-4077-a9e4-011247d28d34" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_013982fd-03f9-404c-a206-f4c543d3a44b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_4f67239f-b38e-4077-a9e4-011247d28d34" xlink:to="loc_us-gaap_FinancialInstrumentAxis_013982fd-03f9-404c-a206-f4c543d3a44b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_013982fd-03f9-404c-a206-f4c543d3a44b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_013982fd-03f9-404c-a206-f4c543d3a44b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_013982fd-03f9-404c-a206-f4c543d3a44b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71538692-0c77-4a7a-8856-77b041b0076b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_013982fd-03f9-404c-a206-f4c543d3a44b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71538692-0c77-4a7a-8856-77b041b0076b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e420d2d0-1e34-4875-a80d-78ceee357741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71538692-0c77-4a7a-8856-77b041b0076b" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e420d2d0-1e34-4875-a80d-78ceee357741" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_cd6e401e-bb11-417b-8084-da0ae9de31d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71538692-0c77-4a7a-8856-77b041b0076b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_cd6e401e-bb11-417b-8084-da0ae9de31d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_7d766339-5600-49b5-b4ce-cc19040aeccf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71538692-0c77-4a7a-8856-77b041b0076b" xlink:to="loc_us-gaap_EquitySecuritiesMember_7d766339-5600-49b5-b4ce-cc19040aeccf" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/BusinessCombinationsAdditionalInformationDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#BusinessCombinationsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/BusinessCombinationsAdditionalInformationDetails" xlink:type="extended" id="i8e77ad0fe2394c669181cfda7a4e61e6_BusinessCombinationsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9e4924ec-6c6b-4b4b-b669-f6b11790dff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fdf3ec64-a630-4e55-84a6-a7fe0230769c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e4924ec-6c6b-4b4b-b669-f6b11790dff5" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fdf3ec64-a630-4e55-84a6-a7fe0230769c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_26cb112d-d713-419f-a44c-54a32c2c9fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e4924ec-6c6b-4b4b-b669-f6b11790dff5" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_26cb112d-d713-419f-a44c-54a32c2c9fd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c19e5d19-a557-4b99-9878-3f154e6e88fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e4924ec-6c6b-4b4b-b669-f6b11790dff5" xlink:to="loc_us-gaap_Goodwill_c19e5d19-a557-4b99-9878-3f154e6e88fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_d32c12c8-8c6e-41c8-a9e3-8b6f21c0e4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e4924ec-6c6b-4b4b-b669-f6b11790dff5" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_d32c12c8-8c6e-41c8-a9e3-8b6f21c0e4c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_IntangibleAssetMeasurementInputRoyaltyRate_3d547b65-bffd-4057-b345-2958bd233c21" xlink:href="cdna-20230331.xsd#cdna_IntangibleAssetMeasurementInputRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e4924ec-6c6b-4b4b-b669-f6b11790dff5" xlink:to="loc_cdna_IntangibleAssetMeasurementInputRoyaltyRate_3d547b65-bffd-4057-b345-2958bd233c21" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_IntangibleAssetMeasurementInputDiscountRate_fba4e077-6a99-438c-b29b-1af683c525a1" xlink:href="cdna-20230331.xsd#cdna_IntangibleAssetMeasurementInputDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e4924ec-6c6b-4b4b-b669-f6b11790dff5" xlink:to="loc_cdna_IntangibleAssetMeasurementInputDiscountRate_fba4e077-6a99-438c-b29b-1af683c525a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_11bd9d5a-a43c-4996-bc90-b92335bd7975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e4924ec-6c6b-4b4b-b669-f6b11790dff5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_11bd9d5a-a43c-4996-bc90-b92335bd7975" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d3be3654-905b-49c9-8e61-f1fe005c6690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_11bd9d5a-a43c-4996-bc90-b92335bd7975" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d3be3654-905b-49c9-8e61-f1fe005c6690" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d3be3654-905b-49c9-8e61-f1fe005c6690_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d3be3654-905b-49c9-8e61-f1fe005c6690" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d3be3654-905b-49c9-8e61-f1fe005c6690_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f123e086-fb8d-41ec-bad7-f564753eb6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d3be3654-905b-49c9-8e61-f1fe005c6690" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f123e086-fb8d-41ec-bad7-f564753eb6cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_HLADataSystemsMember_307a57de-4365-419f-8658-ada6d851ebb8" xlink:href="cdna-20230331.xsd#cdna_HLADataSystemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f123e086-fb8d-41ec-bad7-f564753eb6cb" xlink:to="loc_cdna_HLADataSystemsMember_307a57de-4365-419f-8658-ada6d851ebb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9649653f-e544-4ad7-a147-4a7143ae6ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_11bd9d5a-a43c-4996-bc90-b92335bd7975" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9649653f-e544-4ad7-a147-4a7143ae6ad8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9649653f-e544-4ad7-a147-4a7143ae6ad8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9649653f-e544-4ad7-a147-4a7143ae6ad8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9649653f-e544-4ad7-a147-4a7143ae6ad8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bbbefb9f-27b2-481e-a574-b3242646ab57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9649653f-e544-4ad7-a147-4a7143ae6ad8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bbbefb9f-27b2-481e-a574-b3242646ab57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_ff9e8a78-69fc-4f71-906b-472bedd6b401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bbbefb9f-27b2-481e-a574-b3242646ab57" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_ff9e8a78-69fc-4f71-906b-472bedd6b401" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_be245c6d-511e-4fbe-91db-895af8f1c4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bbbefb9f-27b2-481e-a574-b3242646ab57" xlink:to="loc_us-gaap_TrademarksMember_be245c6d-511e-4fbe-91db-895af8f1c4dd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/BusinessCombinationsSummaryofIdentifiedIntangibleAssetsAcquiredatAcquisitionDateDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#BusinessCombinationsSummaryofIdentifiedIntangibleAssetsAcquiredatAcquisitionDateDetails"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/BusinessCombinationsSummaryofIdentifiedIntangibleAssetsAcquiredatAcquisitionDateDetails" xlink:type="extended" id="icf2378ad81ea4bcd87808b7f47e7d093_BusinessCombinationsSummaryofIdentifiedIntangibleAssetsAcquiredatAcquisitionDateDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_85f8f047-5340-48e8-8d41-93b49ae94c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_a7515518-4ea0-4aeb-8580-9f664da43cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_85f8f047-5340-48e8-8d41-93b49ae94c34" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_a7515518-4ea0-4aeb-8580-9f664da43cb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_dc2708d5-6024-44b3-9bc0-2ea9abca52cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_85f8f047-5340-48e8-8d41-93b49ae94c34" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_dc2708d5-6024-44b3-9bc0-2ea9abca52cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_78f8af95-8e0a-43f1-b03f-80991f346caa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_85f8f047-5340-48e8-8d41-93b49ae94c34" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_78f8af95-8e0a-43f1-b03f-80991f346caa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d56552b0-cf25-43f4-94ca-790c3a0cde22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_78f8af95-8e0a-43f1-b03f-80991f346caa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d56552b0-cf25-43f4-94ca-790c3a0cde22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d56552b0-cf25-43f4-94ca-790c3a0cde22_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d56552b0-cf25-43f4-94ca-790c3a0cde22" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d56552b0-cf25-43f4-94ca-790c3a0cde22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2dd80d9d-0c94-4623-aca2-591f876b1adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d56552b0-cf25-43f4-94ca-790c3a0cde22" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2dd80d9d-0c94-4623-aca2-591f876b1adc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_204f4114-8fab-463b-b3db-074b690984d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2dd80d9d-0c94-4623-aca2-591f876b1adc" xlink:to="loc_us-gaap_CustomerRelationshipsMember_204f4114-8fab-463b-b3db-074b690984d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_cbfd76d1-04aa-4be5-94b1-b053008682f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2dd80d9d-0c94-4623-aca2-591f876b1adc" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_cbfd76d1-04aa-4be5-94b1-b053008682f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_4ecfdd6f-b810-4ddf-9e5e-7216f65ff58a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2dd80d9d-0c94-4623-aca2-591f876b1adc" xlink:to="loc_us-gaap_TrademarksMember_4ecfdd6f-b810-4ddf-9e5e-7216f65ff58a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_df641461-6274-4da1-ad6d-d8dc21d3d934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_78f8af95-8e0a-43f1-b03f-80991f346caa" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_df641461-6274-4da1-ad6d-d8dc21d3d934" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_df641461-6274-4da1-ad6d-d8dc21d3d934_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_df641461-6274-4da1-ad6d-d8dc21d3d934" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_df641461-6274-4da1-ad6d-d8dc21d3d934_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_178e61c3-3f9f-4f5e-a0cc-03d7a5f0dde5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_df641461-6274-4da1-ad6d-d8dc21d3d934" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_178e61c3-3f9f-4f5e-a0cc-03d7a5f0dde5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_HLADataSystemsMember_a25a66df-1091-4079-822a-4b7bc2826ad9" xlink:href="cdna-20230331.xsd#cdna_HLADataSystemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_178e61c3-3f9f-4f5e-a0cc-03d7a5f0dde5" xlink:to="loc_cdna_HLADataSystemsMember_a25a66df-1091-4079-822a-4b7bc2826ad9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails" xlink:type="extended" id="i4d11ce18c4ae455a99d03967a268e580_BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_7b087d14-7e18-46ce-995e-e9c235351cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_7b087d14-7e18-46ce-995e-e9c235351cb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2e5b22f4-2856-4812-a1fa-39a3790c8b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2e5b22f4-2856-4812-a1fa-39a3790c8b37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_ad04742a-f4cc-4b50-ad31-7289eb3cd7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_ad04742a-f4cc-4b50-ad31-7289eb3cd7e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_b36e6099-24c0-421a-b3c9-fb3bbccb3130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_b36e6099-24c0-421a-b3c9-fb3bbccb3130" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_5c79b6da-97c9-4001-b367-901020969ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_5c79b6da-97c9-4001-b367-901020969ad2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_c4ee8979-53c8-48d5-809b-d1d77eba30b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_c4ee8979-53c8-48d5-809b-d1d77eba30b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion_058b104d-a8fc-4deb-b4e6-c119dcf97497" xlink:href="cdna-20230331.xsd#cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:to="loc_cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion_058b104d-a8fc-4deb-b4e6-c119dcf97497" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_634ff74d-f794-4d3b-99b5-50124f3c3fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_634ff74d-f794-4d3b-99b5-50124f3c3fd2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_c21ed540-39ff-482e-840e-3ab43ae44463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_c21ed540-39ff-482e-840e-3ab43ae44463" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_748365d2-b1d4-45d3-8895-6d27b2d8a9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:to="loc_us-gaap_Goodwill_748365d2-b1d4-45d3-8895-6d27b2d8a9a0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e964f061-331e-4d27-82ae-c78198c7b6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e964f061-331e-4d27-82ae-c78198c7b6fd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_04ca82f4-ef2c-439d-96de-12cca86cf188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_04ca82f4-ef2c-439d-96de-12cca86cf188" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_edf1abe3-45fe-4443-b6ad-b71cf7b7f565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_04ca82f4-ef2c-439d-96de-12cca86cf188" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_edf1abe3-45fe-4443-b6ad-b71cf7b7f565" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_edf1abe3-45fe-4443-b6ad-b71cf7b7f565_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_edf1abe3-45fe-4443-b6ad-b71cf7b7f565" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_edf1abe3-45fe-4443-b6ad-b71cf7b7f565_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06d5873a-b2a7-4e4c-a8e6-77db28f27d53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_edf1abe3-45fe-4443-b6ad-b71cf7b7f565" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06d5873a-b2a7-4e4c-a8e6-77db28f27d53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_HLADataSystemsMember_85f82655-2d52-4b18-8039-dee417874d19" xlink:href="cdna-20230331.xsd#cdna_HLADataSystemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06d5873a-b2a7-4e4c-a8e6-77db28f27d53" xlink:to="loc_cdna_HLADataSystemsMember_85f82655-2d52-4b18-8039-dee417874d19" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#GoodwillandIntangibleAssetsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="extended" id="ibfdc23cf9c4d4dca89d985c51516d429_GoodwillandIntangibleAssetsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_cdna_GoodwillAndIntangibleAssetsLineItems_2408ea92-359a-464b-bae0-e1049c283886" xlink:href="cdna-20230331.xsd#cdna_GoodwillAndIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a376ac26-d8f6-4457-b672-9ad979006c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_GoodwillAndIntangibleAssetsLineItems_2408ea92-359a-464b-bae0-e1049c283886" xlink:to="loc_us-gaap_Goodwill_a376ac26-d8f6-4457-b672-9ad979006c5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_8ac32cd9-eea9-4f50-96ba-2e3afafc69c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_GoodwillAndIntangibleAssetsLineItems_2408ea92-359a-464b-bae0-e1049c283886" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_8ac32cd9-eea9-4f50-96ba-2e3afafc69c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_GoodwillAndIntangibleAssetsTable_bdba53b9-39bd-4653-956e-431a07d10bb1" xlink:href="cdna-20230331.xsd#cdna_GoodwillAndIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cdna_GoodwillAndIntangibleAssetsLineItems_2408ea92-359a-464b-bae0-e1049c283886" xlink:to="loc_cdna_GoodwillAndIntangibleAssetsTable_bdba53b9-39bd-4653-956e-431a07d10bb1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dbab5170-c370-4e83-b53b-8f1a39aa91a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cdna_GoodwillAndIntangibleAssetsTable_bdba53b9-39bd-4653-956e-431a07d10bb1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dbab5170-c370-4e83-b53b-8f1a39aa91a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dbab5170-c370-4e83-b53b-8f1a39aa91a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dbab5170-c370-4e83-b53b-8f1a39aa91a3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dbab5170-c370-4e83-b53b-8f1a39aa91a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a11e0f60-648f-4d53-86ef-27dde664f09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dbab5170-c370-4e83-b53b-8f1a39aa91a3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a11e0f60-648f-4d53-86ef-27dde664f09a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CommercializationRightsMember_bd6a9f29-bfd3-4b86-b7be-88923bd386dc" xlink:href="cdna-20230331.xsd#cdna_CommercializationRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a11e0f60-648f-4d53-86ef-27dde664f09a" xlink:to="loc_cdna_CommercializationRightsMember_bd6a9f29-bfd3-4b86-b7be-88923bd386dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AcquiredAndDevelopedTechnologyMember_6c8860e5-e476-4129-bc48-77fd39d4f3f9" xlink:href="cdna-20230331.xsd#cdna_AcquiredAndDevelopedTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a11e0f60-648f-4d53-86ef-27dde664f09a" xlink:to="loc_cdna_AcquiredAndDevelopedTechnologyMember_6c8860e5-e476-4129-bc48-77fd39d4f3f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_587902a9-1433-410e-844b-8c69fdb1ce54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a11e0f60-648f-4d53-86ef-27dde664f09a" xlink:to="loc_us-gaap_CustomerRelationshipsMember_587902a9-1433-410e-844b-8c69fdb1ce54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_ea527d42-f0a4-44ea-84d8-ca0983d88fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a11e0f60-648f-4d53-86ef-27dde664f09a" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_ea527d42-f0a4-44ea-84d8-ca0983d88fc0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_b3fa8d3b-f758-4313-a71a-83fa2be6e88c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a11e0f60-648f-4d53-86ef-27dde664f09a" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_b3fa8d3b-f758-4313-a71a-83fa2be6e88c" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails" xlink:type="extended" id="i1ea1023d8138405b841a2631b50bfa02_GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems_bc543fcb-12f4-4795-965b-db6e48763a6a" xlink:href="cdna-20230331.xsd#cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8bcede4b-54b2-402c-8b1e-b319a64c8ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems_bc543fcb-12f4-4795-965b-db6e48763a6a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8bcede4b-54b2-402c-8b1e-b319a64c8ce2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_567f9da1-7334-4713-a9d5-4f39c9324fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8bcede4b-54b2-402c-8b1e-b319a64c8ce2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_567f9da1-7334-4713-a9d5-4f39c9324fda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5804f1b8-c89e-4184-b22f-5192ef677801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8bcede4b-54b2-402c-8b1e-b319a64c8ce2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5804f1b8-c89e-4184-b22f-5192ef677801" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_FiniteLivedIntangibleForeignCurrencyTranslation_ffba3785-f316-43c7-8281-8544d58259b2" xlink:href="cdna-20230331.xsd#cdna_FiniteLivedIntangibleForeignCurrencyTranslation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8bcede4b-54b2-402c-8b1e-b319a64c8ce2" xlink:to="loc_cdna_FiniteLivedIntangibleForeignCurrencyTranslation_ffba3785-f316-43c7-8281-8544d58259b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5174731c-6a02-49ea-ab24-99e37a882f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8bcede4b-54b2-402c-8b1e-b319a64c8ce2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5174731c-6a02-49ea-ab24-99e37a882f72" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_c9c7088b-e9c2-4ee2-9541-a695ac2e12ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems_bc543fcb-12f4-4795-965b-db6e48763a6a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_c9c7088b-e9c2-4ee2-9541-a695ac2e12ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_87359061-c4d5-4c01-88f3-8ee7fd0aabb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_c9c7088b-e9c2-4ee2-9541-a695ac2e12ed" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_87359061-c4d5-4c01-88f3-8ee7fd0aabb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0ee23216-6899-4dc0-8c9a-24d00b5ac3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems_bc543fcb-12f4-4795-965b-db6e48763a6a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0ee23216-6899-4dc0-8c9a-24d00b5ac3a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_dfe2d378-f0b2-429c-b097-1dc87f60e58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0ee23216-6899-4dc0-8c9a-24d00b5ac3a7" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_dfe2d378-f0b2-429c-b097-1dc87f60e58f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_74e6fbe6-6b2a-4c2a-821b-918ee80d7af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0ee23216-6899-4dc0-8c9a-24d00b5ac3a7" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_74e6fbe6-6b2a-4c2a-821b-918ee80d7af2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7a9f6e81-7cd1-47b3-8894-617ac2d8b358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems_bc543fcb-12f4-4795-965b-db6e48763a6a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7a9f6e81-7cd1-47b3-8894-617ac2d8b358" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable_3a406f15-4df3-4f40-a3b7-b3fb5be12846" xlink:href="cdna-20230331.xsd#cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems_bc543fcb-12f4-4795-965b-db6e48763a6a" xlink:to="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable_3a406f15-4df3-4f40-a3b7-b3fb5be12846" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ea780731-3291-4cf5-bf44-def2e1f02b14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable_3a406f15-4df3-4f40-a3b7-b3fb5be12846" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ea780731-3291-4cf5-bf44-def2e1f02b14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ea780731-3291-4cf5-bf44-def2e1f02b14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ea780731-3291-4cf5-bf44-def2e1f02b14" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ea780731-3291-4cf5-bf44-def2e1f02b14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b1e17db3-08c8-40cc-94e0-0e1025703a27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ea780731-3291-4cf5-bf44-def2e1f02b14" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b1e17db3-08c8-40cc-94e0-0e1025703a27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AcquiredAndDevelopedTechnologyMember_419bb962-6fd4-4d33-9bfb-2d62998c53a8" xlink:href="cdna-20230331.xsd#cdna_AcquiredAndDevelopedTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b1e17db3-08c8-40cc-94e0-0e1025703a27" xlink:to="loc_cdna_AcquiredAndDevelopedTechnologyMember_419bb962-6fd4-4d33-9bfb-2d62998c53a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_95241119-ef62-49fe-be7d-7635f021295d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b1e17db3-08c8-40cc-94e0-0e1025703a27" xlink:to="loc_us-gaap_CustomerRelationshipsMember_95241119-ef62-49fe-be7d-7635f021295d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CommercializationRightsMember_57e7b013-0090-403e-8daa-fbcd056021c2" xlink:href="cdna-20230331.xsd#cdna_CommercializationRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b1e17db3-08c8-40cc-94e0-0e1025703a27" xlink:to="loc_cdna_CommercializationRightsMember_57e7b013-0090-403e-8daa-fbcd056021c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_996ad668-c431-4a7f-b8d4-d3fe8a12cde2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b1e17db3-08c8-40cc-94e0-0e1025703a27" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_996ad668-c431-4a7f-b8d4-d3fe8a12cde2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6952fc1d-ed84-4785-a695-7e9ddf698763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable_3a406f15-4df3-4f40-a3b7-b3fb5be12846" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6952fc1d-ed84-4785-a695-7e9ddf698763" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6952fc1d-ed84-4785-a695-7e9ddf698763_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6952fc1d-ed84-4785-a695-7e9ddf698763" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_6952fc1d-ed84-4785-a695-7e9ddf698763_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c187dccc-583c-44cf-85a8-1980785ad1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6952fc1d-ed84-4785-a695-7e9ddf698763" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c187dccc-583c-44cf-85a8-1980785ad1f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AcquiredInProcessTechnologyMember_f96fe5a5-acb4-476b-a4c2-21d0a8d77fdf" xlink:href="cdna-20230331.xsd#cdna_AcquiredInProcessTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c187dccc-583c-44cf-85a8-1980785ad1f4" xlink:to="loc_cdna_AcquiredInProcessTechnologyMember_f96fe5a5-acb4-476b-a4c2-21d0a8d77fdf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofFiniteLivedIntangibleAssetsAmortizationExpenseDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#GoodwillandIntangibleAssetsSummaryofFiniteLivedIntangibleAssetsAmortizationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofFiniteLivedIntangibleAssetsAmortizationExpenseDetails" xlink:type="extended" id="i9b8efec57a9d4312bda373ef1816e01c_GoodwillandIntangibleAssetsSummaryofFiniteLivedIntangibleAssetsAmortizationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_110650de-43fd-492c-ba66-f015b707545a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_fc03a875-3fb4-4246-a6d7-26900344623e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_110650de-43fd-492c-ba66-f015b707545a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_fc03a875-3fb4-4246-a6d7-26900344623e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f307441e-e00c-49cf-974d-fb9f899c6b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_110650de-43fd-492c-ba66-f015b707545a" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f307441e-e00c-49cf-974d-fb9f899c6b6d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_914a10b0-f9dd-4b58-9fa8-710f4056cc62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f307441e-e00c-49cf-974d-fb9f899c6b6d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_914a10b0-f9dd-4b58-9fa8-710f4056cc62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_914a10b0-f9dd-4b58-9fa8-710f4056cc62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_914a10b0-f9dd-4b58-9fa8-710f4056cc62" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_914a10b0-f9dd-4b58-9fa8-710f4056cc62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d600f1c6-28f8-4854-a8c2-2425e1bcec71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_914a10b0-f9dd-4b58-9fa8-710f4056cc62" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d600f1c6-28f8-4854-a8c2-2425e1bcec71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CostOfTestingMember_7a51c19b-285f-447b-a3b7-d2567863d386" xlink:href="cdna-20230331.xsd#cdna_CostOfTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d600f1c6-28f8-4854-a8c2-2425e1bcec71" xlink:to="loc_cdna_CostOfTestingMember_7a51c19b-285f-447b-a3b7-d2567863d386" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CostOfProductMember_79327cea-0c21-4bea-acaa-b159a57b59c9" xlink:href="cdna-20230331.xsd#cdna_CostOfProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d600f1c6-28f8-4854-a8c2-2425e1bcec71" xlink:to="loc_cdna_CostOfProductMember_79327cea-0c21-4bea-acaa-b159a57b59c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CostOfPatientAndDigitalSolutionsMember_b06011d8-6eac-414e-9278-f28673db4b31" xlink:href="cdna-20230331.xsd#cdna_CostOfPatientAndDigitalSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d600f1c6-28f8-4854-a8c2-2425e1bcec71" xlink:to="loc_cdna_CostOfPatientAndDigitalSolutionsMember_b06011d8-6eac-414e-9278-f28673db4b31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_78abed59-5283-414a-bc1e-c3947edfea45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d600f1c6-28f8-4854-a8c2-2425e1bcec71" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_78abed59-5283-414a-bc1e-c3947edfea45" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails" xlink:type="extended" id="i4590fcafe2e340469175425b0ea3a8a3_GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1bf3b887-0b07-4a43-bc83-a42347bc38dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7973016e-1f77-41c7-93f8-ed42fc6f221b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1bf3b887-0b07-4a43-bc83-a42347bc38dc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7973016e-1f77-41c7-93f8-ed42fc6f221b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5853ba8e-a2ee-4087-87ce-fe0142cf57be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7973016e-1f77-41c7-93f8-ed42fc6f221b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5853ba8e-a2ee-4087-87ce-fe0142cf57be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_768552c1-ef4e-4db7-94a7-aa0b3faa1428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7973016e-1f77-41c7-93f8-ed42fc6f221b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_768552c1-ef4e-4db7-94a7-aa0b3faa1428" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5707543a-e2d3-4f78-8f9b-c84364bdc4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7973016e-1f77-41c7-93f8-ed42fc6f221b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5707543a-e2d3-4f78-8f9b-c84364bdc4ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4f885e49-b11a-4f36-96b0-2329bedfcd81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7973016e-1f77-41c7-93f8-ed42fc6f221b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4f885e49-b11a-4f36-96b0-2329bedfcd81" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fbb7ce4d-d575-41cf-889a-c9e9e04c3f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7973016e-1f77-41c7-93f8-ed42fc6f221b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fbb7ce4d-d575-41cf-889a-c9e9e04c3f2d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_1c4d2705-fcd0-4216-ac11-83e49f511dd6" xlink:href="cdna-20230331.xsd#cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7973016e-1f77-41c7-93f8-ed42fc6f221b" xlink:to="loc_cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_1c4d2705-fcd0-4216-ac11-83e49f511dd6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ecb73f0b-5dc2-4839-ba3d-fd70b81f7df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7973016e-1f77-41c7-93f8-ed42fc6f221b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ecb73f0b-5dc2-4839-ba3d-fd70b81f7df8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f24f5971-0f40-4b14-938d-35c97fecfc67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1bf3b887-0b07-4a43-bc83-a42347bc38dc" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f24f5971-0f40-4b14-938d-35c97fecfc67" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1c8743a1-5587-4e1d-ae8e-8fa5e04a36a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f24f5971-0f40-4b14-938d-35c97fecfc67" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1c8743a1-5587-4e1d-ae8e-8fa5e04a36a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1c8743a1-5587-4e1d-ae8e-8fa5e04a36a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1c8743a1-5587-4e1d-ae8e-8fa5e04a36a2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1c8743a1-5587-4e1d-ae8e-8fa5e04a36a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_46ca1ae4-8fa1-4e11-a5c2-f7b37ce900ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1c8743a1-5587-4e1d-ae8e-8fa5e04a36a2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_46ca1ae4-8fa1-4e11-a5c2-f7b37ce900ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CostOfTestingMember_8e0f03e8-a2ec-47c0-87fc-3b05d123ef74" xlink:href="cdna-20230331.xsd#cdna_CostOfTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_46ca1ae4-8fa1-4e11-a5c2-f7b37ce900ed" xlink:to="loc_cdna_CostOfTestingMember_8e0f03e8-a2ec-47c0-87fc-3b05d123ef74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CostOfProductMember_0964f523-dde0-418b-b448-42720ce45923" xlink:href="cdna-20230331.xsd#cdna_CostOfProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_46ca1ae4-8fa1-4e11-a5c2-f7b37ce900ed" xlink:to="loc_cdna_CostOfProductMember_0964f523-dde0-418b-b448-42720ce45923" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CostOfPatientAndDigitalSolutionsMember_e071e3d2-0ee5-49bd-9487-181037b3ef60" xlink:href="cdna-20230331.xsd#cdna_CostOfPatientAndDigitalSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_46ca1ae4-8fa1-4e11-a5c2-f7b37ce900ed" xlink:to="loc_cdna_CostOfPatientAndDigitalSolutionsMember_e071e3d2-0ee5-49bd-9487-181037b3ef60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_cc18eef1-e33e-4298-b948-8c6cf6c011ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_46ca1ae4-8fa1-4e11-a5c2-f7b37ce900ed" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_cc18eef1-e33e-4298-b948-8c6cf6c011ea" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="i2ea133d4c9ae444286c1a08b3db3d85b_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_59ffd1d0-7da3-481c-a800-b63178e14559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_59ffd1d0-7da3-481c-a800-b63178e14559" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_234a8a2f-b434-434e-8d48-07c3cc616cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_234a8a2f-b434-434e-8d48-07c3cc616cbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_18cb04b0-fa4b-4938-8c37-33ba74d3077b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_18cb04b0-fa4b-4938-8c37-33ba74d3077b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_a1398954-97d5-464a-819b-6e3df53241f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_a1398954-97d5-464a-819b-6e3df53241f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_00c6b276-7578-4755-8c64-416d0966313d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_00c6b276-7578-4755-8c64-416d0966313d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_bc8dfa85-3e2a-48f8-95a3-1f6be6cfa43b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_bc8dfa85-3e2a-48f8-95a3-1f6be6cfa43b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_9bd2a480-80ec-4719-81f3-716d1069d3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_9bd2a480-80ec-4719-81f3-716d1069d3f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_cbeef9c0-3dbb-4a07-b616-4193dd8c93a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_cbeef9c0-3dbb-4a07-b616-4193dd8c93a4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_NumberOfMilestonePayments_4db90f19-3bcf-4c83-938f-44c86f57d7ec" xlink:href="cdna-20230331.xsd#cdna_NumberOfMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_cdna_NumberOfMilestonePayments_4db90f19-3bcf-4c83-938f-44c86f57d7ec" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_26cca3e4-ed11-4d01-bbdd-9208c318901d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_26cca3e4-ed11-4d01-bbdd-9208c318901d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_86808244-8b0d-41a7-9f6d-f78f06a131a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_86808244-8b0d-41a7-9f6d-f78f06a131a5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MalpracticeInsuranceMaximumCoveragePerIncident_3bee7e1d-7439-4668-bdcc-79bd7feee0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MalpracticeInsuranceMaximumCoveragePerIncident"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_us-gaap_MalpracticeInsuranceMaximumCoveragePerIncident_3bee7e1d-7439-4668-bdcc-79bd7feee0d9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e7b7f68f-d5ea-4b77-84a1-5d7cfca5abb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_us-gaap_LossContingenciesTable_e7b7f68f-d5ea-4b77-84a1-5d7cfca5abb6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a97e1b24-da83-41cd-a03f-d0d72e703041" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e7b7f68f-d5ea-4b77-84a1-5d7cfca5abb6" xlink:to="loc_srt_LitigationCaseAxis_a97e1b24-da83-41cd-a03f-d0d72e703041" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a97e1b24-da83-41cd-a03f-d0d72e703041_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_a97e1b24-da83-41cd-a03f-d0d72e703041" xlink:to="loc_srt_LitigationCaseTypeDomain_a97e1b24-da83-41cd-a03f-d0d72e703041_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b52ff18b-a8d2-48ea-a5ac-5582c0cae0d1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_a97e1b24-da83-41cd-a03f-d0d72e703041" xlink:to="loc_srt_LitigationCaseTypeDomain_b52ff18b-a8d2-48ea-a5ac-5582c0cae0d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CAREDXINCVsNateraIncMember_ec78c47f-2c66-42ce-a827-b709b3995289" xlink:href="cdna-20230331.xsd#cdna_CAREDXINCVsNateraIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_b52ff18b-a8d2-48ea-a5ac-5582c0cae0d1" xlink:to="loc_cdna_CAREDXINCVsNateraIncMember_ec78c47f-2c66-42ce-a827-b709b3995289" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_9937c452-ff67-4901-b58a-490d289f87b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesByNatureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e7b7f68f-d5ea-4b77-84a1-5d7cfca5abb6" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_9937c452-ff67-4901-b58a-490d289f87b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyNatureDomain_9937c452-ff67-4901-b58a-490d289f87b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_9937c452-ff67-4901-b58a-490d289f87b7" xlink:to="loc_us-gaap_GainContingencyNatureDomain_9937c452-ff67-4901-b58a-490d289f87b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyNatureDomain_b3365ccf-2ec3-4315-aaab-324721f63a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_9937c452-ff67-4901-b58a-490d289f87b7" xlink:to="loc_us-gaap_GainContingencyNatureDomain_b3365ccf-2ec3-4315-aaab-324721f63a77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CompensatoryDamagesMember_166e7019-b85f-412c-9cf6-f6fe959a5c87" xlink:href="cdna-20230331.xsd#cdna_CompensatoryDamagesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingencyNatureDomain_b3365ccf-2ec3-4315-aaab-324721f63a77" xlink:to="loc_cdna_CompensatoryDamagesMember_166e7019-b85f-412c-9cf6-f6fe959a5c87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_PunitiveDamagesMember_c8c730c9-8d3f-4656-b103-57d0c9faf7bb" xlink:href="cdna-20230331.xsd#cdna_PunitiveDamagesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingencyNatureDomain_b3365ccf-2ec3-4315-aaab-324721f63a77" xlink:to="loc_cdna_PunitiveDamagesMember_c8c730c9-8d3f-4656-b103-57d0c9faf7bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a98e6e20-a34a-4c55-ad14-d1a6bc31dd88" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e7b7f68f-d5ea-4b77-84a1-5d7cfca5abb6" xlink:to="loc_srt_RangeAxis_a98e6e20-a34a-4c55-ad14-d1a6bc31dd88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a98e6e20-a34a-4c55-ad14-d1a6bc31dd88_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a98e6e20-a34a-4c55-ad14-d1a6bc31dd88" xlink:to="loc_srt_RangeMember_a98e6e20-a34a-4c55-ad14-d1a6bc31dd88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7ff96f0a-042d-4a26-9e8c-ea34f0368e13" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a98e6e20-a34a-4c55-ad14-d1a6bc31dd88" xlink:to="loc_srt_RangeMember_7ff96f0a-042d-4a26-9e8c-ea34f0368e13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ca948d84-bf58-4858-9838-89dc86157469" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7ff96f0a-042d-4a26-9e8c-ea34f0368e13" xlink:to="loc_srt_MinimumMember_ca948d84-bf58-4858-9838-89dc86157469" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d7cb7ab9-06d1-4000-96da-11184c835891" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7ff96f0a-042d-4a26-9e8c-ea34f0368e13" xlink:to="loc_srt_MaximumMember_d7cb7ab9-06d1-4000-96da-11184c835891" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CommitmentsandContingenciesSummarizesROUAssetsandLeaseLiabilitiesforLeaseAgreementsDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#CommitmentsandContingenciesSummarizesROUAssetsandLeaseLiabilitiesforLeaseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/CommitmentsandContingenciesSummarizesROUAssetsandLeaseLiabilitiesforLeaseAgreementsDetails" xlink:type="extended" id="i2c43c8b893ea43658f40b39041049d0d_CommitmentsandContingenciesSummarizesROUAssetsandLeaseLiabilitiesforLeaseAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_37711ad9-0bbb-49cb-a8ed-4163060a8e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ff2a114a-b0f5-4355-a46d-51ef95f451cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_37711ad9-0bbb-49cb-a8ed-4163060a8e77" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ff2a114a-b0f5-4355-a46d-51ef95f451cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_954f7c5d-581a-4311-92e5-1e219204fa34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_37711ad9-0bbb-49cb-a8ed-4163060a8e77" xlink:to="loc_us-gaap_OperatingLeaseLiability_954f7c5d-581a-4311-92e5-1e219204fa34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_fffb29f8-4e26-423d-8936-1e7e86a4bbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_37711ad9-0bbb-49cb-a8ed-4163060a8e77" xlink:to="loc_us-gaap_LossContingenciesTable_fffb29f8-4e26-423d-8936-1e7e86a4bbb6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_62cfc0d1-85f6-4627-9774-0d261da1076d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_fffb29f8-4e26-423d-8936-1e7e86a4bbb6" xlink:to="loc_us-gaap_LeaseContractualTermAxis_62cfc0d1-85f6-4627-9774-0d261da1076d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_62cfc0d1-85f6-4627-9774-0d261da1076d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_62cfc0d1-85f6-4627-9774-0d261da1076d" xlink:to="loc_us-gaap_LeaseContractualTermDomain_62cfc0d1-85f6-4627-9774-0d261da1076d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_de8b2364-d089-46d3-bdf8-15d0eda7efed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_62cfc0d1-85f6-4627-9774-0d261da1076d" xlink:to="loc_us-gaap_LeaseContractualTermDomain_de8b2364-d089-46d3-bdf8-15d0eda7efed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_LeasesCommencedInJuly2022Member_134851d0-06d9-4cfe-9bc6-8436bf93ce30" xlink:href="cdna-20230331.xsd#cdna_LeasesCommencedInJuly2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_de8b2364-d089-46d3-bdf8-15d0eda7efed" xlink:to="loc_cdna_LeasesCommencedInJuly2022Member_134851d0-06d9-4cfe-9bc6-8436bf93ce30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_LeasesCommencedInAugust2022Member_c82b1fa2-0843-418b-b241-5891385c1f33" xlink:href="cdna-20230331.xsd#cdna_LeasesCommencedInAugust2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_de8b2364-d089-46d3-bdf8-15d0eda7efed" xlink:to="loc_cdna_LeasesCommencedInAugust2022Member_c82b1fa2-0843-418b-b241-5891385c1f33" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/WarrantsOutstandingWarrantsToPurchaseCommonStockWarrantsDetail" xlink:type="simple" xlink:href="cdna-20230331.xsd#WarrantsOutstandingWarrantsToPurchaseCommonStockWarrantsDetail"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/WarrantsOutstandingWarrantsToPurchaseCommonStockWarrantsDetail" xlink:type="extended" id="i0c22340dd5a74357bd2e393cffa527c1_WarrantsOutstandingWarrantsToPurchaseCommonStockWarrantsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_8a080449-6bdb-482d-8a62-a4e084b4c95f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_WarrantFairValueAssumptionsExpectedTerm_89d001c9-defd-4b26-b735-81fc0fe099f8" xlink:href="cdna-20230331.xsd#cdna_WarrantFairValueAssumptionsExpectedTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8a080449-6bdb-482d-8a62-a4e084b4c95f" xlink:to="loc_cdna_WarrantFairValueAssumptionsExpectedTerm_89d001c9-defd-4b26-b735-81fc0fe099f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_65801bf0-8bbc-4aaa-a26d-dece8d8c69f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8a080449-6bdb-482d-8a62-a4e084b4c95f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_65801bf0-8bbc-4aaa-a26d-dece8d8c69f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b1c5605f-15f7-4086-94f2-fa2c7ecdb4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8a080449-6bdb-482d-8a62-a4e084b4c95f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b1c5605f-15f7-4086-94f2-fa2c7ecdb4ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_5c743975-ae89-433f-938e-98b5044c8b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8a080449-6bdb-482d-8a62-a4e084b4c95f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_5c743975-ae89-433f-938e-98b5044c8b99" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_099f0d65-8e7e-46fb-aacc-acc6128c4cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5c743975-ae89-433f-938e-98b5044c8b99" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_099f0d65-8e7e-46fb-aacc-acc6128c4cc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_099f0d65-8e7e-46fb-aacc-acc6128c4cc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_099f0d65-8e7e-46fb-aacc-acc6128c4cc3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_099f0d65-8e7e-46fb-aacc-acc6128c4cc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0cd851cf-abea-4e0e-9fdb-8855da71478e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_099f0d65-8e7e-46fb-aacc-acc6128c4cc3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0cd851cf-abea-4e0e-9fdb-8855da71478e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_7002ae46-11cd-456f-8a63-cdb46228a577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0cd851cf-abea-4e0e-9fdb-8855da71478e" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_7002ae46-11cd-456f-8a63-cdb46228a577" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0b90038b-fdc2-47b2-9e7f-8a72f7e1a062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5c743975-ae89-433f-938e-98b5044c8b99" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0b90038b-fdc2-47b2-9e7f-8a72f7e1a062" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0b90038b-fdc2-47b2-9e7f-8a72f7e1a062_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0b90038b-fdc2-47b2-9e7f-8a72f7e1a062" xlink:to="loc_us-gaap_EquityComponentDomain_0b90038b-fdc2-47b2-9e7f-8a72f7e1a062_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_95021ca5-961f-4550-a4d0-561c16d42349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0b90038b-fdc2-47b2-9e7f-8a72f7e1a062" xlink:to="loc_us-gaap_EquityComponentDomain_95021ca5-961f-4550-a4d0-561c16d42349" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8b52dae7-3886-438e-af76-6867b4a6fbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_95021ca5-961f-4550-a4d0-561c16d42349" xlink:to="loc_us-gaap_CommonStockMember_8b52dae7-3886-438e-af76-6867b4a6fbed" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail" xlink:type="simple" xlink:href="cdna-20230331.xsd#StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail" xlink:type="extended" id="i38bf17ea6c7947918bb85828d5db46e7_StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdce54cc-0c9e-4cbf-a5ce-b4d16bc7f849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_67c872af-e92b-4069-9652-3a4beb16012b" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdce54cc-0c9e-4cbf-a5ce-b4d16bc7f849" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_67c872af-e92b-4069-9652-3a4beb16012b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b8c2c271-fe92-4654-9fac-01fe10b5b4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_67c872af-e92b-4069-9652-3a4beb16012b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b8c2c271-fe92-4654-9fac-01fe10b5b4fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d24ccfed-c9aa-4df5-a929-55d178877344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_67c872af-e92b-4069-9652-3a4beb16012b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d24ccfed-c9aa-4df5-a929-55d178877344" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices_493d2725-79e2-40bb-8733-f721f45fe55b" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_67c872af-e92b-4069-9652-3a4beb16012b" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices_493d2725-79e2-40bb-8733-f721f45fe55b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_046de311-dbae-4fcb-9359-4155bb2b722f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_67c872af-e92b-4069-9652-3a4beb16012b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_046de311-dbae-4fcb-9359-4155bb2b722f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d6dc1665-087a-4469-88b7-92aaf56235cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_67c872af-e92b-4069-9652-3a4beb16012b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d6dc1665-087a-4469-88b7-92aaf56235cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans_084859b9-b797-4a50-b8b8-193ed378e199" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_67c872af-e92b-4069-9652-3a4beb16012b" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans_084859b9-b797-4a50-b8b8-193ed378e199" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_57c0defc-3b3c-4cd0-b7e0-7b816a7c5ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_67c872af-e92b-4069-9652-3a4beb16012b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_57c0defc-3b3c-4cd0-b7e0-7b816a7c5ab6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0d141416-bdf1-456f-b294-3c9522cb5e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_67c872af-e92b-4069-9652-3a4beb16012b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0d141416-bdf1-456f-b294-3c9522cb5e9a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_b4cadf8f-1ef7-45b0-bacb-c79a86f5ddf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_67c872af-e92b-4069-9652-3a4beb16012b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_b4cadf8f-1ef7-45b0-bacb-c79a86f5ddf5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_26acdb99-c326-4c8d-92e6-5e29224effbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward_9e6e09ba-cdf7-44e7-9f6b-38822a95f483" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdce54cc-0c9e-4cbf-a5ce-b4d16bc7f849" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward_9e6e09ba-cdf7-44e7-9f6b-38822a95f483" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4f4dd417-464f-42bc-99de-0115911ee379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward_9e6e09ba-cdf7-44e7-9f6b-38822a95f483" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4f4dd417-464f-42bc-99de-0115911ee379" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ade35a3a-390f-46a1-b658-9ded6fcea65b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_43e7690f-1e1b-46d6-a572-e6cf362aab39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward_9e6e09ba-cdf7-44e7-9f6b-38822a95f483" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_43e7690f-1e1b-46d6-a572-e6cf362aab39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_496d99b2-2af1-42c2-bedc-52f5c6bbe293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0162dc27-f7c9-4da4-8011-1574ed7c2872" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9a278af8-6a64-4b01-8524-c29ea382e9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f158b378-2703-4c3f-9de5-d631e5b36491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdce54cc-0c9e-4cbf-a5ce-b4d16bc7f849" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f158b378-2703-4c3f-9de5-d631e5b36491" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_48d77c76-f4cd-4d5a-99b4-12227823dbab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f158b378-2703-4c3f-9de5-d631e5b36491" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_48d77c76-f4cd-4d5a-99b4-12227823dbab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cb074bc1-d1be-463e-9935-93e3457e68de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f158b378-2703-4c3f-9de5-d631e5b36491" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cb074bc1-d1be-463e-9935-93e3457e68de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a1ff07a3-1f41-4850-b7da-506d1582753d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f158b378-2703-4c3f-9de5-d631e5b36491" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a1ff07a3-1f41-4850-b7da-506d1582753d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5d55a3c4-711a-4209-baff-4e6a5e68c36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f158b378-2703-4c3f-9de5-d631e5b36491" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5d55a3c4-711a-4209-baff-4e6a5e68c36b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1623b0c8-e08c-4f2a-b443-94f9c4baa9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f158b378-2703-4c3f-9de5-d631e5b36491" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1623b0c8-e08c-4f2a-b443-94f9c4baa9b6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1019c354-37b9-40fa-8323-b9de2d725cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward_2c462f9a-1d96-4121-ac58-ae3666f50f3c" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdce54cc-0c9e-4cbf-a5ce-b4d16bc7f849" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward_2c462f9a-1d96-4121-ac58-ae3666f50f3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_13bcd139-98e0-4600-ae9a-9a2997b207f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward_2c462f9a-1d96-4121-ac58-ae3666f50f3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_13bcd139-98e0-4600-ae9a-9a2997b207f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_271a2a44-47d3-4dea-a77d-537759cb054a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8fa891c4-84b8-4230-beb4-d187c6a39cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward_2c462f9a-1d96-4121-ac58-ae3666f50f3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8fa891c4-84b8-4230-beb4-d187c6a39cf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_57c5d0f7-fa24-4164-91a8-ded1198784b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b4bba5de-c992-4043-b73b-db1ea4f8279d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9c45271-2ef6-4349-817a-83a231f21fab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdce54cc-0c9e-4cbf-a5ce-b4d16bc7f849" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9c45271-2ef6-4349-817a-83a231f21fab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6daae5ba-4d41-4502-9b66-70822a091589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9c45271-2ef6-4349-817a-83a231f21fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6daae5ba-4d41-4502-9b66-70822a091589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a9cdc932-8816-45e3-9d39-fb7b6ecbba65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9c45271-2ef6-4349-817a-83a231f21fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a9cdc932-8816-45e3-9d39-fb7b6ecbba65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a3e166f1-efe6-4221-be03-081a30da917c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9c45271-2ef6-4349-817a-83a231f21fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a3e166f1-efe6-4221-be03-081a30da917c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_20686ad3-c700-45c3-952e-f063cb0be4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9c45271-2ef6-4349-817a-83a231f21fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_20686ad3-c700-45c3-952e-f063cb0be4ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3bb5ec3f-83f2-4c67-b828-045ffeeaa9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d80acfc6-06fc-453e-aeb4-ed3242c22c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdce54cc-0c9e-4cbf-a5ce-b4d16bc7f849" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d80acfc6-06fc-453e-aeb4-ed3242c22c0b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bb099daf-0b6a-4b8d-814c-2f22406b75be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d80acfc6-06fc-453e-aeb4-ed3242c22c0b" xlink:to="loc_us-gaap_AwardTypeAxis_bb099daf-0b6a-4b8d-814c-2f22406b75be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb099daf-0b6a-4b8d-814c-2f22406b75be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bb099daf-0b6a-4b8d-814c-2f22406b75be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb099daf-0b6a-4b8d-814c-2f22406b75be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccf228f1-70b6-4405-a01d-90923d2cf19f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bb099daf-0b6a-4b8d-814c-2f22406b75be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccf228f1-70b6-4405-a01d-90923d2cf19f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_149bad45-e805-414d-9d41-859ec06820ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccf228f1-70b6-4405-a01d-90923d2cf19f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_149bad45-e805-414d-9d41-859ec06820ed" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail" xlink:type="simple" xlink:href="cdna-20230331.xsd#StockIncentivePlansAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail" xlink:type="extended" id="i10742757e88744028c42268beed761ad_StockIncentivePlansAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_da689025-e002-4524-b3c0-e7002601ce43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_da689025-e002-4524-b3c0-e7002601ce43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_66e0663d-bc38-4f44-ab0a-448aa254a59a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_66e0663d-bc38-4f44-ab0a-448aa254a59a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_276553b1-b022-4c0e-abf3-38f8379773f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_276553b1-b022-4c0e-abf3-38f8379773f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b826a588-22ef-4ae4-9395-bb71ced818fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b826a588-22ef-4ae4-9395-bb71ced818fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_3d8499d6-9c17-47fd-bb62-299ee717c13a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_3d8499d6-9c17-47fd-bb62-299ee717c13a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_fd334351-7e7a-40af-a907-7e6f6844ca1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_fd334351-7e7a-40af-a907-7e6f6844ca1b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum_43cc7476-c2bf-4a69-abfa-68c7dd974e43" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum_43cc7476-c2bf-4a69-abfa-68c7dd974e43" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_395827c0-5ad8-4f9b-af22-b41783dd5dae" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_395827c0-5ad8-4f9b-af22-b41783dd5dae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_fe456712-af93-44f5-b2b3-a598be13f56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_fe456712-af93-44f5-b2b3-a598be13f56c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_39b5ab01-f2e4-4ab8-96bb-d1c3acac641e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_39b5ab01-f2e4-4ab8-96bb-d1c3acac641e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_ff39ff1c-148d-4b27-bc34-44758cba8d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_ff39ff1c-148d-4b27-bc34-44758cba8d92" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_746a6bd6-e2c2-40d1-aea7-96842a2a6725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_746a6bd6-e2c2-40d1-aea7-96842a2a6725" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_9b30525e-220b-4f2c-a5cc-a058a320536a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_9b30525e-220b-4f2c-a5cc-a058a320536a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1abd866e-8e4c-484f-9afb-1e061b9c71ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1abd866e-8e4c-484f-9afb-1e061b9c71ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c0c76c26-03d6-4ca4-aadd-e7bc98005cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1abd866e-8e4c-484f-9afb-1e061b9c71ab" xlink:to="loc_us-gaap_AwardTypeAxis_c0c76c26-03d6-4ca4-aadd-e7bc98005cdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0c76c26-03d6-4ca4-aadd-e7bc98005cdf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c0c76c26-03d6-4ca4-aadd-e7bc98005cdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c0c76c26-03d6-4ca4-aadd-e7bc98005cdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_506b0c40-9468-41d4-936e-8abf388da879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c0c76c26-03d6-4ca4-aadd-e7bc98005cdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_506b0c40-9468-41d4-936e-8abf388da879" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d25fa962-88aa-4de6-9845-8a73aaa8c20c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_506b0c40-9468-41d4-936e-8abf388da879" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d25fa962-88aa-4de6-9845-8a73aaa8c20c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0d3e71ff-1db0-47da-933f-a9f7d83dac03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_506b0c40-9468-41d4-936e-8abf388da879" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0d3e71ff-1db0-47da-933f-a9f7d83dac03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_46ced28c-e2e3-432d-a143-b651647bd1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1abd866e-8e4c-484f-9afb-1e061b9c71ab" xlink:to="loc_us-gaap_PlanNameAxis_46ced28c-e2e3-432d-a143-b651647bd1e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_46ced28c-e2e3-432d-a143-b651647bd1e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_46ced28c-e2e3-432d-a143-b651647bd1e7" xlink:to="loc_us-gaap_PlanNameDomain_46ced28c-e2e3-432d-a143-b651647bd1e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_29fecfe2-3735-403c-8e3b-fbe6052df224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_46ced28c-e2e3-432d-a143-b651647bd1e7" xlink:to="loc_us-gaap_PlanNameDomain_29fecfe2-3735-403c-8e3b-fbe6052df224" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_0fd3ae34-6d2a-43aa-9173-21141a10ff7d" xlink:href="cdna-20230331.xsd#cdna_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_29fecfe2-3735-403c-8e3b-fbe6052df224" xlink:to="loc_cdna_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_0fd3ae34-6d2a-43aa-9173-21141a10ff7d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/StockIncentivePlansSummaryofWeightedAverageAssumptionsUsedtoEstimatedFairValuesofShareBasedAwardsDetail" xlink:type="simple" xlink:href="cdna-20230331.xsd#StockIncentivePlansSummaryofWeightedAverageAssumptionsUsedtoEstimatedFairValuesofShareBasedAwardsDetail"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/StockIncentivePlansSummaryofWeightedAverageAssumptionsUsedtoEstimatedFairValuesofShareBasedAwardsDetail" xlink:type="extended" id="i467ba660d5ba487b99cf3fa828017668_StockIncentivePlansSummaryofWeightedAverageAssumptionsUsedtoEstimatedFairValuesofShareBasedAwardsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47c2925f-52bd-44a8-9dee-e527f0cdf11c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a2d0f8e3-ceec-4267-90ce-ce8c83cfb416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47c2925f-52bd-44a8-9dee-e527f0cdf11c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a2d0f8e3-ceec-4267-90ce-ce8c83cfb416" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a2269c6b-077a-410a-a15e-1e10309c1bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47c2925f-52bd-44a8-9dee-e527f0cdf11c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a2269c6b-077a-410a-a15e-1e10309c1bd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a6e3f9f5-96c2-4643-ab68-cce60fab2c50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47c2925f-52bd-44a8-9dee-e527f0cdf11c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a6e3f9f5-96c2-4643-ab68-cce60fab2c50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fe485e0f-8349-40e3-8cd5-0f04b2c3d9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47c2925f-52bd-44a8-9dee-e527f0cdf11c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fe485e0f-8349-40e3-8cd5-0f04b2c3d9fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202dd8f8-62c2-44b6-843a-cb2cf6bd2eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47c2925f-52bd-44a8-9dee-e527f0cdf11c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202dd8f8-62c2-44b6-843a-cb2cf6bd2eaa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_740b4fd4-6d52-48c5-83a2-bcebb5680796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202dd8f8-62c2-44b6-843a-cb2cf6bd2eaa" xlink:to="loc_us-gaap_AwardTypeAxis_740b4fd4-6d52-48c5-83a2-bcebb5680796" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_740b4fd4-6d52-48c5-83a2-bcebb5680796_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_740b4fd4-6d52-48c5-83a2-bcebb5680796" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_740b4fd4-6d52-48c5-83a2-bcebb5680796_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5cc81709-c4a7-416f-8640-707a749f8429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_740b4fd4-6d52-48c5-83a2-bcebb5680796" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5cc81709-c4a7-416f-8640-707a749f8429" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f6345728-ec1f-400a-b4f4-79a2b25e3c17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5cc81709-c4a7-416f-8640-707a749f8429" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f6345728-ec1f-400a-b4f4-79a2b25e3c17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cf4edc60-b935-4fb6-b240-a1eb9947c71e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202dd8f8-62c2-44b6-843a-cb2cf6bd2eaa" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cf4edc60-b935-4fb6-b240-a1eb9947c71e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cf4edc60-b935-4fb6-b240-a1eb9947c71e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cf4edc60-b935-4fb6-b240-a1eb9947c71e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cf4edc60-b935-4fb6-b240-a1eb9947c71e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cf12ccca-6390-4297-a1a2-4fb0246b4306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cf4edc60-b935-4fb6-b240-a1eb9947c71e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cf12ccca-6390-4297-a1a2-4fb0246b4306" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_51315051-2fc9-4641-9595-28830923d0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cf12ccca-6390-4297-a1a2-4fb0246b4306" xlink:to="loc_us-gaap_EmployeeStockMember_51315051-2fc9-4641-9595-28830923d0d4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/StockIncentivePlansSummaryofExpenseRelatingtoEmployeeandNonemployeeStockBasedPaymentAwardsfromStockOptionsandRSUsDetail" xlink:type="simple" xlink:href="cdna-20230331.xsd#StockIncentivePlansSummaryofExpenseRelatingtoEmployeeandNonemployeeStockBasedPaymentAwardsfromStockOptionsandRSUsDetail"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/StockIncentivePlansSummaryofExpenseRelatingtoEmployeeandNonemployeeStockBasedPaymentAwardsfromStockOptionsandRSUsDetail" xlink:type="extended" id="i84c2db356ae341af90cce3c878119cc6_StockIncentivePlansSummaryofExpenseRelatingtoEmployeeandNonemployeeStockBasedPaymentAwardsfromStockOptionsandRSUsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_36e61cb2-29a1-4ee9-829b-c7bf20729231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_cb5a1b88-9480-4ac2-9611-3c1434720349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_36e61cb2-29a1-4ee9-829b-c7bf20729231" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_cb5a1b88-9480-4ac2-9611-3c1434720349" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_851469f0-1e6c-41e6-a30a-e5ae44e2fa63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_36e61cb2-29a1-4ee9-829b-c7bf20729231" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_851469f0-1e6c-41e6-a30a-e5ae44e2fa63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5e667c24-57b6-4810-94ce-3f313bbe16ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_851469f0-1e6c-41e6-a30a-e5ae44e2fa63" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5e667c24-57b6-4810-94ce-3f313bbe16ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5e667c24-57b6-4810-94ce-3f313bbe16ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5e667c24-57b6-4810-94ce-3f313bbe16ce" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5e667c24-57b6-4810-94ce-3f313bbe16ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b6262e67-ca0e-4c4c-aa72-e0320ad01147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5e667c24-57b6-4810-94ce-3f313bbe16ce" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b6262e67-ca0e-4c4c-aa72-e0320ad01147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CostOfTestingMember_ca25d441-d602-4b3e-9741-b03e9b604c8c" xlink:href="cdna-20230331.xsd#cdna_CostOfTestingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b6262e67-ca0e-4c4c-aa72-e0320ad01147" xlink:to="loc_cdna_CostOfTestingMember_ca25d441-d602-4b3e-9741-b03e9b604c8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CostOfProductMember_f88ec4b4-cd35-475a-b142-7e2f0ea7d1e0" xlink:href="cdna-20230331.xsd#cdna_CostOfProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b6262e67-ca0e-4c4c-aa72-e0320ad01147" xlink:to="loc_cdna_CostOfProductMember_f88ec4b4-cd35-475a-b142-7e2f0ea7d1e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CostOfPatientAndDigitalSolutionsMember_45a6e2cb-1f16-427f-a3a8-98b0e120436c" xlink:href="cdna-20230331.xsd#cdna_CostOfPatientAndDigitalSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b6262e67-ca0e-4c4c-aa72-e0320ad01147" xlink:to="loc_cdna_CostOfPatientAndDigitalSolutionsMember_45a6e2cb-1f16-427f-a3a8-98b0e120436c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d33334e8-dbc8-4c66-94b9-25d58998c37f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b6262e67-ca0e-4c4c-aa72-e0320ad01147" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d33334e8-dbc8-4c66-94b9-25d58998c37f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_037b3475-59e0-4e67-bfa3-02cd445e2aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b6262e67-ca0e-4c4c-aa72-e0320ad01147" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_037b3475-59e0-4e67-bfa3-02cd445e2aa7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3d97dc15-5a87-464a-af0b-1ff4eabd9da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b6262e67-ca0e-4c4c-aa72-e0320ad01147" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3d97dc15-5a87-464a-af0b-1ff4eabd9da0" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="cdna-20230331.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended" id="i7f59324566b14278a503a51e116fdba5_IncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_cdna_IncomeTaxesLineItems_539b17cf-7b95-4564-8cbe-adeed598b8b5" xlink:href="cdna-20230331.xsd#cdna_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ade056c0-aa16-4443-9e00-24dc364dc20c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdna_IncomeTaxesLineItems_539b17cf-7b95-4564-8cbe-adeed598b8b5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ade056c0-aa16-4443-9e00-24dc364dc20c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_IncomeTaxesTable_9fc5ad3d-ada6-46a7-93a8-7a1416a826f8" xlink:href="cdna-20230331.xsd#cdna_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cdna_IncomeTaxesLineItems_539b17cf-7b95-4564-8cbe-adeed598b8b5" xlink:to="loc_cdna_IncomeTaxesTable_9fc5ad3d-ada6-46a7-93a8-7a1416a826f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_0f8e085a-fd1d-48f9-84af-9d78308093d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cdna_IncomeTaxesTable_9fc5ad3d-ada6-46a7-93a8-7a1416a826f8" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_0f8e085a-fd1d-48f9-84af-9d78308093d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0f8e085a-fd1d-48f9-84af-9d78308093d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0f8e085a-fd1d-48f9-84af-9d78308093d3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0f8e085a-fd1d-48f9-84af-9d78308093d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_be2c7f86-b2c7-4a93-93bb-bdaef6243a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0f8e085a-fd1d-48f9-84af-9d78308093d3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_be2c7f86-b2c7-4a93-93bb-bdaef6243a39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_4f52863b-3ea2-496f-92bd-20a1fe908c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_be2c7f86-b2c7-4a93-93bb-bdaef6243a39" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_4f52863b-3ea2-496f-92bd-20a1fe908c3a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail" xlink:type="simple" xlink:href="cdna-20230331.xsd#SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail" xlink:type="extended" id="ic396b4835ed34380843348c19ac416f9_SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_bdd1d06a-257b-46a6-9493-8f979a4e9b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b4b2400-7946-4555-8d05-6c5d55df3f65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bdd1d06a-257b-46a6-9493-8f979a4e9b95" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b4b2400-7946-4555-8d05-6c5d55df3f65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_69e05665-cbed-46c9-aac2-cac6b8847629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bdd1d06a-257b-46a6-9493-8f979a4e9b95" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_69e05665-cbed-46c9-aac2-cac6b8847629" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_007c951c-d7d5-4863-9a0f-9c64785f4730" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_69e05665-cbed-46c9-aac2-cac6b8847629" xlink:to="loc_srt_ProductOrServiceAxis_007c951c-d7d5-4863-9a0f-9c64785f4730" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_007c951c-d7d5-4863-9a0f-9c64785f4730_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_007c951c-d7d5-4863-9a0f-9c64785f4730" xlink:to="loc_srt_ProductsAndServicesDomain_007c951c-d7d5-4863-9a0f-9c64785f4730_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fb67394e-8039-4f91-bb23-db6c9548dba0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_007c951c-d7d5-4863-9a0f-9c64785f4730" xlink:to="loc_srt_ProductsAndServicesDomain_fb67394e-8039-4f91-bb23-db6c9548dba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_06fb87db-cdf1-4fa8-a36b-e92102144c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fb67394e-8039-4f91-bb23-db6c9548dba0" xlink:to="loc_us-gaap_ServiceMember_06fb87db-cdf1-4fa8-a36b-e92102144c0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_8fc4b417-6e12-4b4a-91f4-ecdb8f00591e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fb67394e-8039-4f91-bb23-db6c9548dba0" xlink:to="loc_us-gaap_ProductMember_8fc4b417-6e12-4b4a-91f4-ecdb8f00591e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_PatientAndDigitalSolutionsMember_430a49f6-191a-4c4f-a825-b1cd154cb678" xlink:href="cdna-20230331.xsd#cdna_PatientAndDigitalSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_fb67394e-8039-4f91-bb23-db6c9548dba0" xlink:to="loc_cdna_PatientAndDigitalSolutionsMember_430a49f6-191a-4c4f-a825-b1cd154cb678" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8fd7d6b8-0ed2-4549-b5ec-3423fc92f8cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_69e05665-cbed-46c9-aac2-cac6b8847629" xlink:to="loc_srt_StatementGeographicalAxis_8fd7d6b8-0ed2-4549-b5ec-3423fc92f8cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8fd7d6b8-0ed2-4549-b5ec-3423fc92f8cf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8fd7d6b8-0ed2-4549-b5ec-3423fc92f8cf" xlink:to="loc_srt_SegmentGeographicalDomain_8fd7d6b8-0ed2-4549-b5ec-3423fc92f8cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9f4eeb24-8331-4059-a412-d35733ebf8a1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8fd7d6b8-0ed2-4549-b5ec-3423fc92f8cf" xlink:to="loc_srt_SegmentGeographicalDomain_9f4eeb24-8331-4059-a412-d35733ebf8a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7f468e15-786c-4d1b-af60-b283dee9cb6f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9f4eeb24-8331-4059-a412-d35733ebf8a1" xlink:to="loc_country_US_7f468e15-786c-4d1b-af60-b283dee9cb6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_dfd63dfb-5231-4a3a-9f6e-f06e5ac9c641" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9f4eeb24-8331-4059-a412-d35733ebf8a1" xlink:to="loc_srt_EuropeMember_dfd63dfb-5231-4a3a-9f6e-f06e5ac9c641" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_RestOfTheWorldMember_23e4a731-ccae-4d7e-98fd-86dd023f58df" xlink:href="cdna-20230331.xsd#cdna_RestOfTheWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9f4eeb24-8331-4059-a412-d35733ebf8a1" xlink:to="loc_cdna_RestOfTheWorldMember_23e4a731-ccae-4d7e-98fd-86dd023f58df" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/SegmentReportingSummaryofLongLivedAssetsConsistingofPropertyandEquipmentNetbyGeographicRegionsDetail" xlink:type="simple" xlink:href="cdna-20230331.xsd#SegmentReportingSummaryofLongLivedAssetsConsistingofPropertyandEquipmentNetbyGeographicRegionsDetail"/>
  <link:definitionLink xlink:role="http://www.caredxinc.com/role/SegmentReportingSummaryofLongLivedAssetsConsistingofPropertyandEquipmentNetbyGeographicRegionsDetail" xlink:type="extended" id="iaeee97a41a704d7d99cc4e0391328b9e_SegmentReportingSummaryofLongLivedAssetsConsistingofPropertyandEquipmentNetbyGeographicRegionsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_2cc20f60-ff79-4dbf-86f4-82d1313a2be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e8e140ab-c5ce-4c41-933f-3e0447cef3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2cc20f60-ff79-4dbf-86f4-82d1313a2be5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e8e140ab-c5ce-4c41-933f-3e0447cef3f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_795af5f0-3cfe-48d2-88c4-8809e4e2cdf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2cc20f60-ff79-4dbf-86f4-82d1313a2be5" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_795af5f0-3cfe-48d2-88c4-8809e4e2cdf3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_faed3b3b-7928-4419-82ce-bf363c2abcfa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_795af5f0-3cfe-48d2-88c4-8809e4e2cdf3" xlink:to="loc_srt_StatementGeographicalAxis_faed3b3b-7928-4419-82ce-bf363c2abcfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_faed3b3b-7928-4419-82ce-bf363c2abcfa_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_faed3b3b-7928-4419-82ce-bf363c2abcfa" xlink:to="loc_srt_SegmentGeographicalDomain_faed3b3b-7928-4419-82ce-bf363c2abcfa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7174b6a6-e43c-4490-a142-39df0c07d421" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_faed3b3b-7928-4419-82ce-bf363c2abcfa" xlink:to="loc_srt_SegmentGeographicalDomain_7174b6a6-e43c-4490-a142-39df0c07d421" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f157c9a4-73cc-40c2-9590-10eb85c47442" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7174b6a6-e43c-4490-a142-39df0c07d421" xlink:to="loc_country_US_f157c9a4-73cc-40c2-9590-10eb85c47442" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_7f1ecfb3-6850-44cc-ac98-c5851bbddd37" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7174b6a6-e43c-4490-a142-39df0c07d421" xlink:to="loc_srt_EuropeMember_7f1ecfb3-6850-44cc-ac98-c5851bbddd37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_RestOfTheWorldMember_bda8a945-cdbe-483f-9e26-ec542a60ec22" xlink:href="cdna-20230331.xsd#cdna_RestOfTheWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7174b6a6-e43c-4490-a142-39df0c07d421" xlink:to="loc_cdna_RestOfTheWorldMember_bda8a945-cdbe-483f-9e26-ec542a60ec22" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>cdna-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:c6b1ad27-1676-415f-b1d2-9124c5a59c19,g:635f8054-df92-419b-85ba-772c4e54710d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_cdna_AccruedCapitalExpenditures_e6806e82-4c5b-4a08-ad17-3b069d7a8676_terseLabel_en-US" xlink:label="lab_cdna_AccruedCapitalExpenditures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_cdna_AccruedCapitalExpenditures_label_en-US" xlink:label="lab_cdna_AccruedCapitalExpenditures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Capital Expenditures</link:label>
    <link:label id="lab_cdna_AccruedCapitalExpenditures_documentation_en-US" xlink:label="lab_cdna_AccruedCapitalExpenditures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Capital Expenditures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AccruedCapitalExpenditures" xlink:href="cdna-20230331.xsd#cdna_AccruedCapitalExpenditures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_AccruedCapitalExpenditures" xlink:to="lab_cdna_AccruedCapitalExpenditures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_02389f25-718a-4f30-bbcc-dbf25a8b0b97_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_CostOfProductMember_62afed9c-72e6-4a48-98c1-9d117ecf285a_terseLabel_en-US" xlink:label="lab_cdna_CostOfProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Product</link:label>
    <link:label id="lab_cdna_CostOfProductMember_9cf2bcef-f908-4703-8c80-d419a0193ed6_verboseLabel_en-US" xlink:label="lab_cdna_CostOfProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product</link:label>
    <link:label id="lab_cdna_CostOfProductMember_label_en-US" xlink:label="lab_cdna_CostOfProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Product [Member]</link:label>
    <link:label id="lab_cdna_CostOfProductMember_documentation_en-US" xlink:label="lab_cdna_CostOfProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CostOfProductMember" xlink:href="cdna-20230331.xsd#cdna_CostOfProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_CostOfProductMember" xlink:to="lab_cdna_CostOfProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_UnsubmittedReimbursementClaimsForMedicare_2a90bd35-9d3d-4bf3-b491-e7016c70110f_terseLabel_en-US" xlink:label="lab_cdna_UnsubmittedReimbursementClaimsForMedicare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement claims</link:label>
    <link:label id="lab_cdna_UnsubmittedReimbursementClaimsForMedicare_label_en-US" xlink:label="lab_cdna_UnsubmittedReimbursementClaimsForMedicare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsubmitted Reimbursement Claims For Medicare</link:label>
    <link:label id="lab_cdna_UnsubmittedReimbursementClaimsForMedicare_documentation_en-US" xlink:label="lab_cdna_UnsubmittedReimbursementClaimsForMedicare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsubmitted Reimbursement Claims For Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_UnsubmittedReimbursementClaimsForMedicare" xlink:href="cdna-20230331.xsd#cdna_UnsubmittedReimbursementClaimsForMedicare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_UnsubmittedReimbursementClaimsForMedicare" xlink:to="lab_cdna_UnsubmittedReimbursementClaimsForMedicare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_1ff8990d-22f6-46ac-8ebd-d4d6731f9b47_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a516898e-bed1-4e45-b250-f09a8181ee6a_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_b9f69886-04ea-43f0-8526-19016a022910_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_ce2f769a-9f5a-4014-a3ab-6143ebf007d5_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MalpracticeInsuranceMaximumCoveragePerIncident_90a70f1c-f438-47c9-8cd0-5e469741f9a4_terseLabel_en-US" xlink:label="lab_us-gaap_MalpracticeInsuranceMaximumCoveragePerIncident" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance matter</link:label>
    <link:label id="lab_us-gaap_MalpracticeInsuranceMaximumCoveragePerIncident_label_en-US" xlink:label="lab_us-gaap_MalpracticeInsuranceMaximumCoveragePerIncident" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Malpractice Insurance, Maximum Coverage Per Incident</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MalpracticeInsuranceMaximumCoveragePerIncident" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MalpracticeInsuranceMaximumCoveragePerIncident"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MalpracticeInsuranceMaximumCoveragePerIncident" xlink:to="lab_us-gaap_MalpracticeInsuranceMaximumCoveragePerIncident" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_1744bc94-bd74-46cb-bc6b-e62feae5055a_terseLabel_en-US" xlink:label="lab_cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="cdna-20230331.xsd#cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_edcb6a89-8de6-4b82-8842-a4db90f418b7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_CAREDXINCVsNateraIncMember_d92aa1a0-ad5b-427d-a98b-f2e45d0daa91_terseLabel_en-US" xlink:label="lab_cdna_CAREDXINCVsNateraIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAREDX, INC. vs Natera Inc.</link:label>
    <link:label id="lab_cdna_CAREDXINCVsNateraIncMember_label_en-US" xlink:label="lab_cdna_CAREDXINCVsNateraIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAREDX, INC. vs Natera Inc. [Member]</link:label>
    <link:label id="lab_cdna_CAREDXINCVsNateraIncMember_documentation_en-US" xlink:label="lab_cdna_CAREDXINCVsNateraIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAREDX, INC. vs Natera Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CAREDXINCVsNateraIncMember" xlink:href="cdna-20230331.xsd#cdna_CAREDXINCVsNateraIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_CAREDXINCVsNateraIncMember" xlink:to="lab_cdna_CAREDXINCVsNateraIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_c7abd5e6-bc6f-460f-92c5-9ae267e1b7f8_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gain</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_fd737538-ffa1-461d-820a-1600b124193e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_NumberOfUniqueSolutions_e725926e-c3ef-47fe-bf69-1e049c1ce86d_terseLabel_en-US" xlink:label="lab_cdna_NumberOfUniqueSolutions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of unique solutions</link:label>
    <link:label id="lab_cdna_NumberOfUniqueSolutions_label_en-US" xlink:label="lab_cdna_NumberOfUniqueSolutions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Unique Solutions</link:label>
    <link:label id="lab_cdna_NumberOfUniqueSolutions_documentation_en-US" xlink:label="lab_cdna_NumberOfUniqueSolutions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Unique Solutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_NumberOfUniqueSolutions" xlink:href="cdna-20230331.xsd#cdna_NumberOfUniqueSolutions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_NumberOfUniqueSolutions" xlink:to="lab_cdna_NumberOfUniqueSolutions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_eb12e578-361f-40ad-93c1-4eda66a3a132_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_a0ab3869-0627-416b-bc2f-a25a93cd5199_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Addition of estimated fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_9042fa5b-6b7c-475c-a1b4-b144d4a687e2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_IncreaseDecreaseInOperatingLeaseLiabilities_b66ea18a-784c-48f4-843e-6d018551ac6a_terseLabel_en-US" xlink:label="lab_cdna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases liabilities, net</link:label>
    <link:label id="lab_cdna_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_cdna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:label id="lab_cdna_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_cdna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="cdna-20230331.xsd#cdna_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_cdna_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans_40af1ee3-850d-4def-90fc-7161c3857eda_terseLabel_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock under employee incentive plans (in shares)</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans_label_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Repurchases Of Common Stock Under Employee Incentive Plans</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans_documentation_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award, repurchases of common stock under employee incentive plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans" xlink:to="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6ae1377a-f732-48e3-b998-c715b5120657_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_AccruedSampleProcessingFees_323133fc-1d31-428e-9623-43571c8cb631_terseLabel_en-US" xlink:label="lab_cdna_AccruedSampleProcessingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory processing fees and materials</link:label>
    <link:label id="lab_cdna_AccruedSampleProcessingFees_label_en-US" xlink:label="lab_cdna_AccruedSampleProcessingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sample Processing Fees</link:label>
    <link:label id="lab_cdna_AccruedSampleProcessingFees_documentation_en-US" xlink:label="lab_cdna_AccruedSampleProcessingFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sample Processing Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AccruedSampleProcessingFees" xlink:href="cdna-20230331.xsd#cdna_AccruedSampleProcessingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_AccruedSampleProcessingFees" xlink:to="lab_cdna_AccruedSampleProcessingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_1071cc49-95f4-45db-8d5c-9ef2395e541b_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_09b0d350-067c-4657-9a28-5fe645582d5e_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_IncomeTaxesTable_fd04c3ae-0fa2-4530-be1d-3f3782309324_terseLabel_en-US" xlink:label="lab_cdna_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_cdna_IncomeTaxesTable_label_en-US" xlink:label="lab_cdna_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_cdna_IncomeTaxesTable_documentation_en-US" xlink:label="lab_cdna_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_IncomeTaxesTable" xlink:href="cdna-20230331.xsd#cdna_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_IncomeTaxesTable" xlink:to="lab_cdna_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f13bcd9a-4392-407d-aee6-685a07ab5e52_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ab893033-886d-41f4-b447-ef0107bbf2ff_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for cash upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9e994908-1811-4b80-b4b1-eac537ce4b0a_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f8af6d81-07fc-4239-be86-4d753042ec33_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate - Operating leases (%)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_478284de-4dbf-4c32-be77-59f05bdff764_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of short-term marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9e901de6-20ad-4f0e-a112-2911eed766a5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_WarrantFairValueAssumptionsExpectedTerm_4d9fa5e6-d66f-4101-a0f5-e7b99f007a46_verboseLabel_en-US" xlink:label="lab_cdna_WarrantFairValueAssumptionsExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Original Term (in years)</link:label>
    <link:label id="lab_cdna_WarrantFairValueAssumptionsExpectedTerm_label_en-US" xlink:label="lab_cdna_WarrantFairValueAssumptionsExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Fair Value Assumptions Expected Term</link:label>
    <link:label id="lab_cdna_WarrantFairValueAssumptionsExpectedTerm_documentation_en-US" xlink:label="lab_cdna_WarrantFairValueAssumptionsExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant fair value assumptions expected term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_WarrantFairValueAssumptionsExpectedTerm" xlink:href="cdna-20230331.xsd#cdna_WarrantFairValueAssumptionsExpectedTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_WarrantFairValueAssumptionsExpectedTerm" xlink:to="lab_cdna_WarrantFairValueAssumptionsExpectedTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1a3f47dc-00c3-4626-bf08-4fd483159c29_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_e20e4ba3-cc9e-41e0-9c73-f4a0ea52f90d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d20e8ea8-7b5d-4aaa-9181-1d4ccbc1cef1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ee8180d6-83bc-4a71-8ee5-dc9c970dd21f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b1c404c7-0257-40ab-825e-b02b2c6387f5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_765cb6b4-da41-41c2-96a2-cc063657bb90_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c09658a3-86a8-4fb1-8da9-eb166c17b364_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c0489d9b-09c5-4936-8dfb-5e74d1d15994_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential dilutive securities excluded from diluted net loss per share attributable to common stockholders (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_64d4ee2d-494e-4cc9-b85a-63ec275a2931_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_944a876c-f464-4b91-afe8-e1c96827e4ed_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_MarketableSecuritiesFairValueShortTerm_57384203-9536-4c8a-9ed5-4fd91185c4ce_terseLabel_en-US" xlink:label="lab_cdna_MarketableSecuritiesFairValueShortTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_cdna_MarketableSecuritiesFairValueShortTerm_label_en-US" xlink:label="lab_cdna_MarketableSecuritiesFairValueShortTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Fair Value, Short Term</link:label>
    <link:label id="lab_cdna_MarketableSecuritiesFairValueShortTerm_documentation_en-US" xlink:label="lab_cdna_MarketableSecuritiesFairValueShortTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Fair Value, Short Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesFairValueShortTerm" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesFairValueShortTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_MarketableSecuritiesFairValueShortTerm" xlink:to="lab_cdna_MarketableSecuritiesFairValueShortTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_389929c2-d8a9-4810-94db-bcbd451ecd41_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_6b0ad88a-e0dc-4ad0-a83b-d119ba336597_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_1668742b-9334-4ed3-9ddd-0654fa165056_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_33dbe52e-eeb6-486c-93f6-619fae47287b_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_NumberOfWarrantsExercised_d36f13f6-8c26-4483-932e-a9c9da21bbe3_terseLabel_en-US" xlink:label="lab_cdna_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants exercised (in shares)</link:label>
    <link:label id="lab_cdna_NumberOfWarrantsExercised_label_en-US" xlink:label="lab_cdna_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Warrants Exercised</link:label>
    <link:label id="lab_cdna_NumberOfWarrantsExercised_documentation_en-US" xlink:label="lab_cdna_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_NumberOfWarrantsExercised" xlink:href="cdna-20230331.xsd#cdna_NumberOfWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_NumberOfWarrantsExercised" xlink:to="lab_cdna_NumberOfWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_EarningPerShareBasicAndDilutedAbstract_67e2a1d6-d7e5-4dde-881b-2e23aad941cd_terseLabel_en-US" xlink:label="lab_cdna_EarningPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share:</link:label>
    <link:label id="lab_cdna_EarningPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_cdna_EarningPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earning Per Share Basic And Diluted [Abstract]</link:label>
    <link:label id="lab_cdna_EarningPerShareBasicAndDilutedAbstract_documentation_en-US" xlink:label="lab_cdna_EarningPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_EarningPerShareBasicAndDilutedAbstract" xlink:href="cdna-20230331.xsd#cdna_EarningPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_EarningPerShareBasicAndDilutedAbstract" xlink:to="lab_cdna_EarningPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_b4c42593-321b-4b35-a772-0c80ee0cc5b6_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_eebcb266-d375-43b5-9dc6-d2b814081d4b_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_bd3cd927-550e-4bdb-94e8-44b4006acef9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8428e188-7241-437c-9767-1120bf702e18_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets with finite lives:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0fe1ecda-5536-4a84-bbb3-e4503e47fa01_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price - options forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_09ca1deb-803c-49cc-969a-5f3b7dd56389_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_12d0656f-98d4-4bdf-8d83-15f464c50f77_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_16e0374c-3daf-4429-840c-86f205e05004_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_32674ab8-4702-4950-a53b-35cba2ce9948_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e4950008-bd42-4fe2-b421-d3b451c09d2f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_7b026f97-f74e-4537-8fcc-588df98e0510_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measured Using - (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_MarketableSecuritiesAmortizedCostLongTerm_65202cd2-1052-4b3a-a757-3a63ba725ef6_totalLabel_en-US" xlink:label="lab_cdna_MarketableSecuritiesAmortizedCostLongTerm" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_cdna_MarketableSecuritiesAmortizedCostLongTerm_label_en-US" xlink:label="lab_cdna_MarketableSecuritiesAmortizedCostLongTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Amortized Cost, Long Term</link:label>
    <link:label id="lab_cdna_MarketableSecuritiesAmortizedCostLongTerm_documentation_en-US" xlink:label="lab_cdna_MarketableSecuritiesAmortizedCostLongTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Amortized Cost, Long Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAmortizedCostLongTerm" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAmortizedCostLongTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_MarketableSecuritiesAmortizedCostLongTerm" xlink:to="lab_cdna_MarketableSecuritiesAmortizedCostLongTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_6add8041-980e-468c-841c-fe1de1e300d9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ab5c910d-0b6d-4dc1-86e6-4d6c6944e21a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_NumberOfRenalTransplantPatients_e4f82d8b-0d5e-4531-9a2d-2102b315bab1_terseLabel_en-US" xlink:label="lab_cdna_NumberOfRenalTransplantPatients" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of renal transplant patients (more than)</link:label>
    <link:label id="lab_cdna_NumberOfRenalTransplantPatients_label_en-US" xlink:label="lab_cdna_NumberOfRenalTransplantPatients" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Renal Transplant Patients</link:label>
    <link:label id="lab_cdna_NumberOfRenalTransplantPatients_documentation_en-US" xlink:label="lab_cdna_NumberOfRenalTransplantPatients" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Renal Transplant Patients</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_NumberOfRenalTransplantPatients" xlink:href="cdna-20230331.xsd#cdna_NumberOfRenalTransplantPatients"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_NumberOfRenalTransplantPatients" xlink:to="lab_cdna_NumberOfRenalTransplantPatients" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_CostOfPatientAndDigitalSolutionsMember_1b83ffa2-8b76-446c-bda1-de1506e4911e_terseLabel_en-US" xlink:label="lab_cdna_CostOfPatientAndDigitalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Patient and Digital Solutions</link:label>
    <link:label id="lab_cdna_CostOfPatientAndDigitalSolutionsMember_58c2ca03-0014-42cf-a725-3404f1af8781_verboseLabel_en-US" xlink:label="lab_cdna_CostOfPatientAndDigitalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of patient and digital solutions</link:label>
    <link:label id="lab_cdna_CostOfPatientAndDigitalSolutionsMember_label_en-US" xlink:label="lab_cdna_CostOfPatientAndDigitalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Patient And Digital Solutions [Member]</link:label>
    <link:label id="lab_cdna_CostOfPatientAndDigitalSolutionsMember_documentation_en-US" xlink:label="lab_cdna_CostOfPatientAndDigitalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Patient And Digital Solutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CostOfPatientAndDigitalSolutionsMember" xlink:href="cdna-20230331.xsd#cdna_CostOfPatientAndDigitalSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_CostOfPatientAndDigitalSolutionsMember" xlink:to="lab_cdna_CostOfPatientAndDigitalSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_14ec1cf6-3381-44af-8253-fb2b36466354_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_a12a0875-d18b-4785-b526-7d7a547ec155_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_AlloSureHeartMember_2b82903b-3851-44df-83a4-c6822b7b7686_terseLabel_en-US" xlink:label="lab_cdna_AlloSureHeartMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AlloSure Heart</link:label>
    <link:label id="lab_cdna_AlloSureHeartMember_label_en-US" xlink:label="lab_cdna_AlloSureHeartMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AlloSure Heart [Member]</link:label>
    <link:label id="lab_cdna_AlloSureHeartMember_documentation_en-US" xlink:label="lab_cdna_AlloSureHeartMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AlloSure Heart</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AlloSureHeartMember" xlink:href="cdna-20230331.xsd#cdna_AlloSureHeartMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_AlloSureHeartMember" xlink:to="lab_cdna_AlloSureHeartMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_766d9be8-87c5-4048-98a9-03b384764cd3_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_7b254bbb-eb72-4938-808f-bd2c2b053789_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less operating lease liability, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract_c8977dfd-d2d4-4ebb-930c-af2801ad6f9c_terseLabel_en-US" xlink:label="lab_cdna_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_cdna_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract_label_en-US" xlink:label="lab_cdna_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Basic And Diluted Other Disclosure [Abstract]</link:label>
    <link:label id="lab_cdna_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract_documentation_en-US" xlink:label="lab_cdna_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Basic And Diluted Other Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" xlink:href="cdna-20230331.xsd#cdna_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" xlink:to="lab_cdna_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedSalaries_4f38f574-bd74-4c68-b85b-187fd8ba0d35_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedSalaries_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Salaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ca4ee002-8bf9-44b4-b8e6-4d0ce0a9bdfd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d940c063-3fff-4ae8-8c35-2cd0b21192d3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1258a3a2-c01c-40f0-8164-3f8874aa1373_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_58b16e20-2891-447d-bf6f-5fc52df34769_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_PunitiveDamagesMember_51b04b5a-f69f-4f32-9f38-7a9694394cdf_terseLabel_en-US" xlink:label="lab_cdna_PunitiveDamagesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Punitive Damages</link:label>
    <link:label id="lab_cdna_PunitiveDamagesMember_label_en-US" xlink:label="lab_cdna_PunitiveDamagesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Punitive Damages [Member]</link:label>
    <link:label id="lab_cdna_PunitiveDamagesMember_documentation_en-US" xlink:label="lab_cdna_PunitiveDamagesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Punitive Damages</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_PunitiveDamagesMember" xlink:href="cdna-20230331.xsd#cdna_PunitiveDamagesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_PunitiveDamagesMember" xlink:to="lab_cdna_PunitiveDamagesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_EmployeeAndNonEmployeeStockOptionsMember_e2a9bb18-d6bd-4b69-a5bb-9d20c65be588_terseLabel_en-US" xlink:label="lab_cdna_EmployeeAndNonEmployeeStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock subject to outstanding options</link:label>
    <link:label id="lab_cdna_EmployeeAndNonEmployeeStockOptionsMember_label_en-US" xlink:label="lab_cdna_EmployeeAndNonEmployeeStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee And Non Employee Stock Options [Member]</link:label>
    <link:label id="lab_cdna_EmployeeAndNonEmployeeStockOptionsMember_documentation_en-US" xlink:label="lab_cdna_EmployeeAndNonEmployeeStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee and non employee stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_EmployeeAndNonEmployeeStockOptionsMember" xlink:href="cdna-20230331.xsd#cdna_EmployeeAndNonEmployeeStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_EmployeeAndNonEmployeeStockOptionsMember" xlink:to="lab_cdna_EmployeeAndNonEmployeeStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1059ed6c-8f10-41a9-af65-27ecc5fc5a12_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9dc27421-cfd5-4272-a186-14af0faeb277_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_a00d8c9d-40e5-488e-9828-4b0dd0cb7683_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm_d5c4dec1-0eaa-4c91-8a25-2c3e74c8a4f5_terseLabel_en-US" xlink:label="lab_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Holding Losses</link:label>
    <link:label id="lab_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm_label_en-US" xlink:label="lab_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Accumulated Unrecognized Holding Gain (Loss), Short Term</link:label>
    <link:label id="lab_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm_documentation_en-US" xlink:label="lab_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Accumulated Unrecognized Holding Gain (Loss), Short Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm" xlink:to="lab_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_88d03fe5-85d7-48d7-9c78-d9ada644d4c2_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1f53120f-d3ec-479e-87ec-b78fc6f80eba_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_e315b273-bc40-46ef-8c25-ee2217871c48_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39274623-de9f-410e-a9aa-0fbdd31b6ea6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f7845d09-caaa-4d46-bd39-b84faa038abd_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_24a64924-283b-4624-b38c-98837aca545e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premium on short-term marketable securities, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_d835c9b5-337b-4b51-9939-099e147507c2_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_13041a26-3210-4c08-b19f-8b68b6dd49ae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_GoodwillAndIntangibleAssetsTable_d3ed4621-d77f-4a05-81fe-d8d4f37a7101_terseLabel_en-US" xlink:label="lab_cdna_GoodwillAndIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill And Intangible Assets [Table]</link:label>
    <link:label id="lab_cdna_GoodwillAndIntangibleAssetsTable_label_en-US" xlink:label="lab_cdna_GoodwillAndIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill And Intangible Assets [Table]</link:label>
    <link:label id="lab_cdna_GoodwillAndIntangibleAssetsTable_documentation_en-US" xlink:label="lab_cdna_GoodwillAndIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_GoodwillAndIntangibleAssetsTable" xlink:href="cdna-20230331.xsd#cdna_GoodwillAndIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_GoodwillAndIntangibleAssetsTable" xlink:to="lab_cdna_GoodwillAndIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_70393785-4f30-497b-98b3-48bb8de69505_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits_2755a1cb-6dfa-427c-acef-875fcf3ff9c9_negatedLabel_en-US" xlink:label="lab_cdna_TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of restricted stock units</link:label>
    <link:label id="lab_cdna_TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits_label_en-US" xlink:label="lab_cdna_TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Paid Related To Net Share Settlement Of Restricted Stock Units</link:label>
    <link:label id="lab_cdna_TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits_documentation_en-US" xlink:label="lab_cdna_TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits" xlink:href="cdna-20230331.xsd#cdna_TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits" xlink:to="lab_cdna_TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_9822973a-baaf-4be2-9f32-6707ccc40937_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9ab16f40-29ec-477b-9126-517eea096607_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_185dddfa-b660-4813-bccf-17e62257b9ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_2cd2af6a-636d-41b1-bd52-081169953498_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding loss</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_d6c2a5e1-811d-497f-9f4e-ed6428ea6ef7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_723fcb03-4376-4281-a5ae-cfbcaed7bb92_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ebc881e8-bb60-4932-97ed-2372ba46f401_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_17f4046e-6327-4d6d-b27c-d0ce2669d3f4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d35f74bf-cf91-4f6a-81b6-043c23dd492d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_67d4f21b-a9d5-4af9-9fbd-b64359237075_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_AlloSureKidneyMember_071e1297-6fb0-473d-9b66-3190182c2ca3_terseLabel_en-US" xlink:label="lab_cdna_AlloSureKidneyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AlloSure Kidney</link:label>
    <link:label id="lab_cdna_AlloSureKidneyMember_label_en-US" xlink:label="lab_cdna_AlloSureKidneyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AlloSure Kidney [Member]</link:label>
    <link:label id="lab_cdna_AlloSureKidneyMember_documentation_en-US" xlink:label="lab_cdna_AlloSureKidneyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AlloSure Kidney</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AlloSureKidneyMember" xlink:href="cdna-20230331.xsd#cdna_AlloSureKidneyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_AlloSureKidneyMember" xlink:to="lab_cdna_AlloSureKidneyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_3d571a81-f916-4281-a355-732b90c3ffda_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_7896f1ea-4aae-47b5-8339-bf49aa95ccd5_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_c3eec819-dc9e-472c-aead-77f04d082e7c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_efb526df-d804-4c43-84e2-ab9355fc9adf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_SaleOfStockAuthorizedConsiderationAmountMaximum_9d143206-21a4-459f-9cb6-a0325d5475c2_terseLabel_en-US" xlink:label="lab_cdna_SaleOfStockAuthorizedConsiderationAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock amount maximum</link:label>
    <link:label id="lab_cdna_SaleOfStockAuthorizedConsiderationAmountMaximum_label_en-US" xlink:label="lab_cdna_SaleOfStockAuthorizedConsiderationAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Authorized Consideration Amount, Maximum</link:label>
    <link:label id="lab_cdna_SaleOfStockAuthorizedConsiderationAmountMaximum_documentation_en-US" xlink:label="lab_cdna_SaleOfStockAuthorizedConsiderationAmountMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Authorized Consideration Amount, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_SaleOfStockAuthorizedConsiderationAmountMaximum" xlink:href="cdna-20230331.xsd#cdna_SaleOfStockAuthorizedConsiderationAmountMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_SaleOfStockAuthorizedConsiderationAmountMaximum" xlink:to="lab_cdna_SaleOfStockAuthorizedConsiderationAmountMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_210e1594-63a7-42ac-90e2-856af165c792_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_5930324e-2dee-4cef-b1ec-66a1b1d070c8_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_701643a8-f2f6-48b4-8a93-ffa3629e3af6_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_AccruedLicenseAndOtherCollaborationFees_7d705511-c635-415a-a87c-a8ab5a60f7fe_terseLabel_en-US" xlink:label="lab_cdna_AccruedLicenseAndOtherCollaborationFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and other collaboration fees</link:label>
    <link:label id="lab_cdna_AccruedLicenseAndOtherCollaborationFees_label_en-US" xlink:label="lab_cdna_AccruedLicenseAndOtherCollaborationFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued License And Other Collaboration Fees</link:label>
    <link:label id="lab_cdna_AccruedLicenseAndOtherCollaborationFees_documentation_en-US" xlink:label="lab_cdna_AccruedLicenseAndOtherCollaborationFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued License And Other Collaboration Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AccruedLicenseAndOtherCollaborationFees" xlink:href="cdna-20230331.xsd#cdna_AccruedLicenseAndOtherCollaborationFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_AccruedLicenseAndOtherCollaborationFees" xlink:to="lab_cdna_AccruedLicenseAndOtherCollaborationFees" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable_640e16a1-1947-4c07-93e7-e1ef6439df39_terseLabel_en-US" xlink:label="lab_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Finite And Infinite Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Finite And Infinite Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable_documentation_en-US" xlink:label="lab_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of finite and infinite lived intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable" xlink:href="cdna-20230331.xsd#cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable" xlink:to="lab_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_88ef03fe-1a4f-4782-ba9e-4da97e1e86f7_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5ffd9713-e24b-4b9a-bbc4-0ec33ce7d09a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_4e648139-90c6-43f9-8755-4f576fa5ae95_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment, and Other Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_d1c7d9fa-44cc-4335-b7db-925eeac04cb7_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_SummaryOfSignificantAccountingPoliciesTable_c32fceac-685a-4898-be57-66651496bb37_terseLabel_en-US" xlink:label="lab_cdna_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_cdna_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_cdna_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_cdna_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_cdna_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_SummaryOfSignificantAccountingPoliciesTable" xlink:href="cdna-20230331.xsd#cdna_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_cdna_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_5a3e4964-db7e-4487-b2e4-593656d9375a_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_e0c6a2c8-d59f-4f17-b2c9-0eb479d3dee7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_3cd85231-624e-4b81-bdc8-f8075bd343eb_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded from Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6532c817-4728-4e84-8fcd-2b4a73eba51a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_DeferredPaymentsForIntangibleAssets_c31b34b8-4a54-4677-96e3-4c8bef9d36b7_verboseLabel_en-US" xlink:label="lab_cdna_DeferredPaymentsForIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred payments for intangible assets</link:label>
    <link:label id="lab_cdna_DeferredPaymentsForIntangibleAssets_label_en-US" xlink:label="lab_cdna_DeferredPaymentsForIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Payments For Intangible Assets</link:label>
    <link:label id="lab_cdna_DeferredPaymentsForIntangibleAssets_documentation_en-US" xlink:label="lab_cdna_DeferredPaymentsForIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred payments for intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_DeferredPaymentsForIntangibleAssets" xlink:href="cdna-20230331.xsd#cdna_DeferredPaymentsForIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_DeferredPaymentsForIntangibleAssets" xlink:to="lab_cdna_DeferredPaymentsForIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_d4809fc9-5439-4e68-ac23-8e76abf8a8e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Held-to-maturity Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Held-to-Maturity Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_54bf1bd9-ea24-47c8-93d5-c3a7fd8d5d03_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_15761bf0-23d7-4d4d-a59d-a7155a9eae74_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_84b70b6c-5ff9-42ad-a80b-ccd2ff5feb43_terseLabel_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditConcentrationRiskMember" xlink:to="lab_us-gaap_CreditConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_FiniteLivedIntangibleForeignCurrencyTranslation_ea37b7db-6a78-494f-9714-dac41c027428_negatedLabel_en-US" xlink:label="lab_cdna_FiniteLivedIntangibleForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_cdna_FiniteLivedIntangibleForeignCurrencyTranslation_label_en-US" xlink:label="lab_cdna_FiniteLivedIntangibleForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Foreign Currency Translation</link:label>
    <link:label id="lab_cdna_FiniteLivedIntangibleForeignCurrencyTranslation_documentation_en-US" xlink:label="lab_cdna_FiniteLivedIntangibleForeignCurrencyTranslation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Foreign Currency Translation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_FiniteLivedIntangibleForeignCurrencyTranslation" xlink:href="cdna-20230331.xsd#cdna_FiniteLivedIntangibleForeignCurrencyTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_FiniteLivedIntangibleForeignCurrencyTranslation" xlink:to="lab_cdna_FiniteLivedIntangibleForeignCurrencyTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9d124f0b-f30c-49ef-bfc9-82fc4457c1ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price - options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_d09c4ed3-11db-4778-916a-dd1f7c889c7f_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_faaea8f1-98a0-4c75-bd1d-9917d6c9c004_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_03470ad3-67ff-40dd-bff2-50bbd740d5f2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_10260e69-40b0-444b-8519-bc63750e42ff_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0e8d0521-558e-4a50-8413-6e94908460b0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_062d0d66-8664-4f5a-ba93-d0aa3441618f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_bdc2a26e-c2de-4f4e-abe6-cd1c4303a367_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5a731d84-6705-46cc-9982-2aee360eb7ba_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_62792848-020d-45fb-a0d0-21cd73ba3df1_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities" xlink:to="lab_us-gaap_HeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_DeferredPaymentsForIntangibleAssetsNoncurrent_3175bb97-9eaa-44a4-bea4-fcfd4d4ab43c_terseLabel_en-US" xlink:label="lab_cdna_DeferredPaymentsForIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred payments for intangible assets</link:label>
    <link:label id="lab_cdna_DeferredPaymentsForIntangibleAssetsNoncurrent_label_en-US" xlink:label="lab_cdna_DeferredPaymentsForIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Payments For Intangible Assets Noncurrent</link:label>
    <link:label id="lab_cdna_DeferredPaymentsForIntangibleAssetsNoncurrent_documentation_en-US" xlink:label="lab_cdna_DeferredPaymentsForIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred payments for intangible assets, noncurrent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_DeferredPaymentsForIntangibleAssetsNoncurrent" xlink:href="cdna-20230331.xsd#cdna_DeferredPaymentsForIntangibleAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_DeferredPaymentsForIntangibleAssetsNoncurrent" xlink:to="lab_cdna_DeferredPaymentsForIntangibleAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_a76451fd-4dd5-4d99-9cd1-a786fdd84436_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_db382f03-d246-4b8c-b3f8-a115fce68ca8_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5847f006-375a-40f2-8193-84eb41ca3e26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Weighted-Average Assumptions Used to Estimate Fair Values of Share-Based Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8c75b8cd-0c4d-46a6-a650-b94ee06709ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in ROU asset</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_57f09bf7-9f1a-4b85-9344-b080e77efc6e_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_97bec779-4113-45cf-a9f2-b9b8516a439d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of options vested during period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a8b19dc7-df62-4e14-a851-95ddc89e9736_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b4c6a748-d38a-4372-84fc-1fc63dd3149e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and RSUs expected weighted average period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_42ae6804-36da-44b5-877c-42ec0dd6ce8d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_5c78fbe5-e58b-47b8-a9e7-6f9f8f0ad9a7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_CompensatoryDamagesMember_1bf280b2-f32e-4af2-ad5d-1b86eb9c9b6f_terseLabel_en-US" xlink:label="lab_cdna_CompensatoryDamagesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensatory Damages</link:label>
    <link:label id="lab_cdna_CompensatoryDamagesMember_label_en-US" xlink:label="lab_cdna_CompensatoryDamagesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensatory Damages [Member]</link:label>
    <link:label id="lab_cdna_CompensatoryDamagesMember_documentation_en-US" xlink:label="lab_cdna_CompensatoryDamagesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensatory Damages</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CompensatoryDamagesMember" xlink:href="cdna-20230331.xsd#cdna_CompensatoryDamagesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_CompensatoryDamagesMember" xlink:to="lab_cdna_CompensatoryDamagesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_aefffc7c-facc-4563-a0ff-509cd48c529c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_cea6d0f5-dfa2-4999-b59f-a4e15470f12d_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_738a9636-a8af-4f67-9064-ddd270ca5d45_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_RestOfTheWorldMember_e50bddc1-fdaf-470d-8e7d-813e625837b8_terseLabel_en-US" xlink:label="lab_cdna_RestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_cdna_RestOfTheWorldMember_7e1f8942-94de-45c7-a02c-38a65b7c6c1a_verboseLabel_en-US" xlink:label="lab_cdna_RestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_cdna_RestOfTheWorldMember_label_en-US" xlink:label="lab_cdna_RestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest Of The World [Member]</link:label>
    <link:label id="lab_cdna_RestOfTheWorldMember_documentation_en-US" xlink:label="lab_cdna_RestOfTheWorldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of the world.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_RestOfTheWorldMember" xlink:href="cdna-20230331.xsd#cdna_RestOfTheWorldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_RestOfTheWorldMember" xlink:to="lab_cdna_RestOfTheWorldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30638e52-4ab6-45e4-bd25-0a9a6cab5992_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_111be132-5f6c-448b-b0be-47bc8bb0f071_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0519e0b9-2694-46dd-bfad-fa9a7874de11_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_6efa8d46-1967-4758-b898-99f5ca814c97_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">401(K) Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_bfd26656-0c32-4088-9122-a516301019c0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_f135d06f-45a1-4279-afcc-a5764cfca856_verboseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Original Term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8b8aedbf-ab0d-49d4-810c-18f31bd1f457_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b9f26987-b6d2-44d6-a586-a14d2c2eb95c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber_2f1ff27a-6cb9-4c12-a5d7-65c14be42359_verboseLabel_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber_label_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber_documentation_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award options vested outstanding number.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber" xlink:to="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_caf71b00-453b-42b9-ad61-243e27f970fc_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_PatientAndDigitalSolutionsMember_5ad5c4cc-c7d1-45a5-a24d-2f95c328b1ff_terseLabel_en-US" xlink:label="lab_cdna_PatientAndDigitalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient and digital solutions revenue</link:label>
    <link:label id="lab_cdna_PatientAndDigitalSolutionsMember_label_en-US" xlink:label="lab_cdna_PatientAndDigitalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient And Digital Solutions [Member]</link:label>
    <link:label id="lab_cdna_PatientAndDigitalSolutionsMember_documentation_en-US" xlink:label="lab_cdna_PatientAndDigitalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient And Digital Solutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_PatientAndDigitalSolutionsMember" xlink:href="cdna-20230331.xsd#cdna_PatientAndDigitalSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_PatientAndDigitalSolutionsMember" xlink:to="lab_cdna_PatientAndDigitalSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_7b8ca965-1d4c-4e88-a584-393ae18dee8e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_85e77ccb-bf5a-43c3-927a-b303abdf88e9_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_ShortTermMarketableSecuritiesAbstract_320a5d23-b38e-4923-a53f-184d76e77dfb_terseLabel_en-US" xlink:label="lab_cdna_ShortTermMarketableSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities</link:label>
    <link:label id="lab_cdna_ShortTermMarketableSecuritiesAbstract_label_en-US" xlink:label="lab_cdna_ShortTermMarketableSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Marketable Securities [Abstract]</link:label>
    <link:label id="lab_cdna_ShortTermMarketableSecuritiesAbstract_documentation_en-US" xlink:label="lab_cdna_ShortTermMarketableSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShortTermMarketableSecuritiesAbstract" xlink:href="cdna-20230331.xsd#cdna_ShortTermMarketableSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_ShortTermMarketableSecuritiesAbstract" xlink:to="lab_cdna_ShortTermMarketableSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_SummaryOfSignificantAccountingPoliciesLineItems_3b1050d8-1a09-40ca-a591-3778c7e10bc0_terseLabel_en-US" xlink:label="lab_cdna_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_cdna_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_cdna_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_cdna_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_cdna_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="cdna-20230331.xsd#cdna_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_cdna_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_a1b29b2e-128d-4836-ab97-49539acc5e38_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_97305b13-187f-4dc0-acf1-82c308c1550b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_da17dccc-1801-4850-a0d0-c928a37ac1cb_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_e3d4be8d-aa8b-49b3-b9df-99b17d80e3e8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_LeasesCommencedInJuly2022Member_bd0cdb7f-02b4-4e92-9d0c-d233570df6f3_terseLabel_en-US" xlink:label="lab_cdna_LeasesCommencedInJuly2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, Commenced In July 2022</link:label>
    <link:label id="lab_cdna_LeasesCommencedInJuly2022Member_label_en-US" xlink:label="lab_cdna_LeasesCommencedInJuly2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, Commenced In July 2022 [Member]</link:label>
    <link:label id="lab_cdna_LeasesCommencedInJuly2022Member_documentation_en-US" xlink:label="lab_cdna_LeasesCommencedInJuly2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, Commenced In July 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_LeasesCommencedInJuly2022Member" xlink:href="cdna-20230331.xsd#cdna_LeasesCommencedInJuly2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_LeasesCommencedInJuly2022Member" xlink:to="lab_cdna_LeasesCommencedInJuly2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1f006255-8be4-4aa1-8092-bae39739ae2f_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_b3029917-d34e-463e-8c13-17684ed3c2dd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b21b8370-9b63-498b-ab97-dbdf8bf8a7f9_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_fad5e12f-021f-45f3-bfc0-4fa0b8028506_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_5f76f39d-e4e6-4c4b-bc78-4807af62df45_terseLabel_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested, aggregate intrinsic value</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award options vested outstanding aggregate intrinsic value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:to="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_dbbed0b2-4c7e-43cb-8969-36462762ac95_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1be11eeb-027d-46d1-927b-f4128b4db277_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_UnsubmittedClaimsRevenueNotYetRecognized_ee45c8ec-2a31-49ff-a1bb-b99aa1755ae8_terseLabel_en-US" xlink:label="lab_cdna_UnsubmittedClaimsRevenueNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue not yet recognized</link:label>
    <link:label id="lab_cdna_UnsubmittedClaimsRevenueNotYetRecognized_label_en-US" xlink:label="lab_cdna_UnsubmittedClaimsRevenueNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsubmitted Claims, Revenue Not Yet Recognized</link:label>
    <link:label id="lab_cdna_UnsubmittedClaimsRevenueNotYetRecognized_documentation_en-US" xlink:label="lab_cdna_UnsubmittedClaimsRevenueNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsubmitted Claims, Revenue Not Yet Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_UnsubmittedClaimsRevenueNotYetRecognized" xlink:href="cdna-20230331.xsd#cdna_UnsubmittedClaimsRevenueNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_UnsubmittedClaimsRevenueNotYetRecognized" xlink:to="lab_cdna_UnsubmittedClaimsRevenueNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_MarketableSecuritiesAmortizedCost_194a7e31-46d5-4385-988c-45452172f966_totalLabel_en-US" xlink:label="lab_cdna_MarketableSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_cdna_MarketableSecuritiesAmortizedCost_label_en-US" xlink:label="lab_cdna_MarketableSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Amortized Cost</link:label>
    <link:label id="lab_cdna_MarketableSecuritiesAmortizedCost_documentation_en-US" xlink:label="lab_cdna_MarketableSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAmortizedCost" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_MarketableSecuritiesAmortizedCost" xlink:to="lab_cdna_MarketableSecuritiesAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c139d48e-0ae2-47ff-8610-db0b6fe86188_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f6172dd7-392e-45e6-8de0-e0e137078924_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a7c09b5c-302f-4b4d-9ab8-144bf5f91e03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_13730673-3817-4351-8d0a-ddd4e3c51b26_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_9b58f75b-be39-4d0e-a33c-eccf9ff04f43_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_3e4c9c50-2812-4af1-be1b-95b099678622_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss_f14342fd-9aed-4fe5-91d4-23641f96ddb9_terseLabel_en-US" xlink:label="lab_cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Holding Losses</link:label>
    <link:label id="lab_cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss_label_en-US" xlink:label="lab_cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Accumulated Unrecognized Gain (Loss)</link:label>
    <link:label id="lab_cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss_documentation_en-US" xlink:label="lab_cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Accumulated Unrecognized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss" xlink:to="lab_cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_95d3b0aa-a3ca-4785-b833-cf2bd125add2_totalLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_e160cf1d-b7aa-4ea4-bc5d-1913dd74bb8c_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_bfc09768-9bc1-4d53-8e1c-65047cfeca69_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_b3026e80-3b54-4398-a8a6-fd77fd6692b4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_406e2f47-402b-4a6d-9364-5bb8ab0bb74d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_abb1c67c-d33e-4053-94c9-a581895d9611_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c95caece-fd10-4def-b6e1-248d73dc5aca_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_bd06f8f4-a620-4663-a798-126100dfa4fb_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock_6b8fac5a-e681-4679-8c4b-c343cf87d4a2_terseLabel_en-US" xlink:label="lab_cdna_ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Future Minimum Lease Commitments under Operating and Finance Leases</link:label>
    <link:label id="lab_cdna_ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_cdna_ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Finance Lease And Operating Lease Liability Maturity [Table Text Block]</link:label>
    <link:label id="lab_cdna_ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock_documentation_en-US" xlink:label="lab_cdna_ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of finance lease and operating lease liability maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="cdna-20230331.xsd#cdna_ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_cdna_ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_132d2393-3a18-4d7f-8cf3-27fe294c0d51_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_a42443eb-8d23-407b-a448-095ee7e623d3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional options authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_5a883aeb-9c45-464d-9faa-f3441b284f7d_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_a8ce0852-d251-4d10-914e-6b7978d67d39_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_0f18e8c4-0721-4953-ba28-b813b843f03c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_a7641b22-73a7-4dcb-8e3c-956758e00ea3_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_53a00e6d-28e9-4285-a793-8fc0fd8770e3_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets - gross carrying amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3a207810-1c65-48cf-b1d8-b691e4d0d5f2_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_2397a2cb-2c6a-4f30-b7cf-cb339d0943c5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_CommonStockWarrantLiabilityMember_dbc2fcc7-1077-4670-88e7-736ad3c1e4d5_terseLabel_en-US" xlink:label="lab_cdna_CommonStockWarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant Liability</link:label>
    <link:label id="lab_cdna_CommonStockWarrantLiabilityMember_label_en-US" xlink:label="lab_cdna_CommonStockWarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant Liability [Member]</link:label>
    <link:label id="lab_cdna_CommonStockWarrantLiabilityMember_documentation_en-US" xlink:label="lab_cdna_CommonStockWarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrant liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CommonStockWarrantLiabilityMember" xlink:href="cdna-20230331.xsd#cdna_CommonStockWarrantLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_CommonStockWarrantLiabilityMember" xlink:to="lab_cdna_CommonStockWarrantLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_be956c7f-c663-41de-bed4-75b18f41ddbb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_a89f48d9-4e9b-4efd-9817-5dc82c77a765_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="lab_us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_44ce5e63-abc0-4a98-9471-6836924b6ceb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_395ad92f-8eba-40af-8f71-74ae38c19cc4_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ef04cebf-94b8-4626-822b-946fdf8c3654_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a9f9b599-4e10-4dc2-ab00-9c81608cd800_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b4df54cf-04a2-448d-8477-f773ad271e98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value - RSUs forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_a8d3d377-6d48-4635-be4d-de705e328a70_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingencyNatureDomain_fe6d4811-411a-4b2b-ab0b-e0032a715b85_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_GainContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_GainContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyNatureDomain" xlink:to="lab_us-gaap_GainContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_6426f01c-a563-4913-adca-6d5c7a2ef4ef_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5205471f-5f69-483b-bab8-92deee74f5d1_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_da6c600e-b3f3-498d-bc6e-db1ab92c5209_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU settlements, net of shares withheld</link:label>
    <link:label id="lab_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_label_en-US" xlink:label="lab_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock, Value, Shares Issued Net of Tax Withholdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:to="lab_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_672fe3eb-6177-48c5-8cc3-960ff9063fae_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_79512c72-06a2-4d54-95e0-3b5f5613715e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_524a97f8-bc67-49fa-a257-56210612cca1_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_5a5796da-e01c-429a-a60a-489fea455373_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Issuances, Exercises, Changes in Fair Value and Reclassifications of Level 3 Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_b09441d7-fd40-46f3-b3cd-cfb6ec52680a_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_07e5ba53-32d0-4325-b011-a8ec2531ef62_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_de1341bd-640a-4c52-a1c6-5764c2ec10d8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_10c2f9d0-44ad-4c62-85f9-a91b8cd96ca4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_37ff6d92-dbc9-4ec7-b7ce-6e35d3a4cb74_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_98b0d563-9d48-4ae2-a6b7-0fafdba1b74c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum portion of earning an employee may contribute to the ESPP Plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_16375d5f-0cb1-4bc9-821b-938dbd240eda_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Expense Relating to Employee and Nonemployee Stock-Based Payment Awards from Stock Options and RSUs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_a60eea54-416b-4442-885e-cb0000cb39a3_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_601a45c8-5d06-4d6c-b152-63b83dfc8b6a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase and retirement of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_37c0eed3-4f92-4dd6-8013-0ff37be4dbef_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_bf483c11-5742-4ee2-956c-a1b57a1b76db_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_7e016b79-7f86-4130-be1f-15624517862c_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_73a0df90-7dff-455d-a673-24350e8182a7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_b7fd71b6-f871-456a-8320-c573369f9cef_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9b9347e5-c359-4fbf-94b0-584e35e567b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value - RSUs vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_aaa739a5-7f6c-4f78-ad8b-756b2b93ed3d_terseLabel_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Available for Grant</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_label_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Non-Option Equity Instruments, Available For Grant [Roll Forward]</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_documentation_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Non-Option Equity Instruments, Available For Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward" xlink:to="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_68a4672b-5486-4330-819f-07c1ff91cea0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, extension period</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_e663294a-f0e2-4eea-84f3-8a35daa7efbc_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_b7e2db14-0089-4a9a-ae8b-33d2c78057b9_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_7e39b545-ee10-4b09-9b03-14752b4e76ef_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5f1d7e44-9778-4ed6-87b2-6e64f7c6f3b9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5ad73632-a8b6-4eba-ab4d-91a4aac62bfc_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, long-term portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_0c2792eb-af54-4e62-af1f-0a4effd5131f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred related to plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_88ab96b6-d3c3-4dfe-925c-9fb563494eca_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_60489cf9-a457-40d0-a56b-f66d989aa49d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_624673f0-db58-41ba-8102-29ae5486ba9e_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_bc4103f1-c1a0-4675-a877-38efcebb787d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable exercise date an offering period shall be equal to percentage of the lower of fair market value of common stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_1ddf6236-f457-4d22-9905-66be203bd592_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Reportable Revenues by Geographic Regions</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_59722efb-8860-4a5a-92af-cca673e4ab1f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7f13ddd5-5638-4897-b3bd-5e14fdc1de84_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_ae8cb208-53cd-4408-ae05-198738fcb865_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward_054c7645-d59b-4ec1-8cbf-98e972587e11_terseLabel_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Outstanding</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward_label_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Number Of Shares Outstanding [Roll Forward]</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward_documentation_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Number Of Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward" xlink:to="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_b4ec6f3a-a007-4c2b-97b3-d24ea09883dd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_867c9f5c-18a1-4f6e-877b-423ec6c4b763_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_1d60d8f7-fc4a-4ef6-b519-75b3bc4203f7_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_74a68065-4b2c-4d52-a15e-cfad6f4528a1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_e3c0df9e-cfc9-45f6-b5a6-157b3eb0da9e_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_AlloMapHeartMember_e91d7cc5-f6e1-4180-b00e-547eb0b68bb9_terseLabel_en-US" xlink:label="lab_cdna_AlloMapHeartMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AlloMap Heart</link:label>
    <link:label id="lab_cdna_AlloMapHeartMember_label_en-US" xlink:label="lab_cdna_AlloMapHeartMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AlloMap Heart [Member]</link:label>
    <link:label id="lab_cdna_AlloMapHeartMember_documentation_en-US" xlink:label="lab_cdna_AlloMapHeartMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AlloMap Heart</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AlloMapHeartMember" xlink:href="cdna-20230331.xsd#cdna_AlloMapHeartMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_AlloMapHeartMember" xlink:to="lab_cdna_AlloMapHeartMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_afa645be-69c7-49f3-9475-a74dcdc6c578_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price - options expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_f3cb080c-6999-44e2-8ade-d8704f689508_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6f29a8b0-bd77-40b5-a09d-0a7a7536c873_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_0b069779-30c7-4809-b275-848e9be6e50e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Finite-Lived Intangible Assets Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_LiquidityPolicyTextBlock_720b6488-3722-4eee-9286-0e17f99f1810_terseLabel_en-US" xlink:label="lab_cdna_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity and Capital Resources</link:label>
    <link:label id="lab_cdna_LiquidityPolicyTextBlock_label_en-US" xlink:label="lab_cdna_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity [Policy Text Block]</link:label>
    <link:label id="lab_cdna_LiquidityPolicyTextBlock_documentation_en-US" xlink:label="lab_cdna_LiquidityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_LiquidityPolicyTextBlock" xlink:href="cdna-20230331.xsd#cdna_LiquidityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_LiquidityPolicyTextBlock" xlink:to="lab_cdna_LiquidityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dd0a41cd-dede-4a60-abbc-b07f9a22f77a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ba60d085-9a4c-4a40-b786-1a49de6be3de_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6d947f91-f8e4-422b-9708-f871d6a655d8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSU shares beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0dd0e5b7-fcc4-40a1-8a94-c81302906067_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSU shares ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_93526780-e587-4051-90db-c13a63b77af3_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_35bb7bf8-6d5d-4fad-bc5c-6c2fc784b165_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_504cc3a1-6f79-4b1e-8092-0814b88aaff5_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_12677b00-966e-4cef-a795-6863e9162a0c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6fe6039a-be8b-4d06-a53e-c26cd74e4f46_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_094d96c0-7d92-4622-b6ec-b5344b14046f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_843a2a46-8913-4c11-8c3a-cbdb83b73d35_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revaluation of contingent consideration to estimated fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_043d64d7-0002-4d00-ba85-d50f6b17fd9b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalty</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_LongTermMarketableSecuritiesAbstract_de225927-7f79-4c16-a195-e877fbd1b4f7_terseLabel_en-US" xlink:label="lab_cdna_LongTermMarketableSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term marketable securities</link:label>
    <link:label id="lab_cdna_LongTermMarketableSecuritiesAbstract_label_en-US" xlink:label="lab_cdna_LongTermMarketableSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Marketable Securities [Abstract]</link:label>
    <link:label id="lab_cdna_LongTermMarketableSecuritiesAbstract_documentation_en-US" xlink:label="lab_cdna_LongTermMarketableSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_LongTermMarketableSecuritiesAbstract" xlink:href="cdna-20230331.xsd#cdna_LongTermMarketableSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_LongTermMarketableSecuritiesAbstract" xlink:to="lab_cdna_LongTermMarketableSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_2b079312-5ae3-4638-944a-ffdf04bed506_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_8a054d7a-ed87-4749-8e74-838507a87fa1_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenue</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_0b86b2e8-aad3-430f-8732-c24f17cc6a19_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_74a16eb4-b036-4402-8975-3dc6c74dd4ab_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_494f1cf2-6f3c-4ba8-a273-dfbb619fba6e_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9247ac80-bc9b-4894-a417-82c1e26fff2e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_38cab8f0-012f-43c6-8fc6-b53937fe260a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1aa5b4da-fc01-419d-b2e3-28c2c3eec15b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_cc5fe9f5-9f7e-4cee-95ff-6a9bd7c68893_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_a54c1653-d60c-4704-853e-c658c58d17df_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6c29ffd1-dd32-443f-89ba-79b8bf846249_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_9ac5e3a6-ade2-4267-a8f3-873b5236b7bd_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_7291be5d-9f36-495d-97c0-4590fc6df35a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_82b3e97b-db95-4d70-a801-b8a4bb5c9218_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4d75d8a8-e920-4842-b2e0-29ca68401d20_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_AcquiredAndDevelopedTechnologyMember_e22fd942-1b06-4284-9e11-5e662bdcd7f3_terseLabel_en-US" xlink:label="lab_cdna_AcquiredAndDevelopedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired and developed technology</link:label>
    <link:label id="lab_cdna_AcquiredAndDevelopedTechnologyMember_label_en-US" xlink:label="lab_cdna_AcquiredAndDevelopedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired And Developed Technology [Member]</link:label>
    <link:label id="lab_cdna_AcquiredAndDevelopedTechnologyMember_documentation_en-US" xlink:label="lab_cdna_AcquiredAndDevelopedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired And Developed Technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AcquiredAndDevelopedTechnologyMember" xlink:href="cdna-20230331.xsd#cdna_AcquiredAndDevelopedTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_AcquiredAndDevelopedTechnologyMember" xlink:to="lab_cdna_AcquiredAndDevelopedTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_04becb1d-4455-43e7-8dd0-cf7ef6565eea_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Testing services revenue</link:label>
    <link:label id="lab_us-gaap_ServiceMember_53ce5f46-be86-4391-a222-3591ae953c7d_verboseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Testing services revenue</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_ca60d45e-084a-4068-a239-3edde22339d6_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_9179a06b-0a2e-449e-8769-54686a4ef92f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_4130f88e-090d-4a01-a02d-19065d2495a9_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock purchased (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_eaa9910f-84a6-4261-9df0-1c796c48fad6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_dcacc826-29dc-439f-9017-aee46878980d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_f8f5b7fb-8b38-42f5-8c60-03f978bf70a5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_51cff2ce-923c-45ba-8ead-ad811f225d6d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (expense) benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1140b303-d84d-4b7c-8d09-037af089242e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_993cb35f-fad5-4a8e-ad97-251786b6f054_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_21491aba-eb1f-4b66-b1e3-0259038d2f01_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of RSUs</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_c12e848c-10b3-4f7f-9398-9efa04176829_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a36846dd-d6af-4cee-9072-8dc1c11ebb62_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_e8e0d71a-cd90-45a9-91a0-255da471816a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4a8518ee-e377-4c7e-89ee-54c793ae857a_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9c012aac-6324-43bf-b045-5f6422904180_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_e4446353-5b86-486a-a7be-b890535c347b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_8d835faa-d47b-486a-817b-5e51afa5d17d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_6d2435dd-6646-4b93-b9eb-6eb19b1337bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_c8fbe854-0455-497d-84de-f395da531fff_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of testing services, product, digital, and other</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9f503c25-acb3-47eb-8ce3-45c15a50087e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f00262ed-7c00-4447-9b2e-33c8df27e4d3_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used to compute diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_876c0a98-97e4-4858-a302-b55e84312517_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityTable_875a6262-5b16-41d5-92f2-e414a6702286_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCapitalizationEquityTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Capitalization, Equity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="lab_us-gaap_ScheduleOfCapitalizationEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5e8a34b7-3f4c-455e-8809-e6b6e29c00a6_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_2bf84f86-2544-4b52-9a33-150f94395e5c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_0242cb6a-2f35-44f4-b4a3-62ff343c2c8b_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_dfe5a979-ae0e-4b1e-bf85-c2474d840362_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecurities_1a1d29d5-b92a-4e78-90c0-d698a0effad8_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_MarketableSecurities_label_en-US" xlink:label="lab_us-gaap_MarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecurities" xlink:to="lab_us-gaap_MarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion_8d009624-3f77-4745-948a-31fdf061b8b7_negatedTerseLabel_en-US" xlink:label="lab_cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent considerations</link:label>
    <link:label id="lab_cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion_label_en-US" xlink:label="lab_cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Contingent Considerations, Less Current Portion</link:label>
    <link:label id="lab_cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion_documentation_en-US" xlink:label="lab_cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Contingent Considerations, Less Current Portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion" xlink:href="cdna-20230331.xsd#cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion" xlink:to="lab_cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_61b6baa1-5972-4a8a-b78e-8362ba03035f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock: $0.001 par value; 100,000,000 shares authorized at March&#160;31, 2023 and December&#160;31, 2022; 53,712,654 shares and 53,583,301 shares issued at March&#160;31, 2023 and December&#160;31, 2022, respectively; 53,653,182 shares and 53,533,250 shares outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_c9415716-32ce-4e4e-9bef-e37ecfe4227c_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_4838d2a4-43f1-4879-8774-707532ddd08b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_3558f8ae-ede8-4ae3-b858-e92574bae3c9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU settlements, net of shares withheld (in shares)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_label_en-US" xlink:label="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm_b65bee89-05dc-4f0e-8138-283288126632_terseLabel_en-US" xlink:label="lab_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Holding Losses</link:label>
    <link:label id="lab_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm_label_en-US" xlink:label="lab_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Accumulated Unrecognized Holding Gain (Loss), Long Term</link:label>
    <link:label id="lab_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm_documentation_en-US" xlink:label="lab_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Accumulated Unrecognized Holding Gain (Loss), Long Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm" xlink:to="lab_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3e40ac88-9422-46de-b304-0c5f25cce5af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value - RSUs granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f05ef61a-75d0-4c5d-8786-61abb963f0d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Potentially Dilutive Securities Excluded from Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock_4b6edecf-a24a-4c03-b607-d99b6a7793d8_terseLabel_en-US" xlink:label="lab_cdna_ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU Assets and Lease Liabilities for Lease Agreements</link:label>
    <link:label id="lab_cdna_ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock_label_en-US" xlink:label="lab_cdna_ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Right Of Use Assets And Lease Liabilities For Lease Agreements [Table Text Block]</link:label>
    <link:label id="lab_cdna_ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock_documentation_en-US" xlink:label="lab_cdna_ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Right Of Use Assets And Lease Liabilities For Lease Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock" xlink:href="cdna-20230331.xsd#cdna_ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock" xlink:to="lab_cdna_ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_e9fd266c-b9af-4383-a093-f429df6a9706_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Value of Financial Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue_f661475a-0336-4418-a27f-8f7b56e45fd5_terseLabel_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest, aggregate intrinsic value</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award options expected to vest outstanding aggregate intrinsic value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax_ab9f178a-06f5-47c8-bfb9-c656d486d20a_terseLabel_en-US" xlink:label="lab_cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities, unrealized holding gains (losses)</link:label>
    <link:label id="lab_cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax_label_en-US" xlink:label="lab_cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Accumulated Gross Unrealized Gain (Loss), Before Tax</link:label>
    <link:label id="lab_cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax_documentation_en-US" xlink:label="lab_cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Accumulated Gross Unrealized Gain (Loss), Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:href="cdna-20230331.xsd#cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:to="lab_cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_962a8995-bee4-43eb-89a3-19a8e5b30281_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_2c6429f1-482b-44c1-a55c-14a01797db8b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_121258ef-eb05-4f2d-b335-2fd1c529babe_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of investments in convertible preferred shares</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5febf087-cbf1-48f8-bac3-1a131cbde66a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c804e06d-b15a-40ec-9c5e-5883fe74838c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dace568a-1f5a-49fc-92e1-e4b74efc1f8b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash at the end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4ce40a83-01d2-4991-963e-c83e5f625544_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_faeba69d-352f-4c42-a20f-a1c4488fdb93_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_ScheduleOfIntangibleAssetsTableTableTextBlock_fdcec481-2635-44fa-8d87-b495d339a490_terseLabel_en-US" xlink:label="lab_cdna_ScheduleOfIntangibleAssetsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Intangible Assets</link:label>
    <link:label id="lab_cdna_ScheduleOfIntangibleAssetsTableTableTextBlock_label_en-US" xlink:label="lab_cdna_ScheduleOfIntangibleAssetsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Intangible Assets Table [Table Text Block]</link:label>
    <link:label id="lab_cdna_ScheduleOfIntangibleAssetsTableTableTextBlock_documentation_en-US" xlink:label="lab_cdna_ScheduleOfIntangibleAssetsTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ScheduleOfIntangibleAssetsTableTableTextBlock" xlink:href="cdna-20230331.xsd#cdna_ScheduleOfIntangibleAssetsTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_ScheduleOfIntangibleAssetsTableTableTextBlock" xlink:to="lab_cdna_ScheduleOfIntangibleAssetsTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c2852803-7b5f-42fb-996e-9731075cf4b4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_0428eea1-8ac8-4a79-80f2-4f39f56bc85d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ef8e121a-df33-450e-be36-27d7a2b7289e_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_913c805c-01b5-4bf1-a1a6-90e6ebf49dcf_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss used to compute basic net loss per share</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_7955f6cc-0bea-4784-a4bd-37e77ae7925c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_fd463a1c-28b2-45b8-9f2c-5cc8356798e3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_b40fa16d-ff6f-4f94-a4ee-5f3178e1ec4d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_c630fe2a-3590-4c0f-9892-90a5a91e0697_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_a2a43e27-c237-4acd-858d-11ca3d7e5cae_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrant liability</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_3892df52-3644-4648-ac97-255a136c855c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_a542686b-594c-4992-8d64-ae8efc3f714c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f1b5099e-1016-43cf-b584-33ba60dd6b68_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a6a3f0cb-5fb4-4a30-a6cf-3abd0fb980a8_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_a2506797-a0bd-4560-82fc-01b03d6dad68_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b26267c2-53f6-4f2f-899a-5d74e13c676d_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Useful&#160;Life (In&#160;Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_61bd48d5-8b00-4780-9f1a-366885a8cdf9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_e7e36d41-8553-4614-97f5-0a54355b04b7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_79b017f8-d9e7-47ab-b777-0f8eb2017177_verboseLabel_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested, weighted average remaining life</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:to="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_642e5433-1d84-486b-92ab-bf28638b0ff9_terseLabel_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering period for employee stock purchases</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_label_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Offering Period</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_documentation_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award offering period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_f5d6124c-e607-4c1a-8ab4-cddeb8811c8e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims field</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_746a7416-9954-4ae2-9749-f72f14cd75b6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_IntangibleAssetMeasurementInputDiscountRate_620db70c-127a-49a1-a5f3-dc606eb9b85c_terseLabel_en-US" xlink:label="lab_cdna_IntangibleAssetMeasurementInputDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset, measurement input, discount rate</link:label>
    <link:label id="lab_cdna_IntangibleAssetMeasurementInputDiscountRate_label_en-US" xlink:label="lab_cdna_IntangibleAssetMeasurementInputDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset, Measurement Input, Discount Rate</link:label>
    <link:label id="lab_cdna_IntangibleAssetMeasurementInputDiscountRate_documentation_en-US" xlink:label="lab_cdna_IntangibleAssetMeasurementInputDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset, Measurement Input, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_IntangibleAssetMeasurementInputDiscountRate" xlink:href="cdna-20230331.xsd#cdna_IntangibleAssetMeasurementInputDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_IntangibleAssetMeasurementInputDiscountRate" xlink:to="lab_cdna_IntangibleAssetMeasurementInputDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_ac66001c-0f41-4000-980b-8fffd60e8a4b_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_f5767839-50fb-4717-9a63-b6b70c27366d_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_HLADataSystemsMember_fc505f42-cc72-4ac0-885f-53c4374dcacb_terseLabel_en-US" xlink:label="lab_cdna_HLADataSystemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HLA Data Systems</link:label>
    <link:label id="lab_cdna_HLADataSystemsMember_label_en-US" xlink:label="lab_cdna_HLADataSystemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HLA Data Systems [Member]</link:label>
    <link:label id="lab_cdna_HLADataSystemsMember_documentation_en-US" xlink:label="lab_cdna_HLADataSystemsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HLA Data Systems</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_HLADataSystemsMember" xlink:href="cdna-20230331.xsd#cdna_HLADataSystemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_HLADataSystemsMember" xlink:to="lab_cdna_HLADataSystemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2d068943-388a-40ef-bb10-51080cceee04_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, unrealized holding gains (losses)</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_90aa268f-4b35-471a-9c99-fc4baf98009e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice_082258e5-adc4-4444-a7eb-d8a770608d75_terseLabel_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest (in dollars per share)</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice_label_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award options expected to vest weighted average exercise price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice" xlink:to="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8cbcd75d-c29f-4b9e-b870-c517c66e966e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_984d72f7-0e1e-4139-a927-398cdb837cc8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_61f9fff7-13fe-43cf-a6ae-7c11c9fc8852_terseLabel_en-US" xlink:label="lab_cdna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_cdna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_cdna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_cdna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_cdna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="cdna-20230331.xsd#cdna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_cdna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4d750fdf-bc6a-4806-98b8-fa034bf51cc3_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_9934994f-5134-41c9-bb84-7158de53e770_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, impairment loss</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_3b023b24-8909-4c81-a514-7b00cded1fd8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_4ba8f95b-d554-408c-a854-202fe0fa501b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2675a7c6-69d6-4184-88fa-e315ea37e4fb_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_AtTheMarketEquityOfferingMember_d2892d83-e1ce-4a23-bcf7-f943bd0ecfcf_terseLabel_en-US" xlink:label="lab_cdna_AtTheMarketEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Equity Offering</link:label>
    <link:label id="lab_cdna_AtTheMarketEquityOfferingMember_label_en-US" xlink:label="lab_cdna_AtTheMarketEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Equity Offering [Member]</link:label>
    <link:label id="lab_cdna_AtTheMarketEquityOfferingMember_documentation_en-US" xlink:label="lab_cdna_AtTheMarketEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Equity Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AtTheMarketEquityOfferingMember" xlink:href="cdna-20230331.xsd#cdna_AtTheMarketEquityOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_AtTheMarketEquityOfferingMember" xlink:to="lab_cdna_AtTheMarketEquityOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_783f5b3a-37fb-4132-adf5-5329af4c8a11_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Values of Assets Acquired and Liabilities Assumed as of Acquisition Date</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_84871431-f2a5-4a27-b09f-871b3bf08ca5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b31b4c27-b2fa-40c2-8ced-cd387a7735da_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_e50c1882-8f1f-47c1-8add-311c529b98f5_verboseLabel_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_label_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award options vested weighted average exercise price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:to="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_d4b5dd07-c4bd-47b3-98e9-87b65d96ff2e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_e27e174a-ae39-4973-88ac-a326b8756946_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0d1c5b2d-09e1-4f00-b92d-9165ad894a68_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_93167ecc-642f-46c8-85a6-b87be1763ab6_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanTypeExtensibleList_6d9dbb80-2095-4ba2-a57b-23316fba4c27_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanTypeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan, type</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanTypeExtensibleList_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanTypeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Type [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanTypeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanTypeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanTypeExtensibleList" xlink:to="lab_us-gaap_DefinedBenefitPlanTypeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_9cfe06ef-f0ac-496c-aec4-efff399d422a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows used for operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_becb3333-7cc4-4147-8219-05baafc3c770_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Estimated Future Amortization Expense of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_e0d7dbd6-9644-4a50-801b-83d9356bf8c6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Identified Intangible Assets Acquired at Acquisition Date</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b815eb8d-e343-424e-a0be-1a2fa6e88f44_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in estimated fair value of common stock warrant liability and contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_61670715-23b4-4629-a7a5-16e0c0b6feef_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_56825d14-5b90-4d10-b01d-9adeb0459d91_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_59f1bb2c-6810-4a59-ba54-6772894fa055_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales &amp; marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_1bd48ab3-dadf-4ebf-b391-d83a2ec0a07d_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and Marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_0b6c2e9b-8e76-4861-8e72-540e023f497f_netLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and marketing</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpenseMember_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling and Marketing Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpenseMember" xlink:to="lab_us-gaap_SellingAndMarketingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b2dbaf71-b896-4efe-9898-a83c510622b3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_CostOfTestingMember_d69ed51b-fb8a-463b-889e-6d426133f769_terseLabel_en-US" xlink:label="lab_cdna_CostOfTestingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Testing Services</link:label>
    <link:label id="lab_cdna_CostOfTestingMember_e5ecdac0-98be-4fd7-b599-12ff45b8788c_verboseLabel_en-US" xlink:label="lab_cdna_CostOfTestingMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of testing services</link:label>
    <link:label id="lab_cdna_CostOfTestingMember_label_en-US" xlink:label="lab_cdna_CostOfTestingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Testing [Member]</link:label>
    <link:label id="lab_cdna_CostOfTestingMember_documentation_en-US" xlink:label="lab_cdna_CostOfTestingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Testing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CostOfTestingMember" xlink:href="cdna-20230331.xsd#cdna_CostOfTestingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_CostOfTestingMember" xlink:to="lab_cdna_CostOfTestingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_18c189a3-ada2-47da-892d-29a2f5cfd50a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for cash upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_89fe561d-3856-4f64-b603-7463f6563358_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a9241328-a4d7-423f-a4a4-f7548ef00f01_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_cb8a0aa8-3730-40cb-8326-579ca766344f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_aa709bb1-0f51-49aa-bb08-9e7625669098_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e29fdf69-9788-4b11-98da-d489fcb2fc37_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1fc5a0b8-5c07-4bc7-9042-796ba27f490c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_cf1f46d7-4146-4424-a88f-5943d13297ab_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a2cb2ca1-c9c6-41b4-9c72-f9e3e89ea749_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8cbfaa6e-2da2-476e-a3b6-aee3edbf7ad9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8123ab95-22a4-4967-888b-af506a24f18b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_b6e8cff6-d16b-4cd2-b5ff-589c65ba222e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase and retirement of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_44b66c65-39cf-4a01-b0a5-74df93886a5a_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_fe700624-59ae-4155-8002-9e5b18d51db0_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_b0f4f386-21a7-4004-b568-6700c5dccf47_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2c8f0a3f-0252-470b-9b92-0bc9fd665675_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_fc616870-60b9-4f85-a6fc-259f7db726fa_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_b7a43d70-8aad-4dfe-9949-df4a07b4ef54_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_586d10fd-e718-4c18-a9c9-d8650ab80c07_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_cd0f815d-48b9-4880-91be-5630df247f3d_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_8ca1daed-5396-4ac2-9511-bf7a22f979e1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Warrants Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_76ddff0d-ddc8-4216-9c6b-5cc51332a022_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_d8e95935-ae6f-4b4c-b488-164204e2a621_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_29b2212d-7740-45a9-ba64-cc16bd749804_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_9c319123-db82-4a78-b1da-6c83fe6685ae_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_e8766a30-6ffa-4297-8796-74ef10d3fde3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_fcc54337-f717-4eb8-b106-affb56ddc2de_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future amortization expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_CommercializationRightsMember_481274ec-39cc-4ef8-8b30-41a64f8a30e7_terseLabel_en-US" xlink:label="lab_cdna_CommercializationRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization rights</link:label>
    <link:label id="lab_cdna_CommercializationRightsMember_label_en-US" xlink:label="lab_cdna_CommercializationRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization Rights [Member]</link:label>
    <link:label id="lab_cdna_CommercializationRightsMember_documentation_en-US" xlink:label="lab_cdna_CommercializationRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CommercializationRightsMember" xlink:href="cdna-20230331.xsd#cdna_CommercializationRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_CommercializationRightsMember" xlink:to="lab_cdna_CommercializationRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_e54fb571-d86f-4b19-8883-8036c7ba4f4c_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_447f87de-fcb7-44e8-b8d3-1d7b0a5f0192_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Options Outstanding and Exercisable Vested or Expected to Vest</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_a7fe0750-f23f-48e8-a084-951ff0a0e333_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_XynManagementIncMember_f7a70b87-dc20-4e56-bb7e-f719463475c6_terseLabel_en-US" xlink:label="lab_cdna_XynManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XynManagement, Inc.</link:label>
    <link:label id="lab_cdna_XynManagementIncMember_label_en-US" xlink:label="lab_cdna_XynManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XynManagement, Inc. [Member]</link:label>
    <link:label id="lab_cdna_XynManagementIncMember_documentation_en-US" xlink:label="lab_cdna_XynManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XynManagement, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_XynManagementIncMember" xlink:href="cdna-20230331.xsd#cdna_XynManagementIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_XynManagementIncMember" xlink:to="lab_cdna_XynManagementIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_63e3aba2-22ad-4b8f-983f-b7c066be38c2_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_bd220de9-2d85-422d-9590-f6f63a683b9c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation costs related to stock options and RSUs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_82038618-1032-45fd-be28-3ab3d71de59b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense tax benefit recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_58c3be93-8c59-4520-b6a6-8a97869aef6a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase and retirement of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_RemainingOperatingAndFinanceLeaseTerm_bb664bf7-514d-4e3b-8b6e-fb2d43b6e1c5_terseLabel_en-US" xlink:label="lab_cdna_RemainingOperatingAndFinanceLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease terms</link:label>
    <link:label id="lab_cdna_RemainingOperatingAndFinanceLeaseTerm_label_en-US" xlink:label="lab_cdna_RemainingOperatingAndFinanceLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Operating And Finance Lease Term</link:label>
    <link:label id="lab_cdna_RemainingOperatingAndFinanceLeaseTerm_documentation_en-US" xlink:label="lab_cdna_RemainingOperatingAndFinanceLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining operating and finance lease term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_RemainingOperatingAndFinanceLeaseTerm" xlink:href="cdna-20230331.xsd#cdna_RemainingOperatingAndFinanceLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_RemainingOperatingAndFinanceLeaseTerm" xlink:to="lab_cdna_RemainingOperatingAndFinanceLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_034e1f6d-1ef9-410d-9196-53b8eceee3c6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7e0e00c5-1c06-4c63-bcaa-77ba08037d09_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8a30c04a-7e74-43e2-9415-8eef36af5639_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_9ab7c0c9-4743-44f4-875d-8cc718ba177a_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After one year through five years</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, after Year One through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_86a2daa7-7310-49a6-8bec-fdcd09a87e36_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_b5fac89c-0ba0-46f1-ae6b-a7f712afeda7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3249daf6-5f18-48c3-870d-51c49b9097ea_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c9802dad-3ed4-43bf-ac7c-ab9a93221a22_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_72f71f25-0029-414a-ae24-684e991498dc_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_379abc96-592f-4532-88e1-d22eb8405515_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9d1b44ab-e138-4d4a-a541-4ccba4e463d4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a43e540c-63df-465f-ab8a-a18417bc6033_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2672136b-326e-485f-ada3-0afd80971d75_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price - options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ae8ee475-fc8f-43ed-ac39-43a4b3203502_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_37ccfe0e-6b95-4c03-9b93-af7062c4d021_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_9d19e276-2c64-43ae-96ea-1ce1fa1779d7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_bba0b791-9e46-4d69-95c4-3671902101f4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used to compute net loss per share:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_1eb78605-4267-4f1a-994e-03a81563552e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_e20ccd9a-7caa-4b4a-be2a-78fcc1dde64f_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_f6cb6e60-c71f-4990-81be-c188793f69dc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_7ecf4121-ca9c-4d54-9c96-5a105998c1a4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_24bc0a72-ec97-461b-93aa-1b7d8dcb7610_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_55ac5248-a89d-4386-ab65-9839add7b114_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_1e35c44a-65dd-4034-a68d-083859ff2193_totalLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Total</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_87b64bbe-1354-4798-bb69-f11ec885260b_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_LeasesCommencedInAugust2022Member_4c26f9de-eaa8-4313-8f70-5e4bda588284_terseLabel_en-US" xlink:label="lab_cdna_LeasesCommencedInAugust2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, Commenced In August 2022</link:label>
    <link:label id="lab_cdna_LeasesCommencedInAugust2022Member_label_en-US" xlink:label="lab_cdna_LeasesCommencedInAugust2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, Commenced In August 2022 [Member]</link:label>
    <link:label id="lab_cdna_LeasesCommencedInAugust2022Member_documentation_en-US" xlink:label="lab_cdna_LeasesCommencedInAugust2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, Commenced In August 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_LeasesCommencedInAugust2022Member" xlink:href="cdna-20230331.xsd#cdna_LeasesCommencedInAugust2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_LeasesCommencedInAugust2022Member" xlink:to="lab_cdna_LeasesCommencedInAugust2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_6db92854-cb9c-45f9-9950-ed8190b7a6a3_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock subject to outstanding common stock warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_cf14f156-39c1-43c7-b41a-0b9367f5dd52_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b3a8fd9d-d792-4420-8830-ea40e506c2b1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a3e3185b-2bcc-4103-a599-307fbfe7bbf7_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used to compute basic net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_ed32399f-db90-4e3f-aebe-90a3b189a851_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_af0c0966-8d11-4918-bf69-0b991a71a9ac_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock_ce45a0d7-48bc-4489-afa4-93d8a28018eb_terseLabel_en-US" xlink:label="lab_cdna_ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Options, RSUs Activity under 2014 Equity Incentive Plan and 2016 Inducement Plan and Related Information</link:label>
    <link:label id="lab_cdna_ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock_label_en-US" xlink:label="lab_cdna_ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Stock Options And Unvested Restricted Stock Units Activity Table [Table Text Block]</link:label>
    <link:label id="lab_cdna_ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock_documentation_en-US" xlink:label="lab_cdna_ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of share based compensation stock options and unvested restricted stock units activity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock" xlink:href="cdna-20230331.xsd#cdna_ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock" xlink:to="lab_cdna_ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_MarketableSecuritiesFairValueLongTerm_a027de8c-061b-4272-9730-b5792deeb123_terseLabel_en-US" xlink:label="lab_cdna_MarketableSecuritiesFairValueLongTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_cdna_MarketableSecuritiesFairValueLongTerm_label_en-US" xlink:label="lab_cdna_MarketableSecuritiesFairValueLongTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Fair Value, Long Term</link:label>
    <link:label id="lab_cdna_MarketableSecuritiesFairValueLongTerm_documentation_en-US" xlink:label="lab_cdna_MarketableSecuritiesFairValueLongTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Fair Value, Long Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesFairValueLongTerm" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesFairValueLongTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_MarketableSecuritiesFairValueLongTerm" xlink:to="lab_cdna_MarketableSecuritiesFairValueLongTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_63f7f5d4-4987-4cdf-90bc-1475b21f34a0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_09396ac6-1d65-452e-a741-504b6a42f892_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d07a10e6-4191-4e77-a1ff-761d7150eb88_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 9)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a4f343ca-1c5c-4dce-8f45-349b5ba0b7c2_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e20d0f99-f07b-4089-b56f-b12f497913a2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5550a019-a8bb-49e1-b5e1-da5a38fd1db6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_e587fb30-3f0b-441c-8351-1cc7333ffc00_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets with indefinite lives</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber_9734f690-71f8-4e26-9513-2415f292d83b_terseLabel_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest (in shares)</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber_documentation_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award options expected to vest outstanding number.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" xlink:to="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_fd7fecbc-479a-4910-b4f1-ba8a783b5be0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock: $0.001 par value; 10,000,000 shares authorized at March&#160;31, 2023 and December&#160;31, 2022; no shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_IntangibleAssetMeasurementInputRoyaltyRate_442b8a8e-0a6b-4360-bd54-f2ea1a1104de_terseLabel_en-US" xlink:label="lab_cdna_IntangibleAssetMeasurementInputRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset, measurement input, royalty rate</link:label>
    <link:label id="lab_cdna_IntangibleAssetMeasurementInputRoyaltyRate_label_en-US" xlink:label="lab_cdna_IntangibleAssetMeasurementInputRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset, Measurement Input, Royalty Rate</link:label>
    <link:label id="lab_cdna_IntangibleAssetMeasurementInputRoyaltyRate_documentation_en-US" xlink:label="lab_cdna_IntangibleAssetMeasurementInputRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset, Measurement Input, Royalty Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_IntangibleAssetMeasurementInputRoyaltyRate" xlink:href="cdna-20230331.xsd#cdna_IntangibleAssetMeasurementInputRoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_IntangibleAssetMeasurementInputRoyaltyRate" xlink:to="lab_cdna_IntangibleAssetMeasurementInputRoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_19c3d33b-88ab-4167-87be-882db3d31252_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for services</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_827f382b-e4c4-448e-93ae-4fdb93399e31_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_a3b8ff6a-371b-4626-8fc1-5b489eca470f_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_81c623bd-5a10-4234-8f2f-d2fd473de576_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_CommonStockWarrantLiability_f7bf405a-e738-4d4e-8656-3ccda9419970_terseLabel_en-US" xlink:label="lab_cdna_CommonStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrant liability</link:label>
    <link:label id="lab_cdna_CommonStockWarrantLiability_label_en-US" xlink:label="lab_cdna_CommonStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant Liability</link:label>
    <link:label id="lab_cdna_CommonStockWarrantLiability_documentation_en-US" xlink:label="lab_cdna_CommonStockWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrant liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CommonStockWarrantLiability" xlink:href="cdna-20230331.xsd#cdna_CommonStockWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_CommonStockWarrantLiability" xlink:to="lab_cdna_CommonStockWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_NumberOfMilestonePayments_6138b178-85ff-4eb2-8182-4e4e62d94f00_terseLabel_en-US" xlink:label="lab_cdna_NumberOfMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of milestone payments</link:label>
    <link:label id="lab_cdna_NumberOfMilestonePayments_label_en-US" xlink:label="lab_cdna_NumberOfMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Milestone Payments</link:label>
    <link:label id="lab_cdna_NumberOfMilestonePayments_documentation_en-US" xlink:label="lab_cdna_NumberOfMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_NumberOfMilestonePayments" xlink:href="cdna-20230331.xsd#cdna_NumberOfMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_NumberOfMilestonePayments" xlink:to="lab_cdna_NumberOfMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_f124a74a-6b71-477a-8af1-8307481bf947_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_5de42fe7-01d6-4cba-955d-4b6d0881ee1d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_ff375841-f32e-429b-8f46-255b4814c6f7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measured Using - (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_AccruedClinicalAndCostOfOtherStudiesCurrent_6cd4599e-2042-4676-9185-840c1c95e742_terseLabel_en-US" xlink:label="lab_cdna_AccruedClinicalAndCostOfOtherStudiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical studies</link:label>
    <link:label id="lab_cdna_AccruedClinicalAndCostOfOtherStudiesCurrent_label_en-US" xlink:label="lab_cdna_AccruedClinicalAndCostOfOtherStudiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical And Cost Of Other Studies Current</link:label>
    <link:label id="lab_cdna_AccruedClinicalAndCostOfOtherStudiesCurrent_documentation_en-US" xlink:label="lab_cdna_AccruedClinicalAndCostOfOtherStudiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical And Cost Of Other Studies Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AccruedClinicalAndCostOfOtherStudiesCurrent" xlink:href="cdna-20230331.xsd#cdna_AccruedClinicalAndCostOfOtherStudiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_AccruedClinicalAndCostOfOtherStudiesCurrent" xlink:to="lab_cdna_AccruedClinicalAndCostOfOtherStudiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c72a8169-9eb9-445f-9972-c7784ab6df85_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_506f8295-5bc7-46f2-b7b0-12d69b765e05_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in progress</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_a3aa0733-e8ee-461b-98f5-7501cb709d0f_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, fair value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_505810f2-85c9-4b55-ae26-2db398e1c18d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in deferred taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_MedicareMember_1892bfb6-4985-4e8f-9dcc-05c6a8c95b91_terseLabel_en-US" xlink:label="lab_cdna_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_cdna_MedicareMember_label_en-US" xlink:label="lab_cdna_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_cdna_MedicareMember_documentation_en-US" xlink:label="lab_cdna_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MedicareMember" xlink:href="cdna-20230331.xsd#cdna_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_MedicareMember" xlink:to="lab_cdna_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_9d08e741-e82e-4070-9f05-212068c543b2_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramPeriodInForce1_36911a5f-1ea1-4978-9299-0b8c0f019d46_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, period in force</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramPeriodInForce1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Period in Force</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:to="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_29d3065b-70a6-4cbe-8ce7-edb5dce20a87_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c3a216a6-817a-4dc0-8cf1-ac7b1ddd832b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_d931bde8-c8a7-48d2-852f-2653ec942572_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate proceeds from the issuance of shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_LeaseOtherInformationAbstract_8090e9cc-137d-4226-8eef-5be9c7e12f69_terseLabel_en-US" xlink:label="lab_cdna_LeaseOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other information:</link:label>
    <link:label id="lab_cdna_LeaseOtherInformationAbstract_label_en-US" xlink:label="lab_cdna_LeaseOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Other Information [Abstract]</link:label>
    <link:label id="lab_cdna_LeaseOtherInformationAbstract_documentation_en-US" xlink:label="lab_cdna_LeaseOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease other information.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_LeaseOtherInformationAbstract" xlink:href="cdna-20230331.xsd#cdna_LeaseOtherInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_LeaseOtherInformationAbstract" xlink:to="lab_cdna_LeaseOtherInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_37805bba-973e-48aa-be30-b54d0f75e938_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, remaining authorized repurchase amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_fa90ab2b-b2b5-4a05-9333-1550cf16ae97_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9abaf81c-17b4-4b38-ba20-c4db3af8b37e_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1eb4e03f-c18b-49fa-82dc-8b95f4357c8c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of business, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b46c89e2-0a51-4420-9afd-22b4215f0dad_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices_01070ecd-62f6-4aa0-802a-7bd88a6c70eb_negatedLabel_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock awards for services (in shares)</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices_label_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Common Stock Awards For Services</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices_documentation_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award common stock awards for services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices" xlink:to="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_ccce076c-437b-4488-be3c-617c6f4891eb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill expected to be deductible for income tax purposes</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_7b4062e2-b0ee-48ba-8e78-5ecfaa303bc8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measured Using - (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_PaymentsToAcquireCapitalExpendituresNet_035ce604-c2be-4800-b9ea-71957514917a_negatedTerseLabel_en-US" xlink:label="lab_cdna_PaymentsToAcquireCapitalExpendituresNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions of capital expenditures, net</link:label>
    <link:label id="lab_cdna_PaymentsToAcquireCapitalExpendituresNet_label_en-US" xlink:label="lab_cdna_PaymentsToAcquireCapitalExpendituresNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Capital Expenditures, Net</link:label>
    <link:label id="lab_cdna_PaymentsToAcquireCapitalExpendituresNet_documentation_en-US" xlink:label="lab_cdna_PaymentsToAcquireCapitalExpendituresNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Capital Expenditures, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_PaymentsToAcquireCapitalExpendituresNet" xlink:href="cdna-20230331.xsd#cdna_PaymentsToAcquireCapitalExpendituresNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_PaymentsToAcquireCapitalExpendituresNet" xlink:to="lab_cdna_PaymentsToAcquireCapitalExpendituresNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_11f40c98-f286-4295-a15a-67db5224c575_terseLabel_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest, weighted average remaining contractual life</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award options expected to vest outstanding weighted average remaining contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:to="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2ffd352e-6f75-491d-90a6-6417ba2c2d8d_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3eae0302-264c-47ac-b95d-8d6fe8eef0ec_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_d13e8aa4-b8db-402b-b2fc-2c3efc84f831_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_fce4c234-9fb7-4f82-b47d-4c9976835161_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss used to compute diluted net loss per share</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_426ce25e-9ec2-4730-b548-81945922b160_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_b5fd3956-77b6-4afe-8739-95e6eeb3fe70_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_8aad9b25-8360-4c37-b443-bd1881af1335_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_MarketableSecuritiesAmortizedCostShortTerm_e82e1492-f5b6-4523-ab73-d7e0878f9174_totalLabel_en-US" xlink:label="lab_cdna_MarketableSecuritiesAmortizedCostShortTerm" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_cdna_MarketableSecuritiesAmortizedCostShortTerm_label_en-US" xlink:label="lab_cdna_MarketableSecuritiesAmortizedCostShortTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Amortized Cost, Short Term</link:label>
    <link:label id="lab_cdna_MarketableSecuritiesAmortizedCostShortTerm_documentation_en-US" xlink:label="lab_cdna_MarketableSecuritiesAmortizedCostShortTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Amortized Cost, Short Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAmortizedCostShortTerm" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAmortizedCostShortTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_MarketableSecuritiesAmortizedCostShortTerm" xlink:to="lab_cdna_MarketableSecuritiesAmortizedCostShortTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_8e81b3ca-d0ed-4df3-9251-3c6dc759de98_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_2680be93-09d0-41dc-b636-308c7890633a_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and tradenames</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_69ec6647-5336-449b-a4f2-dfdfe34f20c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant Liability and Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_77870b48-4389-4ecf-b2c0-cf5a6ea1a0a3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_609b0dad-3b5b-4556-b6ad-09ae27d31ef3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_68a36028-b89f-4d8e-a0f2-113543aed8d8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revaluation of common stock warrant liability to estimated fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_1df4bd30-9bd0-4693-91ba-46a714f20147_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e1933876-cf58-4f79-a1c4-a2d8226db28a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_19b4e7ad-8144-4128-8196-f865ed4bf913_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_1ce1753f-629f-4634-a8cf-05ac668eeba0_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_9cf8484b-2ef7-4d3b-8a5e-e5a1a3ef523a_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_c69094e5-d4b0-4567-98fd-749df9d72785_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for services (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_b47c7e3b-7882-4de0-a0c9-af4c8ff58584_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2b810875-819b-4548-acca-d7c75d8ad6f7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_037a030d-ba21-4887-ac15-0ff0f6d5ed84_terseLabel_en-US" xlink:label="lab_cdna_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_cdna_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_cdna_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Fourteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_cdna_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_cdna_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Fourteen Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:href="cdna-20230331.xsd#cdna_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:to="lab_cdna_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_IncomeTaxesLineItems_924af30b-8243-40c0-bf2d-27d23fc5a021_terseLabel_en-US" xlink:label="lab_cdna_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_cdna_IncomeTaxesLineItems_label_en-US" xlink:label="lab_cdna_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_cdna_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_cdna_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_IncomeTaxesLineItems" xlink:href="cdna-20230331.xsd#cdna_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_IncomeTaxesLineItems" xlink:to="lab_cdna_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_c0135376-ee84-42fe-b95e-48fe10cdc0ce_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_392951d5-d5ba-4b60-8556-821b813fb0e6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense capitalized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_815b8019-3055-4a0f-9e82-3add2bc77da8_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in estimated fair value of common stock warrant liability</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_b79ad374-4ec7-4396-9c18-a4abd691af8f_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_630e8689-0e8e-4cb1-9e29-f00fd6adbb39_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_f4edc479-6cf0-4696-bce1-46207896e9a9_verboseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_ContingentConsiderationMember_37a8657c-c310-4482-a40c-002c2a865c50_terseLabel_en-US" xlink:label="lab_cdna_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_cdna_ContingentConsiderationMember_label_en-US" xlink:label="lab_cdna_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:label id="lab_cdna_ContingentConsiderationMember_documentation_en-US" xlink:label="lab_cdna_ContingentConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ContingentConsiderationMember" xlink:href="cdna-20230331.xsd#cdna_ContingentConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_ContingentConsiderationMember" xlink:to="lab_cdna_ContingentConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_07c2ae3b-a4e1-4c9f-b5e1-4150096cf966_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RecoveryOfDirectCosts_0bcc60b6-6419-4756-8d44-c06b877938a0_terseLabel_en-US" xlink:label="lab_us-gaap_RecoveryOfDirectCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursement rate</link:label>
    <link:label id="lab_us-gaap_RecoveryOfDirectCosts_label_en-US" xlink:label="lab_us-gaap_RecoveryOfDirectCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Direct Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecoveryOfDirectCosts" xlink:to="lab_us-gaap_RecoveryOfDirectCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_MiromatrixIncMember_09bad0d0-2d50-4f2c-a463-30c77e790f9e_terseLabel_en-US" xlink:label="lab_cdna_MiromatrixIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miromatrix, Inc.</link:label>
    <link:label id="lab_cdna_MiromatrixIncMember_label_en-US" xlink:label="lab_cdna_MiromatrixIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miromatrix, Inc. [Member]</link:label>
    <link:label id="lab_cdna_MiromatrixIncMember_documentation_en-US" xlink:label="lab_cdna_MiromatrixIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miromatrix, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MiromatrixIncMember" xlink:href="cdna-20230331.xsd#cdna_MiromatrixIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_MiromatrixIncMember" xlink:to="lab_cdna_MiromatrixIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6e46931f-431d-4be9-9211-871afe9e91aa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Accrued and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_60c43d75-a7c4-4ba6-ae9f-034e6d1505d0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on long-term marketable equity securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_31e33a41-c5a9-4ffa-aa13-a688c6a64b75_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_24456f4e-6e90-41c7-9ad2-9625cfe82d2b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_f18f12c9-4418-4a01-96b9-e1c84cd5a8e1_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Long-Lived Assets Consisting of Property and Equipment, Net by Geographic Regions</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_9f45a064-b3db-4dce-944d-1c60d916127c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_c9333e4e-bbd1-4ed6-a506-3014cbdf6eeb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of corporate equity securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_ebcb7a11-ca19-43c3-993f-fbd192dca093_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate_6b272bc8-b8a0-4980-bc2c-eb9febbfee6b_terseLabel_en-US" xlink:label="lab_cdna_BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, measurement input, discount rate</link:label>
    <link:label id="lab_cdna_BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate_label_en-US" xlink:label="lab_cdna_BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input, Discount Rate</link:label>
    <link:label id="lab_cdna_BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate_documentation_en-US" xlink:label="lab_cdna_BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate" xlink:href="cdna-20230331.xsd#cdna_BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate" xlink:to="lab_cdna_BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_GoodwillAndIntangibleAssetsLineItems_969082f7-87b7-42b4-b543-4b92ecec2390_terseLabel_en-US" xlink:label="lab_cdna_GoodwillAndIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill And Intangible Assets [Line Items]</link:label>
    <link:label id="lab_cdna_GoodwillAndIntangibleAssetsLineItems_label_en-US" xlink:label="lab_cdna_GoodwillAndIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill And Intangible Assets [Line Items]</link:label>
    <link:label id="lab_cdna_GoodwillAndIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_cdna_GoodwillAndIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_GoodwillAndIntangibleAssetsLineItems" xlink:href="cdna-20230331.xsd#cdna_GoodwillAndIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_GoodwillAndIntangibleAssetsLineItems" xlink:to="lab_cdna_GoodwillAndIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5c1b1ba2-a32b-4d51-98d3-7f88bf29d79e_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_a6d672f4-2f17-4e06-aab6-8bd1e9315cf8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_fdc7138c-a56f-455e-9b27-f41e381b0f02_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_8a240d13-331d-4d26-bdd1-0226d3f3e52a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_a1390942-6a38-4261-9b65-c1631b030644_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_69845d1b-2610-4d90-a55c-d75fa34ed5c0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3993e8a9-ecc4-4bba-9a92-e3957ded47a4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4840e49c-dec8-4bf4-a01a-5b5b8585e1e2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36623f0c-e935-4187-b44d-d2685b229307_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_0dd7bf78-c37b-432f-8e8a-330ece63ac4a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_e25bb5b9-b0c6-4d6c-b177-83e2242e25e8_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Total</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_9ee5d21e-bc73-45a3-9d9a-245f6c1d2eda_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_22b1352f-bea7-4a35-b6c0-d760e6afddbb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_f7d189bf-1651-4f63-a0f7-f5dd3f803e15_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ccc99358-c8d8-464c-b8dd-0c2332dee17a_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_b8f8555b-5c95-4d1b-afc1-812e9afbb922_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_26adc614-9c35-434c-b87b-82c3f769d6be_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_70c2715e-cada-41f6-baa5-c810cdb502f2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_88ad9b39-b61d-43d6-9053-9a77f11af2bb_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_c6ff3884-760f-4fcc-959f-38307d9f14c0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_65760404-91c2-475a-99b0-544bac540b01_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ff0a5b10-44ce-4aea-b9ff-f51c9e32f39e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_27a36540-5f4b-4dce-b1d1-2e8a97de0421_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0dded569-ae4f-436b-b84c-48b5ecb1d8fb_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares underlying warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_02cc78a5-13ae-4386-80f3-c0b322344edb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainContingenciesByNatureAxis_015ddfac-f4e4-4a9c-8704-972f1f17d677_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies, Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesByNatureAxis_label_en-US" xlink:label="lab_us-gaap_GainContingenciesByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain Contingencies, Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesByNatureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis" xlink:to="lab_us-gaap_GainContingenciesByNatureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_AcquiredInProcessTechnologyMember_f3939bf1-1b91-43c5-940e-6e89e3b948e4_terseLabel_en-US" xlink:label="lab_cdna_AcquiredInProcessTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process technology</link:label>
    <link:label id="lab_cdna_AcquiredInProcessTechnologyMember_label_en-US" xlink:label="lab_cdna_AcquiredInProcessTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired In Process Technology [Member]</link:label>
    <link:label id="lab_cdna_AcquiredInProcessTechnologyMember_documentation_en-US" xlink:label="lab_cdna_AcquiredInProcessTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired In Process Technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AcquiredInProcessTechnologyMember" xlink:href="cdna-20230331.xsd#cdna_AcquiredInProcessTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_AcquiredInProcessTechnologyMember" xlink:to="lab_cdna_AcquiredInProcessTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_WarrantsDisclosureTextBlock_3bcfe82a-196e-457b-8990-359f9010ecaa_terseLabel_en-US" xlink:label="lab_cdna_WarrantsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_cdna_WarrantsDisclosureTextBlock_label_en-US" xlink:label="lab_cdna_WarrantsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Disclosure [Text Block]</link:label>
    <link:label id="lab_cdna_WarrantsDisclosureTextBlock_documentation_en-US" xlink:label="lab_cdna_WarrantsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_WarrantsDisclosureTextBlock" xlink:href="cdna-20230331.xsd#cdna_WarrantsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_WarrantsDisclosureTextBlock" xlink:to="lab_cdna_WarrantsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_bb7ae023-267b-4499-ad04-293d1e217f1b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments and write-downs</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_e3132adc-bd79-42bd-9a8b-bb8c0fa16b0b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c2f8a71b-8701-4fc7-89b7-6bb201b88c5c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_d1e3c798-18e4-4651-9c48-7878996fa473_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Computation of Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward_fb84d9f4-67a8-454a-a5cf-b4a8d3c6038c_terseLabel_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSU Shares</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward_label_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Number Of RSU Shares [Roll Forward]</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward_documentation_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Number Of RSU Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward" xlink:to="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_a2ccbd0e-90b4-434c-96c3-43a4257192a8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire minority interest</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems_bb11529e-216e-4f9c-a310-64bf431eee04_terseLabel_en-US" xlink:label="lab_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Finite And Infinite Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Finite And Infinite Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of finite and infinite lived intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems" xlink:href="cdna-20230331.xsd#cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems" xlink:to="lab_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_SaleOfStockCommissionFeePercentage_7cb97608-aa74-4846-b39d-ad14c24bc4e6_terseLabel_en-US" xlink:label="lab_cdna_SaleOfStockCommissionFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, commission fee percentage</link:label>
    <link:label id="lab_cdna_SaleOfStockCommissionFeePercentage_label_en-US" xlink:label="lab_cdna_SaleOfStockCommissionFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission Fee Percentage</link:label>
    <link:label id="lab_cdna_SaleOfStockCommissionFeePercentage_documentation_en-US" xlink:label="lab_cdna_SaleOfStockCommissionFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_SaleOfStockCommissionFeePercentage" xlink:href="cdna-20230331.xsd#cdna_SaleOfStockCommissionFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_SaleOfStockCommissionFeePercentage" xlink:to="lab_cdna_SaleOfStockCommissionFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_72a84aee-c3d4-4a1a-bedf-2c36a45efc4c_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum_33718cf3-5ad1-46fe-a40d-1ff602dfd36c_terseLabel_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum value of shares which an employee can purchase per calendar year</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum_label_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Amount Of Outstanding Stock Maximum</link:label>
    <link:label id="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum_documentation_en-US" xlink:label="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award fair value amount of outstanding stock maximum.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum" xlink:to="lab_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_cdna_AccruedShippingExpenses_c83ee4a4-7812-4bc0-873d-761eaa9e56dc_terseLabel_en-US" xlink:label="lab_cdna_AccruedShippingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued shipping expenses</link:label>
    <link:label id="lab_cdna_AccruedShippingExpenses_label_en-US" xlink:label="lab_cdna_AccruedShippingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Shipping Expenses</link:label>
    <link:label id="lab_cdna_AccruedShippingExpenses_documentation_en-US" xlink:label="lab_cdna_AccruedShippingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Shipping Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AccruedShippingExpenses" xlink:href="cdna-20230331.xsd#cdna_AccruedShippingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdna_AccruedShippingExpenses" xlink:to="lab_cdna_AccruedShippingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PostemploymentRetirementBenefitsMember_label_en-US" xlink:label="lab_us-gaap_PostemploymentRetirementBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Retirement Benefits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentRetirementBenefitsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentRetirementBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentRetirementBenefitsMember" xlink:to="lab_us-gaap_PostemploymentRetirementBenefitsMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>cdna-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:c6b1ad27-1676-415f-b1d2-9124c5a59c19,g:635f8054-df92-419b-85ba-772c4e54710d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.caredxinc.com/role/Cover" xlink:type="simple" xlink:href="cdna-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2ea9a859-37ff-4359-af49-66ee57dcb8bf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_DocumentType_2ea9a859-37ff-4359-af49-66ee57dcb8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_c38e9ffc-8386-4bb7-b8bd-98a9993bbf6e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_DocumentQuarterlyReport_c38e9ffc-8386-4bb7-b8bd-98a9993bbf6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b7ab3cd2-edc6-4f3e-8615-b01806e76299" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_DocumentPeriodEndDate_b7ab3cd2-edc6-4f3e-8615-b01806e76299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_37c0c734-8c45-41ed-8e3f-2e5fcffdb1b9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_DocumentTransitionReport_37c0c734-8c45-41ed-8e3f-2e5fcffdb1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_369db924-3653-4084-ac1f-ffac1412d152" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_EntityFileNumber_369db924-3653-4084-ac1f-ffac1412d152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ca4709e7-ccce-4ec3-a8f8-3ff570e0e62a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_EntityRegistrantName_ca4709e7-ccce-4ec3-a8f8-3ff570e0e62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d8e1e5e1-612b-4bd2-9dac-4d3d04360891" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d8e1e5e1-612b-4bd2-9dac-4d3d04360891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9b1fcd34-e207-4f49-9e72-ef49eeec8b8a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_EntityTaxIdentificationNumber_9b1fcd34-e207-4f49-9e72-ef49eeec8b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_fe11daff-019e-49d0-800e-5358c60ed5c6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_EntityAddressAddressLine1_fe11daff-019e-49d0-800e-5358c60ed5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_41832490-338c-4372-8036-10d25c369aaa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_EntityAddressCityOrTown_41832490-338c-4372-8036-10d25c369aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0b69e0fd-8d5f-492d-bcd7-809d39a5aa39" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_EntityAddressStateOrProvince_0b69e0fd-8d5f-492d-bcd7-809d39a5aa39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4ab28b94-0e07-4121-b312-98a215b44486" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_EntityAddressPostalZipCode_4ab28b94-0e07-4121-b312-98a215b44486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8164fd18-bdae-4443-9605-060c48e7771c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_CityAreaCode_8164fd18-bdae-4443-9605-060c48e7771c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7c5f89e7-1393-47a4-a560-3d34c9586601" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_LocalPhoneNumber_7c5f89e7-1393-47a4-a560-3d34c9586601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c684987c-cda5-4ce9-ae69-6115da3d78ec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_Security12bTitle_c684987c-cda5-4ce9-ae69-6115da3d78ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_41b8d451-b78f-4231-b763-cc51c8717c4f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_TradingSymbol_41b8d451-b78f-4231-b763-cc51c8717c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c94c4da2-9297-4a1b-ba7c-55572107fa8d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_SecurityExchangeName_c94c4da2-9297-4a1b-ba7c-55572107fa8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_45bccdcd-cd6f-44c7-93d9-2b5af6380c57" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_EntityCurrentReportingStatus_45bccdcd-cd6f-44c7-93d9-2b5af6380c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_aac01ce4-4246-422c-8381-1c8d0929dba8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_EntityInteractiveDataCurrent_aac01ce4-4246-422c-8381-1c8d0929dba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_91332c23-d42e-4eec-8bac-cce69fa6b32e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_EntityFilerCategory_91332c23-d42e-4eec-8bac-cce69fa6b32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_b6502c00-0704-47a5-9504-adc2c64610f7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_EntitySmallBusiness_b6502c00-0704-47a5-9504-adc2c64610f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f7c032a5-6cc5-433d-a81a-7fe30db90391" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_EntityEmergingGrowthCompany_f7c032a5-6cc5-433d-a81a-7fe30db90391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5b398f55-4846-4762-b9da-5a4886254bd8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_EntityShellCompany_5b398f55-4846-4762-b9da-5a4886254bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6e4330f9-e5ae-42f4-8863-63ea4522df6d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6e4330f9-e5ae-42f4-8863-63ea4522df6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ea6ca458-57fd-4276-8c98-5ec72a12b8e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_AmendmentFlag_ea6ca458-57fd-4276-8c98-5ec72a12b8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_30ffa913-55b1-4e82-9ed5-37f6c360b485" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_DocumentFiscalYearFocus_30ffa913-55b1-4e82-9ed5-37f6c360b485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_66954d6b-2bff-4970-9782-b965ed21f29b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_66954d6b-2bff-4970-9782-b965ed21f29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5dc8cae7-8dac-451e-8c00-5b7ad28f625b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_EntityCentralIndexKey_5dc8cae7-8dac-451e-8c00-5b7ad28f625b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_7409cbfc-4a61-4069-aa9c-e6c30e636c69" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7dc6a189-4d8a-4064-8c60-c3930827fbc1" xlink:to="loc_dei_CurrentFiscalYearEndDate_7409cbfc-4a61-4069-aa9c-e6c30e636c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cdna-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_05f4f3a4-c2a5-4a5b-964a-8c5b0434c8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_27630f70-d610-4429-a4e8-2ad6fa4b1c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_05f4f3a4-c2a5-4a5b-964a-8c5b0434c8cd" xlink:to="loc_us-gaap_AssetsAbstract_27630f70-d610-4429-a4e8-2ad6fa4b1c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6ff0e800-0dc3-4fb0-8df9-8ff5303ef426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27630f70-d610-4429-a4e8-2ad6fa4b1c45" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6ff0e800-0dc3-4fb0-8df9-8ff5303ef426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ed9ed54e-59d6-4b44-9de6-fcf52da7a6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6ff0e800-0dc3-4fb0-8df9-8ff5303ef426" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ed9ed54e-59d6-4b44-9de6-fcf52da7a6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_0f8f39cf-c08c-4383-8fb8-fe938d157d93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6ff0e800-0dc3-4fb0-8df9-8ff5303ef426" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_0f8f39cf-c08c-4383-8fb8-fe938d157d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_21a46745-d268-4e9a-b8b1-b72f37fee948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6ff0e800-0dc3-4fb0-8df9-8ff5303ef426" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_21a46745-d268-4e9a-b8b1-b72f37fee948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7a28493f-3fa1-45b2-9af3-770234424750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6ff0e800-0dc3-4fb0-8df9-8ff5303ef426" xlink:to="loc_us-gaap_InventoryNet_7a28493f-3fa1-45b2-9af3-770234424750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d7c67554-b62d-4753-b49f-31ca865efda5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6ff0e800-0dc3-4fb0-8df9-8ff5303ef426" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d7c67554-b62d-4753-b49f-31ca865efda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f01f628a-a1ea-4ba5-9147-fa2b9374a167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6ff0e800-0dc3-4fb0-8df9-8ff5303ef426" xlink:to="loc_us-gaap_AssetsCurrent_f01f628a-a1ea-4ba5-9147-fa2b9374a167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_a2b16273-dc9f-46a4-8d2b-00642049c2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27630f70-d610-4429-a4e8-2ad6fa4b1c45" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_a2b16273-dc9f-46a4-8d2b-00642049c2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a0cf0651-fc72-4e7e-b453-249e8b0bfdac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27630f70-d610-4429-a4e8-2ad6fa4b1c45" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a0cf0651-fc72-4e7e-b453-249e8b0bfdac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6b1b07c6-a40f-492d-99aa-4d7e0a303bfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27630f70-d610-4429-a4e8-2ad6fa4b1c45" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6b1b07c6-a40f-492d-99aa-4d7e0a303bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_598e705a-87f9-4fb7-a7f1-aae37554c954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27630f70-d610-4429-a4e8-2ad6fa4b1c45" xlink:to="loc_us-gaap_Goodwill_598e705a-87f9-4fb7-a7f1-aae37554c954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_37ba3ef7-080b-45b1-b9f3-dcaa6aa74d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27630f70-d610-4429-a4e8-2ad6fa4b1c45" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_37ba3ef7-080b-45b1-b9f3-dcaa6aa74d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4d1fc3fe-2292-4853-bf21-dc0f866fb3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27630f70-d610-4429-a4e8-2ad6fa4b1c45" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4d1fc3fe-2292-4853-bf21-dc0f866fb3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_53b3dd96-632b-4cef-85d5-f50d26aacf1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_27630f70-d610-4429-a4e8-2ad6fa4b1c45" xlink:to="loc_us-gaap_Assets_53b3dd96-632b-4cef-85d5-f50d26aacf1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2504c1ff-3c50-4677-9e88-e042e315de9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_05f4f3a4-c2a5-4a5b-964a-8c5b0434c8cd" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2504c1ff-3c50-4677-9e88-e042e315de9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4bbd180f-70e3-4f96-b53c-b268955102c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2504c1ff-3c50-4677-9e88-e042e315de9e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4bbd180f-70e3-4f96-b53c-b268955102c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_76e7419b-1fa7-46b9-8224-bd3a938228ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4bbd180f-70e3-4f96-b53c-b268955102c5" xlink:to="loc_us-gaap_AccountsPayableCurrent_76e7419b-1fa7-46b9-8224-bd3a938228ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_938e5555-7a84-4f42-b176-d186ce3e0532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4bbd180f-70e3-4f96-b53c-b268955102c5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_938e5555-7a84-4f42-b176-d186ce3e0532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_85f69b9c-196e-48d6-8e2f-49125eae3cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4bbd180f-70e3-4f96-b53c-b268955102c5" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_85f69b9c-196e-48d6-8e2f-49125eae3cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ff6a414f-778c-45bc-aafd-0031bfc6880f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4bbd180f-70e3-4f96-b53c-b268955102c5" xlink:to="loc_us-gaap_LiabilitiesCurrent_ff6a414f-778c-45bc-aafd-0031bfc6880f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_50dcf656-84ef-4098-804d-e771a8f11cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2504c1ff-3c50-4677-9e88-e042e315de9e" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_50dcf656-84ef-4098-804d-e771a8f11cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_DeferredPaymentsForIntangibleAssetsNoncurrent_0f71fae6-db33-4fd6-928b-1f85d9e0f670" xlink:href="cdna-20230331.xsd#cdna_DeferredPaymentsForIntangibleAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2504c1ff-3c50-4677-9e88-e042e315de9e" xlink:to="loc_cdna_DeferredPaymentsForIntangibleAssetsNoncurrent_0f71fae6-db33-4fd6-928b-1f85d9e0f670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0bce44f4-6b82-4688-b750-00bd9a41da65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2504c1ff-3c50-4677-9e88-e042e315de9e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0bce44f4-6b82-4688-b750-00bd9a41da65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b26cfd3d-7692-48ea-b14b-4ca2eccebdb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2504c1ff-3c50-4677-9e88-e042e315de9e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b26cfd3d-7692-48ea-b14b-4ca2eccebdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7a34929d-c6cc-41bf-ba36-94ba8f8b5f59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2504c1ff-3c50-4677-9e88-e042e315de9e" xlink:to="loc_us-gaap_Liabilities_7a34929d-c6cc-41bf-ba36-94ba8f8b5f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_03736167-87b5-4874-8b97-8adaa7b7946b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2504c1ff-3c50-4677-9e88-e042e315de9e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_03736167-87b5-4874-8b97-8adaa7b7946b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_1e11b5e8-b27b-417e-9ba5-7e40b4c9b6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2504c1ff-3c50-4677-9e88-e042e315de9e" xlink:to="loc_us-gaap_StockholdersEquityAbstract_1e11b5e8-b27b-417e-9ba5-7e40b4c9b6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2193c2e0-97d0-4ddb-9457-36a90b1e91c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1e11b5e8-b27b-417e-9ba5-7e40b4c9b6cc" xlink:to="loc_us-gaap_PreferredStockValue_2193c2e0-97d0-4ddb-9457-36a90b1e91c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6d78c0cb-dffc-4912-af1d-30a479108198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1e11b5e8-b27b-417e-9ba5-7e40b4c9b6cc" xlink:to="loc_us-gaap_CommonStockValue_6d78c0cb-dffc-4912-af1d-30a479108198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b0e884cb-b6f1-43d9-8a9c-17eecca7f672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1e11b5e8-b27b-417e-9ba5-7e40b4c9b6cc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b0e884cb-b6f1-43d9-8a9c-17eecca7f672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_97d22ba3-19b1-417b-856e-162af8301f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1e11b5e8-b27b-417e-9ba5-7e40b4c9b6cc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_97d22ba3-19b1-417b-856e-162af8301f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d9cd6d18-0092-4a64-917b-12c24324ca76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1e11b5e8-b27b-417e-9ba5-7e40b4c9b6cc" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d9cd6d18-0092-4a64-917b-12c24324ca76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9e8471aa-8512-456c-8a81-489a40114ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_1e11b5e8-b27b-417e-9ba5-7e40b4c9b6cc" xlink:to="loc_us-gaap_StockholdersEquity_9e8471aa-8512-456c-8a81-489a40114ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5f4b99b7-aed2-429c-bc4e-9d3f9892da0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2504c1ff-3c50-4677-9e88-e042e315de9e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_5f4b99b7-aed2-429c-bc4e-9d3f9892da0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cdna-20230331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d89d1c81-35c5-4d16-a7d2-c8b542fb92d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a70de4a1-ef8d-4ef0-aea1-e55031f27307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d89d1c81-35c5-4d16-a7d2-c8b542fb92d8" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a70de4a1-ef8d-4ef0-aea1-e55031f27307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_edd96436-51eb-4057-82d2-dd57235fb7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d89d1c81-35c5-4d16-a7d2-c8b542fb92d8" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_edd96436-51eb-4057-82d2-dd57235fb7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_c47dde92-fbe2-40b3-9ed0-e5f448809e49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d89d1c81-35c5-4d16-a7d2-c8b542fb92d8" xlink:to="loc_us-gaap_PreferredStockSharesIssued_c47dde92-fbe2-40b3-9ed0-e5f448809e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_e67fa23a-96b0-43da-980c-be563653c849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d89d1c81-35c5-4d16-a7d2-c8b542fb92d8" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_e67fa23a-96b0-43da-980c-be563653c849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_198c6a90-42c8-464d-810a-2bcf7204d662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d89d1c81-35c5-4d16-a7d2-c8b542fb92d8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_198c6a90-42c8-464d-810a-2bcf7204d662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_ab6cc6f4-3c42-49e3-aeea-26e5dccfa1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d89d1c81-35c5-4d16-a7d2-c8b542fb92d8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_ab6cc6f4-3c42-49e3-aeea-26e5dccfa1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_882d0edb-3035-4bdb-b90f-afc4fece4c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d89d1c81-35c5-4d16-a7d2-c8b542fb92d8" xlink:to="loc_us-gaap_CommonStockSharesIssued_882d0edb-3035-4bdb-b90f-afc4fece4c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0f6efb8a-4bed-4a4f-80ed-0df5652d21d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d89d1c81-35c5-4d16-a7d2-c8b542fb92d8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0f6efb8a-4bed-4a4f-80ed-0df5652d21d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="cdna-20230331.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_ccd61233-0020-4722-8a5c-d30e5b6e97a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b18fd3da-99ae-4f6d-a906-b02d96cb804b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ccd61233-0020-4722-8a5c-d30e5b6e97a7" xlink:to="loc_us-gaap_StatementTable_b18fd3da-99ae-4f6d-a906-b02d96cb804b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_15289894-5483-4b10-9aab-a9b5a512e8e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b18fd3da-99ae-4f6d-a906-b02d96cb804b" xlink:to="loc_srt_ProductOrServiceAxis_15289894-5483-4b10-9aab-a9b5a512e8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f19ff2c0-2952-4c0d-970d-9a8e8fa96cae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_15289894-5483-4b10-9aab-a9b5a512e8e5" xlink:to="loc_srt_ProductsAndServicesDomain_f19ff2c0-2952-4c0d-970d-9a8e8fa96cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_d38c358b-4722-4a8a-b5d8-d4a100c4177c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f19ff2c0-2952-4c0d-970d-9a8e8fa96cae" xlink:to="loc_us-gaap_ServiceMember_d38c358b-4722-4a8a-b5d8-d4a100c4177c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_bc69f50d-17c5-4904-89e1-fe4e9d524935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f19ff2c0-2952-4c0d-970d-9a8e8fa96cae" xlink:to="loc_us-gaap_ProductMember_bc69f50d-17c5-4904-89e1-fe4e9d524935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_PatientAndDigitalSolutionsMember_e4c28d08-fbba-42e8-81a0-a964b6fbdd0f" xlink:href="cdna-20230331.xsd#cdna_PatientAndDigitalSolutionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f19ff2c0-2952-4c0d-970d-9a8e8fa96cae" xlink:to="loc_cdna_PatientAndDigitalSolutionsMember_e4c28d08-fbba-42e8-81a0-a964b6fbdd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dcab316f-89f4-45aa-980a-92be7bcaa9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b18fd3da-99ae-4f6d-a906-b02d96cb804b" xlink:to="loc_us-gaap_StatementLineItems_dcab316f-89f4-45aa-980a-92be7bcaa9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_7f1f685d-c62a-4c3e-be08-61e62d24bf6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dcab316f-89f4-45aa-980a-92be7bcaa9be" xlink:to="loc_us-gaap_RevenuesAbstract_7f1f685d-c62a-4c3e-be08-61e62d24bf6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_17efefdb-fc27-4fc9-b2f4-92b0ba5b96b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_7f1f685d-c62a-4c3e-be08-61e62d24bf6b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_17efefdb-fc27-4fc9-b2f4-92b0ba5b96b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_ac6cab73-1931-46c0-9e28-eb71254b9dad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dcab316f-89f4-45aa-980a-92be7bcaa9be" xlink:to="loc_us-gaap_OperatingExpensesAbstract_ac6cab73-1931-46c0-9e28-eb71254b9dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_fdb0f82f-6162-438b-903a-8de51b189c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac6cab73-1931-46c0-9e28-eb71254b9dad" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_fdb0f82f-6162-438b-903a-8de51b189c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_47615552-af40-4517-ae54-c9ac7257fda5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac6cab73-1931-46c0-9e28-eb71254b9dad" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_47615552-af40-4517-ae54-c9ac7257fda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_9fc009ed-f3a1-4f56-9353-6dfb87251b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac6cab73-1931-46c0-9e28-eb71254b9dad" xlink:to="loc_us-gaap_SellingAndMarketingExpense_9fc009ed-f3a1-4f56-9353-6dfb87251b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0965c95c-26b7-4ed1-aad3-7f9d41e1bdbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac6cab73-1931-46c0-9e28-eb71254b9dad" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0965c95c-26b7-4ed1-aad3-7f9d41e1bdbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_781c9d3b-a7cb-4306-9441-079cd3cbd53e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_ac6cab73-1931-46c0-9e28-eb71254b9dad" xlink:to="loc_us-gaap_OperatingExpenses_781c9d3b-a7cb-4306-9441-079cd3cbd53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c5980a54-ff40-4707-8c4d-4080c2ce83a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dcab316f-89f4-45aa-980a-92be7bcaa9be" xlink:to="loc_us-gaap_OperatingIncomeLoss_c5980a54-ff40-4707-8c4d-4080c2ce83a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_7202c796-7d78-421b-8507-4bed25b7c7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dcab316f-89f4-45aa-980a-92be7bcaa9be" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_7202c796-7d78-421b-8507-4bed25b7c7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_ab82a076-b06b-425c-a345-7a022f14b93a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_7202c796-7d78-421b-8507-4bed25b7c7f4" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_ab82a076-b06b-425c-a345-7a022f14b93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_769d0045-eebb-44f9-ae7c-775f8b31a508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_7202c796-7d78-421b-8507-4bed25b7c7f4" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_769d0045-eebb-44f9-ae7c-775f8b31a508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_80240041-6725-48a8-a48b-f73ad3efb5ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_7202c796-7d78-421b-8507-4bed25b7c7f4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_80240041-6725-48a8-a48b-f73ad3efb5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_79858f32-31f0-48fa-89f5-5787fe313882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_7202c796-7d78-421b-8507-4bed25b7c7f4" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_79858f32-31f0-48fa-89f5-5787fe313882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d1ee8e28-4979-42b1-a164-4bea0c57854f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dcab316f-89f4-45aa-980a-92be7bcaa9be" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d1ee8e28-4979-42b1-a164-4bea0c57854f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7183bd9c-22b3-4e78-ac03-a5361ba0eb5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dcab316f-89f4-45aa-980a-92be7bcaa9be" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7183bd9c-22b3-4e78-ac03-a5361ba0eb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_91136c42-4de3-4a8e-9f5d-fc905692860a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dcab316f-89f4-45aa-980a-92be7bcaa9be" xlink:to="loc_us-gaap_NetIncomeLoss_91136c42-4de3-4a8e-9f5d-fc905692860a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8cc5d85a-f235-47f6-a109-594d58855a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dcab316f-89f4-45aa-980a-92be7bcaa9be" xlink:to="loc_us-gaap_EarningsPerShareAbstract_8cc5d85a-f235-47f6-a109-594d58855a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_47b00ff2-4045-4c0b-93f3-f61f987bdadd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8cc5d85a-f235-47f6-a109-594d58855a1c" xlink:to="loc_us-gaap_EarningsPerShareBasic_47b00ff2-4045-4c0b-93f3-f61f987bdadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_57a762e2-2c64-4a91-a66c-37a193437d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8cc5d85a-f235-47f6-a109-594d58855a1c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_57a762e2-2c64-4a91-a66c-37a193437d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_60e14c35-4cb1-42db-9232-10e531712364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dcab316f-89f4-45aa-980a-92be7bcaa9be" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_60e14c35-4cb1-42db-9232-10e531712364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a759e187-9b18-4f40-b312-29b99e4934e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_60e14c35-4cb1-42db-9232-10e531712364" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a759e187-9b18-4f40-b312-29b99e4934e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4b22a1fd-f110-49a0-a2af-4ff732546a00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_60e14c35-4cb1-42db-9232-10e531712364" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4b22a1fd-f110-49a0-a2af-4ff732546a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="cdna-20230331.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_be1129b6-b150-4335-a8af-70b074ee2bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_cb6dd709-f431-44b9-a478-75c88251280c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_be1129b6-b150-4335-a8af-70b074ee2bba" xlink:to="loc_us-gaap_ProfitLoss_cb6dd709-f431-44b9-a478-75c88251280c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8fada3d6-c6a7-4adf-a4c8-316f9877bc41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_be1129b6-b150-4335-a8af-70b074ee2bba" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8fada3d6-c6a7-4adf-a4c8-316f9877bc41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8d0bbb42-8add-4729-ac1a-caba1a601f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8fada3d6-c6a7-4adf-a4c8-316f9877bc41" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8d0bbb42-8add-4729-ac1a-caba1a601f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_04031168-1a0f-4e19-b493-159b78ae984d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_be1129b6-b150-4335-a8af-70b074ee2bba" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_04031168-1a0f-4e19-b493-159b78ae984d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="cdna-20230331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_20e738a6-07b6-4ad5-91ae-6a6784bf26a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3622ba34-39fe-4f71-b29b-51dba4f13227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_20e738a6-07b6-4ad5-91ae-6a6784bf26a9" xlink:to="loc_us-gaap_StatementTable_3622ba34-39fe-4f71-b29b-51dba4f13227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_054caeeb-3cb4-473a-b993-78d5f09a1030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3622ba34-39fe-4f71-b29b-51dba4f13227" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_054caeeb-3cb4-473a-b993-78d5f09a1030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7e702860-310b-463f-a8b6-1b8c446b4995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_054caeeb-3cb4-473a-b993-78d5f09a1030" xlink:to="loc_us-gaap_EquityComponentDomain_7e702860-310b-463f-a8b6-1b8c446b4995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_91aedcfc-584f-44b7-a0f1-3f38177d875f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7e702860-310b-463f-a8b6-1b8c446b4995" xlink:to="loc_us-gaap_CommonStockMember_91aedcfc-584f-44b7-a0f1-3f38177d875f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8d0f8996-9628-49a3-9813-a63a292dc956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7e702860-310b-463f-a8b6-1b8c446b4995" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8d0f8996-9628-49a3-9813-a63a292dc956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cb1d0592-f61c-41c9-914f-e7eed9cfc0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7e702860-310b-463f-a8b6-1b8c446b4995" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cb1d0592-f61c-41c9-914f-e7eed9cfc0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_752357a0-2c4a-4cae-a642-9ff9647b5d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7e702860-310b-463f-a8b6-1b8c446b4995" xlink:to="loc_us-gaap_RetainedEarningsMember_752357a0-2c4a-4cae-a642-9ff9647b5d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1f3dd0a3-aa26-434f-98e7-85859aeb96e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3622ba34-39fe-4f71-b29b-51dba4f13227" xlink:to="loc_us-gaap_StatementLineItems_1f3dd0a3-aa26-434f-98e7-85859aeb96e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1f3dd0a3-aa26-434f-98e7-85859aeb96e5" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_454e6dfb-4750-4ee5-ab52-a9321f8db088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_SharesOutstanding_454e6dfb-4750-4ee5-ab52-a9321f8db088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_90be7f5a-4207-422b-9ea2-9631600ca143" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_90be7f5a-4207-422b-9ea2-9631600ca143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_78e2e7e7-086a-41a2-83df-2fd5f6690e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_78e2e7e7-086a-41a2-83df-2fd5f6690e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_218a6638-646a-49b5-9e59-019358d04240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_218a6638-646a-49b5-9e59-019358d04240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_af8f84f6-8754-4069-8a8e-80683b58b8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_af8f84f6-8754-4069-8a8e-80683b58b8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_85e287da-5273-4e68-ab9b-c487fbaf71fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_85e287da-5273-4e68-ab9b-c487fbaf71fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_d361c619-d9f2-416c-abd9-f38fae310fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_d361c619-d9f2-416c-abd9-f38fae310fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_10898719-18ee-4d55-a6a5-e65d4e2e12e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_10898719-18ee-4d55-a6a5-e65d4e2e12e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_a3483b18-104e-4da3-9279-9f9cb0d04a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_a3483b18-104e-4da3-9279-9f9cb0d04a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_f13d16fb-49da-4863-a52e-0620b6d94e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_f13d16fb-49da-4863-a52e-0620b6d94e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11733cdf-7f83-447d-ada6-03dcd03d3d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_11733cdf-7f83-447d-ada6-03dcd03d3d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_55bb8abe-b4f1-449b-b8c8-7f27f5812693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_55bb8abe-b4f1-449b-b8c8-7f27f5812693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d0499393-3b20-4bab-a76b-ba93c57d444c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d0499393-3b20-4bab-a76b-ba93c57d444c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c7807b75-598a-448b-ab1f-06a9c803fbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c7807b75-598a-448b-ab1f-06a9c803fbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ddbc2022-4456-44cc-b300-744f072606d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_NetIncomeLoss_ddbc2022-4456-44cc-b300-744f072606d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a4d1a172-2bc9-4718-86aa-cde44109af15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_SharesOutstanding_a4d1a172-2bc9-4718-86aa-cde44109af15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6a634bbd-e65f-41be-bf3e-29c7149b4205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b2676f2-8208-4951-a923-8d814758bb3d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6a634bbd-e65f-41be-bf3e-29c7149b4205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cdna-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_8ece2b56-2a8b-4814-9787-94960f55fef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ee386574-0f3c-4bf6-b254-0ef3bb5141d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8ece2b56-2a8b-4814-9787-94960f55fef8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ee386574-0f3c-4bf6-b254-0ef3bb5141d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1a540efa-68ca-4c7f-ad85-6127b100320a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ee386574-0f3c-4bf6-b254-0ef3bb5141d5" xlink:to="loc_us-gaap_ProfitLoss_1a540efa-68ca-4c7f-ad85-6127b100320a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_be441844-3b57-4471-b041-d187d0de782e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ee386574-0f3c-4bf6-b254-0ef3bb5141d5" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_be441844-3b57-4471-b041-d187d0de782e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d1d0d14c-756e-4d01-8888-f4933c734cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_be441844-3b57-4471-b041-d187d0de782e" xlink:to="loc_us-gaap_ShareBasedCompensation_d1d0d14c-756e-4d01-8888-f4933c734cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_72e2b04c-d720-4b70-a0c8-400018081d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_be441844-3b57-4471-b041-d187d0de782e" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_72e2b04c-d720-4b70-a0c8-400018081d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9351b0ad-2095-46e6-8bfa-10f755db74bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_be441844-3b57-4471-b041-d187d0de782e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9351b0ad-2095-46e6-8bfa-10f755db74bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_fac5fce7-5b93-48f4-b5fe-a6d7408a4196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_be441844-3b57-4471-b041-d187d0de782e" xlink:to="loc_us-gaap_AssetImpairmentCharges_fac5fce7-5b93-48f4-b5fe-a6d7408a4196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b141ac17-c6e9-4b50-9f38-0d52bbe1ed55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_be441844-3b57-4471-b041-d187d0de782e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_b141ac17-c6e9-4b50-9f38-0d52bbe1ed55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_f8951d53-a382-4db6-9006-0aafb74ebbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_be441844-3b57-4471-b041-d187d0de782e" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_f8951d53-a382-4db6-9006-0aafb74ebbb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e5f24403-83dd-474a-ab5e-98c6b712e757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_be441844-3b57-4471-b041-d187d0de782e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e5f24403-83dd-474a-ab5e-98c6b712e757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_8ca0e2fe-d634-4989-b8a8-77e1fb0aa747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_be441844-3b57-4471-b041-d187d0de782e" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_8ca0e2fe-d634-4989-b8a8-77e1fb0aa747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83212b64-072a-460c-aab9-5be7e33783bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ee386574-0f3c-4bf6-b254-0ef3bb5141d5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83212b64-072a-460c-aab9-5be7e33783bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_73880188-5e45-4db8-8510-12b1f60d8970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83212b64-072a-460c-aab9-5be7e33783bd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_73880188-5e45-4db8-8510-12b1f60d8970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b0bc4857-5d74-406b-858d-65541fe84854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83212b64-072a-460c-aab9-5be7e33783bd" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b0bc4857-5d74-406b-858d-65541fe84854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_bdea5bec-052c-4dd8-a4ff-352d41a9e2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83212b64-072a-460c-aab9-5be7e33783bd" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_bdea5bec-052c-4dd8-a4ff-352d41a9e2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_IncreaseDecreaseInOperatingLeaseLiabilities_e811a138-dd97-4a85-8880-41693fc93742" xlink:href="cdna-20230331.xsd#cdna_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83212b64-072a-460c-aab9-5be7e33783bd" xlink:to="loc_cdna_IncreaseDecreaseInOperatingLeaseLiabilities_e811a138-dd97-4a85-8880-41693fc93742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0b73550d-6e0a-4283-9cbd-d1d2f923a06d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83212b64-072a-460c-aab9-5be7e33783bd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_0b73550d-6e0a-4283-9cbd-d1d2f923a06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_d0d9674c-3588-4f66-87b8-27bc2fa73db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83212b64-072a-460c-aab9-5be7e33783bd" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_d0d9674c-3588-4f66-87b8-27bc2fa73db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_b5572aa4-8737-4b8a-93b1-151edf373476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83212b64-072a-460c-aab9-5be7e33783bd" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_b5572aa4-8737-4b8a-93b1-151edf373476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_8c665869-871e-4f9b-a797-0bfe7eef8b20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83212b64-072a-460c-aab9-5be7e33783bd" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_8c665869-871e-4f9b-a797-0bfe7eef8b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a5ddd029-4a3c-4b2d-80f8-85a74c887cba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ee386574-0f3c-4bf6-b254-0ef3bb5141d5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a5ddd029-4a3c-4b2d-80f8-85a74c887cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e1d95f9-5797-4204-b22e-845bade6b443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8ece2b56-2a8b-4814-9787-94960f55fef8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e1d95f9-5797-4204-b22e-845bade6b443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c971111f-0ad6-4df3-bb64-878a0054febb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e1d95f9-5797-4204-b22e-845bade6b443" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c971111f-0ad6-4df3-bb64-878a0054febb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_e92c8dca-fd6b-4c38-9ffe-37f64d015d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e1d95f9-5797-4204-b22e-845bade6b443" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_e92c8dca-fd6b-4c38-9ffe-37f64d015d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_70f8b36e-ed1b-4ecb-a595-afa35eb0feb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e1d95f9-5797-4204-b22e-845bade6b443" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_70f8b36e-ed1b-4ecb-a595-afa35eb0feb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_b368ec5b-2fa4-4ece-941d-6dae56a4eac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e1d95f9-5797-4204-b22e-845bade6b443" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_b368ec5b-2fa4-4ece-941d-6dae56a4eac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_4f3cef79-81d4-4b83-a54e-355b56f39f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e1d95f9-5797-4204-b22e-845bade6b443" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_4f3cef79-81d4-4b83-a54e-355b56f39f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_PaymentsToAcquireCapitalExpendituresNet_79a650cc-c38f-40be-b175-ad435d415b1b" xlink:href="cdna-20230331.xsd#cdna_PaymentsToAcquireCapitalExpendituresNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e1d95f9-5797-4204-b22e-845bade6b443" xlink:to="loc_cdna_PaymentsToAcquireCapitalExpendituresNet_79a650cc-c38f-40be-b175-ad435d415b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2d0baad0-5378-4feb-85d8-f1a3350d0fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e1d95f9-5797-4204-b22e-845bade6b443" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2d0baad0-5378-4feb-85d8-f1a3350d0fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eee2e161-1431-4cfe-8914-734cd44d37f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8ece2b56-2a8b-4814-9787-94960f55fef8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eee2e161-1431-4cfe-8914-734cd44d37f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_b3116dc6-2428-418e-8908-42309e97b477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eee2e161-1431-4cfe-8914-734cd44d37f0" xlink:to="loc_us-gaap_ProceedsFromStockPlans_b3116dc6-2428-418e-8908-42309e97b477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits_1db690f9-f376-4a39-998e-811f0890a398" xlink:href="cdna-20230331.xsd#cdna_TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eee2e161-1431-4cfe-8914-734cd44d37f0" xlink:to="loc_cdna_TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits_1db690f9-f376-4a39-998e-811f0890a398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_2910fbea-5f7b-4796-921e-4c96ec6f1da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eee2e161-1431-4cfe-8914-734cd44d37f0" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_2910fbea-5f7b-4796-921e-4c96ec6f1da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_156371d3-146c-4c15-80a0-02e539a1ec43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eee2e161-1431-4cfe-8914-734cd44d37f0" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_156371d3-146c-4c15-80a0-02e539a1ec43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a86744f8-381c-4163-b5a5-9789a956f181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eee2e161-1431-4cfe-8914-734cd44d37f0" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a86744f8-381c-4163-b5a5-9789a956f181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_db5721d9-6b17-41d6-9cb9-a085a69148ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_eee2e161-1431-4cfe-8914-734cd44d37f0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_db5721d9-6b17-41d6-9cb9-a085a69148ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_69f22eeb-eb7a-4fde-929c-9dec9eb58019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8ece2b56-2a8b-4814-9787-94960f55fef8" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_69f22eeb-eb7a-4fde-929c-9dec9eb58019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e91c6f6f-0db9-4354-9766-58cf96ed8512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8ece2b56-2a8b-4814-9787-94960f55fef8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e91c6f6f-0db9-4354-9766-58cf96ed8512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c94299fa-51ee-439e-b565-05e906347b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8ece2b56-2a8b-4814-9787-94960f55fef8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c94299fa-51ee-439e-b565-05e906347b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ed40f420-03e8-4fc9-b619-f6952ac7b16f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8ece2b56-2a8b-4814-9787-94960f55fef8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ed40f420-03e8-4fc9-b619-f6952ac7b16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/OrganizationandDescriptionofBusiness" xlink:type="simple" xlink:href="cdna-20230331.xsd#OrganizationandDescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7691dcf8-907a-4fb6-93ac-6bb435316466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_934cd67d-ead2-4eb5-a75b-815aebe0a272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7691dcf8-907a-4fb6-93ac-6bb435316466" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_934cd67d-ead2-4eb5-a75b-815aebe0a272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cdna-20230331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_aab5acc4-dac3-4a4f-a62b-ed731be16123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_581ac32d-7aa5-4111-8451-914a4c814afa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aab5acc4-dac3-4a4f-a62b-ed731be16123" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_581ac32d-7aa5-4111-8451-914a4c814afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/NetLossPerShare" xlink:type="simple" xlink:href="cdna-20230331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_14e8f05f-d597-4780-8a86-601a22485193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_dc3faf8e-bce9-427a-b06d-660ef5635952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_14e8f05f-d597-4780-8a86-601a22485193" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_dc3faf8e-bce9-427a-b06d-660ef5635952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cdna-20230331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cc1ab885-9b81-4c12-bb73-023aeb283956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_ff3c1752-06c4-4822-a1c8-cc6768440a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cc1ab885-9b81-4c12-bb73-023aeb283956" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_ff3c1752-06c4-4822-a1c8-cc6768440a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CashandMarketableSecurities" xlink:type="simple" xlink:href="cdna-20230331.xsd#CashandMarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/CashandMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_66f3aba0-ad20-46fe-a071-ec245d1cf344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_1e802065-608c-46fa-91ae-3def54400bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_66f3aba0-ad20-46fe-a071-ec245d1cf344" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_1e802065-608c-46fa-91ae-3def54400bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/BusinessCombinations" xlink:type="simple" xlink:href="cdna-20230331.xsd#BusinessCombinations"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/BusinessCombinations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_506d5401-d571-48f9-b377-03b1a661bd01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_242efd80-c142-4ec5-8632-ffd684ba4131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_506d5401-d571-48f9-b377-03b1a661bd01" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_242efd80-c142-4ec5-8632-ffd684ba4131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="cdna-20230331.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bd1ca3f6-c436-4c0e-a6fa-4195c164be4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_58147310-ecef-4bbe-902c-9a50e9b85dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bd1ca3f6-c436-4c0e-a6fa-4195c164be4d" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_58147310-ecef-4bbe-902c-9a50e9b85dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="cdna-20230331.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_39b27c28-6fff-4f7c-b1ae-b6924b92d70b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_bb9a5f95-5613-403d-9703-443240750ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_39b27c28-6fff-4f7c-b1ae-b6924b92d70b" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_bb9a5f95-5613-403d-9703-443240750ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="cdna-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9aeada32-3ed4-448f-af7d-d4f21e6f2e08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_537dceb8-e1ae-4be2-ae8f-abc583463e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9aeada32-3ed4-448f-af7d-d4f21e6f2e08" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_537dceb8-e1ae-4be2-ae8f-abc583463e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/A401KPlan" xlink:type="simple" xlink:href="cdna-20230331.xsd#A401KPlan"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/A401KPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_da893b27-1dfa-4bae-9c1d-0297f06005a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_edf6519f-8093-4d2b-9ce2-6b6d91e3ac40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_da893b27-1dfa-4bae-9c1d-0297f06005a1" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_edf6519f-8093-4d2b-9ce2-6b6d91e3ac40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/Warrants" xlink:type="simple" xlink:href="cdna-20230331.xsd#Warrants"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/Warrants" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_2c366b5b-3f69-44e9-81da-4348a9bfd345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_WarrantsDisclosureTextBlock_e2cc18b1-93c9-44de-b931-92fef9172592" xlink:href="cdna-20230331.xsd#cdna_WarrantsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_2c366b5b-3f69-44e9-81da-4348a9bfd345" xlink:to="loc_cdna_WarrantsDisclosureTextBlock_e2cc18b1-93c9-44de-b931-92fef9172592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/StockIncentivePlans" xlink:type="simple" xlink:href="cdna-20230331.xsd#StockIncentivePlans"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/StockIncentivePlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ac7d09fa-b3a8-4274-97df-a7dd7ec8f21d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2131cfa2-5f15-4d5a-9564-805a10434051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ac7d09fa-b3a8-4274-97df-a7dd7ec8f21d" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2131cfa2-5f15-4d5a-9564-805a10434051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cdna-20230331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_334a0850-3ba8-410e-89f2-5cd52a772fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_be556728-d485-4e56-bc96-fef7c4247cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_334a0850-3ba8-410e-89f2-5cd52a772fed" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_be556728-d485-4e56-bc96-fef7c4247cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/SegmentReporting" xlink:type="simple" xlink:href="cdna-20230331.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c4b83aae-cced-46ac-9a0a-78a5f6310f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_b285f77f-1f5f-47e7-99b0-e568b53ed812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c4b83aae-cced-46ac-9a0a-78a5f6310f09" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_b285f77f-1f5f-47e7-99b0-e568b53ed812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/Restructuring" xlink:type="simple" xlink:href="cdna-20230331.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6b796bf0-edc8-4233-a373-815ff5571cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_79af5962-c502-4dce-a280-581230686257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6b796bf0-edc8-4233-a373-815ff5571cfb" xlink:to="loc_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock_79af5962-c502-4dce-a280-581230686257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/SubsequentEvents" xlink:type="simple" xlink:href="cdna-20230331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_cdca08ac-3135-4fe7-b094-45f97166783d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_277b0677-05b0-48e6-9a8e-e3ce3e82ce3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_cdca08ac-3135-4fe7-b094-45f97166783d" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_277b0677-05b0-48e6-9a8e-e3ce3e82ce3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cdna-20230331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_516d599d-c290-4f37-9da2-3ccbc3542fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_LiquidityPolicyTextBlock_f90c8d6d-75fe-44a9-8777-6071ab8a6a12" xlink:href="cdna-20230331.xsd#cdna_LiquidityPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_516d599d-c290-4f37-9da2-3ccbc3542fe3" xlink:to="loc_cdna_LiquidityPolicyTextBlock_f90c8d6d-75fe-44a9-8777-6071ab8a6a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0ea9b071-bdec-4a3e-a2c5-fd466f1ef88f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_516d599d-c290-4f37-9da2-3ccbc3542fe3" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0ea9b071-bdec-4a3e-a2c5-fd466f1ef88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_c5c53794-04b9-49d3-aef6-319f59415e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_516d599d-c290-4f37-9da2-3ccbc3542fe3" xlink:to="loc_us-gaap_UseOfEstimates_c5c53794-04b9-49d3-aef6-319f59415e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_1237dcaf-1cc3-4c61-92c6-c8c08cf5914d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_516d599d-c290-4f37-9da2-3ccbc3542fe3" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_1237dcaf-1cc3-4c61-92c6-c8c08cf5914d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_8eac00d3-ed68-41b9-af20-7e3aa6ca8742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_516d599d-c290-4f37-9da2-3ccbc3542fe3" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_8eac00d3-ed68-41b9-af20-7e3aa6ca8742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_3c3a51d2-561a-4866-989c-ae5375e180be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_516d599d-c290-4f37-9da2-3ccbc3542fe3" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_3c3a51d2-561a-4866-989c-ae5375e180be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f1acf4cc-1d7b-4426-9f75-1398986a0606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_516d599d-c290-4f37-9da2-3ccbc3542fe3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f1acf4cc-1d7b-4426-9f75-1398986a0606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4942e90a-cc08-43ea-a376-ba23d62971cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_516d599d-c290-4f37-9da2-3ccbc3542fe3" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4942e90a-cc08-43ea-a376-ba23d62971cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="cdna-20230331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d45c2833-8280-46dd-9bf3-249d38b8a2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4c801782-7bd5-40bc-b361-7c8539c8708e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d45c2833-8280-46dd-9bf3-249d38b8a2c1" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4c801782-7bd5-40bc-b361-7c8539c8708e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f578f9fe-b475-4542-a250-fb789ccaa78d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d45c2833-8280-46dd-9bf3-249d38b8a2c1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f578f9fe-b475-4542-a250-fb789ccaa78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cdna-20230331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_16452f41-8541-47ad-9a33-3b11faf79001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_26bde010-0b0d-4693-a2d3-fb2d86df351e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_16452f41-8541-47ad-9a33-3b11faf79001" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_26bde010-0b0d-4693-a2d3-fb2d86df351e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1a1bcef8-25f7-4381-8e06-326dcf15b573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_16452f41-8541-47ad-9a33-3b11faf79001" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1a1bcef8-25f7-4381-8e06-326dcf15b573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CashandMarketableSecuritiesTables" xlink:type="simple" xlink:href="cdna-20230331.xsd#CashandMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/CashandMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_00bbffd8-2dbf-44a9-bf23-6e7be183d14c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_a89d5061-9bd6-4437-94e0-5204eb153754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_00bbffd8-2dbf-44a9-bf23-6e7be183d14c" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_a89d5061-9bd6-4437-94e0-5204eb153754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_66350029-79f6-4a93-a5d5-fdc79380b2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_00bbffd8-2dbf-44a9-bf23-6e7be183d14c" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_66350029-79f6-4a93-a5d5-fdc79380b2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="cdna-20230331.xsd#BusinessCombinationsTables"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/BusinessCombinationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e6c24b8d-0c58-40bf-b3ca-d565e4eb7e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_379361e6-e5f6-434d-9e71-fd7d1085dcf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e6c24b8d-0c58-40bf-b3ca-d565e4eb7e90" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock_379361e6-e5f6-434d-9e71-fd7d1085dcf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_dc36a724-8316-418e-9285-8a4dc65fb3de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e6c24b8d-0c58-40bf-b3ca-d565e4eb7e90" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_dc36a724-8316-418e-9285-8a4dc65fb3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="cdna-20230331.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8a86f906-1789-4b7f-a217-9825d4f55542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ScheduleOfIntangibleAssetsTableTableTextBlock_976db8e6-d370-498b-8eaa-9b987420ab0b" xlink:href="cdna-20230331.xsd#cdna_ScheduleOfIntangibleAssetsTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8a86f906-1789-4b7f-a217-9825d4f55542" xlink:to="loc_cdna_ScheduleOfIntangibleAssetsTableTableTextBlock_976db8e6-d370-498b-8eaa-9b987420ab0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_3dfca773-20f8-49a6-b1c7-3f8d53f5e9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8a86f906-1789-4b7f-a217-9825d4f55542" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_3dfca773-20f8-49a6-b1c7-3f8d53f5e9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c0c696ee-a585-4f76-87c4-6139385af81f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8a86f906-1789-4b7f-a217-9825d4f55542" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c0c696ee-a585-4f76-87c4-6139385af81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="cdna-20230331.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27abf616-a712-49db-b112-d62195afa38f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ea60e5e9-5341-48a1-a20e-4563c34812a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27abf616-a712-49db-b112-d62195afa38f" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ea60e5e9-5341-48a1-a20e-4563c34812a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ae873476-2f91-490c-900f-bb77b04fd118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27abf616-a712-49db-b112-d62195afa38f" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ae873476-2f91-490c-900f-bb77b04fd118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="cdna-20230331.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4a692488-9dd6-4dcf-9011-0d327bf164d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_9469e623-e0a6-41df-9bbe-c18db35b7965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4a692488-9dd6-4dcf-9011-0d327bf164d7" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_9469e623-e0a6-41df-9bbe-c18db35b7965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock_bcbc6ba3-a8a8-4901-ade3-8b00bae456cc" xlink:href="cdna-20230331.xsd#cdna_ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4a692488-9dd6-4dcf-9011-0d327bf164d7" xlink:to="loc_cdna_ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock_bcbc6ba3-a8a8-4901-ade3-8b00bae456cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock_5c657364-af5d-4e35-ba86-1be10b620b52" xlink:href="cdna-20230331.xsd#cdna_ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4a692488-9dd6-4dcf-9011-0d327bf164d7" xlink:to="loc_cdna_ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock_5c657364-af5d-4e35-ba86-1be10b620b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/WarrantsTables" xlink:type="simple" xlink:href="cdna-20230331.xsd#WarrantsTables"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/WarrantsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_07ed8353-e43a-48c7-be40-453219a2024b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_42bd1ec7-9ed7-4d3b-9fd5-ac3a3d10efd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_07ed8353-e43a-48c7-be40-453219a2024b" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_42bd1ec7-9ed7-4d3b-9fd5-ac3a3d10efd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/StockIncentivePlansTables" xlink:type="simple" xlink:href="cdna-20230331.xsd#StockIncentivePlansTables"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/StockIncentivePlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82807868-9a32-463c-a706-72c0c5843239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock_8c9a2828-c424-4dea-a94f-e0d7193c2a4c" xlink:href="cdna-20230331.xsd#cdna_ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82807868-9a32-463c-a706-72c0c5843239" xlink:to="loc_cdna_ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock_8c9a2828-c424-4dea-a94f-e0d7193c2a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_d32fb70b-e642-482f-a6fd-4c0a13464f90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82807868-9a32-463c-a706-72c0c5843239" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_d32fb70b-e642-482f-a6fd-4c0a13464f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c0e48622-5ecb-4fae-ba9e-ef1d657a3048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82807868-9a32-463c-a706-72c0c5843239" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c0e48622-5ecb-4fae-ba9e-ef1d657a3048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c74a4633-6023-4041-b455-a071b5e82561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82807868-9a32-463c-a706-72c0c5843239" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c74a4633-6023-4041-b455-a071b5e82561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="cdna-20230331.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_fe2b9f17-1bcd-4edb-a2de-33e558169fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_fd88e692-882e-40ea-b7ec-dcf7fb9340c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_fe2b9f17-1bcd-4edb-a2de-33e558169fa8" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_fd88e692-882e-40ea-b7ec-dcf7fb9340c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_a382a8f9-0169-4e39-b03d-d365b9ce93e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_fe2b9f17-1bcd-4edb-a2de-33e558169fa8" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_a382a8f9-0169-4e39-b03d-d365b9ce93e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#OrganizationandDescriptionofBusinessAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_470158e6-1ce5-4343-a684-44c3167eb231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityTable_d3c47791-e74e-41ec-91a6-62a58d8cd0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_470158e6-1ce5-4343-a684-44c3167eb231" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityTable_d3c47791-e74e-41ec-91a6-62a58d8cd0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a4377ab4-822c-43ea-9b68-0b91b5d1e1c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_d3c47791-e74e-41ec-91a6-62a58d8cd0b7" xlink:to="loc_srt_MajorCustomersAxis_a4377ab4-822c-43ea-9b68-0b91b5d1e1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f38ce9ba-6278-45fb-a76b-78d0ca0c9748" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_a4377ab4-822c-43ea-9b68-0b91b5d1e1c7" xlink:to="loc_srt_NameOfMajorCustomerDomain_f38ce9ba-6278-45fb-a76b-78d0ca0c9748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MedicareMember_0ff6b058-d846-4106-bc6f-9cfa7952389c" xlink:href="cdna-20230331.xsd#cdna_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f38ce9ba-6278-45fb-a76b-78d0ca0c9748" xlink:to="loc_cdna_MedicareMember_0ff6b058-d846-4106-bc6f-9cfa7952389c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3e6ca906-2827-4632-b08f-a11d9c7871b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_d3c47791-e74e-41ec-91a6-62a58d8cd0b7" xlink:to="loc_srt_ProductOrServiceAxis_3e6ca906-2827-4632-b08f-a11d9c7871b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_040dbd97-7a64-4422-9467-ab61ef2651dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3e6ca906-2827-4632-b08f-a11d9c7871b9" xlink:to="loc_srt_ProductsAndServicesDomain_040dbd97-7a64-4422-9467-ab61ef2651dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AlloSureKidneyMember_a94018c7-c492-4a91-8405-c2d8639a46a1" xlink:href="cdna-20230331.xsd#cdna_AlloSureKidneyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_040dbd97-7a64-4422-9467-ab61ef2651dd" xlink:to="loc_cdna_AlloSureKidneyMember_a94018c7-c492-4a91-8405-c2d8639a46a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AlloMapHeartMember_ad73bb69-8cd6-4f8a-afeb-9545a24880de" xlink:href="cdna-20230331.xsd#cdna_AlloMapHeartMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_040dbd97-7a64-4422-9467-ab61ef2651dd" xlink:to="loc_cdna_AlloMapHeartMember_ad73bb69-8cd6-4f8a-afeb-9545a24880de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AlloSureHeartMember_9bd029b4-4dfa-44be-9078-d2af772eabf2" xlink:href="cdna-20230331.xsd#cdna_AlloSureHeartMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_040dbd97-7a64-4422-9467-ab61ef2651dd" xlink:to="loc_cdna_AlloSureHeartMember_9bd029b4-4dfa-44be-9078-d2af772eabf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7b40e4b3-30cb-49e1-b448-5685143b9eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_d3c47791-e74e-41ec-91a6-62a58d8cd0b7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7b40e4b3-30cb-49e1-b448-5685143b9eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_74d8cae8-e01f-4dc8-ab64-289530e00129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7b40e4b3-30cb-49e1-b448-5685143b9eb4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_74d8cae8-e01f-4dc8-ab64-289530e00129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_XynManagementIncMember_4af252b1-1a0c-4493-8ee9-32ff8328d51c" xlink:href="cdna-20230331.xsd#cdna_XynManagementIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_74d8cae8-e01f-4dc8-ab64-289530e00129" xlink:to="loc_cdna_XynManagementIncMember_4af252b1-1a0c-4493-8ee9-32ff8328d51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c5e7a445-7c7b-4841-b5e4-8ec7ebdd4320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_d3c47791-e74e-41ec-91a6-62a58d8cd0b7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c5e7a445-7c7b-4841-b5e4-8ec7ebdd4320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d8d26f9-8bba-4c77-9194-be48da561e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c5e7a445-7c7b-4841-b5e4-8ec7ebdd4320" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d8d26f9-8bba-4c77-9194-be48da561e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AtTheMarketEquityOfferingMember_0f7be3e9-eb6c-47c6-8c69-10eb0199d7f9" xlink:href="cdna-20230331.xsd#cdna_AtTheMarketEquityOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0d8d26f9-8bba-4c77-9194-be48da561e21" xlink:to="loc_cdna_AtTheMarketEquityOfferingMember_0f7be3e9-eb6c-47c6-8c69-10eb0199d7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_64bcf084-70b0-4bc7-9ebe-8a5d1c362729" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_d3c47791-e74e-41ec-91a6-62a58d8cd0b7" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_64bcf084-70b0-4bc7-9ebe-8a5d1c362729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6cfffd0d-0ef3-46c9-a990-427b7654f2e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_64bcf084-70b0-4bc7-9ebe-8a5d1c362729" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6cfffd0d-0ef3-46c9-a990-427b7654f2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MiromatrixIncMember_8a55883f-6444-48ca-aba8-d15bf41e9250" xlink:href="cdna-20230331.xsd#cdna_MiromatrixIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6cfffd0d-0ef3-46c9-a990-427b7654f2e8" xlink:to="loc_cdna_MiromatrixIncMember_8a55883f-6444-48ca-aba8-d15bf41e9250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityTable_d3c47791-e74e-41ec-91a6-62a58d8cd0b7" xlink:to="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_571d8f3d-f225-41dc-b9b0-7ff2a289a3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecoveryOfDirectCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_571d8f3d-f225-41dc-b9b0-7ff2a289a3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_UnsubmittedReimbursementClaimsForMedicare_0d806d42-fd03-40bd-ad61-dd2a49c58a39" xlink:href="cdna-20230331.xsd#cdna_UnsubmittedReimbursementClaimsForMedicare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_cdna_UnsubmittedReimbursementClaimsForMedicare_0d806d42-fd03-40bd-ad61-dd2a49c58a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_UnsubmittedClaimsRevenueNotYetRecognized_9ccd0bb7-d10f-4b58-9d50-596247077909" xlink:href="cdna-20230331.xsd#cdna_UnsubmittedClaimsRevenueNotYetRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_cdna_UnsubmittedClaimsRevenueNotYetRecognized_9ccd0bb7-d10f-4b58-9d50-596247077909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_83be88bb-c4ad-459e-8f9a-befcb6240913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_83be88bb-c4ad-459e-8f9a-befcb6240913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_NumberOfRenalTransplantPatients_60d6cae7-7e97-41a1-bb1e-8ab744ef25f2" xlink:href="cdna-20230331.xsd#cdna_NumberOfRenalTransplantPatients"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_cdna_NumberOfRenalTransplantPatients_60d6cae7-7e97-41a1-bb1e-8ab744ef25f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_NumberOfUniqueSolutions_7a2b3fe5-2419-4069-bc29-53a900998c06" xlink:href="cdna-20230331.xsd#cdna_NumberOfUniqueSolutions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_cdna_NumberOfUniqueSolutions_7a2b3fe5-2419-4069-bc29-53a900998c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aef5ce3c-f72d-4d12-8d3a-1f25fb69a354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aef5ce3c-f72d-4d12-8d3a-1f25fb69a354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_0335629c-0450-4639-b166-883ff9067561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_0335629c-0450-4639-b166-883ff9067561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_SaleOfStockAuthorizedConsiderationAmountMaximum_a2126461-6aa6-466e-90b7-287a0b01da7c" xlink:href="cdna-20230331.xsd#cdna_SaleOfStockAuthorizedConsiderationAmountMaximum"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_cdna_SaleOfStockAuthorizedConsiderationAmountMaximum_a2126461-6aa6-466e-90b7-287a0b01da7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_SaleOfStockCommissionFeePercentage_22a6ddae-9acb-4fa7-9ffd-67777f9c5824" xlink:href="cdna-20230331.xsd#cdna_SaleOfStockCommissionFeePercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_cdna_SaleOfStockCommissionFeePercentage_22a6ddae-9acb-4fa7-9ffd-67777f9c5824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d9ded15a-c006-4386-ae99-2e57409d99d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_d9ded15a-c006-4386-ae99-2e57409d99d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_8c0547b3-1137-4d84-a008-dc2776fb6270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_8c0547b3-1137-4d84-a008-dc2776fb6270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_ff053e52-0e75-49f1-8582-e54f39af3f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_ff053e52-0e75-49f1-8582-e54f39af3f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_d54f552f-6410-4671-9d99-b1bd890692ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_d54f552f-6410-4671-9d99-b1bd890692ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_9b21a844-60b9-4671-818f-c448a48a3fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCapitalizationEquityLineItems_eaad1f9f-8b04-4276-89ca-b950a89d48f2" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_9b21a844-60b9-4671-818f-c448a48a3fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_22782729-28b9-4f74-b94a-2a2f9a4f2b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_3cde6d56-948c-456f-aa19-722034f25691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_22782729-28b9-4f74-b94a-2a2f9a4f2b7d" xlink:to="loc_us-gaap_ConcentrationRiskTable_3cde6d56-948c-456f-aa19-722034f25691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_de450d9c-277d-4bfb-bcfa-036dde8330ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_3cde6d56-948c-456f-aa19-722034f25691" xlink:to="loc_srt_MajorCustomersAxis_de450d9c-277d-4bfb-bcfa-036dde8330ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b5c13d3c-8c70-453e-8fcb-94354e5a63cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_de450d9c-277d-4bfb-bcfa-036dde8330ca" xlink:to="loc_srt_NameOfMajorCustomerDomain_b5c13d3c-8c70-453e-8fcb-94354e5a63cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MedicareMember_e6d5080c-5866-4c2f-8a49-0af9dfff2415" xlink:href="cdna-20230331.xsd#cdna_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b5c13d3c-8c70-453e-8fcb-94354e5a63cc" xlink:to="loc_cdna_MedicareMember_e6d5080c-5866-4c2f-8a49-0af9dfff2415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1d2cf9ee-f562-411a-b025-991b0dd5911f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_3cde6d56-948c-456f-aa19-722034f25691" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1d2cf9ee-f562-411a-b025-991b0dd5911f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_29d72715-2d9a-48c0-9ea4-0c1c2619a7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1d2cf9ee-f562-411a-b025-991b0dd5911f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_29d72715-2d9a-48c0-9ea4-0c1c2619a7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_a1412ffc-34fa-4215-ac0d-2fcd7fcc6185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_29d72715-2d9a-48c0-9ea4-0c1c2619a7bd" xlink:to="loc_us-gaap_SalesRevenueNetMember_a1412ffc-34fa-4215-ac0d-2fcd7fcc6185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_7f3035e9-ef4a-4d35-bf37-1fe97a55415d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_29d72715-2d9a-48c0-9ea4-0c1c2619a7bd" xlink:to="loc_us-gaap_AccountsReceivableMember_7f3035e9-ef4a-4d35-bf37-1fe97a55415d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c3b6678a-39fd-4927-a2d9-e8c7bcadcf1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_3cde6d56-948c-456f-aa19-722034f25691" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c3b6678a-39fd-4927-a2d9-e8c7bcadcf1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e301355d-edb3-4f1b-8eee-dddaeda268f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c3b6678a-39fd-4927-a2d9-e8c7bcadcf1c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e301355d-edb3-4f1b-8eee-dddaeda268f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a61c1f1c-c124-4414-a5a6-f588f86d1871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e301355d-edb3-4f1b-8eee-dddaeda268f5" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a61c1f1c-c124-4414-a5a6-f588f86d1871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_9e8ff09e-438a-4328-b5ca-236bc2afc15c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e301355d-edb3-4f1b-8eee-dddaeda268f5" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_9e8ff09e-438a-4328-b5ca-236bc2afc15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_d9dd65fa-6c84-4710-9a8a-6b9ce84c9b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_3cde6d56-948c-456f-aa19-722034f25691" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_d9dd65fa-6c84-4710-9a8a-6b9ce84c9b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_85a63de4-fede-4a94-8a12-df9a449636b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_d9dd65fa-6c84-4710-9a8a-6b9ce84c9b89" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_85a63de4-fede-4a94-8a12-df9a449636b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#SummaryofSignificantAccountingPoliciesLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ca84863f-3fef-4051-8531-3343cb08766b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_SummaryOfSignificantAccountingPoliciesTable_28e0ac96-3f5c-4809-861c-10337c825fcf" xlink:href="cdna-20230331.xsd#cdna_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca84863f-3fef-4051-8531-3343cb08766b" xlink:to="loc_cdna_SummaryOfSignificantAccountingPoliciesTable_28e0ac96-3f5c-4809-861c-10337c825fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8c310c8c-ad9b-4c64-a989-ccdc6a80773a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_SummaryOfSignificantAccountingPoliciesTable_28e0ac96-3f5c-4809-861c-10337c825fcf" xlink:to="loc_srt_RangeAxis_8c310c8c-ad9b-4c64-a989-ccdc6a80773a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f278457f-e256-410d-9076-124826f38814" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8c310c8c-ad9b-4c64-a989-ccdc6a80773a" xlink:to="loc_srt_RangeMember_f278457f-e256-410d-9076-124826f38814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_70de0d38-7a5e-4805-9e91-fc36ee9181e8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f278457f-e256-410d-9076-124826f38814" xlink:to="loc_srt_MinimumMember_70de0d38-7a5e-4805-9e91-fc36ee9181e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1955ae03-7486-4950-931c-a7ffef1dff0d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f278457f-e256-410d-9076-124826f38814" xlink:to="loc_srt_MaximumMember_1955ae03-7486-4950-931c-a7ffef1dff0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_SummaryOfSignificantAccountingPoliciesLineItems_85f6f96e-ea67-49a0-9551-fd94e03a9256" xlink:href="cdna-20230331.xsd#cdna_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_SummaryOfSignificantAccountingPoliciesTable_28e0ac96-3f5c-4809-861c-10337c825fcf" xlink:to="loc_cdna_SummaryOfSignificantAccountingPoliciesLineItems_85f6f96e-ea67-49a0-9551-fd94e03a9256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_RemainingOperatingAndFinanceLeaseTerm_efc01c0c-6244-438e-9186-75252887daec" xlink:href="cdna-20230331.xsd#cdna_RemainingOperatingAndFinanceLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_SummaryOfSignificantAccountingPoliciesLineItems_85f6f96e-ea67-49a0-9551-fd94e03a9256" xlink:to="loc_cdna_RemainingOperatingAndFinanceLeaseTerm_efc01c0c-6244-438e-9186-75252887daec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesRevenueDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#SummaryofSignificantAccountingPoliciesRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a886da72-067a-4fb0-bd15-6129d15d3d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_UnsubmittedReimbursementClaimsForMedicare_59724c08-a71b-4e4b-8538-1fa2a5256aff" xlink:href="cdna-20230331.xsd#cdna_UnsubmittedReimbursementClaimsForMedicare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a886da72-067a-4fb0-bd15-6129d15d3d7d" xlink:to="loc_cdna_UnsubmittedReimbursementClaimsForMedicare_59724c08-a71b-4e4b-8538-1fa2a5256aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_UnsubmittedClaimsRevenueNotYetRecognized_d6533e5a-07bb-4d4a-bd54-ef0b4a2ab23c" xlink:href="cdna-20230331.xsd#cdna_UnsubmittedClaimsRevenueNotYetRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a886da72-067a-4fb0-bd15-6129d15d3d7d" xlink:to="loc_cdna_UnsubmittedClaimsRevenueNotYetRecognized_d6533e5a-07bb-4d4a-bd54-ef0b4a2ab23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/NetLossPerShareSummaryofComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#NetLossPerShareSummaryofComputationofBasicandDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/NetLossPerShareSummaryofComputationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_adb38dca-b183-4c18-bb01-73fe831c32bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_85ea977c-0cf6-4798-b7ce-076d634634ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_adb38dca-b183-4c18-bb01-73fe831c32bc" xlink:to="loc_us-gaap_NetIncomeLossAbstract_85ea977c-0cf6-4798-b7ce-076d634634ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_76018722-2b0b-4dca-a56d-d5643db93e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_85ea977c-0cf6-4798-b7ce-076d634634ed" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_76018722-2b0b-4dca-a56d-d5643db93e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_0f16e30a-d3a5-496f-a9ab-b63c83dd3355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_85ea977c-0cf6-4798-b7ce-076d634634ed" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_0f16e30a-d3a5-496f-a9ab-b63c83dd3355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract_b862e627-200c-4d60-86e0-8c71b2ac451c" xlink:href="cdna-20230331.xsd#cdna_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_adb38dca-b183-4c18-bb01-73fe831c32bc" xlink:to="loc_cdna_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract_b862e627-200c-4d60-86e0-8c71b2ac451c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3ed5ad51-dfde-4ec7-85a0-de4b97bc57d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract_b862e627-200c-4d60-86e0-8c71b2ac451c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3ed5ad51-dfde-4ec7-85a0-de4b97bc57d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9dd7b6a9-bb0b-4fdc-8221-f772d3244006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract_b862e627-200c-4d60-86e0-8c71b2ac451c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9dd7b6a9-bb0b-4fdc-8221-f772d3244006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_EarningPerShareBasicAndDilutedAbstract_93b3a2d1-dc00-4de1-95eb-0938299d35ec" xlink:href="cdna-20230331.xsd#cdna_EarningPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_adb38dca-b183-4c18-bb01-73fe831c32bc" xlink:to="loc_cdna_EarningPerShareBasicAndDilutedAbstract_93b3a2d1-dc00-4de1-95eb-0938299d35ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a1594cd9-0281-4c3a-bbfc-d5ce7de6376f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_EarningPerShareBasicAndDilutedAbstract_93b3a2d1-dc00-4de1-95eb-0938299d35ec" xlink:to="loc_us-gaap_EarningsPerShareBasic_a1594cd9-0281-4c3a-bbfc-d5ce7de6376f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4ba7794d-ea3d-4121-8f31-ba16a1dbe881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_EarningPerShareBasicAndDilutedAbstract_93b3a2d1-dc00-4de1-95eb-0938299d35ec" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4ba7794d-ea3d-4121-8f31-ba16a1dbe881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f74cb3fb-1e03-4b47-a818-0ca5efa4f8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f6f803e1-e26c-4085-9e4c-9ec340873d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f74cb3fb-1e03-4b47-a818-0ca5efa4f8ea" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f6f803e1-e26c-4085-9e4c-9ec340873d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ed9d7b9f-9c34-4e30-99f5-2d1c0bcc423c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f6f803e1-e26c-4085-9e4c-9ec340873d2d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ed9d7b9f-9c34-4e30-99f5-2d1c0bcc423c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e01c062a-93e9-49ff-805d-b4e1024d3f47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ed9d7b9f-9c34-4e30-99f5-2d1c0bcc423c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e01c062a-93e9-49ff-805d-b4e1024d3f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_EmployeeAndNonEmployeeStockOptionsMember_1631e450-ca69-4dcc-8893-83013983319c" xlink:href="cdna-20230331.xsd#cdna_EmployeeAndNonEmployeeStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e01c062a-93e9-49ff-805d-b4e1024d3f47" xlink:to="loc_cdna_EmployeeAndNonEmployeeStockOptionsMember_1631e450-ca69-4dcc-8893-83013983319c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_fe75e45e-3f21-44e6-b72b-85d54890c9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e01c062a-93e9-49ff-805d-b4e1024d3f47" xlink:to="loc_us-gaap_WarrantMember_fe75e45e-3f21-44e6-b72b-85d54890c9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fd895a6b-9750-4b13-98b4-ca97e0d5476f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_e01c062a-93e9-49ff-805d-b4e1024d3f47" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fd895a6b-9750-4b13-98b4-ca97e0d5476f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_10b1c728-4fe8-4045-8cc7-594700e5c4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f6f803e1-e26c-4085-9e4c-9ec340873d2d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_10b1c728-4fe8-4045-8cc7-594700e5c4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f4e466e8-3dba-4e25-b807-533f6d4f02a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_10b1c728-4fe8-4045-8cc7-594700e5c4a4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f4e466e8-3dba-4e25-b807-533f6d4f02a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fe55b58f-66da-49e9-a6f8-5eb9ba0b63b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83790f60-aa87-40f9-982a-87830a113077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fe55b58f-66da-49e9-a6f8-5eb9ba0b63b8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83790f60-aa87-40f9-982a-87830a113077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c08f8d48-4419-4537-b690-539960ac78c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83790f60-aa87-40f9-982a-87830a113077" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c08f8d48-4419-4537-b690-539960ac78c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a627bd18-cc88-4edb-b392-2884a9c99089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_c08f8d48-4419-4537-b690-539960ac78c3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a627bd18-cc88-4edb-b392-2884a9c99089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d5258e08-4f1e-4300-acef-5e9ee8a23f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a627bd18-cc88-4edb-b392-2884a9c99089" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d5258e08-4f1e-4300-acef-5e9ee8a23f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8ec38e1c-2492-458f-99a7-97eb23cb176a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a627bd18-cc88-4edb-b392-2884a9c99089" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8ec38e1c-2492-458f-99a7-97eb23cb176a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_751b6b57-fa08-4291-9aee-226d3a2fdf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a627bd18-cc88-4edb-b392-2884a9c99089" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_751b6b57-fa08-4291-9aee-226d3a2fdf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8b339871-8f27-480b-a605-82fa1b240e39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83790f60-aa87-40f9-982a-87830a113077" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8b339871-8f27-480b-a605-82fa1b240e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_649f27af-859a-4e59-9b2a-116b40056177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8b339871-8f27-480b-a605-82fa1b240e39" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_649f27af-859a-4e59-9b2a-116b40056177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2428f421-57f1-43bc-ba2e-525be111affc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_649f27af-859a-4e59-9b2a-116b40056177" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2428f421-57f1-43bc-ba2e-525be111affc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_67ba7eab-a3f3-4060-b063-a1c5933b01d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83790f60-aa87-40f9-982a-87830a113077" xlink:to="loc_us-gaap_FinancialInstrumentAxis_67ba7eab-a3f3-4060-b063-a1c5933b01d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2404f045-3155-4d6a-8c87-bf78697a160b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_67ba7eab-a3f3-4060-b063-a1c5933b01d6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2404f045-3155-4d6a-8c87-bf78697a160b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0e4b2562-422d-4df5-bae5-a3ccfc55382e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2404f045-3155-4d6a-8c87-bf78697a160b" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0e4b2562-422d-4df5-bae5-a3ccfc55382e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_efe6a295-b459-494e-b643-21ddfa3b4216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2404f045-3155-4d6a-8c87-bf78697a160b" xlink:to="loc_us-gaap_EquitySecuritiesMember_efe6a295-b459-494e-b643-21ddfa3b4216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_164d727d-04a1-452a-9141-c27979ac01f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_83790f60-aa87-40f9-982a-87830a113077" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_164d727d-04a1-452a-9141-c27979ac01f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_53e7c6df-d9d0-4271-a8a7-3128229a056e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_164d727d-04a1-452a-9141-c27979ac01f9" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_53e7c6df-d9d0-4271-a8a7-3128229a056e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5c912982-3bf2-4e4c-bef4-f3ee03dd390a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_53e7c6df-d9d0-4271-a8a7-3128229a056e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_5c912982-3bf2-4e4c-bef4-f3ee03dd390a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_81a3dd10-d51d-4293-83e0-2a3653b03265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_53e7c6df-d9d0-4271-a8a7-3128229a056e" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_81a3dd10-d51d-4293-83e0-2a3653b03265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f4957524-134e-4880-87b2-4ff39fb916fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_53e7c6df-d9d0-4271-a8a7-3128229a056e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_f4957524-134e-4880-87b2-4ff39fb916fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_76e2b776-61c6-41eb-9b4a-5afdf4d7e42e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_164d727d-04a1-452a-9141-c27979ac01f9" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_76e2b776-61c6-41eb-9b4a-5afdf4d7e42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_313a5f80-fe33-476f-b02f-043e6ab78c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_76e2b776-61c6-41eb-9b4a-5afdf4d7e42e" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_313a5f80-fe33-476f-b02f-043e6ab78c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_202e16a2-6afd-4e68-a07b-74441d79a3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_313a5f80-fe33-476f-b02f-043e6ab78c19" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_202e16a2-6afd-4e68-a07b-74441d79a3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_5c2313b3-c26c-4e82-9885-c2b88aa08406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_76e2b776-61c6-41eb-9b4a-5afdf4d7e42e" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_5c2313b3-c26c-4e82-9885-c2b88aa08406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8cc45c4d-1272-4895-845d-dfc4d66eca0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5c2313b3-c26c-4e82-9885-c2b88aa08406" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8cc45c4d-1272-4895-845d-dfc4d66eca0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CommonStockWarrantLiability_432afe5b-f8d8-4de0-89e4-f9b8524cd885" xlink:href="cdna-20230331.xsd#cdna_CommonStockWarrantLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5c2313b3-c26c-4e82-9885-c2b88aa08406" xlink:to="loc_cdna_CommonStockWarrantLiability_432afe5b-f8d8-4de0-89e4-f9b8524cd885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_0b61b1f4-efe1-4acc-b6a4-bffacb9239ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_76e2b776-61c6-41eb-9b4a-5afdf4d7e42e" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_0b61b1f4-efe1-4acc-b6a4-bffacb9239ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/FairValueMeasurementsSummaryofIssuancesExercisesChangesinFairValueandReclassificationsofLevel3FinancialInstrumentsDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#FairValueMeasurementsSummaryofIssuancesExercisesChangesinFairValueandReclassificationsofLevel3FinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/FairValueMeasurementsSummaryofIssuancesExercisesChangesinFairValueandReclassificationsofLevel3FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c48a8346-a11d-4d6f-923b-1ac7c23034a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2b9ca803-d7d7-4da9-acaa-5d68a79aa287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c48a8346-a11d-4d6f-923b-1ac7c23034a7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2b9ca803-d7d7-4da9-acaa-5d68a79aa287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_acc93cc1-1ab2-44ff-b3d9-3228365fe22a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2b9ca803-d7d7-4da9-acaa-5d68a79aa287" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_acc93cc1-1ab2-44ff-b3d9-3228365fe22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1f7dcccd-3d80-4776-ba26-7b143d31771b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_acc93cc1-1ab2-44ff-b3d9-3228365fe22a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1f7dcccd-3d80-4776-ba26-7b143d31771b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CommonStockWarrantLiabilityMember_41aa3315-a64f-4f8b-8f45-40efab03c09c" xlink:href="cdna-20230331.xsd#cdna_CommonStockWarrantLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1f7dcccd-3d80-4776-ba26-7b143d31771b" xlink:to="loc_cdna_CommonStockWarrantLiabilityMember_41aa3315-a64f-4f8b-8f45-40efab03c09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ContingentConsiderationMember_65950ca1-3388-44df-a78e-0629b36a7eec" xlink:href="cdna-20230331.xsd#cdna_ContingentConsiderationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1f7dcccd-3d80-4776-ba26-7b143d31771b" xlink:to="loc_cdna_ContingentConsiderationMember_65950ca1-3388-44df-a78e-0629b36a7eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_21bbc028-abbc-4c0b-933e-9b915ca92839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_2b9ca803-d7d7-4da9-acaa-5d68a79aa287" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_21bbc028-abbc-4c0b-933e-9b915ca92839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_efad9ce7-16dc-4dee-9599-175f98e78f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_21bbc028-abbc-4c0b-933e-9b915ca92839" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_efad9ce7-16dc-4dee-9599-175f98e78f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1bad8840-3847-4db5-9aea-2519b8047e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_efad9ce7-16dc-4dee-9599-175f98e78f6a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1bad8840-3847-4db5-9aea-2519b8047e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2c1ae2fc-26fa-49af-ad9f-21963aeedb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_efad9ce7-16dc-4dee-9599-175f98e78f6a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2c1ae2fc-26fa-49af-ad9f-21963aeedb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_53762db4-71fd-4cec-8bdc-15af93e1f579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_efad9ce7-16dc-4dee-9599-175f98e78f6a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_53762db4-71fd-4cec-8bdc-15af93e1f579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_7c929314-830e-45b8-809b-01eccba58588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_efad9ce7-16dc-4dee-9599-175f98e78f6a" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_7c929314-830e-45b8-809b-01eccba58588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_05f53f81-92cd-451a-b9ac-33a545ed8e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_efad9ce7-16dc-4dee-9599-175f98e78f6a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_05f53f81-92cd-451a-b9ac-33a545ed8e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#FairValueMeasurementsNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_99c9d83b-8449-4b84-a30f-d198bb5fbcc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_16514a3e-4b18-40d7-ad0d-fe011b181be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_99c9d83b-8449-4b84-a30f-d198bb5fbcc1" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_16514a3e-4b18-40d7-ad0d-fe011b181be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate_b4678bb6-0c8b-4ff3-8837-c7e6a5f951cd" xlink:href="cdna-20230331.xsd#cdna_BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_99c9d83b-8449-4b84-a30f-d198bb5fbcc1" xlink:to="loc_cdna_BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate_b4678bb6-0c8b-4ff3-8837-c7e6a5f951cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CashandMarketableSecuritiesReconciliationofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#CashandMarketableSecuritiesReconciliationofCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/CashandMarketableSecuritiesReconciliationofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_c8dd6978-b3f5-4198-b194-67dc53145557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_346e32fd-9ff5-44db-9620-2eeda9c17051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_c8dd6978-b3f5-4198-b194-67dc53145557" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_346e32fd-9ff5-44db-9620-2eeda9c17051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_ed1a3d87-6c32-493f-9463-5ced8b905c37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_c8dd6978-b3f5-4198-b194-67dc53145557" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_ed1a3d87-6c32-493f-9463-5ced8b905c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c24f99e4-32ed-43ef-8e95-07b80c636efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_c8dd6978-b3f5-4198-b194-67dc53145557" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c24f99e4-32ed-43ef-8e95-07b80c636efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_2613300e-a8d2-4a10-ba06-a3d76b31fc45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_4f67239f-b38e-4077-a9e4-011247d28d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_2613300e-a8d2-4a10-ba06-a3d76b31fc45" xlink:to="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_4f67239f-b38e-4077-a9e4-011247d28d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_013982fd-03f9-404c-a206-f4c543d3a44b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_4f67239f-b38e-4077-a9e4-011247d28d34" xlink:to="loc_us-gaap_FinancialInstrumentAxis_013982fd-03f9-404c-a206-f4c543d3a44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71538692-0c77-4a7a-8856-77b041b0076b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_013982fd-03f9-404c-a206-f4c543d3a44b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71538692-0c77-4a7a-8856-77b041b0076b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e420d2d0-1e34-4875-a80d-78ceee357741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71538692-0c77-4a7a-8856-77b041b0076b" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e420d2d0-1e34-4875-a80d-78ceee357741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_cd6e401e-bb11-417b-8084-da0ae9de31d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71538692-0c77-4a7a-8856-77b041b0076b" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_cd6e401e-bb11-417b-8084-da0ae9de31d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_7d766339-5600-49b5-b4ce-cc19040aeccf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_71538692-0c77-4a7a-8856-77b041b0076b" xlink:to="loc_us-gaap_EquitySecuritiesMember_7d766339-5600-49b5-b4ce-cc19040aeccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_d4fdc8af-e162-4902-bf4f-afa8736a790e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_4f67239f-b38e-4077-a9e4-011247d28d34" xlink:to="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_d4fdc8af-e162-4902-bf4f-afa8736a790e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShortTermMarketableSecuritiesAbstract_9d8a1bc1-e03d-486a-820e-346b6b3782ef" xlink:href="cdna-20230331.xsd#cdna_ShortTermMarketableSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_d4fdc8af-e162-4902-bf4f-afa8736a790e" xlink:to="loc_cdna_ShortTermMarketableSecuritiesAbstract_9d8a1bc1-e03d-486a-820e-346b6b3782ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_db45c96c-9be5-415e-87b0-e25ff59021e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShortTermMarketableSecuritiesAbstract_9d8a1bc1-e03d-486a-820e-346b6b3782ef" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss_db45c96c-9be5-415e-87b0-e25ff59021e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_36d8d40b-0a8c-4fc0-9fc3-c19c698258f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShortTermMarketableSecuritiesAbstract_9d8a1bc1-e03d-486a-820e-346b6b3782ef" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_36d8d40b-0a8c-4fc0-9fc3-c19c698258f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_15b891d2-e0b0-4eea-b373-c511e2649ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShortTermMarketableSecuritiesAbstract_9d8a1bc1-e03d-486a-820e-346b6b3782ef" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_15b891d2-e0b0-4eea-b373-c511e2649ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_88b73126-1ae9-4e72-9166-aeab588ce3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShortTermMarketableSecuritiesAbstract_9d8a1bc1-e03d-486a-820e-346b6b3782ef" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_88b73126-1ae9-4e72-9166-aeab588ce3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAmortizedCostShortTerm_ac62e8ac-acb8-4e0a-b7a0-94503a74ef10" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAmortizedCostShortTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShortTermMarketableSecuritiesAbstract_9d8a1bc1-e03d-486a-820e-346b6b3782ef" xlink:to="loc_cdna_MarketableSecuritiesAmortizedCostShortTerm_ac62e8ac-acb8-4e0a-b7a0-94503a74ef10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm_55259925-514b-4e71-8874-bd4ac474cdd2" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShortTermMarketableSecuritiesAbstract_9d8a1bc1-e03d-486a-820e-346b6b3782ef" xlink:to="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm_55259925-514b-4e71-8874-bd4ac474cdd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesFairValueShortTerm_4aaaf710-12a6-49bd-b714-a6a35f6dee0d" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesFairValueShortTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShortTermMarketableSecuritiesAbstract_9d8a1bc1-e03d-486a-820e-346b6b3782ef" xlink:to="loc_cdna_MarketableSecuritiesFairValueShortTerm_4aaaf710-12a6-49bd-b714-a6a35f6dee0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_LongTermMarketableSecuritiesAbstract_f936477b-3a31-43ff-81c5-94f0b7166e52" xlink:href="cdna-20230331.xsd#cdna_LongTermMarketableSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_d4fdc8af-e162-4902-bf4f-afa8736a790e" xlink:to="loc_cdna_LongTermMarketableSecuritiesAbstract_f936477b-3a31-43ff-81c5-94f0b7166e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_8e3d0a31-dcb1-4b0c-b255-07c5811995ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_LongTermMarketableSecuritiesAbstract_f936477b-3a31-43ff-81c5-94f0b7166e52" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_8e3d0a31-dcb1-4b0c-b255-07c5811995ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax_78725f7b-ef6f-4d39-8f9e-59de9d1c03e1" xlink:href="cdna-20230331.xsd#cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_LongTermMarketableSecuritiesAbstract_f936477b-3a31-43ff-81c5-94f0b7166e52" xlink:to="loc_cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax_78725f7b-ef6f-4d39-8f9e-59de9d1c03e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_c9200169-7808-495a-930d-4bb9bca92f82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_LongTermMarketableSecuritiesAbstract_f936477b-3a31-43ff-81c5-94f0b7166e52" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_c9200169-7808-495a-930d-4bb9bca92f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_37382f15-c49d-4534-99e1-89f64f144861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_LongTermMarketableSecuritiesAbstract_f936477b-3a31-43ff-81c5-94f0b7166e52" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_37382f15-c49d-4534-99e1-89f64f144861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2a0e8608-d12d-4eaf-bc90-bff006b5cdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_LongTermMarketableSecuritiesAbstract_f936477b-3a31-43ff-81c5-94f0b7166e52" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2a0e8608-d12d-4eaf-bc90-bff006b5cdf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc448077-25ab-48c7-8fd9-8fce3da314df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_LongTermMarketableSecuritiesAbstract_f936477b-3a31-43ff-81c5-94f0b7166e52" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bc448077-25ab-48c7-8fd9-8fce3da314df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAmortizedCostLongTerm_6279242b-628e-42e2-9661-569f3eac8add" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAmortizedCostLongTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_LongTermMarketableSecuritiesAbstract_f936477b-3a31-43ff-81c5-94f0b7166e52" xlink:to="loc_cdna_MarketableSecuritiesAmortizedCostLongTerm_6279242b-628e-42e2-9661-569f3eac8add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm_1c018403-82e3-4663-8b6e-41a4ecca53ab" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_LongTermMarketableSecuritiesAbstract_f936477b-3a31-43ff-81c5-94f0b7166e52" xlink:to="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm_1c018403-82e3-4663-8b6e-41a4ecca53ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesFairValueLongTerm_5e25122c-eb2c-49f0-8f83-4c3ecc8a54bf" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesFairValueLongTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_LongTermMarketableSecuritiesAbstract_f936477b-3a31-43ff-81c5-94f0b7166e52" xlink:to="loc_cdna_MarketableSecuritiesFairValueLongTerm_5e25122c-eb2c-49f0-8f83-4c3ecc8a54bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAmortizedCost_7090075f-7215-455d-9a88-ac75b3db542e" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_d4fdc8af-e162-4902-bf4f-afa8736a790e" xlink:to="loc_cdna_MarketableSecuritiesAmortizedCost_7090075f-7215-455d-9a88-ac75b3db542e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss_9ff7bb31-a6ce-4e75-8a20-e6a4383c6ede" xlink:href="cdna-20230331.xsd#cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_d4fdc8af-e162-4902-bf4f-afa8736a790e" xlink:to="loc_cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss_9ff7bb31-a6ce-4e75-8a20-e6a4383c6ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecurities_43051402-6035-4b0f-9fdb-9d50d594ac2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_d4fdc8af-e162-4902-bf4f-afa8736a790e" xlink:to="loc_us-gaap_MarketableSecurities_43051402-6035-4b0f-9fdb-9d50d594ac2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails_1" xlink:type="simple" xlink:href="cdna-20230331.xsd#CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CashandMarketableSecuritiesScheduleofMaturityDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#CashandMarketableSecuritiesScheduleofMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/CashandMarketableSecuritiesScheduleofMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_b581dd6e-eb53-4abd-b41e-e9de8c93e552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_b4f9d6c6-9c33-46c8-9eb5-b1be7208f4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_b581dd6e-eb53-4abd-b41e-e9de8c93e552" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_b4f9d6c6-9c33-46c8-9eb5-b1be7208f4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_3518326d-43fc-44af-8baa-bf64fa6f0b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_b581dd6e-eb53-4abd-b41e-e9de8c93e552" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_3518326d-43fc-44af-8baa-bf64fa6f0b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_cea04b4b-90c2-4a6a-9780-8d3a20af7275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_b581dd6e-eb53-4abd-b41e-e9de8c93e552" xlink:to="loc_us-gaap_HeldToMaturitySecurities_cea04b4b-90c2-4a6a-9780-8d3a20af7275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/BusinessCombinationsAdditionalInformationDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#BusinessCombinationsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/BusinessCombinationsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_18f212b8-de8d-4267-88b7-63890455b708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_11bd9d5a-a43c-4996-bc90-b92335bd7975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_18f212b8-de8d-4267-88b7-63890455b708" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_11bd9d5a-a43c-4996-bc90-b92335bd7975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d3be3654-905b-49c9-8e61-f1fe005c6690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_11bd9d5a-a43c-4996-bc90-b92335bd7975" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d3be3654-905b-49c9-8e61-f1fe005c6690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f123e086-fb8d-41ec-bad7-f564753eb6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d3be3654-905b-49c9-8e61-f1fe005c6690" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f123e086-fb8d-41ec-bad7-f564753eb6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_HLADataSystemsMember_307a57de-4365-419f-8658-ada6d851ebb8" xlink:href="cdna-20230331.xsd#cdna_HLADataSystemsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f123e086-fb8d-41ec-bad7-f564753eb6cb" xlink:to="loc_cdna_HLADataSystemsMember_307a57de-4365-419f-8658-ada6d851ebb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9649653f-e544-4ad7-a147-4a7143ae6ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_11bd9d5a-a43c-4996-bc90-b92335bd7975" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9649653f-e544-4ad7-a147-4a7143ae6ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bbbefb9f-27b2-481e-a574-b3242646ab57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9649653f-e544-4ad7-a147-4a7143ae6ad8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bbbefb9f-27b2-481e-a574-b3242646ab57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_ff9e8a78-69fc-4f71-906b-472bedd6b401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bbbefb9f-27b2-481e-a574-b3242646ab57" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_ff9e8a78-69fc-4f71-906b-472bedd6b401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_be245c6d-511e-4fbe-91db-895af8f1c4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bbbefb9f-27b2-481e-a574-b3242646ab57" xlink:to="loc_us-gaap_TrademarksMember_be245c6d-511e-4fbe-91db-895af8f1c4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9e4924ec-6c6b-4b4b-b669-f6b11790dff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_11bd9d5a-a43c-4996-bc90-b92335bd7975" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_9e4924ec-6c6b-4b4b-b669-f6b11790dff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fdf3ec64-a630-4e55-84a6-a7fe0230769c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e4924ec-6c6b-4b4b-b669-f6b11790dff5" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fdf3ec64-a630-4e55-84a6-a7fe0230769c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_26cb112d-d713-419f-a44c-54a32c2c9fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e4924ec-6c6b-4b4b-b669-f6b11790dff5" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_26cb112d-d713-419f-a44c-54a32c2c9fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c19e5d19-a557-4b99-9878-3f154e6e88fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e4924ec-6c6b-4b4b-b669-f6b11790dff5" xlink:to="loc_us-gaap_Goodwill_c19e5d19-a557-4b99-9878-3f154e6e88fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_d32c12c8-8c6e-41c8-a9e3-8b6f21c0e4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e4924ec-6c6b-4b4b-b669-f6b11790dff5" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_d32c12c8-8c6e-41c8-a9e3-8b6f21c0e4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_IntangibleAssetMeasurementInputRoyaltyRate_3d547b65-bffd-4057-b345-2958bd233c21" xlink:href="cdna-20230331.xsd#cdna_IntangibleAssetMeasurementInputRoyaltyRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e4924ec-6c6b-4b4b-b669-f6b11790dff5" xlink:to="loc_cdna_IntangibleAssetMeasurementInputRoyaltyRate_3d547b65-bffd-4057-b345-2958bd233c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_IntangibleAssetMeasurementInputDiscountRate_fba4e077-6a99-438c-b29b-1af683c525a1" xlink:href="cdna-20230331.xsd#cdna_IntangibleAssetMeasurementInputDiscountRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9e4924ec-6c6b-4b4b-b669-f6b11790dff5" xlink:to="loc_cdna_IntangibleAssetMeasurementInputDiscountRate_fba4e077-6a99-438c-b29b-1af683c525a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/BusinessCombinationsSummaryofIdentifiedIntangibleAssetsAcquiredatAcquisitionDateDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#BusinessCombinationsSummaryofIdentifiedIntangibleAssetsAcquiredatAcquisitionDateDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/BusinessCombinationsSummaryofIdentifiedIntangibleAssetsAcquiredatAcquisitionDateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6912df79-62f2-4236-bbcc-273dde261eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_78f8af95-8e0a-43f1-b03f-80991f346caa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6912df79-62f2-4236-bbcc-273dde261eb4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_78f8af95-8e0a-43f1-b03f-80991f346caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d56552b0-cf25-43f4-94ca-790c3a0cde22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_78f8af95-8e0a-43f1-b03f-80991f346caa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d56552b0-cf25-43f4-94ca-790c3a0cde22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2dd80d9d-0c94-4623-aca2-591f876b1adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d56552b0-cf25-43f4-94ca-790c3a0cde22" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2dd80d9d-0c94-4623-aca2-591f876b1adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_204f4114-8fab-463b-b3db-074b690984d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2dd80d9d-0c94-4623-aca2-591f876b1adc" xlink:to="loc_us-gaap_CustomerRelationshipsMember_204f4114-8fab-463b-b3db-074b690984d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_cbfd76d1-04aa-4be5-94b1-b053008682f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2dd80d9d-0c94-4623-aca2-591f876b1adc" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_cbfd76d1-04aa-4be5-94b1-b053008682f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_4ecfdd6f-b810-4ddf-9e5e-7216f65ff58a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2dd80d9d-0c94-4623-aca2-591f876b1adc" xlink:to="loc_us-gaap_TrademarksMember_4ecfdd6f-b810-4ddf-9e5e-7216f65ff58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_df641461-6274-4da1-ad6d-d8dc21d3d934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_78f8af95-8e0a-43f1-b03f-80991f346caa" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_df641461-6274-4da1-ad6d-d8dc21d3d934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_178e61c3-3f9f-4f5e-a0cc-03d7a5f0dde5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_df641461-6274-4da1-ad6d-d8dc21d3d934" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_178e61c3-3f9f-4f5e-a0cc-03d7a5f0dde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_HLADataSystemsMember_a25a66df-1091-4079-822a-4b7bc2826ad9" xlink:href="cdna-20230331.xsd#cdna_HLADataSystemsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_178e61c3-3f9f-4f5e-a0cc-03d7a5f0dde5" xlink:to="loc_cdna_HLADataSystemsMember_a25a66df-1091-4079-822a-4b7bc2826ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_85f8f047-5340-48e8-8d41-93b49ae94c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_78f8af95-8e0a-43f1-b03f-80991f346caa" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_85f8f047-5340-48e8-8d41-93b49ae94c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_a7515518-4ea0-4aeb-8580-9f664da43cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_85f8f047-5340-48e8-8d41-93b49ae94c34" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_a7515518-4ea0-4aeb-8580-9f664da43cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_dc2708d5-6024-44b3-9bc0-2ea9abca52cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_85f8f047-5340-48e8-8d41-93b49ae94c34" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_dc2708d5-6024-44b3-9bc0-2ea9abca52cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a45ba62c-bf44-41e4-9e1e-f8beefde0bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_04ca82f4-ef2c-439d-96de-12cca86cf188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a45ba62c-bf44-41e4-9e1e-f8beefde0bbe" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_04ca82f4-ef2c-439d-96de-12cca86cf188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_edf1abe3-45fe-4443-b6ad-b71cf7b7f565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_04ca82f4-ef2c-439d-96de-12cca86cf188" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_edf1abe3-45fe-4443-b6ad-b71cf7b7f565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06d5873a-b2a7-4e4c-a8e6-77db28f27d53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_edf1abe3-45fe-4443-b6ad-b71cf7b7f565" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06d5873a-b2a7-4e4c-a8e6-77db28f27d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_HLADataSystemsMember_85f82655-2d52-4b18-8039-dee417874d19" xlink:href="cdna-20230331.xsd#cdna_HLADataSystemsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_06d5873a-b2a7-4e4c-a8e6-77db28f27d53" xlink:to="loc_cdna_HLADataSystemsMember_85f82655-2d52-4b18-8039-dee417874d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_04ca82f4-ef2c-439d-96de-12cca86cf188" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_7b087d14-7e18-46ce-995e-e9c235351cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_7b087d14-7e18-46ce-995e-e9c235351cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2e5b22f4-2856-4812-a1fa-39a3790c8b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_2e5b22f4-2856-4812-a1fa-39a3790c8b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_ad04742a-f4cc-4b50-ad31-7289eb3cd7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_ad04742a-f4cc-4b50-ad31-7289eb3cd7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_b36e6099-24c0-421a-b3c9-fb3bbccb3130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_b36e6099-24c0-421a-b3c9-fb3bbccb3130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_5c79b6da-97c9-4001-b367-901020969ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_5c79b6da-97c9-4001-b367-901020969ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_c4ee8979-53c8-48d5-809b-d1d77eba30b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_c4ee8979-53c8-48d5-809b-d1d77eba30b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion_058b104d-a8fc-4deb-b4e6-c119dcf97497" xlink:href="cdna-20230331.xsd#cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:to="loc_cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion_058b104d-a8fc-4deb-b4e6-c119dcf97497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_634ff74d-f794-4d3b-99b5-50124f3c3fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_634ff74d-f794-4d3b-99b5-50124f3c3fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_c21ed540-39ff-482e-840e-3ab43ae44463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_c21ed540-39ff-482e-840e-3ab43ae44463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_748365d2-b1d4-45d3-8895-6d27b2d8a9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:to="loc_us-gaap_Goodwill_748365d2-b1d4-45d3-8895-6d27b2d8a9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e964f061-331e-4d27-82ae-c78198c7b6fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_9217d0b3-f8a9-4b49-9e25-aedcd5888494" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e964f061-331e-4d27-82ae-c78198c7b6fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#GoodwillandIntangibleAssetsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4f93834a-d635-4e8d-9905-acafc6dd3fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_GoodwillAndIntangibleAssetsTable_bdba53b9-39bd-4653-956e-431a07d10bb1" xlink:href="cdna-20230331.xsd#cdna_GoodwillAndIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4f93834a-d635-4e8d-9905-acafc6dd3fca" xlink:to="loc_cdna_GoodwillAndIntangibleAssetsTable_bdba53b9-39bd-4653-956e-431a07d10bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dbab5170-c370-4e83-b53b-8f1a39aa91a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_GoodwillAndIntangibleAssetsTable_bdba53b9-39bd-4653-956e-431a07d10bb1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dbab5170-c370-4e83-b53b-8f1a39aa91a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a11e0f60-648f-4d53-86ef-27dde664f09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dbab5170-c370-4e83-b53b-8f1a39aa91a3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a11e0f60-648f-4d53-86ef-27dde664f09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CommercializationRightsMember_bd6a9f29-bfd3-4b86-b7be-88923bd386dc" xlink:href="cdna-20230331.xsd#cdna_CommercializationRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a11e0f60-648f-4d53-86ef-27dde664f09a" xlink:to="loc_cdna_CommercializationRightsMember_bd6a9f29-bfd3-4b86-b7be-88923bd386dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AcquiredAndDevelopedTechnologyMember_6c8860e5-e476-4129-bc48-77fd39d4f3f9" xlink:href="cdna-20230331.xsd#cdna_AcquiredAndDevelopedTechnologyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a11e0f60-648f-4d53-86ef-27dde664f09a" xlink:to="loc_cdna_AcquiredAndDevelopedTechnologyMember_6c8860e5-e476-4129-bc48-77fd39d4f3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_587902a9-1433-410e-844b-8c69fdb1ce54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a11e0f60-648f-4d53-86ef-27dde664f09a" xlink:to="loc_us-gaap_CustomerRelationshipsMember_587902a9-1433-410e-844b-8c69fdb1ce54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_ea527d42-f0a4-44ea-84d8-ca0983d88fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a11e0f60-648f-4d53-86ef-27dde664f09a" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_ea527d42-f0a4-44ea-84d8-ca0983d88fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_b3fa8d3b-f758-4313-a71a-83fa2be6e88c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a11e0f60-648f-4d53-86ef-27dde664f09a" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_b3fa8d3b-f758-4313-a71a-83fa2be6e88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_GoodwillAndIntangibleAssetsLineItems_2408ea92-359a-464b-bae0-e1049c283886" xlink:href="cdna-20230331.xsd#cdna_GoodwillAndIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_GoodwillAndIntangibleAssetsTable_bdba53b9-39bd-4653-956e-431a07d10bb1" xlink:to="loc_cdna_GoodwillAndIntangibleAssetsLineItems_2408ea92-359a-464b-bae0-e1049c283886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a376ac26-d8f6-4457-b672-9ad979006c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_GoodwillAndIntangibleAssetsLineItems_2408ea92-359a-464b-bae0-e1049c283886" xlink:to="loc_us-gaap_Goodwill_a376ac26-d8f6-4457-b672-9ad979006c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_8ac32cd9-eea9-4f50-96ba-2e3afafc69c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_GoodwillAndIntangibleAssetsLineItems_2408ea92-359a-464b-bae0-e1049c283886" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_8ac32cd9-eea9-4f50-96ba-2e3afafc69c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_28ef4caa-4508-44a0-93f8-6150f40269e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable_3a406f15-4df3-4f40-a3b7-b3fb5be12846" xlink:href="cdna-20230331.xsd#cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_28ef4caa-4508-44a0-93f8-6150f40269e0" xlink:to="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable_3a406f15-4df3-4f40-a3b7-b3fb5be12846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ea780731-3291-4cf5-bf44-def2e1f02b14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable_3a406f15-4df3-4f40-a3b7-b3fb5be12846" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ea780731-3291-4cf5-bf44-def2e1f02b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b1e17db3-08c8-40cc-94e0-0e1025703a27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ea780731-3291-4cf5-bf44-def2e1f02b14" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b1e17db3-08c8-40cc-94e0-0e1025703a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AcquiredAndDevelopedTechnologyMember_419bb962-6fd4-4d33-9bfb-2d62998c53a8" xlink:href="cdna-20230331.xsd#cdna_AcquiredAndDevelopedTechnologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b1e17db3-08c8-40cc-94e0-0e1025703a27" xlink:to="loc_cdna_AcquiredAndDevelopedTechnologyMember_419bb962-6fd4-4d33-9bfb-2d62998c53a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_95241119-ef62-49fe-be7d-7635f021295d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b1e17db3-08c8-40cc-94e0-0e1025703a27" xlink:to="loc_us-gaap_CustomerRelationshipsMember_95241119-ef62-49fe-be7d-7635f021295d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CommercializationRightsMember_57e7b013-0090-403e-8daa-fbcd056021c2" xlink:href="cdna-20230331.xsd#cdna_CommercializationRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b1e17db3-08c8-40cc-94e0-0e1025703a27" xlink:to="loc_cdna_CommercializationRightsMember_57e7b013-0090-403e-8daa-fbcd056021c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_996ad668-c431-4a7f-b8d4-d3fe8a12cde2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b1e17db3-08c8-40cc-94e0-0e1025703a27" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_996ad668-c431-4a7f-b8d4-d3fe8a12cde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6952fc1d-ed84-4785-a695-7e9ddf698763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable_3a406f15-4df3-4f40-a3b7-b3fb5be12846" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6952fc1d-ed84-4785-a695-7e9ddf698763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c187dccc-583c-44cf-85a8-1980785ad1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_6952fc1d-ed84-4785-a695-7e9ddf698763" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c187dccc-583c-44cf-85a8-1980785ad1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AcquiredInProcessTechnologyMember_f96fe5a5-acb4-476b-a4c2-21d0a8d77fdf" xlink:href="cdna-20230331.xsd#cdna_AcquiredInProcessTechnologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c187dccc-583c-44cf-85a8-1980785ad1f4" xlink:to="loc_cdna_AcquiredInProcessTechnologyMember_f96fe5a5-acb4-476b-a4c2-21d0a8d77fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems_bc543fcb-12f4-4795-965b-db6e48763a6a" xlink:href="cdna-20230331.xsd#cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable_3a406f15-4df3-4f40-a3b7-b3fb5be12846" xlink:to="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems_bc543fcb-12f4-4795-965b-db6e48763a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8bcede4b-54b2-402c-8b1e-b319a64c8ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems_bc543fcb-12f4-4795-965b-db6e48763a6a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8bcede4b-54b2-402c-8b1e-b319a64c8ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_567f9da1-7334-4713-a9d5-4f39c9324fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8bcede4b-54b2-402c-8b1e-b319a64c8ce2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_567f9da1-7334-4713-a9d5-4f39c9324fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5804f1b8-c89e-4184-b22f-5192ef677801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8bcede4b-54b2-402c-8b1e-b319a64c8ce2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5804f1b8-c89e-4184-b22f-5192ef677801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_FiniteLivedIntangibleForeignCurrencyTranslation_ffba3785-f316-43c7-8281-8544d58259b2" xlink:href="cdna-20230331.xsd#cdna_FiniteLivedIntangibleForeignCurrencyTranslation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8bcede4b-54b2-402c-8b1e-b319a64c8ce2" xlink:to="loc_cdna_FiniteLivedIntangibleForeignCurrencyTranslation_ffba3785-f316-43c7-8281-8544d58259b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5174731c-6a02-49ea-ab24-99e37a882f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8bcede4b-54b2-402c-8b1e-b319a64c8ce2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5174731c-6a02-49ea-ab24-99e37a882f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_c9c7088b-e9c2-4ee2-9541-a695ac2e12ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems_bc543fcb-12f4-4795-965b-db6e48763a6a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_c9c7088b-e9c2-4ee2-9541-a695ac2e12ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_87359061-c4d5-4c01-88f3-8ee7fd0aabb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_c9c7088b-e9c2-4ee2-9541-a695ac2e12ed" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_87359061-c4d5-4c01-88f3-8ee7fd0aabb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0ee23216-6899-4dc0-8c9a-24d00b5ac3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems_bc543fcb-12f4-4795-965b-db6e48763a6a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0ee23216-6899-4dc0-8c9a-24d00b5ac3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_dfe2d378-f0b2-429c-b097-1dc87f60e58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0ee23216-6899-4dc0-8c9a-24d00b5ac3a7" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_dfe2d378-f0b2-429c-b097-1dc87f60e58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_74e6fbe6-6b2a-4c2a-821b-918ee80d7af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0ee23216-6899-4dc0-8c9a-24d00b5ac3a7" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_74e6fbe6-6b2a-4c2a-821b-918ee80d7af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7a9f6e81-7cd1-47b3-8894-617ac2d8b358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems_bc543fcb-12f4-4795-965b-db6e48763a6a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7a9f6e81-7cd1-47b3-8894-617ac2d8b358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="cdna-20230331.xsd#GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofFiniteLivedIntangibleAssetsAmortizationExpenseDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#GoodwillandIntangibleAssetsSummaryofFiniteLivedIntangibleAssetsAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofFiniteLivedIntangibleAssetsAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b983ac57-2c28-4800-9ea6-2db2d847a200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f307441e-e00c-49cf-974d-fb9f899c6b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b983ac57-2c28-4800-9ea6-2db2d847a200" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f307441e-e00c-49cf-974d-fb9f899c6b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_914a10b0-f9dd-4b58-9fa8-710f4056cc62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f307441e-e00c-49cf-974d-fb9f899c6b6d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_914a10b0-f9dd-4b58-9fa8-710f4056cc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d600f1c6-28f8-4854-a8c2-2425e1bcec71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_914a10b0-f9dd-4b58-9fa8-710f4056cc62" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d600f1c6-28f8-4854-a8c2-2425e1bcec71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CostOfTestingMember_7a51c19b-285f-447b-a3b7-d2567863d386" xlink:href="cdna-20230331.xsd#cdna_CostOfTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d600f1c6-28f8-4854-a8c2-2425e1bcec71" xlink:to="loc_cdna_CostOfTestingMember_7a51c19b-285f-447b-a3b7-d2567863d386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CostOfProductMember_79327cea-0c21-4bea-acaa-b159a57b59c9" xlink:href="cdna-20230331.xsd#cdna_CostOfProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d600f1c6-28f8-4854-a8c2-2425e1bcec71" xlink:to="loc_cdna_CostOfProductMember_79327cea-0c21-4bea-acaa-b159a57b59c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CostOfPatientAndDigitalSolutionsMember_b06011d8-6eac-414e-9278-f28673db4b31" xlink:href="cdna-20230331.xsd#cdna_CostOfPatientAndDigitalSolutionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d600f1c6-28f8-4854-a8c2-2425e1bcec71" xlink:to="loc_cdna_CostOfPatientAndDigitalSolutionsMember_b06011d8-6eac-414e-9278-f28673db4b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_78abed59-5283-414a-bc1e-c3947edfea45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d600f1c6-28f8-4854-a8c2-2425e1bcec71" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_78abed59-5283-414a-bc1e-c3947edfea45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_110650de-43fd-492c-ba66-f015b707545a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f307441e-e00c-49cf-974d-fb9f899c6b6d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_110650de-43fd-492c-ba66-f015b707545a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_fc03a875-3fb4-4246-a6d7-26900344623e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_110650de-43fd-492c-ba66-f015b707545a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_fc03a875-3fb4-4246-a6d7-26900344623e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_39889258-c8df-4c68-bb29-e689ba1aa587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f24f5971-0f40-4b14-938d-35c97fecfc67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_39889258-c8df-4c68-bb29-e689ba1aa587" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f24f5971-0f40-4b14-938d-35c97fecfc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1c8743a1-5587-4e1d-ae8e-8fa5e04a36a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f24f5971-0f40-4b14-938d-35c97fecfc67" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1c8743a1-5587-4e1d-ae8e-8fa5e04a36a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_46ca1ae4-8fa1-4e11-a5c2-f7b37ce900ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1c8743a1-5587-4e1d-ae8e-8fa5e04a36a2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_46ca1ae4-8fa1-4e11-a5c2-f7b37ce900ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CostOfTestingMember_8e0f03e8-a2ec-47c0-87fc-3b05d123ef74" xlink:href="cdna-20230331.xsd#cdna_CostOfTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_46ca1ae4-8fa1-4e11-a5c2-f7b37ce900ed" xlink:to="loc_cdna_CostOfTestingMember_8e0f03e8-a2ec-47c0-87fc-3b05d123ef74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CostOfProductMember_0964f523-dde0-418b-b448-42720ce45923" xlink:href="cdna-20230331.xsd#cdna_CostOfProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_46ca1ae4-8fa1-4e11-a5c2-f7b37ce900ed" xlink:to="loc_cdna_CostOfProductMember_0964f523-dde0-418b-b448-42720ce45923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CostOfPatientAndDigitalSolutionsMember_e071e3d2-0ee5-49bd-9487-181037b3ef60" xlink:href="cdna-20230331.xsd#cdna_CostOfPatientAndDigitalSolutionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_46ca1ae4-8fa1-4e11-a5c2-f7b37ce900ed" xlink:to="loc_cdna_CostOfPatientAndDigitalSolutionsMember_e071e3d2-0ee5-49bd-9487-181037b3ef60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_cc18eef1-e33e-4298-b948-8c6cf6c011ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_46ca1ae4-8fa1-4e11-a5c2-f7b37ce900ed" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_cc18eef1-e33e-4298-b948-8c6cf6c011ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1bf3b887-0b07-4a43-bc83-a42347bc38dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_f24f5971-0f40-4b14-938d-35c97fecfc67" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1bf3b887-0b07-4a43-bc83-a42347bc38dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7973016e-1f77-41c7-93f8-ed42fc6f221b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_1bf3b887-0b07-4a43-bc83-a42347bc38dc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7973016e-1f77-41c7-93f8-ed42fc6f221b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5853ba8e-a2ee-4087-87ce-fe0142cf57be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7973016e-1f77-41c7-93f8-ed42fc6f221b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_5853ba8e-a2ee-4087-87ce-fe0142cf57be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_768552c1-ef4e-4db7-94a7-aa0b3faa1428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7973016e-1f77-41c7-93f8-ed42fc6f221b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_768552c1-ef4e-4db7-94a7-aa0b3faa1428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5707543a-e2d3-4f78-8f9b-c84364bdc4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7973016e-1f77-41c7-93f8-ed42fc6f221b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5707543a-e2d3-4f78-8f9b-c84364bdc4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4f885e49-b11a-4f36-96b0-2329bedfcd81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7973016e-1f77-41c7-93f8-ed42fc6f221b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4f885e49-b11a-4f36-96b0-2329bedfcd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fbb7ce4d-d575-41cf-889a-c9e9e04c3f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7973016e-1f77-41c7-93f8-ed42fc6f221b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fbb7ce4d-d575-41cf-889a-c9e9e04c3f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_1c4d2705-fcd0-4216-ac11-83e49f511dd6" xlink:href="cdna-20230331.xsd#cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7973016e-1f77-41c7-93f8-ed42fc6f221b" xlink:to="loc_cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_1c4d2705-fcd0-4216-ac11-83e49f511dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ecb73f0b-5dc2-4839-ba3d-fd70b81f7df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7973016e-1f77-41c7-93f8-ed42fc6f221b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ecb73f0b-5dc2-4839-ba3d-fd70b81f7df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/BalanceSheetComponentsSummaryofInventoryDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#BalanceSheetComponentsSummaryofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/BalanceSheetComponentsSummaryofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bfefe201-4edd-4e31-82d8-9cdd4adcbbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_76786fba-e44a-414b-ac63-233b635b8db0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bfefe201-4edd-4e31-82d8-9cdd4adcbbc6" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_76786fba-e44a-414b-ac63-233b635b8db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_3948ccc7-3140-48c0-919e-0292a6d2eb98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bfefe201-4edd-4e31-82d8-9cdd4adcbbc6" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_3948ccc7-3140-48c0-919e-0292a6d2eb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2df4d8bc-0020-4363-9008-26d116f066aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bfefe201-4edd-4e31-82d8-9cdd4adcbbc6" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_2df4d8bc-0020-4363-9008-26d116f066aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_92851005-8c2e-432a-8c06-96d95cf34e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bfefe201-4edd-4e31-82d8-9cdd4adcbbc6" xlink:to="loc_us-gaap_InventoryNet_92851005-8c2e-432a-8c06-96d95cf34e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a14d7c1d-71a1-46ac-bd6f-30fd076103b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AccruedClinicalAndCostOfOtherStudiesCurrent_ae0500ca-ec6a-4aaf-9393-d53ec3a768ff" xlink:href="cdna-20230331.xsd#cdna_AccruedClinicalAndCostOfOtherStudiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a14d7c1d-71a1-46ac-bd6f-30fd076103b8" xlink:to="loc_cdna_AccruedClinicalAndCostOfOtherStudiesCurrent_ae0500ca-ec6a-4aaf-9393-d53ec3a768ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_f193dc4e-c6a0-4fad-8bee-49cc4e6c250b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a14d7c1d-71a1-46ac-bd6f-30fd076103b8" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_f193dc4e-c6a0-4fad-8bee-49cc4e6c250b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8688c274-83df-43f0-ac10-260210d610cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a14d7c1d-71a1-46ac-bd6f-30fd076103b8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8688c274-83df-43f0-ac10-260210d610cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_619c1c80-c827-453c-899e-92532ff838aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a14d7c1d-71a1-46ac-bd6f-30fd076103b8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_619c1c80-c827-453c-899e-92532ff838aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_DeferredPaymentsForIntangibleAssets_cb5172eb-d4a2-4939-8197-83713bf7cc2a" xlink:href="cdna-20230331.xsd#cdna_DeferredPaymentsForIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a14d7c1d-71a1-46ac-bd6f-30fd076103b8" xlink:to="loc_cdna_DeferredPaymentsForIntangibleAssets_cb5172eb-d4a2-4939-8197-83713bf7cc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_68082dfc-9550-478a-9b71-e9eb2c9c9ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a14d7c1d-71a1-46ac-bd6f-30fd076103b8" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_68082dfc-9550-478a-9b71-e9eb2c9c9ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AccruedSampleProcessingFees_0f62e14b-9427-4d14-b8be-eeefea713ff9" xlink:href="cdna-20230331.xsd#cdna_AccruedSampleProcessingFees"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a14d7c1d-71a1-46ac-bd6f-30fd076103b8" xlink:to="loc_cdna_AccruedSampleProcessingFees_0f62e14b-9427-4d14-b8be-eeefea713ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AccruedLicenseAndOtherCollaborationFees_3c292eef-0969-4f47-84fb-d6c6c635b116" xlink:href="cdna-20230331.xsd#cdna_AccruedLicenseAndOtherCollaborationFees"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a14d7c1d-71a1-46ac-bd6f-30fd076103b8" xlink:to="loc_cdna_AccruedLicenseAndOtherCollaborationFees_3c292eef-0969-4f47-84fb-d6c6c635b116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_6092527a-5cc5-4197-a353-319335980b04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a14d7c1d-71a1-46ac-bd6f-30fd076103b8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_6092527a-5cc5-4197-a353-319335980b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AccruedShippingExpenses_22066ef4-bc16-4bfb-a2b0-e242fb499c8e" xlink:href="cdna-20230331.xsd#cdna_AccruedShippingExpenses"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a14d7c1d-71a1-46ac-bd6f-30fd076103b8" xlink:to="loc_cdna_AccruedShippingExpenses_22066ef4-bc16-4bfb-a2b0-e242fb499c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_AccruedCapitalExpenditures_fc57b99c-7167-4025-9ca4-7b33dbb38c66" xlink:href="cdna-20230331.xsd#cdna_AccruedCapitalExpenditures"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a14d7c1d-71a1-46ac-bd6f-30fd076103b8" xlink:to="loc_cdna_AccruedCapitalExpenditures_fc57b99c-7167-4025-9ca4-7b33dbb38c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9dd62416-bb20-4cbc-b25a-03f7f053ef36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a14d7c1d-71a1-46ac-bd6f-30fd076103b8" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9dd62416-bb20-4cbc-b25a-03f7f053ef36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_17bc2c57-d10e-4e01-8da7-f10486c2d14d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a14d7c1d-71a1-46ac-bd6f-30fd076103b8" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_17bc2c57-d10e-4e01-8da7-f10486c2d14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0f85646c-890f-4e37-81c6-0913ba4d6efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e7b7f68f-d5ea-4b77-84a1-5d7cfca5abb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0f85646c-890f-4e37-81c6-0913ba4d6efa" xlink:to="loc_us-gaap_LossContingenciesTable_e7b7f68f-d5ea-4b77-84a1-5d7cfca5abb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_a97e1b24-da83-41cd-a03f-d0d72e703041" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e7b7f68f-d5ea-4b77-84a1-5d7cfca5abb6" xlink:to="loc_srt_LitigationCaseAxis_a97e1b24-da83-41cd-a03f-d0d72e703041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b52ff18b-a8d2-48ea-a5ac-5582c0cae0d1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_a97e1b24-da83-41cd-a03f-d0d72e703041" xlink:to="loc_srt_LitigationCaseTypeDomain_b52ff18b-a8d2-48ea-a5ac-5582c0cae0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CAREDXINCVsNateraIncMember_ec78c47f-2c66-42ce-a827-b709b3995289" xlink:href="cdna-20230331.xsd#cdna_CAREDXINCVsNateraIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_b52ff18b-a8d2-48ea-a5ac-5582c0cae0d1" xlink:to="loc_cdna_CAREDXINCVsNateraIncMember_ec78c47f-2c66-42ce-a827-b709b3995289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_9937c452-ff67-4901-b58a-490d289f87b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesByNatureAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e7b7f68f-d5ea-4b77-84a1-5d7cfca5abb6" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_9937c452-ff67-4901-b58a-490d289f87b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainContingencyNatureDomain_b3365ccf-2ec3-4315-aaab-324721f63a77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_9937c452-ff67-4901-b58a-490d289f87b7" xlink:to="loc_us-gaap_GainContingencyNatureDomain_b3365ccf-2ec3-4315-aaab-324721f63a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CompensatoryDamagesMember_166e7019-b85f-412c-9cf6-f6fe959a5c87" xlink:href="cdna-20230331.xsd#cdna_CompensatoryDamagesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingencyNatureDomain_b3365ccf-2ec3-4315-aaab-324721f63a77" xlink:to="loc_cdna_CompensatoryDamagesMember_166e7019-b85f-412c-9cf6-f6fe959a5c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_PunitiveDamagesMember_c8c730c9-8d3f-4656-b103-57d0c9faf7bb" xlink:href="cdna-20230331.xsd#cdna_PunitiveDamagesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingencyNatureDomain_b3365ccf-2ec3-4315-aaab-324721f63a77" xlink:to="loc_cdna_PunitiveDamagesMember_c8c730c9-8d3f-4656-b103-57d0c9faf7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a98e6e20-a34a-4c55-ad14-d1a6bc31dd88" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e7b7f68f-d5ea-4b77-84a1-5d7cfca5abb6" xlink:to="loc_srt_RangeAxis_a98e6e20-a34a-4c55-ad14-d1a6bc31dd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7ff96f0a-042d-4a26-9e8c-ea34f0368e13" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a98e6e20-a34a-4c55-ad14-d1a6bc31dd88" xlink:to="loc_srt_RangeMember_7ff96f0a-042d-4a26-9e8c-ea34f0368e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ca948d84-bf58-4858-9838-89dc86157469" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7ff96f0a-042d-4a26-9e8c-ea34f0368e13" xlink:to="loc_srt_MinimumMember_ca948d84-bf58-4858-9838-89dc86157469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d7cb7ab9-06d1-4000-96da-11184c835891" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7ff96f0a-042d-4a26-9e8c-ea34f0368e13" xlink:to="loc_srt_MaximumMember_d7cb7ab9-06d1-4000-96da-11184c835891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e7b7f68f-d5ea-4b77-84a1-5d7cfca5abb6" xlink:to="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_59ffd1d0-7da3-481c-a800-b63178e14559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_59ffd1d0-7da3-481c-a800-b63178e14559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_234a8a2f-b434-434e-8d48-07c3cc616cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_234a8a2f-b434-434e-8d48-07c3cc616cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_18cb04b0-fa4b-4938-8c37-33ba74d3077b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_18cb04b0-fa4b-4938-8c37-33ba74d3077b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_a1398954-97d5-464a-819b-6e3df53241f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_a1398954-97d5-464a-819b-6e3df53241f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_00c6b276-7578-4755-8c64-416d0966313d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_00c6b276-7578-4755-8c64-416d0966313d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_bc8dfa85-3e2a-48f8-95a3-1f6be6cfa43b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_bc8dfa85-3e2a-48f8-95a3-1f6be6cfa43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_9bd2a480-80ec-4719-81f3-716d1069d3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_9bd2a480-80ec-4719-81f3-716d1069d3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_cbeef9c0-3dbb-4a07-b616-4193dd8c93a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_cbeef9c0-3dbb-4a07-b616-4193dd8c93a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_NumberOfMilestonePayments_4db90f19-3bcf-4c83-938f-44c86f57d7ec" xlink:href="cdna-20230331.xsd#cdna_NumberOfMilestonePayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_cdna_NumberOfMilestonePayments_4db90f19-3bcf-4c83-938f-44c86f57d7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_26cca3e4-ed11-4d01-bbdd-9208c318901d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_26cca3e4-ed11-4d01-bbdd-9208c318901d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_86808244-8b0d-41a7-9f6d-f78f06a131a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_86808244-8b0d-41a7-9f6d-f78f06a131a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MalpracticeInsuranceMaximumCoveragePerIncident_3bee7e1d-7439-4668-bdcc-79bd7feee0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MalpracticeInsuranceMaximumCoveragePerIncident"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_678434a4-3072-4a46-84a3-0573da36d5ea" xlink:to="loc_us-gaap_MalpracticeInsuranceMaximumCoveragePerIncident_3bee7e1d-7439-4668-bdcc-79bd7feee0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CommitmentsandContingenciesSummaryofLeaseCostDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#CommitmentsandContingenciesSummaryofLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/CommitmentsandContingenciesSummaryofLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f63e2360-aad9-4aa9-bf7b-c3921b016809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_ed75f73a-8aca-4c06-918e-e8cbad322c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f63e2360-aad9-4aa9-bf7b-c3921b016809" xlink:to="loc_us-gaap_OperatingLeaseCost_ed75f73a-8aca-4c06-918e-e8cbad322c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_2ed85076-542c-42ae-9fe6-5c2f0b91149b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f63e2360-aad9-4aa9-bf7b-c3921b016809" xlink:to="loc_us-gaap_LeaseCost_2ed85076-542c-42ae-9fe6-5c2f0b91149b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CommitmentsandContingenciesSummaryofOtherInformationRelatedtoLeaseDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#CommitmentsandContingenciesSummaryofOtherInformationRelatedtoLeaseDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/CommitmentsandContingenciesSummaryofOtherInformationRelatedtoLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_30b3f8df-73dc-4442-9561-a0802d4575b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_LeaseOtherInformationAbstract_d77537bd-19c5-489e-b067-16ef53df4f4d" xlink:href="cdna-20230331.xsd#cdna_LeaseOtherInformationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_30b3f8df-73dc-4442-9561-a0802d4575b9" xlink:to="loc_cdna_LeaseOtherInformationAbstract_d77537bd-19c5-489e-b067-16ef53df4f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_12c13e3d-d6f1-4f6c-8942-b8052e6e17e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_LeaseOtherInformationAbstract_d77537bd-19c5-489e-b067-16ef53df4f4d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_12c13e3d-d6f1-4f6c-8942-b8052e6e17e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_734f0326-6745-482e-985a-f24f9d76b1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_LeaseOtherInformationAbstract_d77537bd-19c5-489e-b067-16ef53df4f4d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_734f0326-6745-482e-985a-f24f9d76b1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CommitmentsandContingenciesSummarizesROUAssetsandLeaseLiabilitiesforLeaseAgreementsDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#CommitmentsandContingenciesSummarizesROUAssetsandLeaseLiabilitiesforLeaseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/CommitmentsandContingenciesSummarizesROUAssetsandLeaseLiabilitiesforLeaseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6d6fbc0a-cc12-41b0-ab96-3c9f4c04ba35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_fffb29f8-4e26-423d-8936-1e7e86a4bbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6d6fbc0a-cc12-41b0-ab96-3c9f4c04ba35" xlink:to="loc_us-gaap_LossContingenciesTable_fffb29f8-4e26-423d-8936-1e7e86a4bbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_62cfc0d1-85f6-4627-9774-0d261da1076d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fffb29f8-4e26-423d-8936-1e7e86a4bbb6" xlink:to="loc_us-gaap_LeaseContractualTermAxis_62cfc0d1-85f6-4627-9774-0d261da1076d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_de8b2364-d089-46d3-bdf8-15d0eda7efed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_62cfc0d1-85f6-4627-9774-0d261da1076d" xlink:to="loc_us-gaap_LeaseContractualTermDomain_de8b2364-d089-46d3-bdf8-15d0eda7efed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_LeasesCommencedInJuly2022Member_134851d0-06d9-4cfe-9bc6-8436bf93ce30" xlink:href="cdna-20230331.xsd#cdna_LeasesCommencedInJuly2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_de8b2364-d089-46d3-bdf8-15d0eda7efed" xlink:to="loc_cdna_LeasesCommencedInJuly2022Member_134851d0-06d9-4cfe-9bc6-8436bf93ce30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_LeasesCommencedInAugust2022Member_c82b1fa2-0843-418b-b241-5891385c1f33" xlink:href="cdna-20230331.xsd#cdna_LeasesCommencedInAugust2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_de8b2364-d089-46d3-bdf8-15d0eda7efed" xlink:to="loc_cdna_LeasesCommencedInAugust2022Member_c82b1fa2-0843-418b-b241-5891385c1f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_37711ad9-0bbb-49cb-a8ed-4163060a8e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fffb29f8-4e26-423d-8936-1e7e86a4bbb6" xlink:to="loc_us-gaap_LossContingenciesLineItems_37711ad9-0bbb-49cb-a8ed-4163060a8e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ff2a114a-b0f5-4355-a46d-51ef95f451cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_37711ad9-0bbb-49cb-a8ed-4163060a8e77" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ff2a114a-b0f5-4355-a46d-51ef95f451cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_954f7c5d-581a-4311-92e5-1e219204fa34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_37711ad9-0bbb-49cb-a8ed-4163060a8e77" xlink:to="loc_us-gaap_OperatingLeaseLiability_954f7c5d-581a-4311-92e5-1e219204fa34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_998dc67b-150e-48b8-9960-cc29066b184f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_062d6e28-499c-4f83-8584-95ea507f9421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_998dc67b-150e-48b8-9960-cc29066b184f" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_062d6e28-499c-4f83-8584-95ea507f9421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_bd5e4426-e68c-454c-8fb7-ba5393e8bdce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_062d6e28-499c-4f83-8584-95ea507f9421" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_bd5e4426-e68c-454c-8fb7-ba5393e8bdce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_431bb10e-4658-4dfb-bf7f-6d5b0177c2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_062d6e28-499c-4f83-8584-95ea507f9421" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_431bb10e-4658-4dfb-bf7f-6d5b0177c2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5f63c004-f286-48ff-9a59-ca52685fc5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_062d6e28-499c-4f83-8584-95ea507f9421" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5f63c004-f286-48ff-9a59-ca52685fc5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3e481132-0187-45a3-a9c9-7bd7fdacd5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_062d6e28-499c-4f83-8584-95ea507f9421" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3e481132-0187-45a3-a9c9-7bd7fdacd5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3a277eb7-ea94-47af-982d-5ee82dee27f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_062d6e28-499c-4f83-8584-95ea507f9421" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3a277eb7-ea94-47af-982d-5ee82dee27f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_be070066-a3cb-4009-a220-664e4ac6dc5b" xlink:href="cdna-20230331.xsd#cdna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_062d6e28-499c-4f83-8584-95ea507f9421" xlink:to="loc_cdna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_be070066-a3cb-4009-a220-664e4ac6dc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69f9e86e-4f01-41e8-a324-36d694a1b169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_062d6e28-499c-4f83-8584-95ea507f9421" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_69f9e86e-4f01-41e8-a324-36d694a1b169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_41ee2497-a034-4ad7-9c9a-5f6de995f398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_062d6e28-499c-4f83-8584-95ea507f9421" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_41ee2497-a034-4ad7-9c9a-5f6de995f398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_424a6481-54b3-4235-9776-a534c6a8472c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_062d6e28-499c-4f83-8584-95ea507f9421" xlink:to="loc_us-gaap_OperatingLeaseLiability_424a6481-54b3-4235-9776-a534c6a8472c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_89502859-483e-432f-92a3-87a66b2c1898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_062d6e28-499c-4f83-8584-95ea507f9421" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_89502859-483e-432f-92a3-87a66b2c1898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fe415bd2-bf20-4d39-925c-34afd73c0889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_062d6e28-499c-4f83-8584-95ea507f9421" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fe415bd2-bf20-4d39-925c-34afd73c0889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails_1" xlink:type="simple" xlink:href="cdna-20230331.xsd#CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.caredxinc.com/role/CommitmentsandContingenciesSummarizestheNoncashInformationDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#CommitmentsandContingenciesSummarizestheNoncashInformationDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/CommitmentsandContingenciesSummarizestheNoncashInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_183b8efc-c95e-4174-adb0-e92e2f800327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_89b2738f-e92b-47d4-ad92-01643124748f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_183b8efc-c95e-4174-adb0-e92e2f800327" xlink:to="loc_us-gaap_OperatingLeasePayments_89b2738f-e92b-47d4-ad92-01643124748f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/A401KPlanAdditionalInformationDetail" xlink:type="simple" xlink:href="cdna-20230331.xsd#A401KPlanAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/A401KPlanAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4f07256c-8f83-44ea-a286-3af03c57af15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanTypeExtensibleList_a8feb998-43b4-4901-8d92-4797976ec1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanTypeExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4f07256c-8f83-44ea-a286-3af03c57af15" xlink:to="loc_us-gaap_DefinedBenefitPlanTypeExtensibleList_a8feb998-43b4-4901-8d92-4797976ec1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_7091ec0e-b453-429b-9b33-b6f13cb70eae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4f07256c-8f83-44ea-a286-3af03c57af15" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_7091ec0e-b453-429b-9b33-b6f13cb70eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/WarrantsAdditionalInformationDetail" xlink:type="simple" xlink:href="cdna-20230331.xsd#WarrantsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/WarrantsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_b58bbe31-e891-415d-ad7b-7c1fc31cae63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_NumberOfWarrantsExercised_10183b73-00c2-4ee4-ac0f-87c5f9989150" xlink:href="cdna-20230331.xsd#cdna_NumberOfWarrantsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_b58bbe31-e891-415d-ad7b-7c1fc31cae63" xlink:to="loc_cdna_NumberOfWarrantsExercised_10183b73-00c2-4ee4-ac0f-87c5f9989150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/WarrantsOutstandingWarrantsToPurchaseCommonStockWarrantsDetail" xlink:type="simple" xlink:href="cdna-20230331.xsd#WarrantsOutstandingWarrantsToPurchaseCommonStockWarrantsDetail"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/WarrantsOutstandingWarrantsToPurchaseCommonStockWarrantsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_95151d15-1ff6-4a8f-a954-9f548e05d0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_5c743975-ae89-433f-938e-98b5044c8b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_95151d15-1ff6-4a8f-a954-9f548e05d0ed" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_5c743975-ae89-433f-938e-98b5044c8b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_099f0d65-8e7e-46fb-aacc-acc6128c4cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5c743975-ae89-433f-938e-98b5044c8b99" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_099f0d65-8e7e-46fb-aacc-acc6128c4cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0cd851cf-abea-4e0e-9fdb-8855da71478e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_099f0d65-8e7e-46fb-aacc-acc6128c4cc3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0cd851cf-abea-4e0e-9fdb-8855da71478e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_7002ae46-11cd-456f-8a63-cdb46228a577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0cd851cf-abea-4e0e-9fdb-8855da71478e" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_7002ae46-11cd-456f-8a63-cdb46228a577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0b90038b-fdc2-47b2-9e7f-8a72f7e1a062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5c743975-ae89-433f-938e-98b5044c8b99" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0b90038b-fdc2-47b2-9e7f-8a72f7e1a062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_95021ca5-961f-4550-a4d0-561c16d42349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0b90038b-fdc2-47b2-9e7f-8a72f7e1a062" xlink:to="loc_us-gaap_EquityComponentDomain_95021ca5-961f-4550-a4d0-561c16d42349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8b52dae7-3886-438e-af76-6867b4a6fbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_95021ca5-961f-4550-a4d0-561c16d42349" xlink:to="loc_us-gaap_CommonStockMember_8b52dae7-3886-438e-af76-6867b4a6fbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_8a080449-6bdb-482d-8a62-a4e084b4c95f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5c743975-ae89-433f-938e-98b5044c8b99" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_8a080449-6bdb-482d-8a62-a4e084b4c95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_WarrantFairValueAssumptionsExpectedTerm_89d001c9-defd-4b26-b735-81fc0fe099f8" xlink:href="cdna-20230331.xsd#cdna_WarrantFairValueAssumptionsExpectedTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8a080449-6bdb-482d-8a62-a4e084b4c95f" xlink:to="loc_cdna_WarrantFairValueAssumptionsExpectedTerm_89d001c9-defd-4b26-b735-81fc0fe099f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_65801bf0-8bbc-4aaa-a26d-dece8d8c69f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8a080449-6bdb-482d-8a62-a4e084b4c95f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_65801bf0-8bbc-4aaa-a26d-dece8d8c69f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b1c5605f-15f7-4086-94f2-fa2c7ecdb4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8a080449-6bdb-482d-8a62-a4e084b4c95f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_b1c5605f-15f7-4086-94f2-fa2c7ecdb4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail" xlink:type="simple" xlink:href="cdna-20230331.xsd#StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e8217fbf-3924-4853-9760-a1adc91eb110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d80acfc6-06fc-453e-aeb4-ed3242c22c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e8217fbf-3924-4853-9760-a1adc91eb110" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d80acfc6-06fc-453e-aeb4-ed3242c22c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bb099daf-0b6a-4b8d-814c-2f22406b75be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d80acfc6-06fc-453e-aeb4-ed3242c22c0b" xlink:to="loc_us-gaap_AwardTypeAxis_bb099daf-0b6a-4b8d-814c-2f22406b75be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccf228f1-70b6-4405-a01d-90923d2cf19f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bb099daf-0b6a-4b8d-814c-2f22406b75be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccf228f1-70b6-4405-a01d-90923d2cf19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_149bad45-e805-414d-9d41-859ec06820ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ccf228f1-70b6-4405-a01d-90923d2cf19f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_149bad45-e805-414d-9d41-859ec06820ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdce54cc-0c9e-4cbf-a5ce-b4d16bc7f849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d80acfc6-06fc-453e-aeb4-ed3242c22c0b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdce54cc-0c9e-4cbf-a5ce-b4d16bc7f849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_67c872af-e92b-4069-9652-3a4beb16012b" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdce54cc-0c9e-4cbf-a5ce-b4d16bc7f849" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_67c872af-e92b-4069-9652-3a4beb16012b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b8c2c271-fe92-4654-9fac-01fe10b5b4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_67c872af-e92b-4069-9652-3a4beb16012b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b8c2c271-fe92-4654-9fac-01fe10b5b4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d24ccfed-c9aa-4df5-a929-55d178877344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_67c872af-e92b-4069-9652-3a4beb16012b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d24ccfed-c9aa-4df5-a929-55d178877344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices_493d2725-79e2-40bb-8733-f721f45fe55b" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_67c872af-e92b-4069-9652-3a4beb16012b" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices_493d2725-79e2-40bb-8733-f721f45fe55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_046de311-dbae-4fcb-9359-4155bb2b722f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_67c872af-e92b-4069-9652-3a4beb16012b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_046de311-dbae-4fcb-9359-4155bb2b722f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d6dc1665-087a-4469-88b7-92aaf56235cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_67c872af-e92b-4069-9652-3a4beb16012b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_d6dc1665-087a-4469-88b7-92aaf56235cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans_084859b9-b797-4a50-b8b8-193ed378e199" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_67c872af-e92b-4069-9652-3a4beb16012b" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans_084859b9-b797-4a50-b8b8-193ed378e199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_57c0defc-3b3c-4cd0-b7e0-7b816a7c5ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_67c872af-e92b-4069-9652-3a4beb16012b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_57c0defc-3b3c-4cd0-b7e0-7b816a7c5ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0d141416-bdf1-456f-b294-3c9522cb5e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_67c872af-e92b-4069-9652-3a4beb16012b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0d141416-bdf1-456f-b294-3c9522cb5e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_b4cadf8f-1ef7-45b0-bacb-c79a86f5ddf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_67c872af-e92b-4069-9652-3a4beb16012b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_b4cadf8f-1ef7-45b0-bacb-c79a86f5ddf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_26acdb99-c326-4c8d-92e6-5e29224effbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward_67c872af-e92b-4069-9652-3a4beb16012b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_26acdb99-c326-4c8d-92e6-5e29224effbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward_9e6e09ba-cdf7-44e7-9f6b-38822a95f483" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdce54cc-0c9e-4cbf-a5ce-b4d16bc7f849" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward_9e6e09ba-cdf7-44e7-9f6b-38822a95f483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4f4dd417-464f-42bc-99de-0115911ee379" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward_9e6e09ba-cdf7-44e7-9f6b-38822a95f483" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4f4dd417-464f-42bc-99de-0115911ee379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ade35a3a-390f-46a1-b658-9ded6fcea65b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward_9e6e09ba-cdf7-44e7-9f6b-38822a95f483" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ade35a3a-390f-46a1-b658-9ded6fcea65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_43e7690f-1e1b-46d6-a572-e6cf362aab39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward_9e6e09ba-cdf7-44e7-9f6b-38822a95f483" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_43e7690f-1e1b-46d6-a572-e6cf362aab39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_496d99b2-2af1-42c2-bedc-52f5c6bbe293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward_9e6e09ba-cdf7-44e7-9f6b-38822a95f483" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_496d99b2-2af1-42c2-bedc-52f5c6bbe293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0162dc27-f7c9-4da4-8011-1574ed7c2872" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward_9e6e09ba-cdf7-44e7-9f6b-38822a95f483" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0162dc27-f7c9-4da4-8011-1574ed7c2872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9a278af8-6a64-4b01-8524-c29ea382e9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward_9e6e09ba-cdf7-44e7-9f6b-38822a95f483" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9a278af8-6a64-4b01-8524-c29ea382e9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f158b378-2703-4c3f-9de5-d631e5b36491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdce54cc-0c9e-4cbf-a5ce-b4d16bc7f849" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f158b378-2703-4c3f-9de5-d631e5b36491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_48d77c76-f4cd-4d5a-99b4-12227823dbab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f158b378-2703-4c3f-9de5-d631e5b36491" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_48d77c76-f4cd-4d5a-99b4-12227823dbab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cb074bc1-d1be-463e-9935-93e3457e68de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f158b378-2703-4c3f-9de5-d631e5b36491" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cb074bc1-d1be-463e-9935-93e3457e68de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a1ff07a3-1f41-4850-b7da-506d1582753d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f158b378-2703-4c3f-9de5-d631e5b36491" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a1ff07a3-1f41-4850-b7da-506d1582753d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5d55a3c4-711a-4209-baff-4e6a5e68c36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f158b378-2703-4c3f-9de5-d631e5b36491" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_5d55a3c4-711a-4209-baff-4e6a5e68c36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1623b0c8-e08c-4f2a-b443-94f9c4baa9b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f158b378-2703-4c3f-9de5-d631e5b36491" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1623b0c8-e08c-4f2a-b443-94f9c4baa9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1019c354-37b9-40fa-8323-b9de2d725cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f158b378-2703-4c3f-9de5-d631e5b36491" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1019c354-37b9-40fa-8323-b9de2d725cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward_2c462f9a-1d96-4121-ac58-ae3666f50f3c" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdce54cc-0c9e-4cbf-a5ce-b4d16bc7f849" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward_2c462f9a-1d96-4121-ac58-ae3666f50f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_13bcd139-98e0-4600-ae9a-9a2997b207f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward_2c462f9a-1d96-4121-ac58-ae3666f50f3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_13bcd139-98e0-4600-ae9a-9a2997b207f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_271a2a44-47d3-4dea-a77d-537759cb054a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward_2c462f9a-1d96-4121-ac58-ae3666f50f3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_271a2a44-47d3-4dea-a77d-537759cb054a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8fa891c4-84b8-4230-beb4-d187c6a39cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward_2c462f9a-1d96-4121-ac58-ae3666f50f3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8fa891c4-84b8-4230-beb4-d187c6a39cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_57c5d0f7-fa24-4164-91a8-ded1198784b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward_2c462f9a-1d96-4121-ac58-ae3666f50f3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_57c5d0f7-fa24-4164-91a8-ded1198784b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b4bba5de-c992-4043-b73b-db1ea4f8279d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward_2c462f9a-1d96-4121-ac58-ae3666f50f3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b4bba5de-c992-4043-b73b-db1ea4f8279d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9c45271-2ef6-4349-817a-83a231f21fab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fdce54cc-0c9e-4cbf-a5ce-b4d16bc7f849" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9c45271-2ef6-4349-817a-83a231f21fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6daae5ba-4d41-4502-9b66-70822a091589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9c45271-2ef6-4349-817a-83a231f21fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6daae5ba-4d41-4502-9b66-70822a091589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a9cdc932-8816-45e3-9d39-fb7b6ecbba65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9c45271-2ef6-4349-817a-83a231f21fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a9cdc932-8816-45e3-9d39-fb7b6ecbba65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a3e166f1-efe6-4221-be03-081a30da917c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9c45271-2ef6-4349-817a-83a231f21fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a3e166f1-efe6-4221-be03-081a30da917c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_20686ad3-c700-45c3-952e-f063cb0be4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9c45271-2ef6-4349-817a-83a231f21fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_20686ad3-c700-45c3-952e-f063cb0be4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3bb5ec3f-83f2-4c67-b828-045ffeeaa9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e9c45271-2ef6-4349-817a-83a231f21fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3bb5ec3f-83f2-4c67-b828-045ffeeaa9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail" xlink:type="simple" xlink:href="cdna-20230331.xsd#StockIncentivePlansAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3cecc8bc-2dfb-48fe-b6fd-090968e10e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1abd866e-8e4c-484f-9afb-1e061b9c71ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3cecc8bc-2dfb-48fe-b6fd-090968e10e20" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1abd866e-8e4c-484f-9afb-1e061b9c71ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c0c76c26-03d6-4ca4-aadd-e7bc98005cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1abd866e-8e4c-484f-9afb-1e061b9c71ab" xlink:to="loc_us-gaap_AwardTypeAxis_c0c76c26-03d6-4ca4-aadd-e7bc98005cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_506b0c40-9468-41d4-936e-8abf388da879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c0c76c26-03d6-4ca4-aadd-e7bc98005cdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_506b0c40-9468-41d4-936e-8abf388da879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d25fa962-88aa-4de6-9845-8a73aaa8c20c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_506b0c40-9468-41d4-936e-8abf388da879" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d25fa962-88aa-4de6-9845-8a73aaa8c20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0d3e71ff-1db0-47da-933f-a9f7d83dac03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_506b0c40-9468-41d4-936e-8abf388da879" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0d3e71ff-1db0-47da-933f-a9f7d83dac03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_46ced28c-e2e3-432d-a143-b651647bd1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1abd866e-8e4c-484f-9afb-1e061b9c71ab" xlink:to="loc_us-gaap_PlanNameAxis_46ced28c-e2e3-432d-a143-b651647bd1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_29fecfe2-3735-403c-8e3b-fbe6052df224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_46ced28c-e2e3-432d-a143-b651647bd1e7" xlink:to="loc_us-gaap_PlanNameDomain_29fecfe2-3735-403c-8e3b-fbe6052df224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_0fd3ae34-6d2a-43aa-9173-21141a10ff7d" xlink:href="cdna-20230331.xsd#cdna_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_29fecfe2-3735-403c-8e3b-fbe6052df224" xlink:to="loc_cdna_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_0fd3ae34-6d2a-43aa-9173-21141a10ff7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1abd866e-8e4c-484f-9afb-1e061b9c71ab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_da689025-e002-4524-b3c0-e7002601ce43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_da689025-e002-4524-b3c0-e7002601ce43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_66e0663d-bc38-4f44-ab0a-448aa254a59a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_66e0663d-bc38-4f44-ab0a-448aa254a59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_276553b1-b022-4c0e-abf3-38f8379773f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_276553b1-b022-4c0e-abf3-38f8379773f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b826a588-22ef-4ae4-9395-bb71ced818fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b826a588-22ef-4ae4-9395-bb71ced818fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_3d8499d6-9c17-47fd-bb62-299ee717c13a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_3d8499d6-9c17-47fd-bb62-299ee717c13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_fd334351-7e7a-40af-a907-7e6f6844ca1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_fd334351-7e7a-40af-a907-7e6f6844ca1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum_43cc7476-c2bf-4a69-abfa-68c7dd974e43" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum_43cc7476-c2bf-4a69-abfa-68c7dd974e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_395827c0-5ad8-4f9b-af22-b41783dd5dae" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_395827c0-5ad8-4f9b-af22-b41783dd5dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_fe456712-af93-44f5-b2b3-a598be13f56c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_fe456712-af93-44f5-b2b3-a598be13f56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_39b5ab01-f2e4-4ab8-96bb-d1c3acac641e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_39b5ab01-f2e4-4ab8-96bb-d1c3acac641e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_ff39ff1c-148d-4b27-bc34-44758cba8d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_ff39ff1c-148d-4b27-bc34-44758cba8d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_746a6bd6-e2c2-40d1-aea7-96842a2a6725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_746a6bd6-e2c2-40d1-aea7-96842a2a6725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_9b30525e-220b-4f2c-a5cc-a058a320536a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a11def8e-7b25-4ecd-98e9-d8ff77c1c409" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_9b30525e-220b-4f2c-a5cc-a058a320536a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail" xlink:type="simple" xlink:href="cdna-20230331.xsd#StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c583e43a-8cee-40b4-b52e-376365cf82f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber_1c5f7237-45cb-4e80-923f-487df03d16f6" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c583e43a-8cee-40b4-b52e-376365cf82f9" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber_1c5f7237-45cb-4e80-923f-487df03d16f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber_359126bd-3af1-4153-9fd7-b0d7d3f67b56" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c583e43a-8cee-40b4-b52e-376365cf82f9" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber_359126bd-3af1-4153-9fd7-b0d7d3f67b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8b5b5e8e-1b88-4df0-9959-94f7febff860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c583e43a-8cee-40b4-b52e-376365cf82f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8b5b5e8e-1b88-4df0-9959-94f7febff860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_09c69de4-4ffc-4363-9e5a-1388a76ebc78" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c583e43a-8cee-40b4-b52e-376365cf82f9" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice_09c69de4-4ffc-4363-9e5a-1388a76ebc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice_6a663562-05aa-41d7-8395-2fb33d7458d7" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c583e43a-8cee-40b4-b52e-376365cf82f9" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice_6a663562-05aa-41d7-8395-2fb33d7458d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_7df0bc95-d877-468e-a142-f1cff584d376" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c583e43a-8cee-40b4-b52e-376365cf82f9" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm_7df0bc95-d877-468e-a142-f1cff584d376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_492fb286-96c4-4171-bacf-ee6aa300af97" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c583e43a-8cee-40b4-b52e-376365cf82f9" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm_492fb286-96c4-4171-bacf-ee6aa300af97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_47dd6d52-4b0b-4805-b090-da547f32ff40" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c583e43a-8cee-40b4-b52e-376365cf82f9" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue_47dd6d52-4b0b-4805-b090-da547f32ff40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue_14fd3dc1-bca3-4d47-b58c-1c0599fcf487" xlink:href="cdna-20230331.xsd#cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c583e43a-8cee-40b4-b52e-376365cf82f9" xlink:to="loc_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue_14fd3dc1-bca3-4d47-b58c-1c0599fcf487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_951cb71d-3325-4638-b39d-50bf233f5af8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c583e43a-8cee-40b4-b52e-376365cf82f9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_951cb71d-3325-4638-b39d-50bf233f5af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/StockIncentivePlansSummaryofWeightedAverageAssumptionsUsedtoEstimatedFairValuesofShareBasedAwardsDetail" xlink:type="simple" xlink:href="cdna-20230331.xsd#StockIncentivePlansSummaryofWeightedAverageAssumptionsUsedtoEstimatedFairValuesofShareBasedAwardsDetail"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/StockIncentivePlansSummaryofWeightedAverageAssumptionsUsedtoEstimatedFairValuesofShareBasedAwardsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e8f219f6-c331-4ed7-be76-5f67ab98fc27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202dd8f8-62c2-44b6-843a-cb2cf6bd2eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e8f219f6-c331-4ed7-be76-5f67ab98fc27" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202dd8f8-62c2-44b6-843a-cb2cf6bd2eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_740b4fd4-6d52-48c5-83a2-bcebb5680796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202dd8f8-62c2-44b6-843a-cb2cf6bd2eaa" xlink:to="loc_us-gaap_AwardTypeAxis_740b4fd4-6d52-48c5-83a2-bcebb5680796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5cc81709-c4a7-416f-8640-707a749f8429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_740b4fd4-6d52-48c5-83a2-bcebb5680796" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5cc81709-c4a7-416f-8640-707a749f8429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f6345728-ec1f-400a-b4f4-79a2b25e3c17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5cc81709-c4a7-416f-8640-707a749f8429" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f6345728-ec1f-400a-b4f4-79a2b25e3c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cf4edc60-b935-4fb6-b240-a1eb9947c71e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202dd8f8-62c2-44b6-843a-cb2cf6bd2eaa" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cf4edc60-b935-4fb6-b240-a1eb9947c71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cf12ccca-6390-4297-a1a2-4fb0246b4306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cf4edc60-b935-4fb6-b240-a1eb9947c71e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cf12ccca-6390-4297-a1a2-4fb0246b4306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_51315051-2fc9-4641-9595-28830923d0d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cf12ccca-6390-4297-a1a2-4fb0246b4306" xlink:to="loc_us-gaap_EmployeeStockMember_51315051-2fc9-4641-9595-28830923d0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47c2925f-52bd-44a8-9dee-e527f0cdf11c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_202dd8f8-62c2-44b6-843a-cb2cf6bd2eaa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47c2925f-52bd-44a8-9dee-e527f0cdf11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a2d0f8e3-ceec-4267-90ce-ce8c83cfb416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47c2925f-52bd-44a8-9dee-e527f0cdf11c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a2d0f8e3-ceec-4267-90ce-ce8c83cfb416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a2269c6b-077a-410a-a15e-1e10309c1bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47c2925f-52bd-44a8-9dee-e527f0cdf11c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a2269c6b-077a-410a-a15e-1e10309c1bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a6e3f9f5-96c2-4643-ab68-cce60fab2c50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47c2925f-52bd-44a8-9dee-e527f0cdf11c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a6e3f9f5-96c2-4643-ab68-cce60fab2c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fe485e0f-8349-40e3-8cd5-0f04b2c3d9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47c2925f-52bd-44a8-9dee-e527f0cdf11c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_fe485e0f-8349-40e3-8cd5-0f04b2c3d9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/StockIncentivePlansSummaryofExpenseRelatingtoEmployeeandNonemployeeStockBasedPaymentAwardsfromStockOptionsandRSUsDetail" xlink:type="simple" xlink:href="cdna-20230331.xsd#StockIncentivePlansSummaryofExpenseRelatingtoEmployeeandNonemployeeStockBasedPaymentAwardsfromStockOptionsandRSUsDetail"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/StockIncentivePlansSummaryofExpenseRelatingtoEmployeeandNonemployeeStockBasedPaymentAwardsfromStockOptionsandRSUsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3aa6f12-9f6f-4ae6-b673-db4bfe44357b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_851469f0-1e6c-41e6-a30a-e5ae44e2fa63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a3aa6f12-9f6f-4ae6-b673-db4bfe44357b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_851469f0-1e6c-41e6-a30a-e5ae44e2fa63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5e667c24-57b6-4810-94ce-3f313bbe16ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_851469f0-1e6c-41e6-a30a-e5ae44e2fa63" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5e667c24-57b6-4810-94ce-3f313bbe16ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b6262e67-ca0e-4c4c-aa72-e0320ad01147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5e667c24-57b6-4810-94ce-3f313bbe16ce" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b6262e67-ca0e-4c4c-aa72-e0320ad01147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CostOfTestingMember_ca25d441-d602-4b3e-9741-b03e9b604c8c" xlink:href="cdna-20230331.xsd#cdna_CostOfTestingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b6262e67-ca0e-4c4c-aa72-e0320ad01147" xlink:to="loc_cdna_CostOfTestingMember_ca25d441-d602-4b3e-9741-b03e9b604c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CostOfProductMember_f88ec4b4-cd35-475a-b142-7e2f0ea7d1e0" xlink:href="cdna-20230331.xsd#cdna_CostOfProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b6262e67-ca0e-4c4c-aa72-e0320ad01147" xlink:to="loc_cdna_CostOfProductMember_f88ec4b4-cd35-475a-b142-7e2f0ea7d1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_CostOfPatientAndDigitalSolutionsMember_45a6e2cb-1f16-427f-a3a8-98b0e120436c" xlink:href="cdna-20230331.xsd#cdna_CostOfPatientAndDigitalSolutionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b6262e67-ca0e-4c4c-aa72-e0320ad01147" xlink:to="loc_cdna_CostOfPatientAndDigitalSolutionsMember_45a6e2cb-1f16-427f-a3a8-98b0e120436c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d33334e8-dbc8-4c66-94b9-25d58998c37f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b6262e67-ca0e-4c4c-aa72-e0320ad01147" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d33334e8-dbc8-4c66-94b9-25d58998c37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpenseMember_037b3475-59e0-4e67-bfa3-02cd445e2aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingAndMarketingExpenseMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b6262e67-ca0e-4c4c-aa72-e0320ad01147" xlink:to="loc_us-gaap_SellingAndMarketingExpenseMember_037b3475-59e0-4e67-bfa3-02cd445e2aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3d97dc15-5a87-464a-af0b-1ff4eabd9da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b6262e67-ca0e-4c4c-aa72-e0320ad01147" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3d97dc15-5a87-464a-af0b-1ff4eabd9da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_36e61cb2-29a1-4ee9-829b-c7bf20729231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_851469f0-1e6c-41e6-a30a-e5ae44e2fa63" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_36e61cb2-29a1-4ee9-829b-c7bf20729231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_cb5a1b88-9480-4ac2-9611-3c1434720349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_36e61cb2-29a1-4ee9-829b-c7bf20729231" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_cb5a1b88-9480-4ac2-9611-3c1434720349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="cdna-20230331.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4055e22b-cfd6-4bdc-9248-8b1b60e47047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_IncomeTaxesTable_9fc5ad3d-ada6-46a7-93a8-7a1416a826f8" xlink:href="cdna-20230331.xsd#cdna_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4055e22b-cfd6-4bdc-9248-8b1b60e47047" xlink:to="loc_cdna_IncomeTaxesTable_9fc5ad3d-ada6-46a7-93a8-7a1416a826f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_0f8e085a-fd1d-48f9-84af-9d78308093d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_IncomeTaxesTable_9fc5ad3d-ada6-46a7-93a8-7a1416a826f8" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_0f8e085a-fd1d-48f9-84af-9d78308093d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_be2c7f86-b2c7-4a93-93bb-bdaef6243a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0f8e085a-fd1d-48f9-84af-9d78308093d3" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_be2c7f86-b2c7-4a93-93bb-bdaef6243a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_4f52863b-3ea2-496f-92bd-20a1fe908c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_be2c7f86-b2c7-4a93-93bb-bdaef6243a39" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_4f52863b-3ea2-496f-92bd-20a1fe908c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_IncomeTaxesLineItems_539b17cf-7b95-4564-8cbe-adeed598b8b5" xlink:href="cdna-20230331.xsd#cdna_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_IncomeTaxesTable_9fc5ad3d-ada6-46a7-93a8-7a1416a826f8" xlink:to="loc_cdna_IncomeTaxesLineItems_539b17cf-7b95-4564-8cbe-adeed598b8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ade056c0-aa16-4443-9e00-24dc364dc20c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdna_IncomeTaxesLineItems_539b17cf-7b95-4564-8cbe-adeed598b8b5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ade056c0-aa16-4443-9e00-24dc364dc20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail" xlink:type="simple" xlink:href="cdna-20230331.xsd#SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_134c109c-766b-4141-9304-ecf728f3d50f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_69e05665-cbed-46c9-aac2-cac6b8847629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_134c109c-766b-4141-9304-ecf728f3d50f" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_69e05665-cbed-46c9-aac2-cac6b8847629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_007c951c-d7d5-4863-9a0f-9c64785f4730" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_69e05665-cbed-46c9-aac2-cac6b8847629" xlink:to="loc_srt_ProductOrServiceAxis_007c951c-d7d5-4863-9a0f-9c64785f4730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fb67394e-8039-4f91-bb23-db6c9548dba0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_007c951c-d7d5-4863-9a0f-9c64785f4730" xlink:to="loc_srt_ProductsAndServicesDomain_fb67394e-8039-4f91-bb23-db6c9548dba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_06fb87db-cdf1-4fa8-a36b-e92102144c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fb67394e-8039-4f91-bb23-db6c9548dba0" xlink:to="loc_us-gaap_ServiceMember_06fb87db-cdf1-4fa8-a36b-e92102144c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_8fc4b417-6e12-4b4a-91f4-ecdb8f00591e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fb67394e-8039-4f91-bb23-db6c9548dba0" xlink:to="loc_us-gaap_ProductMember_8fc4b417-6e12-4b4a-91f4-ecdb8f00591e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_PatientAndDigitalSolutionsMember_430a49f6-191a-4c4f-a825-b1cd154cb678" xlink:href="cdna-20230331.xsd#cdna_PatientAndDigitalSolutionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_fb67394e-8039-4f91-bb23-db6c9548dba0" xlink:to="loc_cdna_PatientAndDigitalSolutionsMember_430a49f6-191a-4c4f-a825-b1cd154cb678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8fd7d6b8-0ed2-4549-b5ec-3423fc92f8cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_69e05665-cbed-46c9-aac2-cac6b8847629" xlink:to="loc_srt_StatementGeographicalAxis_8fd7d6b8-0ed2-4549-b5ec-3423fc92f8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9f4eeb24-8331-4059-a412-d35733ebf8a1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8fd7d6b8-0ed2-4549-b5ec-3423fc92f8cf" xlink:to="loc_srt_SegmentGeographicalDomain_9f4eeb24-8331-4059-a412-d35733ebf8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7f468e15-786c-4d1b-af60-b283dee9cb6f" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9f4eeb24-8331-4059-a412-d35733ebf8a1" xlink:to="loc_country_US_7f468e15-786c-4d1b-af60-b283dee9cb6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_dfd63dfb-5231-4a3a-9f6e-f06e5ac9c641" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9f4eeb24-8331-4059-a412-d35733ebf8a1" xlink:to="loc_srt_EuropeMember_dfd63dfb-5231-4a3a-9f6e-f06e5ac9c641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_RestOfTheWorldMember_23e4a731-ccae-4d7e-98fd-86dd023f58df" xlink:href="cdna-20230331.xsd#cdna_RestOfTheWorldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9f4eeb24-8331-4059-a412-d35733ebf8a1" xlink:to="loc_cdna_RestOfTheWorldMember_23e4a731-ccae-4d7e-98fd-86dd023f58df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_bdd1d06a-257b-46a6-9493-8f979a4e9b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_69e05665-cbed-46c9-aac2-cac6b8847629" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_bdd1d06a-257b-46a6-9493-8f979a4e9b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b4b2400-7946-4555-8d05-6c5d55df3f65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_bdd1d06a-257b-46a6-9493-8f979a4e9b95" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6b4b2400-7946-4555-8d05-6c5d55df3f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/SegmentReportingSummaryofLongLivedAssetsConsistingofPropertyandEquipmentNetbyGeographicRegionsDetail" xlink:type="simple" xlink:href="cdna-20230331.xsd#SegmentReportingSummaryofLongLivedAssetsConsistingofPropertyandEquipmentNetbyGeographicRegionsDetail"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/SegmentReportingSummaryofLongLivedAssetsConsistingofPropertyandEquipmentNetbyGeographicRegionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_79d0a90a-a05e-4e3b-ba0e-f2d2296ffb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_795af5f0-3cfe-48d2-88c4-8809e4e2cdf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_79d0a90a-a05e-4e3b-ba0e-f2d2296ffb5e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_795af5f0-3cfe-48d2-88c4-8809e4e2cdf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_faed3b3b-7928-4419-82ce-bf363c2abcfa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_795af5f0-3cfe-48d2-88c4-8809e4e2cdf3" xlink:to="loc_srt_StatementGeographicalAxis_faed3b3b-7928-4419-82ce-bf363c2abcfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7174b6a6-e43c-4490-a142-39df0c07d421" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_faed3b3b-7928-4419-82ce-bf363c2abcfa" xlink:to="loc_srt_SegmentGeographicalDomain_7174b6a6-e43c-4490-a142-39df0c07d421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f157c9a4-73cc-40c2-9590-10eb85c47442" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7174b6a6-e43c-4490-a142-39df0c07d421" xlink:to="loc_country_US_f157c9a4-73cc-40c2-9590-10eb85c47442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_7f1ecfb3-6850-44cc-ac98-c5851bbddd37" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7174b6a6-e43c-4490-a142-39df0c07d421" xlink:to="loc_srt_EuropeMember_7f1ecfb3-6850-44cc-ac98-c5851bbddd37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdna_RestOfTheWorldMember_bda8a945-cdbe-483f-9e26-ec542a60ec22" xlink:href="cdna-20230331.xsd#cdna_RestOfTheWorldMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7174b6a6-e43c-4490-a142-39df0c07d421" xlink:to="loc_cdna_RestOfTheWorldMember_bda8a945-cdbe-483f-9e26-ec542a60ec22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_2cc20f60-ff79-4dbf-86f4-82d1313a2be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_795af5f0-3cfe-48d2-88c4-8809e4e2cdf3" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_2cc20f60-ff79-4dbf-86f4-82d1313a2be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e8e140ab-c5ce-4c41-933f-3e0447cef3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_2cc20f60-ff79-4dbf-86f4-82d1313a2be5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e8e140ab-c5ce-4c41-933f-3e0447cef3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.caredxinc.com/role/RestructuringDetails" xlink:type="simple" xlink:href="cdna-20230331.xsd#RestructuringDetails"/>
  <link:presentationLink xlink:role="http://www.caredxinc.com/role/RestructuringDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1ec664dc-d7bc-4621-b9dc-7798fc1ec0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_156e834e-f893-429f-9dbe-5f6636c7ca48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_1ec664dc-d7bc-4621-b9dc-7798fc1ec0fd" xlink:to="loc_us-gaap_RestructuringCharges_156e834e-f893-429f-9dbe-5f6636c7ca48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795928259168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 08, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CAREDX, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3316839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8000 Marina Boulevard, 4th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brisbane<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">287-2300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CDNA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,793,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001217234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795923289232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 74,660<span></span>
</td>
<td class="nump">$ 89,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">211,279<span></span>
</td>
<td class="nump">203,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">59,310<span></span>
</td>
<td class="nump">66,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">18,018<span></span>
</td>
<td class="nump">19,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">8,161<span></span>
</td>
<td class="nump">9,216<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">371,428<span></span>
</td>
<td class="nump">387,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">35,506<span></span>
</td>
<td class="nump">35,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating leases right-of-use assets</a></td>
<td class="nump">33,431<span></span>
</td>
<td class="nump">34,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">45,637<span></span>
</td>
<td class="nump">43,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">39,615<span></span>
</td>
<td class="nump">37,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,080<span></span>
</td>
<td class="nump">3,828<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">528,217<span></span>
</td>
<td class="nump">542,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">12,861<span></span>
</td>
<td class="nump">9,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">12,082<span></span>
</td>
<td class="nump">16,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">46,885<span></span>
</td>
<td class="nump">49,131<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">71,828<span></span>
</td>
<td class="nump">75,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Common stock warrant liability</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_DeferredPaymentsForIntangibleAssetsNoncurrent', window );">Deferred payments for intangible assets</a></td>
<td class="nump">4,089<span></span>
</td>
<td class="nump">2,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, less current portion</a></td>
<td class="nump">32,006<span></span>
</td>
<td class="nump">33,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">108,196<span></span>
</td>
<td class="nump">112,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock: $0.001 par value; 10,000,000 shares authorized at March&#160;31, 2023 and December&#160;31, 2022; no shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock: $0.001 par value; 100,000,000 shares authorized at March&#160;31, 2023 and December&#160;31, 2022; 53,712,654 shares and 53,583,301 shares issued at March&#160;31, 2023 and December&#160;31, 2022, respectively; 53,653,182 shares and 53,533,250 shares outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">912,291<span></span>
</td>
<td class="nump">898,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(7,439)<span></span>
</td>
<td class="num">(7,503)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(484,883)<span></span>
</td>
<td class="num">(460,444)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">420,021<span></span>
</td>
<td class="nump">430,911<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 528,217<span></span>
</td>
<td class="nump">$ 542,991<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_DeferredPaymentsForIntangibleAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred payments for intangible assets, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_DeferredPaymentsForIntangibleAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795927030832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">53,712,654<span></span>
</td>
<td class="nump">53,583,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">53,653,182<span></span>
</td>
<td class="nump">53,533,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795924542960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 77,262<span></span>
</td>
<td class="nump">$ 79,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">24,357<span></span>
</td>
<td class="nump">21,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">23,231<span></span>
</td>
<td class="nump">23,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">28,032<span></span>
</td>
<td class="nump">26,559<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">101,586<span></span>
</td>
<td class="nump">98,469<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(24,324)<span></span>
</td>
<td class="num">(19,053)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">2,666<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Change in estimated fair value of common stock warrant liability</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(1,974)<span></span>
</td>
<td class="num">(823)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">699<span></span>
</td>
<td class="num">(607)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(23,625)<span></span>
</td>
<td class="num">(19,660)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(124)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,749)<span></span>
</td>
<td class="num">$ (19,648)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used to compute net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">53,643,216<span></span>
</td>
<td class="nump">53,015,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">53,643,216<span></span>
</td>
<td class="nump">53,015,459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Testing services revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 61,784<span></span>
</td>
<td class="nump">$ 66,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of testing services, product, digital, and other</a></td>
<td class="nump">15,296<span></span>
</td>
<td class="nump">17,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">6,861<span></span>
</td>
<td class="nump">6,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of testing services, product, digital, and other</a></td>
<td class="nump">4,066<span></span>
</td>
<td class="nump">4,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cdna_PatientAndDigitalSolutionsMember', window );">Patient and digital solutions revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">8,617<span></span>
</td>
<td class="nump">6,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of testing services, product, digital, and other</a></td>
<td class="nump">$ 6,604<span></span>
</td>
<td class="nump">$ 4,855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdna_PatientAndDigitalSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdna_PatientAndDigitalSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795926953680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (23,749)<span></span>
</td>
<td class="num">$ (19,648)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments, net of tax</a></td>
<td class="nump">64<span></span>
</td>
<td class="num">(420)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net comprehensive loss</a></td>
<td class="num">$ (23,685)<span></span>
</td>
<td class="num">$ (20,068)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795922900544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,923,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 465,876<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 853,683<span></span>
</td>
<td class="num">$ (4,670)<span></span>
</td>
<td class="num">$ (383,189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">RSU settlements, net of shares withheld (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings', window );">RSU settlements, net of shares withheld</a></td>
<td class="num">(1,482)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,482)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options</a></td>
<td class="nump">1,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee stock-based compensation expense</a></td>
<td class="nump">10,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(19,648)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,648)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,085,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">457,544<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">865,419<span></span>
</td>
<td class="num">(5,090)<span></span>
</td>
<td class="num">(402,837)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,923,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">465,876<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">853,683<span></span>
</td>
<td class="num">(4,670)<span></span>
</td>
<td class="num">(383,189)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,533,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">430,911<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">898,806<span></span>
</td>
<td class="num">(7,503)<span></span>
</td>
<td class="num">(460,444)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase and retirement of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59,472)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchase and retirement of common stock</a></td>
<td class="num">(690)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(690)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">RSU settlements, net of shares withheld (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings', window );">RSU settlements, net of shares withheld</a></td>
<td class="num">(785)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(785)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">$ 93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options (in shares)</a></td>
<td class="nump">820<span></span>
</td>
<td class="nump">820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for cash upon exercise of stock options</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee stock-based compensation expense</a></td>
<td class="nump">13,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,749)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,749)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,653,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 420,021<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 912,291<span></span>
</td>
<td class="num">$ (7,439)<span></span>
</td>
<td class="num">$ (484,883)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795928288240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (23,749)<span></span>
</td>
<td class="num">$ (19,648)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">13,754<span></span>
</td>
<td class="nump">10,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Revaluation of common stock warrant liability to estimated fair value</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,427<span></span>
</td>
<td class="nump">2,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments and write-downs</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">1,337<span></span>
</td>
<td class="nump">915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on long-term marketable equity securities</a></td>
<td class="nump">905<span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Revaluation of contingent consideration to estimated fair value</a></td>
<td class="nump">364<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization of premium on short-term marketable securities, net</a></td>
<td class="num">(773)<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">7,664<span></span>
</td>
<td class="num">(5,591)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">1,217<span></span>
</td>
<td class="num">(1,060)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid and other assets</a></td>
<td class="nump">1,515<span></span>
</td>
<td class="num">(567)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating leases liabilities, net</a></td>
<td class="num">(1,333)<span></span>
</td>
<td class="num">(969)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,590<span></span>
</td>
<td class="num">(1,549)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedSalaries', window );">Accrued compensation</a></td>
<td class="num">(4,888)<span></span>
</td>
<td class="num">(14,634)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="num">(2,352)<span></span>
</td>
<td class="nump">7,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Change in deferred taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(217)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">671<span></span>
</td>
<td class="num">(21,468)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of business, net of cash acquired</a></td>
<td class="num">(4,562)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of short-term marketable securities</a></td>
<td class="num">(86,310)<span></span>
</td>
<td class="num">(148,522)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of short-term marketable securities</a></td>
<td class="nump">78,972<span></span>
</td>
<td class="nump">1,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Purchase of corporate equity securities</a></td>
<td class="num">(100)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_PaymentsToAcquireCapitalExpendituresNet', window );">Additions of capital expenditures, net</a></td>
<td class="num">(2,771)<span></span>
</td>
<td class="num">(8,463)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(14,771)<span></span>
</td>
<td class="num">(156,032)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">456<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits', window );">Taxes paid related to net share settlement of restricted stock units</a></td>
<td class="num">(656)<span></span>
</td>
<td class="num">(1,482)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payment of contingent consideration</a></td>
<td class="num">(250)<span></span>
</td>
<td class="num">(250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase and retirement of common stock</a></td>
<td class="num">(690)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(1,138)<span></span>
</td>
<td class="nump">865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(25)<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(15,263)<span></span>
</td>
<td class="num">(176,590)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">90,443<span></span>
</td>
<td class="nump">348,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">$ 75,180<span></span>
</td>
<td class="nump">$ 172,106<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_PaymentsToAcquireCapitalExpendituresNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Capital Expenditures, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_PaymentsToAcquireCapitalExpendituresNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Taxes paid related to net share settlement of restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in accrued salaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795925210672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of Business</a></td>
<td class="text">ORGANIZATION AND DESCRIPTION OF BUSINESS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CareDx, Inc. (&#8220;CareDx&#8221; or the &#8220;Company&#8221;), together with its subsidiaries, is a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients and caregivers. The Company&#8217;s headquarters are in Brisbane, California. The primary operations are in Brisbane, California; Omaha, Nebraska; Fremantle, Australia; and Stockholm, Sweden.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s commercially available testing services consist of AlloSure&#174; Kidney, a donor-derived cell-free DNA (&#8220;dd-cfDNA&#8221;) solution for kidney transplant patients, AlloMap&#174; Heart, a gene expression solution for heart transplant patients, AlloSure&#174; Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure&#174; Lung, a dd-cfDNA solution for lung transplant patients. The Company has initiated several clinical studies to generate data on its existing and planned future testing services. In April 2020, the Company announced its first biopharma research partnership for AlloCell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants. The Company also offers high-quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. The Company also provides digital solutions to transplant centers following the acquisitions of Ottr Complete Transplant Management (&#8220;Ottr&#8221;) and XynManagement, Inc. (&#8220;XynManagement&#8221;), as well as the acquisitions of TransChart LLC (&#8220;TransChart&#8221;), MedActionPlan.com, LLC (&#8220;MedActionPlan&#8221;) The Transplant Pharmacy, LLC (&#8220;TTP&#8221;) in 2021 and HLA Data Systems, LLC ("HLA Data Systems") in January 2023.</span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Testing Services </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloSure Kidney has been a covered service for Medicare beneficiaries since October 2017 through a Local Coverage Determination (&#8220;LCD&#8221;) first issued by Palmetto MolDX (&#8220;MolDX&#8221;), which was formed to identify and establish coverage and reimbursement for molecular diagnostics tests, and adopted by Noridian Healthcare Solutions, the Company&#8217;s Medicare Administrative Contractor (&#8220;Noridian&#8221;). The Medicare reimbursement rate for AlloSure Kidney is currently $2,841. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloMap Heart has been a covered service for Medicare beneficiaries since January 2006. The Medicare reimbursement rate for AlloMap Heart is currently $3,240. In October 2020, the Company received a final MolDX Medicare coverage decision for AlloSure Heart. Noridian issued a parallel coverage policy granting coverage for AlloSure Heart when used in conjunction with AlloMap Heart, which became effective in December 2020. The Medicare reimbursement rate for AlloSure Heart is currently $2,753.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 2, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MolDX issued a new billing article, with an effective date of March&#160;31, 2023, related to the LCD entitled Molecular Testing for Solid Organ Allograft Rejection (the &#8220;Billing Article&#8221;). Prior to the Billing Article&#8217;s effective date, MolDX informed the affected parties, including CareDx, that enforcement of the revised billing practices outlined in the Billing Article will not be implemented until June&#160;30, 2023.  MolDX informed CareDx that its automatic adjudication process would remain in place until June 30, 2023, though claims submitted prior to that date must comply with the applicable LCDs. On May&#160;4, 2023, MolDX issued a revised new billing article with an effective date of March&#160;31, 2023 (the &#8220;Revised Billing Article&#8221; and together with the Billing Article, the &#8220;Billing Articles&#8221;).  The Revised Billing Article impacts Medicare coverage for AlloSure Kidney, AlloSure Heart and AlloMap Heart and requires certain companies, including CareDx, to implement new processes to address the requirements related to Medicare claim submissions. MolDX has stated that it views the Billing Article as clarifying existing coverage, especially as it relates to when tests are covered in the for-cause and surveillance contexts.  MolDX has acknowledged, however, that the Billing Article is a change as it relates to billing more than one test during a single patient encounter. Noridian has not yet adopted the new Billing Articles.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company believes the Billing Articles are inconsistent with the LCDs, Noridian&#8217;s and MolDX&#8217;s responses to public comments explaining the intended scope of various LCDs, and medical necessity, the Company determined to pause its Medicare reimbursement submissions for AlloSure Kidney commencing on March&#160;7, 2023 to allow the Company further time to evaluate the implications of the Billing Article and update its billing processes for AlloSure Kidney tests by educating clinicians and working with centers to update CareDx&#8217;s test order forms to capture the new information required under the Billing Article. Accordingly, the Company did not submit claims for approximately 3,200 AlloSure Kidney tests for Medicare reimbursement for the period from March&#160;7, 2023 through March&#160;31, 2023 and did not recognize revenue on these claims in the first quarter of 2023 aggregating to approximately $8.9 million (the &#8220;Impacted March Tests&#8221;).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2023, the Company plans to submit claims for Medicare reimbursement for the Impacted March Tests, following the delivery by the Company of a letter to Noridian explaining, among other things, (i) the Company&#8217;s belief that the Billing Articles impose new restrictions on Medicare coverage for the CareDx tests from those contained in the existing LCDs, (ii) that the Company plans to submit claims for reimbursement for the Impacted March Tests for which the Company has not obtained additional information from the ordering physicians to be able to specifically determine whether these tests meet the new coverage restrictions contained in the Billing Articles, and (iii) that AlloSure Kidney orders with a date of service on or after March&#160;31, 2023 for other indications outside the parameters of the Revised Billing Article, or where the reason for testing </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is not specified by the ordering physician, will either be held pending the receipt of additional information regarding medical necessity or submitted with a test description that is intended to identify those tests as falling outside the parameters of the Revised Billing Article.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CareDx continued the Medicare reimbursement submissions for AlloMap Heart or AlloSure Heart following the issuance of the Billing Articles. In addition, CareDx is considering informing Noridian that until Noridian adopts the Revised Billing Article, CareDx will continue to submit AlloSure Heart tests for reimbursement only when used in conjunction with AlloMap Heart. The Company is also considering informing Noridian that (i) until June 30, 2023, it plans to submit claims for reimbursement for AlloMap Heart and AlloSure Heart tests for which the Company has not obtained additional information from the ordering physicians to be able to specifically determine whether these tests meet the new coverage restrictions contained in the Billing Articles, and (ii) AlloSure Heart and AlloMap Heart orders placed on or after June&#160;30, 2023 for other indications outside the surveillance and for-cause parameters of the Billing Article, or where the reason for testing is not specified by the ordering physician, will either be held pending the receipt of additional information regarding medical necessity or submitted with a test description that is intended to identify those tests as falling outside the parameters of the Billing Articles. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloSure Kidney has received positive coverage decisions from several commercial payers, and is reimbursed by other private payers on a case-by-case basis.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloMap Heart has also received positive coverage decisions for reimbursement from many of the largest U.S. private payers.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021 and March 2023, the Company purchased a minority investment of common stock in the biotechnology company Miromatrix Medical, Inc. (&#8220;Miromatrix&#8221;), for an aggregate amount of $5.1 million, and the investment is marked to market. Miromatrix works to eliminate the need for an organ transplant waiting list through the development of implantable engineered biological organs.</span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Studies</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company initiated the Kidney Allograft Outcomes AlloSure Kidney Registry study (&#8220;K-OAR&#8221;), to develop additional data on the clinical utility of AlloSure Kidney for surveillance of kidney transplant recipients. K-OAR is a multicenter, non-blinded, prospective observational cohort study which has enrolled more than 1,700 renal transplant patients who will receive AlloSure Kidney long-term surveillance.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company initiated the Surveillance HeartCare&#8482; Outcomes Registry (&#8220;SHORE&#8221;). SHORE is a prospective, multi-center, observational registry of patients receiving HeartCare for surveillance. HeartCare combines the gene expression profiling technology of AlloMap Heart with the dd-cfDNA analysis of AlloSure&#174; Heart in one surveillance solution.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, AlloSure&#174; Lung became available for lung transplant patients through a compassionate use program while the test is undergoing further studies. In June 2020, the Company submitted an AlloSure Lung application to the Palmetto MolDx Technical Assessment program seeking coverage and reimbursement for Medicare beneficiaries.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company announced the commencement of the Outcomes of KidneyCare on Renal Allografts (&#8220;OKRA&#8221;) study, which is an extension of K-OAR. OKRA is a prospective, multi-center, observational, registry of patients receiving KidneyCare for surveillance. KidneyCare combines the dd-cfDNA analysis of AlloSure Kidney with the gene expression profiling technology of AlloMap Kidney and the predictive artificial intelligence technology of iBox for a multimodality surveillance solution. The Company has not yet made any applications to private payers for reimbursement coverage of AlloMap Kidney or KidneyCare.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Products</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s suite of AlloSeq products are commercial next generation sequencing (&#8220;NGS&#8221;)-based kitted solutions. These products include: AlloSeq&#8482; Tx, a high-resolution Human Leukocyte Antigen (&#8220;HLA&#8221;) typing solution, AlloSeq&#8482; cfDNA, a surveillance solution designed to measure dd-cfDNA in blood to detect active rejection in transplant recipients, and AlloSeq&#8482; HCT, a solution for chimerism testing for stem cell transplant recipients.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's other HLA typing products include: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Olerup </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SSP</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on the sequence specific primer (&#8220;SSP&#8221;) technology; and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QTYPE</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which uses real-time polymerase chain reaction </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;PCR&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> methodology, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to perform HLA typing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company acquired certain assets of BFS Molecular S.R.L. (&#8220;BFS Molecular&#8221;), a software company focused on NGS-based patient testing solutions. BFS Molecular brings extensive software and algorithm development capabilities for NGS transplant surveillance products.</span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Patient and Digital Solutions</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the acquisitions of both Ottr and XynManagement, the Company is a leading provider of transplant patient management software (&#8220;Ottr software&#8221;), as well as of transplant quality tracking and waitlist management solutions. Ottr software provides comprehensive solutions for transplant patient management and enables integration with electronic medical </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">record (&#8220;EMR&#8221;) systems providing patient surveillance management tools and outcomes data to transplant centers. XynManagement provides two unique solutions, XynQAPI software (&#8220;XynQAPI&#8221;) and XynCare. XynQAPI simplifies transplant quality tracking and Scientific Registry of Transplant Recipients reporting. XynCare includes a team of transplant assistants who maintain regular contact with patients on the waitlist to help prepare for their transplant and maintain eligibility.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company launched AlloCare, a mobile app that provides a patient-centric resource for transplant recipients to manage medication adherence, coordinate with Patient Care Managers for AlloSure scheduling and measure health metrics.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company acquired TransChart. TransChart provides EMR software to hospitals throughout the U.S. to care for patients who have or may need an organ transplant. As part of the Company's acquisition of TransChart in January 2021, the Company acquired TxAccess, a cloud-based service that allows nephrologists and dialysis centers to electronically submit referrals to transplant programs, closely follow and assist patients through the transplant waitlist process, and ultimately, through transplantation.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company acquired the Transplant Hero patient application. The application helps patients manage their medications through alarms and interactive logging of medication eve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nts</span><span style="color:#548dd4;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in June 2021, the Company entered into a strategic agreement with OrganX, which was amended in April 2022, to develop clinical decision support tools across the transplant patient journey. Together, the Company and OrganX will develop advanced analytics that integrate AlloSure, the first transplant specific dd-cfDNA assay, with large transplant databases to provide clinical data solutions. This partnership delivers the next level of innovation beyond multi-modality by incorporating a variety of clinical inputs to create a universal composite scoring system. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreed to potential future milestone payments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company acquired MedActionPlan, a New Jersey-based provider of medication safety, medication adherence and patient education. MedActionPlan is a leader in patient medication management for transplant patients and beyond.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company acquired TTP, a transplant focused pharmacy located in Mississippi. TTP provides individualized transplant pharmacy services for patients at multiple transplant centers located throughout the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred significant losses and negative cash flows from operations since its inception and had an accumulated deficit of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$484.9 million at March&#160;31, 2023. As of March&#160;31, 2023, the Company had cash, cash equivalents and marketable securities of $285.9 million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no debt outstanding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At-the-Market Equity Offering</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 14, 2022, the Company entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with Jefferies, LLC as sales agent (&#8220;Jefferies&#8221;), pursuant to which the Company may offer and sell, from time to time, through Jefferies, up to $200.0&#160;million in shares of our common stock, by any method permitted by law deemed to be an &#8220;at-the-market&#8221; offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. Jefferies is entitled to compensation for its services equal to 3% of the gross proceeds of any shares of common stock sold through Jefferies under the Sales Agreement. Any shares of common stock offered and sold pursuant to the Sales Agreement will be issued and sold pursuant to our Registration Statement on Form S-3ASR (File No. 333-239049), filed with the SEC on June 9, 2020 (the &#8220;Registration Statement&#8221;), including a base prospectus dated June 9, 2020, and a prospectus supplement dated April 14, 2022. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Registration Statement will expire on June 9, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Repurchase Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;3, 2022, the Company's Board of Directors approved a stock repurchase program (the "Repurchase Program"), whereby the Company may purchase up to $50&#160;million in shares of our common stock over a period of up to two years, commencing on December&#160;8, 2022. The Repurchase Program may be carried out at the discretion of a committee of the Board of Directors through open market purchases, one or more Rule 10b5-1 trading plans, block trades and in privately negotiated transactions. During the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company purchased an aggregate of 59,472 shares of its common stock under the Repurchase Program for an aggregate purchase price of $0.7 million. As of March&#160;31, 2023, $48.7 million remained available for future share repurchase under the Repurchase Program.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795924534320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies and estimates used in preparation of the unaudited condensed consolidated financial statements are described in the Company&#8217;s audited consolidated financial statements as of and for the year ended December&#160;31, 2022, and the notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the Securities and Exchange Commission (the "SEC") on February&#160;27, 2023. Material changes to the significant accounting policies previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022 are reflected below.</span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;), and follow the requirements of the SEC for interim reporting. As permitted under those rules, certain notes and other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company&#8217;s financial information. The condensed consolidated balance sheet as of December&#160;31, 2022 has been derived from audited consolidated financial statements as of that date but does not include all of the financial information required by U.S. GAAP for complete financial statements. Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023.</span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to transaction price estimates used for testing services revenue; standalone fair value of patient and digital solutions revenue performance obligations; accrued expenses for clinical studies;&#160;inventory valuation;&#160;the fair value of issued common stock warrants and embedded derivatives; the fair value of assets and liabilities acquired in a business combination or an assets acquisition (including identifiable intangible assets acquired);&#160;the fair value of contingent consideration recorded in connection with a business combination or an asset acquisition; the grant date fair value assumptions used to estimate stock-based compensation expense; income taxes; impairment of long-lived assets and indefinite-lived assets (including goodwill); and legal contingencies. Actual results could differ from those estimates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Concentrations of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, approximately 42% and 54%, respectively, of total revenue was derived from Medicare. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, approximately 26% and 27%, respectively, of accounts receivable was due from Medicare. No other payer or customer represented more than 10% of accounts receivable at either March&#160;31, 2023 or December&#160;31, 2022.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketable Securities</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments in securities with a maturity of greater than three months at the time of purchase to be marketable securities. As of March&#160;31, 2023, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s short-term marketable securities consisted of corporate debt securities with maturities of greater than three months but less than twelve months at the time of purchase, which were classified as current assets on the condensed consolidated balance sheet</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its short-term marketable securities as held-to-maturity at the time of purchase and reevaluates such designation at each balance sheet date. The Company has the positive intent and ability to hold these marketable securities to maturity. Short-term marketable securities are carried at amortized cost and are adjusted for amortization of premiums and accretion of discounts to maturity, which is included i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n interest income (expense), net on the condensed consolidated statements of operations. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on short-term marketable securities are included in interest income (expense), net. The cost of securities sold will be determined using specific identification.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers investments in securities with remaining maturities of over one year as long-term investments. As of March&#160;31, 2023, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company's long-term marketable securities consisted of corporate equity securities and corporate debt securities. These long-term marketable securities are classified as other assets on the condensed consolidated balance sheet</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its long-term marketable debt securities as available-for-sale and reevaluates such designation at each balance sheet date. Unrealized gains and losses from the reevaluation of the long-term marketable debt securities, if any, are included in other comprehensive gain (loss) in the condensed consolidated statement of comprehensive income (loss). Realized gains and losses and declines in value judged to be other-than-temporary, if any, on long-term marketable securities are included in interest income, net.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records its long-term marketable equity securities at fair market value. Unrealized gains and losses from the remeasurement of the long-term marketable equity securities to fair value are included in other income (expense), net, in the condensed consolidated statements of operations. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted Accounting Standard Codification (&#8220;ASC&#8221;) Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and determines if an arrangement is or contains a lease at contract inception. A right-of-use (&#8220;ROU&#8221;) asset, representing the underlying asset during the lease term, and a lease liability, representing the payment obligation arising from the lease, are recognized on the condensed consolidated balance sheet at lease commencement based on the present value of the payment obligation. For operating leases, expense is recognized on a straight-line basis over the lease term. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the ROU asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company's facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with an initial term of 12 months or less.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company&#8217;s leases had remaining terms of 0.67 years to 9.85 years, some of which include options to extend the lease term.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from testing services, product sales and patient and digital solutions revenue in the amount that reflects the consideration that it expects to be entitled in exchange for goods or services as it transfers control to its customers. Revenue is recorded considering a five-step revenue recognition model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations and recognizing revenue when, or as, an entity satisfies a performance obligation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Testing Services Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloSure Kidney, AlloMap Heart, AlloSure Heart and AlloSure Lung patient tests are ordered by healthcare providers. The Company receives a test requisition form with payer information along with a collected patient blood sample. The Company considers the patient to be its customer and the test requisition form to be the contract. Testing services are performed in the Company&#8217;s laboratory. Testing services represent one performance obligation in a contract and are performed when results of the test are provided to the healthcare provider, at a point in time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare providers that order the tests and on whose behalf the Company provides testing services are generally not responsible for the payment of these services. The first and second revenue recognition criteria are satisfied when the Company receives a test requisition form with payer information from the healthcare provider. Generally, the Company bills third-party payers upon delivery of an AlloSure Kidney, AlloMap Heart, AlloSure Heart or AlloSure Lung test result to the healthcare provider. Amounts received may vary amongst payers based on coverage practices and policies of the payer. The Company has used the portfolio approach under Accounting Standards Codification ("ASC") Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to identify financial classes of payers. Revenue recognized for Medicare and other contracted payers is based on the agreed current reimbursement rate per test, adjusted for historical collection trends where applicable. The Company estimates revenue for non-contracted payers and self-payers using transaction prices determined for each financial class of payers using history of reimbursements. This includes analysis of an average reimbursement per test and a percentage of tests reimbursed. This estimate requires significant judgment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors revenue estimates at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Changes in transaction price estimates are updated quarterly based on actual cash collected or changes made to contracted rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 2, 2023, MolDX issued a new Billing Article, with an effective date of March&#160;31, 2023. The Billing Article impacts Medicare coverage for AlloSure Kidney, AlloSure Heart and AlloMap and requires the Company to implement new processes to address requirements related to Medicare claim submissions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 606-10-25-1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> requires the Company to assess whether it is probable that it will collect substantially all of the consideration to which it will be entitled. Based upon the Company&#8217;s review of the Billing Article, it was determined to pause Medicare reimbursement submissions for AlloSure Kidney commencing on March&#160;7, 2023 that created uncertainty around the collection of the claims. Accordingly, the Company did not recognize revenue for approximately 3,200 AlloSure Kidney tests aggregating to $8.9 million for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is recognized from the sale of products to end-users, distributors and strategic partners when all revenue recognition criteria are satisfied. The Company generally has a contract or a purchase order from a customer with the specified required terms of order, including the number of products ordered. Transaction prices are determinable and products are delivered and risk of loss passed to the customer upon either shipping or delivery, as per the terms of the agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient and Digital Solutions Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient and digital solutions revenue is mainly derived from a combination of software as a service ("SaaS") and perpetual software license agreements entered into with various transplant centers, which are the Company's customers for this class of revenue. The main performance obligations in connection with the Company's SaaS and perpetual software license agreement are the following: (i) implementation services and delivery of the perpetual software license are considered a single performance obligation, and (ii) post contract support. The Company allocates the transaction price to each performance obligation based on relative stand-alone selling prices of each distinct performance obligation. Digital revenue in connection with perpetual software license agreements is recognized over time based on the Company&#8217;s satisfaction of each distinct performance obligation in each agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Perpetual software license agreements typically require advance payments from customers upon the achievement of certain milestones. The Company records deferred revenue in relation to these agreements when cash payments are received, or invoices are issued in advance of the Company&#8217;s performance, and generally recognizes revenue over the contractual term, as performance obligations are fulfilled.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company derives patient and digital solutions revenue from software subscriptions and medication sales. The Company generally bills software subscription fees in advance. Revenue from software subscriptions is deferred and recognized ratably over the subscription term. The medication sales revenue is recognized based on the negotiated contract price with the governmental, commercial and non-commercial payers with any applicable patient co-pay. The Company recognizes revenue from medication sales when prescriptions are delivered.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which contains amendments that require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model. The disclosures include (1) the types of assistance, (2) an entity&#8217;s accounting for the assistance, and (3) the effect of the assistance on an entity&#8217;s financial statements. The amendments set forth in this ASU are effective for all entities for annual periods beginning after December 15, 2021. Early application of the amendments in this ASU is permitted. The amendments in this ASU should be applied either (1) prospectively to all transactions within the scope of the amendments that are reflected in financial statements at the date of initial application and new transactions that are entered into after the date of initial application or (2) retrospectively to those transactions. The Company adopted the standard prospectively on January 1, 2022. The adoption of this new standard had no impact on the Company's consolidated financial statements and disclosures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that an entity recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with ASC 606 as if it had originated the contracts. The amendments set forth in this ASU are effective for fiscal years beginning after December 15, 2022. Early adoption of the amendments is permitted. The amendments in this ASU should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company adopted the standard prospectively on January 1, 2022. The adoption of this new standard had no material impact on the Company's consolidated financial statements and disclosures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified </span></div>Written Call Options (a consensus of the FASB Emerging Issues Task Force), which contains amendments that clarify and reduce diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after modification or exchange. The amendments set forth in this ASU are effective for all entities for annual periods beginning after December 15, 2021. Early application of the amendments in this ASU is permitted for all entities. The amendments in this ASU should be applied prospectively. The Company adopted the standard prospectively on January 1, 2022. The adoption of this new standard had no impact on the Company's consolidated financial statements and disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795941551968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">NET LOSS PER SHARE<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share have been computed by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of common share equivalents as their effect would have been antidilutive.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the computation of the Company&#8217;s basic and diluted net loss per share (in thousands, except shares and per share data):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:73.825%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.920%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss used to compute basic and diluted net loss per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,749)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,648)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute basic and diluted net loss per share</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,643,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,015,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from diluted net loss per share as of March&#160;31, 2023 and 2022 because their effect would be antidilutive:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock subject to outstanding options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,091,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock subject to outstanding common stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,096,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,047,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,347,842&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,142,211&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795925397344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records its financial assets and liabilities at fair value.&#160;The carrying amounts of certain financial instruments of the Company, including cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities.&#160;&#160;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date.&#160;The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 1: Inputs that include quoted prices in active markets for identical assets and liabilities.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the Company&#8217;s financial assets and liabilities, measured at fair value on a recurring basis, as of March&#160;31, 2023 and December&#160;31, 2022 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measured Using</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,587&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,587&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,939&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,939&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measured Using</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,670&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,670&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,475&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,475&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the issuances, exercises, changes in fair value and reclassifications of the Company&#8217;s Level 3 financial instruments that are measured at fair value on a recurring basis (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrant Liability and Contingent Consideration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in estimated fair value of common stock warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in estimated fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Addition of estimated fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments related to contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,939&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2023, the Company wrote off $1.0&#160;million of its investment in convertible preferred shares from a private company which was carried at cost.  This private company's operations are in the process of being liquidated.  The fair value of this investment was based on Level 3 inputs. &#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining fair value, the Company uses various valuation approaches within the fair value measurement framework.&#160;&#160;The valuation methodologies used for the Company&#8217;s instruments measured at fair value and their classification in the valuation hierarchy are summarized below:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Money market funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Investments in money market funds are classified within Level 1. Money market funds are valued at the closing price reported by the fund sponsor from an actively traded exchange.&#160;At March&#160;31, 2023 and December&#160;31, 2022, money market funds were included as cash and cash equivalents in the condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Short-term marketable securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Investments in short-term marketable securities are classified within Level 2. The securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Long-term marketable equity and debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; Investments in long-term marketable equity securities are classified within Level 1. The securities are recorded at fair value based on readily available quoted market prices in active markets. Investments in long-term marketable debt securities are classified within Level 2. The securities are recorded at fair value based on observable inputs for quoted prices for identical or similar assets in markets that are not active. Long-term marketable securities are located within other assets on the condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration is classified within Level 3. Contingent consideration relates to asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquisitions and business combinations. The Company recorded the estimate of the fair value of the contingent consideration based on its evaluation of the probability of the achievement of the contractual </span></div>conditions that would result in the payment of the contingent consideration. Contingent consideration was estimated using the fair value of the milestones to be paid if the contingency is met multiplied by management&#8217;s estimate of the probability of success at a discounted rate of 7% and 12% at March&#160;31, 2023 and December&#160;31, 2022, respectively. The significant input in the Level 3 measurement that is not supported by market activity is the Company&#8217;s probability assessment of the achievement of the milestones. The value of the liability is subsequently remeasured to fair value at each reporting date, and the change in estimated fair value is recorded as a component of operating expenses until the milestones are paid, expire or are no longer achievable. Increases or decreases in the estimation of the probability percentage result in a directionally similar impact to the fair value measurement of the contingent consideration liability. The carrying amount of the contingent consideration liability represents its fair value. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt">Common stock warrant liability</span> &#8211; Common stock warrant liability is classified within Level 3. The Company utilizes intrinsic value to estimate the fair value of the warrants.&#160;The intrinsic value is computed as the difference between the fair value of the Company&#8217;s common stock on the valuation date and the exercise price of the warrants. Increases (decreases) in the Company's stock price discussed above result in a directionally similar impact to the fair value of the common stock warrant liability.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795925443072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Marketable Securities</a></td>
<td class="text">CASH AND MARKETABLE SECURITIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the amount reported within the condensed consolidated statements of cash flows is shown in the table below (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,180&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,106&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketable Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All short-term marketable securities were considered held-to-maturity at March&#160;31, 2023. At March&#160;31, 2023, some of the Company&#8217;s short-term marketable securities were in an unrealized loss position. The Company determined that it had the positive intent and ability to hold until maturity all short-term marketable securities that have been in a continuous loss position, thus there was no recognition of any other-than-temporary impairment as of March&#160;31, 2023. All short-term marketable securities with unrealized losses as of the balance sheet date have been in a loss position for less than twelve months. Contractual maturities of the short-term marketable securities were within one year or less at March&#160;31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The long-term marketable equity securities were recorded at fair market value with changes in the fair value recognized in earnings at March&#160;31, 2023 and December&#160;31, 2022. The long-term marketable debt securities were considered available-for-sale at March&#160;31, 2023 and December&#160;31, 2022. The contractual maturities of the long-term marketable debt securities are less than three years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding losses, and fair value of the Company&#8217;s marketable securities by major security type at each balance sheet date are summarized in the tables below (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,279&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,335&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,614&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,828)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,828)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,379&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,493)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,886&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,168&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,924)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,924)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,168&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,692)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,476&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of the marketable securities at each balance sheet date are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,279&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,168&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795925229152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations</a></td>
<td class="text">BUSINESS COMBINATIONS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">HLA Data Systems</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company acquired HLA Data Systems, a Texas-based company that provides software and interoperability solutions for the histocompatibility and immunogenetics community. The Company acquired HLA Data Systems with a combination of cash consideration paid upfront and contingent consideration with a fair value of $1.3&#160;million. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounted for the transaction as a business combination using the acquisition method of accounting. Acquisition-related costs of $0.4&#160;million associated with the acquisition were expensed as incurred, and classified as part of general and administrative expenses in the condensed consolidated statement of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill of $2.1&#160;million arising from the acquisition primarily consists of synergies from integrating HLA Data Systems' technology with the current testing and digital solutions offered by the Company. The acquisition of HLA Data Systems will provide a robust and comprehensive Laboratory Information Management System and support the laboratory workflows. None of the goodwill is expected to be deductible for income tax purposes. All of the goodwill has been assigned to the Company&#8217;s existing operating segment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair values of the intangible assets acquired as of the acquisition date ($ in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:69.264%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.340%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Estimated Fair Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Estimated Useful Lives (Years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Customer relationships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Developed technology</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,100&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships acquired by the Company represent the fair value of future projected revenue that is expected to be derived from sales of HLA Data Systems&#8217; products to existing customers. The customer relationships&#8217; fair value has been estimated utilizing a multi-period excess earnings method under the income approach, which reflects the present value of the projected cash flows that are expected to be generated by the customer relationships, less charges representing the contribution of other assets to those cash flows that use projected cash flows with and without the intangible asset in place. The economic useful life was determined based on the distribution of the present value of the cash flows attributable to the intangible asset.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquired developed technology represents the fair value of HLA Data Systems' proprietary software. The trademark acquired consists primarily of the HLA Data Systems brand and markings. The fair value of both the developed technology and the trademark were determined using the relief-from-royalty method under the income approach. This method considers the value of the asset to be the value of the royalty payments from which the Company is relieved due to its ownership of the asset. The royalty rates of 10% and 2% were used to estimate the fair value of the developed technology and the trademark, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A discount rate of 24% was utilized in estimating the fair value of these three intangible assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pro forma impact of the HLA Data Systems acquisition is not material, and the results of operations of the acquisition have been included in the Company's condensed consolidated statements of operations from the respective acquisition date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration Paid</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the consideration paid for HLA Data Systems and the amounts of the assets acquired and liabilities assumed recognized at their estimated fair value at the acquisition date (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.076%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Consideration</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total consideration</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recognized amounts of identifiable assets acquired and liabilities assumed</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Identifiable intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(786)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Contingent considerations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total identifiable net assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,470&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,562&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allocation of the purchase price to assets acquired and liabilities assumed was based on the fair value of such assets and liabilities as of the acquisition date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795925397344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">GOODWILL AND INTANGIBLE ASSETS<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Goodwill</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is recorded when the purchase price of an acquisition exceeds the fair value of the net tangible and identified intangible assets acquired.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested annually for impairment at the reporting unit level during the fourth quarter or earlier upon the occurrence of certain events or substantive changes in circumstances. There were no indicators of impairment in the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended March&#160;31, 2023. The balance of the Company's goodwill was $39.6&#160;million as of March&#160;31, 2023 and $37.5&#160;million as of December&#160;31, 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intangible Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of the Company&#8217;s intangible assets as of March&#160;31, 2023 ($ in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:34.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Useful&#160;Life<br/>(In&#160;Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with finite lives:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired and developed technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,931)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,336)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,067)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercialization rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,549)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and tradenames</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets with finite lives</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,864&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,766)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,711)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,387&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,114&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,766)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,711)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,637&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of the Company&#8217;s intangible assets as of December&#160;31, 2022 ($ in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:34.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Useful&#160;Life<br/>(In&#160;Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with finite lives:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired and developed technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,369)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,459)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercialization rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and tradenames</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(315)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets with finite lives</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,764&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,175)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,788)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,801&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,014&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,175)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,788)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,051&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Acquisition of Intangible Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company acquired commercialization rights in an exclusive partnership for comprehensive data analytics in relation to NGS-based metagenomics testing for infectious diseases. In 2022, the Company incurred additional costs related to this partnership of $1.0 million. These are included within commercialization rights as of March&#160;31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company acquired the Transplant Hero patient application. The patient application is included in Acquired and developed technology as of March&#160;31, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2021, acquisition of intangible assets increased $13.4&#160;million primarily from business combinations. These acquisitions included $4.7&#160;million of Acquired and developed technology, $2.5&#160;million of Commercialization rights, $3.7&#160;million of Customer relationships, $2.2&#160;million of Trademarks and tradenames and $0.3&#160;million of Other intangible assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amortization of Intangible Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are carried at cost less accumulated amortization. Amortization expenses are recorded to cost of testing services, cost of product, cost of patient and digital solutions, and sales and marketing expenses in the condensed consolidated statements of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's amortization expense of intangible assets (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of testing services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of patient and digital solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales &amp; marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,590&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,623&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s estimated future amortization expense of intangible assets with finite lives as of March&#160;31, 2023 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost of Testing Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost of Product</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost of Patient and Digital Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales and Marketing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,077&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,076&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,420&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,975&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,916&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,387&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795929139824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">BALANCE SHEET COMPONENTS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Inventory</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,962&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,018&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accrued and Other Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other liabilities consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical studies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,883&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred payments for intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalty</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory processing fees and materials </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other collaboration fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued shipping expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued and other liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,885&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,131&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795926985024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its operating and office facilities for various terms under long-term, non-cancelable operating lease agreements in Brisbane, California; Columbus, Ohio; West Chester, Pennsylvania; Flowood, Mississippi; Gaithersburg, Maryland; Fremantle, Australia; and Stockholm, Sweden.&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's facility leases expire at various dates through 2033. In the normal course of business, it is expected that these leases will be renewed or replaced by leases on other properties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the carrying value of the ROU asset was $33.4 million. The related current and non-current liabilities as of March&#160;31, 2023 were $5.7 million and $32.0 million, respectively. The current and non-current lease liabilities are included in accrued and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfMTY0OTI2NzQ2ODUyOQ_d306f6fa-aeb4-45bb-9b54-7cf758f0a757">other current liabilities</span> and operating lease liability, less current portion, respectively, in the condensed consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the lease cost for the three months ended March 31, 2023 and 2022 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,983&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,983&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.789%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.05</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate (%)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February and June 2022, the Company entered into various lease agreements to lease office buildings in California, Nebraska, and Australia with lease terms ranging from 2 to 10.5 years. Certain leases have options to renew the respective lease terms ranging from 5 to 10 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company modified the termination date of the lease agreement for its headquarters in South San Francisco, California from December 31, 2022 to July 15, 2022. As a result, the Company remeasured its lease liability using the current incremental borrowing rate and made an adjustment by reducing the ROU asset and lease liability by $0.5&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease liabilities for the lease agreements made in February and June 2022 are recognized at the present value of the fixed lease payments using the current incremental borrowing rate at the lease commencement date.  ROU assets are recognized based on the initial present value of the fixed lease payments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the ROU assets and lease liabilities for certain lease agreements which commenced in July 2022 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,776&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the ROU assets and lease liabilities for certain lease agreements which commenced in August 2022 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities as of March&#160;31, 2023 are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,931&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,604&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,511&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,744&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less operating lease liability, current portion</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,738&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, long-term portion</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,006&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the supplemental cash flow information related to leases for the three months ended March 31, 2023 and 2022 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used for operating leases</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Royalty Commitments</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">The Board of Trustees of the Leland Stanford Junior University (&#8220;Stanford&#8221;)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, the Company entered into a license agreement with Stanford (the &#8220;Stanford License&#8221;), which granted the Company an exclusive license to a patent relating to the diagnosis of rejection in organ transplant recipients using dd-cfDNA. Under the terms of the Stanford License, the Company is required to pay an annual license maintenance fee, six milestone payments and royalties in the low single digits of net sales of products incorporating the licensed technology.  In March 2023. the Stanford License agreement was amended, which reduces the maximum royalty rate to a lower rate at which the Company may be liable to Stanford effective from April 2022. As a result, the Company reversed the excess liability in March 2023.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Illumina</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2018, the Company entered into a license agreement with Illumina, Inc. (the &#8220;Illumina Agreement&#8221;). The Illumina Agreement requires the Company to pay royalties in the mid-single to low-double digits on sales of products covered by the Illumina Agreement.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cibiltech Commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to that certain license and commercialization agreement that the Company entered into with Cibiltech SAS (&#8220;Cibiltech&#8221;) effective April 30, 2019, the Company will share an agreed-upon percentage of revenue with Cibiltech, if and when revenues are generated from iBox.&#160;&#160;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Commitments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Illumina Agreement, the Company has agreed to minimum purchase commitments of finished products and raw materials from Illumina, Inc. through 2023.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation and Indemnification Obligations</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In response to the Company's false advertising suit filed against Natera Inc. (&#8220;Natera&#8221;), on April 10, 2019, Natera filed a counterclaim against the Company on February 18, 2020, in the U.S. District Court for the District of Delaware (the &#8220;Court&#8221;) alleging the Company made false and misleading claims about the performance capabilities of AlloSure. The suit seeks injunctive relief and unspecified monetary relief. On September 30, 2020, Natera requested leave of Court to amend its counterclaims to include additional allegations regarding purportedly false claims the Company made with respect to AlloSure, </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and the Court granted Natera&#8217;s request. The trial commenced on March 7, 2022 and concluded on March 14, 2022, with the jury awarding the Company $44.9&#160;million in damages, comprised of $21.2&#160;million in compensatory damages and $23.7&#160;million in punitive damages. Post-trial motion practice remains pending. The Company will not record the award until cash is received or the matter is otherwise resolved. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2022, the United States Court of Appeals for the Federal Circuit affirmed the Court&#8217;s judgment dismissing the Company&#8217;s patent infringement suit against Natera. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Natera filed suit against the Company on January 13, 2020, in the Court alleging, among other things, that AlloSure infringes Natera&#8217;s U.S. Patent 10,526,658. This case was consolidated with the Company&#8217;s patent infringement suit on February 4, 2020. On March 25, 2020, Natera filed an amendment to the suit alleging, among other things, that AlloSure also infringes Natera&#8217;s U.S. Patent 10,597,724. The suit seeks a judgment that the Company has infringed Natera&#8217;s patents, an order preliminarily and permanently enjoining the Company from any further infringement of such patents and unspecified damages. On May 13, 2022, Natera filed two new complaints alleging that AlloSure infringes Natera&#8217;s U.S. Patents 10,655,180 and 11,111,544. These two cases were consolidated with the patent infringement case on June 15, 2022. On May 17, 2022, Natera agreed to dismiss the case alleging infringement of Natera&#8217;s U.S. Patent 10,526,658. On July 6, 2022, the Company moved to dismiss the rest of Natera&#8217;s claims. On September 6, 2022, the Company withdrew its motion to dismiss. Discovery is ongoing. The Company intends to defend both of these matters vigorously, and believes that the Company has good and substantial defenses to the claims alleged in the suits, but there is no guarantee that the Company will prevail. The Company has not recorded any liabilities for these suits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">United States Department of Justice and United States Securities and Exchange Commission Investigations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in 2021, the Company received a civil investigative demand (&#8220;CID&#8221;) from the United States Department of Justice (&#8220;DOJ&#8221;) requesting that the Company produce certain documents in connection with a False Claims Act investigation being conducted by the DOJ regarding certain business practices related to the Company's kidney testing and phlebotomy services, and a subpoena from the United States Securities and Exchange Commission (&#8220;SEC&#8221;) in relation to an investigation by the SEC in respect of matters similar to those identified in the CID, as well as certain of the Company&#8217;s accounting and public reporting practices. The Company also received an information request from a state regulatory agency.  This state regulatory agency advised the Company that it has completed its review of the Company&#8217;s business practices and determined that no further information or action is required. In late 2022, the Company received a request for information from a separate state regulatory agency concerning specimen collection by a vendor in the state. The Company may receive additional requests for information from the DOJ, SEC, or other regulatory and governmental agencies regarding similar or related subject matters. The Company does not believe that the CID, the SEC subpoena or the state regulatory agency information request raise any issues regarding the safety or efficacy of any of the Company's products or services and are cooperating fully with the investigations and the requests for information. Although the Company remains committed to compliance with all applicable laws and regulations, it cannot predict the outcome of the DOJ or SEC investigations, the state regulatory agency information request, or any other requests or investigations that may arise in the future regarding these or other subject matters.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become involved in litigation and other legal actions. The Company estimates the range of liability related to any pending litigation where the amount and range of loss can be estimated. The Company records its best estimate of a loss when the loss is considered probable. Where a liability is probable and there is a range of estimated loss with no best estimate in the range, the Company records a charge equal to at least the minimum estimated liability for a loss contingency when both of the following conditions are met: (i) information available prior to issuance of the condensed consolidated financial statements indicates that it is probable that a liability had been incurred at the date of the condensed consolidated financial statements, and (ii) the range of loss can be reasonably estimated.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Olymbios Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2022, a complaint was filed by Michael Olymbios against the Company in the Superior Court of the State of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California for the County of San Mateo (the &#8220;San Mateo County Court&#8221;). The complaint alleges that the Company failed to pay certain fees and costs required to continue an arbitration proceeding against Dr. Olymbios, and that the Company has defamed Dr. Olymbios. Dr. Olymbios also seeks to void restrictive covenants previously agreed to by him in favor of the Company and to recover damages purportedly incurred by Dr. Olymbios. The Company filed a motion to compel arbitration and dismiss the case. On April 25, 2022, the San Mateo County Court granted the Company&#8217;s </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex parte</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> application to stay the case and advance the hearing date to June 10, 2022 for the motion to compel arbitration and dismiss. At the June 10, 2022 hearing, the San Mateo County Court found that the decision should be made by the arbitrator, and stayed the case. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2022, Olymbios filed a motion to withdraw from arbitration before JAMS, which was denied on August 18, 2022. The matter is currently proceeding in arbitration. The Company intends to vigorously pursue its arbitration proceeding against Olymbios and to vigorously defend itself against Olymbios&#8217; claims. The Company believes it has good and substantial support for it claims and good and </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantial defenses to the claims alleged in the suit by Olymbios, but there is no guarantee that the Company will prevail if the case continues. The </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company has not recorded any liabilities for this suit.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Class Action</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 23, 2022, Plumbers &amp; Pipefitters Local Union #295 Pension Fund filed a federal securities class action in the U.S. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">District Court for the Northern District of California against the Company, Reginald Seeto, its President, Chief Executive Officer and member of the Company&#8217;s Board of Directors, Ankur Dhingra, its former Chief Financial Officer, Marcel Konrad, its former interim Chief Financial Officer and former Senior Vice President of Finance &amp; Accounting, and Peter Maag, its former President, former Chief Executive Officer, former Chairman of the Board and current member of the Company&#8217;s Board of Directors. The action alleges that the Company and the individual defendants made materially false and/or misleading statements and/or omissions and that such statements violated Section 10(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Rule 10b-5 promulgated thereunder. The action also alleges that the individual defendants are liable pursuant to Section 20(a) of the Exchange Act as controlling persons of the Company. The suit seeks to recover damages caused by the alleged violations of federal securities laws, along with the plaintiffs&#8217; costs incurred in the lawsuit, including their reasonable attorneys&#8217; and experts&#8217; witness fees and other costs. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 25, 2022, the court appointed an investor group led by the Oklahoma Police Pension and Retirement System as lead plaintiffs and appointed Saxena White P.A. and Robbins Geller Rudman &amp; Dowd LLP as lead counsels. Plaintiffs filed an amended complaint on November 28, 2022. On January 27, 2023, defendants moved to dismiss all claims and to strike certain allegations in the amended complaint. A hearing on these motions is scheduled for May 16, 2023. The Company intends to defend itself vigorously, and believes that the Company has good and substantial defenses to the claims alleged in the suit, but there is no guarantee that the Company will prevail. The Company has not recorded any liabilities for this suit. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Derivative Actions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 21, 2022, Jeffrey Edelman brought a stockholder derivative action complaint in the U.S. District Court for the Northern District of California against the Company as nominal defendant and Drs. Seeto and Maag and Mr. Dhingra, and other current and former members of the Company&#8217;s Board of Directors (the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Edelman Derivative Action</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The plaintiff alleges that the individual defendants breached their fiduciary duties as directors and/or officers of the Company and engaged in insider trading, waste of corporate assets, unjust enrichment and violations of Sections 14(a) and 20(a) of the Exchange Act. The action alleges that the individual defendants are liable pursuant to Section 20(a) of the Exchange Act as controlling persons of the Company. The suit seeks a declaration that the individual defendants breached their fiduciary duties to the Company, violated Sections 14(a) and 20(a) of the Exchange Act and were unjustly enriched, and also seeks to recover damages sustained by the Company as a result of the alleged violations, along with the plaintiff&#8217;s costs incurred in the lawsuit, including reasonable attorneys&#8217; and experts&#8217; fees, costs and expenses. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On December 8, 2022, the court stayed the Edelman Derivative Action until twenty (20) days after the earlier of the following events: (a) the securities class action is dismissed in its entirety with prejudice; (b) the motion to dismiss in the securities class action is denied; (c) a joint request by plaintiff and defendants to lift the stay; (d) notification that a related derivative action that has been filed is not stayed or is no longer stayed; or (e) notification that there has been a settlement reached in the securities class action or any related derivative action.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 7, 2023, Jaysen Stevenson brought a stockholder derivative action complaint in the U.S. District Court for the Northern District of California against the Company as nominal defendant and Drs. Seeto and Maag and Mr. Dhingra and other current and former members of the Company&#8217;s Board of Directors (the &#8220;Stevenson Derivative Action&#8221;). The claims and allegations in the Stevenson Derivative Action are substantially similar to those in the Edelman Derivative Action. The plaintiff alleges that the individual defendants breached their fiduciary duties as directors and/or officers of the Company and engaged in insider trading, waste of corporate assets, unjust enrichment and violations of Sections 14(a) and 20(a) of the Exchange Act. The suit seeks declaratory relief and to recover alleged damages sustained by the Company as a result of the alleged violations, along with the plaintiff&#8217;s costs incurred in the lawsuit, including reasonable attorneys&#8217; and experts&#8217; fees, costs and expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to defend itself vigorously, and believes that the Company has good and substantial defenses to the claims alleged in the suits, but there are no guarantees that the Company will prevail.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Insurance Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the Company filed a lawsuit against its Directors and Officers liability insurance carriers in San Mateo County Superior Court.  The Company seeks a declaration that costs and fees incurred by the Company in responding to governmental investigatory requests are covered under its policies.  The Company also asserts breach of contract against its primary insurer Great American Insurance Company for denying the claim.  The policies provide up to $15&#160;million in coverage limits.  The Company intends to vigorously pursue its claims.  The Company believes it has good and substantial support for its claims, but there is no guarantee that the Company will prevail in these claims.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795925390032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(K) Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(K) Plan</a></td>
<td class="text">401(K) PLANThe Company sponsors a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182NC9mcmFnOjE5MTc0ZWRlNzIyMTQzNzk5MGY3ZjY0YTAzNjU2YzA2L3RleHRyZWdpb246MTkxNzRlZGU3MjIxNDM3OTkwZjdmNjRhMDM2NTZjMDZfNDYx_ec00229a-4fdc-4dab-8f7d-959d1d68ae6f">401(k)</span> defined contribution plan (the "401(k) Plan") covering all U.S. employees under the Internal Revenue Code of 1986, as amended. Employee contributions to the 401(k) Plan are voluntary and are determined on an individual basis subject to the maximum allowable under federal tax regulations. The Company incurred expenses related to contributions to the 401(k) Plan of $0.7 million for each of the three months ended March 31, 2023 and 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795925315184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_WarrantsDisclosureTextBlock', window );">Warrants</a></td>
<td class="text">WARRANTS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues common stock warrants in connection with debt or equity financings to lenders, placement agents and investors. Issued warrants are considered standalone financial instruments and the terms of each warrant are analyzed for equity or liability classification in accordance with U.S. GAAP. Warrants that are classified as liabilities usually have various features that would require net-cash settlement by the Company. Warrants that are not liabilities, derivatives and/or meet the exception criteria are classified as equity. Warrants liabilities are remeasured at fair value at each period end with changes in fair value recorded in the condensed consolidated statements of operations until expired or exercised. Warrants that are classified as equity are valued at their relative fair value on the date of issuance, recorded in additional paid in capital and not remeasured.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended March 31, 2023 and 2022, no warrants to purchase shares of common stock were exercised.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, outstanding warrants to purchase common stock were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.355%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classified as</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Original Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Underlying Warrants</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original issue date:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,132&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_WarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_WarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795925290960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Incentive Plans</a></td>
<td class="text">STOCK INCENTIVE PLANS<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock Options and Restricted Stock Units (&#8220;RSU&#8221;)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option and RSU activity under the Company&#8217;s 2014 Equity Incentive Plan, 2016 Inducement Equity Incentive Plan, and 2019 Inducement Equity Incentive Plan, and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:37.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>Available<br/>for Grant</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>RSU Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance&#8212;December 31, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,490,462&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,921,925&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.13&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,094,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.39&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional shares authorized</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,141,330&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock awards for services</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,649)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,262,588)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262,588&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs vested</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170,077)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.76&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(418,564)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418,564&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(820)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.06&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock under employee incentive plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs forfeited</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,291&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,291)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,949&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,949)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options expired</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,024&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,024)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.81&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance&#8212;March 31, 2023</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,175,509&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248,696&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,095,616&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised was $0.0 million and $1.0 million for the three months ended March&#160;31, 2023 and 2022, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, the total intrinsic value of outstanding RSUs was approximately $38.8 million and there were $74.2 million of unrecognized compensation costs related to RSUs, which are expected to be recognized over a weighted-average period of 2.65 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding that have vested and are expected to vest at March&#160;31, 2023 are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Issued <br/>(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic&#160;Value<br/>(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,558&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.97</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,968&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&#8217;s common stock at March&#160;31, 2023 for stock options that were in-the-money.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of options that vested during the three months ended March&#160;31, 2023 was $4.2 million. As of March&#160;31, 2023, there were approximately $26.3 million of unrecognized compensation costs related to stock options, which are expected to be recognized over a weighted-average period of 3.02 years.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2014 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has an Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), under which employees can purchase shares of its common stock based on a percentage of their compensation, but not greater than 15% of their respective earnings; provided, however, an eligible employee&#8217;s right to purchase shares of the Company&#8217;s common stock may not accrue at a rate which exceeds $25,000 of the fair market value of such shares for each calendar year in which such rights are outstanding. The ESPP has consecutive offering periods of approximately six months in length. The purchase price per share must be equal to the lower of 85% of the fair value of the common stock on the first day of the offering period or on the exercise date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the offering period in 2022 that ended on December&#160;31, 2022, 47,025 shares were purchased pursuant to the ESPP for aggregate proceeds of $0.5 million from the issuance of such shares, which occurred on January 2, 2023.&#160;&#160;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Valuation Assumptions</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of employee stock options and ESPP shares were estimated using the Black-Scholes option pricing model based on the following weighted average assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.476%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee stock options</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.63%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.93%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.46%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.88%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.79%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.94%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.06%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free Interest Rate:&#160;The Company based the risk-free interest rate over the expected term of the award based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of grant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">:&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used an average historical stock price volatility of its own stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected Term: The expected term represents the period for which the Company&#8217;s stock-based compensation awards are expected to be outstanding and is based on analyzing the vesting and contractual terms of the awards and the holders&#8217; historical exercise patterns and termination behavior.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected Dividends</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has not paid and does not anticipate paying any dividends in the near future.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expense relating to employee and non-employee stock-based awards for the three months ended March&#160;31, 2023 and 2022, included in the condensed consolidated statements of operations as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.183%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of testing services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of patient and digital solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,814&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,754&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,634&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No tax benefit was recognized related to stock-based compensation expense since the Company has never reported taxable income and has established a full valuation allowance to offset all of the potential tax benefits associated with its deferred tax assets.&#160;&#160;In addition, no amounts of stock-based compensation expense were capitalized for the periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795925205104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective tax rate may vary from the U.S. federal statutory tax rate due to the change in the mix of earnings in tax jurisdictions with different statutory rates, benefits related to tax credits, and the tax impact of non-deductible expenses and other permanent differences between income before income taxes and taxable income.&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2023 and 2022, the Company recorded an income tax expense of $0.1 million and an income tax benefit of $12,000, respectively. The income tax expense of $0.1 million is primarily attributable to the U.S. current tax expense.&#160;The Company assesses the realizability of its net deferred tax assets by evaluating all available evidence, both positive and negative, including (i) cumulative results of operations in recent years, (ii) sources of recent losses, (iii) estimates of future taxable income, and (iv) the length of net operating loss carryforward periods. The Company believes that based on the history of its U.S. losses and other factors, the weight of available evidence indicates that it is more likely than not that it will not be able to realize its U.S. consolidated net deferred tax assets. The Company has also placed a valuation allowance on the net deferred tax assets of its Sweden operations. Accordingly, the U.S. and Sweden net deferred tax assets have been offset by a full valuation allowance.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795925319664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">SEGMENT REPORTING<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the Company's Chief Operating Decision Maker (&#8220;CODM&#8221;), or decision making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its Chief Executive Officer as the CODM. In determining its reportable segments, the Company considered the markets and types of customers served and the products or services provided in those markets. The Company operates in a single reportable segment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic regions are based upon the customers&#8217; ship-to address for product revenue and the region of testing for testing services revenue. The following table summarizes reportable revenues by geographic regions (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Testing services revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,784&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,444&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient and digital solutions revenue</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,617&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,184&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,880&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,989&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Europe</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,545&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Rest of World</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,262&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,416&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-lived assets, consisting of property and equipment, net, by geographic regions (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,506&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795925263504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">RESTRUCTURINGIn January 2023, the Company announced a restructuring plan that is intended to optimize costs and simplify its organizational and corporate structure. The restructuring plan includes the discontinuation of the Company's operations in Fremantle, Australia, terminating its employees in that location and vacating its facilities there. As a result of this plan, the Company incurred $0.06&#160;million in restructuring charges for the three months ended March&#160;31, 2023. The Company expects to complete the closure of its Australia location in June 2024.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795925220192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">SUBSEQUENT EVENT<div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Restructuring Plan</span></div><div style="margin-top:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, the Company announced a reduction of its U.S. workforce to simplify and streamline its organization and strengthen the overall effectiveness of its operations.  The restructuring charges are primarily related to employee severance pay and related costs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795928165680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_LiquidityPolicyTextBlock', window );">Liquidity and Capital Resources</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidity and Capital Resources</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred significant losses and negative cash flows from operations since its inception and had an accumulated deficit of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$484.9 million at March&#160;31, 2023. As of March&#160;31, 2023, the Company had cash, cash equivalents and marketable securities of $285.9 million and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no debt outstanding.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;), and follow the requirements of the SEC for interim reporting. As permitted under those rules, certain notes and other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company&#8217;s financial information. The condensed consolidated balance sheet as of December&#160;31, 2022 has been derived from audited consolidated financial statements as of that date but does not include all of the financial information required by U.S. GAAP for complete financial statements. Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to transaction price estimates used for testing services revenue; standalone fair value of patient and digital solutions revenue performance obligations; accrued expenses for clinical studies;&#160;inventory valuation;&#160;the fair value of issued common stock warrants and embedded derivatives; the fair value of assets and liabilities acquired in a business combination or an assets acquisition (including identifiable intangible assets acquired);&#160;the fair value of contingent consideration recorded in connection with a business combination or an asset acquisition; the grant date fair value assumptions used to estimate stock-based compensation expense; income taxes; impairment of long-lived assets and indefinite-lived assets (including goodwill); and legal contingencies. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Concentrations of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, approximately 42% and 54%, respectively, of total revenue was derived from Medicare. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, approximately 26% and 27%, respectively, of accounts receivable was due from Medicare. No other payer or customer represented more than 10% of accounts receivable at either March&#160;31, 2023 or December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketable Securities</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments in securities with a maturity of greater than three months at the time of purchase to be marketable securities. As of March&#160;31, 2023, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s short-term marketable securities consisted of corporate debt securities with maturities of greater than three months but less than twelve months at the time of purchase, which were classified as current assets on the condensed consolidated balance sheet</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its short-term marketable securities as held-to-maturity at the time of purchase and reevaluates such designation at each balance sheet date. The Company has the positive intent and ability to hold these marketable securities to maturity. Short-term marketable securities are carried at amortized cost and are adjusted for amortization of premiums and accretion of discounts to maturity, which is included i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n interest income (expense), net on the condensed consolidated statements of operations. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on short-term marketable securities are included in interest income (expense), net. The cost of securities sold will be determined using specific identification.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers investments in securities with remaining maturities of over one year as long-term investments. As of March&#160;31, 2023, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company's long-term marketable securities consisted of corporate equity securities and corporate debt securities. These long-term marketable securities are classified as other assets on the condensed consolidated balance sheet</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div>The Company classifies its long-term marketable debt securities as available-for-sale and reevaluates such designation at each balance sheet date. Unrealized gains and losses from the reevaluation of the long-term marketable debt securities, if any, are included in other comprehensive gain (loss) in the condensed consolidated statement of comprehensive income (loss). Realized gains and losses and declines in value judged to be other-than-temporary, if any, on long-term marketable securities are included in interest income, net.The Company records its long-term marketable equity securities at fair market value. Unrealized gains and losses from the remeasurement of the long-term marketable equity securities to fair value are included in other income (expense), net, in the condensed consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted Accounting Standard Codification (&#8220;ASC&#8221;) Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and determines if an arrangement is or contains a lease at contract inception. A right-of-use (&#8220;ROU&#8221;) asset, representing the underlying asset during the lease term, and a lease liability, representing the payment obligation arising from the lease, are recognized on the condensed consolidated balance sheet at lease commencement based on the present value of the payment obligation. For operating leases, expense is recognized on a straight-line basis over the lease term. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the ROU asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company's facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with an initial term of 12 months or less.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from testing services, product sales and patient and digital solutions revenue in the amount that reflects the consideration that it expects to be entitled in exchange for goods or services as it transfers control to its customers. Revenue is recorded considering a five-step revenue recognition model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations and recognizing revenue when, or as, an entity satisfies a performance obligation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Testing Services Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AlloSure Kidney, AlloMap Heart, AlloSure Heart and AlloSure Lung patient tests are ordered by healthcare providers. The Company receives a test requisition form with payer information along with a collected patient blood sample. The Company considers the patient to be its customer and the test requisition form to be the contract. Testing services are performed in the Company&#8217;s laboratory. Testing services represent one performance obligation in a contract and are performed when results of the test are provided to the healthcare provider, at a point in time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare providers that order the tests and on whose behalf the Company provides testing services are generally not responsible for the payment of these services. The first and second revenue recognition criteria are satisfied when the Company receives a test requisition form with payer information from the healthcare provider. Generally, the Company bills third-party payers upon delivery of an AlloSure Kidney, AlloMap Heart, AlloSure Heart or AlloSure Lung test result to the healthcare provider. Amounts received may vary amongst payers based on coverage practices and policies of the payer. The Company has used the portfolio approach under Accounting Standards Codification ("ASC") Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to identify financial classes of payers. Revenue recognized for Medicare and other contracted payers is based on the agreed current reimbursement rate per test, adjusted for historical collection trends where applicable. The Company estimates revenue for non-contracted payers and self-payers using transaction prices determined for each financial class of payers using history of reimbursements. This includes analysis of an average reimbursement per test and a percentage of tests reimbursed. This estimate requires significant judgment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors revenue estimates at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Changes in transaction price estimates are updated quarterly based on actual cash collected or changes made to contracted rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 2, 2023, MolDX issued a new Billing Article, with an effective date of March&#160;31, 2023. The Billing Article impacts Medicare coverage for AlloSure Kidney, AlloSure Heart and AlloMap and requires the Company to implement new processes to address requirements related to Medicare claim submissions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 606-10-25-1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> requires the Company to assess whether it is probable that it will collect substantially all of the consideration to which it will be entitled. Based upon the Company&#8217;s review of the Billing Article, it was determined to pause Medicare reimbursement submissions for AlloSure Kidney commencing on March&#160;7, 2023 that created uncertainty around the collection of the claims. Accordingly, the Company did not recognize revenue for approximately 3,200 AlloSure Kidney tests aggregating to $8.9 million for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is recognized from the sale of products to end-users, distributors and strategic partners when all revenue recognition criteria are satisfied. The Company generally has a contract or a purchase order from a customer with the specified required terms of order, including the number of products ordered. Transaction prices are determinable and products are delivered and risk of loss passed to the customer upon either shipping or delivery, as per the terms of the agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient and Digital Solutions Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient and digital solutions revenue is mainly derived from a combination of software as a service ("SaaS") and perpetual software license agreements entered into with various transplant centers, which are the Company's customers for this class of revenue. The main performance obligations in connection with the Company's SaaS and perpetual software license agreement are the following: (i) implementation services and delivery of the perpetual software license are considered a single performance obligation, and (ii) post contract support. The Company allocates the transaction price to each performance obligation based on relative stand-alone selling prices of each distinct performance obligation. Digital revenue in connection with perpetual software license agreements is recognized over time based on the Company&#8217;s satisfaction of each distinct performance obligation in each agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Perpetual software license agreements typically require advance payments from customers upon the achievement of certain milestones. The Company records deferred revenue in relation to these agreements when cash payments are received, or invoices are issued in advance of the Company&#8217;s performance, and generally recognizes revenue over the contractual term, as performance obligations are fulfilled.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company derives patient and digital solutions revenue from software subscriptions and medication sales. The Company generally bills software subscription fees in advance. Revenue from software subscriptions is deferred and recognized ratably over the subscription term. The medication sales revenue is recognized based on the negotiated contract price with the governmental, commercial and non-commercial payers with any applicable patient co-pay. The Company recognizes revenue from medication sales when prescriptions are delivered.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2021-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which contains amendments that require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model. The disclosures include (1) the types of assistance, (2) an entity&#8217;s accounting for the assistance, and (3) the effect of the assistance on an entity&#8217;s financial statements. The amendments set forth in this ASU are effective for all entities for annual periods beginning after December 15, 2021. Early application of the amendments in this ASU is permitted. The amendments in this ASU should be applied either (1) prospectively to all transactions within the scope of the amendments that are reflected in financial statements at the date of initial application and new transactions that are entered into after the date of initial application or (2) retrospectively to those transactions. The Company adopted the standard prospectively on January 1, 2022. The adoption of this new standard had no impact on the Company's consolidated financial statements and disclosures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires that an entity recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with ASC 606 as if it had originated the contracts. The amendments set forth in this ASU are effective for fiscal years beginning after December 15, 2022. Early adoption of the amendments is permitted. The amendments in this ASU should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company adopted the standard prospectively on January 1, 2022. The adoption of this new standard had no material impact on the Company's consolidated financial statements and disclosures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#8217;s Own Equity (Subtopic 815-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified </span></div>Written Call Options (a consensus of the FASB Emerging Issues Task Force), which contains amendments that clarify and reduce diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after modification or exchange. The amendments set forth in this ASU are effective for all entities for annual periods beginning after December 15, 2021. Early application of the amendments in this ASU is permitted for all entities. The amendments in this ASU should be applied prospectively. The Company adopted the standard prospectively on January 1, 2022. The adoption of this new standard had no impact on the Company's consolidated financial statements and disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_LiquidityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_LiquidityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795925279440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Computation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the computation of the Company&#8217;s basic and diluted net loss per share (in thousands, except shares and per share data):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:73.825%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.920%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss used to compute basic and diluted net loss per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,749)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,648)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used to compute basic and diluted net loss per share</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,643,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,015,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.44)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Potentially Dilutive Securities Excluded from Diluted Net Loss Per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from diluted net loss per share as of March&#160;31, 2023 and 2022 because their effect would be antidilutive:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock subject to outstanding options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,091,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock subject to outstanding common stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,096,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,047,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common stock equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,347,842&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,142,211&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795925210544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Fair Value of Financial Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the Company&#8217;s financial assets and liabilities, measured at fair value on a recurring basis, as of March&#160;31, 2023 and December&#160;31, 2022 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measured Using</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,587&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,587&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,939&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,939&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measured Using</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,670&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,670&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,475&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,475&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Issuances, Exercises, Changes in Fair Value and Reclassifications of Level 3 Financial Instruments</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the issuances, exercises, changes in fair value and reclassifications of the Company&#8217;s Level 3 financial instruments that are measured at fair value on a recurring basis (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Warrant Liability and Contingent Consideration</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2022</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in estimated fair value of common stock warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in estimated fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Addition of estimated fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments related to contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,939&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795925410640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the amount reported within the condensed consolidated statements of cash flows is shown in the table below (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,180&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,106&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding losses, and fair value of the Company&#8217;s marketable securities by major security type at each balance sheet date are summarized in the tables below (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,332&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,279&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,335&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,614&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,828)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,828)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,379&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,493)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,886&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Holding Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,601&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term marketable securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,168&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,924)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,924)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,168&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,692)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,476&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of the marketable securities at each balance sheet date are as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,279&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,168&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795925271728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock', window );">Summary of Identified Intangible Assets Acquired at Acquisition Date</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair values of the intangible assets acquired as of the acquisition date ($ in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:69.264%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.340%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Estimated Fair Value</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Estimated Useful Lives (Years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Customer relationships</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Developed technology</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Trademarks</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,100&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Summary of Fair Values of Assets Acquired and Liabilities Assumed as of Acquisition Date</a></td>
<td class="text">The following table summarizes the consideration paid for HLA Data Systems and the amounts of the assets acquired and liabilities assumed recognized at their estimated fair value at the acquisition date (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.076%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Consideration</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total consideration</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recognized amounts of identifiable assets acquired and liabilities assumed</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Identifiable intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(786)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Contingent considerations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total identifiable net assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,470&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total consideration</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,562&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795927284016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ScheduleOfIntangibleAssetsTableTableTextBlock', window );">Summary of Intangible Assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of the Company&#8217;s intangible assets as of March&#160;31, 2023 ($ in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:34.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Useful&#160;Life<br/>(In&#160;Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with finite lives:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired and developed technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,931)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,336)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,067)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercialization rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,549)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and tradenames</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,434)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets with finite lives</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,864&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,766)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,711)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,387&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,114&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,766)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,711)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,637&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of the Company&#8217;s intangible assets as of December&#160;31, 2022 ($ in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:34.582%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Currency Translation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Useful&#160;Life<br/>(In&#160;Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with finite lives:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired and developed technology</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,369)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,459)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercialization rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and tradenames</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(315)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets with finite lives</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,764&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,175)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,788)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,801&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,014&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,175)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,788)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,051&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Summary of Finite-Lived Intangible Assets Amortization Expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company's amortization expense of intangible assets (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of testing services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of patient and digital solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales &amp; marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,590&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,623&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Summary of Estimated Future Amortization Expense of Intangible Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s estimated future amortization expense of intangible assets with finite lives as of March&#160;31, 2023 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost of Testing Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost of Product</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost of Patient and Digital Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales and Marketing</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,077&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,076&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,420&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,975&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,916&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,387&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_ScheduleOfIntangibleAssetsTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_ScheduleOfIntangibleAssetsTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795925204672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventory</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,962&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,018&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Components of Accrued and Other Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other liabilities consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical studies</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,883&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred payments for intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalty</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory processing fees and materials </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other collaboration fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued shipping expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued and other liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,885&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,131&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795920413168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Cost</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the lease cost for the three months ended March 31, 2023 and 2022 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,983&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,983&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.789%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.05</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate (%)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the supplemental cash flow information related to leases for the three months ended March 31, 2023 and 2022 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used for operating leases</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,333&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock', window );">ROU Assets and Lease Liabilities for Lease Agreements</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the ROU assets and lease liabilities for certain lease agreements which commenced in July 2022 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,776&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the ROU assets and lease liabilities for certain lease agreements which commenced in August 2022 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Lease Commitments under Operating and Finance Leases</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities as of March&#160;31, 2023 are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,931&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,604&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,511&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,744&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less operating lease liability, current portion</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,738&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, long-term portion</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,006&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of finance lease and operating lease liability maturity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Right Of Use Assets And Lease Liabilities For Lease Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795925220192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Components of Warrants Outstanding</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, outstanding warrants to purchase common stock were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.355%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classified as</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Original Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Underlying Warrants</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original issue date:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2016</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,132&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795920409568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock', window );">Summary of Options, RSUs Activity under 2014 Equity Incentive Plan and 2016 Inducement Plan and Related Information</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option and RSU activity under the Company&#8217;s 2014 Equity Incentive Plan, 2016 Inducement Equity Incentive Plan, and 2019 Inducement Equity Incentive Plan, and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:37.225%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares<br/>Available<br/>for Grant</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>RSU Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance&#8212;December 31, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,490,462&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,921,925&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.13&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,094,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.39&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional shares authorized</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,141,330&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock awards for services</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,649)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,262,588)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262,588&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.27&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs vested</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170,077)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.76&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(418,564)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418,564&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(820)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.06&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock under employee incentive plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs forfeited</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,291&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,291)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,949&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,949)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options expired</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,024&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78,024)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.81&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance&#8212;March 31, 2023</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,175,509&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248,696&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,095,616&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock', window );">Summary of Options Outstanding and Exercisable Vested or Expected to Vest</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding that have vested and are expected to vest at March&#160;31, 2023 are as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares Issued <br/>(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic&#160;Value<br/>(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,558&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.97</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,968&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted-Average Assumptions Used to Estimate Fair Values of Share-Based Awards</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of employee stock options and ESPP shares were estimated using the Black-Scholes option pricing model based on the following weighted average assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.476%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee stock options</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.63%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.93%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.46%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.88%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.79%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.94%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.06%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Expense Relating to Employee and Nonemployee Stock-Based Payment Awards from Stock Options and RSUs</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expense relating to employee and non-employee stock-based awards for the three months ended March&#160;31, 2023 and 2022, included in the condensed consolidated statements of operations as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.183%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of testing services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of patient and digital solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,814&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,754&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,634&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of share based compensation stock options and unvested restricted stock units activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795927269360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Summary of Reportable Revenues by Geographic Regions</a></td>
<td class="text">The following table summarizes reportable revenues by geographic regions (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Testing services revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,784&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,444&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patient and digital solutions revenue</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,617&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,184&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total United States</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,880&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,989&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Europe</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,545&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Rest of World</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,262&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,416&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Summary of Long-Lived Assets Consisting of Property and Equipment, Net by Geographic Regions</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes long-lived assets, consisting of property and equipment, net, by geographic regions (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rest of World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,506&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795922998400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">23 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 08, 2022</div></th>
<th class="th">
<div>Apr. 14, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>Claim </div>
<div>unique_solution </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>Claim </div>
<div>unique_solution</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 03, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>patient</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_UnsubmittedReimbursementClaimsForMedicare', window );">Reimbursement claims | unique_solution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_UnsubmittedClaimsRevenueNotYetRecognized', window );">Revenue not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,900,000<span></span>
</td>
<td class="nump">$ 8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_NumberOfRenalTransplantPatients', window );">Number of renal transplant patients (more than) | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484,883,000<span></span>
</td>
<td class="nump">484,883,000<span></span>
</td>
<td class="nump">$ 460,444,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,900,000<span></span>
</td>
<td class="nump">285,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramPeriodInForce1', window );">Stock repurchase program, period in force</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Number of common stock purchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stock repurchased value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock repurchase program, remaining authorized repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,700,000<span></span>
</td>
<td class="nump">48,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cdna_MiromatrixIncMember', window );">Miromatrix, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Payments to acquire minority interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cdna_AtTheMarketEquityOfferingMember', window );">At The Market Equity Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_SaleOfStockAuthorizedConsiderationAmountMaximum', window );">Sale of stock amount maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_SaleOfStockCommissionFeePercentage', window );">Sale of stock, commission fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cdna_XynManagementIncMember', window );">XynManagement, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_NumberOfUniqueSolutions', window );">Number of unique solutions | unique_solution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=cdna_MedicareMember', window );">Medicare | AlloSure Kidney</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecoveryOfDirectCosts', window );">Reimbursement rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_UnsubmittedReimbursementClaimsForMedicare', window );">Reimbursement claims | Claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=cdna_MedicareMember', window );">Medicare | AlloMap Heart</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecoveryOfDirectCosts', window );">Reimbursement rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=cdna_MedicareMember', window );">Medicare | AlloSure Heart</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule of Capitalization, Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RecoveryOfDirectCosts', window );">Reimbursement rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_NumberOfRenalTransplantPatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Renal Transplant Patients</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_NumberOfRenalTransplantPatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_NumberOfUniqueSolutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Unique Solutions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_NumberOfUniqueSolutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_SaleOfStockAuthorizedConsiderationAmountMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Authorized Consideration Amount, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_SaleOfStockAuthorizedConsiderationAmountMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_SaleOfStockCommissionFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Commission Fee Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_SaleOfStockCommissionFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_UnsubmittedClaimsRevenueNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unsubmitted Claims, Revenue Not Yet Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_UnsubmittedClaimsRevenueNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_UnsubmittedReimbursementClaimsForMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unsubmitted Reimbursement Claims For Medicare</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_UnsubmittedReimbursementClaimsForMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecoveryOfDirectCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecoveryOfDirectCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCapitalizationEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCapitalizationEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramPeriodInForce1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramPeriodInForce1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cdna_MiromatrixIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cdna_MiromatrixIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cdna_AtTheMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cdna_AtTheMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cdna_XynManagementIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cdna_XynManagementIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cdna_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cdna_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdna_AlloSureKidneyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdna_AlloSureKidneyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdna_AlloMapHeartMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdna_AlloMapHeartMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdna_AlloSureHeartMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdna_AlloSureHeartMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795928219632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Concentration of Credit Risk (Details) - Medicare<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=cdna_MedicareMember', window );">Revenue Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">42.00%<span></span>
</td>
<td class="nump">54.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=cdna_MedicareMember', window );">Accounts Receivable | Credit Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cdna_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cdna_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795928919744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Leases (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_RemainingOperatingAndFinanceLeaseTerm', window );">Remaining lease terms</a></td>
<td class="text">8 months 1 day<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_RemainingOperatingAndFinanceLeaseTerm', window );">Remaining lease terms</a></td>
<td class="text">9 years 10 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_RemainingOperatingAndFinanceLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining operating and finance lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_RemainingOperatingAndFinanceLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795925271600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>unique_solution</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_UnsubmittedReimbursementClaimsForMedicare', window );">Reimbursement claims | unique_solution</a></td>
<td class="nump">3,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_UnsubmittedClaimsRevenueNotYetRecognized', window );">Revenue not yet recognized | $</a></td>
<td class="nump">$ 8.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_UnsubmittedClaimsRevenueNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unsubmitted Claims, Revenue Not Yet Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_UnsubmittedClaimsRevenueNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_UnsubmittedReimbursementClaimsForMedicare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unsubmitted Reimbursement Claims For Medicare</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_UnsubmittedReimbursementClaimsForMedicare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795920377120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss used to compute basic net loss per share</a></td>
<td class="num">$ (23,749)<span></span>
</td>
<td class="num">$ (19,648)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss used to compute diluted net loss per share</a></td>
<td class="num">$ (23,749)<span></span>
</td>
<td class="num">$ (19,648)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used to compute basic net loss per share (in shares)</a></td>
<td class="nump">53,643,216<span></span>
</td>
<td class="nump">53,015,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used to compute diluted net loss per share (in shares)</a></td>
<td class="nump">53,643,216<span></span>
</td>
<td class="nump">53,015,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_EarningPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_EarningPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share Basic And Diluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_EarningPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share Basic And Diluted Other Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795920376640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive securities excluded from diluted net loss per share attributable to common stockholders (in shares)</a></td>
<td class="nump">7,347,842<span></span>
</td>
<td class="nump">4,142,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cdna_EmployeeAndNonEmployeeStockOptionsMember', window );">Shares of common stock subject to outstanding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive securities excluded from diluted net loss per share attributable to common stockholders (in shares)</a></td>
<td class="nump">3,248,696<span></span>
</td>
<td class="nump">2,091,422<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Shares of common stock subject to outstanding common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive securities excluded from diluted net loss per share attributable to common stockholders (in shares)</a></td>
<td class="nump">3,132<span></span>
</td>
<td class="nump">3,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive securities excluded from diluted net loss per share attributable to common stockholders (in shares)</a></td>
<td class="nump">4,096,014<span></span>
</td>
<td class="nump">2,047,657<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cdna_EmployeeAndNonEmployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cdna_EmployeeAndNonEmployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795920115792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Short-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration</a></td>
<td class="nump">$ 825<span></span>
</td>
<td class="nump">$ 1,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">56,587<span></span>
</td>
<td class="nump">68,670<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Short-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration</a></td>
<td class="nump">825<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">4,089<span></span>
</td>
<td class="nump">2,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_CommonStockWarrantLiability', window );">Common stock warrant liability</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,939<span></span>
</td>
<td class="nump">3,475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">55,315<span></span>
</td>
<td class="nump">66,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Corporate equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Corporate equity securities</a></td>
<td class="nump">1,272<span></span>
</td>
<td class="nump">2,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value Measured Using - (Level 1) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">56,587<span></span>
</td>
<td class="nump">68,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Short-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_CommonStockWarrantLiability', window );">Common stock warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value Measured Using - (Level 1) | Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">55,315<span></span>
</td>
<td class="nump">66,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value Measured Using - (Level 1) | Recurring | Corporate equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Corporate equity securities</a></td>
<td class="nump">1,272<span></span>
</td>
<td class="nump">2,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value Measured Using - (Level 2) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Short-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_CommonStockWarrantLiability', window );">Common stock warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value Measured Using - (Level 2) | Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value Measured Using - (Level 2) | Recurring | Corporate equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Corporate equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value Measured Using - (Level 3) | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Short-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration</a></td>
<td class="nump">825<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">4,089<span></span>
</td>
<td class="nump">2,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_CommonStockWarrantLiability', window );">Common stock warrant liability</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">4,939<span></span>
</td>
<td class="nump">3,475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value Measured Using - (Level 3) | Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value Measured Using - (Level 3) | Recurring | Corporate equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Corporate equity securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_CommonStockWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_CommonStockWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795928216720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Issuances, Exercises, Changes in Fair Value and Reclassifications of Level 3 Financial Instruments (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Common Stock Warrant Liability and Contingent Consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 3,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">4,939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=cdna_CommonStockWarrantLiabilityMember', window );">Common Stock Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Common Stock Warrant Liability and Contingent Consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in estimated fair value of common stock warrant liability and contingent consideration</a></td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=cdna_ContingentConsiderationMember', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Common Stock Warrant Liability and Contingent Consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in estimated fair value of common stock warrant liability and contingent consideration</a></td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements', window );">Addition of estimated fair value of contingent consideration</a></td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements', window );">Payments related to contingent consideration</a></td>
<td class="num">$ (250)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a derivative asset (liability) after deduction of derivative liability, measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=cdna_CommonStockWarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=cdna_CommonStockWarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=cdna_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=cdna_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795928142928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narratives (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">Write-off of investments in convertible preferred shares</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate', window );">Contingent consideration, measurement input, discount rate</a></td>
<td class="nump">0.07<span></span>
</td>
<td class="nump">0.12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability, Measurement Input, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795928272576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Marketable Securities - Reconciliation of Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 74,660<span></span>
</td>
<td class="nump">$ 89,921<span></span>
</td>
<td class="nump">$ 171,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">520<span></span>
</td>
<td class="nump">522<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash at the end of the period</a></td>
<td class="nump">$ 75,180<span></span>
</td>
<td class="nump">$ 90,443<span></span>
</td>
<td class="nump">$ 172,106<span></span>
</td>
<td class="nump">$ 348,696<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795920204160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Marketable Securities - Components of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ShortTermMarketableSecuritiesAbstract', window );"><strong>Short-term marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_MarketableSecuritiesAmortizedCostShortTerm', window );">Amortized Cost</a></td>
<td class="nump">$ 211,279<span></span>
</td>
<td class="nump">$ 203,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm', window );">Unrealized Holding Losses</a></td>
<td class="nump">1,335<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_MarketableSecuritiesFairValueShortTerm', window );">Fair Value</a></td>
<td class="nump">212,614<span></span>
</td>
<td class="nump">203,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_LongTermMarketableSecuritiesAbstract', window );"><strong>Long-term marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_MarketableSecuritiesAmortizedCostLongTerm', window );">Amortized Cost</a></td>
<td class="nump">5,100<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm', window );">Unrealized Holding Losses</a></td>
<td class="num">(3,828)<span></span>
</td>
<td class="num">(2,924)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_MarketableSecuritiesFairValueLongTerm', window );">Fair Value</a></td>
<td class="nump">1,272<span></span>
</td>
<td class="nump">2,076<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_MarketableSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">216,379<span></span>
</td>
<td class="nump">208,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss', window );">Unrealized Holding Losses</a></td>
<td class="num">(2,493)<span></span>
</td>
<td class="num">(2,692)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Fair Value</a></td>
<td class="nump">213,886<span></span>
</td>
<td class="nump">205,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ShortTermMarketableSecuritiesAbstract', window );"><strong>Short-term marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss', window );">Debt securities, amortized cost</a></td>
<td class="nump">92,947<span></span>
</td>
<td class="nump">79,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Unrealized holding gain</a></td>
<td class="nump">1,222<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Debt securities, fair value</a></td>
<td class="nump">94,169<span></span>
</td>
<td class="nump">79,799<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ShortTermMarketableSecuritiesAbstract', window );"><strong>Short-term marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss', window );">Debt securities, amortized cost</a></td>
<td class="nump">118,332<span></span>
</td>
<td class="nump">123,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Unrealized holding gain</a></td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Unrealized holding loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(220)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Debt securities, fair value</a></td>
<td class="nump">118,445<span></span>
</td>
<td class="nump">123,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_LongTermMarketableSecuritiesAbstract', window );"><strong>Long-term marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, unrealized holding gains (losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Corporate equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_LongTermMarketableSecuritiesAbstract', window );"><strong>Long-term marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Equity securities, amortized cost</a></td>
<td class="nump">5,100<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax', window );">Equity securities, unrealized holding gains (losses)</a></td>
<td class="num">(3,828)<span></span>
</td>
<td class="num">(2,924)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Corporate equity securities</a></td>
<td class="nump">$ 1,272<span></span>
</td>
<td class="nump">$ 2,076<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Accumulated Gross Unrealized Gain (Loss), Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_LongTermMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Marketable Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_LongTermMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Accumulated Unrecognized Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Accumulated Unrecognized Holding Gain (Loss), Long Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Accumulated Unrecognized Holding Gain (Loss), Short Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_MarketableSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_MarketableSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_MarketableSecuritiesAmortizedCostLongTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Amortized Cost, Long Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_MarketableSecuritiesAmortizedCostLongTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_MarketableSecuritiesAmortizedCostShortTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Amortized Cost, Short Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_MarketableSecuritiesAmortizedCostShortTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_MarketableSecuritiesFairValueLongTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Fair Value, Long Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_MarketableSecuritiesFairValueLongTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_MarketableSecuritiesFairValueShortTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Fair Value, Short Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_MarketableSecuritiesFairValueShortTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_ShortTermMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-Term Marketable Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_ShortTermMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795920373488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Marketable Securities - Schedule of Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount', window );">Within one year</a></td>
<td class="nump">$ 211,279<span></span>
</td>
<td class="nump">$ 203,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount', window );">After one year through five years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Amortized Cost</a></td>
<td class="nump">$ 211,279<span></span>
</td>
<td class="nump">$ 203,168<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62586-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795922552288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,615<span></span>
</td>
<td class="nump">$ 37,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cdna_HLADataSystemsMember', window );">HLA Data Systems</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 4,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">2,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill expected to be deductible for income tax purposes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_IntangibleAssetMeasurementInputDiscountRate', window );">Intangible asset, measurement input, discount rate</a></td>
<td class="nump">0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cdna_HLADataSystemsMember', window );">HLA Data Systems | Developed Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_IntangibleAssetMeasurementInputRoyaltyRate', window );">Intangible asset, measurement input, royalty rate</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cdna_HLADataSystemsMember', window );">HLA Data Systems | Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_IntangibleAssetMeasurementInputRoyaltyRate', window );">Intangible asset, measurement input, royalty rate</a></td>
<td class="nump">0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_IntangibleAssetMeasurementInputDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset, Measurement Input, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_IntangibleAssetMeasurementInputDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_IntangibleAssetMeasurementInputRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset, Measurement Input, Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_IntangibleAssetMeasurementInputRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cdna_HLADataSystemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cdna_HLADataSystemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795919987504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Summary of Identified Intangible Assets Acquired at Acquisition Date (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cdna_HLADataSystemsMember', window );">HLA Data Systems</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure', window );">Finite-Lived Intangible Assets, Fair Value Disclosure</a></td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 6 months<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | HLA Data Systems</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure', window );">Finite-Lived Intangible Assets, Fair Value Disclosure</a></td>
<td class="nump">$ 3,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology | HLA Data Systems</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure', window );">Finite-Lived Intangible Assets, Fair Value Disclosure</a></td>
<td class="nump">$ 770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks | HLA Data Systems</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure', window );">Finite-Lived Intangible Assets, Fair Value Disclosure</a></td>
<td class="nump">$ 320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cdna_HLADataSystemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cdna_HLADataSystemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795927383872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Summary of Consideration Paid and Provisional Amounts of Assets Acquired and Liabilities Assumed Recognized at Their Estimated Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,615<span></span>
</td>
<td class="nump">$ 37,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=cdna_HLADataSystemsMember', window );">HLA Data Systems</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business Combination, Consideration Transferred, Total</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 4,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets</a></td>
<td class="nump">1,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</a></td>
<td class="num">(786)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Other current liabilities</a></td>
<td class="num">(699)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion', window );">Contingent considerations</a></td>
<td class="num">(1,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other liabilities</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total</a></td>
<td class="nump">2,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">2,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total</a></td>
<td class="nump">$ 4,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Contingent Considerations, Less Current Portion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=cdna_HLADataSystemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=cdna_HLADataSystemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795927351776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,523<span></span>
</td>
<td class="nump">$ 39,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Assets acquired</a></td>
<td class="nump">$ 13,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cdna_CommercializationRightsMember', window );">Commercialization rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Assets acquired</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cdna_AcquiredAndDevelopedTechnologyMember', window );">Acquired and developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Assets acquired</a></td>
<td class="nump">4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Assets acquired</a></td>
<td class="nump">3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and tradenames</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Assets acquired</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_GoodwillAndIntangibleAssetsLineItems', window );"><strong>Goodwill And Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Assets acquired</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_GoodwillAndIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_GoodwillAndIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cdna_CommercializationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cdna_CommercializationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cdna_AcquiredAndDevelopedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cdna_AcquiredAndDevelopedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795920122720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Summary of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with finite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 77,864<span></span>
</td>
<td class="nump">$ 73,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(28,766)<span></span>
</td>
<td class="num">(27,175)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_FiniteLivedIntangibleForeignCurrencyTranslation', window );">Foreign Currency Translation</a></td>
<td class="num">(4,711)<span></span>
</td>
<td class="num">(4,788)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization expense</a></td>
<td class="nump">44,387<span></span>
</td>
<td class="nump">41,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets - gross carrying amount</a></td>
<td class="nump">79,114<span></span>
</td>
<td class="nump">75,014<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets, net</a></td>
<td class="nump">45,637<span></span>
</td>
<td class="nump">43,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cdna_AcquiredInProcessTechnologyMember', window );">Acquired in-process technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net carrying amount</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cdna_AcquiredAndDevelopedTechnologyMember', window );">Acquired and developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with finite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">36,517<span></span>
</td>
<td class="nump">35,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(15,931)<span></span>
</td>
<td class="num">(15,138)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_FiniteLivedIntangibleForeignCurrencyTranslation', window );">Foreign Currency Translation</a></td>
<td class="num">(2,336)<span></span>
</td>
<td class="num">(2,369)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization expense</a></td>
<td class="nump">$ 18,250<span></span>
</td>
<td class="nump">$ 18,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Remaining Useful&#160;Life (In&#160;Years)</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with finite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 24,908<span></span>
</td>
<td class="nump">$ 21,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(7,852)<span></span>
</td>
<td class="num">(7,459)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_FiniteLivedIntangibleForeignCurrencyTranslation', window );">Foreign Currency Translation</a></td>
<td class="num">(2,067)<span></span>
</td>
<td class="num">(2,104)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization expense</a></td>
<td class="nump">$ 14,989<span></span>
</td>
<td class="nump">$ 12,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Remaining Useful&#160;Life (In&#160;Years)</a></td>
<td class="text">9 years 6 months<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cdna_CommercializationRightsMember', window );">Commercialization rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with finite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 11,579<span></span>
</td>
<td class="nump">$ 11,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(3,549)<span></span>
</td>
<td class="num">(3,233)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_FiniteLivedIntangibleForeignCurrencyTranslation', window );">Foreign Currency Translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization expense</a></td>
<td class="nump">$ 8,030<span></span>
</td>
<td class="nump">$ 8,346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Remaining Useful&#160;Life (In&#160;Years)</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and tradenames</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with finite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 4,860<span></span>
</td>
<td class="nump">$ 4,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,434)<span></span>
</td>
<td class="num">(1,345)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_FiniteLivedIntangibleForeignCurrencyTranslation', window );">Foreign Currency Translation</a></td>
<td class="num">(308)<span></span>
</td>
<td class="num">(315)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization expense</a></td>
<td class="nump">$ 3,118<span></span>
</td>
<td class="nump">$ 2,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted Average Remaining Useful&#160;Life (In&#160;Years)</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_FiniteLivedIntangibleForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite Lived Intangible Foreign Currency Translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_FiniteLivedIntangibleForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cdna_AcquiredInProcessTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cdna_AcquiredInProcessTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cdna_AcquiredAndDevelopedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cdna_AcquiredAndDevelopedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cdna_CommercializationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cdna_CommercializationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795920117088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Summary of Finite-Lived Intangible Assets Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of intangible assets</a></td>
<td class="nump">$ 1,590<span></span>
</td>
<td class="nump">$ 1,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=cdna_CostOfTestingMember', window );">Cost of Testing Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of intangible assets</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=cdna_CostOfProductMember', window );">Cost of Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of intangible assets</a></td>
<td class="nump">418<span></span>
</td>
<td class="nump">453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=cdna_CostOfPatientAndDigitalSolutionsMember', window );">Cost of Patient and Digital Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of intangible assets</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales &amp; marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of intangible assets</a></td>
<td class="nump">$ 595<span></span>
</td>
<td class="nump">$ 605<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=cdna_CostOfTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=cdna_CostOfTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=cdna_CostOfProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=cdna_CostOfProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=cdna_CostOfPatientAndDigitalSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=cdna_CostOfPatientAndDigitalSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795926797856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Summary of Estimated Future Amortization Expense of Intangible Assets with Finite Lives (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">$ 4,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">6,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">6,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">5,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">5,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">16,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization expense</a></td>
<td class="nump">44,387<span></span>
</td>
<td class="nump">$ 41,801<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=cdna_CostOfTestingMember', window );">Cost of Testing Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">1,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">1,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">1,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">1,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">2,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization expense</a></td>
<td class="nump">9,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=cdna_CostOfProductMember', window );">Cost of Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">1,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">1,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">1,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">3,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization expense</a></td>
<td class="nump">9,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=cdna_CostOfPatientAndDigitalSolutionsMember', window );">Cost of Patient and Digital Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">1,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization expense</a></td>
<td class="nump">4,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and Marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">1,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">2,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">2,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">2,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">2,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">9,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization expense</a></td>
<td class="nump">$ 20,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=cdna_CostOfTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=cdna_CostOfTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=cdna_CostOfProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=cdna_CostOfProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=cdna_CostOfPatientAndDigitalSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=cdna_CostOfPatientAndDigitalSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795926467200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Summary of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">$ 3,247<span></span>
</td>
<td class="nump">$ 2,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">4,713<span></span>
</td>
<td class="nump">4,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">10,058<span></span>
</td>
<td class="nump">11,964<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 18,018<span></span>
</td>
<td class="nump">$ 19,232<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795927407936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Components of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_AccruedClinicalAndCostOfOtherStudiesCurrent', window );">Clinical studies</a></td>
<td class="nump">$ 13,883<span></span>
</td>
<td class="nump">$ 14,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">8,262<span></span>
</td>
<td class="nump">6,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term lease liability</a></td>
<td class="nump">5,738<span></span>
</td>
<td class="nump">5,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">5,841<span></span>
</td>
<td class="nump">5,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_DeferredPaymentsForIntangibleAssets', window );">Deferred payments for intangible assets</a></td>
<td class="nump">2,641<span></span>
</td>
<td class="nump">2,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalty</a></td>
<td class="nump">2,087<span></span>
</td>
<td class="nump">4,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_AccruedSampleProcessingFees', window );">Laboratory processing fees and materials</a></td>
<td class="nump">1,760<span></span>
</td>
<td class="nump">2,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_AccruedLicenseAndOtherCollaborationFees', window );">License and other collaboration fees</a></td>
<td class="nump">1,017<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration</a></td>
<td class="nump">825<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_AccruedShippingExpenses', window );">Accrued shipping expenses</a></td>
<td class="nump">459<span></span>
</td>
<td class="nump">489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_AccruedCapitalExpenditures', window );">Capital expenditures</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">4,372<span></span>
</td>
<td class="nump">4,553<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">$ 46,885<span></span>
</td>
<td class="nump">$ 49,131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_AccruedCapitalExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Capital Expenditures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_AccruedCapitalExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_AccruedClinicalAndCostOfOtherStudiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical And Cost Of Other Studies Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_AccruedClinicalAndCostOfOtherStudiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_AccruedLicenseAndOtherCollaborationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued License And Other Collaboration Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_AccruedLicenseAndOtherCollaborationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_AccruedSampleProcessingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Sample Processing Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_AccruedSampleProcessingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_AccruedShippingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Shipping Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_AccruedShippingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_DeferredPaymentsForIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred payments for intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_DeferredPaymentsForIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795923687872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 13, 2022 </div>
<div>complaint</div>
</th>
<th class="th">
<div>Mar. 14, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2014 </div>
<div>milestone_payment</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating leases right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, less current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accrued and other liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Decrease in ROU asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating lease, impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_NumberOfMilestonePayments', window );">Number of milestone payments | milestone_payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MalpracticeInsuranceMaximumCoveragePerIncident', window );">Insurance matter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cdna_CAREDXINCVsNateraIncMember', window );">CAREDX, INC. vs Natera Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of claims field | complaint</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cdna_CAREDXINCVsNateraIncMember', window );">CAREDX, INC. vs Natera Inc. | Compensatory Damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=cdna_CAREDXINCVsNateraIncMember', window );">CAREDX, INC. vs Natera Inc. | Punitive Damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_NumberOfMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_NumberOfMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MalpracticeInsuranceMaximumCoveragePerIncident">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum coverage per malpractice claim provided by the insurance arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MalpracticeInsuranceMaximumCoveragePerIncident</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cdna_CAREDXINCVsNateraIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cdna_CAREDXINCVsNateraIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesByNatureAxis=cdna_CompensatoryDamagesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesByNatureAxis=cdna_CompensatoryDamagesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesByNatureAxis=cdna_PunitiveDamagesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesByNatureAxis=cdna_PunitiveDamagesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795925163136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,983<span></span>
</td>
<td class="nump">$ 1,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 1,983<span></span>
</td>
<td class="nump">$ 1,413<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795928961792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Other Information Related to Lease (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_LeaseOtherInformationAbstract', window );"><strong>Other information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">6 years 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - Operating leases (%)</a></td>
<td class="nump">7.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_LeaseOtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease other information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_LeaseOtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795926944528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summarizes ROU Assets and Lease Liabilities for Lease Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU assets</a></td>
<td class="nump">$ 33,431<span></span>
</td>
<td class="nump">$ 34,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">37,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=cdna_LeasesCommencedInJuly2022Member', window );">Leases, Commenced In July 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU assets</a></td>
<td class="nump">13,776<span></span>
</td>
<td class="nump">14,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">14,773<span></span>
</td>
<td class="nump">15,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=cdna_LeasesCommencedInAugust2022Member', window );">Leases, Commenced In August 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU assets</a></td>
<td class="nump">5,698<span></span>
</td>
<td class="nump">5,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">$ 5,937<span></span>
</td>
<td class="nump">$ 6,005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=cdna_LeasesCommencedInJuly2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=cdna_LeasesCommencedInJuly2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=cdna_LeasesCommencedInAugust2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=cdna_LeasesCommencedInAugust2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795926948032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Future Minimum Lease Commitments under Operating and Finance Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">$ 5,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">7,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">7,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">7,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">7,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">10,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">46,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="nump">8,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">37,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less operating lease liability, current portion</a></td>
<td class="nump">5,738<span></span>
</td>
<td class="nump">$ 5,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, long-term portion</a></td>
<td class="nump">$ 32,006<span></span>
</td>
<td class="nump">$ 33,406<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795929063152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Summarizes the Noncash Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows used for operating leases</a></td>
<td class="nump">$ 1,333<span></span>
</td>
<td class="nump">$ 972<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795925279312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(K) Plan - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTypeExtensibleList', window );">Defined benefit plan, type</a></td>
<td class="text">Postemployment Retirement Benefits [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expense incurred related to plan</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanTypeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of defined benefit plan. Includes, but is not limited to, pension plan, other postretirement plan and special and contractual termination benefits payable upon retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(6)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(6)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(8)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(B)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(A)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2410-114920<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(6)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2919-114920<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (n)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6410066&amp;loc=d3e79218-111664<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6410066&amp;loc=d3e79218-111664<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(C)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(9)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(8)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanTypeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795923292848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants and Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_NumberOfWarrantsExercised', window );">Number of warrants exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795923294208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Outstanding Warrants To Purchase Common Stock Warrants (Detail) - Common Stock<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares underlying warrants (in shares) | shares</a></td>
<td class="nump">3,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Original Term</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_WarrantFairValueAssumptionsExpectedTerm', window );">Original Term (in years)</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_WarrantFairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant fair value assumptions expected term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_WarrantFairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795923054128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Summary of Option, Unvested RSU Activity under 2014 Equity Incentive Plan and 2016 Inducement Equity Incentive Plan and Related Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward', window );"><strong>Shares Available for Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant beginning balance (in shares)</a></td>
<td class="nump">1,490,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional options authorized (in shares)</a></td>
<td class="nump">2,141,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices', window );">Common stock awards for services (in shares)</a></td>
<td class="num">(7,649)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (in shares)</a></td>
<td class="num">(1,262,588)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="num">(418,564)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans', window );">Repurchase of common stock under employee incentive plans (in shares)</a></td>
<td class="nump">50,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs forfeited (in shares)</a></td>
<td class="nump">91,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (in shares)</a></td>
<td class="nump">12,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options expired (in shares)</a></td>
<td class="nump">78,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant ending balance (in shares)</a></td>
<td class="nump">2,175,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward', window );"><strong>Stock Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding beginning balance (in shares)</a></td>
<td class="nump">2,921,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="nump">418,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="num">(820)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock options forfeited (in shares)</a></td>
<td class="num">(12,949)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Stock options expired (in shares)</a></td>
<td class="num">(78,024)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding ending balance (in shares)</a></td>
<td class="nump">3,248,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 28.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price - options granted (in dollars per share) | $ / shares</a></td>
<td class="nump">15.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price - options exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">2.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price - options forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">31.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price - options expired (in dollars per share) | $ / shares</a></td>
<td class="nump">33.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 26.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward', window );"><strong>Number of RSU Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (in shares)</a></td>
<td class="nump">1,262,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs forfeited (in shares)</a></td>
<td class="num">(91,291)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward', window );"><strong>Shares Available for Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (in shares)</a></td>
<td class="num">(1,262,588)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs forfeited (in shares)</a></td>
<td class="nump">91,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward', window );"><strong>Number of RSU Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSU shares beginning balance (in shares)</a></td>
<td class="nump">3,094,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (in shares)</a></td>
<td class="nump">1,262,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs vested (in shares)</a></td>
<td class="num">(170,077)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs forfeited (in shares)</a></td>
<td class="num">(91,291)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSU shares ending balance (in shares)</a></td>
<td class="nump">4,095,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 37.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value - RSUs granted (in dollars per share) | $ / shares</a></td>
<td class="nump">15.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value - RSUs vested (in dollars per share) | $ / shares</a></td>
<td class="nump">52.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value - RSUs forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">36.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 29.87<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award common stock awards for services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Non-Option Equity Instruments, Available For Grant</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Number Of RSU Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Number Of Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award, repurchases of common stock under employee incentive plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795943766432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share-based compensation expense tax benefit recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Share-based compensation expense capitalized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdna_TwoThousandAndFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum portion of earning an employee may contribute to the ESPP Plan</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum', window );">Maximum value of shares which an employee can purchase per calendar year</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period for employee stock purchases</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate', window );">Applicable exercise date an offering period shall be equal to percentage of the lower of fair market value of common stock</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Aggregate proceeds from the issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Intrinsic value of RSUs</a></td>
<td class="nump">$ 38,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation costs related to stock options and RSUs</a></td>
<td class="nump">$ 74,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options and RSUs expected weighted average period</a></td>
<td class="text">2 years 7 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation costs related to stock options and RSUs</a></td>
<td class="nump">$ 26,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Stock options and RSUs expected weighted average period</a></td>
<td class="text">3 years 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of options vested during period</a></td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value amount of outstanding stock maximum.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on offering date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cdna_TwoThousandAndFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cdna_TwoThousandAndFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795922916368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Summary of Options Outstanding Vested and Expected to Vest (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber', window );">Vested (in shares) | shares</a></td>
<td class="nump">1,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber', window );">Expected to vest (in shares) | shares</a></td>
<td class="nump">1,695<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Total (in shares) | shares</a></td>
<td class="nump">2,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 25.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice', window );">Expected to vest (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 27.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm', window );">Vested, weighted average remaining life</a></td>
<td class="text">5 years 8 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm', window );">Expected to vest, weighted average remaining contractual life</a></td>
<td class="text">8 years 11 months 19 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue', window );">Vested, aggregate intrinsic value | $</a></td>
<td class="nump">$ 1,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue', window );">Expected to vest, aggregate intrinsic value | $</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Total | $</a></td>
<td class="nump">$ 1,561<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options expected to vest outstanding aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options expected to vest outstanding number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options expected to vest outstanding weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options expected to vest weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested outstanding aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested outstanding number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795920303888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Summary of Weighted-Average Assumptions Used to Estimated Fair Values of Share-Based Awards (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">77.88%<span></span>
</td>
<td class="nump">67.79%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.94%<span></span>
</td>
<td class="nump">1.06%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">78.63%<span></span>
</td>
<td class="nump">76.93%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.46%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795926452528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Incentive Plans - Summary of Expense Relating to Employee and Nonemployee Stock-Based Payment Awards from Stock Options and RSUs (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">$ 13,754<span></span>
</td>
<td class="nump">$ 10,634<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=cdna_CostOfTestingMember', window );">Cost of testing services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">479<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=cdna_CostOfProductMember', window );">Cost of product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=cdna_CostOfPatientAndDigitalSolutionsMember', window );">Cost of patient and digital solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">1,962<span></span>
</td>
<td class="nump">2,190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember', window );">Sales and marketing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">3,737<span></span>
</td>
<td class="nump">3,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense</a></td>
<td class="nump">$ 6,814<span></span>
</td>
<td class="nump">$ 4,982<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=cdna_CostOfTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=cdna_CostOfTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=cdna_CostOfProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=cdna_CostOfProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=cdna_CostOfPatientAndDigitalSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=cdna_CostOfPatientAndDigitalSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795928291488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdna_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdna_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdna_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdna_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795920148112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Summary of Reportable Revenues by Geographic Regions (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 77,262<span></span>
</td>
<td class="nump">$ 79,416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">73,880<span></span>
</td>
<td class="nump">75,989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">2,545<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=cdna_RestOfTheWorldMember', window );">Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">837<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Testing services revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">61,784<span></span>
</td>
<td class="nump">66,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Testing services revenue | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">61,647<span></span>
</td>
<td class="nump">66,223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Testing services revenue | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">6,861<span></span>
</td>
<td class="nump">6,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">3,727<span></span>
</td>
<td class="nump">3,613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">2,461<span></span>
</td>
<td class="nump">2,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">673<span></span>
</td>
<td class="nump">933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cdna_PatientAndDigitalSolutionsMember', window );">Patient and digital solutions revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">8,617<span></span>
</td>
<td class="nump">6,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cdna_PatientAndDigitalSolutionsMember', window );">Patient and digital solutions revenue | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">8,506<span></span>
</td>
<td class="nump">6,153<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cdna_PatientAndDigitalSolutionsMember', window );">Patient and digital solutions revenue | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cdna_PatientAndDigitalSolutionsMember', window );">Patient and digital solutions revenue | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cdna_RestOfTheWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cdna_RestOfTheWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdna_PatientAndDigitalSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdna_PatientAndDigitalSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795926732128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Reporting - Summary of Long-Lived Assets Consisting of Property and Equipment, Net by Geographic Regions (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Long-lived assets</a></td>
<td class="nump">$ 35,506<span></span>
</td>
<td class="nump">$ 35,529<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Long-lived assets</a></td>
<td class="nump">34,917<span></span>
</td>
<td class="nump">35,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Long-lived assets</a></td>
<td class="nump">498<span></span>
</td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=cdna_RestOfTheWorldMember', window );">Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Long-lived assets</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cdna_RestOfTheWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cdna_RestOfTheWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795941483232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring Charges</a></td>
<td class="nump">$ 60<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>cdna-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cdna="http://www.caredxinc.com/20230331"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cdna-20230331.xsd" xlink:type="simple"/>
    <context id="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia0cc34f656aa40379ccfb7e710773180_I20230508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
        </entity>
        <period>
            <instant>2023-05-08</instant>
        </period>
    </context>
    <context id="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0947b2db32e4416394c995e30d617446_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6522c13470244b44971d6dd1d0a8251b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i68b6550537c1477c960fc12e49544478_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idaaeba5a92a4430cb59489d292860cd5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie44565fb103943ffa2a40292b86d6156_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6b1a5c19190949f3825408e0497964b7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:PatientAndDigitalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5765e29984cc4e398fbf04608384a068_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:PatientAndDigitalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic611516b5add4872b60d9c652badf864_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3a6d44a3abca4ba3b4f503e0dcb0f387_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i36c952509b554d799ce4307c24d429f4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i18517199530c487d95a3770298ef6712_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9cd78f083d3d4b31a05c871b74ccd486_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7d0a7130850648eab89a8d43a4c1ce07_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia157657bf6274daf9ecad3067cda452b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9f6f203285f84a9cbfbb59ef13288eed_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9eedb204e8ae4bd78694426f6de765ea_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i095e80c2be4542a187a6b71e2c8912a8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia36947927580425597efbfc7d9f7b2f4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idc0f9c53c619457c8f7d4a6e8c2e7bd8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iadfb87bf8c0c4c87b3a3c4f7ac571e08_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3e2a29906d48436bb130104a234b2747_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iccd28932ec064ace80e89c8bc1d8e174_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b018026854c4fe38de8981410c77132_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36d5eba90bd24be5bcb0bc0710b286df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie6f9bdaf73bf44fd8daa2e9dab7b62d7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3fcff3c7939a4cfb982b7424fcde9b5c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i62ae858d67e14b07a24b5f0253cb996d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6b40220e05cd4b1b8d17422a7fcc2436_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic2db4a258dcb471894674a74f87706e3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icb8496c939a64c02bd82917d2197df9e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i56d4e08f2ddf42d38ac10990bd19ec5b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1a81a2a7282d4109b94562c6de746780_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i30a9b5385be843b8be329d54dfcdc192_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6b98eb7a2f97454dad8515edac4bcb72_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cdna:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:AlloSureKidneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0d63bba5fe4f40ce95ab4d66330c93ad_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cdna:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:AlloMapHeartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7bb05103813e4dd493ad38b4d1893919_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cdna:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:AlloSureHeartMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaefdfbd1b7ec4bf389377b07e872b922_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cdna:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:AlloSureKidneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i784e3baffdcb4192964759f0c56d78ad_D20210501-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">cdna:MiromatrixIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibf4af37bc739426e912a71dac9ba281d_I20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="iab7d98285c4b4d9ea5dd55cf1942b127_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdna:XynManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i696a715cb3c04fb38124dcb7c37602f8_I20220414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdna:AtTheMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-14</instant>
        </period>
    </context>
    <context id="iaaeec918b90c4ba5bb1acfd6106ce79b_D20220414-20220414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdna:AtTheMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-14</startDate>
            <endDate>2022-04-14</endDate>
        </period>
    </context>
    <context id="i13b9c2985d5d4d1e9ce7abfd085614c5_I20221203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
        </entity>
        <period>
            <instant>2022-12-03</instant>
        </period>
    </context>
    <context id="ifcd6a13ba0f945cbb58e45d6f9688338_D20221208-20221208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
        </entity>
        <period>
            <startDate>2022-12-08</startDate>
            <endDate>2022-12-08</endDate>
        </period>
    </context>
    <context id="i3a52955612044b80bdc44719634b8f15_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cdna:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i00bf0bbaedf542d7bd5c59ac9504d720_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cdna:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i380c3aacb19e456dab0fbafc4081feb5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cdna:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if08f4ea8cdfd44269e800431266d73fc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cdna:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8a65e524e31741e4b69720fd09cbf601_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i739a68ac0826477da4feb1f814aab614_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iff28c97b627c426b88f8092a57b829b0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdna:EmployeeAndNonEmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia352f8b90bf24904ace711c2756fde74_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cdna:EmployeeAndNonEmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i98353659a42b486aba5e86487dd2ed3a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6dbca87d33d445efa90f6f1256c6c729_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i916c5dbd66ef41e99dfbf453408341f9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idd28b8c71bc54b94ac5b492390a28cbd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6feff843c95d4820a893f80a14e8974a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i83fa354129c74d06b48b4acdeb58085e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i954505cbda704b1997a446ed7dc5bd79_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1d197e2a742549a0b82fa9569fafad92_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i78df972b73c44af19aec5841bf4e9ad2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8c8f35fd17864198ae29d7c623d57285_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4eb3ec4739c24023b02eae3760c24976_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6385983faf6b4ce4907f11e0e0784a5a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i982c944f16354821a3a11af57a4d12f5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2d76a02eaa334c0ca21f02a12b008068_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib6e9038b180d4f5f9f7579ef703bdcc8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibe1d6bd783044aa7ae7f1fa51bf4c2df_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i78142f02b6eb4ccfb1656d6f5f294a1d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i802bf2c987da4c38af0138cb12b63a7a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie661294c5d0d4cd39e08f501d3969965_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib9400f589c5241c0a57ababdfed3f710_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9a757ccddcac4f5d8f4be791fe555e95_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id9b3c2ab35bb493688fa7d78b10d9620_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie1ba9d00e75545f2a72fabc1672b6a66_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9f8db3692ea64671bcb30a21ef69e03c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4021690bcfc849d6bf7e8343dba5b82b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i548930b493bb4158a0dbc5d41dc95b2c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7530e38c229d4e808c0bcbedf20ea6e4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4527e5b34bee42669774ad27f3195476_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie5c804bdf4f040aca96273d8934d4389_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cdna:CommonStockWarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i76877b7701634ea681c1e7599813ad95_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">cdna:ContingentConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8d7cf5ad6102439bacdb4213332c001a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia96d97ee1a464c7ca2c6ded0200614bc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i84b41750f227461d843bbebd7625f870_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i205add77cb4a43d28264c36e6bb99b5e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i326a94ee25204ee282ab17ca652c83d6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id3863806f5974329a5f25691cef5e10f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i69def961a87843fcb2b9a4f9b65fc946_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5655b5a1a84d4b98979a99a6db9e0ff2_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdna:HLADataSystemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdna:HLADataSystemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i4e8dea3df85a402dbf74f31228595f6c_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdna:HLADataSystemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="ib370105b87eb4834ba579147ac153394_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdna:HLADataSystemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="i58e73d1a09944b02869b176e945eb1ef_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdna:HLADataSystemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="ibd80e498ad9d43fcaa85af5f97ce31df_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdna:HLADataSystemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="i354e7a3f27e044eab26ae4b1d2cde545_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdna:HLADataSystemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i2fe8183fbe32453d99cc54713eadebe2_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdna:HLADataSystemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="ib01dc638da5843b694334d2ca357325f_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">cdna:HLADataSystemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="ia2fc3487bfd640a096722284a0d737e0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cdna:AcquiredAndDevelopedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2aa30743f4a44b15900e7f593b2ae88b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cdna:AcquiredAndDevelopedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i82959e331a5e485bbf7ae6493073076f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib9bc39941c984943b121612207ca37ea_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i81dc9074721e44aba01ef41b26358b4c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cdna:CommercializationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iacaeaa220cfc409e84deae3b9074cbe5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cdna:CommercializationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if342038ec26148cfaed98ce1574cd8a0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0036ec09081944e38ff9a50586cb6917_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic6ec54cc1d354dcc992a0bee7218aeb2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cdna:AcquiredInProcessTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5a7b81e566d3418c8a4da63e000dd0da_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cdna:AcquiredAndDevelopedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iefc3516196544bbba967fcfe05accd44_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cdna:AcquiredAndDevelopedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia62355ec8eeb43cb853e7e57dc207494_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib827b41ea375450e89bc78d2c9d5f1e8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib63ef863071a4109a09043df7d31f2f0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cdna:CommercializationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d9134ab3e244582ae611652d1ce3c6e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cdna:CommercializationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if5e54691c1394d72bf91f3d75605544b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib6c57f7627c542678d43812cf1f234ae_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if016caa1aa6b4d3e9e03eaa31d2e3b97_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cdna:AcquiredInProcessTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie657b500f633441d881331275caa19f4_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia89f50d5989f473cbde4f16140a46923_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cdna:AcquiredAndDevelopedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2c08b28aa3d0463a87a6374e3e679813_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cdna:CommercializationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9ecfb95f5ca641be8f0f195a6fa22f65_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i15c9947ac20a442e90a185154951f24c_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i857e050dfe06462ebf29ac3ad1bbd400_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1f9048fade524f0d937582e2d0737bbd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">cdna:CostOfTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie8d2b80178a040808832e847918f0f37_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">cdna:CostOfTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic5130eca1ccf4f738a701a55a747d5d9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">cdna:CostOfProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifb4b7444c8a54bf5b1e67a533d029b35_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">cdna:CostOfProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i538eccbc464c49cd93e1c60f3af790b5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">cdna:CostOfPatientAndDigitalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id192b96ed2d2443395a41393430289fe_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">cdna:CostOfPatientAndDigitalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icb5085de4360418c9f60a706e826ebd0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib2bb0753ed6b4970916acf1662850bff_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8a267b7775a54bb9a849620727f55b45_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">cdna:CostOfTestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i283ae31574f24307803aaab45920bc0e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">cdna:CostOfProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i369258cc427d43d7bd2ea30b3bff4f3c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">cdna:CostOfPatientAndDigitalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i86b184c24c09473f91a3c5a799e0ecaf_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingAndMarketingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i57bbabe758fa4226abdab65dc6f55edf_I20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="i5afb8931ba0448dfa451bb6fd9433b11_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2ea7fda0a4594bc7876d19e0b646c9d4_I20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="i5f5640bdc5dc463690fc0aee32a95b31_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i195cf846109945d0a76d6e7ce2543162_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i53037b4e60e34295bb200d6c520f42c0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cdna:LeasesCommencedInJuly2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i70089bac7d1149d68e8faf8be4a0818a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cdna:LeasesCommencedInJuly2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id0938e8abbbf424194441e38319e63da_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cdna:LeasesCommencedInAugust2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i38fbe91f8cb446a1a44ae2e5489e72d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">cdna:LeasesCommencedInAugust2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i49912c99c82e4c2a9d7a1da7ab8fdcfa_D20140601-20140630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
        </entity>
        <period>
            <startDate>2014-06-01</startDate>
            <endDate>2014-06-30</endDate>
        </period>
    </context>
    <context id="ib4b52828eb9044d3949685e3c2d4b00d_D20220307-20220314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cdna:CAREDXINCVsNateraIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-14</endDate>
        </period>
    </context>
    <context id="i1b275c7553774ac3ac576327338fbb57_D20220307-20220314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cdna:CAREDXINCVsNateraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cdna:CompensatoryDamagesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-14</endDate>
        </period>
    </context>
    <context id="i33ad911706e74747a0d127ced9ed8f7c_D20220307-20220314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cdna:CAREDXINCVsNateraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">cdna:PunitiveDamagesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-14</endDate>
        </period>
    </context>
    <context id="icd7b677ac2f44bbba944e499e4c5e1c2_D20220513-20220513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cdna:CAREDXINCVsNateraIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-13</startDate>
            <endDate>2022-05-13</endDate>
        </period>
    </context>
    <context id="i0ee630c440d5470482172c2d5805345d_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i445ae0f9731748a8a1bcab34010dc63a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id490782a3afe4f6a9743acac4922431f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iff2ee009736640978c0e8cdec25086bf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i12f532855bf14a43998b04ac7db3ddfd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i565db6f072c74a3dbfeac9d900d2d797_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib2b2e52a6bb948f2b6b0826f266d5493_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i26d6663b7c774332a4c9fa15e23e3b34_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdna:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7773cc52f31449008e2a2da976fb5dbc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdna:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i40b3e213d2c44ed3bf2769319aee962b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdna:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9e23905672f3405495bcc17dd04c3467_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia24f76f7b5ed46cf96e628a538a6e320_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i404725fbc6564a3193b67907dbbe80e6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4783302274d944709ef6bd9aac018c00_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3b063cbad6df47aeadbd66f77725b34e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6a8e83ffc79746499f241de17f14762c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibfc21a0301ce4966b0e2d787749a63dd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4085e2e2596a4c689ebf01b80b2c5c82_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7f7a16d338ed4ab3939bc3f47e6c75cf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6ab6496f097a4ebc957f05bf6f2a67a7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i39f90c981a414baca25472855eb286a8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cdna:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic03e1001adae4271911ad4bdce2d0981_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cdna:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id58767c1d8084713916edd6596399012_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i15533108dd8044e8a8072baeebce60f2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3c59122b69b444ae819cdc8aae3be5b9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9c618998e62f418a831eb3095a8a2c36_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iec20c3548df44cde8bb311b72dae19bd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cdna:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i441bbf95c9a74c9f8bcc5339145c212a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cdna:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5a6d052a98b04c87b9036941a8a6a5c8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:PatientAndDigitalSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i128a8bcd322647b8a897eae3a619355d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:PatientAndDigitalSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iccd964cbefaa49e2a61aabfee7302e19_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:PatientAndDigitalSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaeaf539bfe39471ba59a24aa7f4ce0e0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:PatientAndDigitalSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifcc6d18dcb4b4287b16ec15dafbee2d7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:PatientAndDigitalSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cdna:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib52598d086dd497d8f54897e6cabc808_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdna:PatientAndDigitalSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cdna:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1620b425a8304d7d9b96f7bafd09516e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3b98c1259e7b4de198ec8628fc9720f5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8553922693ab40cfadd6ab80368405fe_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i233add0bbd014f5982408f02ff0d7cef_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic034aa3435224d08892ec111ab99fe01_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cdna:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7961f0ef0c9b4553b4637f426c4f87c8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cdna:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i61c592955b9b4fce84fc074131d238b5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i877626f277b84c4c83cb6ce132b835a6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0849fd3f28ca472abc8fd430de00bd14_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2fd093ee1cfc4c4d8bbb09c7524ee14b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifa00d894ab6f41268315eb34dc054cd4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cdna:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iac91ecb914ad42ab9e94c27584c8b7a8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001217234</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cdna:RestOfTheWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="claim">
        <measure>cdna:Claim</measure>
    </unit>
    <unit id="patient">
        <measure>cdna:patient</measure>
    </unit>
    <unit id="unique_solution">
        <measure>cdna:unique_solution</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="milestone_payment">
        <measure>cdna:milestone_payment</measure>
    </unit>
    <unit id="complaint">
        <measure>cdna:complaint</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180L2ZyYWc6NThiYTg5MmI3M2JlNGNjODhmMGFhYTEwNzFlOThkMjcvdGFibGU6ZTkxZGY2NTM2ZTU5NDE2MDg5NjNlYjE4YjE3NTMxYjQvdGFibGVyYW5nZTplOTFkZjY1MzZlNTk0MTYwODk2M2ViMThiMTc1MzFiNF8zLTEtMS0xLTk1MTMy_d0b38cb1-a9a7-404c-b102-f34dba742387">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180L2ZyYWc6NThiYTg5MmI3M2JlNGNjODhmMGFhYTEwNzFlOThkMjcvdGFibGU6ZTkxZGY2NTM2ZTU5NDE2MDg5NjNlYjE4YjE3NTMxYjQvdGFibGVyYW5nZTplOTFkZjY1MzZlNTk0MTYwODk2M2ViMThiMTc1MzFiNF81LTEtMS0xLTk1MTMy_e24c694b-4218-4558-ad7d-89bf09148fde">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180L2ZyYWc6NThiYTg5MmI3M2JlNGNjODhmMGFhYTEwNzFlOThkMjcvdGFibGU6ZTkxZGY2NTM2ZTU5NDE2MDg5NjNlYjE4YjE3NTMxYjQvdGFibGVyYW5nZTplOTFkZjY1MzZlNTk0MTYwODk2M2ViMThiMTc1MzFiNF82LTEtMS0xLTk1MTMy_657a940d-05ea-40ed-af42-232c6c0fd4f7">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180L2ZyYWc6NThiYTg5MmI3M2JlNGNjODhmMGFhYTEwNzFlOThkMjcvdGFibGU6ZTkxZGY2NTM2ZTU5NDE2MDg5NjNlYjE4YjE3NTMxYjQvdGFibGVyYW5nZTplOTFkZjY1MzZlNTk0MTYwODk2M2ViMThiMTc1MzFiNF85LTEtMS0xLTk1MTMy_4ab7107b-4d66-481d-95a3-6a93a6d1e3f3">0001217234</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180L2ZyYWc6NThiYTg5MmI3M2JlNGNjODhmMGFhYTEwNzFlOThkMjcvdGFibGU6ZTkxZGY2NTM2ZTU5NDE2MDg5NjNlYjE4YjE3NTMxYjQvdGFibGVyYW5nZTplOTFkZjY1MzZlNTk0MTYwODk2M2ViMThiMTc1MzFiNF8xMC0xLTEtMS05NTEzMg_6eb642eb-f59d-4192-abfe-0f7667a0e566">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfMTY0OTI2NzQ2ODUyOQ_d306f6fa-aeb4-45bb-9b54-7cf758f0a757">http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:DefinedBenefitPlanTypeExtensibleList
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182NC9mcmFnOjE5MTc0ZWRlNzIyMTQzNzk5MGY3ZjY0YTAzNjU2YzA2L3RleHRyZWdpb246MTkxNzRlZGU3MjIxNDM3OTkwZjdmNjRhMDM2NTZjMDZfNDYx_ec00229a-4fdc-4dab-8f7d-959d1d68ae6f">http://fasb.org/us-gaap/2022#PostemploymentRetirementBenefitsMember</us-gaap:DefinedBenefitPlanTypeExtensibleList>
    <dei:DocumentType
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNTAx_a13b1806-f00e-47a0-ab86-825c05641251">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGFibGU6ZjU1NjBjNGI5MzllNDJlZWE0Nzg5MmMzMDdhZmY0MzEvdGFibGVyYW5nZTpmNTU2MGM0YjkzOWU0MmVlYTQ3ODkyYzMwN2FmZjQzMV8wLTAtMS0xLTk1MTMy_490b2e52-9d6c-49ba-8315-4a980801ca28">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yMzQ_58e7403a-6302-41df-8969-a4a9e15dbdc5">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGFibGU6ZWQ4MDczYzY2OWFkNGU5ZDljOGZjOGE5NjIxMTU4MjgvdGFibGVyYW5nZTplZDgwNzNjNjY5YWQ0ZTlkOWM4ZmM4YTk2MjExNTgyOF8wLTAtMS0xLTk1MTMy_7c2c9441-e137-4c7a-bae0-fae703a6eb6a">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNTAy_bc3418ab-c0c6-4ffe-bbe1-d73d31d1b061">001-36536</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNTA1_59cab145-7281-4c42-8d28-f784b107cae8">CAREDX, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGFibGU6MDU3ZDJmNWUwZTgyNGUzNGExMGNkODNhN2E1ZTk5NjgvdGFibGVyYW5nZTowNTdkMmY1ZTBlODI0ZTM0YTEwY2Q4M2E3YTVlOTk2OF8wLTAtMS0xLTk1MTMy_897828c6-44e9-4dc6-b87c-7a84a86bdf02">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGFibGU6MDU3ZDJmNWUwZTgyNGUzNGExMGNkODNhN2E1ZTk5NjgvdGFibGVyYW5nZTowNTdkMmY1ZTBlODI0ZTM0YTEwY2Q4M2E3YTVlOTk2OF8wLTItMS0xLTk1MTMy_37ecbc7b-5548-4fbe-a0e0-ce9cf45df568">94-3316839</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNTA2_ab723096-d43b-4ec5-a291-0ec51b6fccd0">8000 Marina Boulevard, 4th Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNTAz_50d15be8-2714-412d-af61-ac5f70e7e097">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNTEw_baecf137-3fd7-423a-874c-151be9a8cd0b">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNTEx_512a8176-af07-4b27-8588-0297b6afb1dc">94005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNTEy_3d958ca2-42dc-4047-8223-c5b81a6e86c2">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNTA0_b6c27122-523b-4436-a9ad-5544a4a079f3">287-2300</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGFibGU6OTg3ZWM4NGIyZDcyNDY2YWFhZTJmOTE4MmRiYzdlOGEvdGFibGVyYW5nZTo5ODdlYzg0YjJkNzI0NjZhYWFlMmY5MTgyZGJjN2U4YV8xLTAtMS0xLTk1MTMy_85eeabb5-2236-4833-b4ed-217c2357e6e5">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGFibGU6OTg3ZWM4NGIyZDcyNDY2YWFhZTJmOTE4MmRiYzdlOGEvdGFibGVyYW5nZTo5ODdlYzg0YjJkNzI0NjZhYWFlMmY5MTgyZGJjN2U4YV8xLTEtMS0xLTk1MTMy_24bb5a34-4ce4-4070-a817-f0889814f941">CDNA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGFibGU6OTg3ZWM4NGIyZDcyNDY2YWFhZTJmOTE4MmRiYzdlOGEvdGFibGVyYW5nZTo5ODdlYzg0YjJkNzI0NjZhYWFlMmY5MTgyZGJjN2U4YV8xLTItMS0xLTk1MTMy_aabf1cda-4d9c-42e4-9c87-2a776b67edfd">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNDk5_34f983c7-67be-44c0-8ae5-8b29890f1191">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNTA4_82bf3bef-7dbf-44c7-b4e7-6b3b2f1d8891">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGFibGU6ZTBmNGRkOWQyZTQ2NDQxN2E3ZjkwMzg1OTJiMDk0YzYvdGFibGVyYW5nZTplMGY0ZGQ5ZDJlNDY0NDE3YTdmOTAzODU5MmIwOTRjNl8wLTAtMS0xLTk1MTMy_69cfaa80-f084-41b2-8fda-4661b1979830">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGFibGU6ZTBmNGRkOWQyZTQ2NDQxN2E3ZjkwMzg1OTJiMDk0YzYvdGFibGVyYW5nZTplMGY0ZGQ5ZDJlNDY0NDE3YTdmOTAzODU5MmIwOTRjNl8yLTQtMS0xLTk1MTMy_7d0df442-2246-453e-98ba-686b675f81a1">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGFibGU6ZTBmNGRkOWQyZTQ2NDQxN2E3ZjkwMzg1OTJiMDk0YzYvdGFibGVyYW5nZTplMGY0ZGQ5ZDJlNDY0NDE3YTdmOTAzODU5MmIwOTRjNl80LTQtMS0xLTk1MTMy_77ee0d1f-1ad3-418c-b5dd-c6785fb99f76">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNTA5_f49b6edb-3788-4a58-b3fd-f2b42bf393bd">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ia0cc34f656aa40379ccfb7e710773180_I20230508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xL2ZyYWc6ODhiZDNjZTk2OTg0NGVhMDg2NGJmMDhhZGE5MTI0MzUvdGV4dHJlZ2lvbjo4OGJkM2NlOTY5ODQ0ZWEwODY0YmYwOGFkYTkxMjQzNV8yNDI0_2bc422e3-f555-439c-94be-b459ecbf1ece"
      unitRef="shares">53793067</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMy0xLTEtMS05NTEzMg_840e10cf-893c-47ee-838a-7d89ffbcf525"
      unitRef="usd">74660000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMy0zLTEtMS05NTEzMg_da0f02e7-662d-4e4e-bd1f-75bf1b8daa7c"
      unitRef="usd">89921000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfNC0xLTEtMS05NTEzMg_264a5fbc-9249-4d0e-8797-ef8231cdc08d"
      unitRef="usd">211279000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfNC0zLTEtMS05NTEzMg_9ee8d728-d799-46d7-a6e6-cca62aef2f8f"
      unitRef="usd">203168000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfNS0xLTEtMS05NTEzMg_30eaca67-d530-4b9b-83ae-db4600d4df3b"
      unitRef="usd">59310000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfNS0zLTEtMS05NTEzMg_19a32e91-e9e2-4cb5-83bd-98c77d7a70f3"
      unitRef="usd">66312000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfNi0xLTEtMS05NTEzMg_dd7dfaa6-5668-4c19-b1aa-e30aa97168f3"
      unitRef="usd">18018000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfNi0zLTEtMS05NTEzMg_3eb6ea2e-ef5b-4c9f-a22f-d1c471d0f8ac"
      unitRef="usd">19232000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfNy0xLTEtMS05NTEzMg_8e5ad845-a13f-462a-a557-bbf088027d26"
      unitRef="usd">8161000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfNy0zLTEtMS05NTEzMg_4de65782-fe35-4766-9e22-543253f3d793"
      unitRef="usd">9216000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfOC0xLTEtMS05NTEzMg_7ee9e63b-23c1-410d-96f2-af312d1b3951"
      unitRef="usd">371428000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfOC0zLTEtMS05NTEzMg_d52d0cd2-334f-4f83-be70-69f6a4a8cc64"
      unitRef="usd">387849000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfOS0xLTEtMS05NTEzMg_0098751f-7f85-4410-8007-4a386ad621b8"
      unitRef="usd">35506000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfOS0zLTEtMS05NTEzMg_86bf74b6-8c35-4f3f-865f-acf178ab8048"
      unitRef="usd">35529000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTAtMS0xLTEtOTUxMzI_05dea15d-e913-4236-befe-780d27536c49"
      unitRef="usd">33431000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTAtMy0xLTEtOTUxMzI_5b48360c-9f61-454d-9d14-0995a2cdc4af"
      unitRef="usd">34689000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTEtMS0xLTEtOTUxMzI_45a38ba8-b679-49f8-921a-ece66885a7be"
      unitRef="usd">45637000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTEtMy0xLTEtOTUxMzI_fff2848c-f71e-4631-ae6a-299541b13e25"
      unitRef="usd">43051000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTItMS0xLTEtOTUxMzI_cb75648d-ad15-4312-8b57-6f36b5930e76"
      unitRef="usd">39615000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTItMy0xLTEtOTUxMzI_77c1e9ba-8eb4-483d-a25b-a43cceeb8800"
      unitRef="usd">37523000</us-gaap:Goodwill>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTMtMS0xLTEtOTUxMzI_adf0097c-5e1a-4c93-aaa7-448262749ce4"
      unitRef="usd">520000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTMtMy0xLTEtOTUxMzI_3b6f66e9-251e-4708-b634-2e10b40558c3"
      unitRef="usd">522000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTQtMS0xLTEtOTUxMzI_0b4cf103-5f66-495d-bafb-bb5ecea4ef2e"
      unitRef="usd">2080000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTQtMy0xLTEtOTUxMzI_693c26eb-9637-4a9d-9d7b-b8c1bd534461"
      unitRef="usd">3828000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTUtMS0xLTEtOTUxMzI_de1376a7-876b-4e40-ada1-a670a9e1cf7e"
      unitRef="usd">528217000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTUtMy0xLTEtOTUxMzI_09e3dbb0-3c7f-48fc-86c0-97ba36ceb4bc"
      unitRef="usd">542991000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTgtMS0xLTEtOTUxMzI_64233050-5ff2-4349-9ca7-412ee69a71cd"
      unitRef="usd">12861000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTgtMy0xLTEtOTUxMzI_826d293f-2975-47f2-839e-0a40db34048a"
      unitRef="usd">9942000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTktMS0xLTEtOTUxMzI_0322e3af-615d-4857-89e1-af9227986f7d"
      unitRef="usd">12082000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMTktMy0xLTEtOTUxMzI_2a81853b-0a87-4d46-b665-65b2aa33edf9"
      unitRef="usd">16902000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjAtMS0xLTEtOTUxMzI_79e3a2b0-91ae-4527-99f5-0ff06a981900"
      unitRef="usd">46885000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjAtMy0xLTEtOTUxMzI_7fef1ff0-388a-446c-82db-3c8d3a321067"
      unitRef="usd">49131000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjItMS0xLTEtOTUxMzI_3bc95966-4b2e-494c-9179-036d3750f7de"
      unitRef="usd">71828000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjItMy0xLTEtOTUxMzI_f56dc911-8d21-4825-b038-b1735277ae27"
      unitRef="usd">75975000</us-gaap:LiabilitiesCurrent>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjQtMS0xLTEtOTUxMzI_c2102a0d-933f-4196-9482-98112de994d3"
      unitRef="usd">25000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjQtMy0xLTEtOTUxMzI_0b70c6cc-435b-4b38-94ae-47cd9f096789"
      unitRef="usd">32000</us-gaap:WarrantsAndRightsOutstanding>
    <cdna:DeferredPaymentsForIntangibleAssetsNoncurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjUtMS0xLTEtOTUxMzI_38a8dace-863d-4e91-8128-045b9ec3a864"
      unitRef="usd">4089000</cdna:DeferredPaymentsForIntangibleAssetsNoncurrent>
    <cdna:DeferredPaymentsForIntangibleAssetsNoncurrent
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjUtMy0xLTEtOTUxMzI_5c95f1b2-599e-404d-9da4-14da2860625d"
      unitRef="usd">2418000</cdna:DeferredPaymentsForIntangibleAssetsNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjYtMS0xLTEtOTUxMzI_151157e0-0901-4d82-b986-e25cedb66530"
      unitRef="usd">32006000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjYtMy0xLTEtOTUxMzI_dfc8b515-943a-4f4e-b462-12963e29311f"
      unitRef="usd">33406000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjctMS0xLTEtOTUxMzI_3b27a433-c1d4-4fdb-8932-d8d297d7cb6f"
      unitRef="usd">248000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjctMy0xLTEtOTUxMzI_12c35c1e-a55a-4a3b-9a45-389512941f47"
      unitRef="usd">249000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjgtMS0xLTEtOTUxMzI_7f775939-dabf-497f-93a9-987e158797ba"
      unitRef="usd">108196000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjgtMy0xLTEtOTUxMzI_00ebeb8b-bea9-4f4a-b886-9c0bce45a7ed"
      unitRef="usd">112080000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjktMS0xLTEtOTUxMzI_ae435f2e-1b37-4fd2-b69e-c8431f0c19cc"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMjktMy0xLTEtOTUxMzI_386bea72-0abb-4292-b7dc-3a68659fce13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzEtMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjpmNTg4MmQ1Y2VhYWM0MzY4YTgwNjEwN2RhYmI5ZWZlY18yMg_c8c9a7f8-340e-4641-a2ca-bc0f8d817cad"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzEtMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjpmNTg4MmQ1Y2VhYWM0MzY4YTgwNjEwN2RhYmI5ZWZlY18yMg_d34136f6-050b-4adf-97f3-e270018817f3"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzEtMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjpmNTg4MmQ1Y2VhYWM0MzY4YTgwNjEwN2RhYmI5ZWZlY18zNg_50f0a352-2b8c-45db-a02c-a6b0478d5d56"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzEtMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjpmNTg4MmQ1Y2VhYWM0MzY4YTgwNjEwN2RhYmI5ZWZlY18zNg_98900e18-f3b0-4d7a-9ee6-6c9aba65c06c"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzEtMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjpmNTg4MmQ1Y2VhYWM0MzY4YTgwNjEwN2RhYmI5ZWZlY183MQ_2703c27c-33d6-4a17-bba9-9a2f9db7ebde"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzEtMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjpmNTg4MmQ1Y2VhYWM0MzY4YTgwNjEwN2RhYmI5ZWZlY183MQ_5244fe44-8eb9-4254-acca-db2e9b9c5481"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzEtMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjpmNTg4MmQ1Y2VhYWM0MzY4YTgwNjEwN2RhYmI5ZWZlY183MQ_9058c1c5-1959-4974-a831-a99b1bb1facf"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzEtMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjpmNTg4MmQ1Y2VhYWM0MzY4YTgwNjEwN2RhYmI5ZWZlY183MQ_ffc5b428-b8a1-4192-8dbe-67885624bdc4"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzEtMS0xLTEtOTUxMzI_95b8b180-455e-4d5b-b67e-78cb28f3eed7"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzEtMy0xLTEtOTUxMzI_b6b0cd48-1c07-45f8-864e-63aef39807f4"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzItMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjphYzRiYTI4NTZhYjk0MDM1OTM2ZjExNmU4ODQ2MzdiMl8xOQ_24df2855-d117-4c01-8f0d-a347018ac1d2"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzItMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjphYzRiYTI4NTZhYjk0MDM1OTM2ZjExNmU4ODQ2MzdiMl8xOQ_d51a9bd3-5be2-47c1-8a3d-81b68d6ec066"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzItMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjphYzRiYTI4NTZhYjk0MDM1OTM2ZjExNmU4ODQ2MzdiMl8zMw_00291993-fba0-4c47-9f4f-cab3ba22e154"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzItMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjphYzRiYTI4NTZhYjk0MDM1OTM2ZjExNmU4ODQ2MzdiMl8zMw_784e37cd-339b-498d-bb80-98315f662d03"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzItMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjphYzRiYTI4NTZhYjk0MDM1OTM2ZjExNmU4ODQ2MzdiMl82OA_4bf42e20-b729-423c-9eee-7ab87040eebf"
      unitRef="shares">53712654</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzItMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjphYzRiYTI4NTZhYjk0MDM1OTM2ZjExNmU4ODQ2MzdiMl84Mg_c8c54ddc-9514-4c4b-912c-796447295bc3"
      unitRef="shares">53583301</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzItMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjphYzRiYTI4NTZhYjk0MDM1OTM2ZjExNmU4ODQ2MzdiMl81NDk3NTU4MTQwOTU_a0feb40f-cd74-4ae5-8e74-0ca91d212bb2"
      unitRef="shares">53653182</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzItMC0xLTEtOTUxMzIvdGV4dHJlZ2lvbjphYzRiYTI4NTZhYjk0MDM1OTM2ZjExNmU4ODQ2MzdiMl81NDk3NTU4MTQxMDM_92e9b0ad-62fe-4ae9-bac3-6b21d1693b8b"
      unitRef="shares">53533250</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzItMS0xLTEtOTUxMzI_a3eb8c45-ebc3-447d-b465-032ccf52963d"
      unitRef="usd">52000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzItMy0xLTEtOTUxMzI_cbaa5f28-a9c8-4fcb-9b92-97ad52ce5ec9"
      unitRef="usd">52000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzMtMS0xLTEtOTUxMzI_092f3d7e-b5ca-4d78-b215-7fca6551727f"
      unitRef="usd">912291000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzMtMy0xLTEtOTUxMzI_b81d14ad-5ab9-41f6-aff4-ba01ccff2cce"
      unitRef="usd">898806000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzQtMS0xLTEtOTUxMzI_5725fc85-e06c-4abe-89c2-02c37397204b"
      unitRef="usd">-7439000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzQtMy0xLTEtOTUxMzI_2b63a18c-94e9-4e65-8cf2-1fc7b835fd03"
      unitRef="usd">-7503000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzUtMS0xLTEtOTUxMzI_e98df74c-7fac-4b99-a1a1-49def63e827d"
      unitRef="usd">-484883000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzUtMy0xLTEtOTUxMzI_0ff6e738-193a-43f6-b44e-cb3c783761f8"
      unitRef="usd">-460444000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzYtMS0xLTEtOTUxMzI_ab37c2ae-2d88-4db5-bd98-edf041f38eff"
      unitRef="usd">420021000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzYtMy0xLTEtOTUxMzI_b3380ab0-6707-43dd-b4c1-51dd4629bc1f"
      unitRef="usd">430911000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzctMS0xLTEtOTUxMzI_e6ae08c2-3b51-40ce-9114-4c117a430578"
      unitRef="usd">528217000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xNi9mcmFnOmI3ZDQ3Y2U1MjE2YTQ3MDE5MmUxOGNmYzMyNmMwOWYyL3RhYmxlOmY5ZmFlNzJmNWVlODQ0YmZhZGQ2ZTU0YzUzMWI5NGIyL3RhYmxlcmFuZ2U6ZjlmYWU3MmY1ZWU4NDRiZmFkZDZlNTRjNTMxYjk0YjJfMzctMy0xLTEtOTUxMzI_cb295d22-fe6e-41c1-9c2b-9e4ff203693a"
      unitRef="usd">542991000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6522c13470244b44971d6dd1d0a8251b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMy01LTEtMS05NTEzMg_6f1165f4-37c6-4f2a-a999-3ab9d325002e"
      unitRef="usd">61784000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68b6550537c1477c960fc12e49544478_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMy03LTEtMS05NTEzMg_4d48ae9b-9684-4670-9443-3f7fcc1a1956"
      unitRef="usd">66444000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idaaeba5a92a4430cb59489d292860cd5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfNC01LTEtMS05NTEzMg_e0f27458-19bd-401f-b254-0d170863a7d8"
      unitRef="usd">6861000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie44565fb103943ffa2a40292b86d6156_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfNC03LTEtMS05NTEzMg_1b8d142e-945f-4fe5-8182-5e322d7c2822"
      unitRef="usd">6788000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b1a5c19190949f3825408e0497964b7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfNS01LTEtMS05NTEzMg_b02b96e0-1e87-48e2-be72-dc8dd053f599"
      unitRef="usd">8617000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5765e29984cc4e398fbf04608384a068_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfNS03LTEtMS05NTEzMg_c8baaaf6-2a41-4033-b606-4590688b7f31"
      unitRef="usd">6184000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfNi01LTEtMS05NTEzMg_4652c80a-4aad-46e9-9856-5e0cbd639241"
      unitRef="usd">77262000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfNi03LTEtMS05NTEzMg_1f0fe443-a4a0-41a1-9b3e-5f7f279ea24a"
      unitRef="usd">79416000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6522c13470244b44971d6dd1d0a8251b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfOC01LTEtMS05NTEzMg_38e37670-cfb8-4a9c-bd7b-55a8dc5b0432"
      unitRef="usd">15296000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i68b6550537c1477c960fc12e49544478_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfOC03LTEtMS05NTEzMg_f3ae3f46-0b62-41b2-809d-b86e4edabfe1"
      unitRef="usd">17628000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="idaaeba5a92a4430cb59489d292860cd5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfOS01LTEtMS05NTEzMg_cccc6396-9310-4301-b184-2343b15c695a"
      unitRef="usd">4066000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie44565fb103943ffa2a40292b86d6156_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfOS03LTEtMS05NTEzMg_968d2b51-b2f3-412b-ae0b-3ac1b0f16e22"
      unitRef="usd">4399000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6b1a5c19190949f3825408e0497964b7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTAtNS0xLTEtOTUxMzI_79d21c79-bc7c-4238-8bc1-49fc67e951a0"
      unitRef="usd">6604000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5765e29984cc4e398fbf04608384a068_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTAtNy0xLTEtOTUxMzI_9c1743c0-73d1-4855-bd9e-04b54087e693"
      unitRef="usd">4855000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTEtNS0xLTEtOTUxMzI_fdca3197-c4a3-40a5-910c-86bf217ac86c"
      unitRef="usd">24357000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTEtNy0xLTEtOTUxMzI_a2199987-f0fb-47c9-95f3-29631577f2da"
      unitRef="usd">21880000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTItNS0xLTEtOTUxMzI_61427c34-7ad7-4a33-ad83-bcb181affa1d"
      unitRef="usd">23231000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTItNy0xLTEtOTUxMzI_01dd931f-28a3-47fc-9903-bfccc26bd089"
      unitRef="usd">23148000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTMtNS0xLTEtOTUxMzI_a3ca07a1-7713-4b18-9785-9074d99a657b"
      unitRef="usd">28032000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTMtNy0xLTEtOTUxMzI_120ba1c5-a889-47b3-be56-7dbc6b53161f"
      unitRef="usd">26559000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTQtNS0xLTEtOTUxMzI_61f4238d-8e7f-4139-b30e-0e9cdc167729"
      unitRef="usd">101586000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTQtNy0xLTEtOTUxMzI_0e9f9bdf-7473-41b0-809a-b1c8c3cc1f00"
      unitRef="usd">98469000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTUtNS0xLTEtOTUxMzI_1b5d43d2-7beb-4a02-90ee-ea4121034521"
      unitRef="usd">-24324000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTUtNy0xLTEtOTUxMzI_2a1f3990-97e1-47f8-b7b7-ed02d2d3aa2e"
      unitRef="usd">-19053000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTctNS0xLTEtOTUxMzI_a4567702-0af0-40c4-874c-de90b6aad54d"
      unitRef="usd">2666000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTctNy0xLTEtOTUxMzI_7b48f8eb-dc5b-45ca-a534-cf6bd79235f4"
      unitRef="usd">189000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTgtNS0xLTEtOTUxMzI_dce63d5d-6100-434a-b550-a6643d15941f"
      unitRef="usd">7000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTgtNy0xLTEtOTUxMzI_a6dba46b-a239-4c92-8c6e-02a5e962f36d"
      unitRef="usd">27000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTktNS0xLTEtOTUxMzI_4cf169c3-bfde-4fe2-8430-fa23a3122acc"
      unitRef="usd">-1974000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMTktNy0xLTEtOTUxMzI_b0429845-7965-4dc8-bdeb-5401d5838c0a"
      unitRef="usd">-823000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjAtNS0xLTEtOTUxMzI_202f4b85-fa48-4f25-8d03-403dfad27ccd"
      unitRef="usd">699000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjAtNy0xLTEtOTUxMzI_253c4d86-1264-4414-b735-ebfce4df2a56"
      unitRef="usd">-607000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjEtNS0xLTEtOTUxMzI_80fef415-a6de-416e-85a0-a1c8aa2d7217"
      unitRef="usd">-23625000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjEtNy0xLTEtOTUxMzI_55557c6d-b8c4-434e-bd66-a641b6780974"
      unitRef="usd">-19660000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjItNS0xLTEtOTUxMzI_768114ed-c76c-49dd-960e-f781072e4d58"
      unitRef="usd">124000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjItNy0xLTEtOTUxMzI_1e5315c3-2d1c-4d95-8877-9737930c6bc7"
      unitRef="usd">-12000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjMtNS0xLTEtOTUxMzI_b05a76e0-9bf8-4620-9a6f-af3d3bbeb9b5"
      unitRef="usd">-23749000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjMtNy0xLTEtOTUxMzI_72c5f981-b2de-4883-977a-415ef14a37ea"
      unitRef="usd">-19648000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjUtNS0xLTEtOTUxMzI_97a77087-675e-450c-a742-43a779c76aaf"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjUtNy0xLTEtOTUxMzI_7432d592-db73-4e60-b8d6-644ab7a178db"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjYtNS0xLTEtOTUxMzI_6aca73d2-944b-4b2a-9ce7-7deb0cbf63da"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjYtNy0xLTEtOTUxMzI_c2ed815d-2846-4745-9253-cff8c229ab65"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjgtNS0xLTEtOTUxMzI_aded7773-2f3c-4d28-afcf-9d97422b6749"
      unitRef="shares">53643216</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjgtNy0xLTEtOTUxMzI_8665af09-5fc9-4bcd-b0c6-de26dbc2e2d7"
      unitRef="shares">53015459</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjktNS0xLTEtOTUxMzI_58a83c1b-3c27-4d33-8c6d-5db261b53343"
      unitRef="shares">53643216</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xOS9mcmFnOmIyYjljYmE4MmViZjRhZTI4YTcxNDM2YjFiNmU1NDYyL3RhYmxlOmE1Y2MxYWNjMjdmZTRmOWFiMjU3OTAwMDQ5MzRhNjhjL3RhYmxlcmFuZ2U6YTVjYzFhY2MyN2ZlNGY5YWIyNTc5MDAwNDkzNGE2OGNfMjktNy0xLTEtOTUxMzI_bdc2c6c9-67f2-4e0c-86de-3f98c9ab44e2"
      unitRef="shares">53015459</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yMi9mcmFnOmM1ZTg2MWJiODczZjRlZjI4YjE4Y2UwZTgxY2VhYTAwL3RhYmxlOjU3ODAwY2U0MjBhNzQ0OGRiYTNlOTFiNDRlMGEwMzY0L3RhYmxlcmFuZ2U6NTc4MDBjZTQyMGE3NDQ4ZGJhM2U5MWI0NGUwYTAzNjRfMi0xLTEtMS05NTEzMg_0c6fd940-3339-4cd0-a680-c19ea9bdbe60"
      unitRef="usd">-23749000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yMi9mcmFnOmM1ZTg2MWJiODczZjRlZjI4YjE4Y2UwZTgxY2VhYTAwL3RhYmxlOjU3ODAwY2U0MjBhNzQ0OGRiYTNlOTFiNDRlMGEwMzY0L3RhYmxlcmFuZ2U6NTc4MDBjZTQyMGE3NDQ4ZGJhM2U5MWI0NGUwYTAzNjRfMi0zLTEtMS05NTEzMg_513461ef-3ade-4f71-a7f2-034e78f7e631"
      unitRef="usd">-19648000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yMi9mcmFnOmM1ZTg2MWJiODczZjRlZjI4YjE4Y2UwZTgxY2VhYTAwL3RhYmxlOjU3ODAwY2U0MjBhNzQ0OGRiYTNlOTFiNDRlMGEwMzY0L3RhYmxlcmFuZ2U6NTc4MDBjZTQyMGE3NDQ4ZGJhM2U5MWI0NGUwYTAzNjRfNC0xLTEtMS05NTEzMg_3af1b193-f221-495f-b206-49913e76d23d"
      unitRef="usd">64000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yMi9mcmFnOmM1ZTg2MWJiODczZjRlZjI4YjE4Y2UwZTgxY2VhYTAwL3RhYmxlOjU3ODAwY2U0MjBhNzQ0OGRiYTNlOTFiNDRlMGEwMzY0L3RhYmxlcmFuZ2U6NTc4MDBjZTQyMGE3NDQ4ZGJhM2U5MWI0NGUwYTAzNjRfNC0zLTEtMS05NTEzMg_45e45b85-918d-4587-b86e-24068c382325"
      unitRef="usd">-420000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yMi9mcmFnOmM1ZTg2MWJiODczZjRlZjI4YjE4Y2UwZTgxY2VhYTAwL3RhYmxlOjU3ODAwY2U0MjBhNzQ0OGRiYTNlOTFiNDRlMGEwMzY0L3RhYmxlcmFuZ2U6NTc4MDBjZTQyMGE3NDQ4ZGJhM2U5MWI0NGUwYTAzNjRfNS0xLTEtMS05NTEzMg_a5e5b71e-f186-40f5-914d-6049b1220c61"
      unitRef="usd">-23685000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yMi9mcmFnOmM1ZTg2MWJiODczZjRlZjI4YjE4Y2UwZTgxY2VhYTAwL3RhYmxlOjU3ODAwY2U0MjBhNzQ0OGRiYTNlOTFiNDRlMGEwMzY0L3RhYmxlcmFuZ2U6NTc4MDBjZTQyMGE3NDQ4ZGJhM2U5MWI0NGUwYTAzNjRfNS0zLTEtMS05NTEzMg_e02632ee-05f8-4ccd-98b9-a4917d93134a"
      unitRef="usd">-20068000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="ic611516b5add4872b60d9c652badf864_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMi0xLTEtMS05NTEzMg_514f49f5-b1bf-49ae-9db8-89a35cf599fc"
      unitRef="shares">53533250</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic611516b5add4872b60d9c652badf864_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMi0zLTEtMS05NTEzMg_40d434dc-1c6d-404d-ac83-2eab8290e2c9"
      unitRef="usd">52000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a6d44a3abca4ba3b4f503e0dcb0f387_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMi01LTEtMS05NTEzMg_df530501-7a14-465f-94d2-16feb1704cf6"
      unitRef="usd">898806000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i36c952509b554d799ce4307c24d429f4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMi03LTEtMS05NTEzMg_1d4518a4-8bea-4423-9454-99aa1f1b3f20"
      unitRef="usd">-7503000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i18517199530c487d95a3770298ef6712_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMi05LTEtMS05NTEzMg_bca27565-cfba-4312-ab2f-5a70ef0ca953"
      unitRef="usd">-460444000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMi0xMS0xLTEtOTUxMzI_cabc6cc2-b55f-4dce-835c-fdbf65447d81"
      unitRef="usd">430911000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i9cd78f083d3d4b31a05c871b74ccd486_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNC0xLTEtMS05NTEzMg_cc5afbd3-b936-4f1f-9c54-018525fa6bb0"
      unitRef="shares">47025</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i7d0a7130850648eab89a8d43a4c1ce07_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNC01LTEtMS05NTEzMg_ebc66d5d-3eaf-4fb8-9ff3-277cce16c4c0"
      unitRef="usd">456000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNC0xMS0xLTEtOTUxMzI_9fe5a070-4bc3-4f26-aa1e-13f38b872ff1"
      unitRef="usd">456000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i9cd78f083d3d4b31a05c871b74ccd486_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNS0xLTEtMS05NjE1NQ_020d44a1-eee9-4b45-a685-de2a679cff23"
      unitRef="shares">59472</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ia157657bf6274daf9ecad3067cda452b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNS05LTEtMS05NjE4NQ_28538cd7-fcfb-462d-a00c-bf4665fc8180"
      unitRef="usd">690000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNS0xMS0xLTEtOTYxOTI_55e8cef5-6234-410a-baa1-c35f02c58731"
      unitRef="usd">690000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="i9cd78f083d3d4b31a05c871b74ccd486_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNS0xLTEtMS05NTEzMg_50f6496f-867a-4480-b2bb-1a9cb39460b4"
      unitRef="shares">123910</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="i7d0a7130850648eab89a8d43a4c1ce07_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNS01LTEtMS05NTEzMg_c312679e-d3b5-44aa-a695-014407544200"
      unitRef="usd">-785000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNS0xMS0xLTEtOTUxMzI_dc6517e7-5520-40c8-a843-ba3009d6ae41"
      unitRef="usd">-785000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i9cd78f083d3d4b31a05c871b74ccd486_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNi0xLTEtMS05NTEzMg_c842c48d-404b-4eae-a81a-96c61b1478f5"
      unitRef="shares">7649</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i7d0a7130850648eab89a8d43a4c1ce07_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNi01LTEtMS05NTEzMg_7a0fb411-3c5d-435a-86e0-440f07f8fda5"
      unitRef="usd">93000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNi0xMS0xLTEtOTUxMzI_62eb1b48-b055-4feb-95e2-b97e9758673c"
      unitRef="usd">93000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9cd78f083d3d4b31a05c871b74ccd486_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNy0xLTEtMS05NTEzMg_82c920bf-3725-4426-ba14-49719f237039"
      unitRef="shares">820</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7d0a7130850648eab89a8d43a4c1ce07_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNy01LTEtMS05NTEzMg_8dec72f1-7d17-4a09-ae75-8993764c001c"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfNy0xMS0xLTEtOTUxMzI_dcef23ee-a482-4c37-979d-4e8501a2a171"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7d0a7130850648eab89a8d43a4c1ce07_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfOS01LTEtMS05NTEzMg_02af9f5e-37bd-4c47-9795-0b0e9370b02e"
      unitRef="usd">13719000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfOS0xMS0xLTEtOTUxMzI_dc94e290-1c7a-4113-a404-44e7ba540c94"
      unitRef="usd">13719000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i9f6f203285f84a9cbfbb59ef13288eed_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMTAtNy0xLTEtOTUxMzI_d2287891-4b11-4631-9e1c-8f4cac1dca25"
      unitRef="usd">64000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMTAtMTEtMS0xLTk1MTMy_50686494-e78e-4775-b4b8-3e50bebbaf9e"
      unitRef="usd">64000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ia157657bf6274daf9ecad3067cda452b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMTEtOS0xLTEtOTUxMzI_154a7416-7b68-41c7-bf2d-9ea213aa1439"
      unitRef="usd">-23749000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMTEtMTEtMS0xLTk1MTMy_87be45b1-e78d-4209-83e7-a2c35a1fca8f"
      unitRef="usd">-23749000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i9eedb204e8ae4bd78694426f6de765ea_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMTItMS0xLTEtOTUxMzI_13ab3f79-1dd5-40c9-b0b5-ce6358edeb2a"
      unitRef="shares">53653182</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9eedb204e8ae4bd78694426f6de765ea_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMTItMy0xLTEtOTUxMzI_77272986-6223-45d2-9615-9fd4bbc784da"
      unitRef="usd">52000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i095e80c2be4542a187a6b71e2c8912a8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMTItNS0xLTEtOTUxMzI_a1a7a0e3-c214-41df-a296-05c19a3e8d95"
      unitRef="usd">912291000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia36947927580425597efbfc7d9f7b2f4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMTItNy0xLTEtOTUxMzI_5e5e73b7-8c88-4e77-a62e-79ce91cecc7e"
      unitRef="usd">-7439000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc0f9c53c619457c8f7d4a6e8c2e7bd8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMTItOS0xLTEtOTUxMzI_994d7872-299b-4908-bb23-5b10e6d4d4a8"
      unitRef="usd">-484883000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjczNjFkMTk2MTAxYjQ1MmI4Mjc5N2FhOWZjMDdlMGMxL3RhYmxlcmFuZ2U6NzM2MWQxOTYxMDFiNDUyYjgyNzk3YWE5ZmMwN2UwYzFfMTItMTEtMS0xLTk1MTMy_939705a2-fcad-4a89-ae97-dfafa50ee1fd"
      unitRef="usd">420021000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="iadfb87bf8c0c4c87b3a3c4f7ac571e08_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMi0xLTEtMS05NTEzMg_efa4c922-0095-440a-93ef-b0a96406e162"
      unitRef="shares">52923360</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iadfb87bf8c0c4c87b3a3c4f7ac571e08_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMi0zLTEtMS05NTEzMg_19db80aa-0eef-4522-b742-5dc995567fe5"
      unitRef="usd">52000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3e2a29906d48436bb130104a234b2747_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMi01LTEtMS05NTEzMg_92d36530-75d2-4f63-b341-8c999be03c0e"
      unitRef="usd">853683000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iccd28932ec064ace80e89c8bc1d8e174_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMi03LTEtMS05NTEzMg_a7c7bc47-f760-4a52-b52c-8a2353833c54"
      unitRef="usd">-4670000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b018026854c4fe38de8981410c77132_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMi05LTEtMS05NTEzMg_f79b35f5-8a33-4c67-8762-908b3b6e63ac"
      unitRef="usd">-383189000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i36d5eba90bd24be5bcb0bc0710b286df_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMi0xMS0xLTEtOTUxMzI_ca8307d0-5cd9-480f-8b73-eaf3b0bcb79e"
      unitRef="usd">465876000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ie6f9bdaf73bf44fd8daa2e9dab7b62d7_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNC0xLTEtMS05NTEzMg_2a244ec7-835c-4359-9736-a9bb83c98ee9"
      unitRef="shares">25852</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i3fcff3c7939a4cfb982b7424fcde9b5c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNC01LTEtMS05NTEzMg_123e3c3a-0ffb-46fd-b2b6-bc2d4561449c"
      unitRef="usd">999000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNC0xMS0xLTEtOTUxMzI_732591c4-569a-409b-a81e-6dc4885821d5"
      unitRef="usd">999000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="ie6f9bdaf73bf44fd8daa2e9dab7b62d7_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNS0xLTEtMS05NTEzMg_118b1221-9984-4718-aa09-b5b0cbb2a32c"
      unitRef="shares">64819</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="i3fcff3c7939a4cfb982b7424fcde9b5c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNS01LTEtMS05NTEzMg_088e0e71-8389-4c80-a630-d8e9c238e0b9"
      unitRef="usd">-1482000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNS0xMS0xLTEtOTUxMzI_b28ca925-e83a-42f4-aa39-92cdca88efe7"
      unitRef="usd">-1482000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="ie6f9bdaf73bf44fd8daa2e9dab7b62d7_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNi0xLTEtMS05NTEzMg_3b1c09e4-47f4-4237-9a0f-af1331a9930d"
      unitRef="shares">1249</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i3fcff3c7939a4cfb982b7424fcde9b5c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNi01LTEtMS05NTEzMg_ec7fca80-7566-486c-8b62-b67d1b13e1e1"
      unitRef="usd">58000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNi0xMS0xLTEtOTUxMzI_330c92d5-73a4-4928-baec-00af1bae1b8a"
      unitRef="usd">58000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie6f9bdaf73bf44fd8daa2e9dab7b62d7_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNy0xLTEtMS05NTEzMg_95ff98ad-bb5a-4c26-ac6c-694e0cd08e58"
      unitRef="shares">69993</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3fcff3c7939a4cfb982b7424fcde9b5c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNy01LTEtMS05NTEzMg_3a8c9ef0-ef3e-4671-b27e-e25b10edc3cf"
      unitRef="usd">1598000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfNy0xMS0xLTEtOTUxMzI_9141ca07-92e4-4aee-b0ee-8af06a10fff2"
      unitRef="usd">1598000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3fcff3c7939a4cfb982b7424fcde9b5c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfOS01LTEtMS05NTEzMg_1e35d310-260d-4c3d-9bca-fad5bff241cd"
      unitRef="usd">10563000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfOS0xMS0xLTEtOTUxMzI_17a4b4ed-46be-45b5-89e8-079c57b59a7d"
      unitRef="usd">10563000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i62ae858d67e14b07a24b5f0253cb996d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMTAtNy0xLTEtOTUxMzI_1c02588e-8c6c-4b8a-9761-59e978621dac"
      unitRef="usd">-420000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMTAtMTEtMS0xLTk1MTMy_d1710de9-2b0b-42a1-b1b6-5661c2da6908"
      unitRef="usd">-420000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i6b40220e05cd4b1b8d17422a7fcc2436_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMTEtOS0xLTEtOTUxMzI_d259200d-59c9-47f2-8831-87bcc6e65cb1"
      unitRef="usd">-19648000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMTEtMTEtMS0xLTk1MTMy_ebedf2b9-d581-455f-bc10-d53be6a2299e"
      unitRef="usd">-19648000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ic2db4a258dcb471894674a74f87706e3_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMTItMS0xLTEtOTUxMzI_e34a021b-a27c-41b4-8c4d-d8e114bbc6ed"
      unitRef="shares">53085273</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic2db4a258dcb471894674a74f87706e3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMTItMy0xLTEtOTUxMzI_a104c100-5607-40ea-a7bf-14966947c86b"
      unitRef="usd">52000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icb8496c939a64c02bd82917d2197df9e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMTItNS0xLTEtOTUxMzI_90f00249-6921-4b6a-ba6b-b54aedb13f2e"
      unitRef="usd">865419000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i56d4e08f2ddf42d38ac10990bd19ec5b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMTItNy0xLTEtOTUxMzI_062c1dc2-f727-4048-86f0-5f7b9d449360"
      unitRef="usd">-5090000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1a81a2a7282d4109b94562c6de746780_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMTItOS0xLTEtOTUxMzI_d3479d2a-ced1-43b8-97aa-c6a26b7729d7"
      unitRef="usd">-402837000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i30a9b5385be843b8be329d54dfcdc192_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yNS9mcmFnOjY3ZjRjZWIyYWYxNDQ1MWVhNDI5MmU1OGE5ZTcyY2IwL3RhYmxlOjMxZDI4MWZhMTgxYzRjNjNhMmU4ODkxYWFhNWUxNGMwL3RhYmxlcmFuZ2U6MzFkMjgxZmExODFjNGM2M2EyZTg4OTFhYWE1ZTE0YzBfMTItMTEtMS0xLTk1MTMy_e82f5add-738a-4be6-b8c8-a4a568544e10"
      unitRef="usd">457544000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMy0xLTEtMS05NTEzMg_a4c25c80-5fc3-47a0-8c88-bb792acdb38a"
      unitRef="usd">-23749000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMy0zLTEtMS05NTEzMg_97f3b5a7-8692-49fb-9cd1-779f3eece735"
      unitRef="usd">-19648000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNS0xLTEtMS05NTEzMg_10959ca2-bf21-40c7-b513-2d254d9cee39"
      unitRef="usd">13754000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNS0zLTEtMS05NTEzMg_2725f613-c521-4084-814c-a0fd9f6d792b"
      unitRef="usd">10634000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNi0xLTEtMS05NTEzMg_c3bf38f8-2269-4071-9a5b-d286a79057a1"
      unitRef="usd">-7000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNi0zLTEtMS05NTEzMg_7efd0da6-f8b6-4d8d-80f3-34919e97f56c"
      unitRef="usd">-27000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNy0xLTEtMS05NTEzMg_2094869e-106f-4b09-a51e-882f1b53a377"
      unitRef="usd">3427000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNy0zLTEtMS05NTEzMg_049dc163-7057-4c60-85a2-77ad1b8c5490"
      unitRef="usd">2619000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AssetImpairmentCharges
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfOC0xLTEtMS05NTEzMg_5344292e-6ad5-490c-b0be-1dbb79fe77c7"
      unitRef="usd">1000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfOC0zLTEtMS05NTEzMg_0e6122e3-4e6c-4195-b1cf-73ac32aeddb9"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfOS0xLTEtMS05NTEzMg_8ba30e1e-7ec0-42f3-9f96-2a32c3f799be"
      unitRef="usd">1337000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfOS0zLTEtMS05NTEzMg_4df26526-5e55-48f4-a012-85117cfa0eb3"
      unitRef="usd">915000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTAtMS0xLTEtOTUxMzI_88774637-ccbe-446c-8608-958a5c76f9ea"
      unitRef="usd">-905000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTAtMy0xLTEtOTUxMzI_21c52517-ea44-4aa8-81b1-c8bd545aa2e8"
      unitRef="usd">-507000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTEtMS0xLTEtOTUxMzI_d795cbf3-4b3b-4a85-9b53-aa9f94ccc5f2"
      unitRef="usd">364000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTEtMy0xLTEtOTUxMzI_d05eb28b-b04d-4654-b363-c58be06e81a7"
      unitRef="usd">64000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTMtMS0xLTEtOTUxMzI_e6ba1109-e43d-470f-a72e-1922de58e19c"
      unitRef="usd">773000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTMtMy0xLTEtOTUxMzI_e11fd507-3652-40a1-a297-9819d7d4ec52"
      unitRef="usd">-139000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTUtMS0xLTEtOTUxMzI_971fc35a-74fa-4b6e-9a4d-7c26afb3f6d2"
      unitRef="usd">-7664000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTUtMy0xLTEtOTUxMzI_98856498-9ec4-4358-9f8a-ee4ff5c2a78e"
      unitRef="usd">5591000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTYtMS0xLTEtOTUxMzI_6de1927d-370d-493f-b1b2-1f9525bb736c"
      unitRef="usd">-1217000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTYtMy0xLTEtOTUxMzI_1a93b7f7-fcb4-43ef-8d27-eb1f62ad8329"
      unitRef="usd">1060000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTctMS0xLTEtOTUxMzI_8ff84566-ae99-4ab1-9a6a-7e2e028db861"
      unitRef="usd">-1515000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTctMy0xLTEtOTUxMzI_33becde1-f064-4769-ade2-2bb2799bc6ae"
      unitRef="usd">567000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <cdna:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTgtMS0xLTEtOTUxMzI_29ee4e16-9daa-4086-93e6-7aa81759da23"
      unitRef="usd">-1333000</cdna:IncreaseDecreaseInOperatingLeaseLiabilities>
    <cdna:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTgtMy0xLTEtOTUxMzI_98f63df2-b950-4aea-af45-0317e9a67e7e"
      unitRef="usd">-969000</cdna:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTktMS0xLTEtOTUxMzI_3c13c9b5-35a4-46e6-8737-a6f7509d359f"
      unitRef="usd">2590000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMTktMy0xLTEtOTUxMzI_6a64ceb5-ebbe-4196-8daa-45067f01feaa"
      unitRef="usd">-1549000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedSalaries
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjAtMS0xLTEtOTUxMzI_3b7aa384-7e01-470f-9782-6f87ce4fa127"
      unitRef="usd">-4888000</us-gaap:IncreaseDecreaseInAccruedSalaries>
    <us-gaap:IncreaseDecreaseInAccruedSalaries
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjAtMy0xLTEtOTUxMzI_7406570f-18e1-40b5-a53d-518b786f3114"
      unitRef="usd">-14634000</us-gaap:IncreaseDecreaseInAccruedSalaries>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjEtMS0xLTEtOTUxMzI_8f5abd07-3e99-4c20-98ad-1daaa48e4228"
      unitRef="usd">-2352000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjEtMy0xLTEtOTUxMzI_b2005ee4-f2f6-4281-a3b1-d625996b8d2a"
      unitRef="usd">7916000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjMtMS0xLTEtOTUxMzI_7a679343-e439-4083-ba29-d7ba0090ea74"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjMtMy0xLTEtOTUxMzI_0f75445b-5df1-4b57-b763-78c7316df075"
      unitRef="usd">217000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjQtMS0xLTEtOTUxMzI_725d612f-9664-490b-bbe5-7f9d1e846eed"
      unitRef="usd">671000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjQtMy0xLTEtOTUxMzI_cc7983e0-331a-4c4e-bbca-13a4b38d4d0b"
      unitRef="usd">-21468000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjYtMS0xLTEtOTUxMzI_5c736fac-e71c-46a5-ae4d-75143fb4846c"
      unitRef="usd">4562000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjYtMy0xLTEtOTUxMzI_d7096355-6fce-49c4-a72a-f137ff37a11d"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjctMS0xLTEtOTUxMzI_e62a9bf1-2b47-404c-95ca-bc19e979c468"
      unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjctMy0xLTEtOTUxMzI_b0f50fb8-f5c7-4f90-abaa-061b1271f4bd"
      unitRef="usd">100000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjgtMS0xLTEtOTUxMzI_84d90f2e-8dbf-43fa-bce7-d797c1381e80"
      unitRef="usd">86310000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjgtMy0xLTEtOTUxMzI_85a97872-4611-4779-968c-e9275dc60375"
      unitRef="usd">148522000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjktMS0xLTEtOTUxMzI_753a766d-68b6-4fff-b571-74eae4625fda"
      unitRef="usd">78972000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjktMy0xLTEtOTUxMzI_b60c5a33-5a0a-4783-99a3-b6c68c93f682"
      unitRef="usd">1053000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjktMS0xLTEtMTAzOTQ5_78f3767b-e516-4a15-8ca8-0ef4119f7506"
      unitRef="usd">100000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMjktMy0xLTEtMTAzOTQ5_50cba429-d636-47a6-a7e8-92030b59c5ca"
      unitRef="usd">0</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <cdna:PaymentsToAcquireCapitalExpendituresNet
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMzEtMS0xLTEtOTUxMzI_6be13171-d93b-4c47-bfde-a5b8b7e7cf47"
      unitRef="usd">2771000</cdna:PaymentsToAcquireCapitalExpendituresNet>
    <cdna:PaymentsToAcquireCapitalExpendituresNet
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMzEtMy0xLTEtOTUxMzI_b370b3d6-ffc4-46d8-b73e-4bba8f0112c8"
      unitRef="usd">8463000</cdna:PaymentsToAcquireCapitalExpendituresNet>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMzItMS0xLTEtOTUxMzI_0dc0cc84-a608-4db3-98b8-6c4980740884"
      unitRef="usd">-14771000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMzItMy0xLTEtOTUxMzI_8629a483-e5bf-464a-9fbb-c85da06a2487"
      unitRef="usd">-156032000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMzctMS0xLTEtOTUxMzI_eb847d90-acb5-4d6a-8dd2-e4c3f3309803"
      unitRef="usd">456000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMzctMy0xLTEtOTUxMzI_aeff1c34-6c5d-409c-8c3c-5a8382ea3907"
      unitRef="usd">999000</us-gaap:ProceedsFromStockPlans>
    <cdna:TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMzgtMS0xLTEtOTUxMzI_027c9f6d-569d-4a19-8476-908f0750c9f0"
      unitRef="usd">656000</cdna:TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits>
    <cdna:TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfMzgtMy0xLTEtOTUxMzI_2973281a-5982-4ba3-abf9-6fa8c6179c65"
      unitRef="usd">1482000</cdna:TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDAtMS0xLTEtOTUxMzI_6bdb6c97-cd85-4711-9a54-e7346011c6fa"
      unitRef="usd">2000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDAtMy0xLTEtOTUxMzI_e0d8f8a1-c9bf-44b7-83db-3a68effbcdfb"
      unitRef="usd">1598000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDItMS0xLTEtOTUxMzI_67ce4b51-9a31-40a6-aa46-5410c8db7671"
      unitRef="usd">250000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDItMy0xLTEtOTUxMzI_3fc6682e-bae6-45bd-b840-efa88b7da9a4"
      unitRef="usd">250000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDMtMS0xLTEtOTc4MDg_b6ace350-9e3c-41c2-9a54-0ec999e9d4a1"
      unitRef="usd">690000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDMtMy0xLTEtOTc4MDg_41c27ac3-ecbb-4c69-ab23-8221aae4ebe1"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDQtMS0xLTEtOTUxMzI_5a341559-5151-4056-8a96-2b14dac901f9"
      unitRef="usd">-1138000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDQtMy0xLTEtOTUxMzI_e3f2788d-5d08-4e61-825b-dd3156ab61e5"
      unitRef="usd">865000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDUtMS0xLTEtOTUxMzI_3e0687e1-a516-402e-bde5-6736b5c27b94"
      unitRef="usd">-25000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDUtMy0xLTEtOTUxMzI_948961fe-8223-47f5-b036-d1fa8b6f4ab6"
      unitRef="usd">45000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDYtMS0xLTEtOTUxMzI_f558220f-46f2-4730-aa8c-395507f26d5e"
      unitRef="usd">-15263000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDYtMy0xLTEtOTUxMzI_6121c81e-2b57-4483-9786-01976a6b58ab"
      unitRef="usd">-176590000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDctMS0xLTEtOTUxMzI_781aab29-0741-4883-af3a-398bb181eb99"
      unitRef="usd">90443000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i36d5eba90bd24be5bcb0bc0710b286df_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDctMy0xLTEtOTUxMzI_85539eb5-17ca-49e5-99b1-91a82ca42226"
      unitRef="usd">348696000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDgtMS0xLTEtOTUxMzI_d70392e7-a3dc-43a6-b6ae-67986d22f763"
      unitRef="usd">75180000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i30a9b5385be843b8be329d54dfcdc192_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18yOC9mcmFnOjU5ODc0MTI3MWMwYzQyYjViYmYyMGU4NzIxMjM4MjZhL3RhYmxlOjNiNDA4MDM1YzFjMDQ1MmQ4NTcyMDMwNmYxZmMxYmYxL3RhYmxlcmFuZ2U6M2I0MDgwMzVjMWMwNDUyZDg1NzIwMzA2ZjFmYzFiZjFfNDgtMy0xLTEtOTUxMzI_1b802e02-cf21-440f-84f4-0d150b4610a2"
      unitRef="usd">172106000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfMTQ0NjM_01b5c6d9-9c63-4d58-b6f7-c00cdcc1f114">ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CareDx, Inc. (&#x201c;CareDx&#x201d; or the &#x201c;Company&#x201d;), together with its subsidiaries, is a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients and caregivers. The Company&#x2019;s headquarters are in Brisbane, California. The primary operations are in Brisbane, California; Omaha, Nebraska; Fremantle, Australia; and Stockholm, Sweden.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s commercially available testing services consist of AlloSure&#xae; Kidney, a donor-derived cell-free DNA (&#x201c;dd-cfDNA&#x201d;) solution for kidney transplant patients, AlloMap&#xae; Heart, a gene expression solution for heart transplant patients, AlloSure&#xae; Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure&#xae; Lung, a dd-cfDNA solution for lung transplant patients. The Company has initiated several clinical studies to generate data on its existing and planned future testing services. In April 2020, the Company announced its first biopharma research partnership for AlloCell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants. The Company also offers high-quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. The Company also provides digital solutions to transplant centers following the acquisitions of Ottr Complete Transplant Management (&#x201c;Ottr&#x201d;) and XynManagement, Inc. (&#x201c;XynManagement&#x201d;), as well as the acquisitions of TransChart LLC (&#x201c;TransChart&#x201d;), MedActionPlan.com, LLC (&#x201c;MedActionPlan&#x201d;) The Transplant Pharmacy, LLC (&#x201c;TTP&#x201d;) in 2021 and HLA Data Systems, LLC ("HLA Data Systems") in January 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Testing Services &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AlloSure Kidney has been a covered service for Medicare beneficiaries since October 2017 through a Local Coverage Determination (&#x201c;LCD&#x201d;) first issued by Palmetto MolDX (&#x201c;MolDX&#x201d;), which was formed to identify and establish coverage and reimbursement for molecular diagnostics tests, and adopted by Noridian Healthcare Solutions, the Company&#x2019;s Medicare Administrative Contractor (&#x201c;Noridian&#x201d;). The Medicare reimbursement rate for AlloSure Kidney is currently $2,841. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AlloMap Heart has been a covered service for Medicare beneficiaries since January 2006. The Medicare reimbursement rate for AlloMap Heart is currently $3,240. In October 2020, the Company received a final MolDX Medicare coverage decision for AlloSure Heart. Noridian issued a parallel coverage policy granting coverage for AlloSure Heart when used in conjunction with AlloMap Heart, which became effective in December 2020. The Medicare reimbursement rate for AlloSure Heart is currently $2,753.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March 2, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, MolDX issued a new billing article, with an effective date of March&#160;31, 2023, related to the LCD entitled Molecular Testing for Solid Organ Allograft Rejection (the &#x201c;Billing Article&#x201d;). Prior to the Billing Article&#x2019;s effective date, MolDX informed the affected parties, including CareDx, that enforcement of the revised billing practices outlined in the Billing Article will not be implemented until June&#160;30, 2023.  MolDX informed CareDx that its automatic adjudication process would remain in place until June 30, 2023, though claims submitted prior to that date must comply with the applicable LCDs. On May&#160;4, 2023, MolDX issued a revised new billing article with an effective date of March&#160;31, 2023 (the &#x201c;Revised Billing Article&#x201d; and together with the Billing Article, the &#x201c;Billing Articles&#x201d;).  The Revised Billing Article impacts Medicare coverage for AlloSure Kidney, AlloSure Heart and AlloMap Heart and requires certain companies, including CareDx, to implement new processes to address the requirements related to Medicare claim submissions. MolDX has stated that it views the Billing Article as clarifying existing coverage, especially as it relates to when tests are covered in the for-cause and surveillance contexts.  MolDX has acknowledged, however, that the Billing Article is a change as it relates to billing more than one test during a single patient encounter. Noridian has not yet adopted the new Billing Articles.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although the Company believes the Billing Articles are inconsistent with the LCDs, Noridian&#x2019;s and MolDX&#x2019;s responses to public comments explaining the intended scope of various LCDs, and medical necessity, the Company determined to pause its Medicare reimbursement submissions for AlloSure Kidney commencing on March&#160;7, 2023 to allow the Company further time to evaluate the implications of the Billing Article and update its billing processes for AlloSure Kidney tests by educating clinicians and working with centers to update CareDx&#x2019;s test order forms to capture the new information required under the Billing Article. Accordingly, the Company did not submit claims for approximately 3,200 AlloSure Kidney tests for Medicare reimbursement for the period from March&#160;7, 2023 through March&#160;31, 2023 and did not recognize revenue on these claims in the first quarter of 2023 aggregating to approximately $8.9 million (the &#x201c;Impacted March Tests&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2023, the Company plans to submit claims for Medicare reimbursement for the Impacted March Tests, following the delivery by the Company of a letter to Noridian explaining, among other things, (i) the Company&#x2019;s belief that the Billing Articles impose new restrictions on Medicare coverage for the CareDx tests from those contained in the existing LCDs, (ii) that the Company plans to submit claims for reimbursement for the Impacted March Tests for which the Company has not obtained additional information from the ordering physicians to be able to specifically determine whether these tests meet the new coverage restrictions contained in the Billing Articles, and (iii) that AlloSure Kidney orders with a date of service on or after March&#160;31, 2023 for other indications outside the parameters of the Revised Billing Article, or where the reason for testing &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;is not specified by the ordering physician, will either be held pending the receipt of additional information regarding medical necessity or submitted with a test description that is intended to identify those tests as falling outside the parameters of the Revised Billing Article.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CareDx continued the Medicare reimbursement submissions for AlloMap Heart or AlloSure Heart following the issuance of the Billing Articles. In addition, CareDx is considering informing Noridian that until Noridian adopts the Revised Billing Article, CareDx will continue to submit AlloSure Heart tests for reimbursement only when used in conjunction with AlloMap Heart. The Company is also considering informing Noridian that (i) until June 30, 2023, it plans to submit claims for reimbursement for AlloMap Heart and AlloSure Heart tests for which the Company has not obtained additional information from the ordering physicians to be able to specifically determine whether these tests meet the new coverage restrictions contained in the Billing Articles, and (ii) AlloSure Heart and AlloMap Heart orders placed on or after June&#160;30, 2023 for other indications outside the surveillance and for-cause parameters of the Billing Article, or where the reason for testing is not specified by the ordering physician, will either be held pending the receipt of additional information regarding medical necessity or submitted with a test description that is intended to identify those tests as falling outside the parameters of the Billing Articles. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AlloSure Kidney has received positive coverage decisions from several commercial payers, and is reimbursed by other private payers on a case-by-case basis.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AlloMap Heart has also received positive coverage decisions for reimbursement from many of the largest U.S. private payers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021 and March 2023, the Company purchased a minority investment of common stock in the biotechnology company Miromatrix Medical, Inc. (&#x201c;Miromatrix&#x201d;), for an aggregate amount of $5.1 million, and the investment is marked to market. Miromatrix works to eliminate the need for an organ transplant waiting list through the development of implantable engineered biological organs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Clinical Studies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2018, the Company initiated the Kidney Allograft Outcomes AlloSure Kidney Registry study (&#x201c;K-OAR&#x201d;), to develop additional data on the clinical utility of AlloSure Kidney for surveillance of kidney transplant recipients. K-OAR is a multicenter, non-blinded, prospective observational cohort study which has enrolled more than 1,700 renal transplant patients who will receive AlloSure Kidney long-term surveillance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, the Company initiated the Surveillance HeartCare&#x2122; Outcomes Registry (&#x201c;SHORE&#x201d;). SHORE is a prospective, multi-center, observational registry of patients receiving HeartCare for surveillance. HeartCare combines the gene expression profiling technology of AlloMap Heart with the dd-cfDNA analysis of AlloSure&#xae; Heart in one surveillance solution.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, AlloSure&#xae; Lung became available for lung transplant patients through a compassionate use program while the test is undergoing further studies. In June 2020, the Company submitted an AlloSure Lung application to the Palmetto MolDx Technical Assessment program seeking coverage and reimbursement for Medicare beneficiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company announced the commencement of the Outcomes of KidneyCare on Renal Allografts (&#x201c;OKRA&#x201d;) study, which is an extension of K-OAR. OKRA is a prospective, multi-center, observational, registry of patients receiving KidneyCare for surveillance. KidneyCare combines the dd-cfDNA analysis of AlloSure Kidney with the gene expression profiling technology of AlloMap Kidney and the predictive artificial intelligence technology of iBox for a multimodality surveillance solution. The Company has not yet made any applications to private payers for reimbursement coverage of AlloMap Kidney or KidneyCare.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s suite of AlloSeq products are commercial next generation sequencing (&#x201c;NGS&#x201d;)-based kitted solutions. These products include: AlloSeq&#x2122; Tx, a high-resolution Human Leukocyte Antigen (&#x201c;HLA&#x201d;) typing solution, AlloSeq&#x2122; cfDNA, a surveillance solution designed to measure dd-cfDNA in blood to detect active rejection in transplant recipients, and AlloSeq&#x2122; HCT, a solution for chimerism testing for stem cell transplant recipients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's other HLA typing products include: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Olerup &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SSP&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;based on the sequence specific primer (&#x201c;SSP&#x201d;) technology; and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;QTYPE&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which uses real-time polymerase chain reaction &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;PCR&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; methodology, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to perform HLA typing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company acquired certain assets of BFS Molecular S.R.L. (&#x201c;BFS Molecular&#x201d;), a software company focused on NGS-based patient testing solutions. BFS Molecular brings extensive software and algorithm development capabilities for NGS transplant surveillance products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Patient and Digital Solutions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the acquisitions of both Ottr and XynManagement, the Company is a leading provider of transplant patient management software (&#x201c;Ottr software&#x201d;), as well as of transplant quality tracking and waitlist management solutions. Ottr software provides comprehensive solutions for transplant patient management and enables integration with electronic medical &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;record (&#x201c;EMR&#x201d;) systems providing patient surveillance management tools and outcomes data to transplant centers. XynManagement provides two unique solutions, XynQAPI software (&#x201c;XynQAPI&#x201d;) and XynCare. XynQAPI simplifies transplant quality tracking and Scientific Registry of Transplant Recipients reporting. XynCare includes a team of transplant assistants who maintain regular contact with patients on the waitlist to help prepare for their transplant and maintain eligibility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company launched AlloCare, a mobile app that provides a patient-centric resource for transplant recipients to manage medication adherence, coordinate with Patient Care Managers for AlloSure scheduling and measure health metrics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company acquired TransChart. TransChart provides EMR software to hospitals throughout the U.S. to care for patients who have or may need an organ transplant. As part of the Company's acquisition of TransChart in January 2021, the Company acquired TxAccess, a cloud-based service that allows nephrologists and dialysis centers to electronically submit referrals to transplant programs, closely follow and assist patients through the transplant waitlist process, and ultimately, through transplantation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company acquired the Transplant Hero patient application. The application helps patients manage their medications through alarms and interactive logging of medication eve&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nts&lt;/span&gt;&lt;span style="color:#548dd4;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also in June 2021, the Company entered into a strategic agreement with OrganX, which was amended in April 2022, to develop clinical decision support tools across the transplant patient journey. Together, the Company and OrganX will develop advanced analytics that integrate AlloSure, the first transplant specific dd-cfDNA assay, with large transplant databases to provide clinical data solutions. This partnership delivers the next level of innovation beyond multi-modality by incorporating a variety of clinical inputs to create a universal composite scoring system. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreed to potential future milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the Company acquired MedActionPlan, a New Jersey-based provider of medication safety, medication adherence and patient education. MedActionPlan is a leader in patient medication management for transplant patients and beyond.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the Company acquired TTP, a transplant focused pharmacy located in Mississippi. TTP provides individualized transplant pharmacy services for patients at multiple transplant centers located throughout the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred significant losses and negative cash flows from operations since its inception and had an accumulated deficit of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$484.9 million at March&#160;31, 2023. As of March&#160;31, 2023, the Company had cash, cash equivalents and marketable securities of $285.9 million and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;no debt outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;At-the-Market Equity Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 14, 2022, the Company entered into a sales agreement (the &#x201c;Sales Agreement&#x201d;) with Jefferies, LLC as sales agent (&#x201c;Jefferies&#x201d;), pursuant to which the Company may offer and sell, from time to time, through Jefferies, up to $200.0&#160;million in shares of our common stock, by any method permitted by law deemed to be an &#x201c;at-the-market&#x201d; offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. Jefferies is entitled to compensation for its services equal to 3% of the gross proceeds of any shares of common stock sold through Jefferies under the Sales Agreement. Any shares of common stock offered and sold pursuant to the Sales Agreement will be issued and sold pursuant to our Registration Statement on Form S-3ASR (File No. 333-239049), filed with the SEC on June 9, 2020 (the &#x201c;Registration Statement&#x201d;), including a base prospectus dated June 9, 2020, and a prospectus supplement dated April 14, 2022. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Registration Statement will expire on June 9, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;3, 2022, the Company's Board of Directors approved a stock repurchase program (the "Repurchase Program"), whereby the Company may purchase up to $50&#160;million in shares of our common stock over a period of up to two years, commencing on December&#160;8, 2022. The Repurchase Program may be carried out at the discretion of a committee of the Board of Directors through open market purchases, one or more Rule 10b5-1 trading plans, block trades and in privately negotiated transactions. During the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three months ended March&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company purchased an aggregate of 59,472 shares of its common stock under the Repurchase Program for an aggregate purchase price of $0.7 million. As of March&#160;31, 2023, $48.7 million remained available for future share repurchase under the Repurchase Program.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="i6b98eb7a2f97454dad8515edac4bcb72_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNTQ5NzU1ODc1NDE2_337f48c1-bbdc-46ff-a311-9401ebffe370"
      unitRef="usd">2841</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="i0d63bba5fe4f40ce95ab4d66330c93ad_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNTQ5NzU1ODc1NDI1_c8998739-9e03-47f7-8a1f-4f00864c0629"
      unitRef="usd">3240</us-gaap:RecoveryOfDirectCosts>
    <us-gaap:RecoveryOfDirectCosts
      contextRef="i7bb05103813e4dd493ad38b4d1893919_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNTQ5NzU1ODc1NDM0_9fcaa934-6d79-4f73-b5f7-de89ee60aed5"
      unitRef="usd">2753</us-gaap:RecoveryOfDirectCosts>
    <cdna:UnsubmittedReimbursementClaimsForMedicare
      contextRef="iaefdfbd1b7ec4bf389377b07e872b922_I20230331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNTQ5NzU1ODc1NjYx_ad0ba58b-3442-4103-a803-ea0ccbcc23ce"
      unitRef="claim">3200</cdna:UnsubmittedReimbursementClaimsForMedicare>
    <cdna:UnsubmittedClaimsRevenueNotYetRecognized
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNTQ5NzU1ODc1NjU1_3d74d8e8-5e1b-45c7-8b08-bd48cd2bb137"
      unitRef="usd">8900000</cdna:UnsubmittedClaimsRevenueNotYetRecognized>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i784e3baffdcb4192964759f0c56d78ad_D20210501-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfMjk1OA_507e8ffa-dc65-49e5-8722-eb41bfa8598f"
      unitRef="usd">5100000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <cdna:NumberOfRenalTransplantPatients
      contextRef="ibf4af37bc739426e912a71dac9ba281d_I20180131"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfMzUwMA_daaa864f-0a54-4820-bce4-e01e4899fd16"
      unitRef="patient">1700</cdna:NumberOfRenalTransplantPatients>
    <cdna:NumberOfUniqueSolutions
      contextRef="iab7d98285c4b4d9ea5dd55cf1942b127_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNjQ0NQ_83ceae4d-08e1-4cf3-97b2-2f108b36d608"
      unitRef="unique_solution">2</cdna:NumberOfUniqueSolutions>
    <cdna:LiquidityPolicyTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfMTQ0Njc_30ed1e80-f1f5-4ead-a475-2b8c510c186e">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred significant losses and negative cash flows from operations since its inception and had an accumulated deficit of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$484.9 million at March&#160;31, 2023. As of March&#160;31, 2023, the Company had cash, cash equivalents and marketable securities of $285.9 million and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;no debt outstanding.&lt;/span&gt;&lt;/div&gt;</cdna:LiquidityPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfMTI2NTY_6657f1dd-2b4e-4be4-954a-bcbd85c054a6"
      unitRef="usd">-484900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfMTI3NDQ_757e4eae-f729-49e4-ba8c-8979de74b365"
      unitRef="usd">285900000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <cdna:SaleOfStockAuthorizedConsiderationAmountMaximum
      contextRef="i696a715cb3c04fb38124dcb7c37602f8_I20220414"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNjU5NzA2OTc4OTcxMA_97c50e36-c904-4d80-99fc-dd6531af8f03"
      unitRef="usd">200000000</cdna:SaleOfStockAuthorizedConsiderationAmountMaximum>
    <cdna:SaleOfStockCommissionFeePercentage
      contextRef="iaaeec918b90c4ba5bb1acfd6106ce79b_D20220414-20220414"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNjU5NzA2OTc4OTcyOQ_1b024e99-cb50-4953-99df-76ece5d17577"
      unitRef="number">0.03</cdna:SaleOfStockCommissionFeePercentage>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i13b9c2985d5d4d1e9ce7abfd085614c5_I20221203"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNjU5NzA2OTc4OTg4Nw_7c5124e2-77e1-405e-89ea-f65ae163be00"
      unitRef="usd">50000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramPeriodInForce1
      contextRef="ifcd6a13ba0f945cbb58e45d6f9688338_D20221208-20221208"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfMjc0ODc3OTA5NTU1NQ_90160a65-1db5-4387-8bf1-1bf0445a7327">P2Y</us-gaap:StockRepurchaseProgramPeriodInForce1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNjU5NzA2OTc5MDI0NQ_c95f7f29-a0e4-490c-a0f0-357c273befc8"
      unitRef="shares">59472</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNjU5NzA2OTc5MDM0MA_1443c92a-3a93-4818-b6b1-7a917d0a0d7c"
      unitRef="usd">700000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNC9mcmFnOjM1MmIxNmQyMDI5NzQ3MWJiYTEzYjc4NGI5N2QwZGExL3RleHRyZWdpb246MzUyYjE2ZDIwMjk3NDcxYmJhMTNiNzg0Yjk3ZDBkYTFfNjU5NzA2OTc5MDM1Ng_a1465332-2c6e-4f81-9480-09bddefd2dd7"
      unitRef="usd">48700000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMTE3NzY_6c0e34db-cf84-48ab-937a-4896bdb1347d">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:10pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant accounting policies and estimates used in preparation of the unaudited condensed consolidated financial statements are described in the Company&#x2019;s audited consolidated financial statements as of and for the year ended December&#160;31, 2022, and the notes thereto, which are included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the Securities and Exchange Commission (the "SEC") on February&#160;27, 2023. Material changes to the significant accounting policies previously disclosed in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022 are reflected below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;), and follow the requirements of the SEC for interim reporting. As permitted under those rules, certain notes and other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company&#x2019;s financial information. The condensed consolidated balance sheet as of December&#160;31, 2022 has been derived from audited consolidated financial statements as of that date but does not include all of the financial information required by U.S. GAAP for complete financial statements. Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to transaction price estimates used for testing services revenue; standalone fair value of patient and digital solutions revenue performance obligations; accrued expenses for clinical studies;&#160;inventory valuation;&#160;the fair value of issued common stock warrants and embedded derivatives; the fair value of assets and liabilities acquired in a business combination or an assets acquisition (including identifiable intangible assets acquired);&#160;the fair value of contingent consideration recorded in connection with a business combination or an asset acquisition; the grant date fair value assumptions used to estimate stock-based compensation expense; income taxes; impairment of long-lived assets and indefinite-lived assets (including goodwill); and legal contingencies. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2023 and 2022, approximately 42% and 54%, respectively, of total revenue was derived from Medicare. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023 and December&#160;31, 2022, approximately 26% and 27%, respectively, of accounts receivable was due from Medicare. No other payer or customer represented more than 10% of accounts receivable at either March&#160;31, 2023 or December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments in securities with a maturity of greater than three months at the time of purchase to be marketable securities. As of March&#160;31, 2023, the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&#x2019;s short-term marketable securities consisted of corporate debt securities with maturities of greater than three months but less than twelve months at the time of purchase, which were classified as current assets on the condensed consolidated balance sheet&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies its short-term marketable securities as held-to-maturity at the time of purchase and reevaluates such designation at each balance sheet date. The Company has the positive intent and ability to hold these marketable securities to maturity. Short-term marketable securities are carried at amortized cost and are adjusted for amortization of premiums and accretion of discounts to maturity, which is included i&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n interest income (expense), net on the condensed consolidated statements of operations. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on short-term marketable securities are included in interest income (expense), net. The cost of securities sold will be determined using specific identification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers investments in securities with remaining maturities of over one year as long-term investments. As of March&#160;31, 2023, the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company's long-term marketable securities consisted of corporate equity securities and corporate debt securities. These long-term marketable securities are classified as other assets on the condensed consolidated balance sheet&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies its long-term marketable debt securities as available-for-sale and reevaluates such designation at each balance sheet date. Unrealized gains and losses from the reevaluation of the long-term marketable debt securities, if any, are included in other comprehensive gain (loss) in the condensed consolidated statement of comprehensive income (loss). Realized gains and losses and declines in value judged to be other-than-temporary, if any, on long-term marketable securities are included in interest income, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records its long-term marketable equity securities at fair market value. Unrealized gains and losses from the remeasurement of the long-term marketable equity securities to fair value are included in other income (expense), net, in the condensed consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted Accounting Standard Codification (&#x201c;ASC&#x201d;) Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and determines if an arrangement is or contains a lease at contract inception. A right-of-use (&#x201c;ROU&#x201d;) asset, representing the underlying asset during the lease term, and a lease liability, representing the payment obligation arising from the lease, are recognized on the condensed consolidated balance sheet at lease commencement based on the present value of the payment obligation. For operating leases, expense is recognized on a straight-line basis over the lease term. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the ROU asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company's facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with an initial term of 12 months or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company&#x2019;s leases had remaining terms of 0.67 years to 9.85 years, some of which include options to extend the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue from testing services, product sales and patient and digital solutions revenue in the amount that reflects the consideration that it expects to be entitled in exchange for goods or services as it transfers control to its customers. Revenue is recorded considering a five-step revenue recognition model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations and recognizing revenue when, or as, an entity satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Testing Services Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AlloSure Kidney, AlloMap Heart, AlloSure Heart and AlloSure Lung patient tests are ordered by healthcare providers. The Company receives a test requisition form with payer information along with a collected patient blood sample. The Company considers the patient to be its customer and the test requisition form to be the contract. Testing services are performed in the Company&#x2019;s laboratory. Testing services represent one performance obligation in a contract and are performed when results of the test are provided to the healthcare provider, at a point in time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The healthcare providers that order the tests and on whose behalf the Company provides testing services are generally not responsible for the payment of these services. The first and second revenue recognition criteria are satisfied when the Company receives a test requisition form with payer information from the healthcare provider. Generally, the Company bills third-party payers upon delivery of an AlloSure Kidney, AlloMap Heart, AlloSure Heart or AlloSure Lung test result to the healthcare provider. Amounts received may vary amongst payers based on coverage practices and policies of the payer. The Company has used the portfolio approach under Accounting Standards Codification ("ASC") Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to identify financial classes of payers. Revenue recognized for Medicare and other contracted payers is based on the agreed current reimbursement rate per test, adjusted for historical collection trends where applicable. The Company estimates revenue for non-contracted payers and self-payers using transaction prices determined for each financial class of payers using history of reimbursements. This includes analysis of an average reimbursement per test and a percentage of tests reimbursed. This estimate requires significant judgment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company monitors revenue estimates at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Changes in transaction price estimates are updated quarterly based on actual cash collected or changes made to contracted rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 2, 2023, MolDX issued a new Billing Article, with an effective date of March&#160;31, 2023. The Billing Article impacts Medicare coverage for AlloSure Kidney, AlloSure Heart and AlloMap and requires the Company to implement new processes to address requirements related to Medicare claim submissions. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC 606-10-25-1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; requires the Company to assess whether it is probable that it will collect substantially all of the consideration to which it will be entitled. Based upon the Company&#x2019;s review of the Billing Article, it was determined to pause Medicare reimbursement submissions for AlloSure Kidney commencing on March&#160;7, 2023 that created uncertainty around the collection of the claims. Accordingly, the Company did not recognize revenue for approximately 3,200 AlloSure Kidney tests aggregating to $8.9 million for the three months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenue is recognized from the sale of products to end-users, distributors and strategic partners when all revenue recognition criteria are satisfied. The Company generally has a contract or a purchase order from a customer with the specified required terms of order, including the number of products ordered. Transaction prices are determinable and products are delivered and risk of loss passed to the customer upon either shipping or delivery, as per the terms of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patient and Digital Solutions Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient and digital solutions revenue is mainly derived from a combination of software as a service ("SaaS") and perpetual software license agreements entered into with various transplant centers, which are the Company's customers for this class of revenue. The main performance obligations in connection with the Company's SaaS and perpetual software license agreement are the following: (i) implementation services and delivery of the perpetual software license are considered a single performance obligation, and (ii) post contract support. The Company allocates the transaction price to each performance obligation based on relative stand-alone selling prices of each distinct performance obligation. Digital revenue in connection with perpetual software license agreements is recognized over time based on the Company&#x2019;s satisfaction of each distinct performance obligation in each agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Perpetual software license agreements typically require advance payments from customers upon the achievement of certain milestones. The Company records deferred revenue in relation to these agreements when cash payments are received, or invoices are issued in advance of the Company&#x2019;s performance, and generally recognizes revenue over the contractual term, as performance obligations are fulfilled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company derives patient and digital solutions revenue from software subscriptions and medication sales. The Company generally bills software subscription fees in advance. Revenue from software subscriptions is deferred and recognized ratably over the subscription term. The medication sales revenue is recognized based on the negotiated contract price with the governmental, commercial and non-commercial payers with any applicable patient co-pay. The Company recognizes revenue from medication sales when prescriptions are delivered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2021-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which contains amendments that require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model. The disclosures include (1) the types of assistance, (2) an entity&#x2019;s accounting for the assistance, and (3) the effect of the assistance on an entity&#x2019;s financial statements. The amendments set forth in this ASU are effective for all entities for annual periods beginning after December 15, 2021. Early application of the amendments in this ASU is permitted. The amendments in this ASU should be applied either (1) prospectively to all transactions within the scope of the amendments that are reflected in financial statements at the date of initial application and new transactions that are entered into after the date of initial application or (2) retrospectively to those transactions. The Company adopted the standard prospectively on January 1, 2022. The adoption of this new standard had no impact on the Company's consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU No. 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires that an entity recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with ASC 606 as if it had originated the contracts. The amendments set forth in this ASU are effective for fiscal years beginning after December 15, 2022. Early adoption of the amendments is permitted. The amendments in this ASU should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company adopted the standard prospectively on January 1, 2022. The adoption of this new standard had no material impact on the Company's consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the FASB issued ASU No. 2021-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified &lt;/span&gt;&lt;/div&gt;Written Call Options (a consensus of the FASB Emerging Issues Task Force), which contains amendments that clarify and reduce diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after modification or exchange. The amendments set forth in this ASU are effective for all entities for annual periods beginning after December 15, 2021. Early application of the amendments in this ASU is permitted for all entities. The amendments in this ASU should be applied prospectively. The Company adopted the standard prospectively on January 1, 2022. The adoption of this new standard had no impact on the Company's consolidated financial statements and disclosures.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMTE3Nzc_6779409b-ee5c-47b6-81fa-3241cf49531b">&lt;div style="margin-top:10pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;), and follow the requirements of the SEC for interim reporting. As permitted under those rules, certain notes and other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments that are necessary for a fair statement of the Company&#x2019;s financial information. The condensed consolidated balance sheet as of December&#160;31, 2022 has been derived from audited consolidated financial statements as of that date but does not include all of the financial information required by U.S. GAAP for complete financial statements. Operating results for the three months ended March&#160;31, 2023 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMTE3ODI_f5976829-25eb-4c26-8c4c-b15cf4acf2cc">&lt;div style="margin-top:10pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the unaudited condensed consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to transaction price estimates used for testing services revenue; standalone fair value of patient and digital solutions revenue performance obligations; accrued expenses for clinical studies;&#160;inventory valuation;&#160;the fair value of issued common stock warrants and embedded derivatives; the fair value of assets and liabilities acquired in a business combination or an assets acquisition (including identifiable intangible assets acquired);&#160;the fair value of contingent consideration recorded in connection with a business combination or an asset acquisition; the grant date fair value assumptions used to estimate stock-based compensation expense; income taxes; impairment of long-lived assets and indefinite-lived assets (including goodwill); and legal contingencies. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMTE3ODg_874c17a0-dae8-4225-bb1a-b0234c0825c1">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2023 and 2022, approximately 42% and 54%, respectively, of total revenue was derived from Medicare. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023 and December&#160;31, 2022, approximately 26% and 27%, respectively, of accounts receivable was due from Medicare. No other payer or customer represented more than 10% of accounts receivable at either March&#160;31, 2023 or December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3a52955612044b80bdc44719634b8f15_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMzEzNw_bbebe8da-0893-4bc1-8d8b-238a7baf00cf"
      unitRef="number">0.42</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i00bf0bbaedf542d7bd5c59ac9504d720_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMzE0NA_25295896-d0d2-4b90-8063-603e9c7926ce"
      unitRef="number">0.54</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i380c3aacb19e456dab0fbafc4081feb5_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMzIzOA_96dc7022-8cb4-467d-8da7-0418de448e72"
      unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if08f4ea8cdfd44269e800431266d73fc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMzI0NQ_f789d90a-77c4-46c0-aa02-c0731fe47189"
      unitRef="number">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMTE3ODM_8abab440-ddc3-4791-9c24-d0e17af482fe">&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments in securities with a maturity of greater than three months at the time of purchase to be marketable securities. As of March&#160;31, 2023, the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&#x2019;s short-term marketable securities consisted of corporate debt securities with maturities of greater than three months but less than twelve months at the time of purchase, which were classified as current assets on the condensed consolidated balance sheet&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies its short-term marketable securities as held-to-maturity at the time of purchase and reevaluates such designation at each balance sheet date. The Company has the positive intent and ability to hold these marketable securities to maturity. Short-term marketable securities are carried at amortized cost and are adjusted for amortization of premiums and accretion of discounts to maturity, which is included i&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n interest income (expense), net on the condensed consolidated statements of operations. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on short-term marketable securities are included in interest income (expense), net. The cost of securities sold will be determined using specific identification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers investments in securities with remaining maturities of over one year as long-term investments. As of March&#160;31, 2023, the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company's long-term marketable securities consisted of corporate equity securities and corporate debt securities. These long-term marketable securities are classified as other assets on the condensed consolidated balance sheet&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;The Company classifies its long-term marketable debt securities as available-for-sale and reevaluates such designation at each balance sheet date. Unrealized gains and losses from the reevaluation of the long-term marketable debt securities, if any, are included in other comprehensive gain (loss) in the condensed consolidated statement of comprehensive income (loss). Realized gains and losses and declines in value judged to be other-than-temporary, if any, on long-term marketable securities are included in interest income, net.The Company records its long-term marketable equity securities at fair market value. Unrealized gains and losses from the remeasurement of the long-term marketable equity securities to fair value are included in other income (expense), net, in the condensed consolidated statements of operations.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMTE3ODk_3315efa1-3c53-4af6-8b22-9ded09662578">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted Accounting Standard Codification (&#x201c;ASC&#x201d;) Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and determines if an arrangement is or contains a lease at contract inception. A right-of-use (&#x201c;ROU&#x201d;) asset, representing the underlying asset during the lease term, and a lease liability, representing the payment obligation arising from the lease, are recognized on the condensed consolidated balance sheet at lease commencement based on the present value of the payment obligation. For operating leases, expense is recognized on a straight-line basis over the lease term. For finance leases, interest expense on the lease liability is recognized using the effective interest method and amortization of the ROU asset is recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company's facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with an initial term of 12 months or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <cdna:RemainingOperatingAndFinanceLeaseTerm
      contextRef="i8a65e524e31741e4b69720fd09cbf601_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMTE3ODU_e55b3ea4-d16d-4ac5-84f2-31a1fd46674b">P0Y8M1D</cdna:RemainingOperatingAndFinanceLeaseTerm>
    <cdna:RemainingOperatingAndFinanceLeaseTerm
      contextRef="i739a68ac0826477da4feb1f814aab614_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMTE3ODY_5d94d058-68f6-4bb9-9b8b-605c976239bb">P9Y10M6D</cdna:RemainingOperatingAndFinanceLeaseTerm>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMjE5OTAyMzI3OTcyNQ_a28287e5-baf0-449b-a43a-5e091595dfb4">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue from testing services, product sales and patient and digital solutions revenue in the amount that reflects the consideration that it expects to be entitled in exchange for goods or services as it transfers control to its customers. Revenue is recorded considering a five-step revenue recognition model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations and recognizing revenue when, or as, an entity satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Testing Services Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AlloSure Kidney, AlloMap Heart, AlloSure Heart and AlloSure Lung patient tests are ordered by healthcare providers. The Company receives a test requisition form with payer information along with a collected patient blood sample. The Company considers the patient to be its customer and the test requisition form to be the contract. Testing services are performed in the Company&#x2019;s laboratory. Testing services represent one performance obligation in a contract and are performed when results of the test are provided to the healthcare provider, at a point in time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The healthcare providers that order the tests and on whose behalf the Company provides testing services are generally not responsible for the payment of these services. The first and second revenue recognition criteria are satisfied when the Company receives a test requisition form with payer information from the healthcare provider. Generally, the Company bills third-party payers upon delivery of an AlloSure Kidney, AlloMap Heart, AlloSure Heart or AlloSure Lung test result to the healthcare provider. Amounts received may vary amongst payers based on coverage practices and policies of the payer. The Company has used the portfolio approach under Accounting Standards Codification ("ASC") Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to identify financial classes of payers. Revenue recognized for Medicare and other contracted payers is based on the agreed current reimbursement rate per test, adjusted for historical collection trends where applicable. The Company estimates revenue for non-contracted payers and self-payers using transaction prices determined for each financial class of payers using history of reimbursements. This includes analysis of an average reimbursement per test and a percentage of tests reimbursed. This estimate requires significant judgment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company monitors revenue estimates at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Changes in transaction price estimates are updated quarterly based on actual cash collected or changes made to contracted rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 2, 2023, MolDX issued a new Billing Article, with an effective date of March&#160;31, 2023. The Billing Article impacts Medicare coverage for AlloSure Kidney, AlloSure Heart and AlloMap and requires the Company to implement new processes to address requirements related to Medicare claim submissions. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC 606-10-25-1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; requires the Company to assess whether it is probable that it will collect substantially all of the consideration to which it will be entitled. Based upon the Company&#x2019;s review of the Billing Article, it was determined to pause Medicare reimbursement submissions for AlloSure Kidney commencing on March&#160;7, 2023 that created uncertainty around the collection of the claims. Accordingly, the Company did not recognize revenue for approximately 3,200 AlloSure Kidney tests aggregating to $8.9 million for the three months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product revenue is recognized from the sale of products to end-users, distributors and strategic partners when all revenue recognition criteria are satisfied. The Company generally has a contract or a purchase order from a customer with the specified required terms of order, including the number of products ordered. Transaction prices are determinable and products are delivered and risk of loss passed to the customer upon either shipping or delivery, as per the terms of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patient and Digital Solutions Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient and digital solutions revenue is mainly derived from a combination of software as a service ("SaaS") and perpetual software license agreements entered into with various transplant centers, which are the Company's customers for this class of revenue. The main performance obligations in connection with the Company's SaaS and perpetual software license agreement are the following: (i) implementation services and delivery of the perpetual software license are considered a single performance obligation, and (ii) post contract support. The Company allocates the transaction price to each performance obligation based on relative stand-alone selling prices of each distinct performance obligation. Digital revenue in connection with perpetual software license agreements is recognized over time based on the Company&#x2019;s satisfaction of each distinct performance obligation in each agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Perpetual software license agreements typically require advance payments from customers upon the achievement of certain milestones. The Company records deferred revenue in relation to these agreements when cash payments are received, or invoices are issued in advance of the Company&#x2019;s performance, and generally recognizes revenue over the contractual term, as performance obligations are fulfilled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company derives patient and digital solutions revenue from software subscriptions and medication sales. The Company generally bills software subscription fees in advance. Revenue from software subscriptions is deferred and recognized ratably over the subscription term. The medication sales revenue is recognized based on the negotiated contract price with the governmental, commercial and non-commercial payers with any applicable patient co-pay. The Company recognizes revenue from medication sales when prescriptions are delivered.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <cdna:UnsubmittedReimbursementClaimsForMedicare
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMzg0ODI5MDcyNjAyOQ_f0f9c07b-80fa-489b-8e29-56503f8f3eb8"
      unitRef="unique_solution">3200</cdna:UnsubmittedReimbursementClaimsForMedicare>
    <cdna:UnsubmittedClaimsRevenueNotYetRecognized
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfNTQ5NzU1ODQyMjc3_3d74d8e8-5e1b-45c7-8b08-bd48cd2bb137"
      unitRef="usd">8900000</cdna:UnsubmittedClaimsRevenueNotYetRecognized>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18zNy9mcmFnOmNmNDUyNmUyOGIzNDQwMTBhY2ZjMWE5OGE3MzYzZjNlL3RleHRyZWdpb246Y2Y0NTI2ZTI4YjM0NDAxMGFjZmMxYTk4YTczNjNmM2VfMTE3ODQ_3b8be661-26b1-439f-854a-0961b68ebb01">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2021-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which contains amendments that require annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model. The disclosures include (1) the types of assistance, (2) an entity&#x2019;s accounting for the assistance, and (3) the effect of the assistance on an entity&#x2019;s financial statements. The amendments set forth in this ASU are effective for all entities for annual periods beginning after December 15, 2021. Early application of the amendments in this ASU is permitted. The amendments in this ASU should be applied either (1) prospectively to all transactions within the scope of the amendments that are reflected in financial statements at the date of initial application and new transactions that are entered into after the date of initial application or (2) retrospectively to those transactions. The Company adopted the standard prospectively on January 1, 2022. The adoption of this new standard had no impact on the Company's consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU No. 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires that an entity recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;). At the acquisition date, an acquirer should account for the related revenue contracts in accordance with ASC 606 as if it had originated the contracts. The amendments set forth in this ASU are effective for fiscal years beginning after December 15, 2022. Early adoption of the amendments is permitted. The amendments in this ASU should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company adopted the standard prospectively on January 1, 2022. The adoption of this new standard had no material impact on the Company's consolidated financial statements and disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the FASB issued ASU No. 2021-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified &lt;/span&gt;&lt;/div&gt;Written Call Options (a consensus of the FASB Emerging Issues Task Force), which contains amendments that clarify and reduce diversity in an issuer's accounting for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after modification or exchange. The amendments set forth in this ASU are effective for all entities for annual periods beginning after December 15, 2021. Early application of the amendments in this ASU is permitted for all entities. The amendments in this ASU should be applied prospectively. The Company adopted the standard prospectively on January 1, 2022. The adoption of this new standard had no impact on the Company's consolidated financial statements and disclosures.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RleHRyZWdpb246YjZkNDdlMGViMjhiNDcxMzg2NzYzYTIwMWUzOTRmYjhfNTk0_5613cab7-7ab7-4fb8-9447-4fcc4c5a8453">NET LOSS PER SHARE&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per share have been computed by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of common share equivalents as their effect would have been antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the computation of the Company&#x2019;s basic and diluted net loss per share (in thousands, except shares and per share data):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss used to compute basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,648)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used to compute basic and diluted net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,643,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,015,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from diluted net loss per share as of March&#160;31, 2023 and 2022 because their effect would be antidilutive:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock subject to outstanding options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,248,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,091,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock subject to outstanding common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,096,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,047,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,347,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,142,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RleHRyZWdpb246YjZkNDdlMGViMjhiNDcxMzg2NzYzYTIwMWUzOTRmYjhfNTkx_1d7f30da-a2d7-4dd0-bece-db00da0b7757">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the computation of the Company&#x2019;s basic and diluted net loss per share (in thousands, except shares and per share data):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.214%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.920%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss used to compute basic and diluted net loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,749)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,648)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used to compute basic and diluted net loss per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,643,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,015,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfMy01LTEtMS05NTEzMg_2b0a312a-c249-49a5-b8bb-4990a34fc25f"
      unitRef="usd">-23749000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfMy01LTEtMS05NTEzMg_aa960fac-62ca-4263-8285-aded1a0ac094"
      unitRef="usd">-23749000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfMy03LTEtMS05NTEzMg_5aca0ac1-feac-4bd8-8d3d-91d1342455a4"
      unitRef="usd">-19648000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfMy03LTEtMS05NTEzMg_9ee5bbc9-a7ca-4524-becc-59adf7d944d7"
      unitRef="usd">-19648000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfNS01LTEtMS05NTEzMg_27555fdf-b150-45bd-8d79-0e160aa5eef5"
      unitRef="shares">53643216</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfNS01LTEtMS05NTEzMg_68a8a31c-d2a1-4e50-89fa-89a4ee7e6f91"
      unitRef="shares">53643216</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfNS03LTEtMS05NTEzMg_c0a28f3c-ff35-4803-9c6d-5afa001f38d2"
      unitRef="shares">53015459</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfNS03LTEtMS05NTEzMg_dd92497a-008b-494d-8ef3-7bd2f0f90bff"
      unitRef="shares">53015459</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfNy01LTEtMS05NTEzMg_4a9506fc-f7b9-4ab8-a340-1f726553cc05"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfNy01LTEtMS05NTEzMg_9fa1ba20-87a2-48cf-8147-bbe08700a6d6"
      unitRef="usdPerShare">-0.44</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfNy03LTEtMS05NTEzMg_add1db06-fa70-4e5a-923a-853cc05f779f"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOmJlMTQ3ZDE5YzM5ZjQ5YTk4MGNlNDE3MjNjYTljNmFlL3RhYmxlcmFuZ2U6YmUxNDdkMTljMzlmNDlhOTgwY2U0MTcyM2NhOWM2YWVfNy03LTEtMS05NTEzMg_dea698bb-4af8-4cef-beba-cd026f5c6aa2"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RleHRyZWdpb246YjZkNDdlMGViMjhiNDcxMzg2NzYzYTIwMWUzOTRmYjhfNTky_cac96c93-07f6-4869-b644-3277d7bf6012">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities have been excluded from diluted net loss per share as of March&#160;31, 2023 and 2022 because their effect would be antidilutive:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock subject to outstanding options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,248,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,091,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock subject to outstanding common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,096,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,047,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common stock equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,347,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,142,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iff28c97b627c426b88f8092a57b829b0_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOjQwODRjZTMzMzRhNDQ5OGY5YmRkYzU4ZjQ0YjYzMGVkL3RhYmxlcmFuZ2U6NDA4NGNlMzMzNGE0NDk4ZjliZGRjNThmNDRiNjMwZWRfMi0xLTEtMS05NTEzMg_37b9dd1b-cf96-40c6-b940-6325ff108536"
      unitRef="shares">3248696</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia352f8b90bf24904ace711c2756fde74_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOjQwODRjZTMzMzRhNDQ5OGY5YmRkYzU4ZjQ0YjYzMGVkL3RhYmxlcmFuZ2U6NDA4NGNlMzMzNGE0NDk4ZjliZGRjNThmNDRiNjMwZWRfMi0zLTEtMS05NTEzMg_6f2ac600-fe4c-4b2e-b18c-b6898d55aa1f"
      unitRef="shares">2091422</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i98353659a42b486aba5e86487dd2ed3a_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOjQwODRjZTMzMzRhNDQ5OGY5YmRkYzU4ZjQ0YjYzMGVkL3RhYmxlcmFuZ2U6NDA4NGNlMzMzNGE0NDk4ZjliZGRjNThmNDRiNjMwZWRfMy0xLTEtMS05NTEzMg_ee1f82d3-b53b-4d8b-8658-6c630537c4c5"
      unitRef="shares">3132</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6dbca87d33d445efa90f6f1256c6c729_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOjQwODRjZTMzMzRhNDQ5OGY5YmRkYzU4ZjQ0YjYzMGVkL3RhYmxlcmFuZ2U6NDA4NGNlMzMzNGE0NDk4ZjliZGRjNThmNDRiNjMwZWRfMy0zLTEtMS05NTEzMg_d3178eb8-2798-40be-a475-848bc6df3d1f"
      unitRef="shares">3132</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i916c5dbd66ef41e99dfbf453408341f9_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOjQwODRjZTMzMzRhNDQ5OGY5YmRkYzU4ZjQ0YjYzMGVkL3RhYmxlcmFuZ2U6NDA4NGNlMzMzNGE0NDk4ZjliZGRjNThmNDRiNjMwZWRfNS0xLTEtMS05NTEzMg_8a256d21-df3d-495f-af4d-e595655dedba"
      unitRef="shares">4096014</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idd28b8c71bc54b94ac5b492390a28cbd_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOjQwODRjZTMzMzRhNDQ5OGY5YmRkYzU4ZjQ0YjYzMGVkL3RhYmxlcmFuZ2U6NDA4NGNlMzMzNGE0NDk4ZjliZGRjNThmNDRiNjMwZWRfNS0zLTEtMS05NTEzMg_c2219d49-6047-43ce-bf6d-f03317bfa315"
      unitRef="shares">2047657</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOjQwODRjZTMzMzRhNDQ5OGY5YmRkYzU4ZjQ0YjYzMGVkL3RhYmxlcmFuZ2U6NDA4NGNlMzMzNGE0NDk4ZjliZGRjNThmNDRiNjMwZWRfNi0xLTEtMS05NTEzMg_cedef7af-e12c-40ce-ac40-9f6888052c83"
      unitRef="shares">7347842</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180MC9mcmFnOmI2ZDQ3ZTBlYjI4YjQ3MTM4Njc2M2EyMDFlMzk0ZmI4L3RhYmxlOjQwODRjZTMzMzRhNDQ5OGY5YmRkYzU4ZjQ0YjYzMGVkL3RhYmxlcmFuZ2U6NDA4NGNlMzMzNGE0NDk4ZjliZGRjNThmNDRiNjMwZWRfNi0zLTEtMS05NTEzMg_05ca5320-18b7-4af2-a1e3-edb0806ce65a"
      unitRef="shares">4142211</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RleHRyZWdpb246YjNjMzVhMmQxYzU4NGQ1MWE1ZjE4YWUyODA1MGEyMjRfNjE2Nw_a0daf0e5-7e5c-4fff-bcfd-beb7fcf2b284">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records its financial assets and liabilities at fair value.&#160;The carrying amounts of certain financial instruments of the Company, including cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities.&#160;&#160;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date.&#160;The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 1: Inputs that include quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the Company&#x2019;s financial assets and liabilities, measured at fair value on a recurring basis, as of March&#160;31, 2023 and December&#160;31, 2022 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measured Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Balance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measured Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Balance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the issuances, exercises, changes in fair value and reclassifications of the Company&#x2019;s Level 3 financial instruments that are measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock Warrant Liability and Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in estimated fair value of common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in estimated fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Addition of estimated fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments related to contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During March 2023, the Company wrote off $1.0&#160;million of its investment in convertible preferred shares from a private company which was carried at cost.  This private company's operations are in the process of being liquidated.  The fair value of this investment was based on Level 3 inputs. &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining fair value, the Company uses various valuation approaches within the fair value measurement framework.&#160;&#160;The valuation methodologies used for the Company&#x2019;s instruments measured at fair value and their classification in the valuation hierarchy are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Investments in money market funds are classified within Level 1. Money market funds are valued at the closing price reported by the fund sponsor from an actively traded exchange.&#160;At March&#160;31, 2023 and December&#160;31, 2022, money market funds were included as cash and cash equivalents in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Short-term marketable securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Investments in short-term marketable securities are classified within Level 2. The securities are valued using third-party pricing sources. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Long-term marketable equity and debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013; Investments in long-term marketable equity securities are classified within Level 1. The securities are recorded at fair value based on readily available quoted market prices in active markets. Investments in long-term marketable debt securities are classified within Level 2. The securities are recorded at fair value based on observable inputs for quoted prices for identical or similar assets in markets that are not active. Long-term marketable securities are located within other assets on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Contingent consideration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration is classified within Level 3. Contingent consideration relates to asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;acquisitions and business combinations. The Company recorded the estimate of the fair value of the contingent consideration based on its evaluation of the probability of the achievement of the contractual &lt;/span&gt;&lt;/div&gt;conditions that would result in the payment of the contingent consideration. Contingent consideration was estimated using the fair value of the milestones to be paid if the contingency is met multiplied by management&#x2019;s estimate of the probability of success at a discounted rate of 7% and 12% at March&#160;31, 2023 and December&#160;31, 2022, respectively. The significant input in the Level 3 measurement that is not supported by market activity is the Company&#x2019;s probability assessment of the achievement of the milestones. The value of the liability is subsequently remeasured to fair value at each reporting date, and the change in estimated fair value is recorded as a component of operating expenses until the milestones are paid, expire or are no longer achievable. Increases or decreases in the estimation of the probability percentage result in a directionally similar impact to the fair value measurement of the contingent consideration liability. The carrying amount of the contingent consideration liability represents its fair value. &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:32.5pt"&gt;Common stock warrant liability&lt;/span&gt; &#x2013; Common stock warrant liability is classified within Level 3. The Company utilizes intrinsic value to estimate the fair value of the warrants.&#160;The intrinsic value is computed as the difference between the fair value of the Company&#x2019;s common stock on the valuation date and the exercise price of the warrants. Increases (decreases) in the Company's stock price discussed above result in a directionally similar impact to the fair value of the common stock warrant liability.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RleHRyZWdpb246YjNjMzVhMmQxYzU4NGQ1MWE1ZjE4YWUyODA1MGEyMjRfNjE2Mw_15e7c17e-e550-4fc7-8f81-4f6e7b23a881">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the Company&#x2019;s financial assets and liabilities, measured at fair value on a recurring basis, as of March&#160;31, 2023 and December&#160;31, 2022 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measured Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Balance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measured Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Balance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6feff843c95d4820a893f80a14e8974a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfNS0xLTEtMS05NTEzMg_b0cae7a9-cfed-4d35-83bc-412ea26c53bd"
      unitRef="usd">55315000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i83fa354129c74d06b48b4acdeb58085e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfNS0zLTEtMS05NTEzMg_49a59c7d-ae55-4b1e-ac15-14924469944a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i954505cbda704b1997a446ed7dc5bd79_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfNS01LTEtMS05NTEzMg_5de66cca-4f29-4628-819a-c652a9a63f8b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1d197e2a742549a0b82fa9569fafad92_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfNS03LTEtMS05NTEzMg_d00bf6e4-e301-430b-8c18-896612c1ffd4"
      unitRef="usd">55315000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i78df972b73c44af19aec5841bf4e9ad2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfNy0xLTEtMS05NTEzMg_2a62cf31-3626-4be3-87e1-7f93cf25b5a6"
      unitRef="usd">1272000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8c8f35fd17864198ae29d7c623d57285_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfNy0zLTEtMS05NTEzMg_f40abad3-539a-415c-944d-54a25ca5f626"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4eb3ec4739c24023b02eae3760c24976_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfNy01LTEtMS05NTEzMg_529d23c5-6aa9-4f38-b92d-cb529b9d9c37"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6385983faf6b4ce4907f11e0e0784a5a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfNy03LTEtMS05NTEzMg_53674581-68a5-454e-9413-6db0db8b91dc"
      unitRef="usd">1272000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i982c944f16354821a3a11af57a4d12f5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfOS0xLTEtMS05NTEzMg_b7e6df9d-c766-466c-901a-e45eb74469b4"
      unitRef="usd">56587000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2d76a02eaa334c0ca21f02a12b008068_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfOS0zLTEtMS05NTEzMg_be64c7cd-5636-4578-b71b-a5ad05e9a84e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib6e9038b180d4f5f9f7579ef703bdcc8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfOS01LTEtMS05NTEzMg_6496835e-9ef7-48df-aa25-319f9204cfd4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibe1d6bd783044aa7ae7f1fa51bf4c2df_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfOS03LTEtMS05NTEzMg_ea9de254-cf4c-41b0-afbf-e7010ee48b45"
      unitRef="usd">56587000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i982c944f16354821a3a11af57a4d12f5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTItMS0xLTEtOTUxMzI_87f48de9-49c5-4d04-a520-c1c86e4aa4c5"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i2d76a02eaa334c0ca21f02a12b008068_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTItMy0xLTEtOTUxMzI_5918ad2f-00d2-46a9-a3b8-fcb9c8885e94"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ib6e9038b180d4f5f9f7579ef703bdcc8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTItNS0xLTEtOTUxMzI_6fad805f-6c86-433b-81e7-96b0ad288d55"
      unitRef="usd">825000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ibe1d6bd783044aa7ae7f1fa51bf4c2df_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTItNy0xLTEtOTUxMzI_a706750c-5827-47c8-a831-6df0def16558"
      unitRef="usd">825000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i982c944f16354821a3a11af57a4d12f5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTQtMS0xLTEtOTUxMzI_11970131-a219-42a8-8298-7c4b778896f1"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i2d76a02eaa334c0ca21f02a12b008068_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTQtMy0xLTEtOTUxMzI_7ea8b507-b87b-4637-8927-6fa7322aefc2"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ib6e9038b180d4f5f9f7579ef703bdcc8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTQtNS0xLTEtOTUxMzI_4b571e34-6907-4265-a570-cdb5a88a10a2"
      unitRef="usd">4089000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ibe1d6bd783044aa7ae7f1fa51bf4c2df_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTQtNy0xLTEtOTUxMzI_15328c1c-35b5-436e-8d70-1bbd8780bca8"
      unitRef="usd">4089000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <cdna:CommonStockWarrantLiability
      contextRef="i982c944f16354821a3a11af57a4d12f5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTUtMS0xLTEtOTUxMzI_b0c92c28-8a35-4ba7-8f18-74234b226474"
      unitRef="usd">0</cdna:CommonStockWarrantLiability>
    <cdna:CommonStockWarrantLiability
      contextRef="i2d76a02eaa334c0ca21f02a12b008068_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTUtMy0xLTEtOTUxMzI_431785b2-9b05-4186-8936-89fba73d20c6"
      unitRef="usd">0</cdna:CommonStockWarrantLiability>
    <cdna:CommonStockWarrantLiability
      contextRef="ib6e9038b180d4f5f9f7579ef703bdcc8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTUtNS0xLTEtOTUxMzI_eab0c277-3901-42e9-97cd-8316480db1d3"
      unitRef="usd">25000</cdna:CommonStockWarrantLiability>
    <cdna:CommonStockWarrantLiability
      contextRef="ibe1d6bd783044aa7ae7f1fa51bf4c2df_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTUtNy0xLTEtOTUxMzI_2a048cff-bc84-46ff-a3cf-885b3473416b"
      unitRef="usd">25000</cdna:CommonStockWarrantLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i982c944f16354821a3a11af57a4d12f5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTYtMS0xLTEtOTUxMzI_97733878-a5b1-4284-b5d2-64556b19c281"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2d76a02eaa334c0ca21f02a12b008068_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTYtMy0xLTEtOTUxMzI_6c7c7fd1-a3f4-4009-bdef-0cf8860be790"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib6e9038b180d4f5f9f7579ef703bdcc8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTYtNS0xLTEtOTUxMzI_999fd05b-d09a-4a70-9d12-8ea82145f209"
      unitRef="usd">4939000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ibe1d6bd783044aa7ae7f1fa51bf4c2df_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmViYWRlNGFhMzNhNTRlZTlhZGEzMWJiZGJlYzM1ZGZjL3RhYmxlcmFuZ2U6ZWJhZGU0YWEzM2E1NGVlOWFkYTMxYmJkYmVjMzVkZmNfMTYtNy0xLTEtOTUxMzI_d9816eb7-122d-499d-99f5-f912f7195fba"
      unitRef="usd">4939000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i78142f02b6eb4ccfb1656d6f5f294a1d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfNS0xLTEtMS05NTEzMg_de335ce2-62fa-43a3-9e5a-d44fef6e3990"
      unitRef="usd">66594000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i802bf2c987da4c38af0138cb12b63a7a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfNS0zLTEtMS05NTEzMg_227b0b85-535d-462e-bc1e-362a277cfc6b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie661294c5d0d4cd39e08f501d3969965_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfNS01LTEtMS05NTEzMg_6999a07d-64cf-4522-a980-bb61a379193b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib9400f589c5241c0a57ababdfed3f710_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfNS03LTEtMS05NTEzMg_ada319dd-cc23-4d3a-a506-06950c651eee"
      unitRef="usd">66594000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9a757ccddcac4f5d8f4be791fe555e95_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfNy0xLTEtMS05NTEzMg_97d5bc92-e277-475e-85ee-ee0cd02c99aa"
      unitRef="usd">2076000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id9b3c2ab35bb493688fa7d78b10d9620_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfNy0zLTEtMS05NTEzMg_6fab2d42-589e-493c-9c36-a3ff807f4671"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie1ba9d00e75545f2a72fabc1672b6a66_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfNy01LTEtMS05NTEzMg_8f1d4e60-6dd6-4b30-964c-6a1b86414c93"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9f8db3692ea64671bcb30a21ef69e03c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfNy03LTEtMS05NTEzMg_dfc47c99-aad3-4b33-8af5-782c879fc253"
      unitRef="usd">2076000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4021690bcfc849d6bf7e8343dba5b82b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfOS0xLTEtMS05NTEzMg_724e36b7-15eb-49f7-875f-bba08e81f089"
      unitRef="usd">68670000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i548930b493bb4158a0dbc5d41dc95b2c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfOS0zLTEtMS05NTEzMg_52aa893c-7227-4787-bef9-7a43f7478cb7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7530e38c229d4e808c0bcbedf20ea6e4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfOS01LTEtMS05NTEzMg_75c19057-c06e-472b-9c5f-0e8679a377bd"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4527e5b34bee42669774ad27f3195476_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfOS03LTEtMS05NTEzMg_5313166e-2a7a-476b-86a3-2d5b589bb64e"
      unitRef="usd">68670000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i4021690bcfc849d6bf7e8343dba5b82b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTItMS0xLTEtOTUxMzI_4040051d-1143-4da9-9e30-9ab35267b73e"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i548930b493bb4158a0dbc5d41dc95b2c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTItMy0xLTEtOTUxMzI_b3beff05-39df-4c5f-bcdd-7d30b557fee0"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i7530e38c229d4e808c0bcbedf20ea6e4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTItNS0xLTEtOTUxMzI_93c8e812-cc84-4d09-88ee-6759084a3343"
      unitRef="usd">1025000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i4527e5b34bee42669774ad27f3195476_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTItNy0xLTEtOTUxMzI_4facfe0a-b71b-4510-a9d8-b3585b01184b"
      unitRef="usd">1025000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i4021690bcfc849d6bf7e8343dba5b82b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTQtMS0xLTEtOTUxMzI_e9c10c6b-ba19-4e09-88ac-f066c71911c0"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i548930b493bb4158a0dbc5d41dc95b2c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTQtMy0xLTEtOTUxMzI_08e138bc-6995-479d-82e3-9c408652f94b"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i7530e38c229d4e808c0bcbedf20ea6e4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTQtNS0xLTEtOTUxMzI_1d86f210-2e89-402a-94dd-c165bbcf8d8e"
      unitRef="usd">2418000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i4527e5b34bee42669774ad27f3195476_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTQtNy0xLTEtOTUxMzI_ad3d0e93-5da0-4a1b-9ed1-78fdec5acc44"
      unitRef="usd">2418000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <cdna:CommonStockWarrantLiability
      contextRef="i4021690bcfc849d6bf7e8343dba5b82b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTUtMS0xLTEtOTUxMzI_f35fc619-6e62-4c55-9746-f8523b3d9718"
      unitRef="usd">0</cdna:CommonStockWarrantLiability>
    <cdna:CommonStockWarrantLiability
      contextRef="i548930b493bb4158a0dbc5d41dc95b2c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTUtMy0xLTEtOTUxMzI_663b324f-8e3a-4844-ac09-d33906137136"
      unitRef="usd">0</cdna:CommonStockWarrantLiability>
    <cdna:CommonStockWarrantLiability
      contextRef="i7530e38c229d4e808c0bcbedf20ea6e4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTUtNS0xLTEtOTUxMzI_f3c4c964-85bf-48f0-9372-b103f11c9aad"
      unitRef="usd">32000</cdna:CommonStockWarrantLiability>
    <cdna:CommonStockWarrantLiability
      contextRef="i4527e5b34bee42669774ad27f3195476_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTUtNy0xLTEtOTUxMzI_6c5019ed-ec04-40a7-93d1-a45f46aff0f3"
      unitRef="usd">32000</cdna:CommonStockWarrantLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4021690bcfc849d6bf7e8343dba5b82b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTYtMS0xLTEtOTUxMzI_23e37576-6796-4c4f-a372-51601624acd5"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i548930b493bb4158a0dbc5d41dc95b2c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTYtMy0xLTEtOTUxMzI_a5814005-1a7d-4ff6-8852-969b356a0b6e"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7530e38c229d4e808c0bcbedf20ea6e4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTYtNS0xLTEtOTUxMzI_448b6546-4093-43f4-906d-903f51b32088"
      unitRef="usd">3475000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4527e5b34bee42669774ad27f3195476_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOjAyY2Y5Y2ZlMjYyYjQyZGM4YTZkY2UwN2E1MDUyMmJkL3RhYmxlcmFuZ2U6MDJjZjljZmUyNjJiNDJkYzhhNmRjZTA3YTUwNTIyYmRfMTYtNy0xLTEtOTUxMzI_3ac389e8-beb9-4ab7-bbb2-05c01e1b3884"
      unitRef="usd">3475000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RleHRyZWdpb246YjNjMzVhMmQxYzU4NGQ1MWE1ZjE4YWUyODA1MGEyMjRfNjE2NA_c9557401-dbe0-483d-8e28-0de5ad301bf4">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the issuances, exercises, changes in fair value and reclassifications of the Company&#x2019;s Level 3 financial instruments that are measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Common Stock Warrant Liability and Contingent Consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in estimated fair value of common stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in estimated fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Addition of estimated fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments related to contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmE1MWY1ZTUzMDQ5MzQ5Mjg4M2ZhZTU1OTdkZWYwYTc4L3RhYmxlcmFuZ2U6YTUxZjVlNTMwNDkzNDkyODgzZmFlNTU5N2RlZjBhNzhfMi0xLTEtMS05NTEzMg_6ad87ca9-11f7-4396-8b34-782e5baa2328"
      unitRef="usd">3475000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ie5c804bdf4f040aca96273d8934d4389_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmE1MWY1ZTUzMDQ5MzQ5Mjg4M2ZhZTU1OTdkZWYwYTc4L3RhYmxlcmFuZ2U6YTUxZjVlNTMwNDkzNDkyODgzZmFlNTU5N2RlZjBhNzhfNC0xLTEtMS05NTEzMg_c7052dbd-1aa2-4ed3-a832-1816eae340af"
      unitRef="usd">-7000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i76877b7701634ea681c1e7599813ad95_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmE1MWY1ZTUzMDQ5MzQ5Mjg4M2ZhZTU1OTdkZWYwYTc4L3RhYmxlcmFuZ2U6YTUxZjVlNTMwNDkzNDkyODgzZmFlNTU5N2RlZjBhNzhfNi0xLTEtMS05NTEzMg_6bca7471-5dd5-46a1-81f5-b02bf1dd9ac5"
      unitRef="usd">421000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
      contextRef="i76877b7701634ea681c1e7599813ad95_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmE1MWY1ZTUzMDQ5MzQ5Mjg4M2ZhZTU1OTdkZWYwYTc4L3RhYmxlcmFuZ2U6YTUxZjVlNTMwNDkzNDkyODgzZmFlNTU5N2RlZjBhNzhfNy0xLTEtMS0xMDMwMTg_323eea26-c130-4a15-994c-dccb14b481cf"
      unitRef="usd">1300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements
      contextRef="i76877b7701634ea681c1e7599813ad95_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmE1MWY1ZTUzMDQ5MzQ5Mjg4M2ZhZTU1OTdkZWYwYTc4L3RhYmxlcmFuZ2U6YTUxZjVlNTMwNDkzNDkyODgzZmFlNTU5N2RlZjBhNzhfNy0xLTEtMS05NTEzMg_9d9d8094-9cf5-4479-88e2-fabcb9e1ea46"
      unitRef="usd">250000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RhYmxlOmE1MWY1ZTUzMDQ5MzQ5Mjg4M2ZhZTU1OTdkZWYwYTc4L3RhYmxlcmFuZ2U6YTUxZjVlNTMwNDkzNDkyODgzZmFlNTU5N2RlZjBhNzhfOC0xLTEtMS05NTEzMg_8b3d0ece-6880-4dc7-95e6-72dde76b11fc"
      unitRef="usd">4939000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RleHRyZWdpb246YjNjMzVhMmQxYzU4NGQ1MWE1ZjE4YWUyODA1MGEyMjRfMjE5OTAyMzI2MzMzMg_fb98c909-a523-4926-ada1-1305fae50f57"
      unitRef="usd">-1000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <cdna:BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RleHRyZWdpb246YjNjMzVhMmQxYzU4NGQ1MWE1ZjE4YWUyODA1MGEyMjRfMjE5OTAyMzI2MzMyOA_ed933709-4602-4509-8f13-95904cc5d34d"
      unitRef="number">0.07</cdna:BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate>
    <cdna:BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate
      contextRef="i8d7cf5ad6102439bacdb4213332c001a_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180My9mcmFnOmIzYzM1YTJkMWM1ODRkNTFhNWYxOGFlMjgwNTBhMjI0L3RleHRyZWdpb246YjNjMzVhMmQxYzU4NGQ1MWE1ZjE4YWUyODA1MGEyMjRfNDE3Mg_138ee33c-4893-4007-bd89-1746797a6e65"
      unitRef="number">0.12</cdna:BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RleHRyZWdpb246NjZhOGNjNmU4YmM0NDM0YTk5YmQyNWE5NDRlNWNmM2JfMTYyOQ_19a462e1-9804-4e46-ae7d-f2ed0f578f71">CASH AND MARKETABLE SECURITIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the amount reported within the condensed consolidated statements of cash flows is shown in the table below (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All short-term marketable securities were considered held-to-maturity at March&#160;31, 2023. At March&#160;31, 2023, some of the Company&#x2019;s short-term marketable securities were in an unrealized loss position. The Company determined that it had the positive intent and ability to hold until maturity all short-term marketable securities that have been in a continuous loss position, thus there was no recognition of any other-than-temporary impairment as of March&#160;31, 2023. All short-term marketable securities with unrealized losses as of the balance sheet date have been in a loss position for less than twelve months. Contractual maturities of the short-term marketable securities were within one year or less at March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The long-term marketable equity securities were recorded at fair market value with changes in the fair value recognized in earnings at March&#160;31, 2023 and December&#160;31, 2022. The long-term marketable debt securities were considered available-for-sale at March&#160;31, 2023 and December&#160;31, 2022. The contractual maturities of the long-term marketable debt securities are less than three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, gross unrealized holding losses, and fair value of the Company&#x2019;s marketable securities by major security type at each balance sheet date are summarized in the tables below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,493)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual maturities of the marketable securities at each balance sheet date are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RleHRyZWdpb246NjZhOGNjNmU4YmM0NDM0YTk5YmQyNWE5NDRlNWNmM2JfMTYzMA_0541b856-ad6d-44b4-846b-83b45ba5e593">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets to the amount reported within the condensed consolidated statements of cash flows is shown in the table below (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.514%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjU5ZDAwMmRlMjdkNjQyMjhiYWE4N2I0MWQ3ZGM1ZmVmL3RhYmxlcmFuZ2U6NTlkMDAyZGUyN2Q2NDIyOGJhYTg3YjQxZDdkYzVmZWZfMS0xLTEtMS05NTEzMg_ff8d817c-b8d7-4120-ba3a-bccc956d016e"
      unitRef="usd">74660000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i30a9b5385be843b8be329d54dfcdc192_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjU5ZDAwMmRlMjdkNjQyMjhiYWE4N2I0MWQ3ZGM1ZmVmL3RhYmxlcmFuZ2U6NTlkMDAyZGUyN2Q2NDIyOGJhYTg3YjQxZDdkYzVmZWZfMS01LTEtMS05NTEzMg_2331ea47-c82a-4459-ac7d-d74f60a850dc"
      unitRef="usd">171892000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjU5ZDAwMmRlMjdkNjQyMjhiYWE4N2I0MWQ3ZGM1ZmVmL3RhYmxlcmFuZ2U6NTlkMDAyZGUyN2Q2NDIyOGJhYTg3YjQxZDdkYzVmZWZfMi0xLTEtMS05NTEzMg_75649166-9782-4a43-b9b1-627528848397"
      unitRef="usd">520000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i30a9b5385be843b8be329d54dfcdc192_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjU5ZDAwMmRlMjdkNjQyMjhiYWE4N2I0MWQ3ZGM1ZmVmL3RhYmxlcmFuZ2U6NTlkMDAyZGUyN2Q2NDIyOGJhYTg3YjQxZDdkYzVmZWZfMi01LTEtMS05NTEzMg_87e21a43-f14f-4cf1-8e14-2baf427fe624"
      unitRef="usd">214000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjU5ZDAwMmRlMjdkNjQyMjhiYWE4N2I0MWQ3ZGM1ZmVmL3RhYmxlcmFuZ2U6NTlkMDAyZGUyN2Q2NDIyOGJhYTg3YjQxZDdkYzVmZWZfMy0xLTEtMS05NTEzMg_e1024d5b-217c-4024-a7ac-a8fab41980b9"
      unitRef="usd">75180000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i30a9b5385be843b8be329d54dfcdc192_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjU5ZDAwMmRlMjdkNjQyMjhiYWE4N2I0MWQ3ZGM1ZmVmL3RhYmxlcmFuZ2U6NTlkMDAyZGUyN2Q2NDIyOGJhYTg3YjQxZDdkYzVmZWZfMy01LTEtMS05NTEzMg_f0b9c75b-52e3-4e6a-9e67-f8f061200e41"
      unitRef="usd">172106000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RleHRyZWdpb246NjZhOGNjNmU4YmM0NDM0YTk5YmQyNWE5NDRlNWNmM2JfMTYzMQ_c99b4993-6f64-4ad4-94a6-37c11b72a46c">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortized cost, gross unrealized holding losses, and fair value of the Company&#x2019;s marketable securities by major security type at each balance sheet date are summarized in the tables below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,493)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.599%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Holding Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual maturities of the marketable securities at each balance sheet date are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.666%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
      contextRef="ia96d97ee1a464c7ca2c6ded0200614bc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfMy0xLTEtMS05NjYyNQ_d06a707d-f307-49b8-ac00-68032778e0df"
      unitRef="usd">92947000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="ia96d97ee1a464c7ca2c6ded0200614bc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfMy0zLTEtMS05NjYyNQ_7228d154-d86e-4aae-9ff3-94771e386175"
      unitRef="usd">1222000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ia96d97ee1a464c7ca2c6ded0200614bc_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfMy01LTEtMS05NjYyNQ_860cab64-ea72-4f7c-b20e-2e95d48b3fe2"
      unitRef="usd">94169000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
      contextRef="i84b41750f227461d843bbebd7625f870_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfMy0xLTEtMS05NTEzMg_2e012d5c-a4af-49c6-b68c-c9de8acbe230"
      unitRef="usd">118332000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i84b41750f227461d843bbebd7625f870_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfMy0zLTEtMS05NTEzMg_a9db434a-7146-462f-b0d4-40209500d9a2"
      unitRef="usd">113000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i84b41750f227461d843bbebd7625f870_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfMy01LTEtMS05NTEzMg_e1804196-3fc1-40a9-9d1e-08e7ddcab055"
      unitRef="usd">118445000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <cdna:MarketableSecuritiesAmortizedCostShortTerm
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfNC0xLTEtMS05NTEzMg_7657e692-c7de-4937-9966-291794a217b9"
      unitRef="usd">211279000</cdna:MarketableSecuritiesAmortizedCostShortTerm>
    <cdna:MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfNC0zLTEtMS05NTEzMg_e0297370-e023-45a7-83d2-cdcfc364fea5"
      unitRef="usd">1335000</cdna:MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm>
    <cdna:MarketableSecuritiesFairValueShortTerm
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfNC01LTEtMS05NTEzMg_e09cffcd-0ade-4767-a634-dd92fde09aed"
      unitRef="usd">212614000</cdna:MarketableSecuritiesFairValueShortTerm>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i205add77cb4a43d28264c36e6bb99b5e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfNi0xLTEtMS05NTEzMg_96b3880e-3e90-4ac2-9c85-3dc05d9f0813"
      unitRef="usd">5100000</us-gaap:EquitySecuritiesFvNiCost>
    <cdna:EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax
      contextRef="i205add77cb4a43d28264c36e6bb99b5e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfNi0zLTEtMS05NTEzMg_eebe3091-69eb-4b58-92a7-eb0722f7e48c"
      unitRef="usd">-3828000</cdna:EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i205add77cb4a43d28264c36e6bb99b5e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfNi01LTEtMS05NTEzMg_01ad7d20-bb86-46d6-bf74-586564b83ce2"
      unitRef="usd">1272000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i84b41750f227461d843bbebd7625f870_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfNy0xLTEtMS05NTEzMg_04731bab-15fa-45fa-8525-205adf4e1c00"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i84b41750f227461d843bbebd7625f870_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfNy0zLTEtMS05NTEzMg_b965744e-ce64-4240-b39f-622f936c8212"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i84b41750f227461d843bbebd7625f870_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfNy01LTEtMS05NTEzMg_e37949c0-5eee-4cb4-974a-a7514a9af3ea"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <cdna:MarketableSecuritiesAmortizedCostLongTerm
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfOC0xLTEtMS05NTEzMg_975e1748-0256-4633-8574-16d2ef224858"
      unitRef="usd">5100000</cdna:MarketableSecuritiesAmortizedCostLongTerm>
    <cdna:MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfOC0zLTEtMS05NTEzMg_6689d1e1-d65a-4e2c-9b92-cf9579f7eb97"
      unitRef="usd">-3828000</cdna:MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm>
    <cdna:MarketableSecuritiesFairValueLongTerm
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfOC01LTEtMS05NTEzMg_ddb36e4b-a204-415a-ad70-e02114223428"
      unitRef="usd">1272000</cdna:MarketableSecuritiesFairValueLongTerm>
    <cdna:MarketableSecuritiesAmortizedCost
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfOS0xLTEtMS05NTEzMg_a7e2ef15-35cd-4064-a026-35058a498a0a"
      unitRef="usd">216379000</cdna:MarketableSecuritiesAmortizedCost>
    <cdna:MarketableSecuritiesAccumulatedUnrecognizedGainLoss
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfOS0zLTEtMS05NTEzMg_5cabf40f-b1a8-4920-a872-5ff9962e839b"
      unitRef="usd">-2493000</cdna:MarketableSecuritiesAccumulatedUnrecognizedGainLoss>
    <us-gaap:MarketableSecurities
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjNhM2I4NmMwN2VkOTRjOWZhMDJmNTRiODA5MTliNGRhL3RhYmxlcmFuZ2U6M2EzYjg2YzA3ZWQ5NGM5ZmEwMmY1NGI4MDkxOWI0ZGFfOS01LTEtMS05NTEzMg_6dede251-939b-4115-8794-f21e2bfad9dd"
      unitRef="usd">213886000</us-gaap:MarketableSecurities>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
      contextRef="i326a94ee25204ee282ab17ca652c83d6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfMy0xLTEtMS05NjY1Mg_8771214d-9e67-43e8-b605-aa0e78768b99"
      unitRef="usd">79347000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="i326a94ee25204ee282ab17ca652c83d6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfMy0zLTEtMS05NjY1Mg_89562a2d-3d78-4efc-bb4c-610ed42d9f6b"
      unitRef="usd">452000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i326a94ee25204ee282ab17ca652c83d6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfMy01LTEtMS05NjY1Mg_25655564-2bd5-4227-b779-135634f27453"
      unitRef="usd">79799000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss
      contextRef="id3863806f5974329a5f25691cef5e10f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNC0xLTEtMS05NjY1Mg_10664323-b875-4dae-904e-5ae54220f2e2"
      unitRef="usd">123821000</us-gaap:DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="id3863806f5974329a5f25691cef5e10f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNC0zLTEtMS05NjY1Mg_3fa5e895-f092-489c-a006-a344107be725"
      unitRef="usd">220000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="id3863806f5974329a5f25691cef5e10f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNC01LTEtMS05NjY1Mg_01a6fe4d-c6ae-4204-857e-17c53e3efa00"
      unitRef="usd">123601000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <cdna:MarketableSecuritiesAmortizedCostShortTerm
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNS0xLTEtMS05NjY1Mg_4a91a320-a497-48eb-8e52-20c590410b3f"
      unitRef="usd">203168000</cdna:MarketableSecuritiesAmortizedCostShortTerm>
    <cdna:MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNS0zLTEtMS05NjY1Mg_22f6b7b1-413a-4784-8a67-10a7e448a6b7"
      unitRef="usd">232000</cdna:MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm>
    <cdna:MarketableSecuritiesFairValueShortTerm
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNS01LTEtMS05NjY1Mg_fa981085-bdc6-4edf-89fd-af14e8252ff8"
      unitRef="usd">203400000</cdna:MarketableSecuritiesFairValueShortTerm>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i69def961a87843fcb2b9a4f9b65fc946_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfMy0xLTEtMS05NTEzMg_cc333e89-03f5-4bc0-8157-4253b656260c"
      unitRef="usd">5000000</us-gaap:EquitySecuritiesFvNiCost>
    <cdna:EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax
      contextRef="i69def961a87843fcb2b9a4f9b65fc946_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfMy0zLTEtMS05NTEzMg_3c7a4beb-4b1f-4a68-b2d0-ba1773866f65"
      unitRef="usd">-2924000</cdna:EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i69def961a87843fcb2b9a4f9b65fc946_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfMy01LTEtMS05NTEzMg_c04b0b0c-0984-4e74-b32d-023a741cb5ad"
      unitRef="usd">2076000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <cdna:MarketableSecuritiesAmortizedCostLongTerm
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNC0xLTEtMS05NTEzMg_174d158a-f1b5-41e1-880f-048ab6c6ae07"
      unitRef="usd">5000000</cdna:MarketableSecuritiesAmortizedCostLongTerm>
    <cdna:MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNC0zLTEtMS05NTEzMg_1551589a-aae0-4e97-a32d-06e00d09a720"
      unitRef="usd">-2924000</cdna:MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm>
    <cdna:MarketableSecuritiesFairValueLongTerm
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNC01LTEtMS05NTEzMg_8896e358-3a2a-4772-9c2e-0e594434c7c8"
      unitRef="usd">2076000</cdna:MarketableSecuritiesFairValueLongTerm>
    <cdna:MarketableSecuritiesAmortizedCost
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNS0xLTEtMS05NTEzMg_f82a267c-cae7-434d-b4d7-7f9cd7c28e16"
      unitRef="usd">208168000</cdna:MarketableSecuritiesAmortizedCost>
    <cdna:MarketableSecuritiesAccumulatedUnrecognizedGainLoss
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNS0zLTEtMS05NTEzMg_6f4e788c-cca8-40e5-b479-d4ab364e8b53"
      unitRef="usd">-2692000</cdna:MarketableSecuritiesAccumulatedUnrecognizedGainLoss>
    <us-gaap:MarketableSecurities
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjcwNjNjZWRmM2RmOTQxODJiNmFhZjliNGNiODBiNjg2L3RhYmxlcmFuZ2U6NzA2M2NlZGYzZGY5NDE4MmI2YWFmOWI0Y2I4MGI2ODZfNS01LTEtMS05NTEzMg_92cbe509-1750-4b08-956d-00cd518e1adc"
      unitRef="usd">205476000</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjRjYTlkZjg0MzZhZTQ2ODI5ZmI5NTE3NTEzNzAyZjU5L3RhYmxlcmFuZ2U6NGNhOWRmODQzNmFlNDY4MjlmYjk1MTc1MTM3MDJmNTlfMS0xLTEtMS05NTEzMg_bdacb43f-1047-4b70-af74-4fbd48fb3afd"
      unitRef="usd">211279000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjRjYTlkZjg0MzZhZTQ2ODI5ZmI5NTE3NTEzNzAyZjU5L3RhYmxlcmFuZ2U6NGNhOWRmODQzNmFlNDY4MjlmYjk1MTc1MTM3MDJmNTlfMS0yLTEtMS05NTEzMg_9bec87ba-338a-4448-87a5-0ed57c75df69"
      unitRef="usd">203168000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjRjYTlkZjg0MzZhZTQ2ODI5ZmI5NTE3NTEzNzAyZjU5L3RhYmxlcmFuZ2U6NGNhOWRmODQzNmFlNDY4MjlmYjk1MTc1MTM3MDJmNTlfMi0xLTEtMS05NTEzMg_ff84118c-2e3b-4a55-af0d-df473b8c689a"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjRjYTlkZjg0MzZhZTQ2ODI5ZmI5NTE3NTEzNzAyZjU5L3RhYmxlcmFuZ2U6NGNhOWRmODQzNmFlNDY4MjlmYjk1MTc1MTM3MDJmNTlfMi0yLTEtMS05NTEzMg_f8c738cf-713e-4d37-a223-2c4ab8153a5e"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjRjYTlkZjg0MzZhZTQ2ODI5ZmI5NTE3NTEzNzAyZjU5L3RhYmxlcmFuZ2U6NGNhOWRmODQzNmFlNDY4MjlmYjk1MTc1MTM3MDJmNTlfMy0xLTEtMS05NTEzMg_1da62c2c-cdbd-40d6-ae75-021dd7266939"
      unitRef="usd">211279000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180Ni9mcmFnOjY2YThjYzZlOGJjNDQzNGE5OWJkMjVhOTQ0ZTVjZjNiL3RhYmxlOjRjYTlkZjg0MzZhZTQ2ODI5ZmI5NTE3NTEzNzAyZjU5L3RhYmxlcmFuZ2U6NGNhOWRmODQzNmFlNDY4MjlmYjk1MTc1MTM3MDJmNTlfMy0yLTEtMS05NTEzMg_2f2f0cb2-47da-4d68-bf54-255160641e57"
      unitRef="usd">203168000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RleHRyZWdpb246MmQxOWJkMDBiMTdmNGE3NGIyZjQ3MTU2NjM2Yjc3MjBfNjMxNQ_cd8f8683-5049-4d1e-81be-444c25b81def">BUSINESS COMBINATIONS&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;HLA Data Systems&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, the Company acquired HLA Data Systems, a Texas-based company that provides software and interoperability solutions for the histocompatibility and immunogenetics community. The Company acquired HLA Data Systems with a combination of cash consideration paid upfront and contingent consideration with a fair value of $1.3&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounted for the transaction as a business combination using the acquisition method of accounting. Acquisition-related costs of $0.4&#160;million associated with the acquisition were expensed as incurred, and classified as part of general and administrative expenses in the condensed consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill of $2.1&#160;million arising from the acquisition primarily consists of synergies from integrating HLA Data Systems' technology with the current testing and digital solutions offered by the Company. The acquisition of HLA Data Systems will provide a robust and comprehensive Laboratory Information Management System and support the laboratory workflows. None of the goodwill is expected to be deductible for income tax purposes. All of the goodwill has been assigned to the Company&#x2019;s existing operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair values of the intangible assets acquired as of the acquisition date ($ in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;Estimated Useful Lives (Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customer relationships acquired by the Company represent the fair value of future projected revenue that is expected to be derived from sales of HLA Data Systems&#x2019; products to existing customers. The customer relationships&#x2019; fair value has been estimated utilizing a multi-period excess earnings method under the income approach, which reflects the present value of the projected cash flows that are expected to be generated by the customer relationships, less charges representing the contribution of other assets to those cash flows that use projected cash flows with and without the intangible asset in place. The economic useful life was determined based on the distribution of the present value of the cash flows attributable to the intangible asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquired developed technology represents the fair value of HLA Data Systems' proprietary software. The trademark acquired consists primarily of the HLA Data Systems brand and markings. The fair value of both the developed technology and the trademark were determined using the relief-from-royalty method under the income approach. This method considers the value of the asset to be the value of the royalty payments from which the Company is relieved due to its ownership of the asset. The royalty rates of 10% and 2% were used to estimate the fair value of the developed technology and the trademark, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A discount rate of 24% was utilized in estimating the fair value of these three intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pro forma impact of the HLA Data Systems acquisition is not material, and the results of operations of the acquisition have been included in the Company's condensed consolidated statements of operations from the respective acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration Paid&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the consideration paid for HLA Data Systems and the amounts of the assets acquired and liabilities assumed recognized at their estimated fair value at the acquisition date (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.076%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Total consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Recognized amounts of identifiable assets acquired and liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Contingent considerations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Total identifiable net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allocation of the purchase price to assets acquired and liabilities assumed was based on the fair value of such assets and liabilities as of the acquisition date.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i5655b5a1a84d4b98979a99a6db9e0ff2_D20230101-20230131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RleHRyZWdpb246MmQxOWJkMDBiMTdmNGE3NGIyZjQ3MTU2NjM2Yjc3MjBfNTQ5NzU1ODM3NzQ5_7334affe-c7d7-4289-b766-56687080b499"
      unitRef="usd">1300000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i5655b5a1a84d4b98979a99a6db9e0ff2_D20230101-20230131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RleHRyZWdpb246MmQxOWJkMDBiMTdmNGE3NGIyZjQ3MTU2NjM2Yjc3MjBfNTQ5NzU1ODM3NzY3_26d32481-142d-4fe6-aa79-278469d63f3d"
      unitRef="usd">400000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:Goodwill
      contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RleHRyZWdpb246MmQxOWJkMDBiMTdmNGE3NGIyZjQ3MTU2NjM2Yjc3MjBfNTQ5NzU1ODM3Nzg1_3120655f-d92f-4e7b-bf3c-825008085ae6"
      unitRef="usd">2100000</us-gaap:Goodwill>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RleHRyZWdpb246MmQxOWJkMDBiMTdmNGE3NGIyZjQ3MTU2NjM2Yjc3MjBfMTA5OTUxMTY1MTk2NA_48a3889c-d2e4-4fa6-b737-17bdf21663bc"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RleHRyZWdpb246MmQxOWJkMDBiMTdmNGE3NGIyZjQ3MTU2NjM2Yjc3MjBfMTY0OTI2NzQ2NTc4NQ_61ba866e-cd55-49ff-a6a8-6b49ac095113">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair values of the intangible assets acquired as of the acquisition date ($ in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.264%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.340%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:112%"&gt;Estimated Useful Lives (Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Developed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure
      contextRef="i4e8dea3df85a402dbf74f31228595f6c_I20230131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjBhYmY1NDA5YTIyNjQwNmY4ZGU1NDEwMjE2ODk3YTA3L3RhYmxlcmFuZ2U6MGFiZjU0MDlhMjI2NDA2ZjhkZTU0MTAyMTY4OTdhMDdfMS0xLTEtMS0xMDAxOTA_6933e97b-a2c7-4116-bf25-36cd5151c6bd"
      unitRef="usd">3010000</us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ib370105b87eb4834ba579147ac153394_D20230101-20230131"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjBhYmY1NDA5YTIyNjQwNmY4ZGU1NDEwMjE2ODk3YTA3L3RhYmxlcmFuZ2U6MGFiZjU0MDlhMjI2NDA2ZjhkZTU0MTAyMTY4OTdhMDdfMS0zLTEtMS0xMDMxNjA_3afceab2-cc1b-45ee-bff9-a3e5468dd605">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure
      contextRef="i58e73d1a09944b02869b176e945eb1ef_I20230131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjBhYmY1NDA5YTIyNjQwNmY4ZGU1NDEwMjE2ODk3YTA3L3RhYmxlcmFuZ2U6MGFiZjU0MDlhMjI2NDA2ZjhkZTU0MTAyMTY4OTdhMDdfMi0xLTEtMS0xMDAxOTA_c068ccae-103a-49d1-a3c0-fc4c76118c7f"
      unitRef="usd">770000</us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ibd80e498ad9d43fcaa85af5f97ce31df_D20230101-20230131"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjBhYmY1NDA5YTIyNjQwNmY4ZGU1NDEwMjE2ODk3YTA3L3RhYmxlcmFuZ2U6MGFiZjU0MDlhMjI2NDA2ZjhkZTU0MTAyMTY4OTdhMDdfMi0zLTEtMS0xMDMxNjA_3aaff3f9-dabc-42f2-9d96-3b57e5da524a">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure
      contextRef="i354e7a3f27e044eab26ae4b1d2cde545_I20230131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjBhYmY1NDA5YTIyNjQwNmY4ZGU1NDEwMjE2ODk3YTA3L3RhYmxlcmFuZ2U6MGFiZjU0MDlhMjI2NDA2ZjhkZTU0MTAyMTY4OTdhMDdfMy0xLTEtMS0xMDAxOTA_fcfc6c3d-51ab-47f9-b239-879d70c68d28"
      unitRef="usd">320000</us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i2fe8183fbe32453d99cc54713eadebe2_D20230101-20230131"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjBhYmY1NDA5YTIyNjQwNmY4ZGU1NDEwMjE2ODk3YTA3L3RhYmxlcmFuZ2U6MGFiZjU0MDlhMjI2NDA2ZjhkZTU0MTAyMTY4OTdhMDdfMy0zLTEtMS0xMDMxNjA_d36f82a7-5209-4852-8d5c-84e7a88a810d">P17Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure
      contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjBhYmY1NDA5YTIyNjQwNmY4ZGU1NDEwMjE2ODk3YTA3L3RhYmxlcmFuZ2U6MGFiZjU0MDlhMjI2NDA2ZjhkZTU0MTAyMTY4OTdhMDdfNC0xLTEtMS0xMDAxOTA_a00f4b9e-069a-46f8-904c-4a6af15f2c95"
      unitRef="usd">4100000</us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure>
    <cdna:IntangibleAssetMeasurementInputRoyaltyRate
      contextRef="i58e73d1a09944b02869b176e945eb1ef_I20230131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RleHRyZWdpb246MmQxOWJkMDBiMTdmNGE3NGIyZjQ3MTU2NjM2Yjc3MjBfNTQ5NzU1ODM3Nzk2_58d9b2f4-90c9-4160-a0b9-2312ffe8f0ad"
      unitRef="number">0.10</cdna:IntangibleAssetMeasurementInputRoyaltyRate>
    <cdna:IntangibleAssetMeasurementInputRoyaltyRate
      contextRef="i354e7a3f27e044eab26ae4b1d2cde545_I20230131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RleHRyZWdpb246MmQxOWJkMDBiMTdmNGE3NGIyZjQ3MTU2NjM2Yjc3MjBfNTQ5NzU1ODM3ODAy_98df6334-8864-4ccd-b4a6-91616ec88c3b"
      unitRef="number">0.02</cdna:IntangibleAssetMeasurementInputRoyaltyRate>
    <cdna:IntangibleAssetMeasurementInputDiscountRate
      contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RleHRyZWdpb246MmQxOWJkMDBiMTdmNGE3NGIyZjQ3MTU2NjM2Yjc3MjBfMTA5OTUxMTY1MTk1NA_9df37599-3d5f-4d83-b1d0-ff061f31b964"
      unitRef="number">0.24</cdna:IntangibleAssetMeasurementInputDiscountRate>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RleHRyZWdpb246MmQxOWJkMDBiMTdmNGE3NGIyZjQ3MTU2NjM2Yjc3MjBfMTY0OTI2NzQ2NTc4Ng_39dd1fe7-afe1-426e-961b-83ccc5677d7e">The following table summarizes the consideration paid for HLA Data Systems and the amounts of the assets acquired and liabilities assumed recognized at their estimated fair value at the acquisition date (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.076%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Total consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Recognized amounts of identifiable assets acquired and liabilities assumed&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Identifiable intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Contingent considerations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Total identifiable net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ib01dc638da5843b694334d2ca357325f_D20210101-20210131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjJjMWM0ZDViODQ1OTRkOWQ5Mjc4MmU0YWMxNzc3YjNkL3RhYmxlcmFuZ2U6MmMxYzRkNWI4NDU5NGQ5ZDkyNzgyZTRhYzE3NzdiM2RfMi0xLTEtMS0xMDMyMzk_459f21bc-48e8-4015-b0fe-f30ef2221df7"
      unitRef="usd">4562000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ib01dc638da5843b694334d2ca357325f_D20210101-20210131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjJjMWM0ZDViODQ1OTRkOWQ5Mjc4MmU0YWMxNzc3YjNkL3RhYmxlcmFuZ2U6MmMxYzRkNWI4NDU5NGQ5ZDkyNzgyZTRhYzE3NzdiM2RfMy0xLTEtMS0xMDMyMzk_62573fa5-3962-4107-b630-e51142742125"
      unitRef="usd">4562000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets
      contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjJjMWM0ZDViODQ1OTRkOWQ5Mjc4MmU0YWMxNzc3YjNkL3RhYmxlcmFuZ2U6MmMxYzRkNWI4NDU5NGQ5ZDkyNzgyZTRhYzE3NzdiM2RfNi0xLTEtMS0xMDMyMzk_6024b899-9a21-41b1-ae3e-64e47b82a137"
      unitRef="usd">1162000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjJjMWM0ZDViODQ1OTRkOWQ5Mjc4MmU0YWMxNzc3YjNkL3RhYmxlcmFuZ2U6MmMxYzRkNWI4NDU5NGQ5ZDkyNzgyZTRhYzE3NzdiM2RfNy0xLTEtMS0xMDMyMzk_9ca5d8ba-d0e5-495d-a21b-73331c96a185"
      unitRef="usd">4100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjJjMWM0ZDViODQ1OTRkOWQ5Mjc4MmU0YWMxNzc3YjNkL3RhYmxlcmFuZ2U6MmMxYzRkNWI4NDU5NGQ5ZDkyNzgyZTRhYzE3NzdiM2RfOC0xLTEtMS0xMDMyMzk_590b2375-a08c-4467-9a37-3196ba4b324b"
      unitRef="usd">786000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
      contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjJjMWM0ZDViODQ1OTRkOWQ5Mjc4MmU0YWMxNzc3YjNkL3RhYmxlcmFuZ2U6MmMxYzRkNWI4NDU5NGQ5ZDkyNzgyZTRhYzE3NzdiM2RfOS0xLTEtMS0xMDMyMzk_eb698f92-d628-4fb3-997e-ad1eddbaf7f7"
      unitRef="usd">699000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <cdna:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion
      contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjJjMWM0ZDViODQ1OTRkOWQ5Mjc4MmU0YWMxNzc3YjNkL3RhYmxlcmFuZ2U6MmMxYzRkNWI4NDU5NGQ5ZDkyNzgyZTRhYzE3NzdiM2RfMTAtMS0xLTEtMTAzMjM5_7943953e-5664-4d12-8f52-c674cb619b0e"
      unitRef="usd">1300000</cdna:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjJjMWM0ZDViODQ1OTRkOWQ5Mjc4MmU0YWMxNzc3YjNkL3RhYmxlcmFuZ2U6MmMxYzRkNWI4NDU5NGQ5ZDkyNzgyZTRhYzE3NzdiM2RfMTEtMS0xLTEtMTAzMjM5_236ec469-60df-480f-a009-6ce0c0aff9c2"
      unitRef="usd">7000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjJjMWM0ZDViODQ1OTRkOWQ5Mjc4MmU0YWMxNzc3YjNkL3RhYmxlcmFuZ2U6MmMxYzRkNWI4NDU5NGQ5ZDkyNzgyZTRhYzE3NzdiM2RfMTItMS0xLTEtMTAzMjM5_bfd503cc-25bf-42a8-ad37-a694c5ac9c17"
      unitRef="usd">2470000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:Goodwill
      contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjJjMWM0ZDViODQ1OTRkOWQ5Mjc4MmU0YWMxNzc3YjNkL3RhYmxlcmFuZ2U6MmMxYzRkNWI4NDU5NGQ5ZDkyNzgyZTRhYzE3NzdiM2RfMTMtMS0xLTEtMTAzMjM5_4c45d22a-df1d-4371-aa7a-bb665b084702"
      unitRef="usd">2092000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i1a8ed8e80cd343d08992fa27dfde5ada_I20230131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN180OS9mcmFnOjJkMTliZDAwYjE3ZjRhNzRiMmY0NzE1NjYzNmI3NzIwL3RhYmxlOjJjMWM0ZDViODQ1OTRkOWQ5Mjc4MmU0YWMxNzc3YjNkL3RhYmxlcmFuZ2U6MmMxYzRkNWI4NDU5NGQ5ZDkyNzgyZTRhYzE3NzdiM2RfMTQtMS0xLTEtMTAzMjM5_8d372774-85c3-4729-ab34-1412dd822074"
      unitRef="usd">4562000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfMjM3OQ_88f72cf4-fa4a-495f-91a7-186be7e66a27">GOODWILL AND INTANGIBLE ASSETS&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is recorded when the purchase price of an acquisition exceeds the fair value of the net tangible and identified intangible assets acquired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is tested annually for impairment at the reporting unit level during the fourth quarter or earlier upon the occurrence of certain events or substantive changes in circumstances. There were no indicators of impairment in the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; months ended March&#160;31, 2023. The balance of the Company's goodwill was $39.6&#160;million as of March&#160;31, 2023 and $37.5&#160;million as of December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents details of the Company&#x2019;s intangible assets as of March&#160;31, 2023 ($ in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Useful&#160;Life&lt;br/&gt;(In&#160;Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets with finite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired and developed technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,931)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercialization rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks and tradenames&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total intangible assets with finite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents details of the Company&#x2019;s intangible assets as of December&#160;31, 2022 ($ in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Useful&#160;Life&lt;br/&gt;(In&#160;Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets with finite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired and developed technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercialization rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks and tradenames&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(315)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total intangible assets with finite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,788)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,788)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Acquisition of Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company acquired commercialization rights in an exclusive partnership for comprehensive data analytics in relation to NGS-based metagenomics testing for infectious diseases. In 2022, the Company incurred additional costs related to this partnership of $1.0 million. These are included within commercialization rights as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company acquired the Transplant Hero patient application. The patient application is included in Acquired and developed technology as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2021, acquisition of intangible assets increased $13.4&#160;million primarily from business combinations. These acquisitions included $4.7&#160;million of Acquired and developed technology, $2.5&#160;million of Commercialization rights, $3.7&#160;million of Customer relationships, $2.2&#160;million of Trademarks and tradenames and $0.3&#160;million of Other intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Amortization of Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are carried at cost less accumulated amortization. Amortization expenses are recorded to cost of testing services, cost of product, cost of patient and digital solutions, and sales and marketing expenses in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's amortization expense of intangible assets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of testing services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of patient and digital solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales &amp;amp; marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s estimated future amortization expense of intangible assets with finite lives as of March&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost of Testing Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost of Product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost of Patient and Digital Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sales and Marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfNjU5NzA2OTc2OTA1NA_0882c184-d0a2-484c-a541-61787c760a5f"
      unitRef="usd">39600000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfNjU5NzA2OTc2OTA0MQ_94eecdd3-5dd3-41a7-92a0-75a6ebf90d20"
      unitRef="usd">37500000</us-gaap:Goodwill>
    <cdna:ScheduleOfIntangibleAssetsTableTableTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfMjM4MA_0081022e-0616-4bce-9ac3-2263a7003df1">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents details of the Company&#x2019;s intangible assets as of March&#160;31, 2023 ($ in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Useful&#160;Life&lt;br/&gt;(In&#160;Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets with finite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired and developed technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,931)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,067)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercialization rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,549)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks and tradenames&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total intangible assets with finite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,766)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents details of the Company&#x2019;s intangible assets as of December&#160;31, 2022 ($ in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.582%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Useful&#160;Life&lt;br/&gt;(In&#160;Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets with finite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired and developed technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,459)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercialization rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks and tradenames&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(315)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total intangible assets with finite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,788)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,788)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cdna:ScheduleOfIntangibleAssetsTableTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia2fc3487bfd640a096722284a0d737e0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfMy0xLTEtMS05NTEzMg_ff0bd697-8a8e-46af-bd2f-633e6a367d1a"
      unitRef="usd">36517000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia2fc3487bfd640a096722284a0d737e0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfMy0zLTEtMS05NTEzMg_4fc3bf8c-4fdd-41d6-ba31-41df91d7acb6"
      unitRef="usd">15931000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <cdna:FiniteLivedIntangibleForeignCurrencyTranslation
      contextRef="ia2fc3487bfd640a096722284a0d737e0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfMy01LTEtMS05NTEzMg_b12377f7-6fa1-4338-accd-dd972b372701"
      unitRef="usd">2336000</cdna:FiniteLivedIntangibleForeignCurrencyTranslation>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia2fc3487bfd640a096722284a0d737e0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfMy03LTEtMS05NTEzMg_b91c10a9-1f7a-4fa2-b73a-77de6d93d211"
      unitRef="usd">18250000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i2aa30743f4a44b15900e7f593b2ae88b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfMy05LTEtMS05NTEzMg_24269283-3610-407b-8612-740a5711ef4d">P7Y6M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i82959e331a5e485bbf7ae6493073076f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNC0xLTEtMS05NTEzMg_f5e17cac-714e-4270-afb6-1531fb6e5b95"
      unitRef="usd">24908000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i82959e331a5e485bbf7ae6493073076f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNC0zLTEtMS05NTEzMg_bb85c5bc-7ac2-4eb2-9d35-01c85e63159b"
      unitRef="usd">7852000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <cdna:FiniteLivedIntangibleForeignCurrencyTranslation
      contextRef="i82959e331a5e485bbf7ae6493073076f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNC01LTEtMS05NTEzMg_e10017b9-d901-4077-9c2e-27dd059f92ee"
      unitRef="usd">2067000</cdna:FiniteLivedIntangibleForeignCurrencyTranslation>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i82959e331a5e485bbf7ae6493073076f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNC03LTEtMS05NTEzMg_405851b6-67be-4262-8119-d8fed8b0006b"
      unitRef="usd">14989000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ib9bc39941c984943b121612207ca37ea_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNC05LTEtMS05NTEzMg_0157b84a-b9e7-4fc7-9396-5b3928ede4fb">P9Y6M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i81dc9074721e44aba01ef41b26358b4c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNS0xLTEtMS05NTEzMg_c8258b82-6472-40db-9ed7-ad47042659e3"
      unitRef="usd">11579000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i81dc9074721e44aba01ef41b26358b4c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNS0zLTEtMS05NTEzMg_b69b6078-982b-4fe8-971e-58dcc0c44e27"
      unitRef="usd">3549000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <cdna:FiniteLivedIntangibleForeignCurrencyTranslation
      contextRef="i81dc9074721e44aba01ef41b26358b4c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNS01LTEtMS05NTEzMg_1f77486e-b532-45a7-85b3-040f23c214f7"
      unitRef="usd">0</cdna:FiniteLivedIntangibleForeignCurrencyTranslation>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i81dc9074721e44aba01ef41b26358b4c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNS03LTEtMS05NTEzMg_7851a29f-e69f-460d-8b53-02e3b6fd29ec"
      unitRef="usd">8030000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="iacaeaa220cfc409e84deae3b9074cbe5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNS05LTEtMS05NTEzMg_8473ad17-0a7b-4825-8c1d-018ab6660816">P6Y3M18D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if342038ec26148cfaed98ce1574cd8a0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNi0xLTEtMS05NTEzMg_274bf4df-0748-4b6f-a2ee-fa0924494247"
      unitRef="usd">4860000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if342038ec26148cfaed98ce1574cd8a0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNi0zLTEtMS05NTEzMg_78324181-7a0b-4763-bd3c-c47357edcac9"
      unitRef="usd">1434000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <cdna:FiniteLivedIntangibleForeignCurrencyTranslation
      contextRef="if342038ec26148cfaed98ce1574cd8a0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNi01LTEtMS05NTEzMg_280a4b2b-5cdf-4de1-a0ca-f199c20bc7cb"
      unitRef="usd">308000</cdna:FiniteLivedIntangibleForeignCurrencyTranslation>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if342038ec26148cfaed98ce1574cd8a0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNi03LTEtMS05NTEzMg_dd8e465e-02f1-428e-b3d4-5cf407f7599c"
      unitRef="usd">3118000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i0036ec09081944e38ff9a50586cb6917_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfNi05LTEtMS05NTEzMg_7e00b21b-174f-4e7f-af1e-96b4e48e55f4">P9Y2M12D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfOC0xLTEtMS05NTEzMg_0a9f3411-f7a5-4bc8-a87a-213a88884042"
      unitRef="usd">77864000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfOC0zLTEtMS05NTEzMg_ac4a99e8-3098-4782-99a1-428b4e6e7535"
      unitRef="usd">28766000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <cdna:FiniteLivedIntangibleForeignCurrencyTranslation
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfOC01LTEtMS05NTEzMg_aee19827-3c48-4b06-a39f-306f2ee2ec45"
      unitRef="usd">4711000</cdna:FiniteLivedIntangibleForeignCurrencyTranslation>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfOC03LTEtMS05NTEzMg_93c2fa3b-79f0-4a30-a35d-a559a083b7ee"
      unitRef="usd">44387000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic6ec54cc1d354dcc992a0bee7218aeb2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfOS0xLTEtMS05NTEzMg_19c6251f-cd16-49be-983a-7ddc31508766"
      unitRef="usd">1250000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ic6ec54cc1d354dcc992a0bee7218aeb2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfOS03LTEtMS05NTEzMg_50ba3d03-1f66-4a77-b890-16b68f4cfa59"
      unitRef="usd">1250000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfMTAtMS0xLTEtOTUxMzI_e0ca68ae-44ec-4190-a1fa-cb025cac8cec"
      unitRef="usd">79114000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfMTAtMy0xLTEtOTUxMzI_20bc3140-9811-4641-92a8-c6b83778ac3b"
      unitRef="usd">28766000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <cdna:FiniteLivedIntangibleForeignCurrencyTranslation
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfMTAtNS0xLTEtOTUxMzI_ef388e49-f7ad-4dba-b786-9d59a2163650"
      unitRef="usd">4711000</cdna:FiniteLivedIntangibleForeignCurrencyTranslation>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjY1MWVlYjRhMzA4YjQ3MTFhYzg2NGE2NDI1MWNlYTA2L3RhYmxlcmFuZ2U6NjUxZWViNGEzMDhiNDcxMWFjODY0YTY0MjUxY2VhMDZfMTAtNy0xLTEtOTUxMzI_be399f1a-fdef-4582-a1e9-51a8ec7b5fd7"
      unitRef="usd">45637000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5a7b81e566d3418c8a4da63e000dd0da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfMy0xLTEtMS05NTEzMg_24ac2494-9ede-401f-949d-609685810246"
      unitRef="usd">35747000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5a7b81e566d3418c8a4da63e000dd0da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfMy0zLTEtMS05NTEzMg_e6a4bfc3-8c18-40d8-b85d-b86740202150"
      unitRef="usd">15138000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <cdna:FiniteLivedIntangibleForeignCurrencyTranslation
      contextRef="i5a7b81e566d3418c8a4da63e000dd0da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfMy01LTEtMS05NTEzMg_9b4bc3fc-b8c1-47ab-b332-17c86e389e20"
      unitRef="usd">2369000</cdna:FiniteLivedIntangibleForeignCurrencyTranslation>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5a7b81e566d3418c8a4da63e000dd0da_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfMy03LTEtMS05NTEzMg_cc3f61b0-49fc-4b37-ba6e-2055c227e5f6"
      unitRef="usd">18240000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="iefc3516196544bbba967fcfe05accd44_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfMy05LTEtMS05NTEzMg_1f0d95d7-9839-473b-8e54-bb972804c245">P7Y6M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia62355ec8eeb43cb853e7e57dc207494_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNC0xLTEtMS05NTEzMg_aaac9426-acc7-4fdb-98dc-98b24a55482c"
      unitRef="usd">21898000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia62355ec8eeb43cb853e7e57dc207494_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNC0zLTEtMS05NTEzMg_ffd9bd19-cb67-4306-b2ea-46bc0f76a1dd"
      unitRef="usd">7459000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <cdna:FiniteLivedIntangibleForeignCurrencyTranslation
      contextRef="ia62355ec8eeb43cb853e7e57dc207494_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNC01LTEtMS05NTEzMg_dc4b863c-8d34-44a8-88cb-88964aa763f0"
      unitRef="usd">2104000</cdna:FiniteLivedIntangibleForeignCurrencyTranslation>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia62355ec8eeb43cb853e7e57dc207494_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNC03LTEtMS05NTEzMg_afa60bc1-2329-4ba2-bf5f-6f20094075b5"
      unitRef="usd">12335000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ib827b41ea375450e89bc78d2c9d5f1e8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNC05LTEtMS05NTEzMg_dc2491b3-6d0a-4fe2-8d41-c7844fdee854">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib63ef863071a4109a09043df7d31f2f0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNS0xLTEtMS05NTEzMg_1acf81ef-af7d-4729-a0e7-c477061a4509"
      unitRef="usd">11579000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib63ef863071a4109a09043df7d31f2f0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNS0zLTEtMS05NTEzMg_7ee48615-e6f5-4dcc-ac4f-ccc2d9d2475a"
      unitRef="usd">3233000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <cdna:FiniteLivedIntangibleForeignCurrencyTranslation
      contextRef="ib63ef863071a4109a09043df7d31f2f0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNS01LTEtMS05NTEzMg_6b46dc1a-1ddf-4e7a-a478-57b3811b8709"
      unitRef="usd">0</cdna:FiniteLivedIntangibleForeignCurrencyTranslation>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib63ef863071a4109a09043df7d31f2f0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNS03LTEtMS05NTEzMg_ebe96bde-b1b9-40cf-83fb-0d6a5f104314"
      unitRef="usd">8346000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i0d9134ab3e244582ae611652d1ce3c6e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNS05LTEtMS05NTEzMg_6b68dd05-6389-4235-9333-4e45f088aeac">P6Y7M6D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if5e54691c1394d72bf91f3d75605544b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNi0xLTEtMS05NTEzMg_f29440e8-2fc3-475d-bd10-95006f9382a6"
      unitRef="usd">4540000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if5e54691c1394d72bf91f3d75605544b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNi0zLTEtMS05NTEzMg_9a254360-f46f-4d91-8cc7-f89acf4d0caa"
      unitRef="usd">1345000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <cdna:FiniteLivedIntangibleForeignCurrencyTranslation
      contextRef="if5e54691c1394d72bf91f3d75605544b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNi01LTEtMS05NTEzMg_0b305fdc-461a-4e4d-8e45-6bcaad81a9bf"
      unitRef="usd">315000</cdna:FiniteLivedIntangibleForeignCurrencyTranslation>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if5e54691c1394d72bf91f3d75605544b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNi03LTEtMS05NTEzMg_5daa1381-7863-4a42-bec8-6d1f25b0c203"
      unitRef="usd">2880000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ib6c57f7627c542678d43812cf1f234ae_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfNi05LTEtMS05NTEzMg_36a1d5c4-e5a8-4719-8ae0-fcb54b458390">P8Y6M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfOC0xLTEtMS05NTEzMg_4a18d912-b7f0-479d-aeeb-f16bb846937b"
      unitRef="usd">73764000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfOC0zLTEtMS05NTEzMg_c08b2246-0793-46ce-8554-83bdc7e35915"
      unitRef="usd">27175000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <cdna:FiniteLivedIntangibleForeignCurrencyTranslation
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfOC01LTEtMS05NTEzMg_9019c222-8c16-473c-89f9-7326352cfcb4"
      unitRef="usd">4788000</cdna:FiniteLivedIntangibleForeignCurrencyTranslation>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfOC03LTEtMS05NTEzMg_e2cc213a-fa9e-4c90-b304-393740beda8c"
      unitRef="usd">41801000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="if016caa1aa6b4d3e9e03eaa31d2e3b97_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfOS0xLTEtMS05NTEzMg_44e2444f-8323-4726-93fe-b378403fbcdb"
      unitRef="usd">1250000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="if016caa1aa6b4d3e9e03eaa31d2e3b97_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfOS03LTEtMS05NTEzMg_726454ad-7486-45ee-bbb1-70ffe6a5fdb7"
      unitRef="usd">1250000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfMTAtMS0xLTEtOTUxMzI_0076958e-f514-4c67-aff6-b3099a292593"
      unitRef="usd">75014000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfMTAtMy0xLTEtOTUxMzI_e1dba62b-0cd9-43c5-8e78-39b4461cfae7"
      unitRef="usd">27175000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <cdna:FiniteLivedIntangibleForeignCurrencyTranslation
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfMTAtNS0xLTEtOTUxMzI_002eadc2-f8e6-4d35-94f3-5613b549b75f"
      unitRef="usd">4788000</cdna:FiniteLivedIntangibleForeignCurrencyTranslation>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjkyMTBhMzQ0MjNhODQyMjJhZTdkYzI3ZDU1OGZhNjJmL3RhYmxlcmFuZ2U6OTIxMGEzNDQyM2E4NDIyMmFlN2RjMjdkNTU4ZmE2MmZfMTAtNy0xLTEtOTUxMzI_fe0c597d-ad9f-4f9e-b08b-a9313e66a645"
      unitRef="usd">43051000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i0d9134ab3e244582ae611652d1ce3c6e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfNTQ5NzU1ODE4MDc0_69ec42a4-acf6-4fb2-864e-14a7f3446c2f"
      unitRef="usd">1000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="ie657b500f633441d881331275caa19f4_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfMTI0OA_feba47d1-60a8-4c91-b9b0-8e9f89d95c49"
      unitRef="usd">13400000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="ia89f50d5989f473cbde4f16140a46923_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfMTMxNw_cf0e00b8-f31a-48a2-ac19-c243cbf2db22"
      unitRef="usd">4700000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i2c08b28aa3d0463a87a6374e3e679813_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfMTM1OA_51162c42-0293-45c3-a542-841efc0bbc96"
      unitRef="usd">2500000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i9ecfb95f5ca641be8f0f195a6fa22f65_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfMTM5MA_83f86670-de2d-4d78-8637-1f6f7b7a302c"
      unitRef="usd">3700000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i15c9947ac20a442e90a185154951f24c_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfMTQyMA_2cf88438-74b3-489a-aa96-42db2b80b5d2"
      unitRef="usd">2200000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i857e050dfe06462ebf29ac3ad1bbd400_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfMTQ1Ng_ab91f64f-2d47-435f-9e58-088540fb6565"
      unitRef="usd">300000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfMjE5OTAyMzI2MDU0Ng_e5a902ec-d59e-4029-b6a3-66bf07f53511">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company's amortization expense of intangible assets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of testing services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of patient and digital solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales &amp;amp; marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1f9048fade524f0d937582e2d0737bbd_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjU3ZjlmZTMyMzE2YTQyYThhMDdkYTlkOTVhMDM5MzM4L3RhYmxlcmFuZ2U6NTdmOWZlMzIzMTZhNDJhOGEwN2RhOWQ5NWEwMzkzMzhfMi0xLTEtMS05Njg5Nw_f29ad979-a47f-485b-8c5d-5f2df0b8eb03"
      unitRef="usd">329000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie8d2b80178a040808832e847918f0f37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjU3ZjlmZTMyMzE2YTQyYThhMDdkYTlkOTVhMDM5MzM4L3RhYmxlcmFuZ2U6NTdmOWZlMzIzMTZhNDJhOGEwN2RhOWQ5NWEwMzkzMzhfMi0zLTEtMS05Njg4Mw_f5270601-3694-49b1-a694-ace6f6412906"
      unitRef="usd">329000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ic5130eca1ccf4f738a701a55a747d5d9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjU3ZjlmZTMyMzE2YTQyYThhMDdkYTlkOTVhMDM5MzM4L3RhYmxlcmFuZ2U6NTdmOWZlMzIzMTZhNDJhOGEwN2RhOWQ5NWEwMzkzMzhfMy0xLTEtMS05Njg5Nw_8cd1f993-d9c0-47b2-977a-362944b37ace"
      unitRef="usd">418000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ifb4b7444c8a54bf5b1e67a533d029b35_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjU3ZjlmZTMyMzE2YTQyYThhMDdkYTlkOTVhMDM5MzM4L3RhYmxlcmFuZ2U6NTdmOWZlMzIzMTZhNDJhOGEwN2RhOWQ5NWEwMzkzMzhfMy0zLTEtMS05Njg4Mw_bd3b358a-8ae1-456e-9009-67acaa93a0bb"
      unitRef="usd">453000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i538eccbc464c49cd93e1c60f3af790b5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjU3ZjlmZTMyMzE2YTQyYThhMDdkYTlkOTVhMDM5MzM4L3RhYmxlcmFuZ2U6NTdmOWZlMzIzMTZhNDJhOGEwN2RhOWQ5NWEwMzkzMzhfNC0xLTEtMS05Njg5Nw_2daa03b1-6411-4739-b848-a13911c4267f"
      unitRef="usd">248000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id192b96ed2d2443395a41393430289fe_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjU3ZjlmZTMyMzE2YTQyYThhMDdkYTlkOTVhMDM5MzM4L3RhYmxlcmFuZ2U6NTdmOWZlMzIzMTZhNDJhOGEwN2RhOWQ5NWEwMzkzMzhfNC0zLTEtMS05Njg4Mw_8bf20b20-4a82-4e84-a0cf-be3c8a3554d5"
      unitRef="usd">236000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icb5085de4360418c9f60a706e826ebd0_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjU3ZjlmZTMyMzE2YTQyYThhMDdkYTlkOTVhMDM5MzM4L3RhYmxlcmFuZ2U6NTdmOWZlMzIzMTZhNDJhOGEwN2RhOWQ5NWEwMzkzMzhfNS0xLTEtMS05Njg5Nw_60649b02-86bd-4d35-9409-a987836c1f6f"
      unitRef="usd">595000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ib2bb0753ed6b4970916acf1662850bff_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjU3ZjlmZTMyMzE2YTQyYThhMDdkYTlkOTVhMDM5MzM4L3RhYmxlcmFuZ2U6NTdmOWZlMzIzMTZhNDJhOGEwN2RhOWQ5NWEwMzkzMzhfNS0zLTEtMS05Njg4Mw_2c1ca40b-2a61-487f-91a1-799efc0cd7d5"
      unitRef="usd">605000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjU3ZjlmZTMyMzE2YTQyYThhMDdkYTlkOTVhMDM5MzM4L3RhYmxlcmFuZ2U6NTdmOWZlMzIzMTZhNDJhOGEwN2RhOWQ5NWEwMzkzMzhfNi0xLTEtMS05Nzg1NA_b901196e-dd54-4c02-9296-fcc56c03b4c3"
      unitRef="usd">1590000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjU3ZjlmZTMyMzE2YTQyYThhMDdkYTlkOTVhMDM5MzM4L3RhYmxlcmFuZ2U6NTdmOWZlMzIzMTZhNDJhOGEwN2RhOWQ5NWEwMzkzMzhfNi0zLTEtMS05Nzg1NA_62e79204-d544-4ec5-a9b3-9c6d748c6b2c"
      unitRef="usd">1623000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RleHRyZWdpb246Y2JjYjdlMzcyMjJhNDc2ZGEzY2E1ZjhkNTFkNzZlMjVfMjM3Nw_34f5d07c-2f19-48b3-9c95-55cad9b230e1">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s estimated future amortization expense of intangible assets with finite lives as of March&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost of Testing Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost of Product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost of Patient and Digital Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sales and Marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i8a267b7775a54bb9a849620727f55b45_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMS0yLTEtMS05NTEzMg_6f5a8584-ebf9-4ef2-834b-463e36a1970c"
      unitRef="usd">987000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i283ae31574f24307803aaab45920bc0e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMS00LTEtMS05NTEzMg_7bb6af11-33e1-49ee-a3dc-77203382fb82"
      unitRef="usd">1263000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i369258cc427d43d7bd2ea30b3bff4f3c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMS02LTEtMS05NTEzMg_c9f6bebf-ef1e-43d7-a416-7ac447632962"
      unitRef="usd">761000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i86b184c24c09473f91a3c5a799e0ecaf_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMS04LTEtMS05NTEzMg_4c857eca-434c-41b4-bf25-16a4619d12d5"
      unitRef="usd">1850000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMS0xMC0xLTEtOTUxMzI_02b9db19-5dc4-4fd2-8fe7-d700b39d7dac"
      unitRef="usd">4861000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i8a267b7775a54bb9a849620727f55b45_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMi0yLTEtMS05NTEzMg_c8a73bd7-4021-4e7b-8beb-390e0e464369"
      unitRef="usd">1316000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i283ae31574f24307803aaab45920bc0e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMi00LTEtMS05NTEzMg_f80c32bc-98be-4002-b7b0-70fb6fd23b6a"
      unitRef="usd">1684000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i369258cc427d43d7bd2ea30b3bff4f3c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMi02LTEtMS05NTEzMg_a5ce8a68-ba85-48a1-ba38-2e025e48c64c"
      unitRef="usd">779000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i86b184c24c09473f91a3c5a799e0ecaf_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMi04LTEtMS05NTEzMg_154eac38-dfa7-4cf5-95a9-e91c74d84b91"
      unitRef="usd">2467000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMi0xMC0xLTEtOTUxMzI_5dd9cf0f-f23c-4e12-9f76-d196c95623fd"
      unitRef="usd">6246000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i8a267b7775a54bb9a849620727f55b45_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMy0yLTEtMS05NTEzMg_ffd6c17d-1339-4599-b8b2-c6e81d00b0fc"
      unitRef="usd">1316000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i283ae31574f24307803aaab45920bc0e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMy00LTEtMS05NTEzMg_079bd5ee-e37c-4262-a82e-2ff6a1d81103"
      unitRef="usd">1684000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i369258cc427d43d7bd2ea30b3bff4f3c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMy02LTEtMS05NTEzMg_f96d2b31-6f52-4a35-8d3b-77e51ac2a9ee"
      unitRef="usd">610000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i86b184c24c09473f91a3c5a799e0ecaf_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMy04LTEtMS05NTEzMg_b1d5727d-0b4d-4ce4-b518-db91dfda39b4"
      unitRef="usd">2467000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfMy0xMC0xLTEtOTUxMzI_33a07b85-fd31-4f14-85cb-4357611f3c92"
      unitRef="usd">6077000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i8a267b7775a54bb9a849620727f55b45_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNC0yLTEtMS05NTEzMg_f3a47a0f-17ba-49a0-a5bc-af0779663713"
      unitRef="usd">1316000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i283ae31574f24307803aaab45920bc0e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNC00LTEtMS05NTEzMg_0b1e2c05-bdeb-476e-aa2f-afec07cba9a2"
      unitRef="usd">745000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i369258cc427d43d7bd2ea30b3bff4f3c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNC02LTEtMS05NTEzMg_8ede7a34-03ba-4d4f-a5fe-e6cb497f4ee1"
      unitRef="usd">610000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i86b184c24c09473f91a3c5a799e0ecaf_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNC04LTEtMS05NTEzMg_65bde8c5-98a6-46aa-b19f-4b99f20eccf2"
      unitRef="usd">2465000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNC0xMC0xLTEtOTUxMzI_73620810-10d0-47d5-b035-6882474ab933"
      unitRef="usd">5136000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i8a267b7775a54bb9a849620727f55b45_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNS0yLTEtMS05NTEzMg_9967c503-ecb5-4b4b-9012-291f3b2cb77c"
      unitRef="usd">1316000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i283ae31574f24307803aaab45920bc0e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNS00LTEtMS05NTEzMg_b2da53b7-1b83-4f2c-9867-3bd65c17286a"
      unitRef="usd">745000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i369258cc427d43d7bd2ea30b3bff4f3c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNS02LTEtMS05NTEzMg_8dfa8724-36d4-4658-af20-3ea378ea221c"
      unitRef="usd">610000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i86b184c24c09473f91a3c5a799e0ecaf_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNS04LTEtMS05NTEzMg_d0fde412-0a09-44eb-b64c-4ad0652990d5"
      unitRef="usd">2451000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNS0xMC0xLTEtOTUxMzI_beb8ed0b-eee0-4d73-8053-a993851fe5f9"
      unitRef="usd">5122000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <cdna:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="i8a267b7775a54bb9a849620727f55b45_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNi0yLTEtMS05NTEzMg_b543c0c5-e058-4927-b7f9-9c4664127f8b"
      unitRef="usd">2825000</cdna:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <cdna:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="i283ae31574f24307803aaab45920bc0e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNi00LTEtMS05NTEzMg_f6dec02a-1bbf-40a2-8dae-0a672a432b28"
      unitRef="usd">3299000</cdna:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <cdna:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="i369258cc427d43d7bd2ea30b3bff4f3c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNi02LTEtMS05NTEzMg_a6479fcb-32c2-4459-8a4a-aebe05871775"
      unitRef="usd">1605000</cdna:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <cdna:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="i86b184c24c09473f91a3c5a799e0ecaf_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNi04LTEtMS05NTEzMg_128478aa-1e2d-4d68-ac9c-08f7833266d0"
      unitRef="usd">9216000</cdna:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <cdna:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNi0xMC0xLTEtOTUxMzI_2a6b1843-6924-45e1-b3a7-4072f145697c"
      unitRef="usd">16945000</cdna:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8a267b7775a54bb9a849620727f55b45_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNy0yLTEtMS05NTEzMg_f968f325-50d8-4b0b-b5f2-7e0751e289f9"
      unitRef="usd">9076000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i283ae31574f24307803aaab45920bc0e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNy00LTEtMS05NTEzMg_f55d9859-bede-4f33-99a4-24db1d69a306"
      unitRef="usd">9420000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i369258cc427d43d7bd2ea30b3bff4f3c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNy02LTEtMS05NTEzMg_45b9b86d-2dab-4917-bcf3-fb9e595b4921"
      unitRef="usd">4975000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i86b184c24c09473f91a3c5a799e0ecaf_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNy04LTEtMS05NTEzMg_fcc70f50-4eb4-41fe-b5c5-8ae6f0e7ba77"
      unitRef="usd">20916000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181Mi9mcmFnOmNiY2I3ZTM3MjIyYTQ3NmRhM2NhNWY4ZDUxZDc2ZTI1L3RhYmxlOjVkOTgwYWIzNzQ5MTRlN2ViMjNmNzRmMDZjOGU1YTNjL3RhYmxlcmFuZ2U6NWQ5ODBhYjM3NDkxNGU3ZWIyM2Y3NGYwNmM4ZTVhM2NfNy0xMC0xLTEtOTUxMzI_a2f313ed-daf1-422a-b20c-39a59d0a1ef5"
      unitRef="usd">44387000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RleHRyZWdpb246YmI2ZTViY2FjOTBhNGFmZmJiMjk1YTE4ZjYwYjNlOWZfMTExOQ_1f04c1ee-7d90-4722-9531-45a37f202f04">BALANCE SHEET COMPONENTS&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Accrued and Other Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical studies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred payments for intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory processing fees and materials &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License and other collaboration fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued shipping expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RleHRyZWdpb246YmI2ZTViY2FjOTBhNGFmZmJiMjk1YTE4ZjYwYjNlOWZfMTExNA_ba315bb2-682f-4268-b412-fd67ba3021ca">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjBkMWFkODhkOWUyYzQ3OWFhMzBkYjZhZTNhNjkwOTI2L3RhYmxlcmFuZ2U6MGQxYWQ4OGQ5ZTJjNDc5YWEzMGRiNmFlM2E2OTA5MjZfMS0xLTEtMS05NTEzMg_b84c5866-7046-4119-b523-206d3a71f215"
      unitRef="usd">3247000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjBkMWFkODhkOWUyYzQ3OWFhMzBkYjZhZTNhNjkwOTI2L3RhYmxlcmFuZ2U6MGQxYWQ4OGQ5ZTJjNDc5YWEzMGRiNmFlM2E2OTA5MjZfMS0zLTEtMS05NTEzMg_0e7720e7-d4d9-47b6-99be-fc361ee96d02"
      unitRef="usd">2962000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjBkMWFkODhkOWUyYzQ3OWFhMzBkYjZhZTNhNjkwOTI2L3RhYmxlcmFuZ2U6MGQxYWQ4OGQ5ZTJjNDc5YWEzMGRiNmFlM2E2OTA5MjZfMi0xLTEtMS05NTEzMg_2a8e2852-c614-427b-b5cf-bea644df591d"
      unitRef="usd">4713000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjBkMWFkODhkOWUyYzQ3OWFhMzBkYjZhZTNhNjkwOTI2L3RhYmxlcmFuZ2U6MGQxYWQ4OGQ5ZTJjNDc5YWEzMGRiNmFlM2E2OTA5MjZfMi0zLTEtMS05NTEzMg_99887d4a-a578-4dc1-9338-2e819b16c4aa"
      unitRef="usd">4306000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjBkMWFkODhkOWUyYzQ3OWFhMzBkYjZhZTNhNjkwOTI2L3RhYmxlcmFuZ2U6MGQxYWQ4OGQ5ZTJjNDc5YWEzMGRiNmFlM2E2OTA5MjZfMy0xLTEtMS05NTEzMg_1497f671-ff3c-4716-ad11-70ac71d29940"
      unitRef="usd">10058000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjBkMWFkODhkOWUyYzQ3OWFhMzBkYjZhZTNhNjkwOTI2L3RhYmxlcmFuZ2U6MGQxYWQ4OGQ5ZTJjNDc5YWEzMGRiNmFlM2E2OTA5MjZfMy0zLTEtMS05NTEzMg_87f4d46a-61d5-4f22-b121-c4bb6581f808"
      unitRef="usd">11964000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjBkMWFkODhkOWUyYzQ3OWFhMzBkYjZhZTNhNjkwOTI2L3RhYmxlcmFuZ2U6MGQxYWQ4OGQ5ZTJjNDc5YWEzMGRiNmFlM2E2OTA5MjZfNC0xLTEtMS05NTEzMg_f4b0b033-dbae-4c67-ac79-1b7e1238f228"
      unitRef="usd">18018000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjBkMWFkODhkOWUyYzQ3OWFhMzBkYjZhZTNhNjkwOTI2L3RhYmxlcmFuZ2U6MGQxYWQ4OGQ5ZTJjNDc5YWEzMGRiNmFlM2E2OTA5MjZfNC0zLTEtMS05NTEzMg_9119ef12-2a12-4832-bd68-5a93658ea7cd"
      unitRef="usd">19232000</us-gaap:InventoryNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RleHRyZWdpb246YmI2ZTViY2FjOTBhNGFmZmJiMjk1YTE4ZjYwYjNlOWZfMTExNQ_668c44ea-88b1-48c4-99bb-2bf72443902e">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.936%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical studies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred payments for intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory processing fees and materials &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License and other collaboration fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued shipping expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <cdna:AccruedClinicalAndCostOfOtherStudiesCurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfMS0xLTEtMS05NTEzMg_172a987e-1864-431f-af14-4a182136c6c9"
      unitRef="usd">13883000</cdna:AccruedClinicalAndCostOfOtherStudiesCurrent>
    <cdna:AccruedClinicalAndCostOfOtherStudiesCurrent
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfMS0zLTEtMS05NTEzMg_fac1b1d2-cb81-4bf1-9c29-c5cf1e1c91f9"
      unitRef="usd">14816000</cdna:AccruedClinicalAndCostOfOtherStudiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfMi0xLTEtMS05NTEzMg_e317d2b0-a920-4720-963c-66aab5f72bfd"
      unitRef="usd">8262000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfMi0zLTEtMS05NTEzMg_ce6b3ad1-c81d-4b1a-820c-9590b7595122"
      unitRef="usd">6115000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNC0xLTEtMS05NTEzMg_55777f27-8a75-4722-b502-fcf485b87f63"
      unitRef="usd">5738000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNC0zLTEtMS05NTEzMg_9778e58e-8d95-43c8-a33b-ab36b0490c15"
      unitRef="usd">5591000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNS0xLTEtMS0xMDA2OTk_51a0b192-d592-421e-a085-7523840d0d34"
      unitRef="usd">5841000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNS0zLTEtMS0xMDA2OTk_432d266d-9680-4546-942b-ca59a3c5a037"
      unitRef="usd">5342000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <cdna:DeferredPaymentsForIntangibleAssets
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNS0xLTEtMS0xMDA3MTI_c859d0b8-4424-4ec0-8b8f-e7524b72b51a"
      unitRef="usd">2641000</cdna:DeferredPaymentsForIntangibleAssets>
    <cdna:DeferredPaymentsForIntangibleAssets
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNS0zLTEtMS0xMDA3MTI_7b4751a1-07e4-46e0-a870-6ba859388eba"
      unitRef="usd">2062000</cdna:DeferredPaymentsForIntangibleAssets>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNS0xLTEtMS05NTEzMg_136f1de0-c54d-4042-9cbe-95fb09567dd3"
      unitRef="usd">2087000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNS0zLTEtMS05NTEzMg_4bb53d0e-cfe0-49ec-a134-86a4b33618ca"
      unitRef="usd">4633000</us-gaap:AccruedRoyaltiesCurrent>
    <cdna:AccruedSampleProcessingFees
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNi0xLTEtMS05NzAyNw_b2a64f76-2577-42a7-9056-52269da3b3e4"
      unitRef="usd">1760000</cdna:AccruedSampleProcessingFees>
    <cdna:AccruedSampleProcessingFees
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNi0zLTEtMS05NzAyNw_2284033a-226b-46ce-a12d-66951cd0f55f"
      unitRef="usd">2189000</cdna:AccruedSampleProcessingFees>
    <cdna:AccruedLicenseAndOtherCollaborationFees
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNi0xLTEtMS05NTEzMg_a64b6c57-f8aa-488b-b2af-b1519a0c5054"
      unitRef="usd">1017000</cdna:AccruedLicenseAndOtherCollaborationFees>
    <cdna:AccruedLicenseAndOtherCollaborationFees
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNi0zLTEtMS05NTEzMg_98f7382a-773b-4534-892f-66fe95e7a355"
      unitRef="usd">1000000</cdna:AccruedLicenseAndOtherCollaborationFees>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNy0xLTEtMS05NTEzMg_de748e7b-a511-4eba-85c7-f78be1da7259"
      unitRef="usd">825000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfNy0zLTEtMS05NTEzMg_b664ad65-6fec-4667-9760-100517741204"
      unitRef="usd">1025000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <cdna:AccruedShippingExpenses
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfOC0xLTEtMS05NTEzMg_0829fabb-1d35-47c9-abc4-fa31936b8cf2"
      unitRef="usd">459000</cdna:AccruedShippingExpenses>
    <cdna:AccruedShippingExpenses
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfOC0zLTEtMS05NTEzMg_c1a618bc-5bac-4a9e-ba55-315ae2bff656"
      unitRef="usd">489000</cdna:AccruedShippingExpenses>
    <cdna:AccruedCapitalExpenditures
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfOS0xLTEtMS05NTEzMg_4e4643d0-b6ce-4257-955c-26de86d98e53"
      unitRef="usd">0</cdna:AccruedCapitalExpenditures>
    <cdna:AccruedCapitalExpenditures
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfOS0zLTEtMS05NTEzMg_302525a5-692b-4bb3-827f-5dcd52a5c4ab"
      unitRef="usd">1316000</cdna:AccruedCapitalExpenditures>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfMTAtMS0xLTEtOTUxMzI_516c0715-dc94-469a-8dc5-db81e5e63ac7"
      unitRef="usd">4372000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfMTAtMy0xLTEtOTUxMzI_b9c5987e-9ccc-41e5-824f-9c1a61cb45f8"
      unitRef="usd">4553000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfMTEtMS0xLTEtOTUxMzI_4a2a53f5-36b9-42e4-bbfe-d7cff20c6800"
      unitRef="usd">46885000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181NS9mcmFnOmJiNmU1YmNhYzkwYTRhZmZiYjI5NWExOGY2MGIzZTlmL3RhYmxlOjQ5NTVlZjZjZmYyNTQxYmM4NjkyOGQzZTFlMTcxNDJhL3RhYmxlcmFuZ2U6NDk1NWVmNmNmZjI1NDFiYzg2OTI4ZDNlMWUxNzE0MmFfMTEtMy0xLTEtOTUxMzI_ee305dad-d39c-42d4-89b1-cd2eeb33bdd4"
      unitRef="usd">49131000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjg2OQ_e024785b-855d-4339-b51d-a4d2a23e66d4">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases its operating and office facilities for various terms under long-term, non-cancelable operating lease agreements in Brisbane, California; Columbus, Ohio; West Chester, Pennsylvania; Flowood, Mississippi; Gaithersburg, Maryland; Fremantle, Australia; and Stockholm, Sweden.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's facility leases expire at various dates through 2033. In the normal course of business, it is expected that these leases will be renewed or replaced by leases on other properties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the carrying value of the ROU asset was $33.4 million. The related current and non-current liabilities as of March&#160;31, 2023 were $5.7 million and $32.0 million, respectively. The current and non-current lease liabilities are included in accrued and &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfMTY0OTI2NzQ2ODUyOQ_d306f6fa-aeb4-45bb-9b54-7cf758f0a757"&gt;other current liabilities&lt;/span&gt; and operating lease liability, less current portion, respectively, in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the lease cost for the three months ended March 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February and June 2022, the Company entered into various lease agreements to lease office buildings in California, Nebraska, and Australia with lease terms ranging from 2 to 10.5 years. Certain leases have options to renew the respective lease terms ranging from 5 to 10 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company modified the termination date of the lease agreement for its headquarters in South San Francisco, California from December 31, 2022 to July 15, 2022. As a result, the Company remeasured its lease liability using the current incremental borrowing rate and made an adjustment by reducing the ROU asset and lease liability by $0.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease liabilities for the lease agreements made in February and June 2022 are recognized at the present value of the fixed lease payments using the current incremental borrowing rate at the lease commencement date.  ROU assets are recognized based on the initial present value of the fixed lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the ROU assets and lease liabilities for certain lease agreements which commenced in July 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the ROU assets and lease liabilities for certain lease agreements which commenced in August 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating lease liabilities as of March&#160;31, 2023 are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less operating lease liability, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the supplemental cash flow information related to leases for the three months ended March 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Royalty Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;The Board of Trustees of the Leland Stanford Junior University (&#x201c;Stanford&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2014, the Company entered into a license agreement with Stanford (the &#x201c;Stanford License&#x201d;), which granted the Company an exclusive license to a patent relating to the diagnosis of rejection in organ transplant recipients using dd-cfDNA. Under the terms of the Stanford License, the Company is required to pay an annual license maintenance fee, six milestone payments and royalties in the low single digits of net sales of products incorporating the licensed technology.  In March 2023. the Stanford License agreement was amended, which reduces the maximum royalty rate to a lower rate at which the Company may be liable to Stanford effective from April 2022. As a result, the Company reversed the excess liability in March 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Illumina&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 4, 2018, the Company entered into a license agreement with Illumina, Inc. (the &#x201c;Illumina Agreement&#x201d;). The Illumina Agreement requires the Company to pay royalties in the mid-single to low-double digits on sales of products covered by the Illumina Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cibiltech Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to that certain license and commercialization agreement that the Company entered into with Cibiltech SAS (&#x201c;Cibiltech&#x201d;) effective April 30, 2019, the Company will share an agreed-upon percentage of revenue with Cibiltech, if and when revenues are generated from iBox.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Illumina Agreement, the Company has agreed to minimum purchase commitments of finished products and raw materials from Illumina, Inc. through 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation and Indemnification Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In response to the Company's false advertising suit filed against Natera Inc. (&#x201c;Natera&#x201d;), on April 10, 2019, Natera filed a counterclaim against the Company on February 18, 2020, in the U.S. District Court for the District of Delaware (the &#x201c;Court&#x201d;) alleging the Company made false and misleading claims about the performance capabilities of AlloSure. The suit seeks injunctive relief and unspecified monetary relief. On September 30, 2020, Natera requested leave of Court to amend its counterclaims to include additional allegations regarding purportedly false claims the Company made with respect to AlloSure, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and the Court granted Natera&#x2019;s request. The trial commenced on March 7, 2022 and concluded on March 14, 2022, with the jury awarding the Company $44.9&#160;million in damages, comprised of $21.2&#160;million in compensatory damages and $23.7&#160;million in punitive damages. Post-trial motion practice remains pending. The Company will not record the award until cash is received or the matter is otherwise resolved. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 19, 2022, the United States Court of Appeals for the Federal Circuit affirmed the Court&#x2019;s judgment dismissing the Company&#x2019;s patent infringement suit against Natera. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, Natera filed suit against the Company on January 13, 2020, in the Court alleging, among other things, that AlloSure infringes Natera&#x2019;s U.S. Patent 10,526,658. This case was consolidated with the Company&#x2019;s patent infringement suit on February 4, 2020. On March 25, 2020, Natera filed an amendment to the suit alleging, among other things, that AlloSure also infringes Natera&#x2019;s U.S. Patent 10,597,724. The suit seeks a judgment that the Company has infringed Natera&#x2019;s patents, an order preliminarily and permanently enjoining the Company from any further infringement of such patents and unspecified damages. On May 13, 2022, Natera filed two new complaints alleging that AlloSure infringes Natera&#x2019;s U.S. Patents 10,655,180 and 11,111,544. These two cases were consolidated with the patent infringement case on June 15, 2022. On May 17, 2022, Natera agreed to dismiss the case alleging infringement of Natera&#x2019;s U.S. Patent 10,526,658. On July 6, 2022, the Company moved to dismiss the rest of Natera&#x2019;s claims. On September 6, 2022, the Company withdrew its motion to dismiss. Discovery is ongoing. The Company intends to defend both of these matters vigorously, and believes that the Company has good and substantial defenses to the claims alleged in the suits, but there is no guarantee that the Company will prevail. The Company has not recorded any liabilities for these suits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;United States Department of Justice and United States Securities and Exchange Commission Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in 2021, the Company received a civil investigative demand (&#x201c;CID&#x201d;) from the United States Department of Justice (&#x201c;DOJ&#x201d;) requesting that the Company produce certain documents in connection with a False Claims Act investigation being conducted by the DOJ regarding certain business practices related to the Company's kidney testing and phlebotomy services, and a subpoena from the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;) in relation to an investigation by the SEC in respect of matters similar to those identified in the CID, as well as certain of the Company&#x2019;s accounting and public reporting practices. The Company also received an information request from a state regulatory agency.  This state regulatory agency advised the Company that it has completed its review of the Company&#x2019;s business practices and determined that no further information or action is required. In late 2022, the Company received a request for information from a separate state regulatory agency concerning specimen collection by a vendor in the state. The Company may receive additional requests for information from the DOJ, SEC, or other regulatory and governmental agencies regarding similar or related subject matters. The Company does not believe that the CID, the SEC subpoena or the state regulatory agency information request raise any issues regarding the safety or efficacy of any of the Company's products or services and are cooperating fully with the investigations and the requests for information. Although the Company remains committed to compliance with all applicable laws and regulations, it cannot predict the outcome of the DOJ or SEC investigations, the state regulatory agency information request, or any other requests or investigations that may arise in the future regarding these or other subject matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may become involved in litigation and other legal actions. The Company estimates the range of liability related to any pending litigation where the amount and range of loss can be estimated. The Company records its best estimate of a loss when the loss is considered probable. Where a liability is probable and there is a range of estimated loss with no best estimate in the range, the Company records a charge equal to at least the minimum estimated liability for a loss contingency when both of the following conditions are met: (i) information available prior to issuance of the condensed consolidated financial statements indicates that it is probable that a liability had been incurred at the date of the condensed consolidated financial statements, and (ii) the range of loss can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Olymbios Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 15, 2022, a complaint was filed by Michael Olymbios against the Company in the Superior Court of the State of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;California for the County of San Mateo (the &#x201c;San Mateo County Court&#x201d;). The complaint alleges that the Company failed to pay certain fees and costs required to continue an arbitration proceeding against Dr. Olymbios, and that the Company has defamed Dr. Olymbios. Dr. Olymbios also seeks to void restrictive covenants previously agreed to by him in favor of the Company and to recover damages purportedly incurred by Dr. Olymbios. The Company filed a motion to compel arbitration and dismiss the case. On April 25, 2022, the San Mateo County Court granted the Company&#x2019;s &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex parte&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; application to stay the case and advance the hearing date to June 10, 2022 for the motion to compel arbitration and dismiss. At the June 10, 2022 hearing, the San Mateo County Court found that the decision should be made by the arbitrator, and stayed the case. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 19, 2022, Olymbios filed a motion to withdraw from arbitration before JAMS, which was denied on August 18, 2022. The matter is currently proceeding in arbitration. The Company intends to vigorously pursue its arbitration proceeding against Olymbios and to vigorously defend itself against Olymbios&#x2019; claims. The Company believes it has good and substantial support for it claims and good and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;substantial defenses to the claims alleged in the suit by Olymbios, but there is no guarantee that the Company will prevail if the case continues. The &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company has not recorded any liabilities for this suit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Securities Class Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 23, 2022, Plumbers &amp;amp; Pipefitters Local Union #295 Pension Fund filed a federal securities class action in the U.S. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;District Court for the Northern District of California against the Company, Reginald Seeto, its President, Chief Executive Officer and member of the Company&#x2019;s Board of Directors, Ankur Dhingra, its former Chief Financial Officer, Marcel Konrad, its former interim Chief Financial Officer and former Senior Vice President of Finance &amp;amp; Accounting, and Peter Maag, its former President, former Chief Executive Officer, former Chairman of the Board and current member of the Company&#x2019;s Board of Directors. The action alleges that the Company and the individual defendants made materially false and/or misleading statements and/or omissions and that such statements violated Section 10(b) of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), and Rule 10b-5 promulgated thereunder. The action also alleges that the individual defendants are liable pursuant to Section 20(a) of the Exchange Act as controlling persons of the Company. The suit seeks to recover damages caused by the alleged violations of federal securities laws, along with the plaintiffs&#x2019; costs incurred in the lawsuit, including their reasonable attorneys&#x2019; and experts&#x2019; witness fees and other costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 25, 2022, the court appointed an investor group led by the Oklahoma Police Pension and Retirement System as lead plaintiffs and appointed Saxena White P.A. and Robbins Geller Rudman &amp;amp; Dowd LLP as lead counsels. Plaintiffs filed an amended complaint on November 28, 2022. On January 27, 2023, defendants moved to dismiss all claims and to strike certain allegations in the amended complaint. A hearing on these motions is scheduled for May 16, 2023. The Company intends to defend itself vigorously, and believes that the Company has good and substantial defenses to the claims alleged in the suit, but there is no guarantee that the Company will prevail. The Company has not recorded any liabilities for this suit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Derivative Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 21, 2022, Jeffrey Edelman brought a stockholder derivative action complaint in the U.S. District Court for the Northern District of California against the Company as nominal defendant and Drs. Seeto and Maag and Mr. Dhingra, and other current and former members of the Company&#x2019;s Board of Directors (the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Edelman Derivative Action&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). The plaintiff alleges that the individual defendants breached their fiduciary duties as directors and/or officers of the Company and engaged in insider trading, waste of corporate assets, unjust enrichment and violations of Sections 14(a) and 20(a) of the Exchange Act. The action alleges that the individual defendants are liable pursuant to Section 20(a) of the Exchange Act as controlling persons of the Company. The suit seeks a declaration that the individual defendants breached their fiduciary duties to the Company, violated Sections 14(a) and 20(a) of the Exchange Act and were unjustly enriched, and also seeks to recover damages sustained by the Company as a result of the alleged violations, along with the plaintiff&#x2019;s costs incurred in the lawsuit, including reasonable attorneys&#x2019; and experts&#x2019; fees, costs and expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;On December 8, 2022, the court stayed the Edelman Derivative Action until twenty (20) days after the earlier of the following events: (a) the securities class action is dismissed in its entirety with prejudice; (b) the motion to dismiss in the securities class action is denied; (c) a joint request by plaintiff and defendants to lift the stay; (d) notification that a related derivative action that has been filed is not stayed or is no longer stayed; or (e) notification that there has been a settlement reached in the securities class action or any related derivative action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 7, 2023, Jaysen Stevenson brought a stockholder derivative action complaint in the U.S. District Court for the Northern District of California against the Company as nominal defendant and Drs. Seeto and Maag and Mr. Dhingra and other current and former members of the Company&#x2019;s Board of Directors (the &#x201c;Stevenson Derivative Action&#x201d;). The claims and allegations in the Stevenson Derivative Action are substantially similar to those in the Edelman Derivative Action. The plaintiff alleges that the individual defendants breached their fiduciary duties as directors and/or officers of the Company and engaged in insider trading, waste of corporate assets, unjust enrichment and violations of Sections 14(a) and 20(a) of the Exchange Act. The suit seeks declaratory relief and to recover alleged damages sustained by the Company as a result of the alleged violations, along with the plaintiff&#x2019;s costs incurred in the lawsuit, including reasonable attorneys&#x2019; and experts&#x2019; fees, costs and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to defend itself vigorously, and believes that the Company has good and substantial defenses to the claims alleged in the suits, but there are no guarantees that the Company will prevail.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Insurance Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, the Company filed a lawsuit against its Directors and Officers liability insurance carriers in San Mateo County Superior Court.  The Company seeks a declaration that costs and fees incurred by the Company in responding to governmental investigatory requests are covered under its policies.  The Company also asserts breach of contract against its primary insurer Great American Insurance Company for denying the claim.  The policies provide up to $15&#160;million in coverage limits.  The Company intends to vigorously pursue its claims.  The Company believes it has good and substantial support for its claims, but there is no guarantee that the Company will prevail in these claims.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjE1_cb07a629-6651-4e47-8a24-782320cf249d"
      unitRef="usd">33400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjgx_266b75f7-7f84-47d9-96a4-0440f763e1be"
      unitRef="usd">5700000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjg4_e021cd0b-7b00-42c3-9743-f7707bf23a49"
      unitRef="usd">32000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjg2NQ_b1be6d7e-8687-4b1f-ab5b-e3883150177c">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the lease cost for the three months ended March 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.598%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate (%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the supplemental cash flow information related to leases for the three months ended March 31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used for operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjRiODU0NGRmY2UzNDRmMDU5MzFjMTk0MTg5YjYzMThiL3RhYmxlcmFuZ2U6NGI4NTQ0ZGZjZTM0NGYwNTkzMWMxOTQxODliNjMxOGJfMi0xLTEtMS05NTEzMg_62bf665e-dc14-4f58-8f9d-96f1106f71f6"
      unitRef="usd">1983000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjRiODU0NGRmY2UzNDRmMDU5MzFjMTk0MTg5YjYzMThiL3RhYmxlcmFuZ2U6NGI4NTQ0ZGZjZTM0NGYwNTkzMWMxOTQxODliNjMxOGJfMi0zLTEtMS05NTEzMg_de40f032-71e6-4296-bb85-6e8002036fe8"
      unitRef="usd">1413000</us-gaap:OperatingLeaseCost>
    <us-gaap:LeaseCost
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjRiODU0NGRmY2UzNDRmMDU5MzFjMTk0MTg5YjYzMThiL3RhYmxlcmFuZ2U6NGI4NTQ0ZGZjZTM0NGYwNTkzMWMxOTQxODliNjMxOGJfNC0xLTEtMS05NTEzMg_6d3497b6-b982-4cf3-a281-a3153f9a91dc"
      unitRef="usd">1983000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjRiODU0NGRmY2UzNDRmMDU5MzFjMTk0MTg5YjYzMThiL3RhYmxlcmFuZ2U6NGI4NTQ0ZGZjZTM0NGYwNTkzMWMxOTQxODliNjMxOGJfNC0zLTEtMS05NTEzMg_796434a0-975b-457b-8cad-32dee490f425"
      unitRef="usd">1413000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjE3MjkwODNhNDNkNDQyZTQ5NzdmMTZlNGRjMzc4NDA1L3RhYmxlcmFuZ2U6MTcyOTA4M2E0M2Q0NDJlNDk3N2YxNmU0ZGMzNzg0MDVfMi0xLTEtMS05NTEzMg_e2b622d6-325a-4dc0-ba8f-8ccc0e923ff1">P6Y18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjE3MjkwODNhNDNkNDQyZTQ5NzdmMTZlNGRjMzc4NDA1L3RhYmxlcmFuZ2U6MTcyOTA4M2E0M2Q0NDJlNDk3N2YxNmU0ZGMzNzg0MDVfNC0xLTEtMS05NTEzMg_63fb6c4b-7c9d-4026-afef-159ee8f28035"
      unitRef="number">0.071</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i57bbabe758fa4226abdab65dc6f55edf_I20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc3NDYwMg_1ba951a8-d507-4cae-8b3f-c5553c6299a6">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i5afb8931ba0448dfa451bb6fd9433b11_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc3NDYwMg_b9fdb76e-828c-497c-a40d-3c5e32c6bc8e">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i2ea7fda0a4594bc7876d19e0b646c9d4_I20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc3NDYwNA_a24c68a2-0c29-4986-837f-69c7c356f8fd">P10Y6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i5f5640bdc5dc463690fc0aee32a95b31_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc3NDYwNA_c1c4c82e-fbe5-46fb-b49d-464ec443b785">P10Y6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i57bbabe758fa4226abdab65dc6f55edf_I20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc3NDYwNg_1185ab0f-954d-4f15-b28b-3d17b483c6e3">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i5afb8931ba0448dfa451bb6fd9433b11_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc3NDYwNg_9ea3d11d-bf82-48c1-bfbf-52cc1c010588">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i2ea7fda0a4594bc7876d19e0b646c9d4_I20220228"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc3NDYwOA_2ec9f44f-6f8d-48fc-b424-5862acfe3c70">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i5f5640bdc5dc463690fc0aee32a95b31_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc3NDYwOA_fe194e58-6706-46ea-90ce-020fc0ff1ba4">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i195cf846109945d0a76d6e7ce2543162_D20220601-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc3NDYyMw_a0656d0e-808c-444d-8985-fcfe3d8398db"
      unitRef="usd">-500000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i195cf846109945d0a76d6e7ce2543162_D20220601-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc3NDYyMw_a0990cf9-a6a0-4382-b4dc-34915e15ab97"
      unitRef="usd">500000</us-gaap:OperatingLeaseImpairmentLoss>
    <cdna:ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfMTY0OTI2NzQ3MzQ2NQ_43d41dd4-434e-46d3-9db2-a7aa4f45eb0a">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the ROU assets and lease liabilities for certain lease agreements which commenced in July 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the ROU assets and lease liabilities for certain lease agreements which commenced in August 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cdna:ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i53037b4e60e34295bb200d6c520f42c0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmU5ZGU3NzJjYTYxNDQ2ZWU5ZWU5MzM5M2Y0MDIwZjAyL3RhYmxlcmFuZ2U6ZTlkZTc3MmNhNjE0NDZlZTllZTkzMzkzZjQwMjBmMDJfMS0xLTEtMS0xMDEyODU_a345f663-7273-4bda-9cb7-5788710f6255"
      unitRef="usd">13776000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i70089bac7d1149d68e8faf8be4a0818a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmU5ZGU3NzJjYTYxNDQ2ZWU5ZWU5MzM5M2Y0MDIwZjAyL3RhYmxlcmFuZ2U6ZTlkZTc3MmNhNjE0NDZlZTllZTkzMzkzZjQwMjBmMDJfMS0zLTEtMS0xMDEyOTU_dfd8f97b-b689-48e1-a789-977c1cb491d3"
      unitRef="usd">14321000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i53037b4e60e34295bb200d6c520f42c0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmU5ZGU3NzJjYTYxNDQ2ZWU5ZWU5MzM5M2Y0MDIwZjAyL3RhYmxlcmFuZ2U6ZTlkZTc3MmNhNjE0NDZlZTllZTkzMzkzZjQwMjBmMDJfMi0xLTEtMS0xMDEyODU_87981409-d1dc-4e1f-8c4f-9e795c00adbb"
      unitRef="usd">14773000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i70089bac7d1149d68e8faf8be4a0818a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmU5ZGU3NzJjYTYxNDQ2ZWU5ZWU5MzM5M2Y0MDIwZjAyL3RhYmxlcmFuZ2U6ZTlkZTc3MmNhNjE0NDZlZTllZTkzMzkzZjQwMjBmMDJfMi0zLTEtMS0xMDEyOTU_ecd32821-358e-4290-b824-5491125eb440"
      unitRef="usd">15302000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id0938e8abbbf424194441e38319e63da_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjcwODQwNmJkYmEyOTQxNTFiYTAzYjQwOWE0OWIzZWJhL3RhYmxlcmFuZ2U6NzA4NDA2YmRiYTI5NDE1MWJhMDNiNDA5YTQ5YjNlYmFfMS0xLTEtMS0xMDEzMDc_69ed6848-8dd0-478d-871b-bb709d0b9810"
      unitRef="usd">5698000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i38fbe91f8cb446a1a44ae2e5489e72d5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjcwODQwNmJkYmEyOTQxNTFiYTAzYjQwOWE0OWIzZWJhL3RhYmxlcmFuZ2U6NzA4NDA2YmRiYTI5NDE1MWJhMDNiNDA5YTQ5YjNlYmFfMS0zLTEtMS0xMDEzMTY_e096bb57-63cf-440a-83c8-b58900a1a7e0"
      unitRef="usd">5814000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="id0938e8abbbf424194441e38319e63da_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjcwODQwNmJkYmEyOTQxNTFiYTAzYjQwOWE0OWIzZWJhL3RhYmxlcmFuZ2U6NzA4NDA2YmRiYTI5NDE1MWJhMDNiNDA5YTQ5YjNlYmFfMi0xLTEtMS0xMDEzMDc_2ca2be11-5e24-468d-bb65-75815cea5ba0"
      unitRef="usd">5937000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i38fbe91f8cb446a1a44ae2e5489e72d5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjcwODQwNmJkYmEyOTQxNTFiYTAzYjQwOWE0OWIzZWJhL3RhYmxlcmFuZ2U6NzA4NDA2YmRiYTI5NDE1MWJhMDNiNDA5YTQ5YjNlYmFfMi0zLTEtMS0xMDEzMTY_ca77946f-19b2-46f1-9c38-a8c069940be0"
      unitRef="usd">6005000</us-gaap:OperatingLeaseLiability>
    <cdna:ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjg3Mw_0dc44458-14ea-47b8-b05a-eaae1f32eb0a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating lease liabilities as of March&#160;31, 2023 are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less operating lease liability, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, long-term portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</cdna:ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmM0NzNiNDJiMzYxYzQ2MWI5OTg3NjQ3Y2JlMTRmNTlkL3RhYmxlcmFuZ2U6YzQ3M2I0MmIzNjFjNDYxYjk5ODc2NDdjYmUxNGY1OWRfMS00LTEtMS05NTEzMg_e07d1cfa-a52b-456f-9b26-102f3bfeb4c5"
      unitRef="usd">5854000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmM0NzNiNDJiMzYxYzQ2MWI5OTg3NjQ3Y2JlMTRmNTlkL3RhYmxlcmFuZ2U6YzQ3M2I0MmIzNjFjNDYxYjk5ODc2NDdjYmUxNGY1OWRfMi00LTEtMS05NTEzMg_bb67e412-efa5-490c-b1f5-29c1ead0e567"
      unitRef="usd">7931000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmM0NzNiNDJiMzYxYzQ2MWI5OTg3NjQ3Y2JlMTRmNTlkL3RhYmxlcmFuZ2U6YzQ3M2I0MmIzNjFjNDYxYjk5ODc2NDdjYmUxNGY1OWRfMy00LTEtMS05NTEzMg_f7a65669-adf7-4d16-b25d-1691ec58a618"
      unitRef="usd">7681000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmM0NzNiNDJiMzYxYzQ2MWI5OTg3NjQ3Y2JlMTRmNTlkL3RhYmxlcmFuZ2U6YzQ3M2I0MmIzNjFjNDYxYjk5ODc2NDdjYmUxNGY1OWRfNC00LTEtMS05NTEzMg_c8ea82bd-8c85-446c-9239-1ad81804ac27"
      unitRef="usd">7019000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmM0NzNiNDJiMzYxYzQ2MWI5OTg3NjQ3Y2JlMTRmNTlkL3RhYmxlcmFuZ2U6YzQ3M2I0MmIzNjFjNDYxYjk5ODc2NDdjYmUxNGY1OWRfNS00LTEtMS05NTEzMg_936815ac-2783-4dc0-a733-84c40b669fd4"
      unitRef="usd">7166000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <cdna:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmM0NzNiNDJiMzYxYzQ2MWI5OTg3NjQ3Y2JlMTRmNTlkL3RhYmxlcmFuZ2U6YzQ3M2I0MmIzNjFjNDYxYjk5ODc2NDdjYmUxNGY1OWRfNi00LTEtMS05NTEzMg_8d7ea38f-ed4e-4444-9b4b-3286c48b6563"
      unitRef="usd">10604000</cdna:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmM0NzNiNDJiMzYxYzQ2MWI5OTg3NjQ3Y2JlMTRmNTlkL3RhYmxlcmFuZ2U6YzQ3M2I0MmIzNjFjNDYxYjk5ODc2NDdjYmUxNGY1OWRfNy00LTEtMS05NTEzMg_ecfb6285-5b1c-4fdd-9a71-33a551df6779"
      unitRef="usd">46255000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmM0NzNiNDJiMzYxYzQ2MWI5OTg3NjQ3Y2JlMTRmNTlkL3RhYmxlcmFuZ2U6YzQ3M2I0MmIzNjFjNDYxYjk5ODc2NDdjYmUxNGY1OWRfOC00LTEtMS05NTEzMg_7074e4db-aa96-42ed-a4c4-0571df5e93d9"
      unitRef="usd">8511000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmM0NzNiNDJiMzYxYzQ2MWI5OTg3NjQ3Y2JlMTRmNTlkL3RhYmxlcmFuZ2U6YzQ3M2I0MmIzNjFjNDYxYjk5ODc2NDdjYmUxNGY1OWRfOS00LTEtMS05NTEzMg_07b15310-98a6-4759-bc53-a786826b8b5b"
      unitRef="usd">37744000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmM0NzNiNDJiMzYxYzQ2MWI5OTg3NjQ3Y2JlMTRmNTlkL3RhYmxlcmFuZ2U6YzQ3M2I0MmIzNjFjNDYxYjk5ODc2NDdjYmUxNGY1OWRfMTAtNC0xLTEtOTUxMzI_b06b2d5e-be4f-4192-be84-2297c805a67a"
      unitRef="usd">5738000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOmM0NzNiNDJiMzYxYzQ2MWI5OTg3NjQ3Y2JlMTRmNTlkL3RhYmxlcmFuZ2U6YzQ3M2I0MmIzNjFjNDYxYjk5ODc2NDdjYmUxNGY1OWRfMTEtNC0xLTEtOTUxMzI_51b98095-649c-4855-94ad-8a6a3fc00bdd"
      unitRef="usd">32006000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeasePayments
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjVjNTZiYjY2YmFlMDRmMTI4MGMyZWE1Njg1NTQ4MDY3L3RhYmxlcmFuZ2U6NWM1NmJiNjZiYWUwNGYxMjgwYzJlYTU2ODU1NDgwNjdfMy0xLTEtMS05NzMyNA_e59f4958-b00f-4911-b3cf-4e9a99f284c2"
      unitRef="usd">1333000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RhYmxlOjVjNTZiYjY2YmFlMDRmMTI4MGMyZWE1Njg1NTQ4MDY3L3RhYmxlcmFuZ2U6NWM1NmJiNjZiYWUwNGYxMjgwYzJlYTU2ODU1NDgwNjdfMy0zLTEtMS05NzMzMg_5ca3287c-e449-4f99-a333-19efacacff7a"
      unitRef="usd">972000</us-gaap:OperatingLeasePayments>
    <cdna:NumberOfMilestonePayments
      contextRef="i49912c99c82e4c2a9d7a1da7ab8fdcfa_D20140601-20140630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfMTYzMQ_61fb1fa0-5d7b-4b3e-b9fd-eba9496b4536"
      unitRef="milestone_payment">6</cdna:NumberOfMilestonePayments>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="ib4b52828eb9044d3949685e3c2d4b00d_D20220307-20220314"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc5MDc1MA_5d706e23-6f39-4bf7-8eb8-639ec2acba4f"
      unitRef="usd">44900000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="i1b275c7553774ac3ac576327338fbb57_D20220307-20220314"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc5MDc2NQ_4228fdea-ddbb-4fde-a30b-3ac8be9712c3"
      unitRef="usd">21200000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="i33ad911706e74747a0d127ced9ed8f7c_D20220307-20220314"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc5MDc5NA_b4e80368-8e03-42d4-83a5-3e5abc9a7898"
      unitRef="usd">23700000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="icd7b677ac2f44bbba944e499e4c5e1c2_D20220513-20220513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNjU5NzA2OTc5MDgxMg_40b2da70-e751-403a-a5aa-ff3c9535ac03"
      unitRef="complaint">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="icd7b677ac2f44bbba944e499e4c5e1c2_D20220513-20220513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfNTQ5NzU1ODQwNzQ4_40b2da70-e751-403a-a5aa-ff3c9535ac03"
      unitRef="complaint">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:MalpracticeInsuranceMaximumCoveragePerIncident
      contextRef="i0ee630c440d5470482172c2d5805345d_D20221201-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN181OC9mcmFnOjdlMTk3NGM3ZWY2MzQ3YjRiMjZmMTVkZWU3ZmI4Njg0L3RleHRyZWdpb246N2UxOTc0YzdlZjYzNDdiNGIyNmYxNWRlZTdmYjg2ODRfMjE5OTAyMzI4NzM1OA_40f50380-6a45-4eb7-9d36-2e9ec34eaec2"
      unitRef="usd">15000000</us-gaap:MalpracticeInsuranceMaximumCoveragePerIncident>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182NC9mcmFnOjE5MTc0ZWRlNzIyMTQzNzk5MGY3ZjY0YTAzNjU2YzA2L3RleHRyZWdpb246MTkxNzRlZGU3MjIxNDM3OTkwZjdmNjRhMDM2NTZjMDZfNDYw_471ecb7e-95fb-4d16-b4bc-7ad9859937ee">401(K) PLANThe Company sponsors a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182NC9mcmFnOjE5MTc0ZWRlNzIyMTQzNzk5MGY3ZjY0YTAzNjU2YzA2L3RleHRyZWdpb246MTkxNzRlZGU3MjIxNDM3OTkwZjdmNjRhMDM2NTZjMDZfNDYx_ec00229a-4fdc-4dab-8f7d-959d1d68ae6f"&gt;401(k)&lt;/span&gt; defined contribution plan (the "401(k) Plan") covering all U.S. employees under the Internal Revenue Code of 1986, as amended. Employee contributions to the 401(k) Plan are voluntary and are determined on an individual basis subject to the maximum allowable under federal tax regulations. The Company incurred expenses related to contributions to the 401(k) Plan of $0.7 million for each of the three months ended March 31, 2023 and 2022.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182NC9mcmFnOjE5MTc0ZWRlNzIyMTQzNzk5MGY3ZjY0YTAzNjU2YzA2L3RleHRyZWdpb246MTkxNzRlZGU3MjIxNDM3OTkwZjdmNjRhMDM2NTZjMDZfNDE3_8954c617-e4b9-430b-b04f-da527b3e954e"
      unitRef="usd">700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182NC9mcmFnOjE5MTc0ZWRlNzIyMTQzNzk5MGY3ZjY0YTAzNjU2YzA2L3RleHRyZWdpb246MTkxNzRlZGU3MjIxNDM3OTkwZjdmNjRhMDM2NTZjMDZfNDE3_ba1864e6-e277-4cf8-8bef-cb299c9aff5c"
      unitRef="usd">700000</us-gaap:DefinedContributionPlanCostRecognized>
    <cdna:WarrantsDisclosureTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182Ny9mcmFnOjZkZTE2MjIyODg3NzQ4ZDI4YzMzOWFmY2IyYjZkMDY5L3RleHRyZWdpb246NmRlMTYyMjI4ODc3NDhkMjhjMzM5YWZjYjJiNmQwNjlfMTA1Ng_b00ab134-5f53-4846-bb35-2274ae4e380d">WARRANTS&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company issues common stock warrants in connection with debt or equity financings to lenders, placement agents and investors. Issued warrants are considered standalone financial instruments and the terms of each warrant are analyzed for equity or liability classification in accordance with U.S. GAAP. Warrants that are classified as liabilities usually have various features that would require net-cash settlement by the Company. Warrants that are not liabilities, derivatives and/or meet the exception criteria are classified as equity. Warrants liabilities are remeasured at fair value at each period end with changes in fair value recorded in the condensed consolidated statements of operations until expired or exercised. Warrants that are classified as equity are valued at their relative fair value on the date of issuance, recorded in additional paid in capital and not remeasured.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the three months ended March 31, 2023 and 2022, no warrants to purchase shares of common stock were exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, outstanding warrants to purchase common stock were:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classified as&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Original Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares Underlying Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Original issue date:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cdna:WarrantsDisclosureTextBlock>
    <cdna:NumberOfWarrantsExercised
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182Ny9mcmFnOjZkZTE2MjIyODg3NzQ4ZDI4YzMzOWFmY2IyYjZkMDY5L3RleHRyZWdpb246NmRlMTYyMjI4ODc3NDhkMjhjMzM5YWZjYjJiNmQwNjlfOTMw_47e5dca7-3391-4f9e-8ee4-dc358f39c689"
      unitRef="shares">0</cdna:NumberOfWarrantsExercised>
    <cdna:NumberOfWarrantsExercised
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182Ny9mcmFnOjZkZTE2MjIyODg3NzQ4ZDI4YzMzOWFmY2IyYjZkMDY5L3RleHRyZWdpb246NmRlMTYyMjI4ODc3NDhkMjhjMzM5YWZjYjJiNmQwNjlfOTMw_55a01862-4f04-4e0e-a76e-793dbccb7a1d"
      unitRef="shares">0</cdna:NumberOfWarrantsExercised>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182Ny9mcmFnOjZkZTE2MjIyODg3NzQ4ZDI4YzMzOWFmY2IyYjZkMDY5L3RleHRyZWdpb246NmRlMTYyMjI4ODc3NDhkMjhjMzM5YWZjYjJiNmQwNjlfMTA1Nw_c23edeb7-aa2d-45ce-9fe1-8a4566569b81">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, outstanding warrants to purchase common stock were:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classified as&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Original Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares Underlying Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Original issue date:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <cdna:WarrantFairValueAssumptionsExpectedTerm
      contextRef="i445ae0f9731748a8a1bcab34010dc63a_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182Ny9mcmFnOjZkZTE2MjIyODg3NzQ4ZDI4YzMzOWFmY2IyYjZkMDY5L3RhYmxlOjYzMjFlYWUzMDIxMTQwNzM5YWJkZDU5ZDhhZjczMDFjL3RhYmxlcmFuZ2U6NjMyMWVhZTMwMjExNDA3MzlhYmRkNTlkOGFmNzMwMWNfMi0zLTEtMS05NTEzMg_c2f35753-353d-4b92-b2c5-19610e258b83">P7Y</cdna:WarrantFairValueAssumptionsExpectedTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i9eedb204e8ae4bd78694426f6de765ea_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182Ny9mcmFnOjZkZTE2MjIyODg3NzQ4ZDI4YzMzOWFmY2IyYjZkMDY5L3RhYmxlOjYzMjFlYWUzMDIxMTQwNzM5YWJkZDU5ZDhhZjczMDFjL3RhYmxlcmFuZ2U6NjMyMWVhZTMwMjExNDA3MzlhYmRkNTlkOGFmNzMwMWNfMi01LTEtMS05NTEzMg_61385b36-c515-49b5-9ac2-52bd62febe1d"
      unitRef="usdPerShare">1.12</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i9eedb204e8ae4bd78694426f6de765ea_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182Ny9mcmFnOjZkZTE2MjIyODg3NzQ4ZDI4YzMzOWFmY2IyYjZkMDY5L3RhYmxlOjYzMjFlYWUzMDIxMTQwNzM5YWJkZDU5ZDhhZjczMDFjL3RhYmxlcmFuZ2U6NjMyMWVhZTMwMjExNDA3MzlhYmRkNTlkOGFmNzMwMWNfMi03LTEtMS05NTEzMg_c92f71bf-358f-4131-92a3-345720823b27"
      unitRef="shares">3132</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i9eedb204e8ae4bd78694426f6de765ea_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN182Ny9mcmFnOjZkZTE2MjIyODg3NzQ4ZDI4YzMzOWFmY2IyYjZkMDY5L3RhYmxlOjYzMjFlYWUzMDIxMTQwNzM5YWJkZDU5ZDhhZjczMDFjL3RhYmxlcmFuZ2U6NjMyMWVhZTMwMjExNDA3MzlhYmRkNTlkOGFmNzMwMWNfMy03LTEtMS05NTEzMg_bf593e3b-d8cf-45f2-950c-3109a4492173"
      unitRef="shares">3132</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMzY2Mw_099de24c-9aa3-43b7-b672-ad400fd30ead">STOCK INCENTIVE PLANS&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Stock Options and Restricted Stock Units (&#x201c;RSU&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes option and RSU activity under the Company&#x2019;s 2014 Equity Incentive Plan, 2016 Inducement Equity Incentive Plan, and 2019 Inducement Equity Incentive Plan, and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;Available&lt;br/&gt;for Grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;RSU Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance&#x2014;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,490,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,921,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,094,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additional shares authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,141,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock awards for services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,649)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,262,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(418,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchase of common stock under employee incentive plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance&#x2014;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,175,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,248,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,095,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of options exercised was $0.0 million and $1.0 million for the three months ended March&#160;31, 2023 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, the total intrinsic value of outstanding RSUs was approximately $38.8 million and there were $74.2 million of unrecognized compensation costs related to RSUs, which are expected to be recognized over a weighted-average period of 2.65 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options outstanding that have vested and are expected to vest at March&#160;31, 2023 are as follows: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares Issued &lt;br/&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic&#160;Value&lt;br/&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&#x2019;s common stock at March&#160;31, 2023 for stock options that were in-the-money.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of options that vested during the three months ended March&#160;31, 2023 was $4.2 million. As of March&#160;31, 2023, there were approximately $26.3 million of unrecognized compensation costs related to stock options, which are expected to be recognized over a weighted-average period of 3.02 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;2014 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has an Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), under which employees can purchase shares of its common stock based on a percentage of their compensation, but not greater than 15% of their respective earnings; provided, however, an eligible employee&#x2019;s right to purchase shares of the Company&#x2019;s common stock may not accrue at a rate which exceeds $25,000 of the fair market value of such shares for each calendar year in which such rights are outstanding. The ESPP has consecutive offering periods of approximately six months in length. The purchase price per share must be equal to the lower of 85% of the fair value of the common stock on the first day of the offering period or on the exercise date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the offering period in 2022 that ended on December&#160;31, 2022, 47,025 shares were purchased pursuant to the ESPP for aggregate proceeds of $0.5 million from the issuance of such shares, which occurred on January 2, 2023.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Valuation Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair values of employee stock options and ESPP shares were estimated using the Black-Scholes option pricing model based on the following weighted average assumptions:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Employee stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.63%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.93%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.46%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.79%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.94%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.06%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free Interest Rate:&#160;The Company based the risk-free interest rate over the expected term of the award based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;:&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company used an average historical stock price volatility of its own stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected Term: The expected term represents the period for which the Company&#x2019;s stock-based compensation awards are expected to be outstanding and is based on analyzing the vesting and contractual terms of the awards and the holders&#x2019; historical exercise patterns and termination behavior.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected Dividends&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company has not paid and does not anticipate paying any dividends in the near future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock-based compensation expense relating to employee and non-employee stock-based awards for the three months ended March&#160;31, 2023 and 2022, included in the condensed consolidated statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of testing services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of patient and digital solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No tax benefit was recognized related to stock-based compensation expense since the Company has never reported taxable income and has established a full valuation allowance to offset all of the potential tax benefits associated with its deferred tax assets.&#160;&#160;In addition, no amounts of stock-based compensation expense were capitalized for the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <cdna:ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMzY2NA_81c5420d-de93-4c3f-b628-dee76735611b">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes option and RSU activity under the Company&#x2019;s 2014 Equity Incentive Plan, 2016 Inducement Equity Incentive Plan, and 2019 Inducement Equity Incentive Plan, and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;Available&lt;br/&gt;for Grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;RSU Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance&#x2014;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,490,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,921,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,094,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additional shares authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,141,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock awards for services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,649)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,262,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,262,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(170,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(418,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchase of common stock under employee incentive plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,291)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance&#x2014;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,175,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,248,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,095,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</cdna:ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMS0xLTEtMS05NTEzMg_ede2510e-ae94-4888-9d7f-087ecf2d0711"
      unitRef="shares">1490462</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMS0zLTEtMS05NTEzMg_d64a1cc5-2001-41a3-8fb7-a3871d9b0a57"
      unitRef="shares">2921925</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMS01LTEtMS05NTEzMg_451c9341-6d0b-40ea-b9c3-7b59950de595"
      unitRef="usdPerShare">28.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id490782a3afe4f6a9743acac4922431f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMS03LTEtMS05NTEzMg_6fc9b981-b171-4755-b6e4-d2107927a765"
      unitRef="shares">3094396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id490782a3afe4f6a9743acac4922431f_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMS05LTEtMS05NTEzMg_35de0a37-dea3-4646-b2cf-baa6aca9a96e"
      unitRef="usdPerShare">37.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMi0xLTEtMS05NTEzMg_4ef83bed-62ab-4368-b85f-578dc4ab4242"
      unitRef="shares">2141330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMy0xLTEtMS05NTEzMg_a94435ef-a1ce-4342-86f7-a30ea0bba7af"
      unitRef="shares">7649</cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfNC0xLTEtMS05NTEzMg_182883d3-15ef-441a-b350-779c012b98f6"
      unitRef="shares">1262588</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iff2ee009736640978c0e8cdec25086bf_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfNC03LTEtMS05NTEzMg_3f170a10-61b1-4e57-80c5-37a9bd8032fb"
      unitRef="shares">1262588</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iff2ee009736640978c0e8cdec25086bf_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfNC05LTEtMS05NTEzMg_5ec88cca-3237-48ce-a45d-eee6a1ee30a6"
      unitRef="usdPerShare">15.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="iff2ee009736640978c0e8cdec25086bf_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfNS03LTEtMS05NTEzMg_d0e8a594-f08f-4b7e-89e3-bdd4e0185adc"
      unitRef="shares">170077</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="iff2ee009736640978c0e8cdec25086bf_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfNS05LTEtMS05NTEzMg_323ed74e-4fed-413c-8ce1-3f3a69ab84a1"
      unitRef="usdPerShare">52.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfNi0xLTEtMS05NTEzMg_3a04f8bd-9021-42b9-822d-3166ad47159a"
      unitRef="shares">418564</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfNi0zLTEtMS05NTEzMg_11e3cb9f-d269-43d8-b764-b5688ba51bc9"
      unitRef="shares">418564</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfNi01LTEtMS05NTEzMg_e070b661-716d-4567-8813-a3a06473295a"
      unitRef="usdPerShare">15.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfNy0zLTEtMS05NTEzMg_4d5af6ff-07a8-4b56-9b11-597a1dc0bcf6"
      unitRef="shares">820</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfNy01LTEtMS05NTEzMg_1c3633b7-6cba-4f01-ab14-5f089deb3f43"
      unitRef="usdPerShare">2.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfOC0xLTEtMS05NTEzMg_6481465a-6155-4048-8a26-60ee97414093"
      unitRef="shares">50254</cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfOS0xLTEtMS05NTEzMg_396b17e2-d387-460e-958c-ed7c40a97fe7"
      unitRef="shares">91291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="iff2ee009736640978c0e8cdec25086bf_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfOS03LTEtMS05NTEzMg_e316ae2e-a4c2-4266-94f6-0cb8fd1a4939"
      unitRef="shares">91291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="iff2ee009736640978c0e8cdec25086bf_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfOS05LTEtMS05NTEzMg_7dd37b43-085a-425f-befd-5a9ed187750f"
      unitRef="usdPerShare">36.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMTAtMS0xLTEtOTUxMzI_77e10518-5d50-4a11-9963-1724485f2982"
      unitRef="shares">12949</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMTAtMy0xLTEtOTUxMzI_5c115322-13e7-4694-b2c2-4077d9ccb135"
      unitRef="shares">12949</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMTAtNS0xLTEtOTUxMzI_1f0a6908-65f4-4d17-8869-65c2e56aa7bf"
      unitRef="usdPerShare">31.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMTEtMS0xLTEtOTUxMzI_0e634e11-e9cf-4047-96af-bf526091e577"
      unitRef="shares">78024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMTEtMy0xLTEtOTUxMzI_703a19bd-c21a-4362-a79b-c59dfbbf1ace"
      unitRef="shares">78024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMTEtNS0xLTEtOTUxMzI_d5d2bb2e-f62b-4c77-8161-57c1c9c04c07"
      unitRef="usdPerShare">33.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMTItMS0xLTEtOTUxMzI_3142c518-96b3-4cd2-8d71-e137b1152fea"
      unitRef="shares">2175509</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMTItMy0xLTEtOTUxMzI_fca9a6d6-3459-4c2f-9d44-bc586b23e753"
      unitRef="shares">3248696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMTItNS0xLTEtOTUxMzI_1073b822-c8d5-4681-8bab-131316839a3a"
      unitRef="usdPerShare">26.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i12f532855bf14a43998b04ac7db3ddfd_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMTItNy0xLTEtOTUxMzI_dfc6de79-c453-4b50-b9ea-dece2de01a10"
      unitRef="shares">4095616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i12f532855bf14a43998b04ac7db3ddfd_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjQ2ZTBhNGFmMWYzYzQwNjA4ZGQxNmM2OTdjYmIxNjVhL3RhYmxlcmFuZ2U6NDZlMGE0YWYxZjNjNDA2MDhkZDE2YzY5N2NiYjE2NWFfMTItOS0xLTEtOTUxMzI_074880fd-fc8a-406b-8940-f648f69a757e"
      unitRef="usdPerShare">29.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMzQy_3e216750-fb8e-4df8-9c71-12a07326bc56"
      unitRef="usd">0.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMzQ5_71a9c2bd-f11f-4a58-9540-08f1dac336a0"
      unitRef="usd">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i12f532855bf14a43998b04ac7db3ddfd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfNDc2_c05bcb01-948d-4257-a58d-da0f1a4f6b1d"
      unitRef="usd">38800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i12f532855bf14a43998b04ac7db3ddfd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfNDk0_96d86626-f988-4cef-8aa3-517dba883c00"
      unitRef="usd">74200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iff2ee009736640978c0e8cdec25086bf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfNjE5_3ee5a857-3fbb-43a1-bb04-ecd359f65df5">P2Y7M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMzY1OQ_9f6f10a1-3ffe-4226-92de-60b8493adb45">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options outstanding that have vested and are expected to vest at March&#160;31, 2023 are as follows: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares Issued &lt;br/&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic&#160;Value&lt;br/&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock>
    <cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjYxNzc4ZjE0MjNmMzQ0NGVhMTI3NzgyYTdjODAwOGQyL3RhYmxlcmFuZ2U6NjE3NzhmMTQyM2YzNDQ0ZWExMjc3ODJhN2M4MDA4ZDJfMS0xLTEtMS05NTEzMg_47239f59-e2a4-4f5d-91b6-00d1b74f8989"
      unitRef="shares">1273</cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber>
    <cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjYxNzc4ZjE0MjNmMzQ0NGVhMTI3NzgyYTdjODAwOGQyL3RhYmxlcmFuZ2U6NjE3NzhmMTQyM2YzNDQ0ZWExMjc3ODJhN2M4MDA4ZDJfMS0zLTEtMS05NTEzMg_11bce669-0cef-4cc5-ad42-ea6cabd52b0a"
      unitRef="usdPerShare">25.39</cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice>
    <cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjYxNzc4ZjE0MjNmMzQ0NGVhMTI3NzgyYTdjODAwOGQyL3RhYmxlcmFuZ2U6NjE3NzhmMTQyM2YzNDQ0ZWExMjc3ODJhN2M4MDA4ZDJfMS01LTEtMS05NTEzMg_43abb107-f93b-4f6c-b653-8cce1986e2f4">P5Y8M19D</cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm>
    <cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjYxNzc4ZjE0MjNmMzQ0NGVhMTI3NzgyYTdjODAwOGQyL3RhYmxlcmFuZ2U6NjE3NzhmMTQyM2YzNDQ0ZWExMjc3ODJhN2M4MDA4ZDJfMS03LTEtMS05NTEzMg_1cd4abd7-80c1-4b1c-85a9-3855537e12a0"
      unitRef="usd">1558000</cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue>
    <cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjYxNzc4ZjE0MjNmMzQ0NGVhMTI3NzgyYTdjODAwOGQyL3RhYmxlcmFuZ2U6NjE3NzhmMTQyM2YzNDQ0ZWExMjc3ODJhN2M4MDA4ZDJfMi0xLTEtMS05NTEzMg_31734775-afe4-4fcd-8897-dfd58b3c04de"
      unitRef="shares">1695</cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber>
    <cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjYxNzc4ZjE0MjNmMzQ0NGVhMTI3NzgyYTdjODAwOGQyL3RhYmxlcmFuZ2U6NjE3NzhmMTQyM2YzNDQ0ZWExMjc3ODJhN2M4MDA4ZDJfMi0zLTEtMS05NTEzMg_b5117f9d-5757-4052-825f-7cf8cbd997a4"
      unitRef="usdPerShare">27.05</cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice>
    <cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjYxNzc4ZjE0MjNmMzQ0NGVhMTI3NzgyYTdjODAwOGQyL3RhYmxlcmFuZ2U6NjE3NzhmMTQyM2YzNDQ0ZWExMjc3ODJhN2M4MDA4ZDJfMi01LTEtMS05NTEzMg_38bde528-250a-4191-b7db-737d3675614c">P8Y11M19D</cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm>
    <cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjYxNzc4ZjE0MjNmMzQ0NGVhMTI3NzgyYTdjODAwOGQyL3RhYmxlcmFuZ2U6NjE3NzhmMTQyM2YzNDQ0ZWExMjc3ODJhN2M4MDA4ZDJfMi03LTEtMS05NTEzMg_a079bb69-df64-4d83-89e3-8b9982bc18bf"
      unitRef="usd">3000</cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjYxNzc4ZjE0MjNmMzQ0NGVhMTI3NzgyYTdjODAwOGQyL3RhYmxlcmFuZ2U6NjE3NzhmMTQyM2YzNDQ0ZWExMjc3ODJhN2M4MDA4ZDJfMy0xLTEtMS05NTEzMg_e709b096-8a33-4732-b56a-0972fc5c25e1"
      unitRef="shares">2968</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOjYxNzc4ZjE0MjNmMzQ0NGVhMTI3NzgyYTdjODAwOGQyL3RhYmxlcmFuZ2U6NjE3NzhmMTQyM2YzNDQ0ZWExMjc3ODJhN2M4MDA4ZDJfMy03LTEtMS05NTEzMg_649a15f1-d78e-4bf5-ad82-34791816760d"
      unitRef="usd">1561000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i565db6f072c74a3dbfeac9d900d2d797_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMTAwNg_5d930c27-ec40-4f58-9275-f9edb91159bb"
      unitRef="usd">4200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ib2b2e52a6bb948f2b6b0826f266d5493_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMTA0NQ_207314e2-8076-4006-a322-025b78a017c6"
      unitRef="usd">26300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i565db6f072c74a3dbfeac9d900d2d797_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMTE3OQ_d73cf192-215b-415d-ab4c-5fbaec171aff">P3Y7D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i26d6663b7c774332a4c9fa15e23e3b34_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMTQwNw_7a2a2a94-bf92-4376-b7de-9dc8e2df1529"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum
      contextRef="i7773cc52f31449008e2a2da976fb5dbc_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMTU3Ng_9cfc1e7e-6421-402f-a14c-6bf375ae9747"
      unitRef="usd">25000</cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum>
    <cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="i7773cc52f31449008e2a2da976fb5dbc_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMTczOQ_2e32644c-d556-42c5-b7cd-f24ada5713d0">P6M</cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
      contextRef="i7773cc52f31449008e2a2da976fb5dbc_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMTgxMg_41b0aa6e-e7e2-417e-8219-3b1e943caf54"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i40b3e213d2c44ed3bf2769319aee962b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMTk2OQ_d7a70ffd-b68a-43d4-8083-6b194b5a3432"
      unitRef="shares">47025</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i40b3e213d2c44ed3bf2769319aee962b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMjA0MQ_d87f0758-c3dd-430d-a294-025efc8ca651"
      unitRef="usd">500000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMzY2MA_86826351-dfbb-47d2-90a7-266313c7a2bf">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair values of employee stock options and ESPP shares were estimated using the Black-Scholes option pricing model based on the following weighted average assumptions:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.476%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Employee stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.63%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.93%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.46%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.79%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.94%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.06%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i565db6f072c74a3dbfeac9d900d2d797_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfMy0yLTEtMS05NTEzMg_06ab5e77-60c6-4d24-9fba-b199a1897c73">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9e23905672f3405495bcc17dd04c3467_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfMy00LTEtMS05NTEzMg_48cbe4f9-6c7b-42be-be05-7d8b730ad207">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i565db6f072c74a3dbfeac9d900d2d797_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfNC0yLTEtMS05NTEzMg_6fe3bcac-a9fe-4f96-b21a-df045c5684e1"
      unitRef="number">0.7863</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9e23905672f3405495bcc17dd04c3467_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfNC00LTEtMS05NTEzMg_91cca92b-faae-4de1-b27a-e194b13d7926"
      unitRef="number">0.7693</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i565db6f072c74a3dbfeac9d900d2d797_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfNS0yLTEtMS05NTEzMg_f0f310b3-eee7-44d0-bdc3-cea9a8c5a2bf"
      unitRef="number">0.0346</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9e23905672f3405495bcc17dd04c3467_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfNS00LTEtMS05NTEzMg_76d4b220-6860-4967-bd33-b42a774edb61"
      unitRef="number">0.0165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i565db6f072c74a3dbfeac9d900d2d797_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfNi0yLTEtMS05NTEzMg_233f7f1c-5cdb-4196-ba16-c41ccc0ed524"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9e23905672f3405495bcc17dd04c3467_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfNi00LTEtMS05NTEzMg_d88d8281-caa4-40d3-8e34-93665a9ad7eb"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia24f76f7b5ed46cf96e628a538a6e320_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfOC0yLTEtMS05NTEzMg_b35f6040-5bc5-479f-be3b-ae41c547fd27">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i404725fbc6564a3193b67907dbbe80e6_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfOC00LTEtMS05NTEzMg_3fcf1b34-08a3-480e-9c7c-d7359f4b13de">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia24f76f7b5ed46cf96e628a538a6e320_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfOS0yLTEtMS05NTEzMg_456f7be8-ec23-4673-a68b-b08f0ae75a3a"
      unitRef="number">0.7788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i404725fbc6564a3193b67907dbbe80e6_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfOS00LTEtMS05NTEzMg_7cd8dfcc-11be-4971-bff2-a0ac376dc5f9"
      unitRef="number">0.6779</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia24f76f7b5ed46cf96e628a538a6e320_D20230101-20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfMTAtMi0xLTEtOTUxMzI_e486794c-0984-4688-ada8-157721fcfee3"
      unitRef="number">0.0494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i404725fbc6564a3193b67907dbbe80e6_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfMTAtNC0xLTEtOTUxMzI_7a0b190c-ae7c-418d-b2fd-ccdf2d7b7120"
      unitRef="number">0.0106</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia24f76f7b5ed46cf96e628a538a6e320_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfMTEtMi0xLTEtOTUxMzI_eceec28d-51b2-4dab-be91-91a67f994eb8"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i404725fbc6564a3193b67907dbbe80e6_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmZkZjQ2MzAzOTdhZDRmM2NhODlmNmUxMTAzODhmZDAxL3RhYmxlcmFuZ2U6ZmRmNDYzMDM5N2FkNGYzY2E4OWY2ZTExMDM4OGZkMDFfMTEtNC0xLTEtOTUxMzI_0aa36272-d137-424c-a32a-7c98b1c649a0"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMzY2MQ_9ce52d5a-2721-4be8-9b33-99537e4e5111">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock-based compensation expense relating to employee and non-employee stock-based awards for the three months ended March&#160;31, 2023 and 2022, included in the condensed consolidated statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of testing services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of patient and digital solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1f9048fade524f0d937582e2d0737bbd_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfMi0xLTEtMS05NTEzMg_2ba2bf5e-4d6e-486c-8d90-2ba24c5571c6"
      unitRef="usd">479000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie8d2b80178a040808832e847918f0f37_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfMi0zLTEtMS05NTEzMg_6e485e60-7705-4af5-ae53-3808afc44e06"
      unitRef="usd">19000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic5130eca1ccf4f738a701a55a747d5d9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfMy0xLTEtMS05NTEzMg_0a308a45-16b3-412c-935b-1b1e2d7d29ad"
      unitRef="usd">360000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifb4b7444c8a54bf5b1e67a533d029b35_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfMy0zLTEtMS05NTEzMg_9ee59da3-9ffd-4e19-8c63-37edf3785ff2"
      unitRef="usd">128000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i538eccbc464c49cd93e1c60f3af790b5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfNC0xLTEtMS05NTEzMg_333e87f4-1b6f-475c-98c9-b72b64d8d4e8"
      unitRef="usd">402000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id192b96ed2d2443395a41393430289fe_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfNC0zLTEtMS05NTEzMg_79b0e61f-f936-4540-97ae-eb1390b7b7d7"
      unitRef="usd">192000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4783302274d944709ef6bd9aac018c00_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfNS0xLTEtMS05NTEzMg_b638dc85-fc4e-493e-9955-053a15646741"
      unitRef="usd">1962000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3b063cbad6df47aeadbd66f77725b34e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfNS0zLTEtMS05NTEzMg_e5134bcf-9a6a-46a7-9fdf-32cb195e2d10"
      unitRef="usd">2190000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icb5085de4360418c9f60a706e826ebd0_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfNi0xLTEtMS05NTEzMg_3e9f40b8-08b4-47d4-9a99-b4959fa91697"
      unitRef="usd">3737000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib2bb0753ed6b4970916acf1662850bff_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfNi0zLTEtMS05NTEzMg_0b6debb4-677f-4fdc-baae-5ca8ab7f0a39"
      unitRef="usd">3123000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6a8e83ffc79746499f241de17f14762c_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfNy0xLTEtMS05NTEzMg_d8fbde7f-34e6-4bcf-b99a-2ea1db3cc954"
      unitRef="usd">6814000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibfc21a0301ce4966b0e2d787749a63dd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfNy0zLTEtMS05NTEzMg_4056f655-3746-4dca-997b-3c3eef9f1a6c"
      unitRef="usd">4982000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfOC0xLTEtMS05NTEzMg_f4f24a1c-c73a-4a7b-ab43-6d42698d3d9c"
      unitRef="usd">13754000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RhYmxlOmUzY2FkNmNhM2YxODQzNzRhYzg3ODA3MmVjNmE5NjFlL3RhYmxlcmFuZ2U6ZTNjYWQ2Y2EzZjE4NDM3NGFjODc4MDcyZWM2YTk2MWVfOC0zLTEtMS05NTEzMg_77e31057-f8f9-490a-a1c2-7e101dbccb7c"
      unitRef="usd">10634000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMzI5OA_505779a7-282a-4915-bb51-7e36ee29b063"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183MC9mcmFnOjU3ZTM3M2YxMDg3ZjRlNDQ5MGRkMDA4MWI5NWQ2OTJiL3RleHRyZWdpb246NTdlMzczZjEwODdmNGU0NDkwZGQwMDgxYjk1ZDY5MmJfMzU3MA_20819e0b-f690-4474-bc83-a90a8e7da902"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183My9mcmFnOmI2N2JjZmU3YWMxNDQ1ZjA5Y2U4ZTVmNGI5MjBkOTNhL3RleHRyZWdpb246YjY3YmNmZTdhYzE0NDVmMDljZThlNWY0YjkyMGQ5M2FfMTM3Ng_db69c249-8b3a-4f35-a064-512f25f2e329">INCOME TAXES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective tax rate may vary from the U.S. federal statutory tax rate due to the change in the mix of earnings in tax jurisdictions with different statutory rates, benefits related to tax credits, and the tax impact of non-deductible expenses and other permanent differences between income before income taxes and taxable income.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2023 and 2022, the Company recorded an income tax expense of $0.1 million and an income tax benefit of $12,000, respectively. The income tax expense of $0.1 million is primarily attributable to the U.S. current tax expense.&#160;The Company assesses the realizability of its net deferred tax assets by evaluating all available evidence, both positive and negative, including (i) cumulative results of operations in recent years, (ii) sources of recent losses, (iii) estimates of future taxable income, and (iv) the length of net operating loss carryforward periods. The Company believes that based on the history of its U.S. losses and other factors, the weight of available evidence indicates that it is more likely than not that it will not be able to realize its U.S. consolidated net deferred tax assets. The Company has also placed a valuation allowance on the net deferred tax assets of its Sweden operations. Accordingly, the U.S. and Sweden net deferred tax assets have been offset by a full valuation allowance.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4085e2e2596a4c689ebf01b80b2c5c82_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183My9mcmFnOmI2N2JjZmU3YWMxNDQ1ZjA5Y2U4ZTVmNGI5MjBkOTNhL3RleHRyZWdpb246YjY3YmNmZTdhYzE0NDVmMDljZThlNWY0YjkyMGQ5M2FfNDQ3_67155dc2-6032-46f6-8a6a-0e1f86c26e4d"
      unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183My9mcmFnOmI2N2JjZmU3YWMxNDQ1ZjA5Y2U4ZTVmNGI5MjBkOTNhL3RleHRyZWdpb246YjY3YmNmZTdhYzE0NDVmMDljZThlNWY0YjkyMGQ5M2FfNTQ5NzU1ODE3MDc3_b533b08f-b745-41ce-8f44-f0b8ece7acce"
      unitRef="usd">-12000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4085e2e2596a4c689ebf01b80b2c5c82_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183My9mcmFnOmI2N2JjZmU3YWMxNDQ1ZjA5Y2U4ZTVmNGI5MjBkOTNhL3RleHRyZWdpb246YjY3YmNmZTdhYzE0NDVmMDljZThlNWY0YjkyMGQ5M2FfNDk4_67155dc2-6032-46f6-8a6a-0e1f86c26e4d"
      unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RleHRyZWdpb246NjZiYzFjMzlhODk2NGIwM2I3MDRmMTI0ZTcxNzY2NjdfMTAwOQ_94b35c91-3e6e-4ac2-a77d-068c5801e628">SEGMENT REPORTING&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the Company's Chief Operating Decision Maker (&#x201c;CODM&#x201d;), or decision making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its Chief Executive Officer as the CODM. In determining its reportable segments, the Company considered the markets and types of customers served and the products or services provided in those markets. The Company operates in a single reportable segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by geographic regions are based upon the customers&#x2019; ship-to address for product revenue and the region of testing for testing services revenue. The following table summarizes reportable revenues by geographic regions (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Testing services revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Patient and digital solutions revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Europe&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes long-lived assets, consisting of property and equipment, net, by geographic regions (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RleHRyZWdpb246NjZiYzFjMzlhODk2NGIwM2I3MDRmMTI0ZTcxNzY2NjdfMTAxMA_103b9871-7f41-49e7-b2b7-edf220f5380d">The following table summarizes reportable revenues by geographic regions (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Testing services revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Patient and digital solutions revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Europe&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f7a16d338ed4ab3939bc3f47e6c75cf_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMy0xLTEtMS05NTEzMg_2723a96c-df9d-40dc-ab2e-b2d0abc0405f"
      unitRef="usd">61647000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ab6496f097a4ebc957f05bf6f2a67a7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMy0zLTEtMS05NTEzMg_b9d76191-1dc2-4536-a78e-e5552643f35a"
      unitRef="usd">66223000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39f90c981a414baca25472855eb286a8_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfNC0xLTEtMS05NTEzMg_fda4f352-ad34-4b95-b2f4-5ad8d81bf7b8"
      unitRef="usd">137000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic03e1001adae4271911ad4bdce2d0981_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfNC0zLTEtMS05NTEzMg_87a6a7fd-4160-4b98-8dd3-ea51555c3eda"
      unitRef="usd">221000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6522c13470244b44971d6dd1d0a8251b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfNS0xLTEtMS05NTEzMg_9e6a1f49-0bf1-44e7-b981-302b94308d2a"
      unitRef="usd">61784000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68b6550537c1477c960fc12e49544478_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfNS0zLTEtMS05NTEzMg_ad6b3157-f5f4-417f-9579-67a49174beb8"
      unitRef="usd">66444000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id58767c1d8084713916edd6596399012_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfNy0xLTEtMS05NTEzMg_506a1cd2-f8b1-4450-af49-c3fa91b1b76c"
      unitRef="usd">3727000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15533108dd8044e8a8072baeebce60f2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfNy0zLTEtMS05NTEzMg_253808fb-e4aa-49da-9128-74a40ca953df"
      unitRef="usd">3613000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c59122b69b444ae819cdc8aae3be5b9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfOC0xLTEtMS05NTEzMg_5c754474-390f-41a9-afde-1cf00fd6c07a"
      unitRef="usd">2461000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c618998e62f418a831eb3095a8a2c36_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfOC0zLTEtMS05NTEzMg_7ddbbc66-6577-4cee-95ba-10c44cccaf71"
      unitRef="usd">2242000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec20c3548df44cde8bb311b72dae19bd_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfOS0xLTEtMS05NTEzMg_ae198235-f8e6-4adb-8476-cc0b0265dbfb"
      unitRef="usd">673000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i441bbf95c9a74c9f8bcc5339145c212a_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfOS0zLTEtMS05NTEzMg_51c9fdcf-37f8-4d26-941c-ec6d79122bcd"
      unitRef="usd">933000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idaaeba5a92a4430cb59489d292860cd5_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTAtMS0xLTEtOTUxMzI_aaead0d6-0ad5-410b-bc98-a4210123093e"
      unitRef="usd">6861000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie44565fb103943ffa2a40292b86d6156_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTAtMy0xLTEtOTUxMzI_bb728009-9119-461b-a400-3793570fe943"
      unitRef="usd">6788000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a6d052a98b04c87b9036941a8a6a5c8_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTItMS0xLTEtOTUxMzI_94e63bb3-767f-430d-8cdf-441445cea410"
      unitRef="usd">8506000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i128a8bcd322647b8a897eae3a619355d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTItMy0xLTEtOTUxMzI_00d63bb7-982b-4009-b8e9-80d98f7fbdbc"
      unitRef="usd">6153000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iccd964cbefaa49e2a61aabfee7302e19_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTMtMS0xLTEtOTUxMzI_a73986e0-e93b-4fd6-9674-fd7d5dacc26a"
      unitRef="usd">84000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaeaf539bfe39471ba59a24aa7f4ce0e0_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTMtMy0xLTEtOTUxMzI_9bbfffa8-8a1b-4acc-a4f7-2bc91c8e6c68"
      unitRef="usd">10000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcc6d18dcb4b4287b16ec15dafbee2d7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTQtMS0xLTEtOTUxMzI_9946df33-4414-41c5-9288-65418625f04c"
      unitRef="usd">27000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib52598d086dd497d8f54897e6cabc808_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTQtMy0xLTEtOTUxMzI_32209506-f97c-4fe3-ae8b-a4442cf87d47"
      unitRef="usd">21000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b1a5c19190949f3825408e0497964b7_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTUtMS0xLTEtOTUxMzI_60b8d295-8c9f-4035-ab7b-38cf50c1575c"
      unitRef="usd">8617000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5765e29984cc4e398fbf04608384a068_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTUtMy0xLTEtOTUxMzI_3874ef81-b689-4e37-b012-c8415b599693"
      unitRef="usd">6184000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1620b425a8304d7d9b96f7bafd09516e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTctMS0xLTEtOTUxMzI_4b959824-7e1e-44da-8578-359fdbb6e121"
      unitRef="usd">73880000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b98c1259e7b4de198ec8628fc9720f5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTctMy0xLTEtOTUxMzI_1d72c0f5-6172-4330-98e4-5c8d695086eb"
      unitRef="usd">75989000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8553922693ab40cfadd6ab80368405fe_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTgtMS0xLTEtOTUxMzI_3101fa2f-4a2a-48e1-a13e-62973bda2b46"
      unitRef="usd">2545000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i233add0bbd014f5982408f02ff0d7cef_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTgtMy0xLTEtOTUxMzI_ef913c2a-b2de-44c5-94ac-9781c8eafa83"
      unitRef="usd">2252000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic034aa3435224d08892ec111ab99fe01_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTktMS0xLTEtOTUxMzI_74348e15-ba4d-4c1c-998a-39a5af451499"
      unitRef="usd">837000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7961f0ef0c9b4553b4637f426c4f87c8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMTktMy0xLTEtOTUxMzI_97c61752-e39e-4f41-a000-5f1b19607fbd"
      unitRef="usd">1175000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMjEtMS0xLTEtOTUxMzI_f7c6769a-1057-4dbf-9fc1-a7451f846454"
      unitRef="usd">77262000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b3e18af342b4ba9834affe5071e0909_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOjcyMzNhMzk2ZDY5OTRjNDY4MTFlYTk3MmIwYWJiZjBkL3RhYmxlcmFuZ2U6NzIzM2EzOTZkNjk5NGM0NjgxMWVhOTcyYjBhYmJmMGRfMjEtMy0xLTEtOTUxMzI_f7042644-c121-419a-a8e9-304b453c1103"
      unitRef="usd">79416000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RleHRyZWdpb246NjZiYzFjMzlhODk2NGIwM2I3MDRmMTI0ZTcxNzY2NjdfMTAxMQ_e3bc8fee-0b15-406d-8ca5-1a20daced2bd">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes long-lived assets, consisting of property and equipment, net, by geographic regions (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rest of World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i61c592955b9b4fce84fc074131d238b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOmM1ODY1MmVlNDg2NDQ1NTg4NmEzZjA5ZWRmYzRjYjg1L3RhYmxlcmFuZ2U6YzU4NjUyZWU0ODY0NDU1ODg2YTNmMDllZGZjNGNiODVfMi0xLTEtMS05NTEzMg_afcc8496-96b5-4df6-b4f6-dd5e8ff87501"
      unitRef="usd">34917000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i877626f277b84c4c83cb6ce132b835a6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOmM1ODY1MmVlNDg2NDQ1NTg4NmEzZjA5ZWRmYzRjYjg1L3RhYmxlcmFuZ2U6YzU4NjUyZWU0ODY0NDU1ODg2YTNmMDllZGZjNGNiODVfMi0zLTEtMS05NTEzMg_fd74b5d9-d599-488c-979c-ea45993e6532"
      unitRef="usd">35020000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0849fd3f28ca472abc8fd430de00bd14_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOmM1ODY1MmVlNDg2NDQ1NTg4NmEzZjA5ZWRmYzRjYjg1L3RhYmxlcmFuZ2U6YzU4NjUyZWU0ODY0NDU1ODg2YTNmMDllZGZjNGNiODVfMy0xLTEtMS05NTEzMg_a0f59602-f35b-4412-855d-107686470fdd"
      unitRef="usd">498000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2fd093ee1cfc4c4d8bbb09c7524ee14b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOmM1ODY1MmVlNDg2NDQ1NTg4NmEzZjA5ZWRmYzRjYjg1L3RhYmxlcmFuZ2U6YzU4NjUyZWU0ODY0NDU1ODg2YTNmMDllZGZjNGNiODVfMy0zLTEtMS05NTEzMg_6dc7f3fe-2910-4d42-8c2d-db426792e7c1"
      unitRef="usd">405000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ifa00d894ab6f41268315eb34dc054cd4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOmM1ODY1MmVlNDg2NDQ1NTg4NmEzZjA5ZWRmYzRjYjg1L3RhYmxlcmFuZ2U6YzU4NjUyZWU0ODY0NDU1ODg2YTNmMDllZGZjNGNiODVfNC0xLTEtMS05NTEzMg_4f9b780f-8b0b-404e-985f-617210500ed0"
      unitRef="usd">91000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iac91ecb914ad42ab9e94c27584c8b7a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOmM1ODY1MmVlNDg2NDQ1NTg4NmEzZjA5ZWRmYzRjYjg1L3RhYmxlcmFuZ2U6YzU4NjUyZWU0ODY0NDU1ODg2YTNmMDllZGZjNGNiODVfNC0zLTEtMS05NTEzMg_ed90c778-62ed-4508-972f-83d68d4926b6"
      unitRef="usd">104000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOmM1ODY1MmVlNDg2NDQ1NTg4NmEzZjA5ZWRmYzRjYjg1L3RhYmxlcmFuZ2U6YzU4NjUyZWU0ODY0NDU1ODg2YTNmMDllZGZjNGNiODVfNS0xLTEtMS05NTEzMg_e0cf1e37-0a4f-4cb2-9485-a37a349f3186"
      unitRef="usd">35506000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0947b2db32e4416394c995e30d617446_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183Ni9mcmFnOjY2YmMxYzM5YTg5NjRiMDNiNzA0ZjEyNGU3MTc2NjY3L3RhYmxlOmM1ODY1MmVlNDg2NDQ1NTg4NmEzZjA5ZWRmYzRjYjg1L3RhYmxlcmFuZ2U6YzU4NjUyZWU0ODY0NDU1ODg2YTNmMDllZGZjNGNiODVfNS0zLTEtMS05NTEzMg_b03099e9-63e4-4c82-83a0-812d855deb04"
      unitRef="usd">35529000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183OS9mcmFnOjhmNTA3Nzc4YTg2MjRhZTk5YzNiNTUyNWRlY2I2NTk2L3RleHRyZWdpb246OGY1MDc3NzhhODYyNGFlOTljM2I1NTI1ZGVjYjY1OTZfMTY0OTI2NzQ0NzQ1Mw_64144445-d0a5-45ff-9a68-5be726913b79">RESTRUCTURINGIn January 2023, the Company announced a restructuring plan that is intended to optimize costs and simplify its organizational and corporate structure. The restructuring plan includes the discontinuation of the Company's operations in Fremantle, Australia, terminating its employees in that location and vacating its facilities there. As a result of this plan, the Company incurred $0.06&#160;million in restructuring charges for the three months ended March&#160;31, 2023. The Company expects to complete the closure of its Australia location in June 2024.</us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN183OS9mcmFnOjhmNTA3Nzc4YTg2MjRhZTk5YzNiNTUyNWRlY2I2NTk2L3RleHRyZWdpb246OGY1MDc3NzhhODYyNGFlOTljM2I1NTI1ZGVjYjY1OTZfNTQ5NzU1ODE5Mzg3_a775da4f-25d2-4e4d-98ce-2a6f04b45274"
      unitRef="usd">60000.00</us-gaap:RestructuringCharges>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ided2d815cb564eca882b1922cf31f38e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmRkMzVjMTVlZTM4MTQ4NWNiMzhmMDUyNzMyNzQ5NTM3L3NlYzpkZDM1YzE1ZWUzODE0ODVjYjM4ZjA1MjczMjc0OTUzN18xMDc3L2ZyYWc6ZGU0MGNkZTBhYmYyNDZkNTg0NjNmYThiNmI1NmY3ZjkvdGV4dHJlZ2lvbjpkZTQwY2RlMGFiZjI0NmQ1ODQ2M2ZhOGI2YjU2ZjdmOV8xNjQ5MjY3NDQxOTE3_d454891d-7526-41af-a7a0-904bbaaf0495">SUBSEQUENT EVENT&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;U.S. Restructuring Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, the Company announced a reduction of its U.S. workforce to simplify and streamline its organization and strengthen the overall effectiveness of its operations.  The restructuring charges are primarily related to employee severance pay and related costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>86
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M[MP"DN 8#]#:1E"+L1MLTH%-O&"_"<W*9P!,K+GI'(=DF%"'63)/PM0-,NU
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MYCC!01H#O)\+H3<;\X+V/T'R!U!+ P04    " "$@JI6DSI#"!((   !00
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MPPV+4U:U!?CW=V79?#QI?W)^_*\'R_\ 4$L#!!0    ( (2"JE9H34M1]P<
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M/9LW52UAB[B( <J )JPNL>EV$;NOL]!]_=AOYQR]&'*DZ][2MT&LN[+J5=N
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M&9AP>]M7[O$[6Q"&C2E#4ORT-NCRLR<JLJ *,I'2CX9BA3^ $OZUDM2?'PX
M)YQ?#"F[11^":DYNQEH:H""G%B8%Z4UQJV*&Q TA-A[=)-,VW:(VT2]G!#>0
M< :,% GQ>VA@(=N-H\/YL_TC<K:^2D+S/!,JV )E^E+%N#X6V0O*]I8F=A;)
M2?OZ(R*K2S^0SF'SBEZ8+OVO,/AP?&,.;V?7O]]Y!V[/7DY.GQ_W6$,F:,":
MSEZ,D'>KF=\3(^W[Q-\=3I]'*=CE?.&TNT7A71<"=M#4"T$G@]H7V,< G([]
MW,)![T<U2H6X_H+?F^6Q?O_[&NG;].LD9_Y'.;KE_J=-@ BR,,1.:H&MP/39
MGK#^YT+\A\;4_!,=<],TIN0_5QQZT@(\7Q@$U>$#79!^L^7M_P!02P,$%
M  @ A(*J5N1OX%A,%@  D$8  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6R]7%MSVSJ2_BLHSYX9NTJ2;=FY3&Y5CG,YV3E.4E$\NUM;^P"1D(0)27
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M6HX+BON)^"$(*G >\*W^=XDXE\;D:UT4("]2F%IRPF4Y(6P$1)(U+:5##J
MH JT5X@LEK,,.TSTB0DD/3#6JF'I4@2X!IWH1GS1[AMM](DP"_[*K-Y6'M>0
MK;P[//;#6H_UZ]J:[\0!Q/_+Z2_TW:/+7S#W.XSS(()B,Z)\8!HZ$#O8&G)?
M+VO>*$P>5A$8@\<']APJ-GH,3!\S ],G0PQX&(I.GBEP)K1@8@/8V6+AH_$
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MB (R6=5.*GTFA4>>4U#!%+C3H@]VOW;-@/DG4E74VR":*B5 N;08%76C@]9
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M5W>/M^S^]NKA\>OM_>V_OSVP;S/!;E1>\F*!^$J43@V3UK")+'B12)XQ;HS
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M@1L4#:#8$B7?TB2 DZ9HL>VBB)/V8;$/M$1;W$JD2])QLU^_,Y0L.['CN+O
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MR3&P(.SW#D[8<YJ8G'#@8?J$]8;,)RSL!@G*[#];=OMZ82C@*3C5A?]*?&$
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M0L#R/2]*J]& =+8.H:N!<&N8N=0PAB\1*9>D"%)V>?-2>!6EA<G,<KT!BI&
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MF9XOY!!'K&_D3<A0^N)7)D6V&]@N?1Q-UB=FLB$QD16V(A,$JG9)"6KD25O
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MR,/WRSIW+)H3<F_CX>S<WSCPWZOQOR9"["ZI>-<[[^Z02]J$#-Y=2_YIEX[
MEE;3SQ)YN6#5GS&\$N> 6TT'A8UJDO0-195RG;ZG34814"M00\TD0!22P"6Q
M]V P[MY,#[^(0'=BJ_WFO+O/_P_JP\>%_D#C/);Y@:)=/W%SV/J%(DATQK_#
M%+[HX'^L*#U-/_5T[G_AJ!GN?R?JG;0S:J44:HJI1_W3\8&P_K>7_)O*+/GW
MCB8&V++@E_13!\K2 'P^-::*;VB#] -8+_X74$L#!!0    ( (2"JE:GHX?W
M$P(  *H$   9    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;(U4VX[3,!#]
M%<M(B)50DR;9!94D4EM H&51U>7R@'APDTECU;&#/=WL_CVVDX8BM867V#.>
M<^9,/..T4WIG:@ DCXV0)J,U8CL+ E/4T# S42U(>U(IW3"TIMX&IM7 2@]J
M1!"%X4W0,"YIGGK?2N>IVJ/@$E::F'W3,/VT *&ZC$[IP;'FVQJ=(\C3EFWA
M'O!KN]+6"D:6DC<@#5>2:*@R.I_.%HF+]P'?.'3F:$]<)1NE=L[X6&8T=()
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M]0Y*W!!LT"G;>%@1!BZV#F!K&UWP/&-:#&4H_)*C+\%3"+H-VW(7_>NR=(R
ML>'0[( SX]0&9<#%^*3L;24C77#H):<Z^ID[Q4%3>,2)-DH'M@Z]$G''W%!Z
MAL4#K% Y]D\W)+N8@)J1;0%<!6T$\Q+-FF(='4@[DCB3%$0DQXDO>,3S@92
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M*\%!=S0!SQ<*?FQO:(/^8]39?P%02P,$%     @ A(*J5M<'Q&:"!   # H
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M GO:$Q>EHO:/=$@>3_RYKI1%8RT)]C[K9$?Q7512*1]$ZG_R%B6W2XI LS:
M8&D!6!4[+.I._2'*"+/MDJC@-B \U#3PG"^0H",%" %+*.-(;D_5Y]/*\I0S
MT;EH-'C,06??VTUWQDP%Q-0/4T=A&HUQXK2G[;R>Q#'U9!Z'/:6QE%0K!06Y
M9IU/APFS<8#&#9HZ#*V%01J!85G2-P>L-Z#[PAC<;GR ]BLV_@M02P,$%
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M*4X#LH%!O<$@^?AA>!9].:)UW&L='V-_WWO\AV(U6\Y_K.:W]S!_<.-JL!S
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MQK6:EIQ[$O$C$ ,M$XH:?I>(<V5M<0<0"WFQP@#6RUY.5/L %>5MQRE9@CA
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M?:)H&,0QHS;V_23I-1(UK\ @-5.6P8ARQ7&/1BSHD[Z_*CG?"WZ#Q2G?/F)
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MU,Z OL^4LNN!2]#^)QG_"U!+ P04    " "$@JI6;@F?D:8#  !5"0  &0
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M=@HD7REEMPL7H'M)3?\%4$L#!!0    ( (2"JE;V*D6"K04  ,X/   9
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M$FQYJKT]M@,CU^[&=B,-GH;N<X47;JZL *XOI#3]P!H8KO#SOP%02P,$%
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;+57ZV_;-A#_5PY:.R2
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M\U=//<\7%EA;TN<$^\N^L &/'^YXS31FY7UK]SK.L"\%!T'N3\''%8>%J%$
MJG8)FK@UJ$#U-U<@.KM!"</\D]VHVW T&E^+IF/MTW??9(&?OE,'0G1>Q/?*
ML"$5^1N'RB$YU38Y9V"XI,#NH=^, /#R%'[MFWL$CNNT[;MBZ*K@)H+@W?<<
M9Z0Q [$#\)TH]YPH"2!P\L#'OQB^A2!S_1!"Q\LC)\P3[ E3-\QA5I8506 U
M*(N!]7HE*)T8E>-'OA.&'@RSO?K$M#:8>&7PLS63I<)U0LG&9:L*]'J<.DF4
MG_RK(T/#)6XB2M&Q[P1)X,19]M)P_ 1^[ :I-7SDBNQ><W[LIY[CI>D)Q(&;
M)AOR;^>+_,R)D^@$A@;YCE]&O['C7[@L*K4SXW$6>"<0N%[R,C+>];)8H5S0
M>A:[";/TY$U7BR?.D1D;UG1&0V//">+H;:G#I"]X1<'DF*'<?YD#VW\"8>*F
MV1C*ULY'VD0YYLH\<9SOAL&!%'251*LT<[P@PF4V3[0*W>SEY,^YBX)<K$9%
M)K:EL1-[.=(TB#(G,30-$C<.($+BQD[BFY[<S5(X((/Q*(/Q?Y1!^-!KI7&7
MDKK09KVQ*VQTYK,E%[+ZYDN'I0"VM3"]^\3MX-3[Q6T#0NR T"NF8<60"P.W
M"17N4TK\B($^ 8[[*J$TC*E!+]79CIH,<O->J1X]C-HR>^02ZZ>7'7><JC+"
M<XUG,IUI/0K&S]6"P_'OG$EU K/E4O(E*AN*GI85UEH%?&9U/^8-:9>&M'PQ
MZ4[LI@&^^$X<9\_R:6+Q<?%C"%+7BR%S\Q1"^"@T3HF<3#)KE_B'.)",'$C>
MRH$74<\P/<VP)I^4A7>C=-50E#^P2MH U9C1H1B8&?W;1XK#6.APXX/_$A8T
MP>,XP:@.5C+$@,N0='Y[NU'O-9>[3GIE2<3AJF;%P^F\6(EZ>U!VLBIH0"-*
M7IN:%/G=FO';4W8]Y 78D!>VS<L9?%Q)!+5;JGU-0W,JW>R'OUUY+ALXKEIX
MLG1*7,_\C0,>!1Z;54VG:IJY27@$:>+F^+BKU,/I0AK=1"]$'TD+%+I1<@2^
MF\1'6R\EU@,EQYP]5;P>9?MHV_@*YRC9I,2OH_7<V/SM19NZ678$2>JF^>MH
M(S>/"*V7_ >T!_B?COQ/W\I_FK95W%9OAC9BFP[BV:^B'5EH*I6OB]_AW)>B
M&2J9#SLLI>-IWYXXB.]_58%FZ4XMF_&<I:A,F64TDR*4.Q'RW0A;T9X^WVB#
MFYV2AC:'-J1O+.GY/M+;HC ('#K-Z[XT!9^Q+02.;RVV5HFZ*LU.1<77IG8T
MNQVORI(-N1L5W# .B[->H7=U\N:]=RV09>A4DRY@U&-1]BU$:4YJFH]C.BFP
MB-58'7A8"63;?D1#:TQQE=6R(C%&\+W%&'E8=^8!4D=Q \ ,XX]X4^\,-; ,
M-06IGWLP9Z1 - (7[($;2*&3AJCRCH^8?^0M!E_;DZ[$FVI%URA3#R5.AN5Z
MY.19,!P("!YML3K"AN<D8;3W4)CN7&L;+I?F\JYP ?I6VQONV#O^/C"SU^+M
M</OC B9XB:<;U'R!IIZ;XD$O[87=OFC1F4ORO=!XY3;-%6=8X-$ _+X00F]>
M:(+Q5Y/+?P!02P,$%     @ A(*J5HG-44FC P    D  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S0N>&ULG59M;]LV$/XKA%8,+:!%$O5F9[:!),U>@'8P
M8G?],.P#+9TEHI*HDE3<]-?W2,F*XSF&L2_2D;Q[[KGCG4ZSG9!?5 F@R;>Z
M:M3<*;5NKSU/92743%V)%AH\V0I9,XU+67BJE<!R:U17'O7]Q*L9;YS%S.XM
MY6(F.EWQ!I:2J*ZNF7RZA4KLYD[@[#<>>%%JL^$M9BTK8 7Z4[N4N/)&E)S7
MT"@N&B)A.W=N@NO;V.A;A;\Y[-2!3$PD&R&^F,6?^=SQ#2&H(-,&@>'K$>Z@
MJ@P0TO@Z8#JC2V-X*._1?[.Q8RP;IN!.5)]YKLNY,W%(#EO65?I![/Z (1Y+
M,!.5LD^R&W1]AV2=TJ(>C)%!S9O^S;X->;C$@ X&U/+N'5F6[YEFBYD4.R*-
M-J(9P89JK9$<;\REK+3$4XYV>K&" E.LR0.T0FK>%.3MFFTJ4.]FGD9\H^5E
M ]9MCT5?P0K)1]'H4I'[)H?\I;V'O$9R=$_NEIX%_,CD%0D#EU"?AF?PPC'8
MT.*%%P?[S\U&:8FE\>^I<'NTZ#2::9=KU;(,Y@[V@P+Y",[BYY^"Q/_U#-=H
MY!J=0U^L^BXA8CO0-;>"XB,T'2BR>2*_@R@D:TN>X7:!):Y.Q7#6R^D8UB60
MK:BP7TV*>L=]T_+OZ%H^TY$'=(IG.K*G0][RANA2=(HUN7IW3=:E!'A1) 2O
M."O'.S8/2M:@[.48.CRS'JT;\JGA&FU6FFG<?4.2P$VBU B)2]'Z 0U-PCX+
M6>4D"%-":=#KI9.HUXNBB"RER+M,OXH;NBE-[3L)0G+?2?P&$NI&28!/&M$C
M1TD:DFD8&GQWDEB'Z&]"EDQS4VX8/<EYP36KB!)5IVUR7G,^<6,_L1A!/#I'
M]H%_Y!8IVN@FR#+M#5!M+8R;8] T="<3WPBQ.YU,!ZT!_ U&%4>Q?=.8#H<O
MG:&;T#@)W""-!PU$2UV:4"-,W2A(R)FZC\>ZCR^M^P^B*7[Y@!_MG-PH!5J1
M.TP<[XL#SY>&O=1/-L'W7SO>FNYVR5\XRR[NC[-L_E=_5(9V96DS2]LEV0O>
M[2%O>.;= #XNZZ2CMGD/&=0;D/L=VN?ND,3U?ZL\<J>V<,+8]:F_KX9H.B&1
M'Q_=_S3  HS&BT>3ODJ-0*<G+]X[F$HUR,+.7H6YZ!K=#ZAQ=QSO-_U4>U;O
M_PTPW()C&BK8HJE_E>*MR7[>]@LM6COC-D+CQ+1BB;\H((T"GF^%T/N%<3#^
M]"Q^ %!+ P04    " "$@JI6 ;GYCF$(  #+40  &0   'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6RUG'MOX[@5Q;\*X1:+62 ;6Y1?F4T,)-%KMDUW,.GN
M%BB*@I%I6Q@]/!253(I^^)*2;%FVS-C%2?Y(+(?W1UH^TJ7ND7C]DHFO^8IS
M2;XG<9K?]%92KC_V^WFXX@G++[,U3]5_%IE(F%2;8MG/UX*S>1F4Q'TZ&(S[
M"8O2WNRZ?.^SF%UGA8RCE'\6)"^2A(G7.QYG+S<]J[=YXTNT7$G]1G]VO69+
M_LCE;^O/0FWUMY1YE/ TC[*4"+ZXZ=U:'P/;U@%EB]\C_I+OO";ZHSQEV5>]
M\6E^TQOH$?&8AU(CF/KSS.]Y'&N2&L>W&MK;]JD#=U]OZ%[YX=6'>6(YO\_B
M/Z*Y7-WTICTRYPM6Q/)+]A+P^@.--"_,XKS\35ZJMI-QCX1%+K.D#E8C2**T
M^LN^USMB)\ :'@F@=0#="Z#T2(!=!]A[ 2/K2,"P#ACN!0R/#6E4!XQ.'=*X
M#AB?&C"I R:G!DSK@&GY[59?1_E=.DRRV;7(7HC0K15-OR@%44:KKS!*M78?
MI5#_C52<G/TJEBR-_L,J(:5SXO \%-&ZW,X6Y*[(542>DY_([7P>Z;=93#ZE
MU5&C&WUPN&11G/]XW9=J0!K;#^O.G:IS>J1SFSQDJ5SEQ$WG?-X1[YKCJ0G0
M5WMBNSOH9G?<42/1X>$E&4PO"!U0VC&@>W/X[5I<$FM8A9/?'AWRX<^=^\6,
M>6 *8ULEQMY@R'W,HH04:?2MX/_.L[@H=W^^8H+G7?L.UD<'W#MA-]9PTW[P
M3_DV[#<Q@1GS"TLWH[&F9*UDRU-I$(N]/7;LDFL?X3ZJ1#(O8JZ/DWNVCB2+
MZR/I@KC?BDB^DG_^5<603Y(G^;\Z!GY7=3#L[D#GK8_YFH7\IJ<24\[%,^_-
M?OB3-1[\W*5-),Q!PEPDS$/"?"0L ,%:8AQNQ3@TT6=?>)0\%2+G:F(A2:B/
MXYS\]X1#^<[(/5>#2)A3P48E3$_"GF>VFI-=]Y]WM75*(P\Y+!\)"T"PEF9&
M6\V,WM#,,T\+3M),DE<U3Q8\S)9J-M"9B^^,K'-U@H0Y%6R\(X'IU4#_[$GE
MQ'8><G ^$A: 8"VUC+=J&1O5\K<B>>)")SO!]210"I;FZYBITTV=4W/R(<D$
M)W+%TA_5R:<SU59B,G9UKIB0, <)<Y$P#PGSD;!@?' .MB8[1U5+;I.MW"9&
MN=V&89$4,9-\KB]&HS#J%)(1<JZ0D#!G<K!3AM/A=&H?GI=.;NE-#LY@P_%@
M.!P>M/21'R4 P5HZF&YU,#7JX)[EJPL2JM^$JTGU,XOUF>:BO%C-5YF0/TDN
M$A*ESSR7>O+3=3%T9^SC7)D@8<[TX"NETU%G^IH>R.1(2P\Y0!\)"T"PEI*N
MMDJZ,BKI46;A5Y6\UH4(5RSG9"VRI6")TE(AE9+TQ(>P)"NZ4Y81?JZ$D# '
M"7.1, \)\Z\.CI318- A_P#4:TMDUJ"IJ W^3YFMN8BRN3I5D44F0MXELC?8
M5,W3F>@ZP]V;(\^5%)3F0FD>E.9#:0&*UM;>3C77.G&.'F9)HLN#I1@W4IR3
M#]&F9*@GZ$>+AW?F?LX]VT%I3DW;382CJ^&$[J5+:*<>E.9#:0&*UA8=;41'
MSSKAS8F:I!7=IS<CZ6Q9(6E.3=O-+Y.N:1BT5P]*\Z&T $5KZZHIKUO&@JDA
MD0JN;=DH7>[.W'8:'I_$F;L\6X#0DGM-:UW=3;LE:'=<,7:U]* C]*&T $5K
MRZLIF%OFBOE#)+*$21%]OR"?TO"R4R[0XCB4YD!I+I3F06D^E!:@:&W9-35W
M:_3>KJ$%+<5#:0Z4YD)I'I3F0VD!BM9695/;M\S%_<_LM:R=$9D1%BH9"JYO
M-U&I5>DQ2B57G78G5&@E'TISH#2WIK7J#U9GSH46ZJ&T $5KRZRIZ5MO%/4E
M^?N*DP<FOG*Y.=W]NEAPH29SG?*"UO>A- =*<Z$T#TKSH;0 16MKL/$3K.F[
M)V"HG0"E.5":"Z5Y4)H/I04H6EN5C3=AO6%.L$J15<&NNH#5-WI&29%T2A!J
M1UB'M74ZZ"RN.]".72C-@])\*"U T=KWM3:N!'W#E=C5UT59'H[R\@[T!>?:
MF0C5](\M.ZMV9O2Y6JMI5SM:&UP.[#V90?MTH30/2O.AM !%:\NL,2"HV8#X
MQVOZP%*E(WTU<;RN8J:<K2BHO0"EN5":!Z7Y4%J HK65U[@0E+[WM(Y"W0DH
MS8'27"C-@])\*"U T=JJ;#P,:O8P&D.VNA.;;.[$/O'F;#/^;$E"_0IZZ$+L
M>[#0#CTHS8?2 A2MK;/&S*!OF!E\'H5,<*6JVSC.'@OU\B_1/.6OG:J"VAI0
MF@.EN5":!Z7Y4%J HK4%V-@:]-UM#0JU-: T!TISH30/2O.AM !%:ZNRL36H
MV=9H/Q4EF.R^OH5Z&%":0P]=!SH=6OMY%OJ@ 93F0VD!BM865&-@4+.!<>0Q
MN_*YV4YI0?T+*,VAA\\==#Q?=U(K#SHR'TH+4+2V9!J_@9H?8-B;FCVP-0DX
M$YUNJAEUMER@Q@*4YD)I'I3F0VD!BM:67V,LT*MWGYA!O08HS8'27"C-@])\
M*"U T=HK)S1VA&VV(TZ;F)DAYPH/2G-JVKB5%X?[V1/:IP>E^5!:@**U!=48
M#[;9>.@J@!Q-LV;6V;J"V@]0F@NE>5":#Z4%*%I;?XW]8+^[_6!#[0<HS8'2
M7"C-@])\*"U T=JJW%FAR&P_G)AFL<L08=<A.GPH@DY&]GZ:Q:XPA%UB"+O&
M$-1GZ.^L')=PL2Q7$<Q)J.\^JA:1V[Z[7:GPMER?K]\TKY8Y?&!B&:4YB?E"
MA0XN)Z,>$=7*@=6&S-;E.G1/F9194KY<<3;G0C=0_U]DF=QLZ ZVZS?._@=0
M2P,$%     @ A(*J5MDGT[L( P  $@P  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S8N>&ULK5=MKYHP%/XK#4N6+=D$ 5_FE.0J6W:3W<1HMGU8]J'"41JA
M96W5NV0_?FU!)@[)O0M?I"WG><XY3SGM<7IB?"\2 (D>LY2*F95(F4]L6T0)
M9%CT6 Y4O=DRGF&IIGQGBYP#C@TH2VW7<89VA@FU@JE96_)@R@XR)126'(E#
MEF'^:PXI.\VLOG5>6)%=(O6"'4QSO(,UR"_YDJN97;'$) ,J"*.(PW9FW?4G
MX5C;&X.O!$[B8HQT)AO&]GIR'\\L1P<$*412,V#U.,("TE03J3!^EIQ6Y5(#
M+\=G]H\F=Y7+!@M8L/0;B64RL\86BF&+#ZE<L=,G*/,9:+Z(I<+\HE-IZU@H
M.@C)LA*L(L@(+9[XL=3A J!XF@%N"7"O ?X-@%<"O&O \ ; +P&^4:9(Q>@0
M8HF#*6<GQ+6U8M,#(Z9!J_0)U=N^EER])0HG@W6QW8AMT9KL*-F2"%.)[J*(
M':@D=(>6+"41 8'>H@6C$5#)L=DR!5EPB(E$*R+VZ%4($I-4O%:&#VHYPARF
MME0Q:D]V5,8S+^)Q;\3CH0=&92+0!QI#W( /V_%]MX7 5N)4"KEGA>9N*^,#
MYCWD]=\@UW&]AH 63X>[3?FTPT.(;L%KV7C5?GN&S[_!MX(CT .@.= H43N_
M1[_1PGQFP*_V5^]JTP:V.M#'U$3D.(*9I<XA ?P(5O#R17_HO&\2KTNRL".R
MFK!^):QOV+T;POZK'?K^6=F@>PF9^-$DI-^ED%V2A1V1U80<5$(.6K_0NI!<
M"YD#UTOJ&FJ2L:![9^CT+7<,G)ZO:N5X*4^3T<"O&X6M@?UGVL,J[6%KVN6)
M*] *(B!'O$E!EV9QP#ZM,%L=//=[ZI(L[(BL)NRH$G;4=6&.NA2R2[*P([*:
MD.-*R'&WA3ENJ#EW>%68K3Z?*T^CQU'EL4C;ONB6U*VW,UVG0*;\BK:@6JT:
MVSO3SUVMS_N31=&?_J4INF5UZ>\(%2B%K:)T>B-ULO"B RTFDN6F)]LPJ:Y>
M,TQ4TPY<&ZCW6\;D>:(=5'\#@C]02P,$%     @ A(*J5KC7_S9O @  ? <
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M:6RW]L/27H^H7(#=SZ4TQXE+T%RXR2]02P,$%     @ A(*J5CA,A;Y+ @
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M#DB%;D:J<:RJ?!LOE:6A\.:&7B'4+H#V"Z7LP7&3T;YKV1]02P,$%     @
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MARAS47>-]43QTC1>3UQA&V>&*7;:(+0![F\X5X>)/J#MW6?_ 5!+ P04
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M0&"&S^/:YS'8I!];@VY/>ENF?=)?U#9>>./R6:;WIX7E C(L0&"&RV&@:WH
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MLF7:3C\Q30!8SZ8&LSL6CM-/#JGVTT],UVOVZM8&Z;?>\-^X\X0X1VN#:<+
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MQX2]E8E1N,O0SB3GE"GRG?(2R!5072K D!M-]LFDNB<BI^1"ZY**%/0>.7L
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MO4,_NC '9<9MC.<&!U8<3?:-5H2U%>%1*^Z8Q-2X<-':*1=F__!]LQ"62*:
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M_P"T!=!^H10^3VS+Z?\PZ1]02P,$%     @ A(*J5A+([WIX!   E!L  !D
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MP%,54P:W LDT28AXO("8;X8.=IX*/M/%4F4%[FBP(@N8@KI?W0I]YU:4B";
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M##1X\L^A-9#2&N@\+0DT:D]B++1F$)2802.U)5"WXX#LF>6WLI;.#/JSGL*
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MND/KG]]T#KI4D,M?30(6&_2:-S"OAE,YQRD,'?W;ER"6X"1OW_BQ][&I^H[
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M31 .[WT !#( @?P X<]@9&,$1E%4+Z$/C$ &(U #1K3)8&3314104*^L#[I
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ME@@M.2MH4W6B(%,%&MUH%M"<6R;00D8YF>$BE,Z^']=S;106Z<\^/QH!2;\
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MQT\?D$8 WV^%T.>!N5RW'U/+[U!+ P04    " "$@JI6?:WPE8X'  #71P
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MUCOP^=(8>C'\- UW8?$74$L#!!0    ( (2"JE;7^GIQ0@,  ,X,   9
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M+K1E _##@BT:C0O@_:76=CMQ!_2FG_X"4$L#!!0    ( (2"JE9^$YM*F0(
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MYAJIB_EI2=\9,"Z SA=:XV[A+FB_7-DO4$L#!!0    ( (2"JE8)9MCV70(
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MWY#O)A00W\SV(#"U9"8QZ87.@B1?)<1$<?(@%<.@XN 398)\H^D.I/9>)53
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M#+ ,937CJHT6A1T3,Z%QZ-AEBI\%((T!WL^%T)N-<=!\:$3_ %!+ P04
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M"!V ^TO.U>-"C\;%IU#P#U!+ P04    " "$@JI6%D@'I2D"  "Q!   &0
M 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6R-5$V/TS 0_2N66:%="35IVBVH
M))'Z 8+#2E7+P@%Q<)-I8JUC!WO2+/\>VTE#0=V*2^(9SWOSQIYQW"K]9$H
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M\S1N4H_I+(R#XWGJX*R-*K!$;E@,R50CL>NHP3O,XZ)KPS_AW3#;VRJX-$3
MP4+#T=M[2G0W()V!JO9-N5=H6]PO2_NF@'8!=O^@%)X,EV!XI=+?4$L#!!0
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M;%!+ 0(4 Q0    ( (2"JE:28T%P[P   "L"   1              "  :\
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M2P$"% ,4    " "$@JI6\C-'N@$#  !9"@  &               @('S%
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ A(*J5A@ %69F
M!@  ]B   !@              ("!*A@  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( (2"JE;P=S3]UP(  !\(   8              "
M@<8>  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "$@JI6
MDSI#"!((   !00  &               @('3(0  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ A(*J5FA-2U'W!P  GR(  !@
M     ("!&RH  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M (2"JE8/PDP+UA<  +]%   8              " @4@R  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " "$@JI6Y&_@6$P6  "01@  &
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M970Q,RYX;6Q02P$"% ,4    " "$@JI6LF:UZ_X'  !B%0  &0
M    @('I>P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M (2"JE8P_#@-Y0,  %D(   9              " @1Z$  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ A(*J5J QESTG&   #$L  !D
M             ("!.H@  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " "$@JI6IZ.']Q,"  "J!   &0              @(&8H   >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( (2"JE9GRM:/- 0
M 'D)   9              " @>*B  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ A(*J5IR[M;)T"@  F!H  !D              ("!
M3:<  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " "$@JI6
MUP?$9H($   ,"@  &0              @('XL0  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( (2"JE;1<M%^TP0   H+   9
M      " @;&V  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ A(*J5E"^SFD: P  T08  !D              ("!N[L  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " "$@JI6S;5WQ)\"  "^!0
M&0              @($,OP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( (2"JE9C^)9(\!4  ")%   9              " @>+!  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ A(*J5A=8">.Y
M P  -0D  !D              ("!"=@  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " "$@JI6HDQ)\G\$  "&#0  &0
M@('YVP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( (2"
MJE8]3FX=CP0  )\,   9              " @:_@  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ A(*J5FX)GY&F P  50D  !D
M         ("!=>4  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " "$@JI6]BI%@JT%  #.#P  &0              @(%2Z0  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( (2"JE:Y-6HY\ ,  -((
M   9              " @3;O  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ A(*J5FU-1,^1!   B0P  !D              ("!7?,
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " "$@JI6!Z(/
M[I<"  "C!0  &0              @($E^   >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( (2"JE8!C_->O08  $$1   9
M  " @?/Z  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
MA(*J5HG-44FC P    D  !D              ("!YP$! 'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " "$@JI6 ;GYCF$(  #+40  &0
M            @('!!0$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( (2"JE;9)].[" ,  !(,   9              " @5D. 0!X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ A(*J5KC7_S9O @
M? <  !D              ("!F!$! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " "$@JI6.$R%ODL"  #C!   &0              @($^
M% $ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( (2"JE9&
M$83Y3P,  ,<+   9              " @< 6 0!X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ A(*J5H"&M<:D P  9!   !D
M     ("!1AH! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (2"JE:$Z[MB P4  - ;   9              "
M@;TN 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ A(*J
M5DAZMWQ^ @  ;08  !D              ("!]S,! 'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    " "$@JI6$LCO>G@$  "4&P  &0
M        @(&L-@$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   ( (2"JE9&[$XG5@0   \<   9              " @5L[ 0!X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ A(*J5@MF#;G5!   ?AP
M !D              ("!Z#\! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"% ,4    " "$@JI6E]\/BBT$  !;&@  &0              @('T1 $
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( (2"JE;<T9YP
MN@8  $0H   9              " @5A) 0!X;"]W;W)K<VAE971S+W-H965T
M-3$N>&UL4$L! A0#%     @ A(*J5@R"\/^? P  !Q$  !D
M ("!25 ! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " "$
M@JI6IW20Q?L%  !.*   &0              @($?5 $ >&PO=V]R:W-H965T
M<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( (2"JE9?*G2<N@(  !T'   9
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M970U."YX;6Q02P$"% ,4    " "$@JI6U_IZ<4(#  #.#   &0
M    @(&0;@$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    (
M (2"JE;;1JWY>@,   H-   9              " @0ER 0!X;"]W;W)K<VAE
M971S+W-H965T-C N>&UL4$L! A0#%     @ A(*J5E1 WR>  @    8  !D
M             ("!NG4! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"
M% ,4    " "$@JI6?A.;2ID"  #%!@  &0              @(%Q> $ >&PO
M=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( (2"JE8)9MCV70(
M +X%   9              " @4%[ 0!X;"]W;W)K<VAE971S+W-H965T-C,N
M>&UL4$L! A0#%     @ A(*J5H\Z&=6^ @  C <  !D              ("!
MU7T! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " "$@JI6
MU]-(U40&  #_'P  &0              @('*@ $ >&PO=V]R:W-H965T<R]S
M:&5E=#8U+GAM;%!+ 0(4 Q0    ( (2"JE8U*]=,]@4  &<A   9
M      " @46' 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%
M  @ A(*J5C@%7XUW P  EPH  !D              ("!<HT! 'AL+W=O<FMS
M:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " "$@JI6'2N\^[ #   H#@
M&0              @($@D0$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+
M 0(4 Q0    ( (2"JE;?25(P:00  -47   9              " @0>5 0!X
M;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ A(*J5ACTWLZI
M @  = @  !D              ("!IYD! 'AL+W=O<FMS:&5E=',O<VAE970W
M,"YX;6Q02P$"% ,4    " "$@JI62Y<F<M$%  #Z*@  &0
M@(&'G $ >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( (2"
MJE9+4VKI*@,  !8-   9              " @8^B 0!X;"]W;W)K<VAE971S
M+W-H965T-S(N>&UL4$L! A0#%     @ A(*J5A9(!Z4I @  L00  !D
M         ("!\*4! 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4
M    " "$@JI6G1LM]#P#  #L$P  #0              @ %0J $ >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( (2"JE:7BKL<P    !,"   +
M  "  ;>K 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( (2"JE;ER.PZ,@4  $DP
M   /              "  :"L 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" "$@JI6M\<#,$("  !"*P  &@              @ '_L0$ >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "$@JI6^,,"'08"  !/*@
M$P              @ %YM $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..40!1 "X6  "PM@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>198</ContextCount>
  <ElementCount>358</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Cash and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/CashandMarketableSecurities</Role>
      <ShortName>Cash and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/BusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - 401(K) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/A401KPlan</Role>
      <ShortName>401(K) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Stock Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/StockIncentivePlans</Role>
      <ShortName>Stock Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.caredxinc.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caredxinc.com/role/NetLossPerShare</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caredxinc.com/role/FairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Cash and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/CashandMarketableSecuritiesTables</Role>
      <ShortName>Cash and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caredxinc.com/role/CashandMarketableSecurities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Business Combinations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/BusinessCombinationsTables</Role>
      <ShortName>Business Combinations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caredxinc.com/role/BusinessCombinations</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caredxinc.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caredxinc.com/role/BalanceSheetComponents</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caredxinc.com/role/CommitmentsandContingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caredxinc.com/role/Warrants</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Stock Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/StockIncentivePlansTables</Role>
      <ShortName>Stock Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caredxinc.com/role/StockIncentivePlans</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.caredxinc.com/role/SegmentReporting</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Organization and Description of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails</Role>
      <ShortName>Organization and Description of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Summary of Significant Accounting Policies - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Summary of Significant Accounting Policies - Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesRevenueDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/NetLossPerShareSummaryofComputationofBasicandDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Fair Value Measurements - Summary of Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Fair Value Measurements - Summary of Issuances, Exercises, Changes in Fair Value and Reclassifications of Level 3 Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/FairValueMeasurementsSummaryofIssuancesExercisesChangesinFairValueandReclassificationsofLevel3FinancialInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Issuances, Exercises, Changes in Fair Value and Reclassifications of Level 3 Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Fair Value Measurements - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/FairValueMeasurementsNarrativesDetails</Role>
      <ShortName>Fair Value Measurements - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Cash and Marketable Securities - Reconciliation of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/CashandMarketableSecuritiesReconciliationofCashandCashEquivalentsDetails</Role>
      <ShortName>Cash and Marketable Securities - Reconciliation of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Cash and Marketable Securities - Components of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails</Role>
      <ShortName>Cash and Marketable Securities - Components of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Cash and Marketable Securities - Schedule of Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/CashandMarketableSecuritiesScheduleofMaturityDetails</Role>
      <ShortName>Cash and Marketable Securities - Schedule of Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Business Combinations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/BusinessCombinationsAdditionalInformationDetails</Role>
      <ShortName>Business Combinations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Business Combinations - Summary of Identified Intangible Assets Acquired at Acquisition Date (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/BusinessCombinationsSummaryofIdentifiedIntangibleAssetsAcquiredatAcquisitionDateDetails</Role>
      <ShortName>Business Combinations - Summary of Identified Intangible Assets Acquired at Acquisition Date (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Business Combinations - Summary of Consideration Paid and Provisional Amounts of Assets Acquired and Liabilities Assumed Recognized at Their Estimated Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails</Role>
      <ShortName>Business Combinations - Summary of Consideration Paid and Provisional Amounts of Assets Acquired and Liabilities Assumed Recognized at Their Estimated Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Summary of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Goodwill and Intangible Assets - Summary of Finite-Lived Intangible Assets Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofFiniteLivedIntangibleAssetsAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Summary of Finite-Lived Intangible Assets Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Goodwill and Intangible Assets - Summary of Estimated Future Amortization Expense of Intangible Assets with Finite Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Summary of Estimated Future Amortization Expense of Intangible Assets with Finite Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Balance Sheet Components - Summary of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/BalanceSheetComponentsSummaryofInventoryDetails</Role>
      <ShortName>Balance Sheet Components - Summary of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Balance Sheet Components - Components of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Components of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Commitments and Contingencies - Summary of Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/CommitmentsandContingenciesSummaryofLeaseCostDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Commitments and Contingencies - Summary of Other Information Related to Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/CommitmentsandContingenciesSummaryofOtherInformationRelatedtoLeaseDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Other Information Related to Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Commitments and Contingencies - Summarizes ROU Assets and Lease Liabilities for Lease Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/CommitmentsandContingenciesSummarizesROUAssetsandLeaseLiabilitiesforLeaseAgreementsDetails</Role>
      <ShortName>Commitments and Contingencies - Summarizes ROU Assets and Lease Liabilities for Lease Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Commitments and Contingencies - Future Minimum Lease Commitments under Operating and Finance Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Future Minimum Lease Commitments under Operating and Finance Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Commitments and Contingencies - Summarizes the Noncash Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/CommitmentsandContingenciesSummarizestheNoncashInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Summarizes the Noncash Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - 401(K) Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/A401KPlanAdditionalInformationDetail</Role>
      <ShortName>401(K) Plan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Warrants - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/WarrantsAdditionalInformationDetail</Role>
      <ShortName>Warrants - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Warrants - Outstanding Warrants To Purchase Common Stock Warrants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/WarrantsOutstandingWarrantsToPurchaseCommonStockWarrantsDetail</Role>
      <ShortName>Warrants - Outstanding Warrants To Purchase Common Stock Warrants (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Stock Incentive Plans - Summary of Option, Unvested RSU Activity under 2014 Equity Incentive Plan and 2016 Inducement Equity Incentive Plan and Related Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail</Role>
      <ShortName>Stock Incentive Plans - Summary of Option, Unvested RSU Activity under 2014 Equity Incentive Plan and 2016 Inducement Equity Incentive Plan and Related Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Stock Incentive Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail</Role>
      <ShortName>Stock Incentive Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Stock Incentive Plans - Summary of Options Outstanding Vested and Expected to Vest (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail</Role>
      <ShortName>Stock Incentive Plans - Summary of Options Outstanding Vested and Expected to Vest (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Stock Incentive Plans - Summary of Weighted-Average Assumptions Used to Estimated Fair Values of Share-Based Awards (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/StockIncentivePlansSummaryofWeightedAverageAssumptionsUsedtoEstimatedFairValuesofShareBasedAwardsDetail</Role>
      <ShortName>Stock Incentive Plans - Summary of Weighted-Average Assumptions Used to Estimated Fair Values of Share-Based Awards (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Stock Incentive Plans - Summary of Expense Relating to Employee and Nonemployee Stock-Based Payment Awards from Stock Options and RSUs (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/StockIncentivePlansSummaryofExpenseRelatingtoEmployeeandNonemployeeStockBasedPaymentAwardsfromStockOptionsandRSUsDetail</Role>
      <ShortName>Stock Incentive Plans - Summary of Expense Relating to Employee and Nonemployee Stock-Based Payment Awards from Stock Options and RSUs (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Segment Reporting - Summary of Reportable Revenues by Geographic Regions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail</Role>
      <ShortName>Segment Reporting - Summary of Reportable Revenues by Geographic Regions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Segment Reporting - Summary of Long-Lived Assets Consisting of Property and Equipment, Net by Geographic Regions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/SegmentReportingSummaryofLongLivedAssetsConsistingofPropertyandEquipmentNetbyGeographicRegionsDetail</Role>
      <ShortName>Segment Reporting - Summary of Long-Lived Assets Consisting of Property and Equipment, Net by Geographic Regions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="cdna-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Restructuring (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.caredxinc.com/role/RestructuringDetails</Role>
      <ShortName>Restructuring (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.caredxinc.com/role/Restructuring</ParentRole>
      <Position>73</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cdna-20230331.htm">cdna-20230331.htm</File>
    <File>cdna-20230331.xsd</File>
    <File>cdna-20230331_cal.xml</File>
    <File>cdna-20230331_def.xml</File>
    <File>cdna-20230331_lab.xml</File>
    <File>cdna-20230331_pre.xml</File>
    <File>cdna-20230331x10qxexx101.htm</File>
    <File>cdna-20230331x10qxexx311.htm</File>
    <File>cdna-20230331x10qxexx312.htm</File>
    <File>cdna-20230331x10qxexx321.htm</File>
    <File>cdna-20230331x10xqxexx102.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="727">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>91
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cdna-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 25,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 727,
    "http://xbrl.sec.gov/dei/2022": 29
   },
   "contextCount": 198,
   "dts": {
    "calculationLink": {
     "local": [
      "cdna-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cdna-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cdna-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cdna-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cdna-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cdna-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 562,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 2,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 7
   },
   "keyCustom": 55,
   "keyStandard": 303,
   "memberCustom": 25,
   "memberStandard": 36,
   "nsprefix": "cdna",
   "nsuri": "http://www.caredxinc.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.caredxinc.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.caredxinc.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.caredxinc.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Cash and Marketable Securities",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.caredxinc.com/role/CashandMarketableSecurities",
     "shortName": "Cash and Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Business Combinations",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.caredxinc.com/role/BusinessCombinations",
     "shortName": "Business Combinations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Goodwill and Intangible Assets",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.caredxinc.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Balance Sheet Components",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.caredxinc.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.caredxinc.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - 401(K) Plan",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.caredxinc.com/role/A401KPlan",
     "shortName": "401(K) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cdna:WarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Warrants",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.caredxinc.com/role/Warrants",
     "shortName": "Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cdna:WarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Stock Incentive Plans",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.caredxinc.com/role/StockIncentivePlans",
     "shortName": "Stock Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.caredxinc.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Segment Reporting",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.caredxinc.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Restructuring",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.caredxinc.com/role/Restructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.caredxinc.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cdna:LiquidityPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "24",
     "role": "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cdna:LiquidityPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.caredxinc.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.caredxinc.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Cash and Marketable Securities (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.caredxinc.com/role/CashandMarketableSecuritiesTables",
     "shortName": "Cash and Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Business Combinations (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.caredxinc.com/role/BusinessCombinationsTables",
     "shortName": "Business Combinations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cdna:ScheduleOfIntangibleAssetsTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cdna:ScheduleOfIntangibleAssetsTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Balance Sheet Components (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.caredxinc.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.caredxinc.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Warrants (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.caredxinc.com/role/WarrantsTables",
     "shortName": "Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cdna:ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Stock Incentive Plans (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.caredxinc.com/role/StockIncentivePlansTables",
     "shortName": "Stock Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cdna:ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Segment Reporting (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.caredxinc.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cdna:UnsubmittedReimbursementClaimsForMedicare",
      "reportCount": 1,
      "unitRef": "unique_solution",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Organization and Description of Business - Additional Information (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails",
     "shortName": "Organization and Description of Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ibf4af37bc739426e912a71dac9ba281d_I20180131",
      "decimals": "-2",
      "lang": "en-US",
      "name": "cdna:NumberOfRenalTransplantPatients",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patient",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i3a52955612044b80bdc44719634b8f15_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails",
     "shortName": "Summary of Significant Accounting Policies - Concentration of Credit Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i3a52955612044b80bdc44719634b8f15_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i8a65e524e31741e4b69720fd09cbf601_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cdna:RemainingOperatingAndFinanceLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Summary of Significant Accounting Policies - Leases (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails",
     "shortName": "Summary of Significant Accounting Policies - Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i8a65e524e31741e4b69720fd09cbf601_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cdna:RemainingOperatingAndFinanceLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cdna:UnsubmittedReimbursementClaimsForMedicare",
      "reportCount": 1,
      "unitRef": "unique_solution",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Summary of Significant Accounting Policies - Revenue (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesRevenueDetails",
     "shortName": "Summary of Significant Accounting Policies - Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.caredxinc.com/role/NetLossPerShareSummaryofComputationofBasicandDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Summary of Computation of Basic and Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Diluted Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.caredxinc.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Fair Value Measurements - Summary of Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Summary of Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ibe1d6bd783044aa7ae7f1fa51bf4c2df_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i0947b2db32e4416394c995e30d617446_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Fair Value Measurements - Summary of Issuances, Exercises, Changes in Fair Value and Reclassifications of Level 3 Financial Instruments (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofIssuancesExercisesChangesinFairValueandReclassificationsofLevel3FinancialInstrumentsDetails",
     "shortName": "Fair Value Measurements - Summary of Issuances, Exercises, Changes in Fair Value and Reclassifications of Level 3 Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i0947b2db32e4416394c995e30d617446_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Fair Value Measurements - Narratives (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.caredxinc.com/role/FairValueMeasurementsNarrativesDetails",
     "shortName": "Fair Value Measurements - Narratives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Cash and Marketable Securities - Reconciliation of Cash and Cash Equivalents (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.caredxinc.com/role/CashandMarketableSecuritiesReconciliationofCashandCashEquivalentsDetails",
     "shortName": "Cash and Marketable Securities - Reconciliation of Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i30a9b5385be843b8be329d54dfcdc192_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cdna:MarketableSecuritiesAmortizedCostShortTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Cash and Marketable Securities - Components of Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails",
     "shortName": "Cash and Marketable Securities - Components of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cdna:MarketableSecuritiesAmortizedCostShortTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Cash and Marketable Securities - Schedule of Maturity (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.caredxinc.com/role/CashandMarketableSecuritiesScheduleofMaturityDetails",
     "shortName": "Cash and Marketable Securities - Schedule of Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Business Combinations - Additional Information (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.caredxinc.com/role/BusinessCombinationsAdditionalInformationDetails",
     "shortName": "Business Combinations - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i5655b5a1a84d4b98979a99a6db9e0ff2_D20230101-20230131",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1a8ed8e80cd343d08992fa27dfde5ada_I20230131",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Business Combinations - Summary of Identified Intangible Assets Acquired at Acquisition Date (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.caredxinc.com/role/BusinessCombinationsSummaryofIdentifiedIntangibleAssetsAcquiredatAcquisitionDateDetails",
     "shortName": "Business Combinations - Summary of Identified Intangible Assets Acquired at Acquisition Date (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1a8ed8e80cd343d08992fa27dfde5ada_I20230131",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Business Combinations - Summary of Consideration Paid and Provisional Amounts of Assets Acquired and Liabilities Assumed Recognized at Their Estimated Fair Value (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails",
     "shortName": "Business Combinations - Summary of Consideration Paid and Provisional Amounts of Assets Acquired and Liabilities Assumed Recognized at Their Estimated Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ib01dc638da5843b694334d2ca357325f_D20210101-20210131",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i0947b2db32e4416394c995e30d617446_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
     "shortName": "Goodwill and Intangible Assets - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ie657b500f633441d881331275caa19f4_D20211001-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:FinitelivedIntangibleAssetsAcquired1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cdna:ScheduleOfIntangibleAssetsTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Goodwill and Intangible Assets - Summary of Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Summary of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cdna:ScheduleOfIntangibleAssetsTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Goodwill and Intangible Assets - Summary of Finite-Lived Intangible Assets Amortization Expense (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofFiniteLivedIntangibleAssetsAmortizationExpenseDetails",
     "shortName": "Goodwill and Intangible Assets - Summary of Finite-Lived Intangible Assets Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Goodwill and Intangible Assets - Summary of Estimated Future Amortization Expense of Intangible Assets with Finite Lives (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails",
     "shortName": "Goodwill and Intangible Assets - Summary of Estimated Future Amortization Expense of Intangible Assets with Finite Lives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Balance Sheet Components - Summary of Inventory (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.caredxinc.com/role/BalanceSheetComponentsSummaryofInventoryDetails",
     "shortName": "Balance Sheet Components - Summary of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cdna:AccruedClinicalAndCostOfOtherStudiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Balance Sheet Components - Components of Accrued Expenses and Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails",
     "shortName": "Balance Sheet Components - Components of Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cdna:AccruedClinicalAndCostOfOtherStudiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i0947b2db32e4416394c995e30d617446_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i195cf846109945d0a76d6e7ce2543162_D20220601-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncreaseDecreaseInOperatingLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Commitments and Contingencies - Summary of Lease Cost (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.caredxinc.com/role/CommitmentsandContingenciesSummaryofLeaseCostDetails",
     "shortName": "Commitments and Contingencies - Summary of Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Commitments and Contingencies - Summary of Other Information Related to Lease (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.caredxinc.com/role/CommitmentsandContingenciesSummaryofOtherInformationRelatedtoLeaseDetails",
     "shortName": "Commitments and Contingencies - Summary of Other Information Related to Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Commitments and Contingencies - Summarizes ROU Assets and Lease Liabilities for Lease Agreements (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.caredxinc.com/role/CommitmentsandContingenciesSummarizesROUAssetsandLeaseLiabilitiesforLeaseAgreementsDetails",
     "shortName": "Commitments and Contingencies - Summarizes ROU Assets and Lease Liabilities for Lease Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cdna:ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i53037b4e60e34295bb200d6c520f42c0_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "iadfb87bf8c0c4c87b3a3c4f7ac571e08_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ie6f9bdaf73bf44fd8daa2e9dab7b62d7_D20220101-20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "cdna:ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Commitments and Contingencies - Future Minimum Lease Commitments under Operating and Finance Leases (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails",
     "shortName": "Commitments and Contingencies - Future Minimum Lease Commitments under Operating and Finance Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "cdna:ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Commitments and Contingencies - Summarizes the Noncash Information (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.caredxinc.com/role/CommitmentsandContingenciesSummarizestheNoncashInformationDetails",
     "shortName": "Commitments and Contingencies - Summarizes the Noncash Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DefinedContributionPlanCostRecognized",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - 401(K) Plan - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.caredxinc.com/role/A401KPlanAdditionalInformationDetail",
     "shortName": "401(K) Plan - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DefinedContributionPlanCostRecognized",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cdna:NumberOfWarrantsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Warrants - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.caredxinc.com/role/WarrantsAdditionalInformationDetail",
     "shortName": "Warrants - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cdna:NumberOfWarrantsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i9eedb204e8ae4bd78694426f6de765ea_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Warrants - Outstanding Warrants To Purchase Common Stock Warrants (Detail)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.caredxinc.com/role/WarrantsOutstandingWarrantsToPurchaseCommonStockWarrantsDetail",
     "shortName": "Warrants - Outstanding Warrants To Purchase Common Stock Warrants (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i9eedb204e8ae4bd78694426f6de765ea_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "cdna:ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i0947b2db32e4416394c995e30d617446_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Stock Incentive Plans - Summary of Option, Unvested RSU Activity under 2014 Equity Incentive Plan and 2016 Inducement Equity Incentive Plan and Related Information (Detail)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail",
     "shortName": "Stock Incentive Plans - Summary of Option, Unvested RSU Activity under 2014 Equity Incentive Plan and 2016 Inducement Equity Incentive Plan and Related Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "cdna:ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i0947b2db32e4416394c995e30d617446_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Stock Incentive Plans - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail",
     "shortName": "Stock Incentive Plans - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Stock Incentive Plans - Summary of Options Outstanding Vested and Expected to Vest (Detail)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail",
     "shortName": "Stock Incentive Plans - Summary of Options Outstanding Vested and Expected to Vest (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "cdna:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ia24f76f7b5ed46cf96e628a538a6e320_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Stock Incentive Plans - Summary of Weighted-Average Assumptions Used to Estimated Fair Values of Share-Based Awards (Detail)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.caredxinc.com/role/StockIncentivePlansSummaryofWeightedAverageAssumptionsUsedtoEstimatedFairValuesofShareBasedAwardsDetail",
     "shortName": "Stock Incentive Plans - Summary of Weighted-Average Assumptions Used to Estimated Fair Values of Share-Based Awards (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ia24f76f7b5ed46cf96e628a538a6e320_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Stock Incentive Plans - Summary of Expense Relating to Employee and Nonemployee Stock-Based Payment Awards from Stock Options and RSUs (Detail)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.caredxinc.com/role/StockIncentivePlansSummaryofExpenseRelatingtoEmployeeandNonemployeeStockBasedPaymentAwardsfromStockOptionsandRSUsDetail",
     "shortName": "Stock Incentive Plans - Summary of Expense Relating to Employee and Nonemployee Stock-Based Payment Awards from Stock Options and RSUs (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Income Taxes - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.caredxinc.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i4085e2e2596a4c689ebf01b80b2c5c82_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Segment Reporting - Summary of Reportable Revenues by Geographic Regions (Detail)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.caredxinc.com/role/SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail",
     "shortName": "Segment Reporting - Summary of Reportable Revenues by Geographic Regions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1620b425a8304d7d9b96f7bafd09516e_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Segment Reporting - Summary of Long-Lived Assets Consisting of Property and Equipment, Net by Geographic Regions (Detail)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.caredxinc.com/role/SegmentReportingSummaryofLongLivedAssetsConsistingofPropertyandEquipmentNetbyGeographicRegionsDetail",
     "shortName": "Segment Reporting - Summary of Long-Lived Assets Consisting of Property and Equipment, Net by Geographic Regions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "i1c1f8f524d4e4c45ba4eeee64682bf3e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Restructuring (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.caredxinc.com/role/RestructuringDetails",
     "shortName": "Restructuring (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": "-4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Organization and Description of Business",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.caredxinc.com/role/OrganizationandDescriptionofBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.caredxinc.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdna-20230331.htm",
      "contextRef": "ided2d815cb564eca882b1922cf31f38e_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 62,
   "tag": {
    "cdna_AccruedCapitalExpenditures": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Capital Expenditures",
        "label": "Accrued Capital Expenditures",
        "terseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "AccruedCapitalExpenditures",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_AccruedClinicalAndCostOfOtherStudiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical And Cost Of Other Studies Current",
        "label": "Accrued Clinical And Cost Of Other Studies Current",
        "terseLabel": "Clinical studies"
       }
      }
     },
     "localname": "AccruedClinicalAndCostOfOtherStudiesCurrent",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_AccruedLicenseAndOtherCollaborationFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued License And Other Collaboration Fees",
        "label": "Accrued License And Other Collaboration Fees",
        "terseLabel": "License and other collaboration fees"
       }
      }
     },
     "localname": "AccruedLicenseAndOtherCollaborationFees",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_AccruedSampleProcessingFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Sample Processing Fees",
        "label": "Accrued Sample Processing Fees",
        "terseLabel": "Laboratory processing fees and materials"
       }
      }
     },
     "localname": "AccruedSampleProcessingFees",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_AccruedShippingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Shipping Expenses",
        "label": "Accrued Shipping Expenses",
        "terseLabel": "Accrued shipping expenses"
       }
      }
     },
     "localname": "AccruedShippingExpenses",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_AcquiredAndDevelopedTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired And Developed Technology",
        "label": "Acquired And Developed Technology [Member]",
        "terseLabel": "Acquired and developed technology"
       }
      }
     },
     "localname": "AcquiredAndDevelopedTechnologyMember",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_AcquiredInProcessTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired In Process Technology",
        "label": "Acquired In Process Technology [Member]",
        "terseLabel": "Acquired in-process technology"
       }
      }
     },
     "localname": "AcquiredInProcessTechnologyMember",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_AlloMapHeartMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AlloMap Heart",
        "label": "AlloMap Heart [Member]",
        "terseLabel": "AlloMap Heart"
       }
      }
     },
     "localname": "AlloMapHeartMember",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_AlloSureHeartMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AlloSure Heart",
        "label": "AlloSure Heart [Member]",
        "terseLabel": "AlloSure Heart"
       }
      }
     },
     "localname": "AlloSureHeartMember",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_AlloSureKidneyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AlloSure Kidney",
        "label": "AlloSure Kidney [Member]",
        "terseLabel": "AlloSure Kidney"
       }
      }
     },
     "localname": "AlloSureKidneyMember",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_AtTheMarketEquityOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Equity Offering",
        "label": "At The Market Equity Offering [Member]",
        "terseLabel": "At The Market Equity Offering"
       }
      }
     },
     "localname": "AtTheMarketEquityOfferingMember",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Liability, Measurement Input, Discount Rate",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input, Discount Rate",
        "terseLabel": "Contingent consideration, measurement input, discount rate"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInputDiscountRate",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "cdna_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Contingent Considerations, Less Current Portion",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Contingent Considerations, Less Current Portion",
        "negatedTerseLabel": "Contingent considerations"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesContingentConsiderationsLessCurrentPortion",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_CAREDXINCVsNateraIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CAREDX, INC. vs Natera Inc.",
        "label": "CAREDX, INC. vs Natera Inc. [Member]",
        "terseLabel": "CAREDX, INC. vs Natera Inc."
       }
      }
     },
     "localname": "CAREDXINCVsNateraIncMember",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_CommercializationRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercialization rights.",
        "label": "Commercialization Rights [Member]",
        "terseLabel": "Commercialization rights"
       }
      }
     },
     "localname": "CommercializationRightsMember",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_CommonStockWarrantLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrant liability.",
        "label": "Common Stock Warrant Liability",
        "terseLabel": "Common stock warrant liability"
       }
      }
     },
     "localname": "CommonStockWarrantLiability",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_CommonStockWarrantLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrant liability.",
        "label": "Common Stock Warrant Liability [Member]",
        "terseLabel": "Common Stock Warrant Liability"
       }
      }
     },
     "localname": "CommonStockWarrantLiabilityMember",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofIssuancesExercisesChangesinFairValueandReclassificationsofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_CompensatoryDamagesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compensatory Damages",
        "label": "Compensatory Damages [Member]",
        "terseLabel": "Compensatory Damages"
       }
      }
     },
     "localname": "CompensatoryDamagesMember",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration.",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofIssuancesExercisesChangesinFairValueandReclassificationsofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_CostOfPatientAndDigitalSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Patient And Digital Solutions",
        "label": "Cost Of Patient And Digital Solutions [Member]",
        "terseLabel": "Cost of Patient and Digital Solutions",
        "verboseLabel": "Cost of patient and digital solutions"
       }
      }
     },
     "localname": "CostOfPatientAndDigitalSolutionsMember",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails",
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofFiniteLivedIntangibleAssetsAmortizationExpenseDetails",
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofExpenseRelatingtoEmployeeandNonemployeeStockBasedPaymentAwardsfromStockOptionsandRSUsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_CostOfProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Product",
        "label": "Cost Of Product [Member]",
        "terseLabel": "Cost of Product",
        "verboseLabel": "Cost of product"
       }
      }
     },
     "localname": "CostOfProductMember",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails",
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofFiniteLivedIntangibleAssetsAmortizationExpenseDetails",
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofExpenseRelatingtoEmployeeandNonemployeeStockBasedPaymentAwardsfromStockOptionsandRSUsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_CostOfTestingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost Of Testing",
        "label": "Cost Of Testing [Member]",
        "terseLabel": "Cost of Testing Services",
        "verboseLabel": "Cost of testing services"
       }
      }
     },
     "localname": "CostOfTestingMember",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails",
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofFiniteLivedIntangibleAssetsAmortizationExpenseDetails",
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofExpenseRelatingtoEmployeeandNonemployeeStockBasedPaymentAwardsfromStockOptionsandRSUsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_DeferredPaymentsForIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred payments for intangible assets.",
        "label": "Deferred Payments For Intangible Assets",
        "verboseLabel": "Deferred payments for intangible assets"
       }
      }
     },
     "localname": "DeferredPaymentsForIntangibleAssets",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_DeferredPaymentsForIntangibleAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred payments for intangible assets, noncurrent.",
        "label": "Deferred Payments For Intangible Assets Noncurrent",
        "terseLabel": "Deferred payments for intangible assets"
       }
      }
     },
     "localname": "DeferredPaymentsForIntangibleAssetsNoncurrent",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_EarningPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share Basic And Diluted",
        "label": "Earning Per Share Basic And Diluted [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "EarningPerShareBasicAndDilutedAbstract",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/NetLossPerShareSummaryofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cdna_EarningsPerShareBasicAndDilutedOtherDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share Basic And Diluted Other Disclosures",
        "label": "Earnings Per Share Basic And Diluted Other Disclosure [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosureAbstract",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/NetLossPerShareSummaryofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cdna_EmployeeAndNonEmployeeStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee and non employee stock options.",
        "label": "Employee And Non Employee Stock Options [Member]",
        "terseLabel": "Shares of common stock subject to outstanding options"
       }
      }
     },
     "localname": "EmployeeAndNonEmployeeStockOptionsMember",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Accumulated Gross Unrealized Gain (Loss), Before Tax",
        "label": "Equity Securities, FV-NI, Accumulated Gross Unrealized Gain (Loss), Before Tax",
        "terseLabel": "Equity securities, unrealized holding gains (losses)"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainLossBeforeTax",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_FiniteLivedIntangibleForeignCurrencyTranslation": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      },
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite Lived Intangible Foreign Currency Translation.",
        "label": "Finite Lived Intangible Foreign Currency Translation",
        "negatedLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "FiniteLivedIntangibleForeignCurrencyTranslation",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_GoodwillAndIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and intangible assets.",
        "label": "Goodwill And Intangible Assets [Line Items]",
        "terseLabel": "Goodwill And Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsLineItems",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cdna_GoodwillAndIntangibleAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and intangible assets.",
        "label": "Goodwill And Intangible Assets [Table]",
        "terseLabel": "Goodwill And Intangible Assets [Table]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsTable",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cdna_HLADataSystemsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HLA Data Systems",
        "label": "HLA Data Systems [Member]",
        "terseLabel": "HLA Data Systems"
       }
      }
     },
     "localname": "HLADataSystemsMember",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails",
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofIdentifiedIntangibleAssetsAcquiredatAcquisitionDateDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cdna_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cdna_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease Liabilities",
        "label": "Increase (Decrease) In Operating Lease Liabilities",
        "terseLabel": "Operating leases liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_IntangibleAssetMeasurementInputDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Asset, Measurement Input, Discount Rate",
        "label": "Intangible Asset, Measurement Input, Discount Rate",
        "terseLabel": "Intangible asset, measurement input, discount rate"
       }
      }
     },
     "localname": "IntangibleAssetMeasurementInputDiscountRate",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "cdna_IntangibleAssetMeasurementInputRoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Asset, Measurement Input, Royalty Rate",
        "label": "Intangible Asset, Measurement Input, Royalty Rate",
        "terseLabel": "Intangible asset, measurement input, royalty rate"
       }
      }
     },
     "localname": "IntangibleAssetMeasurementInputRoyaltyRate",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "cdna_LeaseOtherInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease other information.",
        "label": "Lease Other Information [Abstract]",
        "terseLabel": "Other information:"
       }
      }
     },
     "localname": "LeaseOtherInformationAbstract",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesSummaryofOtherInformationRelatedtoLeaseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cdna_LeasesCommencedInAugust2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases, Commenced In August 2022",
        "label": "Leases, Commenced In August 2022 [Member]",
        "terseLabel": "Leases, Commenced In August 2022"
       }
      }
     },
     "localname": "LeasesCommencedInAugust2022Member",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesSummarizesROUAssetsandLeaseLiabilitiesforLeaseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_LeasesCommencedInJuly2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leases, Commenced In July 2022",
        "label": "Leases, Commenced In July 2022 [Member]",
        "terseLabel": "Leases, Commenced In July 2022"
       }
      }
     },
     "localname": "LeasesCommencedInJuly2022Member",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesSummarizesROUAssetsandLeaseLiabilitiesforLeaseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_LiquidityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity.",
        "label": "Liquidity [Policy Text Block]",
        "terseLabel": "Liquidity and Capital Resources"
       }
      }
     },
     "localname": "LiquidityPolicyTextBlock",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cdna_LongTermMarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Marketable Securities",
        "label": "Long-Term Marketable Securities [Abstract]",
        "terseLabel": "Long-term marketable securities"
       }
      }
     },
     "localname": "LongTermMarketableSecuritiesAbstract",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cdna_MarketableSecuritiesAccumulatedUnrecognizedGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "cdna_MarketableSecuritiesAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Accumulated Unrecognized Gain (Loss)",
        "label": "Marketable Securities, Accumulated Unrecognized Gain (Loss)",
        "terseLabel": "Unrealized Holding Losses"
       }
      }
     },
     "localname": "MarketableSecuritiesAccumulatedUnrecognizedGainLoss",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "cdna_MarketableSecuritiesAmortizedCostLongTerm",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Accumulated Unrecognized Holding Gain (Loss), Long Term",
        "label": "Marketable Securities, Accumulated Unrecognized Holding Gain (Loss), Long Term",
        "terseLabel": "Unrealized Holding Losses"
       }
      }
     },
     "localname": "MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossLongTerm",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "cdna_MarketableSecuritiesAmortizedCostShortTerm",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Accumulated Unrecognized Holding Gain (Loss), Short Term",
        "label": "Marketable Securities, Accumulated Unrecognized Holding Gain (Loss), Short Term",
        "terseLabel": "Unrealized Holding Losses"
       }
      }
     },
     "localname": "MarketableSecuritiesAccumulatedUnrecognizedHoldingGainLossShortTerm",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_MarketableSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Amortized Cost",
        "label": "Marketable Securities, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "MarketableSecuritiesAmortizedCost",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_MarketableSecuritiesAmortizedCostLongTerm": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Amortized Cost, Long Term",
        "label": "Marketable Securities, Amortized Cost, Long Term",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "MarketableSecuritiesAmortizedCostLongTerm",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_MarketableSecuritiesAmortizedCostShortTerm": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Amortized Cost, Short Term",
        "label": "Marketable Securities, Amortized Cost, Short Term",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "MarketableSecuritiesAmortizedCostShortTerm",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_MarketableSecuritiesFairValueLongTerm": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "cdna_MarketableSecuritiesAmortizedCostLongTerm",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Fair Value, Long Term",
        "label": "Marketable Securities, Fair Value, Long Term",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "MarketableSecuritiesFairValueLongTerm",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_MarketableSecuritiesFairValueShortTerm": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "cdna_MarketableSecuritiesAmortizedCostShortTerm",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Fair Value, Short Term",
        "label": "Marketable Securities, Fair Value, Short Term",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "MarketableSecuritiesFairValueShortTerm",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare [Member]",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails",
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_MiromatrixIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Miromatrix, Inc.",
        "label": "Miromatrix, Inc. [Member]",
        "terseLabel": "Miromatrix, Inc."
       }
      }
     },
     "localname": "MiromatrixIncMember",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_NumberOfMilestonePayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Milestone Payments",
        "label": "Number Of Milestone Payments",
        "terseLabel": "Number of milestone payments"
       }
      }
     },
     "localname": "NumberOfMilestonePayments",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cdna_NumberOfRenalTransplantPatients": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Renal Transplant Patients",
        "label": "Number Of Renal Transplant Patients",
        "terseLabel": "Number of renal transplant patients (more than)"
       }
      }
     },
     "localname": "NumberOfRenalTransplantPatients",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cdna_NumberOfUniqueSolutions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Unique Solutions",
        "label": "Number Of Unique Solutions",
        "terseLabel": "Number of unique solutions"
       }
      }
     },
     "localname": "NumberOfUniqueSolutions",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cdna_NumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Warrants Exercised",
        "label": "Number of Warrants Exercised",
        "terseLabel": "Number of warrants exercised (in shares)"
       }
      }
     },
     "localname": "NumberOfWarrantsExercised",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/WarrantsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "cdna_PatientAndDigitalSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patient And Digital Solutions",
        "label": "Patient And Digital Solutions [Member]",
        "terseLabel": "Patient and digital solutions revenue"
       }
      }
     },
     "localname": "PatientAndDigitalSolutionsMember",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.caredxinc.com/role/SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_PaymentsToAcquireCapitalExpendituresNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Capital Expenditures, Net",
        "label": "Payments To Acquire Capital Expenditures, Net",
        "negatedTerseLabel": "Additions of capital expenditures, net"
       }
      }
     },
     "localname": "PaymentsToAcquireCapitalExpendituresNet",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_PunitiveDamagesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Punitive Damages",
        "label": "Punitive Damages [Member]",
        "terseLabel": "Punitive Damages"
       }
      }
     },
     "localname": "PunitiveDamagesMember",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_RemainingOperatingAndFinanceLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining operating and finance lease term.",
        "label": "Remaining Operating And Finance Lease Term",
        "terseLabel": "Remaining lease terms"
       }
      }
     },
     "localname": "RemainingOperatingAndFinanceLeaseTerm",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cdna_RestOfTheWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rest of the world.",
        "label": "Rest Of The World [Member]",
        "terseLabel": "Rest of World",
        "verboseLabel": "Rest of World"
       }
      }
     },
     "localname": "RestOfTheWorldMember",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/SegmentReportingSummaryofLongLivedAssetsConsistingofPropertyandEquipmentNetbyGeographicRegionsDetail",
      "http://www.caredxinc.com/role/SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_SaleOfStockAuthorizedConsiderationAmountMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Authorized Consideration Amount, Maximum",
        "label": "Sale of Stock, Authorized Consideration Amount, Maximum",
        "terseLabel": "Sale of stock amount maximum"
       }
      }
     },
     "localname": "SaleOfStockAuthorizedConsiderationAmountMaximum",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_SaleOfStockCommissionFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Commission Fee Percentage",
        "label": "Sale Of Stock, Commission Fee Percentage",
        "terseLabel": "Sale of stock, commission fee percentage"
       }
      }
     },
     "localname": "SaleOfStockCommissionFeePercentage",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cdna_ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of finance lease and operating lease liability maturity",
        "label": "Schedule Of Finance Lease And Operating Lease Liability Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Commitments under Operating and Finance Leases"
       }
      }
     },
     "localname": "ScheduleOfFinanceLeaseAndOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of finite and infinite lived intangible assets.",
        "label": "Schedule Of Finite And Infinite Lived Intangible Assets [Line Items]",
        "terseLabel": "Schedule Of Finite And Infinite Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cdna_ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of finite and infinite lived intangible assets.",
        "label": "Schedule Of Finite And Infinite Lived Intangible Assets [Table]",
        "terseLabel": "Schedule Of Finite And Infinite Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteAndInfiniteLivedIntangibleAssetsTable",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cdna_ScheduleOfIntangibleAssetsTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of intangible assets.",
        "label": "Schedule Of Intangible Assets Table [Table Text Block]",
        "terseLabel": "Summary of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsTableTableTextBlock",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cdna_ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Right Of Use Assets And Lease Liabilities For Lease Agreements",
        "label": "Schedule Of Right Of Use Assets And Lease Liabilities For Lease Agreements [Table Text Block]",
        "terseLabel": "ROU Assets and Lease Liabilities for Lease Agreements"
       }
      }
     },
     "localname": "ScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForLeaseAgreementsTableTextBlock",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cdna_ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of share based compensation stock options and unvested restricted stock units activity.",
        "label": "Schedule Of Share Based Compensation Stock Options And Unvested Restricted Stock Units Activity Table [Table Text Block]",
        "terseLabel": "Summary of Options, RSUs Activity under 2014 Equity Incentive Plan and 2016 Inducement Plan and Related Information"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsAndUnvestedRestrictedStockUnitsActivityTableTableTextBlock",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award common stock awards for services.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Common Stock Awards For Services",
        "negatedLabel": "Common stock awards for services (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value amount of outstanding stock maximum.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Amount Of Outstanding Stock Maximum",
        "terseLabel": "Maximum value of shares which an employee can purchase per calendar year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAmountOfOutstandingStockMaximum",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Non-Option Equity Instruments, Available For Grant",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Non-Option Equity Instruments, Available For Grant [Roll Forward]",
        "terseLabel": "Shares Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsAvailableForGrantRollForward",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Number Of RSU Shares",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Number Of RSU Shares [Roll Forward]",
        "terseLabel": "Number of RSU Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfRSUSharesRollForward",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Number Of Shares Outstanding",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Number Of Shares Outstanding [Roll Forward]",
        "terseLabel": "Stock Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNumberOfSharesOutstandingRollForward",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award offering period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Offering Period",
        "terseLabel": "Offering period for employee stock purchases"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options expected to vest outstanding aggregate intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value",
        "terseLabel": "Expected to vest, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options expected to vest outstanding number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number",
        "terseLabel": "Expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options expected to vest outstanding weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term",
        "terseLabel": "Expected to vest, weighted average remaining contractual life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options expected to vest weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price",
        "terseLabel": "Expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested outstanding aggregate intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value",
        "terseLabel": "Vested, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested outstanding number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number",
        "verboseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term",
        "verboseLabel": "Vested, weighted average remaining life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price",
        "verboseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "cdna_ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award, repurchases of common stock under employee incentive plans.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Repurchases Of Common Stock Under Employee Incentive Plans",
        "terseLabel": "Repurchase of common stock under employee incentive plans (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "cdna_ShortTermMarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-Term Marketable Securities",
        "label": "Short-Term Marketable Securities [Abstract]",
        "terseLabel": "Short-term marketable securities"
       }
      }
     },
     "localname": "ShortTermMarketableSecuritiesAbstract",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cdna_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cdna_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cdna_TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taxes paid related to net share settlement of restricted stock units.",
        "label": "Taxes Paid Related To Net Share Settlement Of Restricted Stock Units",
        "negatedLabel": "Taxes paid related to net share settlement of restricted stock units"
       }
      }
     },
     "localname": "TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_TwoThousandAndFourteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand And Fourteen Employee Stock Purchase Plan [Member]",
        "label": "Two Thousand And Fourteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2014 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandAndFourteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cdna_UnsubmittedClaimsRevenueNotYetRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsubmitted Claims, Revenue Not Yet Recognized",
        "label": "Unsubmitted Claims, Revenue Not Yet Recognized",
        "terseLabel": "Revenue not yet recognized"
       }
      }
     },
     "localname": "UnsubmittedClaimsRevenueNotYetRecognized",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails",
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdna_UnsubmittedReimbursementClaimsForMedicare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsubmitted Reimbursement Claims For Medicare",
        "label": "Unsubmitted Reimbursement Claims For Medicare",
        "terseLabel": "Reimbursement claims"
       }
      }
     },
     "localname": "UnsubmittedReimbursementClaimsForMedicare",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails",
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesRevenueDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cdna_WarrantFairValueAssumptionsExpectedTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant fair value assumptions expected term.",
        "label": "Warrant Fair Value Assumptions Expected Term",
        "verboseLabel": "Original Term (in years)"
       }
      }
     },
     "localname": "WarrantFairValueAssumptionsExpectedTerm",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/WarrantsOutstandingWarrantsToPurchaseCommonStockWarrantsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "cdna_WarrantsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Disclosure [Text Block]",
        "label": "Warrants Disclosure [Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsDisclosureTextBlock",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/Warrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cdna_XynManagementIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "XynManagement, Inc.",
        "label": "XynManagement, Inc. [Member]",
        "terseLabel": "XynManagement, Inc."
       }
      }
     },
     "localname": "XynManagementIncMember",
     "nsuri": "http://www.caredxinc.com/20230331",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States",
        "verboseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SegmentReportingSummaryofLongLivedAssetsConsistingofPropertyandEquipmentNetbyGeographicRegionsDetail",
      "http://www.caredxinc.com/role/SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe",
        "verboseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SegmentReportingSummaryofLongLivedAssetsConsistingofPropertyandEquipmentNetbyGeographicRegionsDetail",
      "http://www.caredxinc.com/role/SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r248",
      "r583",
      "r639",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails",
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r394",
      "r525",
      "r541",
      "r562",
      "r563",
      "r580",
      "r589",
      "r597",
      "r638",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r394",
      "r525",
      "r541",
      "r562",
      "r563",
      "r580",
      "r589",
      "r597",
      "r638",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r248",
      "r583",
      "r639",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails",
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r244",
      "r526",
      "r581",
      "r595",
      "r632",
      "r633",
      "r639",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails",
      "http://www.caredxinc.com/role/SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r244",
      "r526",
      "r581",
      "r595",
      "r632",
      "r633",
      "r639",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails",
      "http://www.caredxinc.com/role/SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r348",
      "r394",
      "r422",
      "r423",
      "r424",
      "r501",
      "r525",
      "r541",
      "r562",
      "r563",
      "r580",
      "r589",
      "r597",
      "r628",
      "r638",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r293",
      "r294",
      "r295",
      "r296",
      "r348",
      "r394",
      "r422",
      "r423",
      "r424",
      "r501",
      "r525",
      "r541",
      "r562",
      "r563",
      "r580",
      "r589",
      "r597",
      "r628",
      "r638",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r245",
      "r246",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r582",
      "r596",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SegmentReportingSummaryofLongLivedAssetsConsistingofPropertyandEquipmentNetbyGeographicRegionsDetail",
      "http://www.caredxinc.com/role/SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r245",
      "r246",
      "r549",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r582",
      "r596",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SegmentReportingSummaryofLongLivedAssetsConsistingofPropertyandEquipmentNetbyGeographicRegionsDetail",
      "http://www.caredxinc.com/role/SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r12",
      "r594"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r250",
      "r251"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued and other liabilities",
        "totalLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r14",
      "r567"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalty"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r168",
      "r537",
      "r546",
      "r547"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r20",
      "r23",
      "r125",
      "r492",
      "r542",
      "r543",
      "r609",
      "r610",
      "r611",
      "r615",
      "r616",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r432",
      "r433",
      "r434",
      "r615",
      "r616",
      "r617",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r103",
      "r104",
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Employee stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r426"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofExpenseRelatingtoEmployeeandNonemployeeStockBasedPaymentAwardsfromStockOptionsandRSUsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r43",
      "r74",
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofFiniteLivedIntangibleAssetsAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potential dilutive securities excluded from diluted net loss per share attributable to common stockholders (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r43",
      "r85"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairments and write-downs"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r139",
      "r148",
      "r166",
      "r184",
      "r231",
      "r235",
      "r240",
      "r267",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r454",
      "r458",
      "r474",
      "r594",
      "r636",
      "r637",
      "r679"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r160",
      "r170",
      "r184",
      "r267",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r454",
      "r458",
      "r474",
      "r594",
      "r636",
      "r637",
      "r679"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Debt securities, unrealized holding gains (losses)"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r254",
      "r274"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Debt securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r64",
      "r253",
      "r274",
      "r530"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail",
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail",
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofWeightedAverageAssumptionsUsedtoEstimatedFairValuesofShareBasedAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r449",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails",
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofIdentifiedIntangibleAssetsAcquiredatAcquisitionDateDetails",
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r108",
      "r109",
      "r449",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails",
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofIdentifiedIntangibleAssetsAcquiredatAcquisitionDateDetails",
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails",
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofIdentifiedIntangibleAssetsAcquiredatAcquisitionDateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill expected to be deductible for income tax purposes"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r107"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition related costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r117",
      "r118",
      "r120"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total consideration",
        "totalLabel": "Business Combination, Consideration Transferred, Total"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r452",
      "r612"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Revaluation of contingent consideration to estimated fair value"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r116",
      "r119"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      },
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r116",
      "r119"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r122",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "negatedLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other",
        "negatedTerseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r110",
      "r111"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "negatedTerseLabel": "Other liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net, Total"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r45",
      "r162",
      "r564"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesReconciliationofCashandCashEquivalentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesReconciliationofCashandCashEquivalentsDetails",
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "terseLabel": "Cash and Marketable Securities"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r607"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r40",
      "r45",
      "r46"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesReconciliationofCashandCashEquivalentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash at the end of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesReconciliationofCashandCashEquivalentsDetails",
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r40",
      "r137"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/WarrantsOutstandingWarrantsToPurchaseCommonStockWarrantsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/WarrantsOutstandingWarrantsToPurchaseCommonStockWarrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Number of shares underlying warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/WarrantsOutstandingWarrantsToPurchaseCommonStockWarrantsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r93",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/WarrantsOutstandingWarrantsToPurchaseCommonStockWarrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r17",
      "r141",
      "r152"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r87",
      "r290",
      "r291",
      "r552",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r615",
      "r616",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.caredxinc.com/role/WarrantsOutstandingWarrantsToPurchaseCommonStockWarrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in usd per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r3",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r3",
      "r594"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock: $0.001 par value; 100,000,000 shares authorized at March\u00a031, 2023 and December\u00a031, 2022; 53,712,654 shares and 53,583,301 shares issued at March\u00a031, 2023 and December\u00a031, 2022, respectively; 53,653,182 shares and 53,533,250 shares outstanding at March\u00a031, 2023 and December\u00a031, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r24",
      "r172",
      "r174",
      "r178",
      "r531",
      "r538"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Net comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r51",
      "r52",
      "r134",
      "r135",
      "r248",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r51",
      "r52",
      "r134",
      "r135",
      "r248",
      "r548",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r51",
      "r52",
      "r134",
      "r135",
      "r248",
      "r551",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r146",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r51",
      "r52",
      "r134",
      "r135",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r49",
      "r51",
      "r52",
      "r53",
      "r134",
      "r136",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r51",
      "r52",
      "r134",
      "r135",
      "r248",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r312",
      "r313",
      "r324"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r584",
      "r586",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r29",
      "r526"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of testing services, product, digital, and other"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Credit Concentration Risk"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r50",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofIdentifiedIntangibleAssetsAcquiredatAcquisitionDateDetails",
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r253",
      "r255",
      "r256",
      "r530"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss",
        "totalLabel": "Debt securities, amortized cost"
       }
      }
     },
     "localname": "DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanTypeExtensibleList": {
     "auth_ref": [
      "r94",
      "r95",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r377",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates type of defined benefit plan. Includes, but is not limited to, pension plan, other postretirement plan and special and contractual termination benefits payable upon retirement.",
        "label": "Defined Benefit Plan, Type [Extensible Enumeration]",
        "terseLabel": "Defined benefit plan, type"
       }
      }
     },
     "localname": "DefinedBenefitPlanTypeExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/A401KPlanAdditionalInformationDetail"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Expense incurred related to plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/A401KPlanAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r43",
      "r229"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed Technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofIdentifiedIntangibleAssetsAcquiredatAcquisitionDateDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r399",
      "r428",
      "r429",
      "r431",
      "r435",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Incentive Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r179",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r200",
      "r203",
      "r210",
      "r211",
      "r212",
      "r216",
      "r462",
      "r463",
      "r532",
      "r539",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.caredxinc.com/role/NetLossPerShareSummaryofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r179",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r203",
      "r210",
      "r211",
      "r212",
      "r216",
      "r462",
      "r463",
      "r532",
      "r539",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.caredxinc.com/role/NetLossPerShareSummaryofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r671"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r427"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "terseLabel": "Share-based compensation expense capitalized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofExpenseRelatingtoEmployeeandNonemployeeStockBasedPaymentAwardsfromStockOptionsandRSUsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r430"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation costs related to stock options and RSUs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Stock options and RSUs expected weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r426"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Share-based compensation expense tax benefit recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofWeightedAverageAssumptionsUsedtoEstimatedFairValuesofShareBasedAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Employee stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail",
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofWeightedAverageAssumptionsUsedtoEstimatedFairValuesofShareBasedAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r91",
      "r157",
      "r175",
      "r176",
      "r177",
      "r187",
      "r188",
      "r189",
      "r191",
      "r197",
      "r199",
      "r218",
      "r268",
      "r311",
      "r432",
      "r433",
      "r434",
      "r440",
      "r441",
      "r461",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r492",
      "r542",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.caredxinc.com/role/WarrantsOutstandingWarrantsToPurchaseCommonStockWarrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFVNINoncurrent": {
     "auth_ref": [
      "r473"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.",
        "label": "Equity Securities, FV-NI, Noncurrent",
        "terseLabel": "Corporate equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFVNINoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r167",
      "r473",
      "r566"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Corporate equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI, Cost",
        "totalLabel": "Equity securities, amortized cost"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r70",
      "r147",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Corporate equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails",
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r43",
      "r90"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Revaluation of common stock warrant liability to estimated fair value"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r464",
      "r465",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Common Stock Warrant Liability and Contingent Consideration"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofIssuancesExercisesChangesinFairValueandReclassificationsofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r306",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r465",
      "r498",
      "r499",
      "r500",
      "r578",
      "r579",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r131",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofIssuancesExercisesChangesinFairValueandReclassificationsofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r464",
      "r465",
      "r467",
      "r468",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r306",
      "r351",
      "r356",
      "r465",
      "r498",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value Measured Using - (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r306",
      "r351",
      "r356",
      "r465",
      "r499",
      "r578",
      "r579",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value Measured Using - (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r306",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r465",
      "r500",
      "r578",
      "r579",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value Measured Using - (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofIssuancesExercisesChangesinFairValueandReclassificationsofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofIssuancesExercisesChangesinFairValueandReclassificationsofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r129",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofIssuancesExercisesChangesinFairValueandReclassificationsofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r129",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Issuances, Exercises, Changes in Fair Value and Reclassifications of Level 3 Financial Instruments"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r469"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in estimated fair value of common stock warrant liability and contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofIssuancesExercisesChangesinFairValueandReclassificationsofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)",
        "terseLabel": "Addition of estimated fair value of contingent consideration"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofIssuancesExercisesChangesinFairValueandReclassificationsofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofIssuancesExercisesChangesinFairValueandReclassificationsofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r306",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r498",
      "r499",
      "r500",
      "r578",
      "r579",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r470",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements": {
     "auth_ref": [
      "r130",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a derivative asset (liability) after deduction of derivative liability, measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Settlements",
        "negatedTerseLabel": "Payments related to contingent consideration"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofIssuancesExercisesChangesinFairValueandReclassificationsofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r259",
      "r263",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r276",
      "r277",
      "r307",
      "r309",
      "r460",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r576",
      "r620",
      "r621",
      "r622",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails",
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Weighted Average Remaining Useful\u00a0Life (In\u00a0Years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofIdentifiedIntangibleAssetsAcquiredatAcquisitionDateDetails",
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r164",
      "r283"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      },
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Summary of Finite-Lived Intangible Assets Amortization Expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r279",
      "r282",
      "r283",
      "r285",
      "r527",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofIdentifiedIntangibleAssetsAcquiredatAcquisitionDateDetails",
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure": {
     "auth_ref": [
      "r668"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-Lived Intangible Assets, Fair Value Disclosure",
        "terseLabel": "Finite-Lived Intangible Assets, Fair Value Disclosure"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofIdentifiedIntangibleAssetsAcquiredatAcquisitionDateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r79",
      "r528"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r75",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofIdentifiedIntangibleAssetsAcquiredatAcquisitionDateDetails",
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r79",
      "r527"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total future amortization expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails",
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "terseLabel": "Intangible assets with finite lives:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-Lived Intangible Assets Acquired",
        "terseLabel": "Assets acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainContingenciesByNatureAxis": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nature of gain contingency.",
        "label": "Gain Contingencies, Nature [Axis]",
        "terseLabel": "Gain Contingencies, Nature [Axis]"
       }
      }
     },
     "localname": "GainContingenciesByNatureAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingencyNatureDomain": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization.",
        "label": "Gain Contingency, Nature [Domain]",
        "terseLabel": "Gain Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "GainContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofExpenseRelatingtoEmployeeandNonemployeeStockBasedPaymentAwardsfromStockOptionsandRSUsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r163",
      "r278",
      "r529",
      "r577",
      "r594",
      "r625",
      "r626"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails",
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r66",
      "r252",
      "r271",
      "r624"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesScheduleofMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesScheduleofMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": {
     "auth_ref": [
      "r68",
      "r261"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain",
        "terseLabel": "Unrealized holding gain"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "auth_ref": [
      "r69",
      "r262"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss",
        "negatedTerseLabel": "Unrealized holding loss"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount": {
     "auth_ref": [
      "r258",
      "r535"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesScheduleofMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, after Year One through Five",
        "terseLabel": "After one year through five years"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesScheduleofMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount": {
     "auth_ref": [
      "r257",
      "r534"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesScheduleofMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Within one year"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesScheduleofMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r67",
      "r260",
      "r530"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss",
       "weight": 1.0
      },
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesHeldToMaturityAmortizedCostAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Fair Value",
        "terseLabel": "Debt securities, fair value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r25",
      "r138",
      "r143",
      "r154",
      "r231",
      "r234",
      "r239",
      "r242",
      "r533",
      "r575"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails",
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofFiniteLivedIntangibleAssetsAmortizationExpenseDetails",
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofExpenseRelatingtoEmployeeandNonemployeeStockBasedPaymentAwardsfromStockOptionsandRSUsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails",
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofFiniteLivedIntangibleAssetsAmortizationExpenseDetails",
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofExpenseRelatingtoEmployeeandNonemployeeStockBasedPaymentAwardsfromStockOptionsandRSUsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r185",
      "r437",
      "r438",
      "r439",
      "r442",
      "r444",
      "r446",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r186",
      "r198",
      "r199",
      "r230",
      "r436",
      "r443",
      "r445",
      "r540"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax (expense) benefit",
        "terseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.caredxinc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedSalaries": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in accrued salaries.",
        "label": "Increase (Decrease) in Accrued Salaries",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedSalaries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Change in deferred taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "auth_ref": [
      "r180",
      "r265"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "negatedLabel": "Write-off of investments in convertible preferred shares"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r612",
      "r676"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "negatedTerseLabel": "Decrease in ROU asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "negatedLabel": "Prepaid and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r281",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails",
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofFiniteLivedIntangibleAssetsAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Net carrying amount"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "terseLabel": "Intangible assets with indefinite lives"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r76",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Total intangible assets - gross carrying amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r73",
      "r77"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Total intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "terseLabel": "Intangible Assets, Net (Excluding Goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r71",
      "r568"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/BalanceSheetComponentsSummaryofInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BalanceSheetComponentsSummaryofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r169",
      "r565",
      "r594"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/BalanceSheetComponentsSummaryofInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BalanceSheetComponentsSummaryofInventoryDetails",
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r71",
      "r570"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/BalanceSheetComponentsSummaryofInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BalanceSheetComponentsSummaryofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r71",
      "r569"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/BalanceSheetComponentsSummaryofInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BalanceSheetComponentsSummaryofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedTerseLabel": "Amortization of premium on short-term marketable securities, net"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesSummarizesROUAssetsandLeaseLiabilitiesforLeaseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesSummarizesROUAssetsandLeaseLiabilitiesforLeaseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r490",
      "r593"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesSummaryofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r491"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r491"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r491"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r491"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r491"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r678"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r491"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, extension period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lessee, operating lease, term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r13",
      "r184",
      "r267",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r455",
      "r458",
      "r459",
      "r474",
      "r574",
      "r636",
      "r679",
      "r680"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r8",
      "r140",
      "r150",
      "r594",
      "r614",
      "r623",
      "r670"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r161",
      "r184",
      "r267",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r455",
      "r458",
      "r459",
      "r474",
      "r594",
      "r636",
      "r679",
      "r680"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:",
        "verboseLabel": "Short-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded from other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded from Other Party",
        "terseLabel": "Damages awarded"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
        "label": "Long-Lived Assets by Geographic Areas [Table Text Block]",
        "terseLabel": "Summary of Long-Lived Assets Consisting of Property and Equipment, Net by Geographic Regions"
       }
      }
     },
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.caredxinc.com/role/CommitmentsandContingenciesSummarizesROUAssetsandLeaseLiabilitiesforLeaseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r88",
      "r89",
      "r292",
      "r293",
      "r294",
      "r630",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.caredxinc.com/role/CommitmentsandContingenciesSummarizesROUAssetsandLeaseLiabilitiesforLeaseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r630",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Number of claims field"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MalpracticeInsuranceMaximumCoveragePerIncident": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum coverage per malpractice claim provided by the insurance arrangement.",
        "label": "Malpractice Insurance, Maximum Coverage Per Incident",
        "terseLabel": "Insurance matter"
       }
      }
     },
     "localname": "MalpracticeInsuranceMaximumCoveragePerIncident",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "cdna_MarketableSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Unrealized loss on long-term marketable equity securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "verboseLabel": "Original Term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/WarrantsOutstandingWarrantsToPurchaseCommonStockWarrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/WarrantsOutstandingWarrantsToPurchaseCommonStockWarrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/WarrantsOutstandingWarrantsToPurchaseCommonStockWarrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r182"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r182"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r40",
      "r41",
      "r44"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r26",
      "r44",
      "r144",
      "r153",
      "r159",
      "r171",
      "r173",
      "r177",
      "r184",
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r198",
      "r199",
      "r208",
      "r231",
      "r234",
      "r239",
      "r242",
      "r267",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r463",
      "r474",
      "r575",
      "r636"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/NetLossPerShareSummaryofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r195",
      "r200",
      "r201",
      "r209",
      "r212",
      "r231",
      "r234",
      "r239",
      "r242",
      "r575"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss used to compute basic net loss per share"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/NetLossPerShareSummaryofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r202",
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net loss used to compute diluted net loss per share"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/NetLossPerShareSummaryofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r231",
      "r234",
      "r239",
      "r242",
      "r575"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r486",
      "r593"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesSummaryofLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r672"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Operating lease, impairment loss"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of future minimum lease payments",
        "totalLabel": "Present value of future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails",
      "http://www.caredxinc.com/role/CommitmentsandContingenciesSummarizesROUAssetsandLeaseLiabilitiesforLeaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      },
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Less operating lease liability, current portion",
        "verboseLabel": "Short-term lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails",
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, less current portion",
        "verboseLabel": "Operating lease liability, long-term portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.caredxinc.com/role/CommitmentsandContingenciesFutureMinimumLeaseCommitmentsunderOperatingandFinanceLeasesDetails",
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r484",
      "r487"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows used for operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesSummarizestheNoncashInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating leases right-of-use assets",
        "verboseLabel": "ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.caredxinc.com/role/CommitmentsandContingenciesSummarizesROUAssetsandLeaseLiabilitiesforLeaseAgreementsDetails",
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r613"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r489",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate - Operating leases (%)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesSummaryofOtherInformationRelatedtoLeaseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r488",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CommitmentsandContingenciesSummaryofOtherInformationRelatedtoLeaseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BalanceSheetComponentsComponentsofAccruedExpensesandOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment",
        "verboseLabel": "Foreign currency translation adjustments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedTerseLabel": "Payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchase and retirement of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r35",
      "r451"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to Acquire Businesses, Gross"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisition of business, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "auth_ref": [
      "r180",
      "r265"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.",
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "negatedTerseLabel": "Purchase of corporate equity securities"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Acquisition of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "terseLabel": "Payments to acquire minority interest"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of short-term marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r348",
      "r350",
      "r356",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r391",
      "r392",
      "r393",
      "r395",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "401(K) Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/A401KPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in usd per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r2",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r2",
      "r594"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock: $0.001 par value; 10,000,000 shares authorized at March\u00a031, 2023 and December\u00a031, 2022; no shares issued and outstanding at March\u00a031, 2023 and December\u00a031, 2022"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r607"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r37",
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Aggregate proceeds from the issuance of shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "verboseLabel": "Maturities of short-term marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r37",
      "r101"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product revenue",
        "verboseLabel": "Product revenue"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.caredxinc.com/role/SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r159",
      "r171",
      "r173",
      "r181",
      "r184",
      "r190",
      "r198",
      "r199",
      "r231",
      "r234",
      "r239",
      "r242",
      "r267",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r453",
      "r456",
      "r457",
      "r463",
      "r474",
      "r533",
      "r575",
      "r591",
      "r592",
      "r611",
      "r636"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r627",
      "r675"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r86",
      "r151",
      "r536",
      "r594"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Long-lived assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SegmentReportingSummaryofLongLivedAssetsConsistingofPropertyandEquipmentNetbyGeographicRegionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RecoveryOfDirectCosts": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.",
        "label": "Recovery of Direct Costs",
        "terseLabel": "Reimbursement rate"
       }
      }
     },
     "localname": "RecoveryOfDirectCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r105",
      "r156",
      "r687"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofExpenseRelatingtoEmployeeandNonemployeeStockBasedPaymentAwardsfromStockOptionsandRSUsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r45",
      "r46",
      "r550"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesReconciliationofCashandCashEquivalentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesReconciliationofCashandCashEquivalentsDetails",
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.",
        "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings",
        "terseLabel": "RSU settlements, net of shares withheld (in shares)"
       }
      }
     },
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units",
        "verboseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromDilutedNetLossPerShareDetails",
      "http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail",
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.",
        "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings",
        "terseLabel": "RSU settlements, net of shares withheld"
       }
      }
     },
     "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r43",
      "r288",
      "r289",
      "r629"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring Charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/RestructuringDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring, Impairment, and Other Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/Restructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r5",
      "r92",
      "r149",
      "r545",
      "r547",
      "r594"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r157",
      "r187",
      "r188",
      "r189",
      "r191",
      "r197",
      "r199",
      "r268",
      "r432",
      "r433",
      "r434",
      "r440",
      "r441",
      "r461",
      "r542",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r227",
      "r228",
      "r233",
      "r237",
      "r238",
      "r244",
      "r245",
      "r248",
      "r322",
      "r323",
      "r526"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.caredxinc.com/role/SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r325",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Summary of Reportable Revenues by Geographic Regions"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails",
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofWeightedAverageAssumptionsUsedtoEstimatedFairValuesofShareBasedAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r248",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesConcentrationofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Components of Accrued and Other Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of Potentially Dilutive Securities Excluded from Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r108",
      "r109",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofConsiderationPaidandProvisionalAmountsofAssetsAcquiredandLiabilitiesAssumedRecognizedatTheirEstimatedFairValueDetails",
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofIdentifiedIntangibleAssetsAcquiredatAcquisitionDateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCapitalizationEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Capitalization, Equity [Line Items]",
        "terseLabel": "Schedule of Capitalization, Equity [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfCapitalizationEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCapitalizationEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the equity component of the capitalization of the entity. The table may be detailed by subsidiary (legal entity) (if applicable) and include information by component of equity as may be included in the Statement of Changes in Shareholders' Equity.",
        "label": "Schedule of Capitalization, Equity [Table]",
        "terseLabel": "Schedule of Capitalization, Equity [Table]"
       }
      }
     },
     "localname": "ScheduleOfCapitalizationEquityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of Computation of Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r99",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofExpenseRelatingtoEmployeeandNonemployeeStockBasedPaymentAwardsfromStockOptionsandRSUsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Expense Relating to Employee and Nonemployee Stock-Based Payment Awards from Stock Options and RSUs"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Financial Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.",
        "label": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]",
        "terseLabel": "Summary of Identified Intangible Assets Acquired at Acquisition Date"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Held-to-Maturity Securities [Line Items]",
        "terseLabel": "Schedule of Held-to-maturity Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfHeldToMaturitySecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfHeldToMaturitySecuritiesTable": {
     "auth_ref": [
      "r259",
      "r263",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity [Table]",
        "terseLabel": "Debt Securities, Held-to-maturity [Table]"
       }
      }
     },
     "localname": "ScheduleOfHeldToMaturitySecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r82",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails",
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofFiniteLivedIntangibleAssetsAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r9",
      "r10",
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Summary of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Summary of Fair Values of Assets Acquired and Liabilities Assumed as of Acquisition Date"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r57",
      "r58",
      "r59",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SegmentReportingSummaryofLongLivedAssetsConsistingofPropertyandEquipmentNetbyGeographicRegionsDetail",
      "http://www.caredxinc.com/role/SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]",
        "terseLabel": "Summary of Options Outstanding and Exercisable Vested or Expected to Vest"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r396",
      "r398",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail",
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail",
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofWeightedAverageAssumptionsUsedtoEstimatedFairValuesofShareBasedAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Weighted-Average Assumptions Used to Estimate Fair Values of Share-Based Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r93",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Components of Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/WarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Summary of Estimated Future Amortization Expense of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r231",
      "r232",
      "r236",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r247",
      "r248",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SegmentReportingSummaryofLongLivedAssetsConsistingofPropertyandEquipmentNetbyGeographicRegionsDetail",
      "http://www.caredxinc.com/role/SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingAndMarketingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.",
        "label": "Selling and Marketing Expense",
        "terseLabel": "Sales and marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingAndMarketingExpenseMember": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling and marketing expense.",
        "label": "Selling and Marketing Expense [Member]",
        "netLabel": "Sales and marketing",
        "terseLabel": "Sales &amp; marketing",
        "verboseLabel": "Sales and Marketing"
       }
      }
     },
     "localname": "SellingAndMarketingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofEstimatedFutureAmortizationExpenseofIntangibleAssetswithFiniteLivesDetails",
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofFiniteLivedIntangibleAssetsAmortizationExpenseDetails",
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofExpenseRelatingtoEmployeeandNonemployeeStockBasedPaymentAwardsfromStockOptionsandRSUsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Testing services revenue",
        "verboseLabel": "Testing services revenue"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.caredxinc.com/role/SegmentReportingSummaryofReportableRevenuesbyGeographicRegionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on offering date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date",
        "terseLabel": "Applicable exercise date an offering period shall be equal to percentage of the lower of fair market value of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "RSUs forfeited (in shares)",
        "terseLabel": "RSUs forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value - RSUs forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "negatedLabel": "RSUs granted (in shares)",
        "terseLabel": "RSUs granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value - RSUs granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of RSU shares ending balance (in shares)",
        "periodStartLabel": "Number of RSU shares beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r411",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted average grant date fair value ending balance (in dollars per share)",
        "periodStartLabel": "Weighted average grant date fair value beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "RSUs vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value - RSUs vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofWeightedAverageAssumptionsUsedtoEstimatedFairValuesofShareBasedAwardsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofWeightedAverageAssumptionsUsedtoEstimatedFairValuesofShareBasedAwardsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofWeightedAverageAssumptionsUsedtoEstimatedFairValuesofShareBasedAwardsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail",
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail",
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofWeightedAverageAssumptionsUsedtoEstimatedFairValuesofShareBasedAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum portion of earning an employee may contribute to the ESPP Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional options authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Shares available for grant ending balance (in shares)",
        "periodStartLabel": "Shares available for grant beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r418"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Stock options expired (in shares)",
        "terseLabel": "Options expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Stock options forfeited (in shares)",
        "terseLabel": "Options forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "negatedLabel": "Options granted (in shares)",
        "terseLabel": "Stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Stock options outstanding ending balance (in shares)",
        "periodStartLabel": "Stock options outstanding beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price ending balance (in dollars per share)",
        "periodStartLabel": "Weighted average exercise price beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "totalLabel": "Aggregate Intrinsic Value, Total"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "totalLabel": "Total (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionsOutstandingVestedandExpectedtoVestDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail",
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail",
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofWeightedAverageAssumptionsUsedtoEstimatedFairValuesofShareBasedAwardsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price - options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price - options expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price - options forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price - options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Intrinsic value of RSUs"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofWeightedAverageAssumptionsUsedtoEstimatedFairValuesofShareBasedAwardsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r418"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of options vested during period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r47",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r18",
      "r91",
      "r157",
      "r175",
      "r176",
      "r177",
      "r187",
      "r188",
      "r189",
      "r191",
      "r197",
      "r199",
      "r218",
      "r268",
      "r311",
      "r432",
      "r433",
      "r434",
      "r440",
      "r441",
      "r461",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r492",
      "r542",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.caredxinc.com/role/WarrantsOutstandingWarrantsToPurchaseCommonStockWarrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r218",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r2",
      "r3",
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)",
        "verboseLabel": "Shares issued under ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.caredxinc.com/role/StockIncentivePlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock for services (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r2",
      "r3",
      "r91",
      "r92",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Stock options exercised (in shares)",
        "terseLabel": "Issuance of common stock for cash upon exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofOptionUnvestedRSUActivityunder2014EquityIncentivePlanand2016InducementEquityIncentivePlanandRelatedInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r2",
      "r3",
      "r91",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common stock for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r91",
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock for cash upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramPeriodInForce1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Stock Repurchase Program, Period in Force",
        "terseLabel": "Stock repurchase program, period in force"
       }
      }
     },
     "localname": "StockRepurchaseProgramPeriodInForce1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Stock repurchase program, remaining authorized repurchase amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r2",
      "r3",
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Repurchase and retirement of common stock (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r2",
      "r3",
      "r91",
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "negatedTerseLabel": "Repurchase and retirement of common stock"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r2",
      "r3",
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Number of common stock purchased (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r2",
      "r3",
      "r91",
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "terseLabel": "Stock repurchased value"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r3",
      "r6",
      "r7",
      "r62",
      "r594",
      "r614",
      "r623",
      "r670"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r123",
      "r124",
      "r126",
      "r157",
      "r158",
      "r176",
      "r187",
      "r188",
      "r189",
      "r191",
      "r197",
      "r268",
      "r311",
      "r432",
      "r433",
      "r434",
      "r440",
      "r441",
      "r461",
      "r475",
      "r476",
      "r480",
      "r492",
      "r543",
      "r544",
      "r614",
      "r623",
      "r670"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/OrganizationandDescriptionofBusinessAdditionalInformationDetails",
      "http://www.caredxinc.com/role/StockIncentivePlansSummaryofWeightedAverageAssumptionsUsedtoEstimatedFairValuesofShareBasedAwardsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "terseLabel": "Trademarks and tradenames"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsAdditionalInformationDetails",
      "http://www.caredxinc.com/role/GoodwillandIntangibleAssetsSummaryofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/BusinessCombinationsAdditionalInformationDetails",
      "http://www.caredxinc.com/role/BusinessCombinationsSummaryofIdentifiedIntangibleAssetsAcquiredatAcquisitionDateDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r259",
      "r263",
      "r307",
      "r309",
      "r460",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r620",
      "r621",
      "r622",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails",
      "http://www.caredxinc.com/role/FairValueMeasurementsSummaryofFairValueofFinancialAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r572",
      "r584",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CashandMarketableSecuritiesComponentsofMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Change in estimated fair value of common stock warrant liability"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r219",
      "r220",
      "r222",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Shares of common stock subject to outstanding common stock warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/NetLossPerShareSummaryofPotentiallyDilutiveSecuritiesExcludedfromDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Note Disclosure [Abstract]",
        "terseLabel": "Warrants and Rights Note Disclosure [Abstract]"
       }
      }
     },
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Common stock warrant liability"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r202",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "verboseLabel": "Weighted-average shares used to compute diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.caredxinc.com/role/NetLossPerShareSummaryofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted-average shares used to compute net loss per share:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r200",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average shares used to compute basic net loss per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.caredxinc.com/role/CondensedConsolidatedStatementsofOperations",
      "http://www.caredxinc.com/role/NetLossPerShareSummaryofComputationofBasicandDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269825-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r601": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r602": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r603": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r604": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r605": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r606": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "b",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>92
<FILENAME>0001217234-23-000096-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001217234-23-000096-xbrl.zip
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M6[RZ?8_A\Z\?.AI#KSLHRF]EP&%UQ(4COG@&%U[>*)0@X_(;W J^QSP4M7)
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M2@KIL%=(,8FIQB)X+P"04JV!K@N@8U[$#"UPM4G,.5 =*0\\PEA01B%)K D
M6H) D2R 4ED@%ID.4G%<8T*LT):E/8L*:^>=,JF)>.!V'LK+CHM^/\N+Z?#F
MH.B>+B1 T4Y@I;4*@D2&0950'"Q%FAMEB*/SL([TRS'*5#1*< 0YRE--'L:<
M#\I:BK&5!) MUG-13'Y6&.7ID'DN50MCV-JHN=-&IA0]99T#X*(QXXY@8BK5
M,L,<,YW"VT9XQ(DI<]B=DE8C*C3#8(N$X6X1XBL3!;;#3:"_5"EO3 "S6.<I
M(8))"U^T#(!RC<":<CX/:W*_,,M,ISBX\UHP9T,TANE @%6,L3$$21$!+#,G
M6F82])P;"#P576."B9QJ8!6JF<36<&T(,T9&Y@(*:$YTS2_-.%/1.-$YX;'R
MSC++". :+(+#W)MH0THAJ33.'"'CZ:0><<*U\D@)[YF67L54@RQE+QCK%%*5
MZIDC#IJ*#L*"(% ^W"B*F)=>6YUV YCHD>:@C^9$!_T<4)Y+V:=6*X=!_H.T
MS - 5<$I051T6A(4YZ&YV/0I-YU6)AS@(CBFFAK+D(O&>V&L0E0HAGA< )E;
M;,!/4L$RCZSU"+,(!I@PI"(B,2(O79B'1D.S0K_I>/J(@GM&&>6$, !/2A/
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M_P):H1C_B##.+)IVWCI?_;]-F/Q>K1&^UG:Z;=/YO\L]T^EE/7BST8F]_"+
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M$&0R0X+\2\4MMCI?0 RZQ7D5JY@TH+B::E _E=X9F][)[P$([Z6/QHB,"Z%
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M OO.8#"J P#Z*5=AR-&,@PR\K3J'IA6/3[K]LQ@G;YZ,*G]D![$%T]:[4WC
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M >Z:LGYW0K=2B;H9H/=]"O2("4YC:Q&&M8RX /ASBE,D@C=&"*E2%(LH1%W
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M4A0X!X@9;,JNV,1=<<:WHQ@5AGB.A#06<6P<LII$)(/G6@M0VB"68UML1!+
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MN+"61KVV#O)LD!8_*_?'3%1I+Q/SV!O6==1@&QV7G%IH/.FSL)H6[AKY?32
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MZ^PZ/9#]$^=X/^E/W $U)P[O=#1Q,BTGSMD.(L&1C3O1TU,0;\[+"L10KO>
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MM#R5"L,4_5"]!N]MZ\$SJGRE,S["P%@(-;B3>AE:Z-6-K!XH*;^ZL,6? I/
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MQ)[6FVG;4B<C8P?5#&R'9665T'%6:=6U)R4D+%:O7UOXY#D%PBV_LWO06JW
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M'4F@A)TV"5DGUE0!9I>"=YXRYL/X2Q_4*ZR/^H0;;J*G%[V\WZ*^=F:8#^>
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M^QPDN>HDXN[J?N[JXOKJ/#S"!0Y[X5;];6(!X$C!B[\B/*[U;-]]T/0!DB:
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M\[4$\UQ7IM#LEO2N#J0>*4B)I) )!R+.=<8,3143BDEMK.*""FY_,4@5_>_
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M5A0)_BJQ6IM$4U'=[=*761TQFD9*"&M9;)GD>4&CU)C,LD12!E\.D]4K9G+
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M>ZWN6;_XOEC<FCV%);6^"5_^ )D[7.:Q1>Q<"6787>#:']W>MZWQY<FK?O7
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M#JGG1H$2$AW245!$L1=@61#L6 (E!+--(J>3T9<Q'[7*2%\#()BW&58% O.
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MRN>-L4T1&*1^R>]KE4PW%$SP6S]^S:2^-67"/Z%/YY-OPDS;<3_]!A)V$/\
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M+?2Y4J6.N?; B/)'(GR*]ON9)WIQ1HK!DA/X0:G(ETZ+6@ODOQ_<J"F-IT:
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M?M)-/F_YZT>R6*6MW8"!HV:7KTQ)>P$LFZ]O;X5 ]T&@^C0"<<]%H-2BD$A
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M,5H;'5DRA$MOC02=P @B'#7)9V/U)O; +R2);X.J*7_24FH2HU&6A7Y]5L]
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MV#2,+$<)B0JI*J1Z4J0JSI9GPM30US9RM8UYVBJ,6B!&D0F,<H0RI9)",EE
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M/R,MR1;7[D8?.R[V2OIA9+,&<$%K?_\;W $/ZI[!@$/_'V]&E%6^=;3$)77
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M"@<ES% C4?)>2(^9XY[EEA3"+*HEQ2)X:34":BHDK9#T=B15CD6B;6*<.N[
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MX[.BWOH?<#P;).()2%3.29L(08SE?"(3([(L>*14/IC2-#E-\P$'E0L^X*A
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M<>Z1<.YB!N?VOA[8S(I,IAKI1$C$A,/@(L-/,DV-/YA:8DL!YUB#DB6?J?=
M./=(^Y>>5$47HGAWJLR_Y,&?>V7^8U&Q6Z95:G"Z 3CEBR1,I%)@%DMDL36(
M.>RW+K$,2=\/WL2QLEH'<$K396V#7Z$>(+42/RS/J)7X(91X@6$X8RD1!"/*
MA?.M_6*DA2^4 6Z!"7>:L1B4F#=H3%9(B2_O]?#JTP.;H\/18%@G".H$09T@
MJ!,$=8*@3A#4@;,[=+.,)042J[36X(4R+!ECV%%!L70)M:I.$-QPV[@YW=WZ
M=-KJ?/BQW_%T\]-9:^]=OK^W>;$/M'3W&]S[V\[%]V\?CA8:M%UL^NWD9+_S
M&3Z_PUM;V[@)GVMNM7)XG>_O?>+[Q_ \G7?S"8*+YI8Y2*0#1X0))*R-$4N%
M12+%&FF=QM+&&CQ7H+6\D4CQ+.)F=7Z@AKEEPQP5F7829\* DY<HK!A3CCC.
MA'0IL;S.#ZP:S%W,P-S>_H&+9:(U3U%"38; 55=(4".0YD+&,2QIZ@+,";QX
MG/,JPER='J@CBP].Q%Y39/&QL"E?I&#$**(=QH@[PA!+@()IG7"4<E^'[137
M*F"3I(M'A=?9@1>CPP_#,FH=?@@=7N 71J6I9$F&L-3$MT' 2!HJD!(F3J1D
ML?;\(FG$\>).G)5*#ERV8;0\QUH5^X:F(N*EJ#.RGOH0]DEOD(?>L7W75KXO
MPR1R_5^SVQ+*N'<\^8K2P)!&PZN_LA Q?*)L!>&S"8+IOX_ZDWCGH4.Z[]0/
MI#(8[!O5/E7G@[4_9C,*>1?-S>'\XU_YD%GV8 ]92!% 0Z]?] (&Z7-]_RD8
MDUJ9L41'?0^<_\JMI=Q@[H#P8":XT0"E,2<I)2F3G*8'Z=I&V%CDMTCYGBX^
M*_37'VKCLI6<D_<"#F6:&,*E=$I;YKA/VW.6):G2F7 Q2>?/>E=<L<2P-.-2
MLXQ)Y;+8 C<SB=))ZB,J?SW>1JQW>5=UC2MV6G7M%?:AJ8:C/OS[JG=@P?=I
M\_0@M@8(-!<(,Z<02S4XBC%7R"GE8/+)I;NNG@*,RD7S&5 0[=[<D;K3"5(5
M/A%2/(6]J?(\8:.A&I09V,%5V=!GD^L4R3H6-TX?/FV7QILG+_%Z0F[V4#=,
M7CYI .!F:;A]I_K^X'DOT-,IN94_S_M9)3LGYW '>S"X9ZXSR^+,7!W\NB3^
MM;JMI(O.[O @'CH?Y9R)NZ#'[2.0KSU-\7(S%7?KWGW9Z5B+G9G&3/%CV51@
MK!Z>8OKXP7[HS?3BPPR=9MRZ\&&!#S">_;/]BT^D^6V'[^X=TM8Q?)]\@&M^
M[K3VVC_FPPS[?F<_V8F;G9V+UO&[X]86?/_X!]_=,@1XZ?%^Y^M9Z_T^WOWV
MV:<QXOF#$.+48I,II#CQQVDE&9*:) C')*,Z<YH9'K(8_,&S&(^4R'@VM@+T
MBJV6>;@DLOJR ZB/"GY;(]>".^^=NO9/UX1A'-VP:5$-?3> OGP!^K1.4L<P
M02Y3'#$9&Z1QQA&1!CME8\>3=&TC;4AZR_U=3Y*-+6GR<T(WOO+H]BH.;7EZ
MV/,L;^^T5Z/=TM#N? 'MLE0E/$DD4C9+$;,X09IPBW BL3-<J 0+CW:)6)'S
M7%X:ETM6'NUJ4%LZJ!WUG:MA;5FPUGJ[ &M&. 7K9Y$P D@<2PR2A$J$E158
MQ$P9$DA<C&5-XAX"UM*5A[6:Q#T:WKWKC>IPW?+@;C%<)RGP,ZX,(JF@Q;FE
M*J44"5CA6 .]RRSS<(>39?5>JEG<1/OVCES?A>*;E0>]&MNNP[90SG(ML.WU
M_G8?56XW_6K7T+9T:%L,QPF;.D5%AISU?8GA?TAJIA$E(C%,:/!>?;^EN)'$
MMTQ%U%3N)MC6\]W%9WM\KSS*/<1FNE<-C+<E?34B+@T1%T-VSF0Z(>#6<HT-
M8IFU2*H4(TH5Y]AF29K*M0V6- B_=PGX*FPQ>S98Z;4CRCLGHV%Q'#"PPL%P
MY<&R1KY[(]_7KBT/FG=V^\S 1S<[_K<:!I<%@[N+(;XT3F%)K49*R00QXBQ2
ML,(HYBF ('>26H!!T>"XSM,N7P4_SA\(DXV&H[Z+.GDW[XPZ+X Q_J*^M&:,
M]3[?E4#&Q6A@G&K,*8Z1% J0,>42:<.I[U,,JY=HH;E>VZ!I(V7WK]Z[C9K4
M!!$(XE5[9\X;XX.]3GI]OQ8KCYHU!-X# M\6BUTCX=*J6_8VAZVW1=<#&/=9
M\V+G0,>))I8[I!W+$,.2P$^"(4)D:D3,59(J7\><TELVG:I)X@V4;?=JJ&OW
MNH?('Z2[FF!W0WM7[C2D( "V-_+[%H/->Z4]NY8X-;41N9D1:?6ZIK8CR[8C
MVPMVA&,M12PY2I@TB G.D63*(B#8BF8FCK6U0*E)(X[OGV%?GAXMIUW'?*..
MJ[L7N#CS)PW$&MN,988JEV"8,6F(<Y+2=.VJ-M=>\9YH9_L-FH(/1B<G[>JD
M7:,&1U$&'X_R;J%R_O%#(Q)_/GROL'63<X*'OM@OZH2-&Y'K6OC0;/_CT&C\
MKOW!RXE[-IOFN5CG3"Z_Y[983P5]@ ;A5+"'&>S-+GO?!N'R>6X5#P6R4;'9
MR6_,=_8OW?]CTC?\-EO';]$[_,:@NMJS=\,-Y+]^VE<U92^Y]_KE#_W66[(3
M!0OF;94**:N!/U6^/;+%X17>?G7 G(V*<^9]G'^AX<M-).U>FWYO(H6W[;J\
ME$%>?O77T#!UXMB/V= @&@U<(4ES$<Z;=_8O9^)ZYON27>C;3\"+<93OU(7L
MYAYS59ST"MSDX_\<M_:^Y_O'^V2_\Z[=W/H,G]UAS??-\^_?MC%\%K=@O,VM
M?;K0G/);$[<Z'_+6,7S_V]=3<(G/FL>'I_L7']K[>U_)[M97W-HZ/&T=6[^9
M\&R<>/+/NWG@N,R8Y+Z'69PA?UP5TJ$+MI-*RHP(9LC:!FY0NJS3YVZN*4_<
M?;;&O!KS%H_IT]1AH3+*B&9:24&9RC+'XQ2[6,8R8!ZI,(_<'?-J6+L-K%U,
MP9K/IW.C*!&I08XQB5@F)5( 80A+ERFC3);Y))),EW4:W\.#VA7M>*]LO_O8
MD;H%?R5$ZC[WSE5[>!Z][74Z^7"VL.C7(;+'CRU>U]W61QW_[JF^]3[57G\T
M&+JBM:9WN?YQ;1\3_#)4/L)HHP^ (<"KOW9S6-5!#E/PV__[EP! ^+/Z2/@5
M__G[S8\4?(I0ZT[7/XJ+ -)8(SPI+"6,XSP* 8&B:K87*7 OC>M.'ZT8G>;#
MH\F$_.:_.S<%T3_%EZJI:)2G,1[V53=$9J=N!X_NSL#-'<"$CF\6[GRB?,_>
M(IP;XL&]\$6;J\-N;Y"')>J[8U=@.[C(O?XA7&T(-_&QU?!5DY_DX3A(N#Y<
MPH)^9UNMS7580-_B+P2%7;\S7N[Y)YB=&KAGW_W?*.\7T>43%8:ONJ"G[?'8
M?7\T&+COOAME#JYPI16"976#8:_K#LKBO#F;Q*3$Q$AI!'% UY2TJ<)6I4J+
MS)I,>9N$69P$F^1_H/&T3=IIO9O93=4:^6::NUFSNNVE1!P$RG@R?@JS,'#=
ML<&*GZ?!NG-7X.;>_D7STT&",XTS%2-N4XT8L 2D96:1 X[ 9*(9I\G:QB _
M6S XT7AYQ[67(;W0#]#IV_.641V?O_#2V?:R?9@/@S!VW3 :P,2'7T[Z/3LR
M14"HUS_IE2Y]^'(A=2"/SAQU 3P.S]>C"+2["-!Z_VS]4LF>5F@%(^N$?$BE
MJ2#A(U.F7#KJ+-21]DO,A[N7&@HC!R4*OZMA^<UI?>F @N@B0M4.7QD/P@&W
M,KY;?)3U>YUH\Z2?MT/B93W:A,' _0>C]G!6^_K.0VX)'R[4=D_*&/QD3CWR
MLS5&.^WVJ)-WU6I;CUT_V><1\UDS+.YB/ZKG;("LFO49*U*]%6U67ZGLR'KD
M;?7B^Q4J#V8&4B+T@KYU<HM*??,IPMXI*CE=I7W=2S3/]'Z&I]+GX1J+8U@=
MD;N<L;W-05$\2-R6LSV=E'T<]0<C;\>#Y0>$&1_V7,E4UQ8G//=-#MSZHLC_
M3B0M?.E*V0QR.)F6+YM?QEQN_&HE>5. 56 5C8/LRUG9/\W;[6AP%+JKEP.Q
M:'0"@P)OT*=:U*$K:,M/UQVYN2$THCP+SW1ZY+K59P:A5_NAZWIWTD=U/5[F
M?_?.U@N/9LZO64WAVX5)ZC]7P;M,VV>7_<@;T+#8_AO5OHN3$9@CGZ$QD^<.
MVS/@_<$1?'8,+H$6J%.PER">(,F#8I7G,')X!![JX:H9N,L7_)]\F!^6Z@@/
MMP,&KM/-,_""PVN[NEV^O<)N(R:%GP1V!32X\$JF5OV_895@J4#3;7#P@X,Q
M&.5#6. VK*XZ!*@:#*.67U15FKD27XK7)NX13$D!*W@,*^77RFM%Q9:VOFFK
MO#.^]+0,PB7>.=T?J?YYY$TR2 E<JS1Y7]>_K$=;^6#8S\T0OC+J#\=%,>.7
M032WP-<Z]7@S;8_#Q\= J-IM=UBQSPG1LZZ:#5CN3CYH.Q5Z^(<!@X3KWJ@8
M+P!A\#:\>V34R>2P"KC]9KO=^S+JN\+.A[D<./?#6^[C4;> 7W '<U? Y C\
M//!VLAQFJ ,\>^B?O7A_/0**\L6=#,L#!.)J0LII]80!R#E\$0;ZLSPCQL^*
MYRR>"D=Y,/J321_XM\J$;.3C/EYZP>T+\U&(,ESU4/7#8X/N^V):9]OGY;Q4
M%YF?M6 "O(B!>?&WJ.8 _,;9@VKJ,YGFSF1*YB:H/I/IY9_)],LSEN;.9!)&
M*HR%2YBUS,2I2!/I-/CNF<ELII,5JX(,)L=#6P$3'I"JF-G$9.#TST$%8 52
M#CUI*)@PP*KUMJ#PA=-&4<U8$.6JFF3\-F;%^XT"A?Q-CT> H=X&V'F,__<M
MLBF::4X$$4[+F#%+?:A$<$<-L4S'L2VS*31.RVP*9C/9%+ZPYWO,)[ZXX; H
M "TV=F_ZL3K[#@A38)D?5?^F>QJ35Q;2:AU_Y:V+30*?Y\TM@YN;!]RF<>((
M14E&)6(Z2Q$LFD )E<X09;1BV=H&8^M7]68$^6^7X5>K.@"V@X871" S/E(#
M:GX;L<&:I-RD'* B9<I097B: 'A0?TRFYFDM-BL@-J3UZ8 1(C+K%+( OK[O
MB4.*QAK!B@GM9(J)H6"A\?I5>;@IL?'2 MZ\&O8 >4H9"H!U&\FA5%F)L1?F
ME,%_*K:8I("%TEF1I::6G!60'-[:/-#,B9@F F FIHB!/4""*HZHXTJ#L4Z%
M%" Y=/VJ8X^G).?$"X3W"4JI68\^]@9#5%C#3B_(S$GXMO%^@T_,#,#_"(>+
M%89S)F[3[86,D0]/>[L7C"#(W# O-QJ$[(]Q<$, MGX9&A^"5?;O]+PHG +H
M>2[?:\-GUJ/5#G+L^@P@N"?>V2Q(0/ 484I=R'<.X58%!?&>V<F)"W&)\L'?
M.2!_,,MO\[[Q;IK*LKS?<5/$9<Q4CD?V,$3C;#X QW PQRO&GRO3?7DWZ\-'
MB@!>< %G'>E5G]:=[M@[G'/B9QYFSG7_H+J%YT[G//=B!2JGN^%+@V'^@K3!
M^_#2H%&$.2N_<3R!@WG*&(( 'XM9QG&#DZ21<.$5 >37^$"53P0!K(:RVA!L
M'-/"&R_6=!BB8)=Q\,7+W R?\\/+\$:W<+J+H&VOW.B3W^ZY03Q[-W]XF392
MPA8"#6HBK@O!8Q_EJZZ_P,>+"8%!*9^']KGE$Q^)\.&[/@A9,&@GSL<]X&-M
M'XD^[N7=>8X=PG[A!UAU_Z@S$PQZ.!B9H^I>"S&0,0R6Z9E2F,C<;%]I5KTE
M;OOL]9QQ-38%YRI5AF2,:>\],>:8E(X9[K AI7'EF*+JARORT&/KVAL,W@9'
M[1 \EG-0O;<A//+.#[#(4U^?E'[%9O3PK'EXP&)-K$ICY%*.$8NI/QY,*91E
MU("GS96)@8 -3WN+:>DNX-QXI0?3\;S;HLC :U+">0.+. @CQ@T,?S@K% L0
MI9:UYR9K>S#6BZ]X=^O3*8R;W4?23-A\>>KZ[@JK<ID5"8:H5U8GX<)>D FD
MI7.0-DF[E/0B7#A<9"S9\R!Z0[M8$:1DFA^-8[>]GXNW]4T&+[E!$?J="TE?
M>E4_,[8/"NJCSR6#G=PCA/!#(CJ4(H%!["TPV5![9$.PVKK,![(U&,VRO&E0
M,=9!]#,_[/5[HT'[O!%45_NP^<^00;_$[!WV>C9\;##2@Z$"90+N%Z[O5[BT
MV%6HWT_[9,^2-ZY@%G41_O?(,@"F'1T"0_"!+;=XPT#&P7K^5'E[]N'\4"8L
M/1"'\YD#KTMZ.BAO>Z,LV5-1Q>N"N[,L?,N=@(]92>^'T2 X-'XY9C_WQ9GJ
M8'#_YO:9.5(@]D7>%8@W"--.%]9X>)O<V],QZ<U!D((\2*G7 =/N#7R)$D@6
MJ Z>KPXJ73,5F?PG^&SYY%&]BPCN'\S).,&_LS7.: 72M>C[7#[KU06V=C^,
M+U#&8L=&='I818[7C4L7;,^,BDQP"'UTNV7Y8L!$%;T+N:+"0$6;9CC]%/ I
M[4).K=?U>>-)-0H,9BKW5-U*^YI'7R15^<"#Z:WQLYG,'[GM.KA8^1B!K1ZU
M'6!'KW,.W+C_TW^_@ KE4>"DY[KJJJF[@2".JV:WWX[G,2_W[I>HI[KS3U\\
M+7RE^&B1,X/%J4!M 'R[K?K%XX&L@.F&J2[(<>5/[6PU_,GWIPY QKL[Y625
M]9_S?HXR(0<XGI.1;N<&;ATZY?@\7S6ULT 5?)&)1';G^A,$<2G)/FB5KY^#
MY1NUBQB8"CQE/2H<LRO>]EGG?.!F:VF#]($O<Q3\."!8+K2_'?J%_YF#5E[Q
ME)=(BG]:ZWQM++QCBRL#;$_Y)>/G\1M6RQK<27WLNJ]!],)VB96;4M7Q7/1F
MKUG-C==!?Y&K9L$G-5P_^%'!#P+5\GN$VJ56@<2HZ"=8P7#YPA[Y*\VNEB]3
M+,<TG=DMQS:X?'"EWC6\.#;\'!2^Z?0080H/O;7NENTJPIAS-YTGKB2VUQ_K
M)BB7KVFNA'IVJ+;G"A-8VNLIP/&"7:G'6$'+<,U5TW>96/95'M+XGF,,1C.C
M#9=2F1N>^PN[S-=SP%5Z6?CXK'#]]V!2WP(?KB"D0)# ""=[4[-1NWT^H84S
M6E]\HV!7EZ_'.G@MOE7'X=&<E!4!OZ+ZID2]H!5Y*#XH$->CP F\9$):LJU.
MRVJ<8JK\_1M>HXSJ^ED'>V1]J82_3V\TA*NYZK$]!L.X"G":'G_CMBL0I"E,
M:"E1Y6.'IYZ9F;#X7GJ53[=4$EZV?YU9-L^I*Q&=%[#59@'O@K+!%0.JP[]S
M/#R4&(>%@,D)@=<H5 C.U!\5#^X+-=HE5LWIE9_53K!=0=*"M?([[,?EQ5.6
M,YCU(HH\?9_3P&Y#Y#CD"<JJKNI*X(5Z*?+UT-7-[.P8"E8["'BMO296GPL*
M5EPA5 861>.^P7D1K@,KUR_*R;27XO7H6QB*FJZ.'HS?KO2IH.)J,L3QL,I;
M>?T R)\=2BECX4L+J!Z&#_SK" 0''O/__+8(/V'#L/M\6%;?%M5Q4W<;CS+T
M/BBG:N*Q%P\]Y<9,]0CR5"@O8<*W/';#-]%O^>\S:J6\(Q&>_*3O]^[X.IZ!
MK^\S8^7UERG*Z&<<U2SWVSB\KQ/4M^)MUI>Q5:X2@,/TY(;7IF?^2'GGRGD*
M$-J#V:@$;%NN["WO7W"PWW)XR%E1G1*P/LPVF##=/I^2M9NHN5Q!7VBW?=[1
M>6\ _O]P^ERGE42KW7$A'Z_\>S6)MH4 >Q&$!6;2S$%17#L:/^!EN8%2W[Z,
MP%AZX1UG9,H]'84,59,R_<A7[FE\K+EXJ]HY:&$W5^.TT5L/C($I?%$^H#-T
MO=D-9.-7RT_.U!X6<#F9S2+2<$G((E-ACLL- !7%SUQ)/TQO,)S=R545#85,
M1%_GPT(,O5H;YP+25XNSU5\?KUBCQ-)+(B;6P9S"Q:<_OC[S6^$D%&D'&,+/
M7FY# ,G78GHFZ@,]H/[#&2]X$NX" 3K*.UX^,O73V_89]E4,+/@@GH&.\^K3
M=8EC0()+S0YSVBI5!:B3:%1(V+=GYBEX"W/QMQ#O*C?V\.E@U^6+?-GFP+&#
M\E3R'6[U)@?RGIL;2+P[BWS,P*VD.E8\MUI&,"GG4\%23\OMSV 4_8M'3O7#
MCLERLU<1CHW+>K)*GV\J%$#1"Q69O4QYDVO%(O-3-M$Q'^H/ 80!,/ZV-ZU%
M&6T9&ZCNW^L7NND?LI2I0B8O6YJGR[B/L6!1RXI0L#HM7>&I>=4.IA^F<K/Y
MI=JN=QH0IYL7Q7V;H\,1(%59!4X*?9Z4*I1=2MOGT_"6SP#?E3'E2=C80PFX
MAX&M_@(R)XA7@-+41<H8-5S$M;.%+Y3Z/PZ@3P]J'+ NXQV7AJA]M\A>6>ON
MO;@R0AT<\_+C=97U]576:5UEO1IC><0JZSM733\=\;Y;8LJ;C0F9NV..RN_:
M&]O1BDF6:+623."6Z30?A(:Y6NDXT74Z/)6->-M6@Y!7F>YROX*/,]YA3<8E
M/!_;H51A$/T_U3GY,_J8G[@L+](>__0,2/W7KM???Q')HX\@_OZ7=YXZ5=0B
M*TOV!I/I,&$ZU+B!QGBKV$J*[17[UUJ]D)+HSFQDF_(]+_&J&]%G7QF@@#]^
M<6[8:P06X\_1"@FC1O3VR.\QVSZ#J0J^V*X/=;M^L;FMR-]?D4H9-Y+9 M_2
M  \%7-GL_ACUHRU?M=97Q;U\=,KOB WW>3<.\Y3W:81R.:#3_]OK]I6=^4HX
MS! <ORN^&H98?O2+"[UJ_N/SEN.'\V,KON5*4=H<Y[@*SOS1IWU@!.IPYL93
MTS,S^H59FGI?Y;[BK9JK8FZ"!UZ>KG/;N2Q M138*]W_*F'@(W4_<SNJ3((-
MWG1P%ZJ=MN/M>?"=/V"NIG8N3H7\RC=[9?)R,''[0SW>U"?!3R_BQ%_*#!2.
M?]._C^,U$]4;YT0W"X'%DK*0F"P;<<R$1:8_/-DTZ@?Q>=3V_I1&W!/OSJA]
MJ$H?NN\"!,[-V*"W.&V73Y,/IY:-.TZFMD-7ST7BW]3XN68>IJ@A'?9[[7;(
MD )"^2F;7>.%PLM+8A5&A3:FE6=76N]BAO/RDI> FL_AP.3X4TVF*HU"Q"C/
MLHE/$8) XQA(U8L%O@R#:I0[/<OL2=Z?A%1]JQ,0Q:X['U_*+X0[@P<=CE^"
M&X>$ZCCF5&0@PDWO6L'\Y "\.W8M9P,ZIJA1!E<K#Q&<<>(>=,8/^"1J3]9Q
M]T=;'<%8HH^]=@"FTE8%:7;#O&QO_.5\ #KEA<GKX]3Z%9&*\;V^J#.?Y_QV
ME _A6NN;Z\6%>EK[W-][!U+3!RVQ'H8*N-OJG=KHGW\^CJ_MT0_<3[]]8'*7
MV<+D$)BOPHXPV!8(:D N(J8*U*HB;E(4J8'IGH:=^8(QGWJ<<DA#1*:?_YB4
MBDSO+"[%<V$PZ]'F.%33ZU8U7KWR2T#<S)&SHW;9#3A4T!6%9_1796.E2_ZH
M=6*/6R96\=J5WE!P';'=@@O^+,J;"DJ[X@5=,_6/!%<0\L%E6=^=1]O6M;V:
MZM#F8AA*8WKFQU&O[<OI[>1A2VLVT<@;=#FX TN,@ACY"OXIPQBD>\LSD< <
MPZ^>*A4_@+D=T[PIU"_9SA0U*XC/O%6\AOD4?& E>7E)4IXRLEJ)SH)&K.Z$
MX2>=L#*7-C:K-V6%/L;G34K)BC+X '@??N/FJ"CW&X!]JT2VHLV%6S O[ 5M
MZAZJT@CD12&#[]]H@R]RJ@9%=K/J>0>:/Q@XGP(?=8\]#7%=T.2C3J5;L]2P
M9*J#"#-/58N3?:X@K=?[%2M!D)5/?;15&66_YS+-UG\V%MR6&TU:T:K*V^IB
M.<*N)K\@OD8WL+29!.<\O1_ 5U0H+BR9X13L5@T J]LNDO^K&?ZD[/ZF#/^6
MW-YS^D9Y]>IMSV]6F$C$:6%^MYPIK*]8Y.]3J;(KX;3<#CL\=3Y!]QN)?X?E
M/(=I\$'_\%7@HD 0QR[]I%+'=S,;#MY$7I@"W[LJ##6H&'()"T-_5)?W"X9E
MB2!POF-8../^C+QO/9N'K-AUQ2JON4O(E\$US.]^VY_W)\8UD""14] 82F''
MNN5[!N;9L*KJ.X<KV-\]WYRTMRJ+@*J:L47J$C[@:6JH#"I\C;P@K>4R]/HE
M _92[HOVPLM_^M=_<Y?=KF#-XVOZVMEJWWI4H<$O)J4L.[QRV"L= 0[R/=YZ
M.O; /H!XPG1\&7KY&_1>"+M\$'(Y;N)<3=6"^L\5XDR<UTM<U6LN$TSGE(<(
MAF.Q<K][/1+5_&61OTRQA8HK],8=T>8K@BJ3^G+-\6JCU>I%7V8RH%Y%I^,O
ME]QR)@"SRI-];;_E[F#4#\F0YU!>NC-%X1;WU529OE*GQE;'4ZBM:52K,C6S
M_;.KB3"JW\_]FR ;"T59LX6H89/29 !7>BH3[0P!\>G*P[EBUZ+9IBW[_<]L
MGYEL?BA0K=P646PF*;HSAX4-SWOBH\NY)^6+&[,\"O?'QJ! :/#'E)F=LI-^
MWO&F(<P,7/8]?'P8;8:C=Y7?2EE-V'C^>YY(=,^KK3)!U<H!5./Q:1HP2^ S
MG?@'O$V/H]BYA,:&L=AREL;,PQ\QQ'(1<\IXV50-!*4XH@:3N2-JDOF=\4W5
MKC9\C1^F631[?^LG%.S"1]??Z9J0]JM;'%UZ3,#Q-M_=VSQO7L"U+IIX=_.
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M+;:)@)G-"KGY49V(YEW2$&@(K#L'3A'V#;1A1D,<:JWXM*_&Z*[]7I"@L)T
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M1CQ4%;>7 WAW+*:S8.I_1%6=.YG"OJK..HCHCG_PX6\1^3QU$\_VW(#9Q U
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MBT!3K_8'D$0 .W.E4CG&*=!'UAA/*<2BCW(=Y+N3&#\(!\$,>T4/]0K(7>0
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M ^I[U(YX$C.78U='YUF2D;[;MK&ZPSK48VU'2"H@;J%BO-;%9-M]<70-2BQ
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M>!I'@D2@R.N?1?<,\,]CE?1[[HRJ6[__LS'!(7-IP-W$39R$)*D?>P%Q8NF
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M'@8P](IZ&T7M8H)0\"CU4VE[B>N KT) 4;DG;,&(%T:))R,.O@IQ'BKO]$D
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M>C.IRXS!@,\SN': U<8P4*'U!.Q(5OU"9">(=RWE:Z/&_-(O^@]:])SA5CP
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MV_WJ_2C@4DBE<6?@NXW5.66]^\'3Z8F. \TD'?=+\J.69$S/9.6<I_.113G
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M,"DU=ZAYKRM28+Z;Y-+IEM[*<EGSS.?J.%M9.'@CE*=TCOI?=0P5=<X**)'
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M;)><PHCVV^.J7T7UF@UW0_O6ZDC5/&+38,YU-O2/(A=S/BO76R'^JI.7!GB
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MJK/5[H)N6;S4F'?A/C.5%6\.0I:/@[1C4.6A-Y7?AJW)U$FZBGFO)A [@:0
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MP2/OSOYMU<:3F03]U0X87'NIR=&?ZQBY.VN%SAAVHP+Z5D'L9^Z-W]\Z]/M
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M;1)M^'N5J]F!A08@M<M@Q9;Z591'3L'<(BB=<:P?X-%)PYKJN3US*P$8W4H
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M#US-QW6.*,-.?+2 AS#!*_[+TG@I\X#H$(+)I%I4+&=A!*^(2<>^V#_>;Y[
MH.RZ,0;\GZ<D49WV[E5$+[/95/Y",Z6ZWEP9'1^TQH*SS[C,.:O*HH0_@"CW
M7&/^AL2XN!5\\BI4D\S/1ZNT"%9*>&O,+1!:JU(E1#ZMF"\W@W]S:'?5*,.U
M8?)BRWT#RRB_$BHL<"I/NUZQP.%JF,KH0@+/M,.>EHX#-'M6S>:L(C'&648I
MJ,4Q'%;4;;!<Z:Q >I'__(_CT6CW55#NP$QV>,_I;\-7]HN^;*S[0S-$^J\
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M*O<1',03RR<-2C;E)N0IY:7()I;69G2,I86+9&R$U(G;C6N''^DV9#V6_RK
MM[2X*<STJ,,.+WYKGGZ&97/&5?@L'-+PE8^FV1C=^*-7-[18-)S*.9$PEI07
M=$J&HJ2(F$"!?!L8Q]_YA,)Q9:23:<0SW-WY^S><PI/^GD*8'OQGZBQNSR\L
M]#V#";.$DEU3I0%H7JYH[!1<;68'5P)VK1<N$$,XBLQM.960<5?[F*)9M"@<
M=J9"G#188%:9&M_,LV3A>^=741BQD+Y%KE=0\^!XGU8(A@3/4MM2*L>$<,'I
M$VM\-2B,\._90OA."NY"Z2:W^;J)J$(KS1"^3U\95SD.@FYA'77T5=@MW6XP
M/CX!13JLN*UE[LTP]II*4>H,6W#R%V%!G89Y:":N617\MR3D>=(@ PS)PC#Q
MG@[1](R<2JIZ<\)MFY5:\N_X7MJL#$?;-BO??<IP>(RG@O,G.TDT!<V.>#@:
M7(P*L/QEY^CI+I1W%V\^B%TC*K#]OW__Q^FO%^\N3B_>_9\WWNFOKSWXPWO]
M[]?OSL_>?SS_!Y4;_NGC/RZ\#Z>?__;FPOO\[OQOS]9;?4?0L:+T/J/3\SDN
MOO3[FA7^,;PT!-HG40?D'3+18.)K16<';H*\,(W0-(A1$X#?FEV8O6]KP-S9
M#%JA*4I"S%BK(/V"7A=>"W"_+3+$O&L0I4*2 ,9QY<N,Z@&H]Z_;9MA<Q&)8
M&PO;G0&-\V1O,&R-4R%K]2[S-P^5%Z4U6EG5ORC3M<O 1NTL[*:!W0(7?9A1
MO-A<ZO M9BNW7S/W-F]OR P+;$?0;L<JOU0H//!.O?EJB>' DMQRN"6DQGP)
M_KJ#.,?71_+OK<<83FU;RRH^"N)D"TY'< TWVQ>IRXRKF6%:^*9XB,%Q"U_F
M^4;"U(8_HW3.9.6]40NP4\\\^O"'(Z>EO-.?&C$1UH@VEK.M8L NJ5SV:$Q.
M)Q:,XD*84]L!WJ)6)4'BT)ZYOKDQ977%2.QK_<35=N:NYXT?2'L"C"MK_#BP
M]C>ZP*M:'$M<"PXFC4OLL8O6?AI(OJW]>)G3QZY&5THA@Z<MAZ.0Q\216'LB
MY>E"!"7G[K,4E.H\POVA?5SC$<;/?U/EF?N\CH2K303<>J!H$@E[!;KJ>(+U
M&=>OV*I-IUK_V#A%N-,J,&XG+<<]8=U(H3?EM,?'A(9N4'05#9W +'EK?"C8
MV*3I;WF&N&]=.ALP,>*>>J]I]GH?&-I/=SI)A8$D7M6V<KYFMJ2M9;HIN':V
M#_QP]P_:!N'F1YAD@R/),'8"<N*QO%&>U]_75KVGQ(!.Z.U8:7CQG59;:T<Q
M)?S8K*TI!E]?[ [V&Q=SRD]O'@G^\E[MR[*"9YHO9WYZ<L/U9L(^K$'.==34
MMI7(@BA9+.4"Q)69>/,HG EA/]7:HVD5$W-2Y$3_R)YH;<IEACXP@F<'QJAJ
M4=/B95M@"HGV"^_+ ,2*+#C) M.Y0OY(]JF9<[XF8QL(U9W#8<.#F\)AS\7#
MV5_KX9Q]_/7B\\?WY^3=?/K\\>S-:W1H>F-B=,_L#?>B$(V(T=HD(]@XQ>JS
MQ&32)Q%8;GV'!]G0LWNQH^R?S9&Y_\U7,/&9F6(*=H&@.O@S&XZ6SWS3J,.-
MT<./*5DK]T=H5VSBKMC2K!A9!<3-BHI"B<.G2DV,/: +;[@7[ P/7D8_TX^'
M!Z'\%SQF426SH*SUT3#&WNF$&>&ZLPLBJN^T+D!QDS(MTR1A@RE8J*5M>U%8
M+MJUOTM1!1%^;YY=L6UD:A1(&]/UB\QOB+]4$ UQ9S.],4=%"QB=@J9 L\71
MI>WP4%"3$1F!E]$%"IO4Y O7+\](T&^>,S??RJ-IPHD9QCL;]I2<C<U<,@_D
M:\#E'JMC*UA6LVI$P2D-4;C;!UYY\.7?JW"F!F5C8Y@8BN\%\-N*&-=BW7 U
M5BI8MUC:C@Z\/VDY'LE@9,Z[?]=S@4.0? K.4@6P^ZZ'62540B4&E/$ZKZ+@
M"^/FE/(YY@.!HR*?,0T2NZU(D>@:!<I!Q7328XSY1TEVY7L;GDJN^<++W-((
M"/2K4_ (F&XLO_KO'+!JYV^E(+NC-0XS*\IH+54Y3X^:R4[C1+N!$9/[.B4
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MR(*<VF2N?<B+*N9!U\<' ZP'?E4(\+_5B>I8&NY'8JUEIY3B;BMU^;/.G0D
M6F_$9#JU@J:U(4LW(D0L%W68=B64=)=H$*PCS$#LW?H;'+\)0RW1%;,!N[Y
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M.J>&4#NF*/=ZYMKM8M]VL8MJ:;F+EE&4[V"-='05*5OU.GS%M6;+4U&&M?P
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MJ93>C%$U@@,7#&7DM9J5VL1@+A@V(">2([]&]B0ITC2R&=)ZR2F8<$C3\C5
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MME<^8W'L<'>\<T"Q]RJ9!=+P/(_H #86I\CJ*[1^:8CJFYK8U+*N.I?1[LO
MS*4V ?:%RCR3YMAP\TM+;4KU4P'4JN504 D>ET=K((2(VDW[+C6L>%6U2W>'
ML8#130R^98J-(3.:+/IX.BW$]GS2"@H,N%.4%27<V(H2EFVT*HFU%PIM!9BM
M8"U$*YT&%TPAY5EI_@23)IJ_:12YC ;TTF[;F**Z"?+4/H8]_$CF\)/K?7!J
M3JM9!2:=N/,279IP:&*YS&**6E(;)R2I@U-.X&TOL6+_\4L2S&$LWB<$KT3&
M9*;#'Y4">?#.5P6H'3Q[1!1FQ9T3O^9=Y\'7* V\W^9Q"<\:G [X0=EXC-'
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M)+NAUB$IEH\),#(-+K.<8CIKV&B=(*?3;9DI=)%1+4O18J)R,#/9OFN%U[P
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M:)QG01CE-7? !$=O2MGRG\^HH>T-X&CZ!W^3G+N-41=.TI]KC@PM*+4:OW<
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MBHUI-<K,1 Y1]:WN3D7&IRD6CT?2Q<7P\S5ZF!Z:!.&8:@Q\Q"];<*!H+GX
MSP453TB@"\T<(4FG!CYDXLDSUT9  8K6@^,'&1_I69K5Y,:$ 9.+H4>FC]B=
M\K](88 I:10D1N.YW!*EFM;L*777D@-#,J-&09V.\3"@)"AB[9"@C1"$XJ1E
MJG8$7(LI70U^[/ A,B<@-Q3<<W@&J$'(QO1 _-&H2-GZ2J51N"@_P,!T^W0^
M(CS3,;B%&ZZ"3ASVR/MN(5H."I%QL5AG3(#&Y#!)PP#*C(2WT%H750YR!(NR
M6I^LG!*".7*P&?X^Z^@J%Q<B0_?=E 1B0CT-K"GC)-@=SG3+MPN?(U-G/7T?
M2:T1@E>-S-V>&[E1L-\:W8(S[[F$O]1C#O^(6?O30?S.=P\4]OQS<#>15(HQ
M=4?<N^.7(@84OI#/)?/ZD!M%5J(#OQ RCHDY),PF)4J-V9;-*"=A9M;1Q'6X
M83^1F8>3^D4G%T:NL819!-9%(:,GA_?,91V"*6D]^N][$^^78?3N!<FUWGBK
M$R;#(!BB#@2&9 Z95DL0!/7BNOXN/ ZN '.,Y:QC]^#'R#K6*>U*2G:'LXZ_
M2M;Q-*:>:KK15Q:X_HCO;[9>$J%_8;0EH.O*7-]EM6YUNLZAALYL'!A^D4:9
MMR7 (;^>7AUIQ)#7+9*V[D_91) @[QSA)+LED;K%XA_=!U=6 %Q5_@T%T/8N
MP:NF*B+J1;];.MN?O:WPM4O-7F1H23(6O9D@QNWCC#C?IUP\BV92IMAWTV*[
MR$E@8]4F,;?//\0DB&(GUN>^D98F4'\4VOS)<C"]]:B0L20-;\-(75,%*?W$
M]A'C.YUE;6E;6G)@?NZ3=>7,X(A;2!WP2%@.6 _YH0Z2ER51=4F8*+/^B.B3
M<7IECX5^N!F4+M3S^>"!++,3.KV:IW/D-.B,4VO&[D#HY#1@1F*KRUN$B4Z4
MK$YT%8-\F@A:!>Z2P**S0?.M?:;R#5PM6"Y<QB*7'?JD\KLD_>(&SQ8MVM#/
M!4:=&3]],*?^FPQY#I,DQBI?&:[9=_ZP/&(BYZZ9HWD$10\TGID%!V,>2O>,
M;L$3D@G=+2%^!NW_VEY0CE*2?1!+_[D5%W3]6X:6-\6AP==HCZ>:L(,"BUH2
M,$$X0S4N>!K-%I'V H7^B?L5G5?@<Y/5)*=JY(,^,K#X$8-5<8(X0]X^!%1M
M2CY*)1_]IN1C,\;RE"4?C>WW"-OO7(>PSHBM^E!G[/\%VF ,1OHS,?I$)[QA
MDA'M<5HB""^U7+KXW8)S2PML)%.W0#$&G2M+N6S!!<ID(>XD0ACB$N$YR9;3
MVI>A,R5&2IJ.", (F17T7./9K.AT'[GYV$N$)4PHGW*67ONQ$,UHAFOO"E1!
M !J B);#C +D6T=GEV>OO?=@^BDTD#;F.HR+B *(!JME K.S-(U8[7YY!G:+
MC-N-[*O()714YK946%FL:<RPK9-)$<N1;LF?YFZ98[_I&C+YQ ZPY;*.5SR9
MT4P0@::*R+R-B2]PPSBF^<!290!90348?"M'-R&(!#<X-!^7(CQ+)!$21T+A
MW$>.I:X3*B@.S(AT6&X.X1<1-^=>(JB8',6BD8[2)&/L]<0YC0:I%VM+0AYT
M>7PP0):%FA%)'P+\;^W\UBP-A=\<+X=(T?_,2MV^UG/GZKBY-]:$7,&M\77,
M5G<RU83$Q4\IO\'Q=YGC4I" '!^.LM44LLPS[9<CL# 'YS%T*6>9^AECH6Z3
M9="AY[EIV[-++@E&*UO5^LKY8)>^J90CP:2I>,C&?\&*C<@?2=4F#XD&SG/0
M.T%U)E;Y6:0!H_TTH=D#XO//+0EQM3"Y0\O+05P5VW10(&%$6CU)?G\;]963
MA<ZV&C!<%5_[UYP*D'YF??V,3\[^/+\?3R-5Z@B(-T&V<*')_!1@=T=I.,0Q
M#V'+VMYOR9VZE0+?VE^XD6O6!,[$,;00E<ZFCX,&N9SEA@@/?S5_@HQ++656
MSI6S%5=X;O@B"9SR=7A;QE+6?K:F1]1=)!/E9TS_(84=13X20&!=CEDZ][CE
M^B>4'(#]P[??VV):TVEER&=XJYI2_AKK+N>2E?6Q[U25@P6+LYI5J/;:C$BF
M6W?G4R+?3DIQZ3?5/SXL2R+H#%S2JBP$D>RS%'<%<J;"D4@F73TK)9?*)W/=
M0+TABKEHFC'&RD:F'D"+]WGIKHD1*C(PTU>K7/4E ""V&,84P?H!(M[C!-GD
MI[B5W #Y#IUD!QS;P;.HQ:JXLDCEE_0R!BKW/GPX:EF$:%W!YK#G2;R,X[9E
MV'Y:5[=>Q FR<F1,RP0#RK_A@O]]D>+\)U26%HZ=G.>,*BVP'&-!YM,MBS&U
M:/!]) 5=DC;5D/FU%;\2"C>G'S.1=0E(MALUW(6.TKF5U?;B?I=D)J6C:88C
M<%9=-@E;*U'R%J+06F4.;F/DWY6*+]VT/-]POLQB"Y>N+TW&P6UW  3*?!ZP
MN)FH2[?,T]YT''K$3!GN7:^[REH-5\@DZ!&!0E)0Y?)BD!,U0GB+G/65(IH$
MG7RV^N9.JEM0=M-L4%!RZAMKJ9ROX9ORN>JDEB$1<)1H20<DU)XB*U%WAO%=
MMTF(EC+Q:?B1K7R:^W;-/0Z#O[WZ=N"MV]M_]>VJH[)_O=^KQA[V5UJ9M+R[
MZNKDH\#GM_E_Y__OYT\7)[^>7EZ=7)P<>Y>''TXNO;/WWLD_/I]>_0<%[>>+
MTZM3^./AIV/O\^4)?GA^<79T<G)\>:^ZK,X&U66=8H=OZIV;"CJXJB=PST"$
M79J+OME2'^YH!IHR R$_4BG)+"JM'JN W%N&_"9#RO]*,@RKZ4@L@7>IE6Q0
M8'^!V**D?EENZ02ETKCAV*[A^7<(L(&:6=))G(LM/=T0TDH![5!QM1,L>"!=
M.:5Z(&98PP=CY6!!]0S+:^XYC^>6V-;4=\<EMT;/#-W+2">AP6,.)\5DV?IP
MOX.MQ<A94JN<*J]A&*YK7:W]7C(%6Q<96!0@&H.*R**K;NWR/7Q@ ;0I$Y'I
MZ&061F^QL#?RIYGZ6?_C+8)1@9'Z<QC3*:0?O94[(!DP3/F ]4?G0;);)/KX
M8YL-:G<X(Y2G\/\#_6;YN$T?;>?!_&>]0;O?&2S\N-/N+OQLV6.[_7;G8/%/
M'_W8]F!_\:=_8K#]_?ZC'KOLLUY[O_>XIZYHL"]J90_N]<MMN@]\)^#:X>7\
MVZO^*YN%);OBYX[7)76CG[?DJ[WI5_SRV[ET<_6:3L#ZB=3WUF&#;ZDP$@-7
M"9;#?S(R_Y(%IM;*%D3CV_-]:4MS*+CRYV2HG_LA10)XA7[@9?G6B4$WYES(
MV\ZIR1RLDT,#U'=.X490M=*U\ .OY*%MEO>.4=.GWC]U9YRL*CE\'\%S^P^8
M5>^4L\J?36M1=44S;POC;-RQE+U^[ )_0R#.]R&-1DJ-QV^7; $Z9=4-8//D
MZ0UXVH&_8PU6.O/$*//>>/HOVDY;N'J];Z^$6'/D>4USC\*8GIZ4NTP=KV:Q
M"#QTHU:K-V@-!EVV8ZOK\MW6 C^E-;G_6BPYV=_KE,*XUR,CMKIS%WBUQV[C
M[NA/JYO_9E^W;J\]Z+VLV[90@_\9:?H<16EWO[7?^=Z;^]UW]AZ[\@S7?FOG
MP2+U.RWL"H_X"Q;;STEF[PS:W]M :F[U)M_J!WM)@M;PG+PD3?[LN$GF3[V#
M/^$GU:S%,SEM.YW63N^A^KM^ZU=J?SWNM*W/V^DM#E>\S(/4W6OO[#Z[<_0H
M._[Y;M*@U>MU-F.37N8"/T1Y-PO[,'NT.;@O[^#^"+%Y*IIP3$[^[^\1EW^&
MYZP_:/6[_<=YEIL?75_-TM[3Y.P_SN1\OF>IVVEW'FIRKO\H_9G0\3/<I'ZO
MM;O[4-6]HEUZF2N\OC#P"U]8!$QM#NZ+.[A/%.E<0>SIGNM*A4U_)OPD(7RI
MQ^W#.@=)@=6]>NPK* A9WW)U.X/6?F_O<=[E]UNJ^Q]G7JJ5A+TVY1G-(:T<
M4@82?_9G=&7!D_7MS)-%3C;PVI,JW:8FCB=O;3JX5V?35I>1]]*0Z*/&/WM;
M_FNOVVOU#@;?Z@NB_AEJ05*3:93,E+(<"5-_9AKG_:_8&8R?<'<PM4A+S34W
M1TYUS34#ZU>;>\S+9$!W?N;]A/TD>_+$5 D4<U9Z>"T519F^I=RZY'3]<#_U
MUA 6@TIX[MMA1$ I@KYI>T#GL=D9FKVZ#M19;1_&RX$L!MU>^Z#;H.J54/5V
M&E2]S1C+$Z/J/7G\L"<I:P/SL09!/2^D^]U6;[E<V@ AO=<^V'T*(4V9VW7+
MZ-UV=XF,W@AUWZ]3]WNM_;W^AA^D3GM_YRD.$L=CUWR2!NW!IA^DG=?>0EJ^
M&G8;AK!4P=)5LMC+V&,M'!USS'SLY#T-/=^/P,'W:*".?N>E '7T%P)U')^\
M/_S\X>K2^WQ^]LF[//ET>G;A '1L-FS%)S@XC\=AZ?=?RO;N+-S>CZ>?3KS+
MP_<G5__QCD\OCSZ<77Z^V/QMS1TLHS^QP7LO98-W%V[PV=5O)Q?>Z:?W9Q<?
M#Z].SSYM^M;6WM@?V<O?7>SE/^2L#UZM,#:@OPJ3'+V!A4M!N?Z<%1,X4[/%
MZ[;VP$%IN.KK33@,\[=K'^#*HPEUN_1VJ=@#0W!W \3<WD(Q=_+OWT[?G5X9
MQ?6T8$.#07N_L_\8K*%!N]/=7P$83'=G[[LCUQSLM7?Z]QOL/3%FUEHU]TT_
MCZ3;"4N%OP[3[5\8"F0U.!YUB!05M<<4N:MYX_>#RW@V51#]=K<&<^#[+-B#
M)K^.V'IGTU7D\@&*BKS)\^G/V]MW=W=M&&;[.KG=/DQ'-PB(OZV":S_=1MJH
M[6ZON]_K[VS#<+O=0;_;V^WN]'N[_4%W.]C?W0?E&JBO_6[[)@<A<SAA*#N,
M'UPH C4,O"/<-R(0(5U[&L.8IC*L=HW&;2[QDUWBWK)6NN82O^!+W,/_W>D?
M; >#_EZ_Y]SARG6E*ZWIA3!$^> [3@:VGZKCKRW\H-U"U&7XS=^+6&%^'&.E
MW480K%40])<U.#2"X,<2!+TEROS=+/+OLN:VKO&V[H#M/5\6U]S6EW=;\9;.
MF]^[W6Y_O]O;#@YV>SO[!W!C=T1U$_4/:-L+=1TB/4Z<(Y5==_]M5F$"L=JZ
MN<EKO<F]K=W7_Z>YRL_\*F</U+S\SUX7_SWH;(_ . Z^OI&9[8CZ[76Z.YKJ
M ,QFY,RX91C7%G& L'9N[N]:[V]_:Z^YO\_^_CY:%>_W.P<[._O;P<Y>=Z\_
M %4\& 3]LC(^FY(3?'B=*J9"*@PF\^(K3B5PN +\Z\;@7N\UW]G:;Z[YCWO-
M=WK[/534P?[NP:"#/O+.KJNDI:15J.\,"SE=9/2>D7F&2@Q]+02H^#15-,SF
M;J_U;N]N'31W^]G?[3]I@FO;VU[K/=#(03%BE5VKHYM[N]9[N[<U:()@S_W:
M/EHE[^WN@%K>V0[@D_T>JN1NIV)X_\M/,0367-.U7M/]K6ZGT:_/_J)^)_VZ
M+SEF)QV,7O"@4;:;?(N[G7;W?YL[_)SO\"B(_3<(B=GI][N@*__XJK["_W1K
M[N-9D6=AH$R'&?5\JCCC8H[S) I'LY:GB#H>K^?A- TC#<'9W-/UWM/>_V+*
MK[<SAV/3W-9G?%N_RG75E1DFEGQA".W/;1?U13+S(^3%IN#3_0JX3KZ.HB+#
MZ_PA!+V;J1:11\-7ABJ_4RJF7E;3?7J5%EFNN&\6G_E!1?C=R]Q'FF6J[0I!
M<GR.X8EIANH</\ZI'5;GID&&8&L0D4UC!W0LX+V]08TH6<=U\AHYMJ9ZM"[8
M&XT >T$"C.17OSM78BKEH>?48A^.L%D^27,4/4<WH1J#6%*C@JR,LS'\0*62
M/;L48OI^IZ=%T*6?#OU896_.OD9JYAV.2!;V.B T&YMDK7>YU]SE%WB7>P^]
MR^_#V(]'H1\U=_FYWN4>Z.7F,K^\R]Q;I)@7:6&TYA?=ZG,'UJA[X'UN7[:/
MVN:6=_N[':Q?.PR2*3H>[K?U=P:=O482;+0DP,C1Z:?+39 %ZYC^O]]=?/!.
M8_"=XY'RCI-1@0YV:3&:8_A$Q_#RZ+<?^AA>^5^3.)G,0$KG*LY0?EZ.;M3$
M;\[E6L_ET>&'YER6S^61'XV*B(V+#V'\98A5<LTI7><I/3YYWYS2\BD]5N,P
M#IM#NAF[A(?TP^&[YI"6#^D'?ZBBYGRN?X/P?)Y?G#3GLWP^SQEDN='U&[)/
MW<[.#WI"CPC&^1R1LT\QW^QSU<JQG_O>^S!2WA:V9_@Y!J/\S&,X.X_.-4:Y
M1O "'_Y"@,@":.;!I7_=G.&GWLG-0!Q;Q\PMG@Z<P^',2]58I0IC3WEB#F6_
MW=4E'C4  %05W>V\^8>@[Q!P/D58U:A(0U,N<O)U=./'<%F.$'H\(V&^A=^C
MNJ+.V\N3(_I7]^UK+-DX+*Z++/=Z!'G>W6G7W8IGO_R;@9+UG _>P9O?Y\[=
MR1$>($*!ZG4-"M1+/#X;@:VTP<>GUQR?9<=G(\!^-O;X[-Q+[2TZ/UQRV*<#
MU-U]H0=HMSE 2P_0-^5/K=VD!5 TTR6K+U4 [37G9\GY&0RV@M?(C35WB/XB
MQ^?RR+LZ>W.ZX 2=C?($68.Z/1)"^R_T$.TWAVBI$-K]EA"Z?'.P3 9U7[8+
M=M <GS]W?'YP';818 $;>WZZG7;_\4Z8= #ND #:>Z$'J-MI3M!2";3?2*!E
MJ[@)_=/K.3T!(<UF'CS*O^:^1<RJ8"8&F2E'NKTX26?$1HE_).P._O++/ X_
M:L+X/=U_!#]#&5"SM]O$)/7+>@GL:EF^-H;5;N])N>N7K<GB%6CXZ=;.=K^$
MBJZA>'M!%&]K5&(_K!8KTCC,;I9KLA>PP9L#)K*6TB$8B!_&7HALQ>$XI"(@
MKA;"LH@;/_.&"(V1$$=[@*SKII?M-%<3;Z_3W1J^1M=1:!ET]?LE^-)#-?*+
M#*1P,;HI/3>$QR;@'VV%K[TXR<%N!O6-'798G[$5PE_=;^<WPAUOW2XO![6?
M9UC.)!3N;&?'8YZ)'VEJ>O,+/,;@VI&BROTOL(8PAS&?<ACA=!J1+0Z#&"73
MT )_%'&J M"P,'O1L5XQA5&EZH]"9=3]*VY>8^H]QM3;_RX$QCN]5RLT$#?7
M!ES[6)[4W.N49>D3'=QZWN'+TU\_'5Y]OCBY+$]@\=#7=,/<_F.45"BXPE1
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M$[C[,Z:2DOT9?10(7S;%&M\[CE4T/H(A8@Z_4=>L:UI]+WFT^I8M?:37MU#
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ML*84V']A\?/:R];+V+=DO=H\&CR=,D3D7DF\A6CS&O_=&V\/WYR'N>-A B#
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MJ;@5.)BG6XRZOL#./O%T<7I\W'TG&R_Q^/SOJ[YKQ8+EK"<)K$1. ]F5$[_
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MJ+]=@96TU5$4SGCBA6GC+(O%!Z85%..R-:39&NN*!T$-R=]MI3#:2J(=06J
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MWE^1-^?U6J5K4:NK9S%)9A7G4BV2V=7SA.621"<"8$,PR?KZ:PX1$HB <#]
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M(.+Y)TR_?4Y_^WG2O_@\2*NO?1JGO!']:LD%E"QP_E?YM%\.QO0)@8S#S"?
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M:,7<UPFW.V^8(UJ!)PHW*(8GD^-"@G:HRTQQO^.N,BFVP76$$Z&B+D>-%='
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MIP>4O[N0&\0U;H-ZUA_,IBGVI'9:L<2 A6)9.(LVAE(!N';4<L'1+*\=!=\
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M;G5I)$:GF"EE%@U:2;S-2G$K$R%"):-]KQ*&0YM[7_OX\K$O+Q/DHXU1R>Q
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M[8,D45HAY" E-]7+#=8CZ=X^.YYV1]55T\!TNUU2M9H0GI-RS"(6(4NS )'
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M8+5]F74XSH\EU:3>(/CR\-H75<TB*\VX+25SQ8HN[I4K,^T)I4SHR$SDM8=
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MZ.$HA"$*]UW-'7CF-(A49L":5.;=1<],9CK*5H[>XT@(;LN37<3?24)PZ9;
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M>^WZG?K@+177Y%[L7KAK7[IM(#?RQ?> >QQ_O"D-=J-<-1UVGUZR%GJ@1L>
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M;K!416(5GKF\=OCU851G0Z3*"FB0D[4.X;LT3'^Z00':\\'$[(P$GLI0JU)
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M<VT/M3_Z=;U=?+4Y7,=DL>WNJ(K=7(,I0'0I09%98\;LC.Q>H_\\4%^?N!Z
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MH\[8;/?.@\=Z-G/SWHSI78CWZ&G\B":O?]R^))S3?_W'_P-02P,$%     @
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M-[\$GA?^TEW]A_;R'\^N_SVLK_8QQK_4O]U=6F;'+E2/]7_YCU\_?&6WXH[
M+"\KDC,]0)G]J:Q_^*%@I*HQ/RL7.'F%_A?L+H/Z1] /8.C_\4?)__!O_P1
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M??=:1%!(T IIL<0?0P\K@"@3$DJL+$J4J+U]RE(/<N1CXODX%#Q>/8@-+>;
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MQ 6EEO<*E+7$H-B+#'[*\O;'/]OZ?X>Q-W4*.T-T8L;;@_FU ;,1%O2D=>D
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M:,#B,$VDE>=]/&!SM()T )C9XC8:AHG7(8U FS;YDQ;M9W!=*1N4;IN0GZH
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MZ*&0!:'.6PUX^\:]S:=N>/:B[UNGWHN_;:)IGOJ_W:LVL?_TA5Z>Y7M4&V!
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MO!D/I.VU/#R&'G'_.'/K+=GH"M^EVA77I4!WW5\B$@I%\@ARF@AEA:4)I(%
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MC@<5/KHA'KYC'']\WHA[DO&W/^[['3@;IVBW08M($OH\13!.O BBF#&H7JD
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MA)P/(G%!V/GQY\X<>CZHW//P\^'+1SECBDU5QU <J>&S6Q3#P",1#T)% *F
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M9[M^U!/01I52[C%.U;[3"RB"2.  8O4CR(,PC!*/RUB&QCZ4,X,MC0(;<:_
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M)A55>7VGO>+_7<O==MOX3T$V[]37N^*4"N[10-DLB="5&RA,<8QA&*,X2.*
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M^O\'63NYC(^OC)+S#8V;57+1X:/,DLMW]*W+1M<E9Y6K,[,LH:%0) 294 K
M-!6 HBP!,4S24.((QS1SVJ_;>_S4R&%K7;TTZ'HX?!\[RVBM-R)#QUC68/0H
MKW;*9V^EU?8>/G)9M5..'9=4.WE5S].?M/AA_FL*M3S3N5G7N%^(KS^6J[6I
MKO!^\2R+=;G<,6.9$EG$$% XB_3'C"C 21P"GF9)@H@BW$[4W+WIJ7WHQNJ[
M@.O_+2LMUL;?E>N@A;$?K$UMD'SG@>.I4OM.L6.)8: >F$$JE,W_!F\/42Y-
M!V4%EO<6*+L?4G4&S-?I5?N&QSW6Z@S(T7E7]R=,K4+DW[6%1D&JVHJ^7+N/
M,)+ 3*: )RD!4%6%MD.08BB35*8H8TX'Z2?CV=0(V:U.Y'/I[,2+1+J^:P,O
M[MWR#9K^:J!EJ<@*(Z,P5*'T/ZE>9,_^O_7*HW>_?HZERJ&Z<[S"D7T-=(LI
MN%C0*Q9HE[6U1]X<+=9^T0.1_MG<-:.49@FA*<@4XCILR#"@ C.0I8C%.J20
M(A$V8<,MC)]:9-!C=^;V+T#W6#[U;AUEN&;=P_6K9KAF)S?OE@M0@7!BY+YK
MO2SOFI<E^-V $=1H6"[LW>3=$4M>7E45-/I9WZ$]+_Z'O4O71W.W[+TJ8#,6
MF"@L"9,D*B.QF]@T2K!U2[2;>.JF-O0]7%\44FZK#I3G=K_(A?RCJML[0YA"
ME,4,I-!L(B=)"'!$% @S'BE%(BZI8]7MSO:F%ICL*FO,JS/E\L^U[E+#(]59
M)M>#]]UHVRT/>,1PX"B@LO2N5:"D/II?FUM6Y_9Y'M\*&&_G\KM;&_E\OI7K
MQ^?T[6YSK[S[IHX-_M\-7>DO=?Y2Z1/-)$))3" %*I3ET48*,%0)P#1)A9Y2
M2<6L3J5TM#$U$FG,#+9VU@);]I5VSZ'931B>,!J8)-SA<:JL>P& 7D5USSUS
MM'JZ%YQJE]*]=&F_N.'5IL@7FCQTC,/R11GB[)( WPO=7JYRVJICJ6.:E13W
M"]$26-9_TZ:)ZI(9RV0L6 1!&&("(#5Z^1(SD"0BYAD.TXR1V=K(<MF%&OY-
M="*6K:'#?3F-AT'+Q;M@YV30]K*N'1LT?I8[M&VY]=K5NVV1V5("S2W &>"U
ML(N);MO9 S/DH/WL+_P:K@\\16P#&#AJD#<<P(=QX8 M]1MOJH?4%>"W)88R
MF1"6PA1(&84 LI  PL($1#!+8P9EAMP..YUL96KA9&U>75?3L533:1SM./9J
M= :FR6;<:@ :HB)3)P:>:.IT&Z,R3:>;AV31?7&_[WU_2MJ0RLM';7[5SBQ5
MD<@DA(!D&=8329,FF;$8((F@RCA2"7.J1WZQQ:GQP,':U+:X[LN=_H4.%FJS
M&V4[-YZPP)^*+-%S>4 Q0QI_IL-U!@4@$864<A0SQ6?/<L66-^F!=LNWZ8/E
MXJ$Z83I0!]B1ME=0!R;PHV7"#SLX=P;[(W-K;#P1^^7V1B5Y:_</"=_^QG[D
M;XI\+,S^2:VWJ3\>([)I]$1V4>@LY'%&8LD 548$2")-12I2(*10*B72*(F<
M@C^K5J<V"#0Z<7D%O5'XJ JEK)?!D[,PJ1WP=L3C'<ZAER$K>X.VP:6VJV\)
M="=@/#&/79NCLH\3#(<,Y':S&PL5J_7LB]FLO?\S+V884T:0CG!$PA, A9*
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M3B-12;%\7N5<?E)*FE+@)G%IQCB,PD1%@$?4%./.4D!QEH$$2\4E8QG.K)*
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M,1V&AT2 D&8T2Q/$<69UBJ&CC:F1R[;8565G8 P-2DO=BX$=PMG-*)Y &IA
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M)E,PV!152C,OA17+%.B<E]L)Y9^WDNQN1./:.W;L,R#F U.2@7MO63C8FF_
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MDP'C]N?<^W;?H,EO#N;\#*?E^V+L-<&M1_/]UKA^72[%'_E\?K\X5&(JS)F
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M.\=9'06BO091JX+C>97=)%B>+7F'-O0Y4#^4T>]ASFJ<8/)UKF(WZ+AG($Y
MG)Q7N-T]C*3>/'Z?+Y^E_"Q73R67YT]&WB\73_61ASD$65=A5]V_OUJN-^^7
MF_^2F[VI.6,B26(A"4@$S@!*$@%(1F*@<I6G-,<I(TX.T&"23HT*ZZBV[6*U
MWVSR[ADNUSJLHY6L6Q9MEG71_VC9> $J9^#G+XX\&>X]L*/62<SNB*?RN\/V
M_:%C53*ZUJ\]@S<*&9=N]"PWG<.'*@5@Z[-P8'#X/;%\.#E'71B"PWV\EH0?
M,.#R\T!__"P74I6;MQK)[E_:O""<Q"G.(08P3A. ,B4 DPD&VK!.10&%S(A3
M_RP_8DUM8:GYAU7\<["B--'2T8;^B%BM4K1??0(L)-=GU..JX76>7GJ):$2^
M,PT(HT:MD9<!:SS'Y/SK0DV/X*V!',3F]D\/V=.K+ATPRS!/F20IP#PCFJ"3
M&+"<Y@!34N"<4*ER&JRI5RW#1/V$UEV];JC[X3)3EB<AOH&?8(^O6OJQFWP=
M8C9JEZ]FZ FV^3H$95B?KZ-G#/!=?9*F"H%^X"Y[5X_TMER8JCQ5'J_FB\<9
M8WF.F"I !I$ 2*8,8)9+H%@B4*K_!7EF[<JR&G)J=N9.Z&AN1(STF(\NB31V
M.%NXNKRC%YB>]L#MZP!HB:-&Y+HF0&2$]HZF@UO,.ZHC><GVZ"YWZ!KZ5PVZ
M^Y?5E_?,":E>9YK=D\;SK3EI=N!J<[MS:/L&OC*/>BWK_[Y;- ?HZT^2R_*I
MZN4<ITA"E0L I=(F*8P%()#D($L9UE=)F?*\-4GMK%&;80=8H8'9NI71[/@;
M(5U;,UB@;6=6>D-PK%8,M9C13ZW ?XJTD;Y#]--U1 >T7["'R%O;!8LA1VZW
M8 _":9L%AWO=JZ-_EEP;G9MGF+"'<J/?_$+&TO3N Y#'.4 \3P'CE(*B8#3&
M<5J(F-B61C]^^-0LOTHHLW&%R4_L3U$KKGUE]!/T^GGC5DP"\X,K'$Y5T2_I
M/:@D^LG#1JN'?DF-;C'TB]<,+ 2W^DH736;PJ^5BO9R7HLX 6(B/>OY;4_2#
MJNV2DLX_Z]_463/[[+Q.@72:QCQ&^IN6!0(HE0D@"&8 2ZG2G*HL3ZT^\5 "
M3HTFNOI5)OAKN>:K\GM;6,ZMHT*P:;6S65YRL@+S5U<UXXSN*%=-6U<],V\[
M!:.]A@?)R$'"C4)-@*^"=K[%&[?@72!P3PKBA1IGV!+Q?^1</"Q_HYMJW6G6
MGU*N7TNV:7YKPN259LL/"_GP;;7<?OWVMGR2_R7IRM3H:?N&UH$:,T)-."?7
M^\P"I0 AA0 N,@$PYP7$C,*BH"XKA&?YIK9 5()'RX6,GK6\T::6/U):@>HW
MCBN#[]FT6QA><(X"KPM&@VBOT%UD5 6;)6B5W=4HK?*/39XPK6;T?CY?_E$=
MMJGE*GJUDJ+<1+\NU_H1G5OG%><WSIG/&@!M1+=_CEY3T]ZC?IP!*M+8[5X0
M@YZ_A270!'I:5WQ+-^JR$@C:XU4EU##>\GCUZE:7?-VW:',L6^/VT F1R+D,
MR^J+KV0_[",8H(C-,-S")3SV#?[2N8L6P%BD(=H\9=B']6I.U^L/JJFFT_3X
MJ5+P9SBGB:"T $4*8X"(B3EAD@,EN(@)Q85,K1(+KP\U-1NJDK33EVS7":NI
MT^%8;*L'8SNB\H-<8%(:#IHS 5W'PQ/9] PT*K%<5_B81"SN\-$*HLUO?IZQ
M3%&."0<QHYHM<@5-LRD&:*$*F% E!75J?7QAG*E11;/!CIY,_PWS]C<EE1_+
M1?FX?6P\X]_K>-2;>CSLH4X31 15.<B4Z3*->:IWQ+$ &>2(,!*30E*7RM4^
MH!ZA9/5+0&UYCGD[@*&/(X^;8^R$#-7]X@2%($TN]J.\8"^+$U7[6U:<7CZ,
MB;]\_F7Y)%>+JL325[G@S>YLOU=K\O8YP;&VY 1(I3 ^%J8 Y04'E!%*TB2!
M-'%*D[8=>&I<_>7/G_\<T:]5#ZOU3E8WHK &W8XY0D 9F$J^?([V,D>MT-'1
MP=;ULA/._.**E2?"L1YV5 9R!>.8DISO'YCI(+^:$3[)[^9,<_'UG*^P2+2%
MJ)(,Q'%BHLD0U99C@D".D20$(H*%4[:SQ9A38Z9&Y&@GLV.6@@7*=GSD&;O
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MA#/3NC58Z0$U.\H>BD5@.MZ)=1=IP7S&GIZJZRV\M//HD2-(3Y4Z#1(]<\U
MOTA33%6;DV:3VK20GJF<LUSF,> %5  1$@,,F00<8ER05.7$+3_F_#!3X[==
M)>#OM9B.3HWS4%JZ+FX&*/!'O,.FD? N:F3TZ(;HQ<"7L^'\(..Z%'H5/7$<
M]%\][+O_)+4IM.6;JN/&*VTH?97K62&Y0C"!@%/"]18N0X!4V2H4QIE^03BD
M3ENX<X-,[9L_D#%JA'3[\,]B:??9WXI0X(_>#1SG#[Y/>T^?^]DA1OW8^Y0\
M_M1[KQV<G+9\E _TQ_UV\VUIZJK=_RC7LP0Q'M,B 9(3O6W)(0,DU08Y9(7
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MA73KI6T-36\?[>M/&:^'MK5&!_VS[>\:&*9;%]MOWMU<,))@;8IQ9ARXF2*
MD"P&4F!(8E;0G#K5J#EX^M2HM0GE7"H32ONHMY=5)9IHO67_K8UCLTM<[@WC
MPVO^J/5R]/,>8FUGFPU&,#"WM@TS_)=,/JNQKW#6@V>/&ZMZ3JV30-2S%[EW
MI7ZSV&A+[6TYEZM7>C/W=;EZGG$%D8)9#E+"H;:C> $8@A3$C*1YH3(A,JN*
MZA>>/[6ONQ8QJF2,6B'M.U.?0[#_B_6 2^A-E!,D3MVI>Q0?U*#ZW/-&ZU'=
MHTRW377?96%S9DQ2()^QE&(EB "B( E *(D!QJE>K"F*91;G/&%.>=5.HT_M
M<Z^$JBH?U6DRCN6.W)"GJ4PASAA(&-=F$HQ30#-"0!H7BBE9,*:*F7X26[XX
M]ETI EH#EKE*K)JETXREL2;.TN8*-1FA;3*WM*5*_/$SE0Y0&SE-J1Y[DCE*
M![ ,35 Z?(CC<9P)$M96SI?/,RG2)"5$ ;T=C &2J0)4,@E(3%,&,:$XLUI9
M]H^<VG+QQ12*%77?>LM=7 <?JF(>DSP'6$!M2A.( 5,Y,:8T@;2 E%!NQ__#
M$!J'U&_#Z,I9XB"] _/GE_?O'MZ\CCX_W#^\^>SA'.M$QQY3N+FX)KOFASW/
M=1XUSH'5B>B[0ZG3OPPX]=\' YUW:58U4!NGY?U"?%D\59[+*KRY-([+Z@+S
M@J[O^:9\TG9X%3U4_\^N?PR7**.Q* #"3-MI"!- %46 I +3!,<02V;M.AA'
MYJD1Y>?MXR-=/1L;8A=3\>GSEW74ZA!M%WK2HR2&J"TX_$Z_6WIO]"2CC_I9
M5>R%_G.N?R^VO([>V/WADYQ7O=_?+=1R]5@!Z7 :/])[9.$7F=[;$9@L6X6C
M#XUU&9T)V*F4:E^<2.L=M8I'>\V;JRK=]Z]5I7@3T!G9M$5ZL;?#P>$SO;=D
M)*_1[FW1/%+O^%CUMO#NVU*?K;?5C T[;-NW9;5_6^JKMM7;0AL0_NS)ZS3N
M_/2ZKD8293S_U[C8'CC11AYZ@$'T&UW]0V[,XSKA%6WEL%^7BZ\/<O4XHW%2
M"(DYB$V^%4J*!) BC0'+"I((*1E,K-QS]D-.S1S95]US6 ?LP+58Y+U#%GB-
MWLM[&#G5*5UHI(Z,V-[Q=%@6O>,ZTJKF!5^W%<H)JMX%QNY)XZT/3IH=T+O;
MG3>W^=D]>M\)<E<:*T^5<:4B@ C6VTXN%""QWGM"5&0L@2I%U"DMUF[8J;&T
M3:? 6U"V.\;WCUU@NNX(W"61@P:Q87OY6.#DOY-/WZ OU<?' HB>+CXV=P\L
MMS.OYE-;I&<-V::SV2PF*<DISP$4>090EDA "P1!%B.64Y0H3*QB/=R&G1H-
M?;ZTT92UO([E>>R@M^,F_X"&/NXYEVNU3SRI&ROV8>I>S<<)(E_5?>P&';?:
MCQ,0)]5_W.X>1DLF/K7<5/5D]?[YU7)A&F7+!3==DT5<4!C+'"!(($"R* "%
M2H$BAZ* 62P9QBY<U#/6U BH(VIUG,6[PD8_O5]N9$0< Q[ZH+;C'D\ !B:<
M8^P.Y/3',A9@>**6OI%&Y1,+E8])Q.86]RC59K?V_.8'_V86DO?Z=9A1I#=)
M*3=EYS-30XQ+@!7*0(H(RZH2T=PZ3/7< %/CB%;&J!4R,E+:!ZJ>!;&?"'Q
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MY:OE8KV<EZ*V,Q="#[=N-Q ?U-MRH??X)9U_UK^I3H7VM3<(951AJ+?:!4,
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MJ81"5+R_KAVLE>25&=B*7GE?'4X$;*?"XB3')[(C.U<?]L[51NCHS0&H[X.
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MXWD^_'B'? OE9BL*6<Z:5KAORS6G\_^2=/5F(5Y79365$FF62)"K(@-ZHR\
M,04V<P0+1A.>"&P59-@WR-0LJT;.J!8T,I)&6M3HM74YS%Y(^^T97T %-C,&
M863-N38@G#D57$O^YZ_+I_^E;Z\/!/4_]N> O0\=A;ILU&H9Q>K:@<4-37BS
M_/!=DXFI.5X5<6A+G3U_T8RSYL8Q(<6;'Z9;7.,V3"65<1HG(,D1!ZB@'#"2
M"8!%KDQG-Q5+[N),&"3%U*C"*!&5C]^WQAQIZ^8ZUCH<-!MV#H?@& =FF5K^
MNVBG052I<!?ME+B+NFI$M1[>G;4WX>BKI.(@&<:MLW@+3"?%%V]ZV#!F_(VN
M_B$WE,WEOG-=0\(S 5.)*46 8<$ BJL:"(J#A*=2<8P43JW:.UF,-366VXO:
M:6/IQG)]R-IQF2>\ C-6!ZINT\I&4'^,9(&&)][I&VE4=K%0^9A#;&X9QA3O
MY:;N(O?K4G//$RWG9I2'92?0KRD5^[J<&^M@IKA$/$D1((H50--% A@R9?\X
M(46.TPSF3OSA+,'46,5D3,ZU[-%V71_TF",C+6@D:GFK]-7J KT&U&=&;ISC
M/D=V3!04^<#\9$!O6E;^9,3_4[13P$Q!-\2]T>$N:K3P1UZ# ?1$:>[CCTIT
M@^$YIK_A#QJ8X4I7YEAJ_5&NJH.N]K-"2<YEDDE )$_TUK$NQ8<!A@1E)$D8
MS&.G3-7SXTR-X!JQJD0@L9S/Z:I#98[!9Y>@M6,L#X %YJ560M,FJO9-!>"=
M*S#XRJF\,,JXN9']JI[D.%ZY?&A-N8V>XRK4M2J-IOEH5Z6[C8R=L4R)E&0Y
M* K3.Y<J"7"1$D RF4O)4B4+)W*P&71J3+&7N2DBYQ ]Y@2VWL *PI(,X#2/
MM>F9%MH(12E@ F(,J8)IFKFT+?$.]FBM2\JQ(+=C:-] !J;KS@M[WZ!G+,N?
M]D7X6Z$OKW,#JO;98^2M9I_%D"-7[+,'X;1>G\.]0QJBG]ENWS^:SJ;_DE46
M_.=O^H<JT,*T)8:()$!EAO6S) 64%2D0A8QQ@16!!;(A(L=QI\9%.RFK<B(N
M?<3MH>XGH(  OLQ1VR&DIG&(_MDU$,D!7I<6[D%@'JN]NS>X'=N_.X/6WQK>
M_G$CMHUWUO&PI;S[[0-K\M.Y::%B#@[>ZU?E@WI8T<6:<O/FO5Z:J)09EABR
ME%,@8BD $BH%),D@2'DN>)$1(8E;[?VK0T[-F#<25YV+C,R.!?.OXVMG3OI%
M+3"1'P 6_5[+Y[,#O348OLK77Q]PW#+UU@"<E*.WOW,8H^CG"?FH^<MTV*M^
M,..LF[3*),<QDR0%,1%ZNPH%!RQ/<Y#&F!>8Q'F:4A<RZ1UM:CRR%[8J6;8Q
M/U;7NW%*/\)V=.(-M\!,<@19]6-4B1H@<]4*%$^,TC_6J&1BI?8QC]C==&,&
M?+VI;=.]/RP^&6-HI?>V/]-UN?ZR6#)3L\>82546K2G3MN#EO*PK'],YW\ZK
M?WY:SN=OERL3F3O+B>1YC@J0I9IW$"(,4*02()10,M7_BKE36_F0PDZ-P [J
M9?V]R@'8[".WZCJ,RX4)[C&1I*;T="FJ:)_E8F!F?H@WP(XAIS*O@0FV6QN@
MUG1?7D%/]4[9J-+6!.?M]:V+"42'&M]%'9VCWXW64:-VB"(# 6?'=Y6"$**^
M3)F#@*!?K),0<LQAR]2]^._M>M/F_#;E ^C\(RW%NT63_%OYWMAQ!LDG69>9
M:2N0UE5%FRJCYH)*XUE1X")F" .48@*0Y JPA,> JXSFDD(:T]1EJ0HM\-26
MJ[;.:UWJ#YQ)8Y-U"6&WQ2GXO-LM4%.:S<"+U/W'=Z\L&D;OFD^9&FU5->^.
M3O[6GK& ][3^!!=WU#5H+/"/UZ'1QAVX92KUL^2OY9,4QS[!W0KZNESS^=(L
MG[,\)LQT$P IRQA 698#ENL?8T)E4H@42N6TLK@-/[5UHI8>5.)'9QSAG=)C
M>R4<-S1N\V.Y10F&>NA-AU? W3</@W#SM1UP&WQ< W\0,"<F^["GW'I6M"/H
M#ZHYFEC/<DS3/$XP8)@H@ 26@,8J 1"F&4JI%%@,JY=X;K2IT=HG^:1%W;6(
M.RA[_4=S>#/?'=YLEI%<;\I'4V\M4N8#-'>[TESO;+@>O-R(\6@G)]%>4@-T
M*VN(TXX>2+P?5YP;ZX7.&WK4OGQ@T'?3,+)Y9>0V%1HJNZY<_^/GYP?]I/L?
MY7H&A4),I#$@S'BV<I(" AG5_Z(%-,?*$#F=*_>,-36B.1 U,K)&1E0WZNC#
MUHXX/"$6F#8N@!7];N3T>$)J@88GQN@;:52^L%#YF"UL;AE8DZ%963MIL1*2
M-,5%;@[P,$"J((!"C@!-!$Z27+ $4Y=8[=,AIA8-64=F\Z:TR'POKV-%A5,L
M[2CA-H0",T%'N #YQ)=5]U6^X'2 <6L37%3PI/# Y2L#U%MIZX"^WDI3X>7A
MC^4,$H9D007 $"& 8%)ERN5 X3R3 C%%H--QB^/X4[,7]*N4>2RI<@9P2W8(
M!V-HZK HHU)W+C$'E'=U-2>MPD@%5"YC-T;IE#.C3Z=HRF5HG,JE]#QFX-9&
M[Y66CW)U8A U86602UADJ0)Y8DY2\E2;+9@K$&>4YSF6DE&GI+XKXTV-LEIQ
MHU/SW7&;<P5GRZV./_1";W<N Q<@@L\2%U\;GRNCC;OYL5/]9 -D>=O ^@'_
MW&JRVN<P-"\YX0HCC!A(I"H $BD#F&82R(Q"FDJ5)6Y1P.>'F1R'+%??EQI@
M&<E*WL&EERZ@:D<=MV,5F#%J 3LI20%XHA\$7V4#S@\R;M6 7D5/B@;T7STP
MQ<@X'-ZMUULI7F]-P%;M *^<Y>OZ]]V6ISPG,4$R WI?% .4Y04@6 E0("(4
M$4528*L6 \.&GQIG& &IGND3!\YMC8D'SHT=PX1#/##SU''-M811+7I4R]X$
M'ZWOVK\JFR[![GE-@Y#SE>/D-OBX^4Z#@#G)?1KVE*&^HF:U?RW9YF2M9JC@
MA=1V3X%QHBT@&0,:<P*H0APKE>$,(S=O4<]H4R.UO2$DM+2#S:!^A&U]1IYP
M"^XU:B$S@H8UCJPP\>8[ZAMK9.^1A=JG_B.;F]S+][]9;+0E=B_$RE3"K?_S
M:[F0<)8P#&-<9.8$V83N(0PH-]G9FE R@:G(E96?N7>4J3%&+6C4B'C7_B,R
MPD8?%@Y%_"\#VT\8WN *O7L:BI13*?^K2 RJY7_YJ:,5\[^J6+>:__6+!Y3<
M>?AC^?!MN5W3A;A?:'MDN]I(N6A3&2H39M>:6,]\L]K%:4'C-!: T00"A'&A
M60%F(%8J5KG(I+"S)X:+,#7*, $WT2X#I#;M6ZDC([9#\9AA<])/*.,@'9AM
MM/Q1JT"D-8A:%7J1OVZS^)H"AU(^P:=BI*H^H:;$K<;/36CVEOL9]N3Q*O_<
MI/E!$:#;GC1@Z:E+"S_0'[):QMYMY.-Z1A)$51HS@!.4 A3S&#"5") 4(DD5
MSVB<6%4YOSC"U!:.IIAV)63T>V4W57*ZL-59)"W6@UOQ"4SWP:!QX.E;(1J)
MAMVA<B/8/AAZ^?/LC>/18Y_<!^S7>^'0ZL7-(^^WFV]+O5-_;DIP\1BF65KD
M0$J, $J4-)VPI+:CE80Q%SSFTJUB\?F!IDMUT4[2Z^6ZW+"U.X?S@=AHY.<"
MUH":N/U(>*N#>V&8D6O?]BM[6N_VRO4#PQ1:FZH^^K_0]G->39[^UP?59._^
M2XK:A6"2S==-%K#Y;=MACR0D@R(#(C.9("R/ 3:YMCB!#,-4L5CF3G$.8>2<
M&BW5B?Z7RS5$?*^!8^1$H(FV([D)3%]H#^JU$@VUQ-$KBPET#^H("Z^OJ)!
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M5Y8VPBB6B.A-C.18K_\* 1I#"C*6,9SA3$)IY<(:,/;4UN;^HPI#N)7\4:6
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MH_9)U)O530-ZJ]_S?V[+E3E2^;A:<KE>/TC^;;&<+[\^_R:-13]3*4D)4Q!
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MB^!#U,B,C=PZZ1P_+57=]?;]T-%P9;.::%N"R/O98NDF_]_X:Q<Z">>9\58
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M*3XK+98KAJZY^6TVG=VLDM_*N%UOF".Z%/(5&E*&WM=Q449D( XR1;O,:Y]
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M"ERR%EB2&G/6:&W])NO[D;8?YG[H4GP?2FH6>ZL.=V^FKV>XIN@(,Q@IM.=
M*2]=X8T 1XB!&)C6"N-.IJN?'MV#KOU0]T,6\'M33WN0BR\OR\&T%4]=&\;%
M*&<B>9(,2-(2A,T4#!IM2%)D;EWFF;I^ ;>!JOW@]D,6^'M23>-@*]UOTRC*
M,O*9E9,@M"0SFD*QTIC1^&@PF;',U1[G\B11^T'MAR[<UU5,>TB[-M4?4CF[
M5-KKW48*=S]S$S-8SZ@S0H BWJXX-=1D"$(8A__C.9S'O^Y#[7[8_"%W LZL
MRF8[&GZ\O+AP\ZM9_CC^/!WG<7#3Y;,0"H=EC<XFXS*!#;/WDG"MLO=9?H&/
M&2\_C!?_.*&O8:4W5VHSW(,8*O4X?$S&W11DIDTY%@O,% 1F+1#S N7L6+9.
M9.;U7MU+#C FVZDYN7Q\7[A%J*NC>CS$I*)48(4)931X!N>H!<T8X<BB5+9Z
MJ7@C)<,>0:N$@D>5X-.%WE[OP)B$)-$&P)PH@O#9@P_9 >$JQF0X)V&OE.('
MZQU80Y>[VP4>(MAFVP5Z&2B//( )NINQ5TZ$!(_BX5(DZ11?GQC\)VX7>)!&
M]VH7>(AXAZ[FK_6^*\N$&!) &J5 !,Q',)"S0%RV,>?,!)5/134_2+O @[2T
MHUW@(2)K('%[9"*?7SU/T_ %8[_5S5T:6<@V)<A2,1"48A9!F 1KJ2<Q2DMI
M[CO:6*-IZ%GBU9Q*+TIH$E0WW%PO-F:C9II*8-%V\UT)V.0$D$ #4]0Z[6N'
MZ4_1U%BD<A("GH37">IH %YE$_3V ':Z[:Y&!64Y!\#5ADPP6@;WD@@LAZAS
M"(J:ZAN$FPAI#4BGZ'I#)X;3!-\ >J[S1N0CI/&W8KNO^= 9@Q99V@)DS!5%
M+!/L,]= <[+:28F.NZ?:P2-:&O-P-3%41?P-P&B#Q?Z$O[KJ=L*]4MHXX+;,
MS+1,ER$RR!G&ECZX&/)Z(ZH^8J8;<H:]FG.><.DHT;>(HL+(]2I+G% N9804
M/0>1J2_]MQ+$<KHG.J9,KNW0=I#3FEL[4N5/5ON.DW\+4+K.9Q^Q=..F%0T4
M10&!ENG:@@IPF-9B0&E,-BI2HZN7C7>3U!BDCE7].J0JZJ$%6'5;.MN8L<GD
M3&PJ9[W0:7-FP,O@@''E W,Y4%G=T^TBJ+' J1:DJNF@!4"MLW&W;1UMC$IB
M$J%"&?ND*<:5#GE291R>$<%Z4[L7['9JAKT^>HZPZ3C!MPBAN^//=&1*K38F
M 3G%5/KK"S".,HAEZT]8A:NB][#I'CV-.;DC=?X4E(Y5P ]^"N1M<HNTZ/W(
MQ\/7G/-\QPX&^S_,$9P11O$,/*<,@LARVI)3X%SPX(G12M4^G%C_,,?JVL9*
MV.]V"WMEXIE)Q 6KD&N))MX0"P9#1J (&AT,DSGDIV!UZ$N;/<EQ" 0>7I3I
M2>(#;^)_<-//JZS7!$Y)P"# 1>M!!(5IA#460HA!.4.TYC6.=-R^<!B(]*O+
MV:F";0$-UUE 9MH(J3,D# ++F+I8YHLHP"33,)6Y,72O:^O[X&'H7?PCE;6N
M[B,D-_31KO&T7!"]J9B3F$CD!K23J6!=@DV60@Y<)?Q@:)7>J@]>.K#2CU'9
MK(;\AE;\ZF;P->'42ND2X:#1.8*P$D-WCD;.Z8QNDL:<28T9?0]>.MQPKBJ*
M/UI^0Y_(VL_YW:5U1F:5K4J0G-+(FT/>)(9-.5J!+#N+@JL8/AY6+JF.C[/$
M![WK86B,W5[N>/>UZT<P_?QL&E>3VE.7 98>&*.4 Z&!!%"L= WF)@':2 5:
M,LF,T=&E_9I#[/6ZYN/-(U4]ZU7N/W@]Y?IL2>\%E;7WG+.BLHO%_DLJSA@5
MG69 E'8@LB?@(Y6@*+/X=^3Q![@?<V"#5VDU$X$8=.\4<X0D?*DA&*#9,8=K
M2+F\7T&E;F_=(<HIAZC_R':ZATA[:+^W=U?7J"3G23H@VB-343B4FQ20,O$"
M^?*,[^?ZJK;3[6T?LV<$U9-UL^[NM[1\.ULLWJ=YUSG@UC6\F%U\O5Q>WY9\
M[A;%2<27X\DEBF7M=TYP@A7?7L<U]B6.2@[SIN?@S;ONT!X]-[%<G*:&@PC4
M@/>$@N8Y&<P8.?.UCS=LH^74/5,4YYLI*B05H=XR:&1R5NL )&3,A+5%!G5(
MN/945%S@_U+M>& C(<-ZS"KZ7]\C/5W@#>RT/V3B&Z[ DD5_FI7F8[-IURK@
MRVR"VEETJW>D%:%&,P;,DV*\RV09J2)$J02/WO)D:S=S.)#$89%6 10[8597
M0S\4 *_=QHADJA(G#B)WI4=/.2)CG0>O># \1LYE[?,?!Q,Y;'@W) B/T=+0
M:<*Z>^@6TK/;0.7=\DN:OQPOPF2VN+SG/+Q1+"FF$2]E?G)4!(Q*I%PPI9ZY
M(/8=1WW<^X?%6%67>BXM-&#O_I[&G[\@.\^^I;G[G&[:KJ_ZC[V[7"Z6&"&C
M&%;&G*<H79048BY'K5+0F&P[ A'3;JM]D#KNM0-X@*T[B, !B[CG@,OL7+H[
M&IA(B9_U"\UK@3[B<F1CU%XY6]9W:40; QC&*&2M6>1,"+(^<:$O<&XC<< ]
MJW;@645_@P+TOD"WR/-6@)9[[EC$51<(00$F"E8F#\1RPZR-7.ZYB;7?^X:]
M>]>;$ZXIY0:<[L;%.')46A&B!<(,12%Q%)?/ 3.ED'1,BFM5N_/%1D*&=Z)5
MU3VK+?L& 723Y0COM+8B0G(\@J!H/4WF%+RCRM%8!G'5OG.WA93A7=TY072,
M_'^XO83WLR4^?^PFDZN.W_&W]#&%R_EX.4Z+5]_#Y#*F6'1QMOV%2A3UN^?0
MA]CZWH?(6@3/LP=:3JT)+S0X@TZ;!"=3=B*;5+LE>%_[$'<M;)^A%N)6#;Q&
M#=S;'GJ7UPE:G>?**AO"T58DIC @)J:<X10!_P@<O](\LMH;&'4Y:'3GXQ#$
M;9\'?G85-Q +G,CS\ZO-#^B.NZ=H,2>S&2RR#B)Q M;FTH>%!N)#$(_.(9Q^
M?*<_=EH987Y^E*[WQ&D$,LVNGM*V\>8>?3D+J9B#LE-51C!D,$1&\")1PD3D
M6>BS+($[F@8^[M4*>/8"]9&:''P+",/BV55*F+?\-IO>?-5M;+W[VDU"O;E:
MH#@M'60A.&7+]FH 8RP'4]H_6(,1M-VSOK3G&UL$W[%*GO4M\08,W-_=?.ZF
M-[WS<M(2B4_ ,^:F0B0%7K-R9#)*82P)-M2V9@\(&/B<81_H.5W0#:#D0\(X
M?!Q*7;X@_O?I>+GX\/'W&V:BL=(I#U:7$:2><K#&"UP!5B>"#-6O3.XD:-@J
M=Z\HJJ>()O;P3@P6WM[>>:'$TZ"9 9$3_D&$!!."!FF%)B3)(%SM*=FU:!_6
MYOUYTH[CP-" <3V1[]6THU$6J4SF-<"C=Q@;,PG>$&2:\ZRBR(2YVMO;50AO
M,6#L&W-U@7\$ )K=7'CMQO-NXMROR963!MV,\]M:^>V_XL?N6N+839XM%FFY
M<-/X=NS\>-*)[OJ7XVSZH8AS?GW(Y93.2.<AK,Y6PP!"K+3C<$O;W5F3NQ.A
M.4GII<F@5$2 6PR>'+H;D,E;[XA7W-<^7;:+GE/-_NVS5\)_ME'X[^Z$O\H\
MYP]TL7*ZAFM+LB+@G-%H>[+%L _C2Z,QZ724<J)K9VW5B!_6_%?#V[I)'T:Y
M#00SMXP_O[K]^#_':8Y$?;EZF[ZER:I),C'91&%*PUE;QMMH\,H2=%;6*N*"
M-H'W!=F=E#6"Q_/"9AMXZ^FP)63>]XJ/^;M.TIUBVD=J( 2#'*;HP7/+@!DC
MG W6DNJ]7P\BL!&<5D3(-A!65U=+6'PSQ;A^T4F,7A=QHF32)%(R"5J:*!-<
MPR%E=#LV)>,8SZQV*6,'.8W@K#X(ML'M1(TT"BYVS8I)@9M$ S"!@A$ENK'6
M:; ZE8OLGFI5^^3.#G*&+7T-"ZYC--(HN/A- SM)O?)20W9EL3!+P;J4@#$5
MN6,Y9E.[0>X.<H;=!1@67,=HI"5P/;^Z)[;7\_3/RS0-5ZL6FYYS:\HH]\QT
MZ9CF,2LC$@S+CGHF2.*]!6;;R6K$DK62-E317DN W,30]=I5PB(O+H.19?I8
MDB@RCR*C5'E!B%2TO^K+=K(:B=MJ06&/Y. 4O30*M<7MBKVVYTPPDP6C('6F
M&(GZ -ZQ!!B@^D0I=3G7/G"Y#UV-@*T6&/;)1$_13 MHNZG\OYDNEO/+PE*W
M*)7V3B>'2Y%GCO8?/8$GBH.C05K./:&Q]B[B%E(:"=^&]:@5M-0 V#[-W721
MRT3[:?R8YM_&H?08S1NX6Y0)58O-_W0S[%,0D<OV*J=2EBO'*,J DO59&V6U
MHXK43C)JTC^PJ:P!J%DCVFT V;_.INGJ5S?_1UJ^OIS&FS.@) G/NL'8C$7D
M(DMT!DFB=$/(04IN6*J,T<V4#(NVX9 QJZZF!L#VZI^7X^75W0&1:RZ0&.68
M1=J%+,<)10*O! =&8\R.>PQ*:KOLS90,FP,W [8*:FH ;#4"H+=WIZ.4*".Z
M(Q#A,#J6Y? K%10"TU9;%PC-O15M:C P[/#%1H+1P1#1P')8\;SAN,CM:1')
MDPXJ9H@V$O0HFH(S3J,%888QZS#'K.WSGR2JD;S\_(!9/V!957L-P/&%6WQ!
M<96_BKOYYB8/MA?N&!S)8"G#-0[<9U;ZGP?P*0O(/"52&AM:4GO#;V_B!C[Z
M6Q<4ZR-)>]%0 ]!;#V]>?_MM/#+4(:640)0TEGVF<M\M$6".*XGI(V>J=I/3
M370,?'VL5T"=+/<&L+-50J,LK-22":!<E-EGAF!,XG$YY,QM]I:J7'T0R#9B
M!KX^UBN*ZFC@>"C-EFY2!4KW0HE=LM(J,:^U D5#&="6/%@O'$B78\: (HGJ
ME9C]*/OQ-XSKA&8]Z+$!0W>/JQ<HLE)FO>&$4^YDQM65$^=0;F2")RRC['A2
MSFL3:.U4>#LUPT9@?>A^.[Q.4403EV6?7RYPR2T6+V87?CSMM/1BUHW%*9./
M9M/%.'9CV\I]H1775]<\CQ 2B2K'0*',,,94!AS1'K00@D9<HSS5OJ%]/+7-
M@/(DQ,P&45Y;M@]]1EB3H0P,Q>@Y.H=R03AAWF.-D?BE-\8Y8D3U+LP["1K6
M#Y_7 IZHC@:P=<0JNF-Z9$(0,H@(E&D,;(V58(2,$#-^4ZD47/5:R$D$-V,(
M3P7.Z;;P2"T.W:?IWL"1Z_XOMQR-!&<N)^DAFVA*@UE,N&P2D*TWF(>%B.)\
MB,8MK9EVO*09ZU8)056%VH ]VVW_1\0KZFDNPP83)E8N!/#*"? YN^ MX[9Z
MV+:;HF%+(^?UEJ<JI%J1Y+P]%MXL%I=EX//BU?<T#^,%AL%?RL1[--FWO^BF
M\4,*$[=8='.%N_9GL[RZ>;!Q5[VOO@M]$GN.7@QG$_8Y^C,$89SA0H&CI1@=
M,3W"%>&!NJ!#4:EPO1V$[[,_P^[26%<+^WTZ\XLT_U8VV;MK.&6 +"IF,N[T
MM=I\9]X&9PB'J*-&^3@++CBT2U$9AVF<8Z8W^53BH9$-Y5/1M_5HPQ"J;B ,
MN7==XZ[Z4"Q.=S@4O9SE(5 49=D/$#F#Y]$"___9>[,FMXYD3?"OC,V[=\6^
MF/4+BQ*KU4,M1E)5<Y]@L7B0F,H$V$ F)=Y?/QX <M^PQ,$)I.K6-8F;>,+=
MO_#PW85PTNB"0@S6,_K8@3H!X2A8>;KEZD#!]83"PSE[GQV;LCY>;$XI99#9
M,5#51HQ!&+"1*YDEMY8/UJ Z%%&=W(;# 3B<3FZ AHX#"9OZ4L5#(*-90S"J
M@"HN@BM*@V)80F0RL2TG/;_XJ4X0UP<NM@Q,["&D\2'W:$AN0XG17K,4.$A9
M.]95+A"L0V!&^"A-L+CEXKIG/]-)EKQ'J+42SNMZ^&^*$@2/,3'A(-"_0246
MP4N)X*/G.@5/+]!@)><-Z7@U-Z"AL3L63'JZ*NO"G3W)?QO.TN79ZH<?YF=G
M[^:+/\(B3^@-RCZA!6YRW>:*Q ;M/7"KBW=H71EN.-  ]+P:.V5/M#[?OS$>
M='JZ1K>BLO^:7GQY0/SR+O7+#_=*X#9O^NKOFO 8LG.*@72J*K>HZ[0=,GHT
M]]$Q9;%Y;<,@A'1R<4;'Z19S((X+FKUOSE=<3.?YXT587(QZ?Y[@Q#_(%JY+
M+7^:K4>>_S2[FG$^$8D'%"6!,*4.X0UDRF9?0'!O9$#,40P6LAF:N$YLN]=R
MSX8%UPF_6D\PYK?+1?H2EKC\&,YP>9V*_(@7%V?K/.5$2VM$C@HLKZ6'"1.X
M2 +E.A0OD1=MCS$%=U BNQHT\VIO86.P]70;?\&+'^A]_1;J_HZ5&&^%_;84
MYSTFWF:+35YXR57=((>@='3@F(_ .*84@W;:#;;V8%C2NNJJ[_#F=02LW>^;
M7]^W&7X.%Y@_C?X(/F^%,UVT+(Z#%XETC^8!H@\)I Q::<P.A\MQ']UUTW_=
M*S4:: YTW7Z<Y6-7!/Y24UA5\S0OWWOX-P]8:_<"&<<HC/,^^>QD!*>4!Q6=
M@B!9@<R]BU&7F!(?2KD,4!A'CM2"&(P_X/K?Y% ]UIO.C>8J2*Q[*.M&M&S)
MN6(9"C+.Z9=X1-:8ZNU.UDEXZU"DW-=Q XCET%?_\"3T'JTBMR[_2J57/M<%
M>1_H1).HC"5.&F#)Q55O.S@G+22+)M [HGG*+^FT(0[622BH%29'EUVW"P[K
M0)@PR^MAA-7LN+F>=TV/>=G\T7LC9 YXC)M]N\US/0PK&CWHC\_ON:DV=CD;
M;QU$630HN@H0N5=@;$Z:?"JM=>M:[N=/-,Q$J3<7;\E\^DY7=FWQ2F50BI+!
METJVRA&\$0P$8@X^<<MT:TMFJX.-^Z0WQ,IV8Z0.$4L7HPQNUI@_3N"M=D_,
M=<:1LV"2%*"\+."5D: 3.5C1,YUDZYNV_>G&?;8'Q-U  NH"?)64>^0\(/?N
M+]SZDY,D5/&UI50*)*=?8@&'7@.ST;%DI,$RQ$"]O0\\;GIC8-5X'#%VV\GY
MC 55-X;/9Y74>7GL]X<Q([?]ZN &Y%[D'\=T%(9+R1A"<)GT9> ,8F"&G*IL
M392\)-5Z5N*PIN/'] 7SY1G^6OX7GN5/\Y_#1>7RK<##NO93%6.%]+4'Q"$H
M9BV$>@,9YT+9+%R6K1=;;GFTKLW'7?!R7T<.(9H>4J]/K+%@7'I7[6 FBR<R
M5((@B%5%)5WKZ8-2S8N%#MA>,QBB!A'[EKMI=I%!!U!JNC; <BV=\0)8(E:J
M8 ,XIPU8&YGBD3&ZL(WQ]_IWT^P$J"%WT^PBW0Z0_?O'?\S);9JM&/D9B:AJ
M]L2+AYLIE&!99 8<I0+EK*:GAF6P+B&BU-:JUD&=;<_VBO;7[(2>^1%$V0%$
MW\X77^>+<(&/$I.R0<4X0HR<DW-H(SCF%.3  OJ,LOTNNF</](KVVQP"QG9"
MZP"!3RSKL61:&RD]:,,8*!_KVIZ$D!+W3!$E*;4>O'7 3J7!HC?=8*Z!F#H
MV\MF^?OK3J^L2DXN%$!>%Y1Y)B 652"4X&QMX?6L]>#R'8XWKBH\AGLSE*S&
M[NK_^&6^N/B$B_/'HF(W.?_L H^)0]U 0G9$W7\F&()4)IHHK1/W!P\^42:Q
MU>=Z=Y;WE/1\4+9WH,_N&@!WN??FG B>_C?FM_/EQ9M"'WUS=C;_HQ;]OYLO
MWM)AIQ>U*V>2H]+)FP0^8DT!:*Q[)QB@T*5HXC#'UN7M+<X]#F:'PM)\9,%V
ML%#DJ<O_)J7+\UJ.C/GWN@%C_GE6J?]?\[-,QE!M+IM(DUU6+ (++H$JB8$O
M20)9(<EX)[1KOMUP_]..\W0?";A'$F('NG<_2E<7D^OH/,^"&$S742$&,I L
M4:HY1V&4SSEU =>M]6QS!ZAKN.XLQ'Z:=YXB^+H =>)<M)(+ SR@)[JL ,^-
M@8 A:N<2RB*.!,[K0XW3IS8R!O<3R=CNS:-LNFVQ7#-T$I(1Z$*"D*(CLAC=
M(!M(ZRO-9+ *"V=;^3C;?W.<[JR!@30DWT>T"Y\FZT5;HBKH&WJU%MI[H4%S
M%>OUX>"<51"S"DE9E7(6^^-LM\-L!4#S:@ XH*1Z5'37*ON&)!5"*)8SX"*8
M&B'-=-FX@F""U,5D1+9=O\MVW]L*7_:UX.M ?H\-H??SV><7&5:\-,K:"#)(
M#DJ6 HXG3=JZ,*+,&-3;::]MOM9[6+E!(+ YTSOP11_K,ZQO_L2AS*R2D%,D
M.B)+$(6N1;9).\Z]UZ'U5M^GSC)BO*Z]R+=8#;TS_\<VM1X0\<]??KKU@/]C
M04]U?<7#67W#KQ[OOV.9+_!3^'-BG16Z$ .QF (J2P^N> 3M,_K,$Y/(MU)4
M!QYDQ/C:8$ [NH!Z5&I$[JVNE^3IH]QXL(Z1%T,W";QD9%+$Z&.=Q%E<ZSC%
M\R<:,5!V? 6WORPZ0-:;;V%Z5KGT;KZHT[#N9EON>,VKJ2,3::43A6M(RM<Y
M(U*!]TC.B2]&%:[(C&U=H+?K&4<,D0V.OD'EU4'FZP7ZGE7Q-^I=!(;.T/W+
M7-0MQ60;Q^1978W'F(DZY>9)L"8''S$F-S9R!Y!LA^KU=M/7;?(G,=%-K$5!
M0H<(RB5+!DFN5DDBNYFXK7+K(K]MSS9BG.[HH&PBGU$;B[>+@%\Q=F*$]4*)
M"$;4LC2! KPQ'+3Q16)(+N3]8W*/?G+$L-RP/LDP3!_;%=X_EGU-+KE3W"DF
MP0F4H(RA'T5#A/.@,*6@98C[8VRGLVP%/O=:P#><F,8.%S\; ;^F2*/07(@$
M&.D?RA=&^MH1;4D202YH%;>K'-WJ<UMAR[\2;!W&[![A<T=53RSSC%E=P KR
MG936&7QP#D*R.LH<]:V]W8>]B^-V51PES]"6W2?T(E[IV(DOQ<9(URZ8A#6;
MJ\$%P0!-4-+)9# ? *?G/S[N9.OQ -90)!UXDH^1.%&2::Z(389)77,J!7RI
M [>R9EE[%9)H[34^=HYQ!ST/C;!F$CC%.9!;SJZ9W(LA'FMX#WVWE_$]]UEP
M/<#G;T/(Y0KT]4AKN \S1.GI[PS.]RU)/,Z@I*@=SYF\(8R:;-I0:VD4IY_Z
MC"YYB?I^Z4GG@Y*>TI4U[K7Y5?I9G4L_G?TZP__"L/@%KT<]DO5V.2.NJ.*S
M209\DM5E3 X\UL97'M$*YHIJ7E/1XMQ=CUC:!6G;UD\/)M0.#*/M:%XUAQ')
MG[XLYI>?O[R;?EM1OWQ(OM3<26'J'+Y"?JPB8\'%$,A.,*H$0[XR:SU3L3$)
M70\"'1[>PXBZ8Z1/$@:FHB*KDZ4ZE<T$\-8Q<%F21Q.*%;;U%+^GSM+UA,\A
ML+<3\[L=WOG(>/SEFYRG]0=U?D:9+\Y7OWJ E;GS-]I8F(>1ULBZ?.00A-/5
M9J(WB9"Z7!WG&JC<%<%%=$"X).TDC(7:^ 1&.L^4UM&RUGWHNYVPW?21J^_>
M^LCR[]]O_6P]/H/SF,FG#A"4K-%E;S9Y?R^DU#%;WUS%[7K&<:W* 1'V]#B2
M 837P3O["%6KX7]91I1&*]+T.A(9R8-#PZ'P@HSI9(QOO43HB:/T,J1D"/G/
MVPNC4TS5'RX0-R.I"A<2F3-08KV1'!/$D"T4;935$J-)K>=UOGBH/E3:0:+?
M D[[RV'L/.;_>O_FAW 1/GY?UNCV9A"99#9HFY&\&K.:8T]>C=$.0@XF.\TQ
M1O>2K?;DW]X?(@Z0WKPE*SM0,N^FL^D%OB>'-_]$4IE]GI+V7:^__/OWG\/_
M-U^\/0O$O7J)O%'>:%D M5+DMM35:URM9N%Q)0.:D)MO\MW^>+TTWQWA@1M*
M:'WC\8:P7\+YU>6-,6*)=>>]C>1*.W+-Z?HIB%*0A:I,B,T76>UXQ-&G4@\#
ME>TA>;#<.H#E#_@-S^9?ZRR9]&4V/YM__OYA^OG+Q976+\6C"]:!\34L6"PG
M2\.0I6%%Q)Q-5*QUB\L+1^H6=H?#X<&TMW:RZ0!JGQ8AXWE8_/OJ_!&%(@LU
M0QV-1.>/")[G",[K4%SA2=VOMVXQE?_.&49>[WE$,!W$_0[0\XCU\?ZZE,6C
M\D*1?6M2Q7^-0$?R?*"8R+GU+)?2.B+VW'EZ*6,<)R2QGU@Z@MC=O;@WVW"O
MIF[3R?BDY"(QF3I!1-8Y;UJ#4\% L.1XD_=HC6\]K&^7\W7GF^Z)BB?@UEQ$
M?<+O%O\^X*I\LU8(+R>"/'=>F_ZRY7+MBP>E$F@5I$@B^9);;^S:_G3COJG'
MA%X+\70 O'_,Y_F/Z=G9)'&/.G-/5H4F[RAZ#]Z1?2D+UPH-.E=:S[:_^O:X
M3^9@H-F+M1U XA&&_':Y2%_"$G];3!/6T=)I)9XK"G_\\RO6?9Z?PI\_D/F1
M+E:V[+JV)!/JN4@.7%KU4-&/@L=52U41/#%4::@4;A,"QNT:&%RC'5_(8^<*
M[GE;/V-87BZP+D7Y:?;U\N+#_'LXN_C^@33Z1&:M;#2Z=M5G4(QN;Y1*@_#:
MQ4P&<A+;C2_:_IOCMA TA]N0'.\<2#],EZE>CA5=)0:%M6W>!-+^2KHZ],M'
MX*$8)Y,6.C1!TNV/CC.O8%0H[<WS;EM2'JO:^GAY?AX6W^?EITS?F);IPQ#2
M)AN8P^VBEQ]6^\&:UJVU.,IPY6W-&35.%9SQY$\4Z\&((D ):2#&E$!8F3,*
MPS$>P^/KJ K.NN)"\>33UTG5B@QIB$P6<,Q[7J0R*;2N37_557"[(.S@*KA=
MA->!.[1+LC%KH[6(#%(1NI*FP*L4@)ZT) -+Q,O6W5&MBPGZJ9;;"2<'%!/L
M(K2^\?AHXDCD[%CV&5CR"I01$D(* C0QT5DRN$+SS3*OMIA@)Z@<6$RPB]PZ
M@.7;R^7%_!P7JV!HO=%?IE^OTHV"J:(X5^!*'1IF))G[,D=@5D7CF7<JMRX8
M?N8XW<+M<!C<WPK<2"8=P.NE>H@42[8F<V JT&-1M]MY%>N+H25CSCC1?$51
MBUJ5;LH+#H%92]ET +4'U1(*4\G9%(B.,U Y%_"HL<[H,<74Q8FNM;>Q5ZW*
M8"F28X+I(.YW@)XGB_6+45P93BZ6)9[DP"%DDR&[G 3/,GLYE!._3]-,/S7%
MA[@!+831*:;NEOMS6SL_D@19? %5Z'Z0.9J R6R#+HR\^",409U$T\PNHM^Y
M:687.8R=OWBTTR,('8PA'<N9YW4]NP<G1'VU;4S""1/RO8GAKZAI9B?IO=@T
MLPLK^U0R-PD;IXLK3%G04M$C[-"!RXJ#EU'Y@.0$'^/UNC[/B159-G["]A-+
M!Q![QHZ\GJ-:4WAG\YK5FP2KN=:\[J,,1%W "$Z[N@+:&%+<2J9XQ#:81T[8
MG3[;$QG;1ZH.%5/7(/Q]B>7R[/VTX(1L <M<UF"8("M!10D^)@8"@P\Q!2V:
M-R%O<ZZ.RRN' =R>(CG-=/Z=:N;?PC2'6?YM,?]&O*XC6M:U5LMYN9>YGN7W
MTQ"G9^NA3\OEY3GF#]=S7L/%IR\X7?RXO)B>URK5FQL\4"7 .%0<H8B@ _&,
M4W\0E([!B%1'Q*K:2Z[ (T<H+B*6C"S&UJ7!G=<?,)6"$T4!ECKC7?H,WF0$
M+A+]ADF%N]9%K:^Z_F 7A!U<?["+\#JP5YX*9& NG/ZT!*4+TGNH)$1R*>MJ
MXU1LM$6;8X1\3J^N8"?Y;QE0W$48G6+J;BB$F:R=E0&B")8L>Y4@.#1@;8["
M%6&SED= UPD$%'<2_<X!Q5WDT&5 L?H%PF@-(FL!*I*?Z)CTD!$5M\ZJS%]O
M0'$GZ;T84-R%E7TJF1MWT0MN,R,?KKC@:P6XIQ=?: B8$_',.>6["RCVDQ-K
M_(3M)Y8.(/9;^%YK_Y>?YIN+=T4<+E?;,R<V,F<S5V"Q!JCJAA/O=9UTFX34
M4O,46R] ?>E,W>FL/:4_'U 4'4!KIVYS@3J*>A^%TZ8.YQ 0> D@?9"U-M!%
MV3I2W7P@P$A=V0= ;C 1=;#_^1':;H)&5^TLX4$;RYO'HDUOURO9UW]R$C)3
M5HD 125Z.Z)F$++D8(7S&&7*%H>:WMJ<F)X[Q]L">P3A]ZF$]V;$369A.8G2
MH&'>@U")@1*<+'29/)0H:]]+E%SV? =ND=)S>WHG-V!?P;\R_&\4P:W?F.AD
M?32Y+FH@'BC&.''#6/",,\&\\2&W+IH>EJ*>N^<[N0T'PF#W2^'7EV*&GVM^
MZP2NQ:\77VK1ND)TWGK0,I&[4A//COD(F6=K,0;)XE#A]0')ZGDF0+<79'=
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MV7CYC..@L#4VGK7)&@NJ=R#6ZUN#BA_H62$_.U4?VZZ*U(4!8U5EIB!3P^D
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M&HCVT5S-07SN$BU7;A6*9(NKO86)G)[@);$F1H@Y8#%"R2!;VSY/G:43)7.
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M<\@BF#)IHTHL$' X#?*CQ9UTTHXA.J4\,(QYI5>CXL#)1,#Z1@VN5&)N+C9
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M,*  3!H!0&"57#!92=EYCK8W[8V4M2KRJ_Z"P'> 3THM*.VA!B[) Q2X8T
MDSNZSE"7]Y51Q%,EIQS+8TS'V0F\SDB31XE4<PZMLXGR-$DW, T8_%.T0_$9
MR("D6_>\E?48 4RY+L#R2YH8WEQ\N0"&3R2=-T7L%M%UNM@<'W__GV*E (F1
M_7[J0.:;5Z\&%,O^]0"KX3];S)PU%UU3R;(=;6?%QEGMR>9RL?)TUR\,6VL4
M:R=/-_^_PU:+Y^??P=G38KU1WVO8DEM?O\:01I/0^%VNEEMTR*#?K"8/I++Y
MS@+NAJU,JN2O)PB'DP[L.5=JR2]T3BKEO'O998GY;!F^$&$9X\OM9;KG8GA$
M_Z#U>#_?%!ZO(ZJW;^I >NYS\_6 C3CWQ/0W9/S/-<WHT[%K FN(!ZQDL7@O
M*1TO-P4O:97;$\%#<KTLZ;?^X>KO]?Y.ZWWTT9_3PE*W5H>WJ,"W<G"\G822
M$ST[9-:C=R 3Y5\";?H?8Z9\ZZW(%5TXX51>=:$CX(S4;G?YRHN4V:=_K=.]
M8'KU/U!+ P04    " "$@JI6$ER;/JL&  ">(@  '    &-D;F$M,C R,S S
M,S%X,3!Q>&5X>#,R,2YH=&WM6NM3VS@0_WY_Q3;,M3"3^)6$1T*9"4F8YH97
M(5S;3S>*+6,=CN639$+NK[^59 /AT7)<CT>GG4ZPK=5J'S^MUKO>?#,XZ(^_
M' XA4=,4#D^V=T=]J#5<]U.S[[J#\0 ^C/=VH>5X/HP%R213C&<D==WA?@UJ
MB5)YQW5GLYDS:SI<G+KC(U>S:KDIYY(ZD8IJ6YOZ"?Y2$FW]LOFFT8 !#XLI
MS12$@A)%(R@DRT[A4T3E&30:)56?YW/!3A,%@1<TX1,79^R<V''%5$JW*CZ;
MKKW?=,TBFQ,>S;<V(W8.+'I?8VN^O['AA['G3UJMF) )75^-Z!II!P'%&_J'
MCT*Z2&[G2#5/Z?O:E&6-A.KU.ZW 66OGJCMCD4HZON?]6C.D6YLQSQ2N)W"^
MO;1L;C,CXA3Y*9[C=.2DZ(5JD)2=9AVC8LVRJLA#GG+16?+,OZX>:<1DRM)Y
MY]V83:F$?3J#(SXEV;NZ1+<T)!4LMH22_4WM(N9V9E580SXIRVBEDA]H)887
M"9LP!<W \1<U>)CL(1J?BF<2OC\\&H]V1OW>>'2P#P<[<'@TVN^/#GN[,/P\
M[)^,1[\/\3%2#(^@MS^X-KXSVN_A)5Y5XX<G1\<GO?TQC _N-<1+4=Q?AQ/G
MV.D[<#SL&^7]9MNK0^\8>H.#P_%P\*K4J938\%:U%\<?AG#<.]KN[0^/&P>?
M=X=?H-<?ZY' \X)_AU*61:A9I[F:__\[K'6G<J,,0IYE--2!$V9,): 2"A\+
M(M#BZ1R.:,Z% AS<X6(*OM?X"#R&/A%T<%&'418ZL*RGO%U:#P*OV^?3G&1S
M<^=W5R#FPG#,43X> 46-(]@C(DS>+OFK7K?IUVW\)!)BEN+@I1#'-"P$1G34
MEF01#"_"A&2G% /O=,JDU +C?TT9892&A J*DET7Q@I?R5(WM 5*("2B"I?2
M4R9S"*E0+)[7(2^$+ AZ07&XAN+2.A;%*">)>*Z/A>OD%9%&"4IAY"=B0C(J
M&P<7*9U#+U1Z1*.DKF<@"1-PEO$9:HUJJ82@J.WU[H,QE),HPH.ID=(8P1O<
M0%7C&6&U[*]46CS]\HMV"5I.LZ4-,4:7E&B.BQ2A'2)44XVN2\0)^E?!!-5G
MMM2^NO+\,ED!1++?7HY6+OU[A<]+;)9.]C>:+0N5J4$\^G6CJU'\+=].N%)\
M:O5\1>X.7J:[68;A9TJ,#S',*<+TKF<V:%18($S'N5Q0J=U>U\,D30&GH30D
M15#(''$@;?B(64:R4#]'AI')-TUT0JHBM:CA&.O,FK)"2AD4_X/ST;&*3%):
MS9AP@6&L@19.22YII[KH1DSF*9EW6&;L9"9U%_GK5/%<A[R0I.4!:X!DA\LL
M<F/#\8- )Y(*LT<550N7.:9C<DQ71;?'FHZ_MG;OJ.?XCQQK-Q_']:NRKCKK
M7ON[L_6;CM?>^/[2OC;+KC^(K6L09E&&.):X5=[7FK5J0KF].T%^ ?YB?J]W
M_$TH6Q0_?2 T;UW;\\43O%3]*UIY6J?:@TCO,(!-C%^4"=XNM=:ZTOQBB,6P
M0]((CTJJ>!WVMK>/G\PV/\'QLL'1FR1,)O0,?L-C><$H#PP(#[!.>4R:4S1'
M;7G*(JC4_-Y\7H<+GFY/_O3/8_SS%-OBAXTOAYB&,_TZ9'+R?L)HC.]F^)ZF
MV#F%@SAF^*[_;&C_8<UN#;US^6ITEZ%_HM?<:HX=IG"U\ &&73X4#$V:HTUO
MP7CE)XZ?U &],.1%IG0G2 >76VA?>=%PORL;QN/RF0+&@"AJDF'8(W/P/5L#
M?N6 ?G4F-AAU38GH\1V+.]J++[_MT8.R \ %,^FPK=0Q"3/!E*(9"H3V,TW@
MLB@<P61>%81MZT*7^A,B84*1/A?\G.G>AJWL5R4_$RIF+$V1"CF5%4CD=),F
M+D2F\[Z*@5WBJL1L[^_M@PA@2FJAXQB*')]HJ:E4SFOSS%@[P39D<!O9\FH8
M&D/I0OM5X;8.2)AQ!1%%/T5E\TBWF_)"Y%S2ZQ5\:SU__1&E^X6&TG7BR[:2
M9<Y%^1?)Q8Q)"K*8_(G+5XA(&9FPE*FY%8*@::UP=51#@$QTU9DI#912)3QY
M.*HBS#<(B!E!8RIH%NK"-C+5T$&M]8%DFEHW-;M2J'E=H3J4+;D%S9=G"=62
MPY1$%&5 0U)-2&)5<C9-MM)^U@4KZ -1EL=U8H*#6J93FE&!6^I*?.W%%)<J
M"*ZV4(B719B42MP/U1N?.:!S3=V](VA*],*W/GRX>BTT!6_O:@J9X+MAH6Y/
M^<:W$N6O_7+#?$.R]0]02P,$%     @ A(*J5N!XRV J#P  N%4  !T   !C
M9&YA+3(P,C,P,S,Q>#$P>'%X97AX,3 R+FAT;>U<;7/;-A+^?K\"=:YMTJ%>
M+;_)KF=L2TF=<VR/)#>73S<0"4E(*((%0"NZ7W^["Y(2)3IU>FTM:]*9*A9!
M HM]?7:QU,EWG9N+P8?;+IO8:<AN[\ZO+B_83J56>[][4:MU!AWVR^#=%6M5
MZPTVT#PRTDH5\;!6ZU[OL)V)M7&[5IO-9M79;E7I<6W0J^%4K5JHE!'5P 8[
MIR=X!3X%#T[_<?)=I<(ZRD^F(K+,UX);$;#$R&C,W@?"?&*52GK7A8KG6HXG
MEC7KS5WV7NE/\IZ[<2MM*$ZS>4YJ[OM)C18Y&:I@?GH2R'LF@Y]WI-^HB\,#
MP9L'P6&+UP_Y_M'^7KW%17TH]EJMX#^[AT!E#>YW#QD[#\7/.U,9528""6@?
M-&-[/).!G;0;]?KW.X7[K/AL*SR4XZA-Y,+H2,'FTF%?A4JW7]3IOV,<J8SX
M5(;S]H\#.16&78L9ZZDICW[T#+"X8H26(W>CD?\5[08N3E]G*34P3R@CD5'G
M2.I^GLBAM*Q1KS9/:GA_R9X>H!58ID^+#ZVS@^LQ<&2HK%531]32;#Z(0>@G
MVOI//_UT(;3E,@*! R%R)$&I9#12>LI18]F$&S84(F)J*BUJW$BK*;,3:9A(
M^384/D^,8/ G7(5M3MA+^8I%RC*8! CC(>-1 !?AZO+<=L(M? C6$V-I+)@)
M?$7%-@Q6C34HK15,:>:K:.3HXV&5]1-_DI.S/!^L+J- ^F09PSD;:NY_$C#;
MRQ]>'#:;]>,?7APUCJO5*FP;/N';[C&--(Z1L,*NJ@QN>E ;-EBD9V]ZW>Z[
M[O6 ];IOSGJ=R^LW[/;L UVY><UZ-Q_.K@:7W3X[N^ZP,[C<H:'!#1O\TG47
MNAT:['7[@[,!?.G^^^+JKG_Y:Y>!E^M>][M?P9>_G NM<IL>C81OY;T@_=K5
M 0OXG*D1>RV&.N%Z3J[1HSV?WP";D#>#WEU_T 76X-\P<-6]0CX %ZY?W\ M
M;^^N+V]Z##Y_[?;ZEX,/N6+U+4<]##)M\D#A0:,,>->$5!-6G@!Y0C,1)'YF
M6O?HO&,U$]JP) I@%*D-^<S@ _@W3(PF,&(7H%JP0B2Y1\9TP;7H?/;89>17
M<S+<Q24B6$? ;' 53$C'2KN%9Q),% CD0:"% 6.S[!#$P=YQ#8QDY^%]4/78
MN99FR"/A+:W-CH#=>S#Q6 N!1CI28:AFYH<7>X?'7V,M,:P-FZ^$8F3;N_N9
M_8#Y@NVT*WCEB>RG4<WV\?>O7F1+\P"9<'YV\:\WO9N[Z\YSXV^Y9?*_B;]E
MJZ_RM[I_B'S(K)<,ZW(Z3=X)JV5F7&@],==6 A56@4V]Y9'S( <>>)%&BYT!
ME J$>[PGC*7XT_WLAX#.P .=H;$0:GN))IW:ZI6$,&&61C.SK6Z'G(<;)&=D
M@O.-C/N_)5*+$CF#8WR;@/MKM%*QHCBY,0"4E^^FFU%6C8-CPP@+&KI5#2'X
MDX-==N9K8MX2\?H;)-[4C"\CE-N1E\9&B+^0=)$MAO"'$PU$+HYQF5TC,N69
MB8/XNHE6(QABOTJ C4JG0P0+!;NK]JNL@R!5^A82K$1;B'U.Q/EE"--YO'T)
M*19@3W:M3)4UCBK^?65O_X!6<M\:A_76*\;#$+ OH # L1!\Q\Y/P$1W0#Q0
M3O'?L%OXA.O7R70(>G7H'=1WO?V]IO?%VXZ\P]:>USHZ<(CA2[<VZMYN\\C;
MKQ\4?)2[R>08&:?)G>4,PC_( ?V>89'P 4F@5T17.2?>@"., D(X"6 /(Q"=
M@_T!;P,>^<+!$%P-)#'-$<^V&DRP00:#3+B)6%_$5I#\FX?H\YH-KZC03L_'
MF)B!F)W)Y*YOV6C2BVRJR,A(^LETBOKP,0G&*$:/!<(/$6&.%XE?JF ,$##D
MC]$] ,U@2^0M-DC>J8.\P0@7SEG#21O<!QAD1_C2H-#P2J511U1#'J_@+IPF
M@(F>Q;'@H<F=WVL!D0X2_ NI_41:QD<CJ3%BKBM2KCE!MB2J$-Z7PJM,BV)A
M9:Y'6D#V;R2NXC(IC:F+B!CD)CZ,WDO@&/HBD+@4VZ(]H\W1GJ-JO;'F,'(-
MRF#5<F2@\@?59@@OA\+"=Y<S4GC#0HX-X88TS#Q=PO7X<LG3B6/G-(V_["GY
MA,'>I3E/R8F\TG'E=&HM>6)C=2]TY((,.I8Y:1RJIQ:Q C<#(\M(G4HKI,)!
MHK/'KG*\Z+%(S9CX'&/.L"6^9;PYOJ60F17 I303S+:-$)_^:KVG&=O2 OCP
M'\&^?A)KT#D7TY[4&-+@EP+GE4B<1]M"R%_$WLR27$!_ML6'<F_5W+ BWFVB
M#:(C$-53*7,YHYY F<L)28$E.P,O0/4T\MO@ 4ISPN>FI<^F%)KZ8CSUPS*)
M3GPK2C&ZKQ*02)C[Z((B/=(S9;ZHFH5@,^%AR(8"GC<QHOYA*/),(Q1CF&,D
MA$L]?64LA6\Z<,P*M-P8Y;NB3UY><'6@<,/"B"^ 8J4A(7[2&)+E6L_.\3^/
MJO.ELX#-4[V-4#H\L4^K2]ZRDTD=0<EQ/19,'^<)9.0GVF6A6(#,PB^NPEVH
MB>&Y;Y)Y0#(EO-\2%[&!)Q?]9/A1^ 1W?#6-0[FHC_>QC0$3U?-J@[3]O-ID
M? A9KL>2R,K0/2&R+@-J&BC$XA[%8CP#F+.0@!35Y'\W,Q[.L[",$3B%8 &[
MU2H 5  VJL(@/Q[I?^G(:Q'736+BQ5FIN_R@5BVWD(&MDEZVM0@Y]G4\V%26
M*F%]\0@? JF)77_D=UJXW.=$9S/'?"PJ0RWXIPH?6:';/)SQN=GY?WO?"NU"
M?["A;,W<GBK^"E!'JKMPQ&XJ@MR38U-5C)TF\,4(.C@#S991IMR@TVP/"[O[
MH".AFE49&ZRJ\>+$U4'+7*4"U+$@LP)LB8RQLLQF&AO$(BH+@[-/3:-06O[F
M^Y?7=V TA^[:8W*%9ZO16AJ3D*<"YO(-X^;F5&GRB@MH7"#-%+BVT$>?&^JC
MDM-8JWOJ<00C2;F\)0%WTTX^.XM"+P6CR)^71LX5EY.==11[/ZA$(32X?6S4
M(Z#)7>$B<VZ-/8C<#QUNHTWE07%+Y+V!)Y^7CRM$H#1&20@6""(7&N$.&.T]
M]Q<%!:Q,I% - 5465M)S;(AIE&@ =EI3)Z]8Y8 0"4ZS!&9_SP37$:RGU9R'
M=HZ-2=<0-?L\%)CF4*\E>\E?$0&KN,R=K>-Y*.&S6$LLG[@R6KY-#'ZSB?0G
M+%+Y,GFG=\QED)>';SDD23VZ):W^8)D8:#@Z=DW=PP?HH.5=>VAF;>76E5/E
MX&S6$((&M81IURTGH_!U8A,MUFD$%'&;@ER8H\!3S ^1!\7-@8!32)&(,L&X
M-IH,../SJTOG,TQY(*C;!?Z*(L+%G&R=SK(-M=Z0.CGYQ)J#KX! ZD#T+=<<
M0D \88=?<!VPO]?X;-9<0_?!$@L.9<?KZ[Q#7+8XN\7+U-M(S??L#&36QWW%
M&=0'S<BT9"A<"\=:/@#D+)W> !NP_Q_0.NFOP99]FIV6GP@MD#O&=2%C2%Q^
M'V!./9=K*SBEFZ@9VJ;G-ALHH!Q7"N44[&ZY#]LUJ0QE*(%LV%Q&"YFMQ5;L
M&,3O,42FU)\"S!PY@5(+)U)J0.8^?L*82LDT:7L+["CE/>%5(";S^#R&%,YQ
M-#-YLMUQJ(8<O0L)1A6L&A04)BRWHB%Z"I,,7?8FUM8[K^ZE3@75BWK.15G-
M%L_=87>+@_A5C[;B>#2&M%(]SS2KU'T5'I^"FT/Y@%&,P.J1[1I;X)UKY<''
MQ!!HCT+L1+>KVY+YL3.:$V)Z5+[4O:;;2PV!*COW2@89) U4,K0.J49BAFQ/
M9RH0Z!CGE-4DH26S!15QI#EK09I'8)NN(27G@G.U@OJ#Y:JO3?OVBR:Y)1%^
M [M3OA5:OUC.<YU4E-G)K%5J*2'!C Z^/9SPL6%B'Q/#<W]<@%$+%/45(*JL
M LG8>WA>EI8GE\!&:?!.73'%)@1?>;0"LE>  +D <!<JP6ZEWQ).YURESBZE
M?<5S.L^@$G#>%&IF$I@ +A!B%WG^?.TO5<U@BG(>H+<3GSD6/"A)_V<9-U8Q
MSQRE2>M__9H+YKDM854G$FXK!5:64D(%F?*=E%^EX);AK#\EL)6>)$2@]$1;
MNI17<@P9"FZREQY15;,8MBB49CQ842% 251G58DM(CB\N&WQ8-,ZB@9%'(P8
MA'1VN$@MLD+A%* -F'=6+5RH4.Z4,HPQ6#J?0@"+J,S_%*E9*(*Q<&^+T&MQ
M>7=S:;:?@9 'JJ(.&L-R@,+3QGATIX$8R4@$^5NJJ[7U"4]?=9P*3MUOA3IK
M*3$>K.^+V+)%:Q^]:XL]VO0:<$[*"CO!%O&-8>,<GS,]\BEYPW^1=VO62'1R
M;. S93N_= 1#Z'!B0+O#-X!#>L="X\E>ED7Y*%,[PZQUY46"98J]AQA EU<Z
M"3W783Q/X=QJ\^I+\XIN6+2H(-UX^+A$1[9QH--?ZD8L<;=1X>640!A?RV'.
M>V]I5RL"+=$!E(M6X;K 4FU%OKF70 6=[@"FA0$$R_DA4V._TCC:]C<Q)AOF
MK0KZ3LZCV$EM7"-U),8*WV?*4U!\*'W_K-@G%2S>JW ],%('F4YZZUFZ'&4G
M?0\+^-M9W*//XIY(JXE6^/^2WN^.,)MVGLE;]198<H:]NM](H%P5.T1Y8B=*
MPX)T'NQJ(B1=LQH*UY3D],32:5\N=0W!H (;#WEL1#O[XQB2C3CD\[:,B'QZ
MZ+C(P#W8ZSUV1OD\3$5"TG'#"PE6ZV[3%C9M@VSE=+A*0S4;K(^U#JM']8>'
MZ]7&@V-_TK0U(MF1#9PQ,8]^WMG=62@V^8=V,_[,(+%E^&^KVECYA0GT'FM\
M4O$3==LB,CI7'%.I$1MHK.@LM.8*G,1R9_?;),*X>A=)3 VEG>?JE')N2YBR
M_ ,-A2U^G0(\;H-?$XJKC:5+%#_<M2?R6WW8!<?RHCO7>,+03)P.A)_^3$:;
M,"W>A6_@M Z.#7VR/BBPY:S'/P;B_H\CH@T3PZV6^#HPX-I-EL-V\GZ ;\-M
M,ML[D.+Y%KPV%5P:QP T1Y U^!*S!X"4-X.KK1%&!Z#S)LNB>51YQW4%?[YH
M!9H^.GY^BRF;(,CEF((_@!;Q$&"2$%9Y[-WY>7]K+.IYA):M%L'&1YA;2#BI
M^PU"S"Y0>=&]V1KF/^^(0NE*C7+U0LK_0(%DXVI&-?>;IO3KJJ?_ U!+ 0(4
M Q0    ( (2"JE;*2TXU9:," ((\&@ 1              "  0    !C9&YA
M+3(P,C,P,S,Q+FAT;5!+ 0(4 Q0    ( (2"JE:UEH%KMQ8  -;_   1
M          "  92C @!C9&YA+3(P,C,P,S,Q+GAS9%!+ 0(4 Q0    ( (2"
MJE;]/ T(U2D   2I 0 5              "  7JZ @!C9&YA+3(P,C,P,S,Q
M7V-A;"YX;6Q02P$"% ,4    " "$@JI6A.GZ<JIC   =< 0 %0
M    @ &"Y ( 8V1N82TR,#(S,#,S,5]D968N>&UL4$L! A0#%     @ A(*J
M5KT4R-[7$ $ /'<+ !4              ( !7T@# &-D;F$M,C R,S S,S%?
M;&%B+GAM;%!+ 0(4 Q0    ( (2"JE9&>%UZVJ   )Q?!P 5
M  "  6E9! !C9&YA+3(P,C,P,S,Q7W!R92YX;6Q02P$"% ,4    " "$@JI6
M9?HZ7A8-  # 6@  '               @ %V^@0 8V1N82TR,#(S,#,S,7@Q
M,'%X97AX,3 Q+FAT;5!+ 0(4 Q0    ( (2"JE:6N-ZO90@  +LJ   <
M          "  <8'!0!C9&YA+3(P,C,P,S,Q>#$P<7AE>'@S,3$N:'1M4$L!
M A0#%     @ A(*J5EQ7#:IE"   NRH  !P              ( !91 % &-D
M;F$M,C R,S S,S%X,3!Q>&5X>#,Q,BYH=&U02P$"% ,4    " "$@JI6$ER;
M/JL&  ">(@  '               @ $$&04 8V1N82TR,#(S,#,S,7@Q,'%X
M97AX,S(Q+FAT;5!+ 0(4 Q0    ( (2"JE;@>,M@*@\  +A5   =
M      "  >D?!0!C9&YA+3(P,C,P,S,Q>#$P>'%X97AX,3 R+FAT;5!+!08
1    "P + /T"  !.+P4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
